-DOCSTART- -X- O O

Independent NNP O
prognostic JJ O
information NN O
provided VBN O
by IN O
sphygmomanometrically RB B-INTV
determined VBN I-INTV
pulse JJ I-INTV
pressure NN I-INTV
and CC I-INTV
mean JJ I-INTV
arterial JJ I-INTV
pressure NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
left JJ I-POPU
ventricular JJ I-POPU
dysfunction NN I-POPU
. . O

OBJECTIVES CC O
The DT O
purpose NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
evaluate VB O
the DT O
relationship NN O
of IN O
baseline NN O
pulse JJ O
pressure NN O
and CC O
mean JJ O
arterial JJ O
pressure NN O
to TO O
mortality NN O
in IN O
patients NNS B-POPU
with IN I-POPU
left JJ I-POPU
ventricular JJ I-POPU
dysfunction NN I-POPU
. . O

BACKGROUND NNP O
Increased VBD O
conduit NN O
vessel NN O
stiffness NN O
increases VBZ O
pulse JJ O
pressure NN O
and CC O
pulsatile NN O
load NN O
, , O
potentially RB O
contributing VBG O
to TO O
adverse VB O
outcomes NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
left JJ I-POPU
ventricular JJ I-POPU
dysfunction NN I-POPU
. . O

METHODS NNP O
Pulse NNP O
and CC O
mean VB O
arterial JJ O
pressure NN O
were VBD O
analyzed VBN O
for IN O
their PRP$ O
effect NN O
on IN O
mortality NN B-OC
, , O
adjusting VBG O
for IN O
other JJ O
modifiers NNS O
of IN O
risk NN O
, , O
using VBG O
Cox NNP O
proportional JJ O
hazards NNS O
regression NN O
analysis NN O
of IN O
data NNS O
collected VBN O
from IN O
6,781 CD B-POPU
patients NNS I-POPU
randomized VBN I-POPU
into IN I-POPU
the DT I-POPU
Studies NNPS I-POPU
of IN I-POPU
Left NNP I-POPU
Ventricular NNP I-POPU
Dysfunction NNP I-POPU
trials NNS I-POPU
. . O

RESULTS NNP O
Pulse NNP B-OC
and CC I-OC
mean VB I-OC
arterial JJ I-OC
pressure NN I-OC
were VBD O
related VBN O
positively RB O
to TO O
each DT O
other JJ O
, , O
age NN O
, , O
ejection NN O
fraction NN O
and CC O
prevalence NN O
of IN O
diabetes NNS O
and CC O
hypertension NN O
and CC O
inversely RB O
to TO O
prior VB O
myocardial JJ O
infarction NN O
and CC O
beta-adrenergic JJ O
blocking NN O
agent NN O
use NN O
. . O

Higher JJR B-OC
pulse JJ I-OC
pressure NN I-OC
was VBD O
associated VBN O
with IN O
increased JJ O
prevalence NN O
of IN O
female JJ O
gender NN O
, , O
greater JJR O
calcium NN B-INTV
channel NN I-INTV
blocking VBG I-INTV
agent NN I-INTV
, , I-INTV
digoxin NN I-INTV
and CC O
diuretic JJ B-INTV
use NN O
, , O
lower JJR O
heart NN O
rate NN O
and CC O
a DT O
higher JJR O
rate NN O
of IN O
reported VBN O
smoking NN O
history NN O
. . O

Higher JJR B-OC
mean JJ I-OC
arterial JJ I-OC
pressure NN I-OC
was VBD O
associated VBN O
with IN O
higher JJR O
heart NN O
rate NN O
, , O
lower JJR O
calcium NN B-INTV
channel NN I-INTV
blocker NN I-INTV
and CC O
digoxin NN B-INTV
use NN O
and CC O
lower JJR O
New NNP O
York NNP O
Heart NNP O
Association NNP O
functional JJ O
class NN O
. . O

Over IN O
a DT O
61-month JJ O
follow-up JJ O
1,582 CD O
deaths NNS B-OC
( ( O
1,397 CD O
cardiovascular NN O
) ) O
occurred VBD O
. . O

In IN O
a DT O
multivariate NN O
analysis NN O
adjusting VBG O
for IN O
the DT O
above JJ O
covariates NNS O
and CC O
treatment NN O
assignment NN O
, , O
higher JJR O
pulse JJ B-OC
pressure NN I-OC
remained VBD O
an DT O
independent JJ O
predictor NN O
of IN O
total JJ B-OC
and CC I-OC
cardiovascular JJ I-OC
mortality NN I-OC
( ( O
total JJ O
mortality NN O
relative NN O
risk NN O
, , O
1.05 CD O
per IN O
10 CD O
mm NN O
Hg NNP O
increment NN O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
1.01 CD O
to TO O
1.10 CD O
; : O
p NN O
= VBZ O
0.02 CD O
) ) O
. . O

Mean JJ B-OC
arterial JJ I-OC
pressure NN I-OC
was VBD O
inversely RB O
related VBN O
to TO O
total JJ B-OC
and CC I-OC
cardiovascular JJ I-OC
mortality NN I-OC
( ( O
total JJ O
mortality NN O
relative NN O
risk NN O
, , O
0.89 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
0.85 CD O
to TO O
0.94 CD O
; : O
p NN O
< VBZ O
0.0001 CD O
) ) O
. . O

CONCLUSIONS NNP O
One CD O
noninvasive JJ B-INTV
blood NN I-INTV
pressure NN I-INTV
measurement NN I-INTV
provides VBZ O
two CD O
independent JJ O
prognostic JJ O
factors NNS O
for IN O
survival NN B-OC
. . O

Increased VBD B-OC
conduit NN I-OC
vessel NN I-OC
stiffness NN I-OC
, , O
as IN O
assessed VBN O
by IN O
pulse JJ O
pressure NN O
, , O
may MD O
contribute VB O
to TO O
increased VBN O
mortality NN B-OC
in IN O
patients NNS O
with IN O
left JJ O
ventricular JJ O
dysfunction NN O
, , O
independent JJ O
of IN O
mean JJ O
arterial JJ O
pressure NN O
. . O

-DOCSTART- -X- O O

Epinephrine-induced JJ O
panic NN O
attacks NNS O
and CC O
hyperventilation NN O
. . O

To TO O
assess VB O
the DT O
effects NNS O
of IN O
epinephrine NN B-INTV
on IN O
ventilation NN O
in IN O
patients NNS B-POPU
with IN I-POPU
panic JJ I-POPU
disorder NN I-POPU
and CC I-POPU
in IN I-POPU
social JJ I-POPU
phobics NNS I-POPU
, , O
analyses NNS O
were VBD O
performed VBN O
on IN O
pooled VBN O
data NNS O
from IN O
two CD O
previous JJ O
infusion NN O
studies NNS O
. . O

Throughout IN O
the DT O
infusion NN O
, , O
changes NNS B-OC
in IN I-OC
transcutaneous JJ I-OC
PCO2 NNP I-OC
( ( I-OC
tcPCO2 NN I-OC
) ) I-OC
, , I-OC
subjective JJ I-OC
anxiety NN I-OC
, , I-OC
heart NN I-OC
rate NN I-OC
and CC I-OC
blood NN I-OC
pressure NN I-OC
were VBD O
recorded VBN O
continuously RB O
. . O

Twenty-nine JJ B-POPU
patients NNS I-POPU
received VBD I-POPU
epinephrine JJ I-POPU
, , I-POPU
ten JJ I-POPU
patients NNS I-POPU
received VBD I-POPU
placebo NN I-POPU
. . O

Thirteen JJ O
patients NNS O
( ( O
45 CD O
% NN O
) ) O
had VBD O
a DT O
panic JJ O
attack NN O
during IN O
epinephrine NN B-INTV
. . O

The DT O
fall NN B-OC
in IN I-OC
tcPCO2 NN I-OC
and CC I-OC
the DT I-OC
cardiovascular JJ I-OC
response NN I-OC
was VBD O
greater JJR O
in IN O
panicking VBG O
patients NNS O
than IN O
patients NNS O
who WP O
did VBD O
not RB O
panic JJ O
. . O

Although IN O
the DT O
fall NN O
in IN O
tcPCO2 NN B-OC
associated VBN O
with IN O
panic NN O
was VBD O
not RB O
substantial JJ O
and CC O
did VBD O
not RB O
indicate VB O
clinically RB O
significant JJ O
acute JJ B-OC
hyperventilation NN I-OC
, , O
it PRP O
appears VBZ O
to TO O
be VB O
a DT O
sensitive JJ O
index NN O
for IN O
epinephrine-induced JJ O
panic NN O
. . O

The DT O
fall NN B-OC
in IN I-OC
tcPCO2 NN I-OC
was VBD O
predicted VBN O
rather RB O
by IN O
the DT O
frequency NN O
of IN O
occurrence NN B-OC
of IN I-OC
anxiety-related JJ I-OC
somatic NN I-OC
symptoms NNS I-OC
than IN O
by IN O
the DT O
fear NN O
of IN O
these DT O
symptoms NNS O
. . O

These DT O
findings NNS O
further RB O
reduce VB O
a DT O
role NN O
for IN O
fear NN O
of IN O
bodily JJ O
sensations NNS O
in IN O
epinephrine-induced JJ B-INTV
panic NN O
attacks NNS O
and CC O
favor VBP O
a DT O
biological JJ O
sensitivity NN O
to TO O
sympathetic JJ O
stimulation NN O
. . O

-DOCSTART- -X- O O

Protocol NN O
for IN O
the DT O
Multicenter NNP O
Acute NNP O
Stroke NNP O
Trial NNP O
-- : O
thrombolysis NN O
study NN O
. . O

The DT O
rationale NN O
for IN O
the DT O
Multicenter NNP O
Acute NNP O
Stroke NNP O
Trial NNP O
( ( O
MAST NNP O
) ) O
is VBZ O
presented VBN O
in IN O
a DT O
companion NN O
article NN O
appearing VBG O
in IN O
this DT O
issue NN O
. . O

Acute NNP O
ischaemic JJ O
stroke NN O
is VBZ O
the DT O
third JJ O
major JJ O
cause NN O
of IN O
death NN B-OC
in IN O
developed JJ O
countries NNS O
, , O
and CC O
a DT O
major JJ O
cause NN O
of IN O
disability NN B-OC
. . O

Despite IN O
a DT O
very RB O
poor JJ O
prognosis NN O
, , O
no DT O
treatment NN O
has VBZ O
demonstrated VBN O
an DT O
efficacy NN O
in IN O
lowering VBG O
the DT O
mortality NN B-OC
and CC I-OC
disability NN I-OC
resulting VBG O
from IN O
stroke NN O
events NNS O
. . O

Thrombolysis NN B-INTV
has VBZ O
been VBN O
proven VBN O
to TO O
reduce VB O
mortality NN B-OC
in IN I-OC
myocardial JJ I-OC
infarction NN I-OC
, , O
and CC O
it PRP O
has VBZ O
been VBN O
shown VBN O
able JJ O
to TO O
induce VB O
recanalisation NN B-OC
when WRB O
administered VBN O
to TO O
acute VB B-POPU
stroke NN I-POPU
patients NNS I-POPU
. . O

A DT O
recent JJ O
meta NN O
analysis NN O
of IN O
small-sized JJ O
studies NNS O
suggests VBZ O
that IN O
thrombolysis NN B-INTV
could MD O
offer VB O
some DT O
benefit NN O
to TO O
stroke VB B-POPU
patients NNS I-POPU
, , O
by IN O
reducing VBG O
the DT O
mortality NN B-OC
and CC I-OC
severe JJ I-OC
invalidity NN I-OC
by IN O
56 CD O
% NN O
; : O
these DT O
results NNS O
need VBP O
to TO O
be VB O
confirmed VBN O
in IN O
adequately RB O
designed VBN O
and CC O
sized VBN O
studies NNS O
. . O

-DOCSTART- -X- O O

High-pressure NN B-INTV
, , I-INTV
rapid-inflation NN I-INTV
pneumatic JJ I-INTV
compression NN I-INTV
improves VBZ O
venous JJ O
hemodynamics NNS O
in IN O
healthy JJ B-POPU
volunteers NNS I-POPU
and CC I-POPU
patients NNS I-POPU
who WP I-POPU
are VBP I-POPU
post-thrombotic JJ I-POPU
. . O

PURPOSE NNP O
Deep NNP B-POPU
vein NN I-POPU
thrombosis NN I-POPU
( ( I-POPU
DVT NNP I-POPU
) ) I-POPU
is VBZ O
a DT O
preventable JJ O
cause NN O
of IN O
morbidity NN B-POPU
and CC I-POPU
mortality NN I-POPU
in IN I-POPU
patients NNS I-POPU
who WP I-POPU
are VBP I-POPU
hospitalized VBN I-POPU
. . O

An DT O
important JJ O
part NN O
of IN O
the DT O
mechanism NN O
of IN O
DVT NNP O
prophylaxis NN O
with IN O
intermittent JJ O
pneumatic JJ O
compression NN O
( ( O
IPC NNP O
) ) O
is VBZ O
reduced VBN O
venous JJ O
stasis NN O
with IN O
increased JJ O
velocity NN O
of IN O
venous JJ O
return NN O
. . O

The DT O
conventional JJ O
methods NNS O
of IN O
IPC NNP O
use NN O
low JJ O
pressure NN O
and CC O
slow JJ O
inflation NN O
of IN O
the DT O
air NN O
bladder NN O
on IN O
the DT O
leg NN O
to TO O
augment VB O
venous JJ O
return NN O
. . O

Recently RB O
, , O
compression NN O
devices NNS O
have VBP O
been VBN O
designed VBN O
that IN O
produce VBP O
high JJ O
pressure NN O
and CC O
rapid JJ O
inflation NN O
of IN O
air NN O
cuffs NNS O
on IN O
the DT O
plantar NN O
plexus NN O
of IN O
the DT O
foot NN O
and CC O
the DT O
calf NN O
. . O

The DT O
purpose NN O
of IN O
this DT O
study NN O
is VBZ O
to TO O
evaluate VB O
the DT O
venous JJ O
velocity NN O
response NN O
to TO O
high-pressure NN O
, , O
rapid-inflation NN O
compression NN O
devices NNS O
versus VBP O
standard JJ O
, , O
low-pressure JJ O
, , O
slow-inflation JJ O
compression NN O
devices NNS O
in IN O
healthy JJ B-POPU
volunteers NNS I-POPU
and CC I-POPU
patients NNS I-POPU
with IN I-POPU
severe JJ I-POPU
post-thrombotic JJ I-POPU
venous JJ I-POPU
disease NN I-POPU
. . O

METHOD NNP O
Twenty-two NNP B-POPU
lower JJR I-POPU
extremities NNS I-POPU
from IN I-POPU
healthy JJ I-POPU
volunteers NNS I-POPU
and CC I-POPU
11 CD I-POPU
lower JJR I-POPU
extremities NNS I-POPU
from IN I-POPU
patients NNS I-POPU
with IN I-POPU
class NN I-POPU
4 CD I-POPU
to TO I-POPU
class NN I-POPU
6 CD I-POPU
post-thrombotic JJ I-POPU
chronic JJ I-POPU
venous JJ I-POPU
insufficiency NN I-POPU
were VBD I-POPU
studied VBN I-POPU
. . O

With IN O
duplex JJ B-INTV
ultrasound NN I-INTV
scanning NN I-INTV
( ( O
ATL-Ultramark NNP O
9 CD O
, , O
Advanced NNP O
Tech NNP O
Laboratory NNP O
, , O
Bothell NNP O
, , O
Wash NNP O
) ) O
, , O
acute JJ O
DVT NNP O
was VBD O
excluded VBN O
before IN O
subject JJ O
evaluation NN O
. . O

Venous JJ O
velocities NNS O
were VBD O
monitored VBN O
after IN O
the DT O
application NN O
of IN O
each DT O
of IN O
five CD O
IPC NNP O
devices NNS O
, , O
with IN O
all PDT O
the DT O
patients NNS O
in IN O
the DT O
supine JJ O
position NN O
. . O

Three CD B-INTV
high-pressure NN I-INTV
, , I-INTV
rapid-compression NN I-INTV
devices NNS I-INTV
and CC I-INTV
two CD I-INTV
standard NN I-INTV
, , I-INTV
low-pressure JJ I-INTV
, , I-INTV
slow-inflation JJ I-INTV
compression NN I-INTV
devices NNS I-INTV
were VBD O
applied VBN O
in IN O
a DT O
random JJ O
sequence NN O
. . O

Maximal NNP O
venous JJ O
velocities NNS O
were VBD O
obtained VBN O
at IN O
the DT O
common JJ O
femoral JJ O
vein NN O
and CC O
the DT O
popliteal NN O
vein NN O
for IN O
all PDT O
the DT O
devices NNS O
and CC O
were VBD O
recorded VBN O
as IN O
the DT O
mean JJ O
peak JJ O
velocity NN O
of IN O
three CD O
compression NN O
cycles NNS O
and CC O
compared VBN O
with IN O
baseline NN O
velocities NNS O
. . O

RESULTS VB O
The DT O
baseline NN O
venous JJ O
velocities NNS O
were VBD O
higher JJR O
in IN O
the DT O
femoral JJ O
veins NNS O
than IN O
in IN O
the DT O
popliteal NN O
veins NNS O
in IN O
both DT O
the DT O
volunteers NNS O
and CC O
the DT O
post-thrombotic JJ O
subjects NNS O
. . O

Standard NNP B-OC
and CC I-OC
high-pressure NN I-OC
, , I-OC
rapid-inflation NN I-OC
compression NN I-OC
significantly RB O
increased VBD O
the DT O
popliteal NN B-OC
and CC I-OC
femoral JJ I-OC
vein NN I-OC
velocities NNS I-OC
in IN O
healthy JJ O
and CC O
post-thrombotic JJ O
subjects NNS O
. . O

High-pressure NN O
, , O
rapid-inflation NN O
compression NN O
produced VBD O
significantly RB O
higher JJR O
maximal JJ B-OC
venous JJ I-OC
velocities NNS I-OC
in IN I-OC
the DT I-OC
popliteal NN I-OC
and CC I-OC
femoral JJ I-OC
veins NNS I-OC
in IN O
both DT O
healthy JJ O
volunteers NNS O
and CC O
patients NNS O
who WP O
were VBD O
post-thrombotic JJ O
as IN O
compared VBN O
with IN O
standard JJ O
compression NN O
. . O

Compared VBN O
with IN O
the DT O
healthy JJ O
volunteers NNS O
, , O
the DT O
patients NNS O
who WP O
were VBD O
post-thrombotic JJ O
had VBD O
a DT O
significantly RB O
attenuated VBN O
velocity NN B-OC
response NN I-OC
at IN O
both DT O
the DT O
popliteal NN O
and CC O
the DT O
femoral JJ O
vein NN O
levels NNS O
. . O

CONCLUSION NNP O
High-pressure NNP O
, , O
rapid-inflation NN O
pneumatic JJ O
compression NN O
increases NNS O
popliteal NN B-OC
and CC I-OC
femoral JJ I-OC
vein NN I-OC
velocity NN I-OC
as IN O
compared VBN O
with IN O
standard JJ O
, , O
low-pressure JJ O
, , O
slow-inflation JJ O
pneumatic JJ O
compression NN O
. . O

Patients NNS B-POPU
with IN I-POPU
post-thrombotic JJ I-POPU
venous JJ I-POPU
disease NN I-POPU
have VBP O
a DT O
compromised JJ O
hemodynamic JJ O
response NN O
to TO O
all DT O
IPC NNP O
devices NNS O
. . O

However RB O
, , O
an DT O
increased VBN O
velocity NN O
response NN O
to TO O
the DT O
high-pressure NN O
, , O
rapid-inflation NN O
compression NN O
device NN O
is VBZ O
preserved VBN O
. . O

High-pressure NN O
, , O
rapid-inflation NN O
pneumatic JJ O
compression NN O
may MD O
offer VB O
additional JJ O
protection NN O
from IN O
thrombotic JJ O
complications NNS O
on IN O
the DT O
basis NN O
of IN O
an DT O
improved JJ O
hemodynamic JJ B-OC
response NN I-OC
, , O
both DT O
in IN O
healthy JJ B-POPU
volunteers NNS I-POPU
and CC I-POPU
in IN I-POPU
patients NNS I-POPU
who WP I-POPU
were VBD I-POPU
post-thrombotic JJ I-POPU
. . O

-DOCSTART- -X- O O

Thrombolysis NN O
is VBZ O
superior JJ O
to TO O
heparin VB O
for IN O
non-obstructive JJ B-POPU
mitral JJ I-POPU
mechanical JJ I-POPU
valve NN I-POPU
thrombosis NN I-POPU
. . O

BACKGROUND NNP O
AND NNP O
AIM NNP O
OF IN O
THE NNP O
STUDY NNP O
Non-obstructive NNP B-POPU
prosthetic JJ I-POPU
valve NN I-POPU
thrombosis NN I-POPU
( ( I-POPU
PVT NNP I-POPU
) ) I-POPU
is VBZ O
a DT O
unique JJ O
subset NN O
that WDT O
features VBZ O
clinical JJ O
presentation NN O
without IN O
heart NN O
failure NN O
, , O
and CC O
may MD O
be VB O
asymptomatic JJ O
. . O

Thrombolysis NN O
has VBZ O
been VBN O
accepted VBN O
for IN O
obstructive JJ O
PVT NNP O
, , O
but CC O
treatment NN O
strategies NNS O
of IN O
non-obstructive JJ O
PVT NNP O
are VBP O
controversial JJ O
. . O

This DT O
study NN O
compared VBN O
the DT O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
thrombolysis NN O
and CC O
heparin NN O
treatment NN O
in IN O
these DT O
patients NNS O
. . O

METHODS NNP O
Between NNP O
1993 CD O
and CC O
1998 CD O
, , O
20 CD B-POPU
consecutive JJ I-POPU
patients NNS I-POPU
were VBD I-POPU
found VBN I-POPU
by IN I-POPU
multiplane NN I-POPU
transesophageal NN I-POPU
echocardiography NN I-POPU
( ( I-POPU
TEE NNP I-POPU
) ) I-POPU
to TO I-POPU
have VB I-POPU
non-obstructive JJ I-POPU
PVT NNP I-POPU
. . O

TEE NNP O
was VBD O
performed VBN O
for IN O
peripheral JJ O
embolism NN O
in IN O
two CD O
patients NNS O
, , O
stroke VBD O
or CC O
transient JJ O
ischemic JJ O
attack NN O
in IN O
six CD O
, , O
stroke NN O
and CC O
fever NN O
in IN O
two CD O
, , O
fever RB O
in IN O
one CD O
patient NN O
, , O
as IN O
a DT O
routine JJ O
postoperative JJ O
examination NN O
in IN O
two CD O
patients NNS O
, , O
and CC O
for IN O
other JJ O
reasons NNS O
in IN O
seven CD O
. . O

Patients NNS O
were VBD O
allocated VBN O
to TO O
two CD O
groups NNS O
: : O
group NN O
I PRP O
( ( O
n JJ O
= NNP O
8 CD O
) ) O
received VBD O
streptokinase-mediated JJ B-INTV
fibrinolysis NN I-INTV
; : I-INTV
group NN O
II NNP O
( ( O
n JJ O
= NNP O
12 CD O
) ) O
received VBD O
intravenous JJ B-INTV
heparin NNS I-INTV
by IN I-INTV
infusion NN I-INTV
. . O

Treatment NN O
was VBD O
monitored VBN O
using VBG O
TEE NNP O
. . O

RESULTS NNP O
There EX O
was VBD O
no DT O
difference NN O
between IN O
patient JJ O
groups NNS O
with IN O
regard NN O
to TO O
sex NN O
, , O
age NN O
, , O
type NN O
of IN O
prosthesis NN O
and CC O
time NN O
since IN O
operation NN O
, , O
though IN O
anticoagulant JJ O
status NN O
was VBD O
more RBR O
often RB O
inadequate JJ O
in IN O
group NN O
II NNP O
. . O

By IN O
TEE NNP O
, , O
valve FW B-OC
motion NN I-OC
was VBD O
normal JJ O
in IN O
all DT O
patients NNS O
. . O

In IN O
group NN O
I PRP O
, , O
all DT O
thrombi NNS B-OC
were VBD O
mobile JJ B-OC
and CC O
5-13 JJ O
mm NN O
in IN O
diameter NN O
; : O
in IN O
group NN O
II NNP O
, , O
all DT O
thrombi NNS O
but CC O
three CD O
were VBD O
mobile JJ B-OC
and CC O
3-18 JJ O
mm NN O
in IN O
diameter NN O
. . O

In IN O
group NN O
I PRP O
, , O
thrombolysis NN O
was VBD O
successful JJ O
in IN O
all DT O
patients NNS O
, , O
without IN O
complications NNS B-OC
, , O
within IN O
6-72 JJ O
h. NN O
In IN O
group NN O
II NNP O
, , O
heparin NN B-INTV
treatment NN O
was VBD O
successful JJ O
in IN O
six CD O
patients NNS O
in IN O
3-32 JJ O
days NNS O
. . O

In IN O
one CD O
patient NN O
, , O
seven CD O
days NNS O
' CD O
of IN O
unsuccessful JJ O
heparin NN O
was VBD O
followed VBN O
by IN O
two CD O
months NNS O
' POS O
successful JJ O
coumarin NN O
therapy NN O
. . O

Among IN O
five CD O
unsuccessful JJ O
cases NNS O
, , O
the DT O
thrombus JJ B-OC
size NN I-OC
increased VBD O
in IN O
four CD O
( ( O
three CD O
became VBD O
obstructive JJ O
in IN O
7-35 JJ O
days NNS O
) ) O
; : O
all DT O
four CD O
patients NNS O
were VBD O
switched VBN O
to TO O
fibrinolysis NN O
, , O
which WDT O
was VBD O
successful JJ O
without IN O
complications NNS O
in IN O
12-60 JJ O
h. NN O
The DT O
fifth JJ O
patient NN O
developed VBD O
a DT O
stroke NN B-OC
after IN O
nine CD O
days NNS O
of IN O
heparin JJ O
treatment NN O
and CC O
was VBD O
subsequently RB O
operated VBN O
on IN O
. . O

CONCLUSIONS NNP O
Non-obstructive JJ O
PVT NNP O
may MD O
be VB O
asymptomatic JJ O
in IN O
one-third NN O
of IN O
patients NNS O
. . O

Thrombolysis NNP O
is VBZ O
an DT O
efficient JJ B-OC
and CC I-OC
safe JJ I-OC
treatment NN O
, , O
and CC O
may MD O
be VB O
first-line JJ O
therapy NN O
if IN O
there EX O
is VBZ O
no DT O
contraindication NN O
. . O

Heparin NNP B-INTV
treatment NN O
was VBD O
successful JJ O
in IN O
about IN O
one-half NN O
of IN O
our PRP$ O
cases NNS O
in IN O
the DT O
presence NN O
of IN O
sessile NN O
or CC O
small JJ O
thrombi NN O
and CC O
inadequate JJ O
anticoagulant NN O
status NN O
. . O

In IN O
unsuccessful JJ O
cases NNS O
, , O
thrombi NN O
became VBD O
obstructive JJ O
or CC O
caused JJ O
stroke NN B-OC
during IN O
heparin JJ O
therapy NN O
, , O
the DT O
adequate JJ O
duration NN O
of IN O
which WDT O
remains VBZ O
unclear JJ O
. . O

-DOCSTART- -X- O O

Emerging VBG O
treatment NN B-OC
of IN O
acute JJ B-POPU
coronary JJ I-POPU
syndromes NNS I-POPU
with IN O
platelet NN B-INTV
glycoprotein NN I-INTV
IIB/IIIA NNP I-INTV
inhibitors NNS I-INTV
. . O

-DOCSTART- -X- O O

Moderate-intensity NNP B-INTV
exercise NN I-INTV
training NN I-INTV
with IN O
elements NNS O
of IN O
step NN O
aerobics NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
severe JJ I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

OBJECTIVE NN O
To TO O
evaluate VB O
whether IN O
a DT O
specific JJ O
program NN O
of IN O
moderate-intensity JJ B-INTV
step NN I-INTV
aerobics NNS I-INTV
training NN I-INTV
may MD O
be VB O
sufficient JJ O
to TO O
improve VB O
the DT O
exercise NN O
tolerance NN O
of IN O
patients NNS B-POPU
with IN I-POPU
severe JJ I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

PATIENTS VB O
Twenty-six JJ B-POPU
patients NNS I-POPU
( ( I-POPU
22 CD I-POPU
men NNS I-POPU
, , I-POPU
4 CD I-POPU
women NNS I-POPU
; : I-POPU
mean VB I-POPU
+/- JJ I-POPU
SD NNP I-POPU
age NN I-POPU
, , I-POPU
54 CD I-POPU
+/- JJ I-POPU
9yrs CD I-POPU
) ) I-POPU
with IN I-POPU
a DT I-POPU
history NN I-POPU
of IN I-POPU
severe JJ I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
( ( I-POPU
left JJ I-POPU
ventricular JJ I-POPU
ejection NN I-POPU
fraction NN I-POPU
of IN I-POPU
18 CD I-POPU
% NN I-POPU
+/- JJ I-POPU
8 CD I-POPU
% NN I-POPU
) ) I-POPU
. . O

STUDY NNP O
DESIGN NNP O
Prospective NNP O
, , O
randomized VBD O
, , O
controlled VBD O
trial NN O
. . O

Patients NNS O
were VBD O
randomized VBN O
into IN O
exercise NN O
and CC O
control NN O
groups NNS O
. . O

All DT O
patients NNS O
underwent VBD O
a DT O
clinical JJ O
examination NN O
and CC O
a DT O
ramp NN O
pattern JJ O
cycle NN O
exercise NN O
test NN O
before IN O
and CC O
after IN O
the DT O
observation NN O
period NN O
. . O

The DT O
exercise NN O
group NN O
underwent VBD O
a DT O
moderate-intensity NN B-INTV
( ( I-INTV
50 CD I-INTV
% NN I-INTV
of IN I-INTV
peak NN I-INTV
oxygen NN I-INTV
uptake NN I-INTV
) ) I-INTV
12-week JJ I-INTV
training NN I-INTV
program NN I-INTV
, , I-INTV
progressing VBG I-INTV
to TO I-INTV
100 CD I-INTV
minutes NNS I-INTV
per IN I-INTV
week NN I-INTV
of IN I-INTV
step NN I-INTV
aerobics NNS I-INTV
and CC I-INTV
50 CD I-INTV
minutes NNS I-INTV
per IN I-INTV
week NN I-INTV
of IN I-INTV
cycling NN I-INTV
. . O

The DT O
control NN O
group NN O
did VBD O
not RB O
perform VB B-INTV
a DT I-INTV
training NN I-INTV
program NN I-INTV
. . O

MAIN NNP O
OUTCOME NNP O
MEASURES NNP O
Peak NNP B-OC
oxygen NN I-OC
uptake NN I-OC
, , I-OC
peak JJ I-OC
workload NN I-OC
, , I-OC
percent NN I-OC
of IN I-OC
predicted JJ I-OC
power NN I-OC
ability NN I-OC
. . O

RESULTS NNP O
Significant JJ O
increases NNS O
in IN O
peak NN B-OC
oxygen NN I-OC
uptake NN I-OC
( ( O
15 CD O
+/- JJ O
3.4 CD O
to TO O
18.5 CD O
+/- JJ O
2.9mL/kg/min CD O
; : O
p NN O
= NNP O
.001 NNP O
) ) O
, , O
peak JJ B-OC
workload NN I-OC
( ( O
77 CD O
+/- JJ O
26 CD O
to TO O
99 CD O
+/- JJ O
31 CD O
watts NN O
; : O
p CC O
= NNP O
.000 NNP O
) ) O
, , O
and CC O
percent NN B-OC
of IN I-OC
predicted JJ I-OC
power NN I-OC
ability NN I-OC
( ( O
43 CD O
% NN O
+/- JJ O
10 CD O
% NN O
to TO O
56 CD O
% NN O
+/- JJ O
13 CD O
% NN O
; : O
p CC O
= NNP O
.000 NNP O
) ) O
were VBD O
observed VBN O
in IN O
the DT O
exercise NN O
group NN O
. . O

No DT O
significant JJ O
changes NNS B-OC
in IN O
baseline NN O
parameters NNS O
occurred VBD O
in IN O
the DT O
control NN O
group NN O
. . O

There EX O
were VBD O
no DT O
critical JJ O
changes NNS O
in IN O
heart NN B-OC
rate NN I-OC
or CC I-OC
blood NN I-OC
pressure NN I-OC
in IN O
either DT O
group NN O
. . O

CONCLUSION NNP O
Moderate-intensity NNP O
step NN O
aerobics NNS O
training VBG O
significantly RB O
increases VBZ O
peak JJ B-OC
oxygen NN I-OC
uptake NN I-OC
and CC O
peak JJ B-OC
workloads NNS I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
severe JJ I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

-DOCSTART- -X- O O

Changes NNS O
in IN O
cardiac JJ B-OC
muscle NN I-OC
mass NN I-OC
and CC O
function NN O
in IN O
hemodialysis NN B-POPU
patients NNS I-POPU
during IN I-POPU
growth NN I-POPU
hormone CD I-POPU
treatment NN I-POPU
. . O

BACKGROUND NNP O
Adult NNP B-POPU
patients NNS I-POPU
with IN I-POPU
chronic JJ I-POPU
renal JJ I-POPU
failure NN I-POPU
( ( I-POPU
CRF NNP I-POPU
) ) I-POPU
often RB O
show VBP O
symptoms NNS O
as IN O
fatigue NN O
, , O
wasting NN O
, , O
and CC O
reduced VBD O
working VBG O
capacity NN O
with IN O
concomitant JJ O
findings NNS O
of IN O
reduced JJ O
cardiac JJ O
performance NN O
and CC O
muscle NN O
mass NN O
. . O

This DT O
state NN O
may MD O
in IN O
part NN O
be VB O
caused VBN O
by IN O
an DT O
imbalance NN O
in IN O
the DT O
somatostatin/somatomedine NN O
axis NN O
resulting VBG O
in IN O
increased JJ O
catabolism NN O
. . O

During IN O
an DT O
attempt NN O
to TO O
correct VB O
this DT O
catabolic JJ O
state NN O
by IN O
administration NN B-INTV
of IN I-INTV
exogenous JJ I-INTV
growth NN I-INTV
hormone NN I-INTV
, , O
cardiac JJ O
muscle NN O
mass NN O
and CC O
performance NN O
were VBD O
studied VBN O
. . O

METHODS NNP O
In IN O
a DT O
double-blind JJ O
, , O
placebo-controlled JJ B-INTV
6-month JJ O
study NN O
comprising VBG O
20 CD B-POPU
adult NN I-POPU
enfeebled VBD I-POPU
hemodialysis NN I-POPU
patients NNS I-POPU
, , O
9 CD O
patients NNS O
were VBD O
treated VBN O
with IN O
a DT O
single JJ O
daily JJ O
subcutaneous JJ O
injection NN O
of IN O
recombinant JJ B-INTV
human JJ I-INTV
growth NN I-INTV
hormone NN I-INTV
( ( I-INTV
rhGH NN I-INTV
) ) I-INTV
4 CD O
IU/m2 NNP O
and CC O
11 CD O
with IN O
placebo JJ B-INTV
injections NNS O
. . O

Left NNP B-OC
ventricular JJ I-OC
muscle NN I-OC
mass NN I-OC
( ( I-OC
LVM NNP I-OC
) ) I-OC
and CC O
ejection NN B-OC
fraction NN I-OC
( ( I-OC
EF NNP I-OC
) ) I-OC
were VBD O
evaluated VBN O
by IN O
echocardiography NN O
and CC O
the DT O
maximal JJ O
working NN O
capacity NN O
( ( O
MWC NNP O
) ) O
was VBD O
measured VBN O
by IN O
a DT O
bicycle NN B-INTV
exercise NN I-INTV
test NN I-INTV
performed VBD O
before IN O
and CC O
after IN O
the DT O
treatment NN O
period NN O
. . O

Supplementary JJ O
electrocardiography NN B-OC
( ( I-OC
ECG NNP I-OC
) ) I-OC
was VBD O
performed VBN O
before IN O
and CC O
after IN O
6-month JJ O
treatment NN O
. . O

RESULTS NNP O
Median JJ B-OC
LVM NNP I-OC
increased VBD O
significantly RB O
from IN O
172 CD O
to TO O
220 CD O
g NN O
( ( O
p JJ O
= NNP O
0.03 CD O
) ) O
in IN O
the DT O
rhGH-treated JJ O
group NN O
, , O
while IN O
an DT O
insignificant JJ O
decrease NN O
was VBD O
observed VBN O
in IN O
the DT O
placebo NN O
group NN O
from IN O
281 CD O
to TO O
200 CD O
g NN O
( ( O
p JJ O
= NNP O
0.3 CD O
) ) O
. . O

The DT O
EF NNP B-OC
showed VBD O
no DT O
significant JJ O
changes NNS O
in IN O
the DT O
two CD O
groups NNS O
. . O

MWC NNP B-OC
showed VBD O
a DT O
slight NN O
, , O
insignificant JJ O
decrease NN O
in IN O
both DT O
groups NNS O
. . O

From IN O
ECG NNP O
no DT O
significant JJ O
ST NNP B-OC
deviations NNS I-OC
were VBD O
found VBN O
and CC O
no DT O
significant JJ O
changes NNS O
regarding VBG O
B-Hb NNP O
, , O
blood NN O
pressure NN O
or CC O
pulse NN O
were VBD O
observed VBN O
in IN O
the DT O
two CD O
groups NNS O
. . O

Irregular JJ B-OC
heart NN I-OC
rhythm NN I-OC
aggravated VBD O
in IN O
one CD O
patient NN O
during IN O
the DT O
first JJ O
month NN O
of IN O
treatment NN O
with IN O
rhGH NN O
, , O
but CC O
was VBD O
overcome VBN O
by IN O
a DT O
-blocking JJ O
agent NN O
. . O

CONCLUSION VB O
The DT O
treatment NN O
with IN O
rhGH NN O
of IN O
adult NN O
chronic JJ O
hemodialysis NN O
patients NNS O
for IN O
6 CD O
months NNS O
increased VBD O
the DT B-OC
left NN I-OC
ventricular JJ I-OC
mass NN I-OC
significantly RB O
, , O
but CC O
without IN O
any DT O
effect NN O
on IN O
ejection NN O
fraction NN O
or CC O
maximal JJ O
working JJ O
capacity NN O
. . O

No DT O
electrocardiographic JJ O
signs NNS O
of IN O
ischemia NN O
were VBD O
associated VBN O
with IN O
the DT O
increasing VBG O
muscle NN O
mass NN O
and CC O
only RB O
one CD O
patient NN O
developed VBD O
symptoms NNS O
that WDT O
might MD O
relate VB O
to TO O
ischemia VB O
. . O

No DT O
changes NNS O
in IN O
B-Hb NNP B-OC
, , I-OC
blood NN I-OC
pressure NN I-OC
or CC O
pulse NN O
were VBD O
observed VBN O
during IN O
the DT O
treatment NN O
period NN O
. . O

-DOCSTART- -X- O O

Low JJ B-INTV
molecular-weight JJ I-INTV
heparin NN I-INTV
versus NN I-INTV
aspirin NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
acute JJ I-POPU
ischaemic JJ I-POPU
stroke NN I-POPU
and CC I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
: : I-POPU
a DT O
double-blind NN O
randomised VBN O
study NN O
. . O

HAEST NNP O
Study NNP O
Group NNP O
. . O

Heparin NNP O
in IN O
Acute NNP O
Embolic NNP O
Stroke NNP O
Trial NNP O
. . O

BACKGROUND NNP O
Patients NNPS B-POPU
with IN I-POPU
acute JJ I-POPU
ischaemic JJ I-POPU
stroke NN I-POPU
and CC I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
have VBP O
an DT O
increased VBN O
risk NN O
of IN O
early JJ B-OC
stroke NN I-OC
recurrence NN I-OC
, , O
and CC O
anticoagulant JJ O
treatment NN O
with IN O
heparins NNS B-INTV
has VBZ O
been VBN O
widely RB O
advocated VBN O
, , O
despite IN O
missing VBG O
data NNS O
on IN O
the DT O
balance NN O
of IN O
risk NN O
and CC O
benefit NN O
. . O

METHODS NNP O
Heparin NNP B-INTV
in IN O
Acute NNP O
Embolic NNP O
Stroke NNP O
Trial NNP O
( ( O
HAEST NNP O
) ) O
was VBD O
a DT O
multicentre NN O
, , O
randomised VBN O
, , O
double-blind JJ O
, , O
and CC O
double-dummy JJ O
trial NN O
on IN O
the DT O
effect NN O
of IN O
low-molecular-weight JJ B-POPU
heparin NN I-POPU
( ( I-POPU
LMWH NNP I-POPU
, , I-POPU
dalteparin VBZ I-POPU
100 CD I-POPU
IU/kg NNP I-POPU
subcutaneously RB I-POPU
twice RB I-POPU
a DT I-POPU
day NN I-POPU
) ) I-POPU
or CC I-POPU
aspirin NN I-POPU
( ( I-POPU
160 CD I-POPU
mg NN I-POPU
every DT I-POPU
day NN I-POPU
) ) I-POPU
for IN O
the DT O
treatment NN O
of IN O
449 CD B-POPU
patients NNS I-POPU
with IN I-POPU
acute JJ I-POPU
ischaemic JJ I-POPU
stroke NN I-POPU
and CC I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
. . O

The DT O
primary JJ O
aim NN O
was VBD O
to TO O
test VB O
whether IN O
treatment NN O
with IN O
LMWH NNP B-INTV
, , O
started VBD O
within IN O
30 CD O
h NN O
of IN O
stroke NN O
onset NN O
, , O
is VBZ O
superior JJ O
to TO O
aspirin VB B-INTV
for IN O
the DT O
prevention NN O
of IN O
recurrent JJ B-OC
stroke NN I-OC
during IN O
the DT O
first JJ O
14 CD O
days NNS O
. . O

FINDINGS IN O
The DT O
frequency NN B-OC
of IN I-OC
recurrent JJ I-OC
ischaemic JJ I-OC
stroke NN I-OC
during IN O
the DT O
first JJ O
14 CD O
days NNS O
was VBD O
19/244 CD O
( ( O
8.5 CD O
% NN O
) ) O
in IN O
dalteparin-allocated JJ O
patients NNS O
versus IN O
17/225 CD O
( ( O
7.5 CD O
% NN O
) ) O
in IN O
aspirin-allocated JJ O
patients NNS O
( ( O
odds NNS O
ratio=1.13 NN O
, , O
95 CD O
% NN O
CI NNP O
0.57-2.24 NN O
) ) O
. . O

The DT O
secondary JJ O
events NNS O
during IN O
the DT O
first JJ O
14 CD O
days NNS O
also RB O
revealed VBD O
no DT O
benefit NN O
of IN O
dalteparin NN B-INTV
compared VBN O
with IN O
aspirin NN B-INTV
: : I-INTV
symptomatic JJ B-OC
cerebral JJ I-OC
haemorrhage NN I-OC
6/224 CD O
versus NN O
4/225 CD O
; : O
symptomatic JJ B-OC
and CC I-OC
asymptomatic JJ I-OC
cerebral JJ I-OC
haemorrhage NN I-OC
26/224 CD O
versus NN O
32/225 CD O
; : O
progression NN B-OC
of IN I-OC
symptoms NNS I-OC
within IN I-OC
the DT I-OC
first JJ I-OC
48 CD I-OC
hours NNS I-OC
24/224 CD O
versus NN O
17/225 CD O
; : O
and CC O
death NN O
21/224 CD O
versus NN O
16/225 CD O
. . O

There EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
functional JJ B-OC
outcome NN I-OC
or CC I-OC
death NN I-OC
at IN O
14 CD O
days NNS O
or CC O
3 CD O
months NNS O
. . O

INTERPRETATION NNP O
The DT O
present JJ O
data NNS O
do VBP O
not RB O
provide VB O
any DT O
evidence NN O
that IN O
LMWH NNP B-INTV
is VBZ O
superior JJ O
to TO O
aspirin VB O
for IN O
the DT O
treatment NN O
of IN O
acute JJ O
ischaemic JJ O
stroke NN O
in IN O
patients NNS O
with IN O
atrial JJ O
fibrillation NN O
. . O

However RB O
, , O
the DT O
study NN O
could MD O
not RB O
exclude VB O
the DT O
possibility NN O
of IN O
smaller JJR O
, , O
but CC O
still RB O
worthwhile JJ O
, , O
effects NNS O
of IN O
either DT O
of IN O
the DT O
trial NN O
drugs NNS O
. . O

-DOCSTART- -X- O O

Heparin-coated JJ B-INTV
cardiopulmonary JJ I-INTV
bypass NN I-INTV
circuits NNS I-INTV
reduce VB O
circulating VBG O
complement JJ O
factors NNS O
and CC O
interleukin-6 NN O
in IN O
paediatric JJ B-POPU
heart NN I-POPU
surgery NN I-POPU
. . O

Children NNP B-POPU
are VBP O
sensitive JJ O
to TO O
the DT O
inflammatory JJ O
side NN O
effects NNS O
of IN O
cardiopulmonary JJ O
bypass NN O
( ( O
CPB NNP O
) ) O
. . O

Our PRP$ O
intention NN O
was VBD O
to TO O
investigate VB O
if IN O
the DT O
biocompatibility NN O
benefits NNS O
of IN O
heparin-coated JJ B-INTV
CPB NNP I-INTV
circuits NNS I-INTV
apply VBP O
to TO O
children NNS B-POPU
. . O

In IN O
20 CD O
operations NNS O
, , O
19 CD B-POPU
children NNS I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO I-POPU
heparin-coated JJ I-POPU
( ( B-INTV
group NN I-INTV
HC NNP I-INTV
, , I-INTV
n JJ I-INTV
= NNP I-INTV
10 CD I-INTV
) ) I-INTV
or CC I-INTV
standard JJ I-INTV
( ( I-INTV
group NN I-INTV
C NNP I-INTV
, , I-INTV
n JJ I-INTV
= NNP I-INTV
10 CD I-INTV
) ) I-INTV
bypass NN I-INTV
circuits NNS I-INTV
. . O

Plasma NNP B-OC
levels NNS I-OC
of IN I-OC
acute JJ I-OC
phase NN I-OC
reactants NNS I-OC
, , I-OC
interleukins NNS I-OC
, , I-OC
granulocytic JJ I-OC
proteins NNS I-OC
and CC I-OC
complement JJ I-OC
factors NNS I-OC
were VBD O
measured VBN O
. . O

All DT O
were VBD O
significantly RB O
elevated VBN O
after IN O
CPB NNP O
. . O

Levels NNP B-OC
of IN I-OC
complement NN I-OC
factor NN I-OC
C3a NNP I-OC
( ( O
851 CD O
( ( O
791-959 CD O
) ) O
ng/ml FW O
[ JJ O
median NN O
with IN O
quartiles NNS O
] VBP O
in IN O
group NN O
C NNP O
, , O
497 CD O
( ( O
476-573 JJ O
) ) O
ng/ml NN O
in IN O
group NN O
HC NNP O
, , O
p NN O
< NNP O
0.001 CD O
) ) O
, , O
Terminal NNP B-OC
Complement NNP I-OC
Complex NNP I-OC
( ( O
114 CD O
( ( O
71-130 CD O
) ) O
AU/ml NNP O
in IN O
group NN O
C NNP O
, , O
35.5 CD O
( ( O
28.9-51.4 JJ O
) ) O
AU/ml NNP O
in IN O
group NN O
HC NNP O
, , O
p NN O
< NNP O
0.001 CD O
) ) O
, , O
and CC O
interleukin-6 NN B-OC
( ( O
570 CD O
( ( O
203-743 JJ O
) ) O
pg/ml NN O
in IN O
group NN O
C NNP O
, , O
168 CD O
( ( O
111-206 CD O
) ) O
pg/ml NN O
in IN O
group NN O
HC NNP O
, , O
p NN O
= NNP O
0.005 CD O
) ) O
, , O
were VBD O
significantly RB O
reduced VBN O
in IN O
group NN O
HC NNP O
. . O

Heparin-coated JJ B-INTV
CPB NNP I-INTV
circuits NNS I-INTV
improve VBP O
the DT O
biocompatibility NN O
of IN O
CPB NNP O
during IN O
heart NN O
surgery NN O
in IN O
the DT O
paediatric JJ B-POPU
patient NN I-POPU
population NN O
, , O
as IN O
reflected VBN O
by IN O
significantly RB O
reduced VBN O
levels NNS O
of IN O
circulating VBG O
complement JJ O
factors NNS O
and CC O
interleukin-6 NN O
. . O

-DOCSTART- -X- O O

Outcomes NNS B-OC
of IN I-OC
early JJ I-OC
endovascular JJ I-OC
versus NN I-OC
surgical JJ B-INTV
treatment NN I-INTV
of IN O
ruptured JJ B-POPU
cerebral JJ I-POPU
aneurysms NNS I-POPU
. . O

A DT O
prospective JJ O
randomized NN O
study NN O
. . O

BACKGROUND NNP O
AND CC O
PURPOSE NNP O
This DT O
prospective JJ O
study NN O
was VBD O
conducted VBN O
to TO O
compare VB O
the DT O
outcomes NNS B-OC
of IN I-OC
surgical JJ B-INTV
clipping NN I-INTV
and CC I-INTV
endovascular JJ I-INTV
treatment NN I-INTV
in IN O
acute NN B-POPU
( ( I-POPU
< JJ I-POPU
72 CD I-POPU
hours NNS I-POPU
) ) I-POPU
aneurysmal VBP I-POPU
subarachnoid JJ I-POPU
hemorrhage NN I-POPU
( ( I-POPU
SAH NNP I-POPU
) ) I-POPU
. . O

METHODS NNP O
One CD B-POPU
hundred VBD I-POPU
nine CD I-POPU
consecutive JJ I-POPU
patients NNS I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO O
either DT O
surgical JJ B-INTV
( ( O
n=57 JJ O
) ) O
or CC B-INTV
endovascular JJ I-INTV
( ( O
n=52 JJ O
) ) O
treatment NN O
. . O

Clinical JJ B-OC
and CC I-OC
neuropsychological JJ I-OC
outcome NN I-OC
was VBD O
assessed VBN O
at IN O
3 CD O
and CC O
12 CD O
months NNS O
after IN O
treatment NN O
; : O
MRI NNP O
of IN O
the DT O
brain NN O
was VBD O
performed VBN O
at IN O
12 CD O
months NNS O
. . O

Follow-up NNP B-INTV
angiography NN I-INTV
was VBD O
scheduled VBN O
after IN O
clipping VBG O
and CC O
3 CD O
and CC O
12 CD O
months NNS O
after IN O
endovascular JJ O
treatment NN O
. . O

RESULTS NNP O
One CD B-POPU
year NN I-POPU
postoperatively RB I-POPU
, , I-POPU
43/41 CD I-POPU
( ( I-POPU
surgical/endovascular JJ I-POPU
) ) I-POPU
patients NNS I-POPU
had VBD O
good JJ O
or CC O
moderate JJ O
recovery NN B-OC
, , O
5/4 CD O
had VBD O
severe JJ B-OC
disability NN I-OC
or CC I-OC
were VBD I-OC
in IN I-OC
a DT I-OC
vegetative JJ I-OC
state NN I-OC
, , O
and CC O
9/7 CD O
had VBD O
died VBN B-OC
( ( O
NS NNP O
) ) O
according VBG O
to TO O
intention NN O
to TO O
treat VB O
. . O

Patients NNS O
with IN O
good JJ O
clinical JJ O
recovery NN B-OC
did VBD O
not RB O
differ VB O
in IN O
their PRP$ O
neuropsychological JJ B-OC
test NN I-OC
scores NNS I-OC
. . O

Symptomatic JJ B-OC
vasospasm NN I-OC
( ( O
OR NNP O
2.47 CD O
; : O
95 CD O
% NN O
CI NNP O
1.45 CD O
to TO O
4.19 CD O
; : O
P NNP O
< NNP O
0.001 CD O
) ) O
, , O
poorer JJR O
Hunt NNP B-OC
and CC I-OC
Hess NNP I-OC
grade NN I-OC
( ( O
OR NNP O
2.50 CD O
; : O
95 CD O
% NN O
CI NNP O
1.31 CD O
to TO O
4.75 CD O
; : O
P=0.005 NNP O
) ) O
, , O
need VBP B-OC
for IN I-OC
permanent JJ I-OC
shunt NN I-OC
( ( O
OR NNP O
8.90 CD O
; : O
95 CD O
% NN O
CI NNP O
1.80 CD O
to TO O
44.15 CD O
; : O
P=0.008 NNP O
) ) O
, , O
and CC O
larger JJR B-OC
size NN I-OC
of IN I-OC
the DT I-OC
aneurysm NN I-OC
( ( O
OR CC O
1 CD O
. . O

22 CD O
; : O
95 CD O
% NN O
CI NNP O
1.02 CD O
to TO O
1.45 CD O
; : O
P=0.032 NNP O
) ) O
independently RB O
predicted VBN O
worsened VBD O
clinical JJ B-OC
outcome NN I-OC
regardless NN O
of IN O
the DT O
treatment NN O
modality NN O
. . O

In IN O
MRI NNP B-INTV
, , O
superficial JJ B-OC
brain NN I-OC
retraction NN I-OC
deficits NNS I-OC
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
and CC O
ischemic JJ B-OC
lesions NNS I-OC
in IN O
the DT O
territory NN O
of IN O
the DT O
ruptured JJ B-OC
aneurysm NN I-OC
( ( O
P=0.025 NNP O
) ) O
were VBD O
more RBR O
frequent JJ O
in IN O
the DT O
surgical JJ O
group NN O
. . O

Kaplan-Meier JJR O
analysis NN O
( ( O
mean+/-SD JJ O
follow-up JJ O
39+/-18 JJ O
months NNS O
) ) O
revealed VBD O
equal JJ O
survival NN B-OC
in IN O
both DT O
treatment NN O
groups NNS O
. . O

No DT O
late JJ B-OC
rebleedings NNS I-OC
have VBP O
occurred VBN O
. . O

CONCLUSIONS NNP O
One-year JJ O
clinical JJ B-OC
and CC I-OC
neuropsychological JJ I-OC
outcomes NNS I-OC
seem VBP O
comparable JJ O
after IN O
early JJ O
surgical JJ O
and CC O
endovascular JJ O
treatment NN O
of IN O
ruptured JJ O
intracranial JJ O
aneurysms NN O
. . O

The DT O
long-term JJ O
efficacy NN O
of IN O
endovascular JJ O
treatment NN O
in IN O
preventing VBG O
rebleeding NN B-OC
remains VBZ O
open JJ O
. . O

-DOCSTART- -X- O O

Short- JJ O
and CC O
long-term JJ O
results NNS O
after IN O
thrombolytic JJ B-INTV
treatment NN I-INTV
of IN O
deep JJ O
venous JJ O
thrombosis NN O
. . O

OBJECTIVES CC O
The DT O
goal NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
assess VB O
the DT O
short- JJ O
and CC O
long-term JJ O
efficacy NN O
of IN O
different JJ O
thrombolytic JJ B-INTV
therapy NN I-INTV
regimens NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
leg NN I-POPU
or CC I-POPU
pelvic JJ I-POPU
deep JJ I-POPU
venous JJ I-POPU
thrombosis NN I-POPU
( ( I-POPU
DVT NNP I-POPU
) ) I-POPU
. . O

BACKGROUND VB O
It PRP O
is VBZ O
unclear JJ O
whether IN O
locoregional JJ O
or CC O
systemic JJ O
thrombolysis NN O
is VBZ O
superior JJ O
in IN O
treating VBG O
acute JJ O
leg NN O
DVT NNP O
or CC O
even RB O
whether IN O
lysis NN O
is VBZ O
more RBR O
effective JJ O
than IN O
anticoagulation NN O
therapy NN O
in IN O
preventing VBG O
postthrombotic JJ O
syndrome NN O
. . O

METHODS NNP O
A NNP O
total NN O
of IN O
250 CD B-POPU
patients NNS I-POPU
averaging VBG I-POPU
40 CD I-POPU
years NNS I-POPU
of IN I-POPU
age NN I-POPU
with IN I-POPU
acute JJ I-POPU
DVT NNP I-POPU
were VBD O
randomized VBN O
into IN O
five CD O
groups NNS O
to TO O
receive VB O
full JJ B-INTV
heparinization NN I-INTV
( ( I-INTV
1,000 CD I-INTV
IU/h NNP I-INTV
) ) I-INTV
and CC I-INTV
compression NN I-INTV
treatment NN I-INTV
, , I-INTV
with IN I-INTV
four CD I-INTV
groups NNS I-INTV
also RB I-INTV
administered VBD I-INTV
locoregional JJ I-INTV
tissue NN I-INTV
plasminogen NN I-INTV
activator NN I-INTV
( ( I-INTV
20 CD I-INTV
mg/day NN I-INTV
) ) I-INTV
or CC I-INTV
urokinase JJ I-INTV
( ( I-INTV
100,000 CD I-INTV
IU/day NNP I-INTV
) ) I-INTV
or CC I-INTV
systemic JJ I-INTV
streptokinase NN I-INTV
( ( I-INTV
3,000,000 CD I-INTV
IU NNP I-INTV
daily RB I-INTV
) ) I-INTV
or CC I-INTV
urokinase JJ I-INTV
( ( I-INTV
5,000,000 CD I-INTV
IU NNP I-INTV
daily RB I-INTV
) ) I-INTV
. . O

All DT O
groups NNS O
then RB O
received VBD O
anticoagulation NN B-INTV
and CC I-INTV
compression NN I-INTV
treatment NN I-INTV
for IN I-INTV
one CD I-INTV
year NN I-INTV
. . O

Primary NNP O
efficacy NN O
criteria NNS O
included VBD O
the DT O
change NN O
after IN O
one CD O
year NN O
in IN O
the DT O
number NN O
of IN O
closed JJ B-OC
vein NN I-OC
segments NNS I-OC
and CC O
the DT O
occurrence NN O
of IN O
postthrombotic JJ O
syndrome NN O
. . O

RESULTS NNP O
Systemic NNP B-INTV
thrombolytic JJ I-INTV
therapy NN I-INTV
significantly RB O
reduced VBD O
the DT O
number NN O
of IN O
closed JJ B-OC
vein NN I-OC
segments NNS I-OC
after IN O
12 CD O
months NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
acute JJ I-POPU
DVT NNP I-POPU
compared VBN O
with IN O
conventional JJ O
treatment NN O
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
. . O

Postthrombotic JJ B-OC
syndrome NN I-OC
also RB O
occurred VBD O
with IN O
less JJR O
frequency NN O
in IN O
systemically RB O
treated JJ O
patients NNS O
versus NN O
controls NNS O
( ( O
p VB O
< RB O
0.001 CD O
) ) O
. . O

High-dose JJ O
thrombolysis NN O
led VBD O
to TO O
better RBR O
rates NNS O
of IN O
complete JJ B-OC
recanalization NN I-OC
after IN O
seven CD O
days NNS O
( ( O
p JJ O
< NNP O
0.01 CD O
) ) O
than IN O
locoregional JJ O
lysis NN O
. . O

However RB O
, , O
12 CD B-POPU
patients NNS I-POPU
receiving VBG I-POPU
thrombolysis NN I-POPU
( ( O
9 CD O
systemic NN O
, , O
3 CD O
local JJ O
) ) O
suffered VBD O
major JJ B-OC
bleeding NN I-OC
complications NNS I-OC
; : I-OC
9 CD B-POPU
patients NNS I-POPU
on IN I-POPU
systemic JJ I-POPU
treatment NN I-POPU
developed VBD O
pulmonary JJ B-OC
emboli NN I-OC
. . O

CONCLUSIONS NNP O
Systemic NNP B-INTV
thrombolytic JJ I-INTV
treatment NN I-INTV
for IN O
acute JJ O
DVT NNP O
achieved VBD O
a DT O
significantly RB O
better JJR O
short- NN O
and CC O
long-term JJ O
clinical JJ O
outcome NN O
than IN O
conventional JJ O
heparin/anticoagulation NN O
therapy NN O
but CC O
at IN O
the DT O
expense NN O
of IN O
a DT O
serious JJ O
increase NN O
in IN O
major JJ O
bleeding NN O
and CC O
pulmonary JJ O
emboli NN O
. . O

Given VBN O
the DT O
inherent JJ O
risks NNS O
for IN O
such JJ O
serious JJ O
complications NNS O
, , O
systemic JJ O
thrombolysis NN O
, , O
although IN O
effective JJ O
, , O
should MD O
be VB O
used VBN O
selectively RB O
in IN O
limb-threatening JJ O
thrombotic JJ O
situations NNS O
. . O

-DOCSTART- -X- O O

VLDL NNP B-OC
, , I-OC
apolipoproteins VBZ I-OC
B NNP I-OC
, , I-OC
CIII NNP I-OC
, , I-OC
and CC I-OC
E NNP I-OC
, , O
and CC O
risk NN O
of IN O
recurrent JJ B-OC
coronary JJ I-OC
events NNS I-OC
in IN O
the DT O
Cholesterol NNP O
and CC O
Recurrent NNP O
Events NNP O
( ( O
CARE NNP O
) ) O
trial NN O
. . O

BACKGROUND NNP O
Plasma NNP O
triglyceride NN O
concentration NN O
has VBZ O
been VBN O
an DT O
inconsistent JJ O
independent JJ O
risk NN O
factor NN O
for IN O
coronary JJ O
heart NN O
disease NN O
, , O
perhaps RB O
because IN O
of IN O
the DT O
metabolic JJ O
heterogeneity NN O
among IN O
VLDL NNP O
particles NNS O
, , O
the DT O
main JJ O
carriers NNS O
of IN O
triglycerides NNS O
in IN O
plasma NN O
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
We PRP O
conducted VBD O
a DT O
prospective JJ O
, , O
nested JJ O
case-control NN O
study NN O
in IN O
the DT O
Cholesterol NNP O
and CC O
Recurrent NNP O
Events NNP O
( ( O
CARE NNP O
) ) O
trial NN O
, , O
a DT O
randomized JJ O
placebo-controlled JJ B-INTV
trial NN O
of IN O
pravastatin NN B-INTV
in IN O
4159 CD B-POPU
patients NNS I-POPU
with IN I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
and CC I-POPU
average JJ I-POPU
LDL NNP I-POPU
concentrations NNS I-POPU
at IN I-POPU
baseline NN I-POPU
( ( I-POPU
115 CD I-POPU
to TO I-POPU
174 CD I-POPU
mg/dL NNS I-POPU
, , I-POPU
mean VBP I-POPU
139 CD I-POPU
mg/dL NN I-POPU
) ) I-POPU
. . O

Baseline NNP O
concentrations NNS O
of IN O
VLDL-apolipoprotein NNP B-OC
( ( O
apo NN O
) ) O
B NNP B-OC
( ( I-OC
the DT I-OC
VLDL NNP I-OC
particle NN I-OC
concentration NN I-OC
) ) I-OC
, , I-OC
VLDL NNP I-OC
lipids NNS I-OC
, , O
and CC O
apoCIII NN B-OC
and CC I-OC
apoE NN I-OC
in IN I-OC
VLDL+LDL NNP I-OC
and CC I-OC
in IN I-OC
HDL NNP I-OC
were VBD O
compared VBN O
in IN O
patients NNS B-POPU
who WP I-POPU
had VBD I-POPU
either CC I-POPU
a DT I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
or CC I-POPU
coronary JJ I-POPU
death NN I-POPU
( ( I-POPU
cases NNS I-POPU
, , I-POPU
n=418 NN I-POPU
) ) I-POPU
with IN O
those DT O
in IN O
patients NNS B-POPU
who WP I-POPU
did VBD I-POPU
not RB I-POPU
have VB I-POPU
a DT I-POPU
cardiovascular JJ I-POPU
event NN I-POPU
( ( I-POPU
control NN I-POPU
subjects VBZ I-POPU
, , I-POPU
n=370 NN I-POPU
) ) I-POPU
in IN O
5 CD O
years NNS O
of IN O
follow-up JJ O
. . O

VLDL-cholesterol NN B-OC
, , I-OC
VLDL-triglyceride NNP I-OC
, , I-OC
VLDL-apoB NNP I-OC
, , I-OC
apoCIII NN I-OC
and CC I-OC
apoE NN I-OC
in IN I-OC
VLDL+LDL NNP I-OC
and CC I-OC
apoE NN I-OC
in IN I-OC
HDL NNP I-OC
were VBD O
all DT O
interrelated VBN O
, , O
and CC O
each DT O
was VBD O
a DT O
univariate JJ O
predictor NN O
of IN O
subsequent JJ O
coronary JJ O
events NNS O
. . O

The DT O
significant JJ O
independent JJ O
predictors NNS O
were VBD O
VLDL-apoB NNP B-OC
( ( O
relative JJ O
risk NN O
[ NNP O
RR NNP O
] VBZ O
3.2 CD O
for IN O
highest JJS O
to TO O
lowest JJS O
quintiles NNS O
, , O
P NNP O
: : O
=0.04 NN O
) ) O
, , O
apoCIII RB B-OC
in IN I-OC
VLDL+LDL NNP I-OC
( ( O
RR NNP O
2.3 CD O
, , O
P NNP O
: : O
=0.04 NN O
) ) O
, , O
and CC O
apoE NN B-OC
in IN I-OC
HDL NNP I-OC
( ( O
RR NNP O
1.8 CD O
, , O
P NNP O
: : O
=0.02 NN O
) ) O
. . O

Plasma NNP B-OC
triglycerides NNS I-OC
, , O
a DT O
univariate JJ O
predictor NN O
of IN O
coronary JJ B-OC
events NNS I-OC
( ( O
RR NNP O
1.6 CD O
, , O
P NNP O
: : O
=0.03 NN O
) ) O
, , O
was VBD O
not RB O
related VBN O
to TO O
coronary JJ B-OC
events NNS I-OC
( ( O
RR NNP O
1.3 CD O
, , O
P NNP O
: : O
=0.6 NN O
) ) O
when WRB O
apoCIII NN B-OC
in IN I-OC
VLDL+LDL NNP I-OC
was VBD O
included VBN O
in IN O
the DT O
model NN O
, , O
whereas JJ O
apoCIII NN B-OC
remained VBD O
significant JJ O
. . O

Adjustment NN O
for IN O
LDL- NNP B-OC
and CC I-OC
HDL-cholesterol NNP I-OC
did VBD O
not RB O
affect VB O
these DT O
results NNS O
. . O

CONCLUSIONS NNP O
The DT O
plasma JJ O
concentrations NNS O
of IN O
VLDL NNP B-OC
particles NNS I-OC
and CC I-OC
apoCIII NN I-OC
in IN I-OC
VLDL NNP I-OC
and CC I-OC
LDL NNP I-OC
are VBP O
more RBR O
specific JJ O
measures NNS O
of IN O
coronary JJ O
heart NN O
disease NN O
risk NN O
than IN O
plasma JJ O
triglycerides NNS O
perhaps RB O
because IN O
their PRP$ O
known VBN O
metabolic NN O
properties NNS O
link VBP O
them PRP O
more RBR O
closely RB O
to TO O
atherosclerosis NN O
. . O

-DOCSTART- -X- O O

Cardiovascular JJ O
effects NNS O
of IN O
tamoxifen NN B-INTV
in IN O
women NNS B-POPU
with IN I-POPU
and CC I-POPU
without IN I-POPU
heart NN I-POPU
disease NN I-POPU
: : I-POPU
breast NN O
cancer NN O
prevention NN O
trial NN O
. . O

National NNP O
Surgical NNP O
Adjuvant NNP O
Breast NNP O
and CC O
Bowel NNP O
Project NNP O
Breast NNP O
Cancer NNP O
Prevention NNP O
Trial NNP O
Investigators NNP O
. . O

BACKGROUND NNP O
The DT O
overall JJ O
effect NN O
of IN O
prophylactic JJ O
tamoxifen NN O
in IN O
women NNS O
depends NNS O
on IN O
the DT O
balance NN O
between IN O
the DT O
effects NNS O
of IN O
the DT O
drug NN O
, , O
which WDT O
include VBP O
preventing VBG B-OC
breast NN I-OC
cancer NN I-OC
and CC O
altering VBG O
cardiovascular JJ B-OC
risk NN I-OC
. . O

In IN O
a DT O
recent JJ O
clinical JJ O
trial NN O
, , O
postmenopausal JJ O
estrogen-progestin JJ O
therapy NN O
was VBD O
shown VBN O
to TO O
increase VB O
the DT O
risk NN O
of IN O
early JJ B-OC
cardiovascular JJ I-OC
events NNS I-OC
among IN O
women NNS B-POPU
with IN I-POPU
a DT I-POPU
history NN I-POPU
of IN I-POPU
coronary JJ I-POPU
heart NN I-POPU
disease NN I-POPU
( ( I-POPU
CHD NNP I-POPU
) ) I-POPU
. . O

The DT O
cardiovascular JJ B-OC
effects NNS I-OC
of IN O
tamoxifen NN O
in IN O
women NNS B-POPU
with IN I-POPU
and CC I-POPU
without IN I-POPU
CHD NNP I-POPU
are VBP O
not RB O
known VBN O
. . O

The DT O
National NNP O
Surgical NNP O
Adjuvant NNP O
Breast NNP O
and CC O
Bowel NNP O
Project NNP O
Breast NNP O
Cancer NNP O
Prevention NNP O
Trial NNP O
( ( O
BCPT NNP O
) ) O
is VBZ O
the DT O
only JJ O
clinical JJ O
trial NN O
that WDT O
provides VBZ O
data NNS O
to TO O
assess VB O
the DT O
cardiovascular JJ B-OC
effects NNS I-OC
of IN O
tamoxifen NN O
in IN O
women NNS O
with IN O
and CC O
without IN O
CHD NNP O
. . O

METHODS NNP O
A NNP O
total NN O
of IN O
13 CD B-POPU
388 CD I-POPU
women NNS I-POPU
at IN I-POPU
increased VBN I-POPU
risk NN I-POPU
for IN I-POPU
breast NN I-POPU
cancer NN I-POPU
were VBD O
randomly RB O
assigned VBN O
in IN O
the DT O
BCPT NNP O
to TO O
receive VB O
either DT O
tamoxifen NN B-INTV
( ( I-INTV
20 CD I-INTV
mg/day NN I-INTV
) ) I-INTV
or CC I-INTV
placebo NN I-INTV
. . O

Cardiovascular JJ B-POPU
follow-up NN I-POPU
was VBD I-POPU
available JJ I-POPU
for IN I-POPU
13 CD I-POPU
194 CD I-POPU
women NNS I-POPU
, , I-POPU
1048 CD I-POPU
of IN I-POPU
whom WP I-POPU
had VBD I-POPU
prior RB I-POPU
clinical JJ I-POPU
CHD NNP I-POPU
. . O

Fatal NNP B-OC
and CC I-OC
nonfatal JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
unstable JJ I-OC
angina NN I-OC
, , I-OC
and CC I-OC
severe JJ I-OC
angina NN I-OC
were VBD O
tabulated VBN O
( ( O
mean JJ O
follow-up NN O
: : O
49 CD O
months NNS O
) ) O
. . O

All DT O
statistical JJ O
tests NNS O
were VBD O
two-sided JJ O
. . O

RESULTS NNP O
Cardiovascular JJ B-OC
event NN I-OC
rates NNS I-OC
were VBD O
not RB O
statistically RB O
significantly RB O
different JJ O
between IN O
women NNS O
assigned VBN O
to TO O
receive VB O
tamoxifen NN O
and CC O
those DT O
assigned VBN O
to TO O
receive VB O
placebo NN O
, , O
independent JJ O
of IN O
pre-existing JJ O
CHD NNP O
. . O

Among IN O
women NNS O
without IN O
CHD NNP O
( ( O
6074 CD O
on IN O
tamoxifen NN O
versus NN O
6072 CD O
on IN O
placebo NN O
) ) O
, , O
risk JJ O
ratios NNS O
( ( O
95 CD O
% NN O
confidence NN O
intervals NNS O
[ VBP O
CIs NNP O
] NNP O
) ) O
for IN O
tamoxifen NN O
users NNS O
were VBD O
1.75 CD O
( ( O
0.44 CD O
to TO O
8.13 CD O
) ) O
for IN O
fatal JJ B-OC
myocardial JJ I-OC
infarction NN I-OC
, , O
1.11 CD O
( ( O
0.55 CD O
to TO O
2.28 CD O
) ) O
for IN O
nonfatal JJ B-OC
myocardial JJ I-OC
infarction NN I-OC
, , O
0.69 CD O
( ( O
0.29 CD O
to TO O
1.57 CD O
) ) O
for IN O
unstable JJ B-OC
angina NN I-OC
, , O
and CC O
0.83 CD O
( ( O
0.32 CD O
to TO O
2.10 CD O
) ) O
for IN O
severe JJ B-OC
angina NN I-OC
. . O

In IN O
women NNS O
with IN O
CHD NNP O
( ( O
516 CD O
on IN O
tamoxifen NNS O
versus $ O
532 CD O
on IN O
placebo NN O
) ) O
, , O
risk JJ B-OC
ratios NNS I-OC
( ( O
95 CD O
% NN O
CIs NNP O
) ) O
for IN O
tamoxifen NN O
users NNS O
were VBD O
0.00 CD O
( ( O
0 CD O
to TO O
1.58 CD O
) ) O
for IN O
fatal JJ B-OC
myocardial JJ I-OC
infarction NN I-OC
, , O
1.25 CD O
( ( O
0.32 CD O
to TO O
5.18 CD O
) ) O
for IN O
nonfatal JJ B-OC
myocardial JJ I-OC
infarction NN I-OC
, , O
2.26 CD O
( ( O
0.87 CD O
to TO O
6.55 CD O
) ) O
for IN O
unstable JJ B-OC
angina NN I-OC
, , O
and CC O
1.39 CD O
( ( O
0.23 CD O
to TO O
9.47 CD O
) ) O
for IN O
severe JJ B-OC
angina NN I-OC
. . O

There EX O
was VBD O
no DT O
evidence NN O
that IN O
the DT O
lack NN O
of IN O
association NN O
between IN O
tamoxifen NN O
and CC O
cardiovascular JJ B-OC
events NNS I-OC
was VBD O
related VBN O
to TO O
an DT O
early JJ O
increase NN B-OC
in IN I-OC
risk NN I-OC
that WDT O
may MD O
have VB O
been VBN O
offset VBN O
by IN O
a DT O
late JJ O
decrease NN O
in IN O
risk NN O
. . O

CONCLUSION NN O
When WRB O
used VBN O
for IN O
breast NN O
cancer NN O
prevention NN O
in IN O
women NNS B-POPU
with IN I-POPU
or CC I-POPU
without IN I-POPU
heart NN I-POPU
disease NN I-POPU
, , O
tamoxifen NN O
is VBZ O
not RB O
associated VBN O
with IN O
beneficial JJ O
or CC O
adverse JJ O
cardiovascular JJ B-OC
effects NNS I-OC
. . O

-DOCSTART- -X- O O

Clinical JJ O
implications NNS O
of IN O
a DT O
reduction NN O
in IN O
psychological JJ O
distress NN O
on IN O
cardiac JJ O
prognosis NN O
in IN O
patients NNS B-POPU
participating VBG I-POPU
in IN I-POPU
a DT I-POPU
psychosocial JJ I-POPU
intervention NN I-POPU
program NN I-POPU
. . O

OBJECTIVE CC O
The DT O
objective NN O
of IN O
this DT O
secondary JJ O
analysis NN O
was VBD O
to TO O
examine VB O
the DT O
relationships NNS O
between IN O
a DT O
reduction NN O
in IN O
psychological JJ O
distress NN O
and CC O
long-term JJ O
cardiac NN O
and CC O
psychological JJ O
outcomes NNS O
in IN O
post-myocardial JJ B-POPU
infarction NN I-POPU
patients NNS I-POPU
who WP I-POPU
participated VBD I-POPU
in IN I-POPU
a DT I-POPU
randomized JJ I-POPU
trial NN I-POPU
of IN I-POPU
home-based JJ I-POPU
psychosocial JJ I-POPU
nursing NN I-POPU
interventions NNS I-POPU
( ( I-POPU
the DT I-POPU
Montreal NNP I-POPU
Heart NNP I-POPU
Attack NNP I-POPU
Readjustment NNP I-POPU
Trial NNP I-POPU
[ NNP I-POPU
M-HART NNP I-POPU
] NNP I-POPU
) ) I-POPU
. . O

Gender VB O
differences NNS O
were VBD O
considered VBN O
. . O

METHODS NNP O
We PRP O
studied VBD B-INTV
433 CD B-POPU
patients NNS I-POPU
( ( I-POPU
36.0 CD I-POPU
% NN I-POPU
women NNS I-POPU
) ) I-POPU
from IN I-POPU
the DT I-POPU
M-HART NNP I-POPU
treatment NN I-POPU
group NN I-POPU
who WP I-POPU
received VBD I-POPU
two CD I-POPU
home NN I-POPU
visits NNS I-POPU
after IN I-POPU
achieving VBG I-POPU
a DT I-POPU
high JJ I-POPU
psychological JJ I-POPU
distress NN I-POPU
score NN I-POPU
( ( I-POPU
ie JJ I-POPU
, , I-POPU
> JJ I-POPU
or CC I-POPU
=5 NN I-POPU
) ) I-POPU
on IN I-POPU
the DT I-POPU
General NNP I-POPU
Health NNP I-POPU
Questionnaire NNP I-POPU
( ( I-POPU
GHQ NNP I-POPU
) ) I-POPU
. . O

Short-term JJ O
GHQ NNP B-OC
success NN I-OC
was VBD O
determined VBN O
by IN O
a DT O
return NN O
to TO O
a DT O
normal JJ O
GHQ NNP B-OC
score NN I-OC
( ( O
< JJ O
5 CD O
) ) O
or CC O
a DT O
reduction NN O
of IN O
> NN O
or CC O
=50 CD O
% NN O
after IN O
the DT O
two CD O
visits NNS O
. . O

Patients NNS O
with IN O
short-term JJ O
successful JJ O
and CC O
unsuccessful JJ O
GHQ NNP O
outcomes NNS O
were VBD O
compared VBN O
for IN O
mid-term JJ O
maintenance NN O
of IN O
success NN O
, , O
1-year JJ O
death NN O
and CC O
readmission NN O
rates NNS O
, , O
and CC O
1-year JJ O
depression NN O
and CC O
anxiety NN O
symptoms NNS O
. . O

RESULTS JJ O
Patients NNS O
with IN O
short-term JJ O
GHQ NNP O
success NN O
were VBD O
more RBR O
likely JJ O
to TO O
show VB O
mid-term JJ B-OC
GHQ NNP I-OC
success NN I-OC
( ( O
p JJ O
< NNP O
.001 NNP O
) ) O
, , O
marginally RB O
less RBR O
likely JJ O
to TO O
die VB B-OC
of IN I-OC
any DT I-OC
causes NNS I-OC
( ( O
p JJ O
= NNP O
.087 NNP O
) ) O
, , O
less RBR O
likely JJ O
to TO O
die VB B-OC
of IN I-OC
cardiac JJ I-OC
causes NNS I-OC
( ( O
p JJ O
= NNP O
.043 NNP O
) ) O
, , O
less RBR O
likely JJ O
to TO O
be VB O
readmitted VBN B-OC
for IN O
any DT O
reason NN O
( ( O
p JJ O
< NNP O
.001 NNP O
) ) O
and CC O
for IN O
cardiac JJ O
reasons NNS O
( ( O
p JJ O
< NNP O
.001 NNP O
) ) O
, , O
and CC O
less RBR O
likely JJ O
to TO O
have VB O
high JJ B-OC
depression NN I-OC
( ( O
p JJ O
< NNP O
.001 NNP O
) ) O
and CC O
anxiety NN B-OC
( ( O
p JJ O
< NNP O
.001 NN O
) ) O
at IN O
1-year JJ O
than IN O
patients NNS O
with IN O
short-term JJ O
unsuccessful JJ O
GHQ NNP B-OC
outcomes NNS I-OC
. . O

Results NNS O
held VBD O
for IN O
men NNS B-POPU
and CC I-POPU
women NNS I-POPU
and CC O
were VBD O
not RB O
altered VBN O
by IN O
controlling VBG O
for IN O
potential JJ O
confounders NNS O
. . O

However RB O
, , O
the DT O
number NN O
of IN O
deaths NNS B-OC
prevented VBN O
analysis NN O
with IN O
statistical JJ O
controls NNS O
. . O

CONCLUSIONS NNP O
Post-myocardial JJ O
infarction NN O
interventions NNS O
that WDT O
reduce VB O
psychological JJ O
distress NN O
have VBP O
the DT O
potential NN O
to TO O
improve VB O
long-term JJ B-OC
prognosis NN I-OC
and CC O
psychological JJ B-OC
status NN I-OC
for IN O
both DT O
men NNS B-POPU
and CC I-POPU
women NNS I-POPU
. . O

-DOCSTART- -X- O O

Psychosocial JJ B-INTV
nursing NN I-INTV
therapy NN I-INTV
following VBG B-POPU
sudden JJ I-POPU
cardiac JJ I-POPU
arrest NN I-POPU
: : I-POPU
impact NN O
on IN O
two-year JJ B-OC
survival NN I-OC
. . O

BACKGROUND NNP O
Although IN O
psychosocial JJ B-INTV
therapy NN I-INTV
has VBZ O
been VBN O
shown VBN O
to TO O
reduce VB O
mortality NN B-OC
after IN O
myocardial JJ O
infarction NN O
, , O
it PRP O
is VBZ O
unknown JJ O
whether IN O
the DT O
benefits NNS O
of IN O
psychosocial JJ B-INTV
therapy NN I-INTV
on IN O
mortality NN B-OC
reduction NN I-OC
extend VBP O
to TO O
out-of-hospital JJ O
sudden JJ O
cardiac NN O
arrest NN O
, , O
a DT O
main JJ O
cause NN O
of IN O
cardiovascular JJ B-OC
mortality NN I-OC
. . O

OBJECTIVE NNP O
Describe NNP O
efficacy NN O
of IN O
psychosocial JJ B-INTV
therapy NN I-INTV
on IN O
two-year JJ O
cardiovascular JJ B-OC
mortality NN I-OC
in IN O
sudden JJ B-POPU
cardiac JJ I-POPU
arrest NN I-POPU
survivors NNS I-POPU
. . O

METHOD NNP O
Survivors NNPS B-POPU
of IN I-POPU
out-of-hospital JJ I-POPU
ventricular JJ I-POPU
fibrillation NN I-POPU
or CC I-POPU
asystole NN I-POPU
( ( I-POPU
N NNP I-POPU
= NNP I-POPU
129 CD I-POPU
) ) I-POPU
, , I-POPU
documented VBN I-POPU
by IN I-POPU
electrocardiograms NNS I-POPU
from IN I-POPU
registries NNS I-POPU
of IN I-POPU
a DT I-POPU
citywide NN I-POPU
Medic NNP I-POPU
One NNP I-POPU
unit NN I-POPU
and CC I-POPU
two CD I-POPU
countywide NN I-POPU
emergency NN I-POPU
units NNS I-POPU
, , O
were VBD O
randomized VBN O
into IN O
a DT O
two CD O
group NN O
, , O
experimental JJ O
, , O
longitudinal JJ O
design NN O
. . O

The DT O
intervention NN O
consisted VBD O
of IN O
11 CD O
individual JJ O
sessions NNS O
, , O
implementing VBG O
three CD O
components NNS O
: : O
physiologic JJ O
relaxation NN O
with IN O
biofeedback NN O
training NN O
focused VBD O
on IN O
altering VBG O
autonomic JJ O
tone NN O
; : O
cognitive JJ B-INTV
behavioral JJ I-INTV
therapy NN I-INTV
aimed VBN O
at IN O
self-management JJ O
and CC O
coping VBG O
strategies NNS O
for IN O
depression NN O
, , O
anxiety NN O
, , O
and CC O
anger NN O
; : O
and CC O
cardiovascular JJ O
health NN O
education NN O
. . O

The DT O
primary JJ O
outcome NN O
measure NN O
was VBD O
cardiovascular JJ B-OC
mortality NN I-OC
. . O

RESULTS NNP O
Risk NNP B-OC
of IN I-OC
cardiovascular JJ I-OC
death NN I-OC
was VBD O
significantly RB O
reduced VBN O
86 CD O
% NN O
by IN O
psychosocial JJ O
therapy NN O
, , O
p NN O
= NNP O
.03 NNP O
. . O

Six NNP O
of IN O
the DT O
seven CD O
cardiovascular JJ B-OC
deaths NNS I-OC
in IN O
the DT O
control NN O
group NN O
were VBD O
caused VBN O
by IN O
ventricular JJ O
arrhythmias NN O
. . O

The DT B-OC
cardiovascular JJ I-OC
death NN I-OC
in IN O
the DT O
therapy NN O
group NN O
was VBD O
due JJ O
to TO O
stroke VB O
. . O

Controlling VBG O
for IN O
depression NN B-OC
, , I-OC
previous JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
low JJ I-OC
ejection NN I-OC
fraction NN I-OC
, , I-OC
decreased JJ I-OC
heart NN I-OC
rate NN I-OC
variability NN I-OC
, , I-OC
and CC I-OC
ventricular JJ I-OC
ectopic NN I-OC
beats NNS I-OC
had VBD O
little JJ O
impact NN O
on IN O
estimated VBN O
treatment NN O
effect NN O
. . O

The DT O
risk NN B-OC
of IN I-OC
all-cause JJ I-OC
mortality NN I-OC
was VBD O
reduced VBN O
by IN O
62 CD O
% NN O
in IN O
the DT O
therapy NN O
group NN O
, , O
p VBP O
= JJ O
.13 NNP O
. . O

There EX O
were VBD O
a DT O
total NN O
of IN O
three CD O
deaths NNS B-OC
in IN O
the DT O
therapy NN O
group NN O
and CC O
eight CD O
deaths NNS B-OC
in IN O
the DT O
control NN B-INTV
group NN O
. . O

CONCLUSIONS NNP O
Psychosocial NNP B-INTV
therapy NN I-INTV
significantly RB O
reduced VBD O
the DT O
risk NN O
of IN O
cardiovascular JJ B-OC
death NN I-OC
in IN O
sudden JJ B-POPU
cardiac JJ I-POPU
arrest NN I-POPU
survivors NNS I-POPU
. . O

-DOCSTART- -X- O O

L-arginine JJ B-INTV
and CC O
S-nitrosoglutathione JJ B-INTV
reduce VB O
embolization NN B-OC
in IN O
humans NNS B-POPU
. . O

BACKGROUND NNP O
L-Arginine JJ B-INTV
reduces NNS O
platelet POS B-OC
aggregation NN I-OC
and CC I-OC
adhesion NN I-OC
in IN O
ex JJ O
vivo NN O
studies NNS O
, , O
but CC O
there EX O
is VBZ O
no DT O
evidence NN O
as IN O
yet RB O
that IN O
it PRP O
has VBZ O
a DT O
therapeutic JJ O
effect NN O
on IN O
clinical JJ O
end NN O
points NNS O
. . O

Doppler NNP O
ultrasound NN O
can MD O
detect VB O
cerebral JJ O
emboli NN O
noninvasively RB O
. . O

Such JJ O
embolic JJ O
signals NNS O
are VBP O
common JJ O
after IN O
carotid JJ O
endarterectomy NN O
, , O
and CC O
their PRP$ O
frequency NN O
predicts VBZ O
risk NN O
of IN O
stroke NN O
recurrence NN O
. . O

We PRP O
used VBD O
this DT O
situation NN O
to TO O
determine VB O
the DT O
antiplatelet NN B-OC
efficacy NN I-OC
of IN O
L-arginine NNP B-INTV
and CC O
S-nitrosoglutathione NNP B-INTV
( ( I-INTV
GSNO NNP I-INTV
) ) I-INTV
, , O
a DT O
physiological JJ O
nitric JJ O
oxide IN O
donor NN O
with IN O
possible JJ O
platelet NN O
specificity NN O
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
Patients NNP B-POPU
undergoing JJ I-POPU
carotid NNS I-POPU
endarterectomy VBP I-POPU
were VBD O
randomized VBN O
in IN O
a DT O
double-blind JJ O
manner NN O
between IN O
L-arginine NNP B-INTV
( ( B-POPU
n=14 NN I-POPU
) ) I-POPU
, , O
GSNO NNP B-INTV
( ( B-POPU
n=14 NN I-POPU
) ) I-POPU
, , O
or CC O
placebo NN B-INTV
( ( B-POPU
n=14 JJ I-POPU
) ) I-POPU
administered VBD O
intravenously RB O
for IN O
90 CD O
minutes NNS O
, , O
starting VBG O
30 CD O
minutes NNS O
after IN O
skin JJ O
closure NN O
. . O

All DT B-POPU
patients NNS I-POPU
were VBD I-POPU
pretreated VBN I-POPU
with IN I-POPU
aspirin NN I-POPU
and CC I-POPU
given VBN I-POPU
heparin NNS I-POPU
during IN I-POPU
surgery NN I-POPU
. . O

Transcranial NNP O
Doppler NNP O
recordings NNS O
were VBD O
made VBN O
from IN O
the DT O
ipsilateral JJ O
middle JJ O
cerebral JJ O
artery NN O
for IN O
4 CD O
hours NNS O
after IN O
surgery NN O
, , O
beginning VBG O
30 CD O
minutes NNS O
after IN O
skin JJ O
closure NN O
, , O
and CC O
also RB O
at IN O
6 CD O
and CC O
24 CD O
hours NNS O
. . O

There EX O
were VBD O
highly RB O
significant JJ O
reductions NNS O
in IN O
the DT O
number NN B-OC
of IN I-OC
Doppler NNP I-OC
embolic JJ I-OC
signals NNS I-OC
in IN I-OC
the DT I-OC
L-arginine NNP B-INTV
and CC B-OC
GSNO NNP B-INTV
groups NNS O
; : O
first RB O
4 CD O
hours NNS O
, , O
median JJ O
( ( O
range NN O
) ) O
number NN B-OC
of IN I-OC
embolic JJ I-OC
signals NNS I-OC
, , O
placebo NN B-INTV
44.7 CD O
( ( O
6 CD O
to TO O
778 CD O
) ) O
, , O
L-arginine JJ B-INTV
9.5 CD O
( ( O
0 CD O
to TO O
225 CD O
) ) O
, , O
and CC O
GSNO NNP B-INTV
0.8 NNP O
( ( O
0 CD O
to TO O
8 CD O
) ) O
, , O
both DT O
P NNP O
< VBD O
0.001 CD O
versus NN O
control NN O
values NNS O
. . O

The DT B-OC
reduction NN I-OC
in IN I-OC
the DT I-OC
signals NNS I-OC
persisted VBN O
at IN O
the DT O
24-hour JJ O
recording NN O
. . O

CONCLUSIONS NNP O
Intravenous NNP O
L-arginine NNP B-INTV
and CC O
GSNO NNP B-INTV
attenuate VBP B-OC
Doppler NNP I-OC
embolic JJ I-OC
signals NNS I-OC
in IN O
humans NNS O
. . O

Modulation NN O
of IN O
the DT O
NO NNP O
system NN O
with IN O
these DT O
agents NNS O
may MD O
have VB O
applications NNS O
in IN O
the DT O
treatment NN O
of IN O
thromboembolic JJ B-POPU
disease NN I-POPU
. . O

This DT O
study NN O
demonstrates VBZ O
the DT O
potential JJ O
application NN O
of IN O
ultrasonic JJ O
embolic JJ O
signal JJ O
detection NN O
to TO O
examine VB O
the DT O
efficacy NN O
of IN O
new JJ O
antiplatelet NN O
agents NNS O
in IN O
relatively RB B-POPU
small JJ I-POPU
numbers NNS I-POPU
of IN I-POPU
patients NNS I-POPU
. . O

-DOCSTART- -X- O O

Carvedilol NNP B-INTV
increases VBZ O
plasma JJ B-OC
vascular JJ I-OC
endothelial JJ I-OC
growth NN I-OC
factor NN I-OC
( ( I-OC
VEGF NNP I-OC
) ) I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
ischaemic JJ B-INTV
preconditioning NN I-INTV
, , I-INTV
cardiopulmonary JJ I-INTV
bypass NN I-INTV
and CC I-INTV
myocardial JJ I-INTV
ischaemic/reperfusion NN I-INTV
on IN O
free JJ B-OC
radical JJ I-OC
generation NN I-OC
in IN O
CABG NNP B-POPU
patients NNS I-POPU
. . O

OBJECTIVE NNP O
To TO O
investigate VB O
the DT O
free JJ O
radicals NNS O
( ( O
FR NNP O
) ) O
generation NN O
after IN O
ischaemic JJ B-INTV
preconditioning NN I-INTV
and CC O
cardiopulmonary JJ B-INTV
bypass NN I-INTV
and CC O
during IN O
reperfusion NN O
in IN O
CABG NNP B-POPU
patients NNS I-POPU
, , O
and CC O
the DT O
role NN O
of IN O
ischaemic JJ B-INTV
preconditioning NN I-INTV
. . O

METHODS NNP O
Forty-three JJ B-POPU
CABG NNP I-POPU
patients NNS I-POPU
were VBD O
randomised VBN O
into IN O
an DT O
ischaemic JJ B-INTV
preconditioning NN I-INTV
and CC O
a DT O
control NN B-INTV
group NN I-INTV
. . O

The DT O
protocol NN O
for IN O
ischaemic JJ B-INTV
preconditioning NN I-INTV
was VBD O
two CD B-INTV
cycles NNS I-INTV
of IN I-INTV
2-min JJ I-INTV
ischaemia NN I-INTV
followed VBN I-INTV
by IN I-INTV
3-min JJ I-INTV
reperfusion NN I-INTV
. . O

Free JJ B-OC
radicals NNS I-OC
were VBD O
measured VBN O
using VBG O
electron NN O
spin NN O
resonance NN O
spectroscopy NN O
. . O

Global NNP B-OC
and CC I-OC
right JJ I-OC
heart NN I-OC
functions NNS I-OC
were VBD O
collected VBN O
. . O

RESULTS VB O
The DT O
free JJ B-OC
radicals NNS I-OC
generation NN I-OC
in IN I-OC
coronary JJ I-OC
sinus NN I-OC
blood NN I-OC
in IN O
the DT O
ischaemic JJ B-INTV
preconditioning NN I-INTV
group NN O
was VBD O
9.7 CD O
and CC O
16.6 CD O
% NN O
after IN O
the DT O
ischaemic JJ B-INTV
preconditioning NN I-INTV
protocol NN O
and CC O
10 CD O
min NN O
after IN O
declamping VBG O
, , O
6.8 CD O
and CC O
13.3 CD O
% NN O
in IN O
the DT O
controls NNS O
. . O

The DT O
free JJ B-OC
radicals NNS I-OC
in IN I-OC
arterial JJ I-OC
samples NNS I-OC
were VBD O
, , O
respectively RB O
, , O
21 CD O
, , O
14 CD O
, , O
10 CD O
and CC O
9 CD O
% NN O
at IN O
10 CD O
min NN O
, , O
1 CD O
, , O
2 CD O
and CC O
24 CD O
h NN O
after IN O
reperfusion NN O
. . O

Cardiac NNP B-OC
index NN I-OC
( ( I-OC
CI NNP I-OC
) ) I-OC
and CC I-OC
right JJ I-OC
ventricular NN I-OC
ejection NN I-OC
fraction NN I-OC
( ( I-OC
RVEF NNP I-OC
) ) I-OC
were VBD O
improved VBN O
by IN O
ischaemic JJ B-INTV
preconditioning NN I-INTV
. . O

CONCLUSION NNP O
Both NNP O
ischaemic JJ B-INTV
preconditioning NN I-INTV
and CC O
cardiopulmonary JJ B-INTV
bypass NN I-INTV
induced VBD O
free JJ B-OC
radicals NNS I-OC
generation NN I-OC
. . O

Although IN O
ischaemic JJ B-INTV
preconditioning NN I-INTV
had VBD O
no DT O
effect NN O
on IN O
free JJ B-OC
radicals NNS I-OC
generation NN I-OC
after IN O
the DT O
operation NN O
, , O
it PRP O
protected VBD O
against IN O
postoperative JJ O
stunning NN O
. . O

-DOCSTART- -X- O O

Patient NN O
positioning VBG O
influences NNS O
oxygen JJ B-OC
saturation NN I-OC
in IN O
the DT O
acute JJ B-POPU
phase NN I-POPU
of IN I-POPU
stroke NN I-POPU
. . O

We PRP O
evaluated VBD O
arterial JJ B-OC
oxygen NN I-OC
saturation NN I-OC
( ( I-OC
SaO NNP I-OC
( ( I-OC
2 CD I-OC
) ) I-OC
) ) I-OC
and CC I-OC
heart NN I-OC
rate NN I-OC
in IN O
acute JJ B-POPU
stroke NN I-POPU
patients NNS I-POPU
to TO O
determine VB O
whether IN O
routine JJ O
positioning NN O
affected VBD O
these DT O
physiological JJ O
parameters NNS O
. . O

Measurements NNS O
were VBD O
recorded VBN O
at IN O
the DT O
bedside JJ O
non-invasively RB O
in IN O
five CD B-INTV
different JJ I-INTV
positions NNS I-INTV
assigned VBN O
in IN O
random JJ O
order NN O
each DT O
maintained VBD O
for IN O
10 CD O
min NN O
. . O

One CD B-POPU
hundred CD I-POPU
and CC I-POPU
twenty-nine JJ I-POPU
patients NNS I-POPU
examined VBD I-POPU
within IN I-POPU
a DT I-POPU
median NN I-POPU
of IN I-POPU
72 CD I-POPU
h NN I-POPU
, , I-POPU
lying VBG I-POPU
on IN I-POPU
the DT I-POPU
left JJ I-POPU
side NN I-POPU
resulted VBD I-POPU
in IN I-POPU
slightly RB I-POPU
lower JJR I-POPU
SaO NNP I-POPU
( ( I-POPU
2 CD I-POPU
) ) I-POPU
than IN I-POPU
lying VBG I-POPU
on IN I-POPU
the DT I-POPU
right JJ I-POPU
side NN I-POPU
, , I-POPU
which WDT I-POPU
was VBD I-POPU
statistically RB I-POPU
significant JJ I-POPU
in IN I-POPU
the DT I-POPU
patients NNS I-POPU
with IN I-POPU
a DT I-POPU
right NN I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
66 CD I-POPU
) ) I-POPU
, , I-POPU
but CC I-POPU
not RB I-POPU
left VBD I-POPU
, , I-POPU
hemiparesis NN I-POPU
. . O

Patients NNS O
able JJ O
to TO O
sit VB B-INTV
in IN I-INTV
a DT I-INTV
chair NN I-INTV
( ( O
n JJ O
= NNP O
65 CD O
) ) O
, , O
who WP O
mostly RB O
had VBD O
less RBR O
severe JJ O
strokes NNS O
, , O
had VBD O
a DT O
significantly RB O
higher JJR O
mean JJ B-OC
SaO NNP I-OC
( ( I-OC
2 CD I-OC
) ) I-OC
and CC I-OC
heart NN I-OC
rate NN I-OC
when WRB O
sitting VBG O
in IN O
the DT O
chair NN O
than IN O
when WRB O
placed VBN O
in IN O
any DT O
other JJ O
position NN O
. . O

About IN O
10 CD O
% NN O
of IN O
patients NNS O
, , O
especially RB O
those DT O
with IN O
a DT O
severe JJ O
stroke NN O
, , O
with IN O
right JJ O
hemiparesis NN O
and CC O
concomitant JJ O
chest NN O
disease NN O
, , O
experienced VBD O
falls NNS O
in IN O
SaO NNP B-OC
( ( I-OC
2 CD I-OC
) ) I-OC
to TO O
90 CD O
% NN O
or CC O
less JJR O
for IN O
> NN O
/=2 NNP O
min NN O
in IN O
certain JJ O
positions NNS O
; : O
the DT O
hypoxia NN B-OC
was VBD O
more RBR O
likely JJ O
when WRB O
they PRP O
were VBD O
lying VBG B-INTV
on IN I-INTV
their PRP$ I-INTV
left JJ I-INTV
side NN I-INTV
. . O

These DT O
results NNS O
may MD O
have VB O
implications NNS O
for IN O
current JJ O
practice NN O
and CC O
for IN O
future JJ O
patient JJ O
positioning VBG O
strategies NNS O
to TO O
improve VB O
outcome NN O
after IN O
stroke NN O
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
enoxaparin NN B-INTV
and CC I-INTV
standard JJ I-INTV
heparin NN I-INTV
in IN O
gynaecologic JJ B-POPU
oncologic JJ I-POPU
surgery NN I-POPU
: : I-POPU
a DT O
randomised JJ O
prospective JJ O
double-blind NN O
clinical JJ O
study NN O
. . O

OBJECTIVE NNP O
This DT O
study NN O
aimed VBD O
to TO O
compare VB O
the DT O
haemorrhagic JJ O
complications NNS O
and CC O
efficacy NN O
of IN O
enoxaparin NN B-INTV
, , O
a DT O
low JJ O
molecular JJ O
weight NN O
heparin NN O
( ( O
LMWH NNP O
) ) O
, , O
and CC O
conventional JJ O
standard NN B-INTV
heparin NN I-INTV
( ( I-INTV
SH NNP I-INTV
) ) I-INTV
in IN O
gynaecological JJ B-POPU
oncologic NN I-POPU
surgery NN I-POPU
. . O

MATERIALS NNP O
METHODS NNP O
A NNP O
double JJ O
blind NN O
, , O
randomised VBD O
trial NN O
was VBD O
performed VBN O
on IN O
102 CD B-POPU
consecutive JJ I-POPU
women NNS I-POPU
undergoing VBG I-POPU
gynaecologic JJ I-POPU
cancer NN I-POPU
surgery NN I-POPU
with IN I-POPU
pelvic NN I-POPU
and CC I-POPU
paraaortic JJ I-POPU
lymphadenectomy NN I-POPU
. . O

The DT O
women NNS O
were VBD O
separated VBN O
into IN O
those DT O
who WP O
were VBD O
given VBN O
2,500 CD B-INTV
IU NNP I-INTV
enoxaparin NN I-INTV
once RB I-INTV
daily JJ I-INTV
and CC I-INTV
SH NNP I-INTV
in IN I-INTV
a DT I-INTV
dose NN I-INTV
of IN I-INTV
5,000 CD I-INTV
IU NNP I-INTV
three CD I-INTV
times NNS I-INTV
daily RB I-INTV
. . O

The DT O
groups NNS O
were VBD O
analysed VBN O
for IN O
intraoperative JJ O
blood NN O
loss NN O
, , O
drainage NN O
, , O
transfusion NN O
requirements NNS O
, , O
perioperative JJ O
haemoglobin NN O
decrease NN O
, , O
wound NN O
haematoma NN O
, , O
and CC O
clinical JJ O
deep NN O
venous JJ O
thrombosis NN O
. . O

RESULTS VB O
The DT B-POPU
two CD I-POPU
groups NNS I-POPU
were VBD I-POPU
well RB I-POPU
matched VBN I-POPU
for IN I-POPU
age NN I-POPU
, , I-POPU
weight NN I-POPU
, , I-POPU
and CC I-POPU
other JJ I-POPU
factors NNS I-POPU
, , O
which WDT O
could MD O
predispose VB O
to TO O
the DT O
development NN B-OC
of IN I-OC
deep JJ I-OC
venous JJ I-OC
thrombosis NN I-OC
( ( I-OC
DVT NNP I-OC
) ) I-OC
and CC I-OC
haemorrhage NN I-OC
. . O

No DT O
patient NN O
developed VBD O
clinical JJ B-OC
significant JJ I-OC
DVT NNP I-OC
, , I-OC
wound NN I-OC
haematoma NN I-OC
or CC I-OC
intra-abdominal JJ I-OC
bleeding NN I-OC
. . O

There EX O
was VBD O
no DT O
significant JJ O
difference NN O
in IN O
bleeding VBG B-OC
complications NNS I-OC
between IN O
the DT O
two CD O
regimens NNS O
. . O

The DT O
antiFXa JJ B-OC
level NN I-OC
in IN O
the DT O
plasma NN O
was VBD O
correlated VBN O
strongly RB O
with IN O
patient JJ O
weight NN O
. . O

CONCLUSIONS VB O
A NNP O
dose NN O
of IN O
2,500 CD O
IU NNP O
enoxaparin/day NN B-INTV
does VBZ O
not RB O
cause VB O
more RBR O
bleeding JJ O
complications NNS O
than IN O
SH NNP O
5,000 CD O
IU NNP O
three CD O
times NNS O
daily RB O
when WRB O
used VBN O
to TO O
prevent VB O
thrombosis NN O
. . O

However RB O
, , O
the DT O
dose NN O
of IN O
enoxaparin NN O
must MD O
be VB O
adjusted VBN O
to TO O
the DT O
patient NN O
's POS O
weight NN O
. . O

-DOCSTART- -X- O O

Acute NNP B-OC
hemodynamic JJ I-OC
effects NNS I-OC
of IN O
conivaptan NN B-INTV
, , O
a DT O
dual JJ O
V NNP O
( ( O
1A CD O
) ) O
and CC O
V NNP O
( ( O
2 CD O
) ) O
vasopressin NN O
receptor NN O
antagonist NN O
, , O
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

BACKGROUND NNP O
Arginine NNP O
vasopressin NN O
may MD O
contribute VB O
to TO O
abnormalities NNS B-OC
in IN I-OC
hemodynamics NNS I-OC
and CC I-OC
fluid JJ I-OC
balance NN I-OC
in IN O
heart NN O
failure NN O
through IN O
its PRP$ O
actions NNS O
on IN O
V NNP B-OC
( ( I-OC
1A CD I-OC
) ) I-OC
( ( I-OC
vascular JJ I-OC
and CC I-OC
myocardial JJ I-OC
effects NNS I-OC
) ) I-OC
and CC I-OC
V NNP I-OC
( ( I-OC
2 CD I-OC
) ) I-OC
receptors NNS I-OC
( ( I-OC
renal JJ I-OC
effects NNS I-OC
) ) I-OC
. . O

Inhibiting VBG O
the DT O
action NN O
of IN O
vasopressin NN O
may MD O
be VB O
beneficial JJ O
in IN O
patients NNS B-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

METHODS NNP O
AND NNP O
RESULTS NNP O
A NNP O
total NN O
of IN O
142 CD B-POPU
patients NNS I-POPU
with IN I-POPU
symptomatic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
( ( I-POPU
New NNP I-POPU
York NNP I-POPU
Heart NNP I-POPU
Association NNP I-POPU
class NN I-POPU
III NNP I-POPU
and CC I-POPU
IV NNP I-POPU
) ) I-POPU
were VBD O
randomized VBN O
to TO O
double-blind VB O
, , O
short-term JJ O
treatment NN O
with IN O
conivaptan NN B-INTV
, , O
a DT O
dual JJ O
V NNP O
( ( O
1a CD O
) ) O
/V NN O
( ( O
2 CD O
) ) O
vasopressin NN B-INTV
receptor NN O
antagonist NN O
, , O
at IN O
a DT O
single JJ O
intravenous JJ O
dose NN O
( ( O
10 CD O
, , O
20 CD O
, , O
or CC O
40 CD O
mg NN O
) ) O
or CC O
placebo NN B-INTV
. . O

Compared VBN O
with IN O
placebo NN O
, , O
conivaptan NN O
at IN O
20 CD O
and CC O
40 CD O
mg NN O
significantly RB O
reduced VBD O
pulmonary JJ B-OC
capillary JJ I-OC
wedge NN I-OC
pressure NN I-OC
( ( O
-2.6+/-0.7 UH O
, , O
-5.4+/-0.7 NNP O
, , O
and CC O
-4.6+/-0.7 NNP O
mm VBP O
Hg NNP O
for IN O
placebo NN O
and CC O
20 CD O
and CC O
40 CD O
mg NN O
groups NNS O
, , O
respectively RB O
; : O
P NNP O
< NNP O
0.05 CD O
) ) O
and CC O
right JJ B-OC
atrial JJ I-OC
pressure NN I-OC
( ( O
-2.0+/-0.4 UH O
, , O
-3.7+/-0.4 NNP O
, , O
and CC O
-3.5+/-0.4 NNP O
mm VBP O
Hg NNP O
for IN O
placebo NN O
and CC O
20 CD O
and CC O
40 CD O
mg NN O
groups NNS O
, , O
respectively RB O
; : O
P NNP O
< NNP O
0.05 CD O
) ) O
during IN O
the DT O
3- JJ O
to TO O
6-hour JJ O
interval NN O
after IN O
intravenous JJ O
administration NN O
. . O

Conivaptan NNP B-INTV
significantly RB O
increased VBD O
urine JJ B-OC
output NN I-OC
in IN O
a DT O
dose-dependent JJ O
manner NN O
( ( O
-11+/-17 JJ O
, , O
68+/-17 JJ O
, , O
152+/-19 JJ O
, , O
and CC O
176+/-18 JJ O
mL/hour NN O
for IN O
placebo NN O
and CC O
10 CD O
, , O
20 CD O
, , O
and CC O
40 CD O
mg NN O
groups NNS O
, , O
respectively RB O
; : O
P NNP O
< NNP O
0.001 CD O
) ) O
during IN O
the DT O
first JJ O
4 CD O
hours NNS O
after IN O
the DT O
dose NN O
. . O

Changes NNS O
in IN O
cardiac JJ B-OC
index NN I-OC
, , I-OC
systemic JJ I-OC
and CC I-OC
pulmonary JJ I-OC
vascular NN I-OC
resistance NN I-OC
, , I-OC
blood NN I-OC
pressure NN I-OC
, , I-OC
and CC I-OC
heart NN I-OC
rate NN I-OC
did VBD O
not RB O
significantly RB O
differ VBP O
from IN O
placebo NN O
. . O

CONCLUSIONS NNP O
In IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
heart NN I-POPU
failure NN I-POPU
, , O
vasopressin NN O
receptor NN O
antagonism NN O
with IN O
conivaptan NN B-INTV
resulted VBN O
in IN O
favorable JJ O
changes NNS O
in IN O
hemodynamics NNS B-OC
and CC I-OC
urine JJ I-OC
output NN I-OC
without IN O
affecting VBG O
blood NN B-OC
pressure NN I-OC
or CC I-OC
heart NN I-OC
rate NN I-OC
. . O

These DT O
data NNS O
suggest VBP O
that IN O
vasopressin NN O
is VBZ O
functionally RB O
significant JJ O
in IN O
advanced JJ O
heart NN O
failure NN O
and CC O
that IN O
further JJ O
investigations NNS O
are VBP O
warranted VBN O
to TO O
examine VB O
the DT O
effects NNS O
of IN O
conivaptan NN O
on IN O
symptom JJ O
relief NN O
and CC O
natural JJ O
history NN O
in IN O
such JJ O
patients NNS O
. . O

-DOCSTART- -X- O O

Liposome-encapsulated JJ B-INTV
doxorubicin NNS I-INTV
compared VBN O
with IN O
conventional JJ B-INTV
doxorubicin NN I-INTV
in IN O
a DT O
randomized JJ O
multicenter NN O
trial NN O
as IN O
first-line JJ O
therapy NN O
of IN O
metastatic JJ B-POPU
breast NN I-POPU
carcinoma NN I-POPU
. . O

BACKGROUND IN O
The DT O
objective NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
compare VB O
the DT O
efficacy NN O
and CC O
toxicity NN O
of IN O
the DT O
liposome-encapsulated JJ B-INTV
doxorubicin NN I-INTV
, , I-INTV
TLC NNP I-INTV
D-99 NNP I-INTV
( ( I-INTV
Myocet NNP I-INTV
, , I-INTV
Elan NNP I-INTV
Pharmaceuticals NNP I-INTV
, , I-INTV
Princeton NNP I-INTV
, , I-INTV
NJ NNP I-INTV
) ) I-INTV
, , O
and CC O
conventional JJ B-INTV
doxorubicin NN I-INTV
in IN O
first-line JJ O
treatment NN O
of IN O
metastatic JJ O
breast NN O
carcinoma NN O
( ( O
MBC NNP O
) ) O
. . O

METHODS NNP O
Two CD B-POPU
hundred VBD I-POPU
twenty-four JJ I-POPU
patients NNS I-POPU
with IN I-POPU
MBC NNP I-POPU
and CC I-POPU
no DT I-POPU
prior JJ I-POPU
therapy NN I-POPU
for IN I-POPU
metastatic JJ I-POPU
disease NN I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
either DT O
TLC NNP B-INTV
D-99 NNP I-INTV
( ( I-INTV
75 CD I-INTV
mg/m NN I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
) ) I-INTV
or CC I-INTV
doxorubicin NN I-INTV
( ( O
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
every DT O
3 CD O
weeks NNS O
, , O
in IN O
the DT O
absence NN O
of IN O
disease NN O
progression NN O
or CC O
unacceptable JJ O
toxicity NN O
. . O

The DT O
primary JJ O
efficacy NN O
endpoint NN O
was VBD O
response NN O
rate NN O
. . O

Responses NNS O
were VBD O
assessed VBN O
using VBG O
World NNP O
Health NNP O
Organization NNP O
criteria NNS O
and CC O
were VBD O
required VBN O
to TO O
be VB O
of IN O
at IN O
least JJS O
6 CD O
weeks NNS O
' POS O
duration NN O
. . O

The DT O
primary JJ O
safety NN O
endpoint NN O
was VBD O
cardiotoxicity NN O
. . O

Cardiac NNP O
function NN O
was VBD O
monitored VBN O
by IN O
multiple-gated JJ B-INTV
radionuclide NN I-INTV
cardioangiography NN I-INTV
scan JJ I-INTV
, , O
and CC O
the DT O
left JJ O
ventricular JJ O
ejection NN O
fraction NN O
( ( O
LVEF NNP O
) ) O
was VBD O
scored VBN O
at IN O
a DT O
central JJ O
laboratory NN O
. . O

Patients NNS B-POPU
were VBD I-POPU
removed VBN I-POPU
from IN I-POPU
study NN I-POPU
if IN I-POPU
LVEF NNP I-POPU
declined VBD I-POPU
20 CD I-POPU
or CC I-POPU
more JJR I-POPU
EF JJ I-POPU
units NNS I-POPU
from IN I-POPU
baseline NN I-POPU
to TO I-POPU
a DT I-POPU
final JJ I-POPU
value NN I-POPU
of IN I-POPU
greater JJR I-POPU
than IN I-POPU
or CC I-POPU
equal JJ I-POPU
to TO I-POPU
50 CD I-POPU
% NN I-POPU
, , I-POPU
or CC I-POPU
by IN I-POPU
10 CD I-POPU
or CC I-POPU
more JJR I-POPU
units NNS I-POPU
to TO I-POPU
a DT I-POPU
final JJ I-POPU
value NN I-POPU
of IN I-POPU
less JJR I-POPU
than IN I-POPU
50 CD I-POPU
% NN I-POPU
, , I-POPU
or CC I-POPU
onset NN I-POPU
of IN I-POPU
clinical JJ I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
( ( I-POPU
CHF NNP I-POPU
) ) I-POPU
. . O

RESULTS NNP O
Median JJ B-POPU
age NN I-POPU
was VBD I-POPU
54 CD I-POPU
years NNS I-POPU
in IN I-POPU
both DT I-POPU
treatment NN I-POPU
groups NNS I-POPU
. . O

All DT O
relevant JJ O
prognostic JJ O
factors NNS O
were VBD O
balanced VBN O
, , O
with IN O
the DT O
exception NN O
that IN O
there EX O
were VBD O
significantly RB O
more JJR O
progesterone JJ O
receptor NN O
positive JJ O
patients NNS O
in IN O
the DT O
doxorubicin-treated JJ B-INTV
group NN O
. . O

Protocol-defined JJ B-OC
cardiotoxicity NN I-OC
was VBD O
observed VBN O
in IN O
13 CD O
% NN O
of IN O
TLC NNP O
D-99 NNP O
patients NNS O
( ( O
including VBG O
2 CD O
cases NNS O
of IN O
CHF NNP O
) ) O
compared VBN O
to TO O
29 CD O
% NN O
of IN O
doxorubicin NN B-INTV
patients NNS O
( ( O
including VBG O
9 CD O
cases NNS O
of IN O
CHF NNP O
) ) O
. . O

Median JJ B-OC
cumulative JJ I-OC
doxorubicin NN B-INTV
dose NN B-OC
at IN I-OC
onset NN I-OC
of IN I-OC
cardiotoxicity NN I-OC
was VBD O
785 CD O
mg/m NN O
( ( O
2 CD O
) ) O
for IN O
TLC NNP B-INTV
D-99 NNP I-INTV
versus NN O
570 CD O
mg/m NN O
( ( O
2 CD O
) ) O
for IN O
doxorubicin NN B-INTV
( ( O
P NNP O
= NNP O
0.0001 CD O
; : O
hazard NN O
ratio NN O
, , O
3.56 CD O
) ) O
. . O

The DT O
overall JJ B-OC
response NN I-OC
rate NN I-OC
was VBD O
26 CD O
% NN O
in IN O
both DT O
treatment NN O
groups NNS O
. . O

The DT O
median JJ B-OC
TTP NNP I-OC
was VBD O
2.9 CD O
months NNS O
on IN O
TLC NNP O
D-99 NNP O
versus NN O
3.1 CD O
months NNS O
on IN O
doxorubicin NN B-INTV
. . O

Median JJ B-OC
survival NN I-OC
was VBD O
16 CD O
versus NN O
20 CD O
months NNS O
with IN O
a DT O
nonsignificant JJ O
trend NN O
in IN O
favor NN O
of IN O
doxorubicin NN B-INTV
( ( O
P NNP O
= NNP O
0.09 CD O
) ) O
. . O

Clinical JJ B-OC
toxicities NNS I-OC
, , O
commonly RB O
associated VBN O
with IN O
doxorubicin NN O
, , O
appeared VBD O
less RBR O
common JJ O
with IN O
TLC NNP O
D-99 NNP O
, , O
although IN O
the DT O
difference NN O
was VBD O
not RB O
statistically RB O
significant JJ O
. . O

There EX O
was VBD O
only RB O
one CD O
report NN O
of IN O
palmar-plantar JJ B-OC
erythrodysesthesia NN I-OC
( ( O
Grade NNP O
2 CD O
) ) O
with IN O
this DT O
liposomal JJ O
formulation NN O
of IN O
doxorubicin NN B-INTV
. . O

CONCLUSIONS NNP O
Single-agent JJ O
TLC NNP B-INTV
D-99 NNP I-INTV
produces VBZ O
less JJR O
cardiotoxicity NN O
than IN O
doxorubicin NNS B-INTV
, , O
while IN O
providing VBG O
comparable JJ O
antitumor NN O
activity NN O
. . O

-DOCSTART- -X- O O

Regional JJ B-INTV
ischemic JJ I-INTV
preconditioning NN I-INTV
enhances NNS O
myocardial JJ B-OC
performance NN O
in IN O
off-pump JJ O
coronary JJ O
artery NN B-POPU
bypass NN I-POPU
grafting NN I-POPU
. . O

OBJECTIVES IN O
We PRP O
intended VBD O
to TO O
investigate VB O
whether IN O
ischemic JJ O
preconditioning NN O
( ( O
IP NNP O
) ) O
enhances VBZ O
myocardial JJ B-OC
performance NN O
in IN O
patients NNS B-POPU
who WP I-POPU
undergo VBP I-POPU
off-pump JJ I-POPU
coronary JJ I-POPU
artery NN I-POPU
bypass NN I-POPU
grafting NN I-POPU
( ( I-POPU
CABG NNP I-POPU
) ) I-POPU
. . O

DESIGN VB O
A DT O
controlled VBN O
, , O
randomized VBN O
, , O
prospective JJ O
study NN O
. . O

SETTING VB O
A DT O
university NN O
hospital NN O
. . O

PATIENTS VB O
Thirty-two JJ B-POPU
patients NNS I-POPU
with IN I-POPU
left JJ I-POPU
anterior JJ I-POPU
descending VBG I-POPU
coronary JJ I-POPU
artery NN I-POPU
( ( I-POPU
LAD NNP I-POPU
) ) I-POPU
or CC I-POPU
two-vessel JJ I-POPU
heart NN I-POPU
disease NN I-POPU
( ( I-POPU
including VBG I-POPU
LAD NNP I-POPU
) ) I-POPU
who WP I-POPU
were VBD I-POPU
to TO I-POPU
undergo VB I-POPU
off-pump JJ I-POPU
CABG NNP I-POPU
were VBD O
randomized VBN O
into IN O
an DT O
IP NNP O
group NN O
and CC O
a DT O
control NN O
group NN O
. . O

INTERVENTIONS NNP O
IP NNP O
was VBD O
induced VBN O
by IN O
occluding VBG B-INTV
the DT I-INTV
LAD NNP I-INTV
twice NN I-INTV
for IN I-INTV
a DT I-INTV
2-min JJ I-INTV
period NN I-INTV
followed VBN I-INTV
by IN I-INTV
3-min JJ I-INTV
LAD NNP I-INTV
reperfusion NN I-INTV
before IN I-INTV
bypass NN I-INTV
grafting NN I-INTV
of IN I-INTV
the DT I-INTV
first JJ I-INTV
coronary JJ I-INTV
vessel NN I-INTV
. . O

MEASUREMENTS NNP O
AND CC O
RESULTS NNP O
Registration NNP O
included VBD O
hemodynamic JJ O
data NNS O
from IN O
the DT O
peripheral JJ O
artery NN O
and CC O
the DT O
pulmonary JJ O
artery NN O
, , O
and CC O
the DT O
measurement NN O
of IN O
cardiac JJ B-OC
troponin NN I-OC
I PRP I-OC
( ( I-OC
CTnI NNP I-OC
) ) I-OC
and CC I-OC
creatine JJ I-OC
kinase NN I-OC
isoenzyme NN I-OC
MB NNP I-OC
( ( I-OC
CK-MB NNP I-OC
) ) I-OC
values NNS I-OC
. . O

IP NNP O
resulted VBD O
in IN O
a DT O
complete JJ O
recovery NN B-OC
of IN I-OC
the DT I-OC
mean JJ I-OC
stroke NN I-OC
volume NN I-OC
index NN I-OC
( ( I-OC
SVI NNP I-OC
) ) I-OC
after IN O
the DT O
operation NN O
. . O

In IN O
the DT O
control NN O
subjects VBZ O
, , O
the DT O
mean NN B-OC
SVI NNP I-OC
showed VBD O
a DT O
significant JJ B-OC
reduction NN I-OC
postoperatively RB O
( ( O
p JJ O
= NNP O
0.039 CD O
) ) O
. . O

On IN O
the DT O
first JJ O
postoperative JJ O
day NN O
, , O
the DT O
increase NN O
in IN O
the DT O
mean JJ B-OC
heart NN I-OC
rate NN I-OC
( ( I-OC
HR NNP I-OC
) ) I-OC
was VBD O
also RB O
significantly RB O
lower JJR O
in IN O
the DT O
IP NNP O
patients NNS O
. . O

The DT O
CTnI NNP B-OC
level NN I-OC
was VBD O
statistically RB O
significantly RB B-OC
lower JJR I-OC
in IN O
the DT O
IP NNP O
group NN O
( ( O
p JJ O
= NNP O
0.043 CD O
) ) O
, , O
and CC O
IP NNP O
patients NNS O
tended VBD O
to TO O
have VB O
a DT O
smaller JJR O
CK-MB JJ B-OC
release NN I-OC
after IN O
surgery NN O
( ( O
not RB O
significant JJ O
) ) O
. . O

The DT O
duration NN B-OC
of IN I-OC
mechanical JJ I-OC
ventilation NN I-OC
, , I-OC
the DT I-OC
length NN I-OC
of IN I-OC
stay NN I-OC
in IN O
the DT O
ICU NNP B-OC
, , O
and CC O
the DT O
use NN B-OC
of IN I-OC
inotropic JJ I-OC
medication NN I-OC
did VBD O
not RB O
increase VB O
after IN O
the DT O
IP NNP O
protocol NN O
. . O

CONCLUSIONS NNP O
Two CD O
cycles NNS O
of IN O
regional JJ O
2-min JJ O
IP NNP O
in IN O
the DT O
LAD NNP O
, , O
followed VBN O
by IN O
3 CD O
min NN O
of IN O
reperfusion NN O
, , O
proved VBD O
to TO O
be VB O
applicable JJ O
and CC O
safe JJ O
in IN O
patients NNS B-POPU
undergoing VBG I-POPU
off-pump JJ I-POPU
myocardial JJ I-POPU
revascularization NN I-POPU
, , O
it PRP O
tended VBD O
to TO O
decrease VB O
the DT O
immediate JJ O
myocardial JJ B-OC
enzyme NN I-OC
release NN O
, , O
it PRP O
prohibited VBD O
the DT O
postoperative JJ O
increase NN O
in IN O
HR NNP B-OC
, , O
and CC O
it PRP O
enhanced VBD O
the DT O
recovery NN O
of IN O
SVI NNP B-OC
. . O

-DOCSTART- -X- O O

Diet NNP B-INTV
and CC O
tobacco NN O
use NN O
: : O
analysis NN O
of IN O
data NNS O
from IN O
the DT O
diabetic JJ O
control NN O
and CC O
complications NNS O
trial NN O
, , O
a DT O
randomized VBN O
study NN O
. . O

CONTEXT NNP O
The DT O
Diabetic NNP O
Control NNP O
and CC O
Complications NNP O
Trial NNP O
( ( O
DCCT NNP O
) ) O
researchers NNS O
kept VBD O
careful JJ O
records NNS O
of IN O
the DT O
food NN O
consumption NN O
and CC O
tobacco NN O
using VBG O
habits NNS O
of IN B-POPU
type NN I-POPU
1 CD I-POPU
diabetic JJ I-POPU
subjects NNS I-POPU
. . O

However RB O
, , O
they PRP O
did VBD O
not RB O
report VB O
the DT O
relationship NN O
of IN O
tobacco NN B-OC
using VBG I-OC
habits NNS I-OC
with IN O
dietary JJ B-OC
intake NN I-OC
. . O

OBJECTIVE NNP O
Analyze NNP O
the DT O
relationship NN B-OC
between IN I-OC
tobacco NN I-OC
smoking NN I-OC
and CC I-OC
intake NN B-INTV
of IN I-INTV
macro NN I-INTV
and CC I-INTV
micronutrients NNS I-INTV
. . O

DESIGN NNP O
Randomized NNP O
controlled VBD O
trial NN O
. . O

SETTING NNP O
Referral JJ B-POPU
clinics NNS I-POPU
in IN I-POPU
27 CD I-POPU
academic JJ I-POPU
centers NNS I-POPU
. . O

PATIENTS NNP B-POPU
Type NNP I-POPU
1 CD I-POPU
diabetics NNS I-POPU
. . O

INTERVENTION NNP O
Using VBG O
the DT O
data NNS B-INTV
sets NNS I-INTV
of IN I-INTV
the DT I-INTV
DCCT NNP I-INTV
, , O
this DT O
study NN O
analyzed VBD O
the DT O
strengths NNS O
of IN O
the DT O
associations NNS B-OC
between IN I-OC
smoking NN I-OC
and CC I-OC
macronutrient NN B-INTV
consumption NN I-INTV
, , B-OC
hemoglobin NN I-OC
A1c NNP I-OC
( ( I-OC
HbA1c NNP I-OC
) ) I-OC
, , I-OC
body JJ I-OC
mass NN I-OC
index NN I-OC
( ( I-OC
BMI NNP I-OC
) ) I-OC
, , I-OC
and CC I-OC
serum VB I-OC
lipid JJ I-OC
levels NNS I-OC
at IN O
the DT O
study NN O
baseline NN O
, , O
2 CD O
years NNS O
, , O
and CC O
4 CD O
years NNS O
. . O

MAIN NNP O
OUTCOME NNP O
MEASURES NNP O
Statistically NNP B-OC
significant JJ I-OC
correlations NNS I-OC
between IN I-OC
smoking NN I-OC
and CC I-OC
nutrient JJ I-OC
intake NN I-OC
, , I-OC
HbA1c NNP I-OC
, , I-OC
and CC I-OC
serum VB I-OC
lipid JJ I-OC
levels NNS I-OC
. . O

RESULTS NNP O
Cigarette NNP B-OC
, , I-OC
cigar NN I-OC
, , I-OC
or CC I-OC
pipe NN I-OC
use NN I-OC
at IN O
each DT O
time NN O
interval NN O
correlated VBD O
with IN O
significantly RB O
increased VBN O
caloric JJ B-OC
intake NN I-OC
in IN O
males NNS O
but CC O
not RB O
in IN O
females NNS O
. . O

In IN O
both DT O
males NNS B-POPU
and CC I-POPU
females NNS I-POPU
, , I-POPU
tobacco NN I-POPU
users NNS I-POPU
consumed VBD B-OC
more RBR I-OC
fat JJ I-OC
, , I-OC
cholesterol NN I-OC
, , I-OC
and CC I-OC
alcohol NN I-OC
. . O

Female JJ B-POPU
smokers NNS I-POPU
had VBD O
higher JJR O
serum JJ B-OC
low-density NN I-OC
lipoprotein NN I-OC
( ( I-OC
LDL NNP I-OC
) ) I-OC
/high-density NN I-OC
lipoprotein NN I-OC
( ( I-OC
HDL NNP I-OC
) ) I-OC
ratios NNS I-OC
and CC I-OC
triglycerides NNS I-OC
. . O

Serum NNP B-OC
cholesterols NNS I-OC
, , I-OC
LDL/HDL NNP I-OC
ratios NNS I-OC
, , I-OC
LDL NNP I-OC
cholesterols VBZ I-OC
, , I-OC
and CC I-OC
triglyceride JJ I-OC
determinations NNS I-OC
in IN O
male JJ B-POPU
tobacco NN I-POPU
users NNS I-POPU
significantly RB O
exceeded VBD O
those DT O
in IN O
nonsmoking JJ O
males NNS O
. . O

HDL NNP B-OC
cholesterols NNS I-OC
were VBD O
lower JJR O
in IN O
both DT O
female JJ B-POPU
and CC I-POPU
male JJ I-POPU
tobacco NN I-POPU
users NNS I-POPU
. . O

Nutrient NNP B-OC
intake NN I-OC
of IN O
former JJ B-POPU
tobacco NN I-POPU
users NNS I-POPU
resembled VBD O
that IN O
of IN O
nonusers NNS O
rather RB O
than IN O
current JJ O
users NNS O
. . O

CONCLUSIONS VB O
A NNP O
significant JJ O
association NN O
exists NNS O
between IN O
smoking NN O
and CC O
a DT O
diet JJ B-OC
with IN I-OC
higher JJR I-OC
risks NNS I-OC
of IN I-OC
atherosclerosis NN I-OC
, , I-OC
cancer NN I-OC
, , I-OC
and CC I-OC
other JJ I-OC
degenerative JJ I-OC
diseases NNS I-OC
. . O

The DT O
strong JJ O
association NN O
of IN O
tobacco NN O
with IN O
heart NN O
disease NN O
, , O
stroke NN O
, , O
vasculopathies NNS O
, , O
and CC O
various JJ O
malignancies NNS O
may MD O
be VB O
in IN O
part NN O
due JJ O
to TO O
its PRP$ O
association NN O
with IN O
a DT O
higher JJR O
fat JJ B-OC
diet NN O
. . O

The DT O
higher JJR O
fat JJ O
diet NNS O
of IN O
tobacco NN O
users NNS O
probably RB O
accounts NNS O
in IN O
part NN O
for IN O
their PRP$ O
higher JJR O
risk NN O
of IN O
developing VBG O
type JJ O
2 CD O
diabetes NNS O
and CC O
hyperlipidemia NN O
. . O

Tobacco NN O
users NNS O
should MD O
be VB O
informed VBN O
about IN O
the DT O
diet JJ B-OC
and CC I-OC
tobacco NN I-OC
use NN I-OC
association NN O
. . O

-DOCSTART- -X- O O

Treatment NN O
of IN O
acute JJ O
ischaemic JJ O
stroke NN O
with IN O
the DT O
low-affinity NN O
, , O
use-dependent JJ O
NMDA NNP B-INTV
antagonist NN I-INTV
AR-R15896AR NNP I-INTV
. . O

A NNP O
safety NN B-OC
and CC I-OC
tolerability NN I-OC
study NN O
. . O

BACKGROUND NNP O
AND NNP O
PURPOSE NNP O
A NNP O
low-affinity NN O
, , O
use-dependent JJ O
N-Methyl-D-Aspartate NNP B-INTV
( ( I-INTV
NMDA NNP I-INTV
) ) I-INTV
antagonist NN I-INTV
AR-R15896AR NNP I-INTV
has VBZ O
neuroprotective JJ O
properties NNS O
in IN O
animal JJ B-POPU
models NNS I-POPU
of IN I-POPU
ischaemic JJ I-POPU
stroke NN I-POPU
. . O

The DT O
aim NN O
of IN O
the DT O
present JJ O
study NN O
was VBD O
to TO O
examine VB O
the DT O
safety NN O
and CC O
tolerability NN O
of IN O
a DT O
new JJ O
and CC O
higher JJR O
dosage NN O
regimen NNS O
that WDT O
would MD O
enable VB O
acute JJ B-POPU
stroke NN I-POPU
patients NNS I-POPU
to TO O
achieve VB O
and CC O
maintain VB O
neuroprotective JJ O
plasma NN O
concentrations NNS O
. . O

METHODS NNP O
A DT O
randomised JJ O
, , O
multi-centre JJ O
, , O
double-blind JJ O
, , O
placebo-controlled JJ B-INTV
, , O
parallel JJ O
group NN O
study NN O
was VBD O
carried VBN O
out RP O
at IN O
19 CD B-POPU
centres NNS I-POPU
in IN I-POPU
France NNP I-POPU
, , I-POPU
Germany NNP I-POPU
and CC I-POPU
the DT I-POPU
Netherlands NNP I-POPU
in IN I-POPU
patients NNS I-POPU
with IN I-POPU
a DT I-POPU
clinical JJ I-POPU
diagnosis NN I-POPU
of IN I-POPU
acute JJ I-POPU
ischaemic JJ I-POPU
stroke NN I-POPU
, , I-POPU
and CC I-POPU
onset NN I-POPU
of IN I-POPU
symptoms NNS I-POPU
within IN I-POPU
12 CD I-POPU
hours NNS I-POPU
before IN I-POPU
start NN I-POPU
of IN I-POPU
study JJ I-POPU
drug NN I-POPU
administration NN I-POPU
. . O

Two CD B-INTV
loading VBG I-INTV
doses NNS I-INTV
of IN I-INTV
3.5 CD I-INTV
mg/kg NNS I-INTV
of IN I-INTV
AR-R15896AR NNP I-INTV
over IN O
60 CD O
minutes NNS O
, , O
followed VBN O
by IN O
a DT O
2.5 CD O
mg/kg NN O
infusion NN O
over IN O
the DT O
next JJ O
120 CD O
minutes NNS O
were VBD O
given VBN O
. . O

Eight NNP O
hours NNS O
after IN O
the DT O
start NN O
of IN O
the DT O
loading VBG O
dose JJ O
infusion NN O
, , O
the DT O
first JJ O
maintenance NN O
dose NN O
( ( O
120 CD O
mg NN O
) ) O
was VBD O
administered VBN O
over IN O
60 CD O
minutes NNS O
. . O

Eight NNP O
further JJ O
maintenance NN O
infusions NNS O
were VBD O
administered VBN O
at IN O
intervals NNS O
of IN O
8 CD O
hours NNS O
over IN O
a DT O
total JJ O
treatment NN O
period NN O
of IN O
3 CD O
days NNS O
. . O

Main JJ O
variables NNS O
were VBD O
safety NN B-OC
, , I-OC
tolerability NN I-OC
and CC I-OC
pharmacokinetics NNS I-OC
. . O

Follow-up JJ O
assessments NNS O
also RB O
included VBD O
the DT O
Barthel NNP B-OC
Index NNP I-OC
( ( I-OC
BI NNP I-OC
) ) I-OC
and CC O
the DT O
NIH NNP B-OC
Stroke NNP I-OC
Scale NNP I-OC
( ( I-OC
NIHSS NNP I-OC
) ) I-OC
at IN O
4-7 JJ O
days NNS O
after IN O
the DT O
end NN O
of IN O
the DT O
last JJ O
infusion NN O
and CC O
at IN O
30 CD O
days NNS O
after IN O
the DT O
onset NN O
of IN O
stroke NN O
. . O

RESULTS CC O
103 CD B-POPU
patients NNS I-POPU
with IN I-POPU
acute JJ I-POPU
ischaemic JJ I-POPU
stroke NN I-POPU
were VBD I-POPU
randomised VBN I-POPU
to TO O
either DT O
treatment NN O
with IN O
AR-R15896AR NNP B-INTV
( ( O
70 CD O
patients NNS O
) ) O
or CC O
placebo NN B-INTV
( ( O
33 CD O
patients NNS O
) ) O
. . O

Mortality NNP B-OC
was VBD O
not RB O
significantly RB O
different JJ O
in IN O
the DT O
AR-R15896AR NNP B-INTV
group NN O
compared VBN O
with IN O
the DT O
placebo NN B-INTV
group NN O
( ( O
10 CD O
% NN O
vs. FW O
6 CD O
% NN O
) ) O
. . O

Serious JJ B-OC
adverse JJ I-OC
events NNS I-OC
during IN O
treatment NN O
due JJ O
to TO O
psychiatric JJ O
conditions NNS O
were VBD O
associated VBN O
with IN O
AR-R15896AR NNP B-INTV
( ( O
3 CD O
vs. FW O
0 CD O
) ) O
. . O

Other JJ O
side NN O
effects NNS O
were VBD O
more JJR O
common JJ O
in IN O
the DT O
group NN O
treated VBD O
with IN O
AR-R15896AR NNP B-INTV
: : I-INTV
vomiting NN B-OC
( ( O
29 CD O
% NN O
vs. FW O
9 CD O
% NN O
) ) O
, , O
nausea NN B-OC
( ( O
23 CD O
% NN O
vs. FW O
12 CD O
% NN O
) ) O
, , O
fever RB B-OC
( ( O
17 CD O
% NN O
vs. FW O
12 CD O
% NN O
) ) O
, , O
agitation NN B-OC
( ( O
7 CD O
% NN O
vs. FW O
3 CD O
% NN O
) ) O
, , O
dizziness NN B-OC
( ( O
7 CD O
% NN O
vs. FW O
0 CD O
% NN O
) ) O
, , O
and CC O
hallucinations NNS B-OC
( ( O
6 CD O
% NN O
vs. FW O
0 CD O
% NN O
) ) O
. . O

No DT O
significant JJ O
difference NN O
between IN O
the DT O
two CD O
groups NNS O
( ( O
with IN O
respect NN O
to TO O
the DT O
proportions NNS O
of IN O
patients NNS O
with IN O
favourable JJ O
outcome NN O
) ) O
was VBD O
detected VBN O
in IN O
either CC O
the DT O
analysis NN O
of IN O
the DT O
BI NNP O
or CC O
the DT O
NIHSS NNP O
. . O

Pharmacokinetic NNP O
data NN O
showed VBD O
that IN O
plasma JJ B-OC
concentrations NNS I-OC
of IN I-OC
AR-R15896AR NNP B-INTV
were VBD O
in IN O
the DT O
expected JJ O
neuroprotective JJ O
range NN O
. . O

CONCLUSION NNP O
In IN O
most JJS O
of IN O
the DT O
patients NNS O
with IN O
acute JJ O
stroke NN O
receiving VBG O
AR-R15896AR NNP B-INTV
the DT O
intended JJ O
high JJ B-OC
plasma NN I-OC
levels NNS I-OC
were VBD O
reached VBN O
within IN O
a DT O
short JJ O
time NN O
period NN O
. . O

However RB O
, , O
active JJ O
treatment NN O
produced VBD O
more JJR O
side NN B-OC
effects NNS I-OC
than IN O
placebo NN B-INTV
, , O
thus RB O
indicating VBG O
safety NN O
concerns NNS O
and CC O
tolerability NN O
issues NNS O
for IN O
use NN O
in IN O
high JJ O
doses NNS O
in IN O
an DT O
acute JJ O
stroke NN O
population NN O
. . O

-DOCSTART- -X- O O

Postoperative JJ B-INTV
fondaparinux NN I-INTV
versus NN I-INTV
postoperative JJ I-INTV
enoxaparin NN I-INTV
for IN O
prevention NN O
of IN O
venous JJ B-POPU
thromboembolism NN I-POPU
after IN I-POPU
elective JJ I-POPU
hip-replacement JJ I-POPU
surgery NN I-POPU
: : I-POPU
a DT O
randomised JJ O
double-blind JJ O
trial NN O
. . O

BACKGROUND NNP O
Elective NNP O
hip-replacement NN O
surgery NN O
carries VBZ O
significant JJ O
risk NN O
of IN O
venous JJ B-OC
thromboembolism NN I-OC
, , O
despite IN O
use NN O
of IN O
thromboprophylaxis NN B-INTV
. . O

We PRP O
aimed VBD O
to TO O
see VB O
whether IN O
the DT O
pentasaccharide NN B-INTV
fondaparinux NN I-INTV
, , O
the DT O
first JJ O
drug NN O
of IN O
a DT O
new JJ O
class NN O
of IN O
synthetic JJ B-INTV
antithrombotic JJ I-INTV
agents NNS I-INTV
, , O
could MD O
reduce VB O
this DT O
risk NN O
to TO O
a DT O
greater JJR O
extent NN O
than IN O
other JJ O
available JJ O
treatments NNS O
. . O

METHODS NNP O
In IN O
a DT O
double-blind NN O
study NN O
, , O
we PRP B-POPU
randomly VBP I-POPU
assigned JJ I-POPU
2275 CD I-POPU
consecutive JJ I-POPU
patients NNS I-POPU
aged VBN I-POPU
18 CD I-POPU
years NNS I-POPU
or CC I-POPU
older JJR I-POPU
who WP I-POPU
were VBD I-POPU
undergoing VBG I-POPU
elective JJ I-POPU
hip-replacement JJ I-POPU
surgery NN I-POPU
to TO I-POPU
receive VB I-POPU
postoperative JJ I-POPU
subcutaneous JJ I-POPU
injections NNS I-POPU
of IN I-POPU
either DT I-POPU
2.5 CD I-POPU
mg NN I-POPU
fondaparinux NN I-POPU
once RB I-POPU
daily JJ I-POPU
or CC I-POPU
30 CD I-POPU
mg NNS I-POPU
enoxaparin JJ I-POPU
twice RB I-POPU
daily RB I-POPU
. . O

The DT O
primary JJ O
efficacy NN O
outcome NN O
was VBD O
venous JJ B-OC
thromboembolism NN I-OC
to TO O
day NN O
11 CD O
. . O

The DT O
main JJ O
safety NN O
outcomes NNS O
were VBD O
bleeding VBG B-OC
and CC I-OC
death NN I-OC
. . O

Patients NNS O
were VBD O
followed VBN O
up RP O
for IN O
6 CD O
weeks NNS O
. . O

FINDINGS IN O
We PRP O
assessed VBD O
venous JJ B-OC
thromboembolism NN I-OC
to TO O
day NN O
11 CD O
in IN O
1584 CD O
( ( O
70 CD O
% NN O
) ) O
of IN O
2275 CD O
patients NNS O
. . O

By IN O
day NN O
11 CD O
, , O
venous JJ B-OC
thromboembolisms NNS I-OC
were VBD O
recorded VBN O
in IN O
48 CD O
( ( O
6 CD O
% NN O
) ) O
of IN O
787 CD O
patients NNS O
on IN O
fondaparinux NN B-INTV
and CC O
in IN O
66 CD O
( ( O
8 CD O
% NN O
) ) O
of IN O
797 CD O
patients NNS O
on IN O
enoxaparin NN B-INTV
. . O

The DT O
relative JJ O
reduction NN O
in IN O
risk NN B-OC
was VBD O
26.3 CD O
% NN O
( ( O
95 CD O
% NN O
CI NNP O
-10.8 NNP O
to TO O
52.8 CD O
, , O
p=0.099 NN O
) ) O
. . O

The DT O
two CD O
groups NNS O
did VBD O
not RB O
differ VB O
in IN O
the DT O
number NN O
of IN O
patients NNS B-OC
who WP I-OC
died VBD I-OC
or CC O
in IN O
the DT O
number NN O
who WP O
had VBD O
clinically RB B-OC
relevant JJ I-OC
bleeding NN I-OC
. . O

INTERPRETATION NNP O
In IN O
patients NNS O
undergoing VBG O
elective JJ O
hip-replacement JJ O
surgery NN O
, , O
2.5 CD O
mg NN O
fondaparinux NN B-INTV
once RB O
daily RB O
was VBD O
not RB O
significantly RB O
more RBR O
effective JJ O
than IN O
30 CD O
mg JJ O
enoxaparin JJ B-INTV
twice RB O
daily RB O
in IN O
reducing VBG O
risk NN O
of IN O
venous JJ B-OC
thromboembolism NN I-OC
. . O

However RB O
, , O
the DT O
lower JJR O
risk NN O
recorded VBN O
with IN O
fondaparinux NN B-INTV
than IN O
enoxaparin NN B-INTV
was VBD O
clinically RB O
important JJ O
, , O
with IN O
no DT O
increase NN O
in IN O
clinically RB B-OC
relevant JJ I-OC
bleeding NN I-OC
. . O

-DOCSTART- -X- O O

Impact NN O
of IN O
different JJ O
platelet NN O
glycoprotein NN O
IIb/IIIa NNP O
receptor NN O
inhibitors NNS O
among IN O
diabetic JJ B-POPU
patients NNS I-POPU
undergoing VBG I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
: : I-POPU
: : O
Do VB O
Tirofiban NNP O
and CC O
ReoPro NNP O
Give NNP O
Similar NNP O
Efficacy NNP O
Outcomes NNP O
Trial NNP O
( ( O
TARGET NNP O
) ) O
1-year JJ O
follow-up NN O
. . O

BACKGROUND IN O
The DT O
platelet NN O
glycoprotein NN O
IIb/IIIa NNP O
receptor NN O
inhibitor NN O
abciximab NN O
, , O
a DT O
monoclonal JJ O
antibody NN O
, , O
has VBZ O
been VBN O
shown VBN O
to TO O
improve VB O
early JJ O
and CC O
late JJ O
outcomes NNS O
among IN O
diabetic JJ B-POPU
patients NNS I-POPU
undergoing VBG I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
( ( I-POPU
PCI NNP I-POPU
) ) I-POPU
. . O

It PRP O
is VBZ O
unknown JJ O
whether IN O
small-molecule JJ O
agents NNS O
confer VBP O
similar JJ O
benefits NNS O
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
In IN B-POPU
18 CD I-POPU
countries NNS I-POPU
, , I-POPU
4809 CD I-POPU
patients NNS I-POPU
undergoing VBG I-POPU
PCI NNP I-POPU
with IN I-POPU
stent JJ I-POPU
implantation NN I-POPU
were VBD O
randomized VBN O
to TO O
tirofiban VB B-INTV
or CC I-INTV
abciximab VB I-INTV
. . O

At IN O
the DT O
time NN O
of IN O
enrollment NN O
, , O
patients NNS O
were VBD O
stratified VBN O
according VBG O
to TO O
diabetes NNS O
status NN O
. . O

As IN O
compared VBN O
with IN O
non-diabetic JJ O
patients NNS O
, , O
patients NNS O
with IN O
diabetes NNS O
( ( O
n=1117 NN O
) ) O
showed VBD O
similar JJ O
30-day JJ O
ischemic JJ O
outcomes NNS O
, , O
an DT O
increased JJ O
incidence NN B-OC
of IN I-OC
any DT I-OC
target NN I-OC
vessel NN I-OC
revascularization NN I-OC
( ( I-OC
TVR NNP I-OC
) ) I-OC
at IN O
6 CD O
months NNS O
( ( O
10.3 CD O
% NN O
versus IN O
7.8 CD O
% NN O
; : O
P= NNP O
0.008 CD O
) ) O
, , O
and CC O
a DT O
trend NN O
toward IN O
higher JJR B-OC
1-year JJ I-OC
mortality NN I-OC
( ( O
2.5 CD O
% NN O
versus IN O
1.6 CD O
% NN O
; : O
P=0.056 NNP O
) ) O
. . O

Among IN O
diabetic JJ O
patients NNS O
randomized VBN O
to TO O
tirofiban VB O
( ( O
n=560 NN O
) ) O
, , O
the DT O
incidence NN B-OC
of IN I-OC
death NN I-OC
, , I-OC
myocardial JJ I-OC
infarction NN I-OC
( ( I-OC
MI NNP I-OC
) ) I-OC
, , I-OC
or CC I-OC
urgent JJ I-OC
TVR NNP I-OC
at IN O
30 CD O
days NNS O
was VBD O
6.2 CD O
% NN O
, , O
and CC O
among IN O
those DT O
randomized VBN O
to TO O
abciximab VB O
( ( O
n=557 NN O
) ) O
it PRP O
was VBD O
5.4 CD O
% NN O
( ( O
hazard JJ O
ratio NN O
[ NNP O
HR NNP O
] NNP O
1.16 CD O
; : O
P=0.540 NNP O
) ) O
. . O

At IN O
6 CD O
months NNS O
, , O
the DT O
composite NN O
of IN O
death NN B-OC
, , I-OC
MI NNP I-OC
, , I-OC
or CC I-OC
any DT I-OC
TVR NNP I-OC
occurred VBD O
in IN O
15.7 CD O
% NN O
and CC O
in IN O
16.9 CD O
% NN O
of IN O
tirofiban NN O
and CC O
abciximab NN O
patients NNS O
, , O
respectively RB O
( ( O
HR NNP O
0.93 CD O
; : O
P=0.610 NNP O
) ) O
. . O

Any DT O
TVR NNP B-OC
occurred VBD O
in IN O
9.5 CD O
% NN O
and CC O
11.1 CD O
% NN O
, , O
respectively RB O
( ( O
HR NNP O
0.84 CD O
; : O
P= NNP O
0.366 CD O
) ) O
. . O

The DT O
1-year JJ B-OC
mortality NN I-OC
was VBD O
2.1 CD O
% NN O
in IN O
the DT O
tirofiban NN O
group NN O
and CC O
2.9 CD O
% NN O
in IN O
the DT O
abciximab NN O
group NN O
( ( O
HR NNP O
0.74 CD O
; : O
P= NNP O
0.436 CD O
) ) O
. . O

CONCLUSIONS NNP O
Among IN O
diabetic JJ B-POPU
patients NNS I-POPU
undergoing VBG I-POPU
PCI NNP I-POPU
, , O
tirofiban NN O
and CC O
abciximab NN O
were VBD O
associated VBN O
with IN O
comparable JJ O
event NN O
rates NNS O
, , O
including VBG O
similar JJ O
rates NNS O
of IN O
6-month JJ O
TVR NNP O
and CC O
1-year JJ O
mortality NN O
. . O

These DT O
findings NNS O
suggest VBP O
that IN O
the DT O
non-glycoprotein JJ O
IIb/IIIa NNP O
properties NNS O
of IN O
abciximab NNS O
do VBP O
not RB O
translate VB O
into IN O
a DT O
discernible JJ O
long-term JJ O
clinical JJ O
benefit NN O
among IN O
diabetic JJ B-POPU
patients NNS I-POPU
. . O

-DOCSTART- -X- O O

Bovine NNP B-INTV
pericardium NN I-INTV
vs NN I-INTV
dacron NN I-INTV
for IN O
patch NN O
angioplasty NN O
after IN B-POPU
carotid JJ I-POPU
endarterectomy NN I-POPU
: : I-POPU
a DT O
prospective JJ O
randomized NN O
study NN O
. . O

HYPOTHESIS NNP O
Bovine NNP B-INTV
pericardium NN I-INTV
( ( I-INTV
BP NNP I-INTV
) ) I-INTV
demonstrates VBZ O
improved JJ O
intraoperative JJ O
hemostasis NN O
and CC O
equivalent JJ O
perioperative JJ O
morbidity NN O
compared VBN O
with IN O
Dacron NNP B-INTV
when WRB O
used VBN O
as IN O
patch JJ O
material NN O
for IN O
angioplasty NN O
following VBG O
carotid JJ B-INTV
endarterectomy NN I-INTV
. . O

OBJECTIVE UH O
To TO O
prospectively RB O
compare VB O
BP NNP B-INTV
and CC I-INTV
Dacron NNP I-INTV
patch NN I-INTV
angioplasty NN I-INTV
after IN O
carotid JJ O
endarterectomy NN O
in IN O
a DT O
randomized JJ O
fashion NN O
. . O

METHODS NNP O
Ninety-five JJ B-POPU
consecutive JJ I-POPU
primary JJ I-POPU
carotid NN I-POPU
endarterectomies NNS I-POPU
were VBD I-POPU
performed VBN I-POPU
in IN I-POPU
a DT I-POPU
prospective JJ I-POPU
randomized VBN I-POPU
fashion NN I-POPU
in IN I-POPU
92 CD I-POPU
patients NNS I-POPU
. . O

Fifty-one CD B-POPU
procedures NNS I-POPU
were VBD O
performed VBN O
using VBG O
BP NNP B-INTV
and CC O
44 CD O
using VBG O
Dacron NNP B-INTV
. . O

Intraoperative JJ O
suture NN O
line NN O
bleeding NN O
was VBD O
subjectively RB O
evaluated VBN O
by IN O
observing VBG O
bleeding VBG O
at IN O
3 CD O
and CC O
4 CD O
minutes NNS O
following VBG O
carotid JJ B-INTV
cross-clamp JJ I-INTV
removal NN I-INTV
and CC O
then RB O
objectively RB O
weighing VBG O
the DT O
sponge NN O
used VBN O
to TO O
tamponade VB O
bleeding VBG O
during IN O
these DT O
time NN O
intervals NNS O
. . O

Perioperative JJ B-OC
morbidity NN I-OC
, , I-OC
including VBG I-OC
cervical JJ I-OC
wound NN I-OC
hematoma NN I-OC
, , I-OC
transient JJ I-OC
ischemic JJ I-OC
attack NN I-OC
, , I-OC
and CC I-OC
stroke NN I-OC
, , I-OC
and CC I-OC
perioperative JJ I-OC
mortality NN I-OC
were VBD O
recorded VBN O
. . O

Statistical JJ O
analysis NN O
was VBD O
performed VBN O
using VBG O
paired JJ O
t NN O
tests NNS O
, , O
chi NN O
( ( O
2 CD O
) ) O
analysis NN O
, , O
Fisher NNP O
exact JJ O
test NN O
, , O
or CC O
multiple JJ O
linear JJ O
regression NN O
as IN O
appropriate JJ O
. . O

RESULTS JJ O
Suture NNP B-OC
line NN I-OC
bleeding VBG I-OC
at IN I-OC
3 CD I-OC
minutes NNS I-OC
was VBD O
present JJ O
in IN O
7 CD O
( ( O
14 CD O
% NN O
) ) O
of IN O
51 CD O
patients NNS O
in IN O
the DT O
BP NNP B-INTV
group NN O
and CC O
24 CD O
( ( O
55 CD O
% NN O
) ) O
of IN O
44 CD O
patients NNS O
in IN O
the DT O
Dacron NNP B-INTV
group NN O
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
. . O

Suture JJ B-OC
line NN I-OC
bleeding NN I-OC
evaluated VBD I-OC
at IN I-OC
4 CD I-OC
minutes NNS I-OC
was VBD O
present JJ O
in IN O
2 CD O
( ( O
4 CD O
% NN O
) ) O
of IN O
51 CD O
patients NNS O
in IN O
the DT O
BP NNP B-INTV
group NN O
and CC O
13 CD O
( ( O
30 CD O
% NN O
) ) O
of IN O
44 CD O
patients NNS O
in IN O
the DT O
Dacron NNP B-INTV
group NN O
( ( O
P NNP O
=.001 NNP O
) ) O
. . O

Net JJ B-OC
+/- JJ I-OC
SEM NNP I-OC
sponge NN I-OC
weight NN I-OC
( ( I-OC
total JJ I-OC
intraoperative JJ I-OC
suture NN I-OC
line NN I-OC
bleeding VBG I-OC
) ) I-OC
was VBD O
6.25 CD O
+/- JJ O
0.55 CD O
g NN O
in IN O
the DT O
BP NNP B-INTV
group NN O
and CC O
16.34 CD O
+/- JJ O
1.85 CD O
g NN O
in IN O
the DT O
Dacron NNP B-INTV
group NN O
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
. . O

Total JJ B-OC
suture NN I-OC
line NN I-OC
bleeding NN I-OC
was VBD O
significantly RB O
affected VBN O
by IN O
activated JJ O
clotting NN O
time NN O
; : O
however RB O
, , O
multivariate JJ O
analysis NN O
demonstrated VBD O
that IN O
bleeding NN B-OC
was VBD O
significantly RB O
less JJR O
with IN O
BP NNP B-INTV
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
even RB O
after IN O
adjusting VBG O
for IN O
differences NNS O
in IN O
activated JJ O
clotting NN O
time NN O
. . O

CONCLUSIONS NNP O
Bovine NNP B-INTV
pericardium NN I-INTV
demonstrated VBD O
a DT O
statistically RB O
significant JJ O
decrease NN O
in IN O
intraoperative JJ O
suture NN O
line NN O
bleeding VBG O
compared VBN O
with IN O
Dacron NNP B-INTV
. . O

Handling VBG O
characteristics NNS O
were VBD O
judged VBN O
by IN O
the DT O
surgeons NNS O
to TO O
be VB O
superior JJ O
for IN O
BP NNP B-INTV
. . O

Therefore RB O
, , O
we PRP O
believe VBP O
BP NNP B-INTV
may MD O
be VB O
an DT O
alternative JJ O
to TO O
Dacron NNP B-INTV
when WRB O
performing VBG O
patch NN O
angioplasty NN O
of IN O
the DT O
carotid NN O
artery NN O
after IN O
endarterectomy NN O
. . O

-DOCSTART- -X- O O

Relation NN O
between IN O
early JJ O
mitral JJ O
regurgitation NN O
and CC O
left VBD O
ventricular JJ O
thrombus NN O
formation NN O
after IN O
acute JJ O
myocardial JJ O
infarction NN O
: : O
results NNS O
of IN O
the DT O
GISSI-3 NNP O
echo NN O
substudy NN O
. . O

OBJECTIVE UH O
To TO O
evaluate VB O
the DT O
prevalence NN O
and CC O
correlates NNS O
of IN O
left JJ O
ventricular JJ O
thrombosis NN O
in IN O
patients NNS B-POPU
with IN I-POPU
acute JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
, , O
and CC O
whether IN O
the DT O
occurrence NN O
of IN O
early JJ O
mitral JJ O
regurgitation NN O
has VBZ O
a DT O
protective JJ O
effect NN O
against IN O
the DT O
formation NN O
of IN O
left JJ O
ventricular JJ O
thrombus NN O
. . O

DESIGN NNP O
AND CC O
SETTING NNP O
Multicentre NNP O
clinical JJ O
trial NN O
carried VBD O
out IN O
in IN O
47 CD B-POPU
Italian JJ I-POPU
coronary JJ I-POPU
care NN I-POPU
units NNS I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
757 CD B-POPU
patients NNS I-POPU
from IN I-POPU
the DT I-POPU
GISSI-3 NNP I-POPU
echo NN I-POPU
substudy NN I-POPU
population NN I-POPU
with IN I-POPU
their PRP$ I-POPU
first JJ I-POPU
acute JJ I-POPU
myocardial JJ I-POPU
infarct NN I-POPU
were VBD I-POPU
studied VBN I-POPU
by IN O
echocardiography NN B-INTV
at IN I-INTV
24-48 JJ I-INTV
hours NNS I-INTV
from IN I-INTV
symptom JJ I-INTV
onset NN I-INTV
( ( O
S1 NNP O
) ) O
, , O
at IN O
discharge NN O
( ( O
S2 NNP O
) ) O
, , O
at IN O
six CD O
weeks NNS O
( ( O
S3 NNP O
) ) O
, , O
and CC O
at IN O
six CD O
months NNS O
( ( O
S4 NNP O
) ) O
. . O

The DT O
diagnosis NN O
of IN O
left JJ O
ventricular JJ O
thrombosis NN O
was VBD O
based VBN O
on IN O
the DT O
detection NN O
of IN O
an DT O
echo JJ O
dense NN O
mass NN O
with IN O
defined JJ O
margins NNS O
visible JJ O
throughout IN O
the DT O
cardiac JJ O
cycle NN O
in IN O
at IN O
least JJS O
two CD O
orthogonal JJ O
views NNS O
. . O

RESULTS NNP O
In IN O
64 CD O
patients NNS O
( ( O
8 CD O
% NN O
) ) O
, , O
left VBD B-OC
ventricular JJ I-OC
thrombosis NN I-OC
was VBD O
detected VBN O
in IN O
one CD O
or CC O
more JJR O
examinations NNS O
. . O

Compared VBN O
with IN O
the DT O
remaining VBG O
693 CD O
patients NNS O
, , O
subjects NNS O
with IN O
left JJ B-OC
ventricular JJ I-OC
thrombosis NN I-OC
were VBD O
older JJR O
( ( O
mean NN O
( ( O
SD NNP O
) ) O
age NN O
: : O
64.6 CD O
( ( O
13.0 CD O
) ) O
v NN O
59.8 CD O
( ( O
11.7 CD O
) ) O
years NNS O
, , O
p NN O
< NNP O
0.005 CD O
) ) O
, , O
and CC O
had VBD O
larger JJR B-OC
infarcts NNS I-OC
( ( O
extent NN O
of IN O
wall NN O
motion NN O
asynergy NN O
: : O
40.9 CD O
( ( O
11.5 CD O
) ) O
% NN O
v JJ O
24.9 CD O
( ( O
14 CD O
) ) O
% NN O
, , O
p NN O
< NNP O
0.001 CD O
) ) O
, , O
greater JJR O
depression NN B-OC
of IN I-OC
left JJ I-OC
ventricular JJ I-OC
ejection NN I-OC
fraction NN I-OC
at IN I-OC
S1 NNP I-OC
( ( O
43.3 CD O
( ( O
6.9 CD O
) ) O
% NN O
v JJ O
48.1 CD O
( ( O
6.8 CD O
) ) O
% NN O
, , O
p NN O
< NNP O
0.001 CD O
) ) O
, , O
and CC O
greater JJR O
left VBD B-OC
ventricular JJ I-OC
volumes NNS I-OC
at IN I-OC
S1 NNP I-OC
( ( O
end VB O
diastolic NN O
volume NN O
: : O
87 CD O
( ( O
22 CD O
) ) O
v NN O
78 CD O
( ( O
18 CD O
) ) O
ml/m NN O
( ( O
2 CD O
) ) O
, , O
p JJ O
< VBP O
0.001 CD O
; : O
end VB O
systolic JJ O
volume NN O
: : O
50 CD O
( ( O
17 CD O
) ) O
v NN O
41 CD O
( ( O
14 CD O
) ) O
ml/m NN O
( ( O
2 CD O
) ) O
, , O
p JJ O
< NNP O
0.001 CD O
) ) O
. . O

The DT O
prevalence NN B-OC
of IN I-OC
moderate JJ I-OC
to TO I-OC
severe VB I-OC
mitral JJ I-OC
regurgitation NN I-OC
on IN I-OC
colour NN I-OC
Doppler NNP I-OC
at IN I-OC
S1 NNP I-OC
was VBD O
greater JJR O
in IN O
patients NNS O
who WP O
had VBD O
left VBN B-OC
ventricular JJ I-OC
thrombosis NN I-OC
at IN O
any DT O
time NN O
( ( O
10.2 CD O
% NN O
v JJ O
4.2 CD O
% NN O
, , O
p NN O
< NNP O
0.05 CD O
) ) O
. . O

On IN O
stepwise NN O
multiple JJ O
logistic JJ O
regression NN O
analysis NN O
the DT O
only JJ O
independent JJ O
variables NNS O
related VBN O
to TO O
the DT O
presence NN O
of IN O
left JJ B-OC
ventricular JJ I-OC
thrombosis NN I-OC
were VBD O
the DT O
extent NN O
of IN O
wall NN O
motion NN O
asynergy NN O
and CC O
anterior JJ O
site NN O
of IN O
infarction NN O
. . O

CONCLUSIONS NNP O
Left NNP B-OC
ventricular JJ I-OC
thrombosis NN I-OC
is VBZ O
not RB O
reduced VBN O
, , O
and CC O
may MD O
even RB O
be VB O
increased VBN O
, , O
by IN O
early JJ O
moderate NN O
to TO O
severe VB O
mitral JJ O
regurgitation NN O
after IN O
acute JJ O
myocardial JJ O
infarction NN O
. . O

The DT O
only JJ O
independent JJ O
determinant NN O
of IN O
left JJ O
ventricular JJ O
thrombosis NN O
is VBZ O
the DT O
extent NN O
of IN O
the DT O
akinetic-dyskinetic JJ O
area NN O
detected VBN O
on IN O
echocardiography NN O
between IN O
24-48 JJ O
hours NNS O
from IN O
symptom JJ O
onset NN O
. . O

-DOCSTART- -X- O O

Therapeutic JJ B-OC
angiogenesis NN I-OC
for IN O
patients NNS B-POPU
with IN I-POPU
limb JJ I-POPU
ischaemia NN I-POPU
by IN O
autologous JJ B-INTV
transplantation NN I-INTV
of IN I-INTV
bone-marrow JJ I-INTV
cells NNS I-INTV
: : I-INTV
a DT O
pilot NN O
study NN O
and CC O
a DT O
randomised VBN O
controlled VBN O
trial NN O
. . O

BACKGROUND NNP O
Preclinical NNP O
studies NNS O
have VBP O
established VBN O
that IN O
implantation NN O
of IN O
bone NN O
marrow-mononuclear JJ O
cells NNS O
, , O
including VBG O
endothelial JJ O
progenitor NN O
cells NNS O
, , O
into IN O
ischaemic JJ O
limbs NN O
increases VBZ O
collateral JJ B-OC
vessel NN I-OC
formation NN I-OC
. . O

We PRP O
investigated VBD O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
autologous JJ B-INTV
implantation NN I-INTV
of IN I-INTV
bone NN I-INTV
marrow-mononuclear JJ I-INTV
cells NNS I-INTV
in IN I-INTV
patients NNS B-POPU
with IN I-POPU
ischaemic JJ I-POPU
limbs NNS I-POPU
because IN I-POPU
of IN I-POPU
peripheral JJ I-POPU
arterial JJ I-POPU
disease NN I-POPU
. . O

METHODS NNP O
We PRP O
first RB O
did VBD O
a DT O
pilot NN O
study NN O
, , O
in IN O
which WDT O
25 CD B-POPU
patients NNS I-POPU
( ( I-POPU
group NN I-POPU
A DT I-POPU
) ) I-POPU
with IN I-POPU
unilateral JJ I-POPU
ischaemia NN I-POPU
of IN I-POPU
the DT I-POPU
leg NN I-POPU
were VBD O
injected VBN B-INTV
with IN I-INTV
bone NN I-INTV
marrow-mononuclear JJ I-INTV
cells NNS I-INTV
into IN I-INTV
the DT I-INTV
gastrocnemius NN I-INTV
of IN I-INTV
the DT I-INTV
ischaemic JJ I-INTV
limb NN I-INTV
and CC I-INTV
with IN I-INTV
saline NN I-INTV
into IN I-INTV
the DT I-INTV
less JJR I-INTV
ischaemic JJ I-INTV
limb NN I-INTV
. . O

We PRP O
then RB O
recruited VBD O
22 CD B-POPU
patients NNS I-POPU
( ( I-POPU
group NN I-POPU
B NNP I-POPU
) ) I-POPU
with IN I-POPU
bilateral JJ I-POPU
leg NN I-POPU
ischaemia NN I-POPU
, , O
who WP O
were VBD O
randomly RB O
injected VBN B-INTV
with IN I-INTV
bone NN I-INTV
marrow-mononuclear JJ I-INTV
cells NNS I-INTV
in IN I-INTV
one CD I-INTV
leg NN I-INTV
and CC I-INTV
peripheral JJ I-INTV
blood-mononuclear JJ I-INTV
cells NNS I-INTV
in IN I-INTV
the DT I-INTV
other JJ I-INTV
as IN I-INTV
a DT I-INTV
control NN I-INTV
. . O

Primary JJ O
outcomes NNS O
were VBD O
safety NN B-OC
and CC I-OC
feasibility NN I-OC
of IN I-OC
treatment NN I-OC
, , O
based VBN O
on IN O
ankle-brachial JJ B-OC
index NN I-OC
( ( I-OC
ABI NNP I-OC
) ) I-OC
and CC O
rest NN B-OC
pain NN I-OC
, , O
and CC O
analysis NN O
was VBD O
per IN O
protocol NN O
. . O

FINDINGS NNP O
Two CD B-POPU
patients NNS I-POPU
were VBD I-POPU
excluded VBN I-POPU
from IN I-POPU
group NN I-POPU
B NNP I-POPU
after IN I-POPU
randomisation NN I-POPU
. . O

At IN O
4 CD O
weeks NNS O
in IN O
group NN B-POPU
B NNP I-POPU
patients NNS I-POPU
, , O
ABI NNP B-OC
was VBD O
significantly RB O
improved VBN O
in IN O
legs NNS O
injected VBN O
with IN O
bone NN B-INTV
marrow-mononuclear JJ I-INTV
cells NNS I-INTV
compared VBN O
with IN O
those DT O
injected VBN O
with IN O
peripheral JJ B-INTV
blood-mononuclear JJ I-INTV
cells NNS I-INTV
( ( O
difference NN O
0.09 CD O
[ JJ O
95 CD O
% NN O
CI NNP O
0.06-0.11 CD O
] NNP O
; : O
p VBZ O
< $ O
0.0001 CD O
) ) O
. . O

Similar JJ O
improvements NNS O
were VBD O
seen VBN O
for IN O
transcutaneous JJ B-OC
oxygen NN I-OC
pressure NN I-OC
( ( O
13 CD O
[ RB O
9-17 CD O
] NNS O
; : O
p VB O
< $ O
0.0001 CD O
) ) O
, , O
rest VBP B-OC
pain NN I-OC
( ( O
-0.85 JJ O
[ NNP O
-1.6 NN O
to TO O
-0.12 VB O
] NNP O
; : O
p=0.025 NN O
) ) O
, , O
and CC O
pain-free JJ B-OC
walking NN I-OC
time NN I-OC
( ( O
1.2 CD O
[ RB O
0.7-1.7 JJ O
] NN O
; : O
p=0.0001 NN O
) ) O
. . O

These DT O
improvements NNS B-OC
were VBD O
sustained VBN O
at IN O
24 CD O
weeks NNS O
. . O

Similar JJ O
improvements NNS B-OC
were VBD O
seen VBN O
in IN O
group NN B-POPU
A DT I-POPU
patients NNS I-POPU
. . O

Two CD B-POPU
patients NNS I-POPU
in IN O
group NN O
A NNP O
died VBD B-OC
after IN I-OC
myocardial JJ I-OC
infarction NN I-OC
unrelated VBD O
to TO O
treatment NN O
. . O

INTERPRETATION NNP O
Autologous NNP B-INTV
implantation NN I-INTV
of IN I-INTV
bone NN I-INTV
marrow-mononuclear JJ I-INTV
cells NNS I-INTV
could MD O
be VB O
safe JJ B-OC
and CC I-OC
effective JJ I-OC
for IN O
achievement NN O
of IN O
therapeutic JJ B-OC
angiogenesis NN I-OC
, , O
because IN O
of IN O
the DT O
natural JJ O
ability NN O
of IN O
marrow NN O
cells NNS O
to TO O
supply VB O
endothelial JJ O
progenitor NN O
cells NNS O
and CC O
to TO O
secrete VB O
various JJ O
angiogenic JJ O
factors NNS O
or CC O
cytokines NNS O
. . O

-DOCSTART- -X- O O

Acute NNP O
cardiac JJ O
effects NNS O
of IN O
nicotine NN B-INTV
in IN O
healthy JJ B-POPU
young JJ I-POPU
adults NNS I-POPU
. . O

BACKGROUND NNP O
Nicotine NNP O
is VBZ O
known VBN O
to TO O
have VB O
many JJ O
physiologic JJ O
effects NNS O
. . O

The DT O
influence NN O
of IN O
nicotine NN B-INTV
delivered VBN O
in IN O
chewing VBG B-INTV
gum NN I-INTV
upon IN O
cardiac JJ O
hemodynamics NNS O
and CC O
conduction NN O
has VBZ O
not RB O
been VBN O
well-characterized JJ O
. . O

METHODS NNP O
We PRP O
studied VBD O
the DT O
effects NNS O
of IN O
nicotine NN B-INTV
in IN O
nonsmoking VBG B-POPU
adults NNS I-POPU
( ( I-POPU
6 CD I-POPU
male NN I-POPU
, , I-POPU
5 CD I-POPU
female NN I-POPU
; : I-POPU
ages VBZ I-POPU
23-36 CD I-POPU
years NNS I-POPU
) ) I-POPU
using VBG O
a DT O
double-blind NN O
, , O
randomized VBN O
, , O
cross-over JJ O
study NN O
. . O

Subjects NNS O
chewed VBD O
nicotine JJ B-INTV
gum NN I-INTV
( ( I-INTV
4 CD I-INTV
mg NN I-INTV
) ) I-INTV
or CC I-INTV
placebo NN I-INTV
. . O

After IN O
20 CD O
minutes NNS O
( ( O
approximate JJ O
time NN O
to TO O
peak VB O
nicotine JJ O
levels NNS O
) ) O
, , O
echocardiograms JJ B-INTV
and CC I-INTV
signal-averaged JJ I-INTV
electrocardiograms NNS I-INTV
( ( O
SAECG NNP O
) ) O
were VBD O
obtained VBN O
. . O

After IN O
40 CD O
minutes NNS O
, , O
subjects NNS O
were VBD O
again RB O
given VBN O
nicotine JJ B-INTV
gum NN I-INTV
or CC O
placebo NN B-INTV
in IN O
cross-over JJ O
fashion NN O
. . O

Standard NNP O
echocardiographic JJ O
measurements NNS O
were VBD O
made VBN O
from IN O
two-dimensional JJ O
images NNS O
. . O

We PRP O
then RB O
calculated VBD O
end-systolic JJ B-OC
wall NN I-OC
stress NN I-OC
( ( I-OC
ESWS NNP I-OC
) ) I-OC
, , I-OC
shortening VBG I-OC
fraction NN I-OC
( ( I-OC
SF NNP I-OC
) ) I-OC
, , I-OC
systemic JJ I-OC
vascular NN I-OC
resistance NN I-OC
( ( I-OC
SVR NNP I-OC
) ) I-OC
, , I-OC
velocity NN I-OC
for IN I-OC
circumferential JJ I-OC
fiber NN I-OC
shortening NN I-OC
corrected VBN I-OC
for IN I-OC
heart NN I-OC
rate NN I-OC
( ( I-OC
Vcfc NNP I-OC
) ) I-OC
, , I-OC
stroke VBD I-OC
volume NN I-OC
, , I-OC
and CC I-OC
cardiac JJ I-OC
output NN I-OC
. . O

P NNP B-OC
wave NN I-OC
and CC I-OC
QRS NNP I-OC
duration NN I-OC
were VBD O
measured VBN O
from IN O
SAECG NNP O
. . O

RESULTS NNP O
Significant JJ O
differences NNS O
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
from IN O
control NN O
or CC O
placebo NN O
were VBD O
found VBN O
for IN O
ESWS NNP B-OC
, , I-OC
mean JJ I-OC
blood NN I-OC
pressure NN I-OC
, , I-OC
cardiac JJ I-OC
output NN I-OC
, , I-OC
SVR NNP I-OC
, , I-OC
heart NN I-OC
rate NN I-OC
, , I-OC
and CC I-OC
P NNP I-OC
wave VBP I-OC
duration NN I-OC
. . O

No DT O
significant JJ O
changes NNS O
were VBD O
seen VBN O
in IN O
left JJ B-OC
ventricular JJ I-OC
ejection NN I-OC
time NN I-OC
( ( I-OC
LVET NNP I-OC
) ) I-OC
, , I-OC
LV NNP I-OC
dimensions NNS I-OC
, , I-OC
SF NNP I-OC
, , I-OC
contractility NN I-OC
( ( I-OC
Vcfc NNP I-OC
) ) I-OC
, , I-OC
or CC I-OC
QRS NNP I-OC
duration NN I-OC
. . O

CONCLUSIONS NNP O
These DT O
results NNS O
suggest VBP O
that IN O
nicotine JJ O
chewing VBG O
gum NN O
increases NNS O
afterload NN B-OC
and CC I-OC
cardiac JJ I-OC
output NN I-OC
. . O

Cardiac JJ B-OC
contractility NN I-OC
does VBZ O
not RB O
change VB O
acutely RB O
in IN O
response NN O
to TO O
nicotine VB O
gum NN O
. . O

Heart NNP B-OC
rate NN I-OC
and CC O
P NNP B-OC
wave VBP I-OC
duration NN I-OC
are VBP O
increased VBN O
by IN O
chewing VBG O
nicotine JJ O
gum NN O
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
percutaneous JJ O
transmitral JJ O
commissurotomy NN O
with IN O
Inoue NNP O
balloon NN O
technique NN O
and CC O
metallic JJ O
commissurotomy NN O
: : O
immediate JJ O
and CC O
short-term JJ O
follow-up JJ O
results NNS O
of IN O
a DT O
randomized JJ O
study NN O
. . O

BACKGROUND NNP O
The DT O
Inoue NNP O
balloon NN O
technique NN O
for IN O
mitral JJ O
commissurotomy NN O
is VBZ O
well RB O
established VBN O
and CC O
carried VBN O
out RP O
worldwide NN O
. . O

Metallic NNP O
commissurotomy NN O
is VBZ O
reported VBN O
to TO O
be VB O
a DT O
cheaper JJR O
and CC O
effective JJ O
alternative NN O
to TO O
balloon VB O
mitral JJ O
commissurotomy NN O
. . O

METHODS NNP O
One CD B-POPU
hundred VBD I-POPU
patients NNS I-POPU
were VBD I-POPU
randomized VBN I-POPU
into IN I-POPU
2 CD I-POPU
groups NNS I-POPU
to TO I-POPU
undergo VB I-POPU
percutaneous JJ I-POPU
transmitral JJ I-POPU
commissurotomy NN I-POPU
( ( I-POPU
PTMC NNP I-POPU
) ) I-POPU
by IN I-POPU
means NNS I-POPU
of IN I-POPU
the DT I-POPU
Inoue NNP I-POPU
balloon NN I-POPU
technique NN I-POPU
( ( I-POPU
IBMC NNP I-POPU
, , I-POPU
n JJ I-POPU
= NNP I-POPU
49 CD I-POPU
) ) I-POPU
or CC I-POPU
metallic JJ I-POPU
commissurotomy NN I-POPU
( ( I-POPU
PMMC NNP I-POPU
, , I-POPU
n JJ I-POPU
= NNP I-POPU
51 CD I-POPU
) ) I-POPU
. . O

Patients NNS O
were VBD O
crossed VBN O
over IN O
to TO O
the DT O
other JJ O
technique NN B-INTV
when WRB O
the DT O
initial JJ O
technique NN O
was VBD O
a DT O
failure NN O
. . O

Success NN B-OC
of IN I-OC
valvotomy NN I-OC
, , I-OC
procedure-related JJ I-OC
complications NNS I-OC
, , I-OC
and CC I-OC
follow-up JJ I-OC
events NNS I-OC
of IN O
the DT O
2 CD O
techniques NNS O
were VBD O
compared VBN O
. . O

RESULTS NNP O
Basal NNP B-OC
echocardiographic JJ I-OC
and CC I-OC
hemodynamic JJ I-OC
data NNS I-OC
were VBD O
similar JJ O
in IN O
both DT O
groups NNS O
. . O

Procedural NNP B-OC
success NN I-OC
was VBD O
similar JJ O
in IN O
both DT O
groups NNS O
: : O
45 CD O
of IN O
49 CD O
procedures NNS O
( ( O
91.8 CD O
% NN O
) ) O
in IN O
the DT O
IBMC NNP O
group NN O
, , O
compared VBN O
with IN O
46 CD O
of IN O
51 CD O
procedures NNS O
( ( O
90.18 CD O
% NN O
) ) O
in IN O
the DT O
PMMC NNP O
group NN O
( ( O
P NNP O
= NNP O
1.0 CD O
) ) O
. . O

Crossover NNP O
was VBD O
also RB O
comparable JJ O
, , O
with IN O
1 CD O
occurring VBG O
in IN O
the DT O
IBMC NNP O
group NN O
, , O
compared VBN O
with IN O
3 CD O
in IN O
the DT O
PMMC NNP O
group NN O
. . O

Complications NNS O
such JJ O
as IN O
cardiac JJ B-OC
tamponade NN I-OC
and CC I-OC
mitral JJ I-OC
regurgitation NN I-OC
( ( O
requiring VBG O
or CC O
not RB O
requiring VBG O
mitral JJ O
valve FW O
replacement NN O
) ) O
were VBD O
similar JJ O
in IN O
both DT O
groups NNS O
, , O
with IN O
3 CD O
complications NNS O
in IN O
the DT O
IBMC NNP O
group NN O
, , O
compared VBN O
with IN O
4 CD O
complications NNS O
in IN O
the DT O
PMMC NNP O
group NN O
( ( O
P NNP O
=.29 NNP O
) ) O
. . O

After IN O
a DT O
follow-up JJ O
period NN O
of IN O
approximately RB O
4 CD O
months NNS O
, , O
both DT O
groups NNS O
had VBD O
similar JJ O
event NN O
rates NNS O
and CC O
comparable JJ O
hemodynamic JJ O
parameters NNS O
( ( O
P NNP O
= NNP O
not RB O
significant JJ O
) ) O
. . O

CONCLUSIONS NNP O
Both NNP O
IBMC NNP O
and CC O
PMMC NNP O
are VBP O
successful JJ O
means NNS O
of IN O
providing VBG O
relief NN O
from IN O
severe JJ B-POPU
mitral JJ I-POPU
stenosis NN I-POPU
with IN O
a DT O
gain NN O
in IN O
valve JJ O
area NN O
and CC O
reduction NN O
in IN O
transmitral JJ O
gradient NN O
. . O

Both DT O
techniques NNS O
have VBP O
similar JJ O
procedural JJ O
success NN O
, , O
complication NN O
rates NNS O
, , O
and CC O
follow-up JJ O
events NNS O
. . O

-DOCSTART- -X- O O

Treatment JJ O
effects NNS O
of IN O
eptifibatide NN B-INTV
in IN O
planned JJ O
coronary JJ O
stent NN O
implantation NN O
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
kidney NN I-POPU
disease NN I-POPU
( ( O
ESPRIT NNP O
Trial NNP O
) ) O
. . O

The DT O
role NN O
of IN O
platelet NN B-INTV
glycoprotein NN I-INTV
IIb/IIIa NNP I-INTV
inhibitor NN I-INTV
therapy NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
mild JJ I-POPU
renal JJ I-POPU
impairment NN I-POPU
is VBZ O
not RB O
well RB O
characterized VBN O
. . O

Our PRP$ O
objective NN O
was VBD O
to TO O
explore VB O
the DT O
associations NNS B-OC
of IN I-OC
creatinine JJ I-OC
clearance NN I-OC
( ( I-OC
CrCl NNP I-OC
) ) I-OC
with IN O
outcomes NNS B-OC
in IN O
a DT O
trial NN O
of IN O
eptifibatide JJ B-INTV
therapy NN I-INTV
in IN O
patients NNS B-POPU
who WP I-POPU
underwent VBP I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
( ( I-POPU
PCI NNP I-POPU
) ) I-POPU
. . O

We PRP O
analyzed VBD O
48-hour CD O
and CC O
30-day JJ O
outcomes NNS O
of IN O
patients NNS B-POPU
enrolled VBN I-POPU
in IN I-POPU
the DT I-POPU
Enhanced NNP I-POPU
Suppression NNP I-POPU
of IN I-POPU
the DT I-POPU
Platelet NNP I-POPU
IIb/IIIa NNP I-POPU
Receptor NNP I-POPU
with IN I-POPU
Integrilin NNP I-POPU
Therapy NNP I-POPU
( ( I-POPU
ESPRIT NNP I-POPU
) ) I-POPU
trial NN I-POPU
. . O

Patients NNS B-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO I-POPU
placebo VB I-POPU
or CC I-POPU
eptifibatide VB I-POPU
as IN B-INTV
an DT I-INTV
adjunct NN I-INTV
to TO I-INTV
stent VB I-INTV
implantation NN I-INTV
( ( I-INTV
1,755 CD I-INTV
with IN I-INTV
CrCl NNP I-INTV
> NNP I-INTV
or CC I-INTV
=60 NNP I-INTV
ml/min NN I-INTV
and CC I-INTV
289 CD I-INTV
with IN I-INTV
CrCl NNP I-INTV
< NNP I-INTV
60 CD I-INTV
ml/min NN I-INTV
) ) I-INTV
. . O

CrCl NNP B-OC
was VBD O
calculated VBN O
using VBG O
the DT B-OC
Cockcroft NNP I-OC
and CC I-OC
Gault NNP I-OC
formula NN I-OC
, , O
and CC O
the DT O
associations NNS O
of IN O
CrCl NNP B-OC
with IN O
outcomes NNS O
were VBD O
evaluated VBN O
using VBG O
logistic JJ B-OC
regression NN I-OC
models NNS I-OC
. . O

Patients NNS B-POPU
with IN I-POPU
CrCl NNP I-POPU
< NNP I-POPU
60 CD I-POPU
ml/min NN I-POPU
were VBD I-POPU
more RBR I-POPU
likely JJ I-POPU
to TO I-POPU
be VB I-POPU
older JJR I-POPU
, , I-POPU
women NNS I-POPU
, , O
hypertensive JJ O
, , O
and CC O
have VBP O
a DT O
history NN O
of IN O
coronary JJ O
artery NN O
bypass NN O
surgery NN O
, , O
stroke NN O
, , O
or CC O
peripheral JJ O
vascular JJ O
disease NN O
. . O

The DT O
interaction NN O
of IN O
eptifibatide NN B-INTV
with IN O
CrCl NNP O
had VBD O
borderline JJ O
significance NN O
for IN O
the DT O
30-day JJ O
outcome NN O
( ( O
p JJ O
= NNP O
0.109 CD O
) ) O
. . O

Treatment JJ O
effect NN O
trended VBD O
toward IN O
a DT O
greater JJR O
magnitude NN O
in IN O
patients NNS O
with IN O
lower JJR O
CrCl NNP O
( ( O
60 CD O
ml/min NN O
) ) O
( ( O
odds NNS O
ratio VBP O
0.53 CD O
, , O
confidence NN O
interval NN O
0.34 CD O
to TO O
0.83 CD O
) ) O
compared VBN O
with IN O
those DT O
with IN O
higher JJR O
CrCl NNP O
( ( O
90 CD O
ml/min NN O
) ) O
( ( O
odds NNS O
ratio VBP O
0.68 CD O
, , O
confidence NN O
interval NN O
0.49 CD O
to TO O
0.94 CD O
) ) O
. . O

An DT O
accompanying VBG O
increase NN O
in IN O
bleeding VBG B-OC
risk NN I-OC
also RB O
was VBD O
not RB O
apparent JJ O
with IN O
lower JJR O
CrCl NNP O
. . O

The DT O
treatment NN O
effect NN O
of IN O
eptifibatide NN B-INTV
is VBZ O
realized VBN O
regardless RB O
of IN O
renal JJ O
function NN O
and CC O
trends VBZ O
toward IN O
being VBG O
greater JJR O
in IN O
patients NNS B-POPU
with IN I-POPU
mild JJ I-POPU
renal JJ I-POPU
impairment NN I-POPU
. . O

-DOCSTART- -X- O O

Intravenous JJ O
levosimendan NN B-INTV
treatment NN O
is VBZ O
cost-effective JJ O
compared VBN O
with IN O
dobutamine NN B-INTV
in IN O
severe JJ B-POPU
low-output JJ I-POPU
heart NN I-POPU
failure NN I-POPU
: : I-POPU
an DT O
analysis NN O
based VBN O
on IN O
the DT O
international JJ O
LIDO NNP O
trial NN O
. . O

BACKGROUND NNP O
Levosimendan NNP B-INTV
, , O
a DT O
novel JJ O
calcium NN O
sensitiser NN O
, , O
improves VBZ O
cardiac JJ O
performance NN O
and CC O
symptoms NNS O
without IN O
increasing VBG O
oxygen NN O
consumption NN O
, , O
and CC O
decreases VBZ O
the DT O
mortality NN O
of IN O
patients NNS B-POPU
with IN I-POPU
low-output JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

AIMS NNP O
To TO O
estimate VB O
the DT O
cost-effectiveness NN O
of IN O
intravenous JJ O
treatment NN O
with IN O
levosimendan NNS B-INTV
compared VBN O
with IN O
dobutamine NN B-INTV
in IN O
patients NNS O
with IN O
severe JJ O
low-output JJ O
heart NN O
failure NN O
. . O

METHODS NNP O
This DT O
economic JJ O
evaluation NN O
was VBD O
based VBN O
on IN O
a DT O
European JJ O
clinical JJ O
trial NN O
( ( O
LIDO NNP O
) ) O
, , O
in IN O
which WDT O
203 CD B-POPU
patients NNS I-POPU
with IN I-POPU
severe JJ I-POPU
heart NN I-POPU
failure NN I-POPU
randomly RB O
received VBD O
a DT O
24 CD O
h NN O
infusion NN O
with IN O
either DT O
levosimendan NN B-INTV
or CC I-INTV
dobutamine NN I-INTV
. . O

Survival NNP O
and CC O
resource VB O
utilisation NN O
data NNS O
were VBD O
collected VBN O
for IN O
6 CD O
months NNS O
; : O
survival NN O
was VBD O
extrapolated VBN O
assuming VBG O
a DT O
mean JJ O
additional JJ O
lifetime NN O
of IN O
3 CD O
years NNS O
based VBN O
on IN O
data NNS O
from IN O
the DT O
Cooperative NNP O
North NNP O
Scandinavian JJ O
Enalapril NNP O
Survival NNP O
Study NNP O
trial NN O
. . O

Costs NNS O
were VBD O
based VBN O
on IN O
study JJ O
drug NN O
usage NN O
and CC O
hospitalisation NN O
in IN O
the DT O
6-month JJ O
follow-up NN O
. . O

A DT O
sensitivity NN O
analysis NN O
on IN O
dosage NN B-OC
of IN I-OC
drug NN I-OC
and CC I-OC
duration NN I-OC
of IN I-OC
survival NN I-OC
was VBD O
performed VBN O
. . O

RESULTS VB O
The DT O
mean JJ B-OC
survival NN I-OC
over IN I-OC
6 CD I-OC
months NNS I-OC
was VBD O
157+/-52 JJ O
days NNS O
in IN O
the DT O
levosimendan NN B-INTV
group NN O
and CC O
139+/-64 JJ O
days NNS O
in IN O
the DT O
dobutamine NN B-INTV
group NN O
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

When WRB O
extrapolated VBD O
up RB O
to TO O
3 CD O
years NNS O
, , O
the DT O
gain NN B-OC
in IN I-OC
life NN I-OC
expectancy NN I-OC
was VBD O
estimated VBN O
at IN O
0.35 CD O
years NNS O
( ( O
discounted VBN O
at IN O
3 CD O
% NN O
) ) O
. . O

Levosimendan NNP B-INTV
increased VBD O
the DT O
mean NN B-OC
cost NN I-OC
per IN I-OC
patient NN I-OC
by IN O
1108 CD O
, , O
which WDT O
was VBD O
entirely RB O
due JJ O
to TO O
the DT O
cost NN O
of IN O
the DT O
study NN O
drug NN O
. . O

The DT O
incremental JJ B-OC
cost NN I-OC
per IN I-OC
life-year JJ I-OC
saved NN O
( ( O
LYS NNP O
) ) O
was VBD O
3205 CD O
at IN O
the DT O
European NNP O
level NN O
; : O
in IN O
the DT O
individual JJ O
countries NNS O
the DT O
cost NN O
per IN O
LYS NNP O
ranged VBD O
between IN O
3091 CD O
and CC O
3331 CD O
. . O

The DT O
result NN O
was VBD O
robust JJ O
in IN O
the DT O
sensitivity NN O
analysis NN O
. . O

CONCLUSIONS NNP O
Although IN O
the DT O
patients NNS O
in IN O
the DT O
levosimendan NN O
group NN O
were VBD O
alive JJ O
for IN O
more JJR O
days NNS O
and CC O
thus RB O
at IN O
risk NN B-OC
of IN I-OC
hospitalisation NN I-OC
for IN O
longer JJR O
, , O
there EX O
was VBD O
no DT O
increase NN O
in IN O
hospitalisation NN B-OC
or CC I-OC
hospitalisation NN I-OC
costs NNS I-OC
with IN O
levosimendan JJ B-INTV
treatment NN O
. . O

The DT O
cost NN O
per IN O
LYS NNP O
using VBG O
levosimendan JJ B-INTV
compares NNS O
favourably RB O
with IN O
other JJ O
cost-effectiveness JJ B-OC
analyses NNS I-OC
in IN O
cardiology NN O
. . O

-DOCSTART- -X- O O

[ VB O
The DT O
effect NN O
of IN O
losartan JJ B-INTV
versus NN I-INTV
atenolol NN I-INTV
on IN O
cardiovascular JJ B-OC
morbidity NN I-OC
and CC I-OC
mortality NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
diabetes NNS I-POPU
mellitus NNS I-POPU
in IN I-POPU
the DT I-POPU
LIFE-study NNP I-POPU
] NNP I-POPU
. . O

INTRODUCTION NNP O
The DT O
most RBS O
suitable JJ O
antihypertensive JJ O
drug NN O
to TO O
reduce VB O
the DT O
risk NN O
of IN O
cardiovascular JJ O
disease NN O
in IN O
patients NNS B-POPU
with IN I-POPU
hypertension NN I-POPU
and CC I-POPU
diabetes VBZ I-POPU
is VBZ O
unclear JJ O
. . O

In IN O
a DT O
prespecified JJ O
analysis NN O
of IN O
the DT O
LIFE-study NNP O
we PRP O
compared VBN O
the DT O
effects NNS O
of IN O
losartan NN B-INTV
and CC I-INTV
atenolol NN I-INTV
on IN O
cardiovascular JJ B-OC
morbidity NN I-OC
and CC I-OC
mortality NN I-OC
in IN O
diabetic JJ B-POPU
patients NNS I-POPU
. . O

MATERIAL NNP O
AND NNP O
METHODS NNP O
A NNP B-POPU
total NN I-POPU
of IN I-POPU
1195 CD I-POPU
patients NNS I-POPU
in IN I-POPU
the DT I-POPU
LIFE-study NNP I-POPU
had VBD I-POPU
diabetes NNS I-POPU
at IN O
the DT O
time NN O
of IN O
the DT O
randomisation NN O
. . O

The DT O
patients NNS O
were VBD O
randomised VBN O
for IN O
double-blind JJ O
treatment NN O
with IN O
losartan JJ B-INTV
versus NN I-INTV
atenolol NN I-INTV
. . O

The DT O
patients NNS B-POPU
had VBD I-POPU
ECG-verified JJ I-POPU
left JJ I-POPU
ventricular NN I-POPU
hypertrophy NN I-POPU
, , I-POPU
mean JJ I-POPU
age NN I-POPU
67 CD I-POPU
years NNS I-POPU
, , I-POPU
blood NN I-POPU
pressure NN I-POPU
177/96 CD I-POPU
mmHg NN I-POPU
after IN I-POPU
two CD I-POPU
weeks NNS I-POPU
placebo JJ I-POPU
run-in JJ I-POPU
period NN I-POPU
. . O

Patients NNS B-POPU
were VBD I-POPU
followed VBN I-POPU
for IN I-POPU
at IN I-POPU
least JJS I-POPU
four CD I-POPU
years NNS I-POPU
( ( I-POPU
mean JJ I-POPU
4.7 CD I-POPU
years NNS I-POPU
) ) I-POPU
. . O

The DT O
primary JJ O
composite JJ O
endpoint NN O
was VBD O
cardiovascular JJ B-OC
death NN I-OC
, , I-OC
stroke VBD I-OC
or CC I-OC
myocardial JJ I-OC
infarction NN I-OC
. . O

RESULTS NNP O
Blood NNP B-OC
pressure NN I-OC
was VBD O
reduced VBN O
to TO O
146/79 CD O
and CC O
148/79 CD O
in IN O
losartan-treated JJ B-INTV
patients NNS O
and CC O
atenolol-treated JJ B-INTV
patients NNS O
, , O
respectively RB O
. . O

The DT O
primary JJ O
endpoint NN O
occurred VBD O
in IN O
103 CD O
patients NNS O
assigned VBN O
losartan JJ B-INTV
( ( O
n JJ O
= NNP O
586 CD O
) ) O
and CC O
139 CD O
assigned VBN O
atenolol NN B-INTV
( ( O
n JJ O
= NNP O
609 CD O
) ) O
. . O

Relative JJ B-OC
risk NN I-OC
reduction NN I-OC
24 CD O
% NN O
( ( O
p JJ O
< NNP O
0.031 CD O
) ) O
. . O

Cardiovascular JJ B-OC
mortality NN I-OC
was VBD O
reduced VBN O
by IN O
37 CD O
% NN O
in IN O
favour NN O
of IN O
losartan NN B-INTV
( ( O
p JJ O
< NNP O
0.028 CD O
) ) O
, , O
and CC O
all DT O
cause NN O
mortality NN B-OC
by IN O
39 CD O
% NN O
( ( O
p JJ O
< NNP O
0.002 CD O
) ) O
. . O

DISCUSSION NNP O
Losartan NNP B-INTV
was VBD O
very RB O
effective JJ O
in IN O
reducing VBG O
cardiovascular JJ B-OC
morbidity NN I-OC
and CC I-OC
mortality NN I-OC
as RB O
compared VBN O
to TO O
atenolol VB B-INTV
. . O

These DT O
results NNS O
will MD O
have VB O
a DT O
major JJ O
impact NN O
on IN O
the DT O
choice NN O
of IN O
anti-hypertensive JJ O
treatment NN O
for IN O
patients NNS B-POPU
with IN I-POPU
hypertension NN I-POPU
and CC I-POPU
diabetes NNS I-POPU
. . O

-DOCSTART- -X- O O

ACE NNP B-INTV
inhibitors NNS I-INTV
or CC I-INTV
AT-1 JJ I-INTV
antagonists NNS I-INTV
- : O
which WDT O
is VBZ O
OPTIMAAL NNP O
after IN O
acute JJ O
myocardial JJ O
infarction NN O
? . O
OPTIMAAL NNP O
( ( O
Optimal NNP O
Trial NNP O
in IN O
Myocardial NNP O
Infarction NNP O
with IN O
the DT O
Angiotensin NNP O
II NNP O
Antagonist NNP O
Losartan NNP O
) ) O
is VBZ O
the DT O
first JJ O
major JJ O
study NN O
to TO O
compare VB O
an DT O
angiotensin NN B-INTV
II NNP I-INTV
Type NNP I-INTV
1 CD I-INTV
antagonist NN I-INTV
losartan NN I-INTV
( ( O
Cozaar NNP O
trade NN O
mark NN O
, , O
Merck NNP O
) ) O
with IN O
an DT O
ACE NNP O
inhibitor NN O
captonpril NN B-INTV
( ( O
Capoten NNP O
trade NN O
mark NN O
, , O
Elan NNP O
) ) O
after IN B-POPU
myocardial JJ I-POPU
infarction NN I-POPU
in IN I-POPU
patients NNS I-POPU
with IN I-POPU
left JJ I-POPU
ventricular JJ I-POPU
dysfunction NN I-POPU
. . O

Patients NNS B-POPU
were VBD O
assigned VBN O
to TO O
a DT O
target NN O
dose NN O
of IN O
losartan JJ B-INTV
50 CD O
mg/day NN O
and CC O
captopril NN B-INTV
50 CD O
mg NN O
t.i.d. NN O
, , O
as IN O
tolerated VBN O
. . O

The DT O
primary JJ O
end NN O
point NN O
was VBD O
all-cause JJ B-OC
mortality NN I-OC
and CC O
there EX O
were VBD O
499 CD O
( ( O
18 CD O
% NN O
) ) O
and CC O
447 CD O
( ( O
16 CD O
% NN O
) ) O
deaths NNS B-OC
in IN O
the DT O
losartan NN B-INTV
and CC I-INTV
captopril NN I-INTV
group NN O
, , O
respectively RB O
( ( O
p JJ O
= NNP O
0.07 CD O
) ) O
. . O

However RB O
, , O
there EX O
were VBD O
significantly RB O
more JJR O
cardiovascular JJ B-OC
deaths NNS I-OC
with IN O
losartan NN O
( ( O
420 CD O
, , O
15 CD O
% NN O
) ) O
than IN O
with IN O
captopril NN B-INTV
( ( O
363 CD O
, , O
13 CD O
% NN O
; : O
p CC O
= VB O
0.03 CD O
) ) O
. . O

Losartan NNP B-INTV
was VBD O
better RBR O
tolerated VBN B-OC
than IN O
captopril NN B-INTV
with IN O
fewer JJR O
patients NNS B-OC
discontinuing VBG I-OC
medication NN I-OC
( ( O
17 CD O
versus RB O
23 CD O
% NN O
for IN O
losartan NN B-INTV
and CC O
captopril NN B-INTV
, , O
respectively RB O
) ) O
. . O

In IN O
conclusion NN O
, , O
if IN O
tolerated VBN O
, , O
captopril NN B-INTV
should MD O
remain VB O
the DT O
preferred JJ O
treatment NN O
for IN O
patients NNS B-POPU
after IN O
complicated VBN O
acute JJ B-OC
myocardial JJ I-OC
infarction NN I-OC
. . O

-DOCSTART- -X- O O

Optimal JJ O
therapy NN O
for IN O
advanced JJ O
chronic JJ O
venous JJ O
insufficiency NN O
. . O

INTRODUCTION NNP O
While IN O
definitive JJ O
therapy NN O
awaits NNS O
level VBP O
I PRP O
evidence NN O
, , O
controversy NN O
persists NNS O
regarding VBG O
the DT O
optimal JJ O
operation NN O
for IN O
treatment NN O
of IN O
advanced JJ B-POPU
chronic JJ I-POPU
venous JJ I-POPU
insufficiency NN I-POPU
( ( I-POPU
CVI NNP I-POPU
) ) I-POPU
. . O

We PRP O
propose VBP O
a DT O
pragmatic JJ O
approach NN O
to TO O
the DT O
correction NN O
or CC O
amelioration NN O
of IN O
venous JJ O
hypertension NN O
resulting VBG O
from IN O
hydrodynamic JJ O
and CC O
hydrostatic JJ O
venous JJ O
reflux NN O
. . O

We PRP O
evaluated VBD O
a DT O
strategy NN O
of IN O
balloon NN O
dissection NN O
, , O
subfascial JJ O
endoscopic NN O
perforating VBG O
vein NN O
surgery NN O
( ( O
SEPS NNP O
) ) O
with IN O
routine JJ O
posterior JJ O
deep JJ O
compartment NN O
fasciotomy NN O
, , O
including VBG O
ligation NN O
and CC O
stripping NN O
of IN O
the DT O
superficial JJ O
system NN O
, , O
for IN O
use NN O
when WRB O
reflux NN O
is VBZ O
documented VBN O
at IN O
duplex JJ O
ultrasound NN O
( ( O
US NNP O
) ) O
scanning NN O
. . O

METHODS NNP O
This DT O
is VBZ O
a DT O
cooperative JJ O
, , O
multicenter NN O
, , O
retrospective JJ O
review NN O
of IN O
832 CD B-POPU
patients NNS I-POPU
stratified VBN I-POPU
by IN I-POPU
CEAP NNP I-POPU
classification NN I-POPU
. . O

The DT O
series NN O
consisted VBD O
of IN O
300 CD B-POPU
patients NNS I-POPU
with IN I-POPU
C4 NNP I-POPU
CVI NNP I-POPU
, , I-POPU
119 CD I-POPU
patients NNS I-POPU
with IN I-POPU
C5 NNP I-POPU
CVI NNP I-POPU
, , I-POPU
and CC I-POPU
413 CD I-POPU
patients NNS I-POPU
with IN I-POPU
C6 NNP I-POPU
CVI NNP I-POPU
. . O

A NNP O
subset NN O
of IN O
92 CD B-POPU
patients NNS I-POPU
with IN I-POPU
C4 NNP I-POPU
disease NN I-POPU
were VBD O
prospectively RB O
randomized VBN O
, , O
and CC O
ambulatory RB O
venous JJ O
pressure NN O
( ( O
AVP NNP O
) ) O
was VBD O
determined VBN O
preoperatively RB O
and CC O
postoperatively RB O
. . O

All DT O
patients NNS O
underwent JJ O
duplex JJ B-INTV
US NNP I-INTV
scanning VBG I-INTV
to TO O
document VB O
reflux NN O
in IN O
the DT O
deep JJ O
, , O
superficial JJ O
, , O
and CC O
perforating VBG O
venous JJ O
systems NNS O
. . O

Efficacy NNP B-OC
, , I-OC
safety NN I-OC
, , I-OC
and CC I-OC
durability NN I-OC
were VBD O
evaluated VBN O
over IN O
follow-up NN O
of IN O
1 CD O
to TO O
9 CD O
years NNS O
( ( O
mean NN O
, , O
31/2 CD O
years NNS O
) ) O
. . O

Uniformity NN O
was VBD O
attempted VBN O
by IN O
adoption NN O
of IN O
the DT O
senior JJ O
author NN O
's POS O
protocol NN O
and CC O
technique NN O
through IN O
on-site JJ O
preceptorship NN O
in IN O
each DT O
surgeon NN O
's POS O
operative JJ O
theater NN O
. . O

RESULTS VB O
This DT O
technique NN O
interrupted VBD O
3 CD O
to TO O
14 CD O
( ( O
mean NN O
, , O
7 CD O
) ) O
incompetent NN O
perforating VBG O
veins NNS O
per IN O
patient NN O
. . O

Of IN O
the DT O
832 CD O
patients NNS O
undergoing JJ O
SEPS NNP B-INTV
, , O
460 CD O
( ( O
55 CD O
% NN O
) ) O
underwent NN O
saphenous JJ B-INTV
vein NN I-INTV
ligation NN I-INTV
and CC I-INTV
stripping NN I-INTV
at IN O
the DT O
same JJ O
operation NN O
. . O

In IN O
92 CD O
% NN O
ulcers NNS B-OC
healed VBD I-OC
or CC I-OC
were VBD I-OC
significantly RB I-OC
improved VBN I-OC
within IN O
4 CD O
to TO O
14 CD O
weeks NNS O
. . O

In IN O
64 CD O
( ( O
8 CD O
% NN O
) ) O
patients NNS O
, , O
ulcers NNS B-OC
failed VBD I-OC
to TO I-OC
heal VB I-OC
or CC O
there EX O
was VBD O
no DT O
benefit NN O
from IN O
the DT O
operation NN B-OC
. . O

Thirty-two JJ O
patients NNS O
( ( O
4 CD O
% NN O
) ) O
experienced VBD O
recurrent JJ B-OC
ulceration NN I-OC
or CC I-OC
skin JJ I-OC
deterioration NN I-OC
at IN O
6 CD O
months-2 JJ O
years NNS O
( ( O
mean NN O
, , O
15 CD O
mo NN O
) ) O
. . O

Repeat NNP O
SEPS NNP O
was VBD O
successful JJ O
in IN O
25 CD O
of IN O
these DT O
96 CD O
patients NNS O
, , O
and CC O
deep JJ O
valve NN O
repair NN O
was VBD O
successful JJ O
in IN O
4 CD O
patients NNS O
. . O

In IN O
the DT O
92 CD B-POPU
randomized VBD I-POPU
patients NNS I-POPU
with IN I-POPU
C4 NNP I-POPU
disease NN I-POPU
, , O
41 CD O
refused VBD O
postoperative JJ O
AVP NNP O
, , O
leaving VBG O
51 CD O
compliant JJ O
patients NNS O
. . O

The DT O
SEPS NNP O
group NN O
( ( O
n JJ O
= NNP O
25 CD O
) ) O
had VBD O
significantly RB O
reduced VBN O
AVP NNP B-OC
( ( O
P NNP O
< NNP O
.01 NNP O
) ) O
compared VBN O
with IN O
the DT O
control NN O
group NN O
( ( O
n JJ O
= NNP O
26 CD O
) ) O
. . O

Complications NNS O
in IN O
825 CD O
patients NNS O
were VBD O
less JJR O
than IN O
3 CD O
% NN O
and CC O
consisted VBD O
mostly RB O
of IN O
transient NN B-OC
neurologic NN I-OC
disorders NNS I-OC
( ( O
eg NN O
, , O
paradysthesia NN B-OC
) ) I-OC
, , I-OC
but CC I-OC
deep RB I-OC
venous JJ I-OC
thrombosis NN I-OC
occurred VBD O
in IN O
2 CD O
patients NNS O
, , O
with IN O
pulmonary JJ O
embolus NN O
in IN O
1 CD O
. . O

No DT O
operative JJ O
deaths NNS B-OC
occurred VBD O
. . O

Follow-up NN O
for IN O
1 CD O
to TO O
9 CD O
years NNS O
( ( O
mean NN O
, , O
31/2 CD O
years NNS O
) ) O
demonstrated VBD O
durability NN B-OC
. . O

CONCLUSION VB O
The DT O
efficacy NN O
, , O
safety NN O
, , O
and CC O
durability NN O
of IN O
this DT O
operative JJ O
protocol NN O
proved VBD O
beneficial JJ O
in IN O
our PRP$ O
clinical JJ O
experience NN O
with IN O
832 CD B-POPU
patients NNS I-POPU
during IN O
9 CD O
years NNS O
of IN O
follow-up NN O
. . O

The DT O
SEPS NNP O
subset NN O
of IN O
randomized JJ O
patients NNS O
with IN O
C4 NNP O
disease NN O
experienced VBD O
significant JJ O
decrease NN O
in IN O
AVP NNP O
, , O
objectively RB O
supporting VBG O
the DT O
effectiveness NN O
of IN O
reflux NN O
surgery NN O
in IN O
advanced JJ O
CVI NNP O
. . O

Until IN O
definitive JJ O
level NN O
I PRP O
evidence NN O
is VBZ O
available JJ O
, , O
this DT O
operative JJ O
technique NN O
is VBZ O
advocated VBN O
as IN O
optimal JJ O
therapy NN O
for IN O
CVI NNP O
. . O

-DOCSTART- -X- O O

Multiple NNP B-INTV
risk NN I-INTV
factor NN I-INTV
intervention NN I-INTV
reduces VBZ O
cardiovascular JJ O
risk NN O
in IN O
hypertensive JJ B-POPU
patients NNS I-POPU
with IN I-POPU
echolucent JJ I-POPU
plaques NNS I-POPU
in IN I-POPU
the DT I-POPU
carotid NN I-POPU
artery NN I-POPU
. . O

OBJECTIVE NNP O
In IN O
a DT O
previously RB O
published VBN O
randomized VBN O
6-year JJ O
study NN O
we PRP O
observed VBD O
that IN O
multiple JJ B-INTV
risk NN I-INTV
factor NN I-INTV
intervention NN I-INTV
reduced VBD O
cardiovascular JJ O
risk NN O
in IN O
high-risk JJ B-POPU
hypertensive JJ I-POPU
men NNS I-POPU
, , O
and CC O
that IN O
this DT O
effect NN O
was VBD O
confined VBN O
to TO O
patients NNS B-POPU
with IN I-POPU
carotid JJ I-POPU
artery NN I-POPU
plaques NNS I-POPU
. . O

Hypothetically RB O
, , O
the DT O
underlying VBG O
mechanism NN O
might MD O
have VB O
been VBN O
a DT O
stabilization NN O
of IN O
echolucent NN O
, , O
instable JJ O
, , O
rupture-prone JJ O
plaques NNS O
. . O

The DT O
aim NN O
of IN O
the DT O
present JJ O
study NN O
was VBD O
to TO O
examine VB O
plaque NN B-OC
characteristics NNS I-OC
by IN O
B-mode NNP B-INTV
ultrasound NN I-INTV
in IN O
the DT O
previous JJ O
intervention NN O
study NN O
, , O
and CC O
also RB O
to TO O
investigate VB O
the DT O
relationship NN O
between IN O
plaque NN B-OC
characteristics NNS I-OC
at IN O
baseline NN O
and CC O
cardiovascular JJ B-OC
events NNS I-OC
during IN O
the DT O
6-year JJ O
follow-up NN O
in IN O
the DT O
two CD O
randomization NN O
groups NNS O
. . O

METHODS NNP O
High NNP B-INTV
resolution NN I-INTV
B-mode NNP I-INTV
ultrasound NN I-INTV
was VBD O
used VBN O
to TO O
characterize VB B-OC
plaque JJ I-OC
echogenicity NN I-OC
in IN O
four CD O
subgroups NNS O
- : O
dominantly RB O
echolucent NN O
, , O
substantially RB O
echolucent JJ O
, , O
dominantly RB O
echogenic JJ O
, , O
and CC O
uniformly RB O
echogenic JJ O
. . O

RESULTS NNP O
In IN O
the DT O
usual JJ B-POPU
care NN I-POPU
group NN I-POPU
17 CD I-POPU
of IN I-POPU
32 CD I-POPU
( ( I-POPU
53 CD I-POPU
% NN I-POPU
) ) I-POPU
patients NNS I-POPU
with IN I-POPU
echolucent JJ I-POPU
plaques NNS I-POPU
at IN I-POPU
baseline NN I-POPU
suffered VBN O
from IN O
a DT O
combined VBN O
end-point NN O
( ( O
any DT O
death NN B-OC
or CC I-OC
nonfatal JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
or CC I-OC
nonfatal JJ I-OC
stroke NN I-OC
) ) I-OC
during IN O
follow-up JJ O
compared VBN O
with IN O
seven CD O
of IN O
28 CD O
( ( O
25 CD O
% NN O
) ) O
patients NNS O
in IN O
the DT O
intervention NN B-INTV
group NN I-INTV
( ( O
P NNP O
= NNP O
0.036 CD O
) ) O
. . O

The DT O
corresponding JJ B-OC
numbers NNS I-OC
in IN O
patients NNS O
with IN O
echogenic JJ B-OC
plaques NNS I-OC
were VBD O
n JJ O
= JJ O
4/13 CD O
( ( O
31 CD O
% NN O
) ) O
and CC O
n JJ O
= NN O
4/17 CD O
( ( O
24 CD O
% NN O
) ) O
, , O
respectively RB O
( ( O
NS NNP O
) ) O
. . O

In IN O
the DT O
usual JJ B-INTV
care NN I-INTV
group NN I-INTV
11 CD O
of IN O
33 CD O
( ( O
33 CD O
% NN O
) ) O
patients NNS O
with IN O
no DT O
plaques NNS O
suffered VBD O
from IN O
a DT O
combined JJ O
end-point NN O
during IN O
follow-up JJ O
compared VBN O
with IN O
11 CD O
of IN O
30 CD O
( ( O
37 CD O
% NN O
) ) O
in IN O
the DT O
intervention NN B-INTV
group NN I-INTV
. . O

CONCLUSION NNP O
Our PRP$ O
data NNS O
indicate VBP O
that IN O
the DT O
beneficial JJ B-OC
effect NN I-OC
of IN O
the DT O
multiple NN B-INTV
risk NN I-INTV
intervention NN I-INTV
programme NN I-INTV
was VBD O
confined VBN O
to TO O
those DT O
patients NNS O
with IN O
echolucent JJ O
plaques NNS O
. . O

The DT O
data NNS O
have VBP O
to TO O
be VB O
confirmed VBN O
with IN O
a DT O
large-scale JJ O
trial NN O
. . O

-DOCSTART- -X- O O

Sustained VBN O
ventricular JJ O
arrhythmias NNS O
and CC O
mortality NN O
among IN O
patients NNS B-POPU
with IN I-POPU
acute JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
: : I-POPU
results NNS O
from IN O
the DT O
GUSTO-III NNP O
trial NN O
. . O

BACKGROUND NNP O
In IN O
many JJ O
patients NNS O
, , O
ventricular JJ O
arrhythmias NN O
will MD O
develop VB O
early JJ O
after IN O
acute JJ B-POPU
myocardial JJ I-POPU
infarction NN I-POPU
. . O

We PRP O
studied VBD O
the DT O
incidence NN O
, , O
timing NN O
, , O
and CC O
outcomes NNS O
of IN O
such JJ O
arrhythmias NNS O
in IN O
the DT O
international JJ O
Global NNP O
Utilization NNP O
of IN O
Streptokinase NNP O
and CC O
TPA NNP O
( ( O
alteplase NN O
) ) O
for IN O
Occluded NNP O
Coronary NNP O
Arteries NNP O
( ( O
GUSTO NNP O
) ) O
-III VBP O
trial NN O
. . O

METHODS NNP O
We PRP B-INTV
identified VBD I-INTV
independent JJ I-INTV
predictors NNS I-INTV
of IN I-INTV
inhospital JJ B-POPU
ventricular JJ I-POPU
fibrillation NN I-POPU
( ( I-POPU
VF NNP I-POPU
) ) I-POPU
and CC I-POPU
ventricular JJ I-POPU
tachycardia NN I-POPU
( ( I-POPU
VT NNP I-POPU
) ) I-POPU
and CC I-POPU
compared VBN I-POPU
30-day JJ I-POPU
and CC I-POPU
1-year JJ I-POPU
mortality NN I-POPU
rates NNS I-POPU
of IN I-POPU
patients NNS I-POPU
who WP I-POPU
did VBD I-POPU
( ( I-POPU
n VB I-POPU
= NNP I-POPU
1121 CD I-POPU
) ) I-POPU
and CC I-POPU
did VBD I-POPU
not RB I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
13,921 CD I-POPU
) ) I-POPU
have VBP I-POPU
these DT I-POPU
arrhythmias NNS I-POPU
during IN I-POPU
the DT I-POPU
index NN I-POPU
hospitalization NN I-POPU
. . O

RESULTS NNP O
Significant NNP O
independent JJ O
predictors NNS O
of IN O
inhospital JJ O
VF NNP O
were VBD O
higher JJR O
Killip NNP B-OC
class NN I-OC
, , I-OC
lower JJR I-OC
baseline NN I-OC
systolic JJ I-OC
pressure NN I-OC
, , I-OC
intravenous JJ I-OC
preenrollment NN I-OC
lidocaine NN B-INTV
use NN I-INTV
, , O
shorter JJR O
time NN O
to TO O
thrombolysis VB B-OC
, , O
and CC O
beta-blocker NN B-INTV
use NN I-INTV
< VBZ O
2 CD O
weeks NNS O
before IN O
enrollment NN O
; : O
independent JJ O
predictors NNS O
of IN O
inhospital JJ O
VT NNP O
were VBD O
lower JJR O
baseline NN B-OC
systolic JJ I-OC
pressure NN I-OC
, , I-OC
intravenous JJ I-OC
lidocaine NN I-OC
use NN O
before IN O
enrollment NN O
, , O
higher JJR O
Killip NNP O
class NN O
, , O
faster JJR O
baseline JJ B-OC
heart NN I-OC
rate NN I-OC
, , O
and CC O
advanced JJ O
age NN O
. . O

The DT O
30-day JJ B-OC
mortality NN I-OC
rate NN I-OC
was VBD O
31 CD O
% NN O
in IN O
patients NNS O
with IN O
VF NNP O
, , O
24 CD O
% NN O
in IN O
those DT O
with IN O
VT NNP O
, , O
44 CD O
% NN O
in IN O
those DT O
with IN O
both DT O
, , O
and CC O
6 CD O
% NN O
in IN O
those DT O
with IN O
neither DT O
( ( O
P NNP O
=.001 NNP O
) ) O
. . O

The DT O
corresponding JJ O
1-year JJ B-OC
mortality NN I-OC
rates NNS I-OC
were VBD O
34 CD O
% NN O
, , O
29 CD O
% NN O
, , O
49 CD O
% NN O
, , O
and CC O
9 CD O
% NN O
( ( O
P NNP O
=.001 NNP O
) ) O
. . O

The DT O
30-day JJ B-OC
and CC I-OC
1-year JJ I-OC
mortality NN I-OC
rates NNS I-OC
were VBD O
higher JJR O
for IN O
patients NNS O
with IN O
late JJ O
( ( O
> JJ O
48 CD O
hours NNS O
after IN O
enrollment NN O
) ) O
versus FW O
early JJ O
arrhythmias NN O
( ( O
< CD O
or CC O
=48 VB O
hours NNS O
after IN O
enrollment NN O
) ) O
. . O

CONCLUSIONS NNP O
Despite IN O
thrombolysis NN O
, , O
inhospital JJ O
ventricular NN O
arrhythmias NNS O
are VBP O
associated VBN O
with IN O
higher JJR O
30-day JJ O
and CC O
1-year JJ O
mortality NN B-OC
rates NNS I-OC
after IN O
acute JJ B-POPU
myocardial JJ I-POPU
infarction NN I-POPU
, , O
particularly RB O
when WRB O
occurring VBG O
later RB O
during IN O
the DT O
initial JJ O
hospitalization NN O
. . O

Better JJR O
therapies NNS O
are VBP O
needed VBN O
to TO O
improve VB O
outcomes NNS O
of IN O
these DT O
arrhythmias NNS O
. . O

-DOCSTART- -X- O O

Efficacy NN B-OC
and CC I-OC
tolerability NN I-OC
of IN O
donepezil NN B-INTV
in IN O
vascular JJ B-POPU
dementia NN I-POPU
: : I-POPU
positive JJ O
results NNS O
of IN O
a DT O
24-week JJ O
, , O
multicenter NN O
, , O
international JJ O
, , O
randomized VBN O
, , O
placebo-controlled JJ B-INTV
clinical JJ O
trial NN O
. . O

BACKGROUND NNP O
AND CC O
PURPOSE NNP O
Clinical NNP O
observations NNS O
suggest VBP O
that IN O
patients NNS B-POPU
with IN I-POPU
vascular JJ I-POPU
dementia NN I-POPU
( ( I-POPU
VaD NNP I-POPU
) ) I-POPU
may MD O
benefit VB O
from IN O
treatment NN O
with IN O
cholinesterase NN B-INTV
inhibitors NNS I-INTV
. . O

This DT O
study NN O
evaluated VBD O
the DT O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
donepezil NN B-INTV
for IN O
relieving VBG O
symptoms NNS O
of IN O
dementia NN O
in IN O
VaD NNP O
. . O

METHODS NNP O
Patients NNPS B-POPU
( ( I-POPU
n=603 JJ I-POPU
; : I-POPU
mean JJ I-POPU
age NN I-POPU
, , I-POPU
73.9 CD I-POPU
years NNS I-POPU
; : I-POPU
55.2 CD I-POPU
% NN I-POPU
men NNS I-POPU
) ) I-POPU
with IN I-POPU
probable JJ I-POPU
( ( I-POPU
70.5 CD I-POPU
% NN I-POPU
) ) I-POPU
or CC I-POPU
possible JJ I-POPU
( ( I-POPU
29.5 CD I-POPU
% NN I-POPU
) ) I-POPU
VaD NNP I-POPU
, , I-POPU
according VBG I-POPU
to TO I-POPU
criteria NNS I-POPU
of IN I-POPU
the DT I-POPU
National NNP I-POPU
Institute NNP I-POPU
of IN I-POPU
Neurological NNP I-POPU
Disorders NNP I-POPU
and CC I-POPU
Stroke NNP I-POPU
( ( I-POPU
NINDS NNP I-POPU
) ) I-POPU
and CC I-POPU
the DT I-POPU
Association NNP I-POPU
Internationale NNP I-POPU
pour VBP I-POPU
la NN I-POPU
Recherche NNP I-POPU
et CC I-POPU
l'Enseignement JJ I-POPU
en NN I-POPU
Neurosciences NNP I-POPU
( ( I-POPU
AIREN NNP I-POPU
) ) I-POPU
, , O
were VBD O
randomized VBN O
to TO O
24 CD O
weeks NNS O
of IN O
treatment NN O
with IN O
donepezil JJ B-INTV
5 CD O
mg/d NN O
( ( O
n=198 JJ O
) ) O
, , O
donepezil $ B-INTV
10 CD O
mg/d NN O
( ( O
5 CD O
mg/d NN O
for IN O
first JJ O
28 CD O
days NNS O
; : O
n=206 CC O
) ) O
, , O
or CC O
placebo NN B-INTV
( ( O
n=199 JJ O
) ) O
. . O

Analyses NNS O
were VBD O
based VBN O
on IN O
the DT O
intent-to-treat JJ O
population NN O
. . O

RESULTS NNP O
At IN O
week NN O
24 CD O
, , O
both DT O
donepezil NN B-INTV
groups NNS O
showed VBD O
significant JJ O
improvement NN B-OC
in IN I-OC
cognition NN I-OC
versus NN O
placebo NN B-INTV
on IN O
the DT O
Alzheimer NNP B-OC
's POS I-OC
Disease NNP I-OC
Assessment NNP I-OC
Scale-cognitive JJ I-OC
subscale NN I-OC
( ( O
mean JJ O
change NN O
from IN O
baseline NN O
score NN O
effect NN O
size NN O
: : O
donepezil NN B-INTV
5 CD O
mg/d NN O
, , O
-1.90 NNP O
; : O
P=0.001 NNP O
; : O
donepezil VBZ B-INTV
10 CD O
mg/d NN O
, , O
-2.33 NNP O
; : O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

Significant JJ O
improvements NNS O
in IN O
patients NNS B-OC
' POS I-OC
global JJ I-OC
function NN I-OC
were VBD O
seen VBN O
versus NN O
placebo NN B-INTV
at IN O
week NN O
24 CD O
( ( O
observed JJ O
cases NNS O
) ) O
, , O
on IN O
the DT O
Clinician NNP B-OC
's POS I-OC
Interview-Based JJ I-OC
Impression NN I-OC
of IN I-OC
Change-Plus NNP I-OC
version NN I-OC
only RB O
for IN O
patients NNS O
on IN O
donepezil JJ B-INTV
5 CD O
mg/d NN O
( ( O
P=0.014 NNP O
) ) O
, , O
and CC O
on IN O
the DT O
Sum NNP B-OC
of IN I-OC
the DT I-OC
Boxes NNP I-OC
of IN I-OC
the DT I-OC
Clinical NNP I-OC
Dementia NNP I-OC
Rating NNP I-OC
only RB O
for IN O
patients NNS O
on IN O
10 CD O
mg/d NN O
( ( O
P=0.007 NNP O
) ) O
. . O

Donepezil-treated JJ B-INTV
patients NNS O
showed VBD O
significant JJ O
benefits NNS O
in IN O
activities NNS B-OC
of IN I-OC
daily JJ I-OC
living NN I-OC
over IN O
placebo NN B-INTV
on IN O
the DT O
Alzheimer NNP B-OC
's POS I-OC
Disease NNP I-OC
Functional NNP I-OC
Assessment NNP I-OC
and CC I-OC
Change NNP I-OC
Scale NNP I-OC
( ( O
mean JJ O
change NN O
from IN O
baseline NN O
score NN O
effect NN O
size NN O
at IN O
week NN O
24 CD O
: : O
donepezil NN B-INTV
5 CD O
mg/d NN O
, , O
-1.31 NNP O
, , O
P=0.02 NNP O
; : O
donepezil VBZ B-INTV
10 CD O
mg/d NN O
, , O
-1.31 NNP O
, , O
P=0.02 NNP O
) ) O
. . O

Donepezil NNP B-INTV
was VBD O
well RB B-OC
tolerated VBN I-OC
. . O

Withdrawal NNP B-OC
rates NNS I-OC
due JJ I-OC
to TO I-OC
adverse JJ I-OC
events NNS I-OC
were VBD O
relatively RB O
low JJ O
( ( B-INTV
placebo NN I-INTV
, , O
11.1 CD O
% NN O
; : O
donepezil CC B-INTV
5 CD O
mg/d NN O
, , O
11.1 CD O
% NN O
; : O
donepezil CC B-INTV
10 CD O
mg/d NN O
, , O
21.8 CD O
% NN O
; : O
P=0.005 NNP O
versus IN O
placebo NN B-INTV
) ) I-INTV
. . O

CONCLUSIONS NNP O
These DT O
data NNS O
demonstrate NN O
that IN O
donepezil NN B-INTV
is VBZ B-OC
an DT I-OC
effective JJ I-OC
and CC I-OC
well-tolerated JJ I-OC
treatment NN I-OC
for IN I-OC
VaD NNP I-OC
and CC O
show VB O
it PRP O
may MD O
have VB O
an DT O
important JJ O
place NN O
in IN O
the DT O
management NN O
of IN O
this DT O
condition NN O
. . O

-DOCSTART- -X- O O

Long-term JJ O
anticoagulant NN B-INTV
treatment NN I-INTV
after IN O
acute JJ O
myocardial JJ O
infarction NN O
. . O

The DT O
Warfarin NNP O
Re-Infarction NNP O
Study NNP O
. . O

High NNP O
levels NNS O
of IN O
fibrinogen NN O
and CC O
clotting VBG O
factor NN O
VII NNP O
are VBP O
associated VBN O
with IN O
an DT O
increased VBN B-OC
risk NN I-OC
for IN O
subsequent JJ B-OC
death NN I-OC
and CC O
cardiovascular JJ B-OC
disease NN I-OC
in IN O
apparently RB B-POPU
healthy JJ I-POPU
individuals NNS I-POPU
. . O

Furthermore RB O
, , O
pathoanatomic JJ O
studies NNS O
and CC O
coronary JJ O
angiography NN O
have VBP O
confirmed VBN O
a DT O
relationship NN B-OC
between IN I-OC
coronary JJ I-OC
thrombus NN I-OC
formation NN I-OC
and CC I-OC
acute JJ I-OC
Q-wave NNP I-OC
infarction NN I-OC
. . O

Effective JJ O
antithrombotic JJ O
agents NNS O
may MD O
prevent VB O
or CC O
limit VB O
thrombus JJ B-OC
formation NN I-OC
and CC O
events NNS B-OC
related VBN I-OC
to TO I-OC
thrombosis NN I-OC
. . O

The DT O
Warfarin NNP O
Re-Infarction NNP O
Study NNP O
( ( O
WARIS NNP O
) ) O
studied VBD O
the DT O
effect NN O
of IN O
warfarin NN B-INTV
in IN O
survivors NNS B-POPU
of IN I-POPU
acute JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
. . O

Patients NNS B-POPU
aged VBD I-POPU
75 CD I-POPU
years NNS I-POPU
or CC I-POPU
less JJR I-POPU
were VBD O
randomized VBN O
in IN O
a DT O
double-blind JJ O
, , O
placebo-controlled JJ B-INTV
study NN O
to TO O
test VB O
whether IN O
long-term JJ O
treatment NN O
with IN O
warfarin JJ B-INTV
reduces NNS O
the DT O
risk NN B-OC
of IN O
death NN B-OC
, , I-OC
reinfarction NN I-OC
, , O
and CC O
thromboembolic JJ B-OC
morbidity NN I-OC
. . O

A DT B-POPU
total NN I-POPU
of IN I-POPU
1918 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
screened VBN I-POPU
for IN I-POPU
participation NN I-POPU
; : I-POPU
1214 CD I-POPU
were VBD I-POPU
recruited VBN I-POPU
. . O

The DT O
mean JJ O
follow-up NN O
was VBD O
37 CD O
months NNS O
. . O

Analyzed VBN O
on IN O
an DT O
intention-to-treat JJ O
basis NN O
, , O
123 CD O
( ( O
20 CD O
% NN O
) ) O
in IN O
the DT O
placebo NN B-INTV
group NN O
died VBD B-OC
, , O
versus FW O
94 CD O
( ( O
15 CD O
% NN O
) ) O
in IN O
the DT O
warfarin NN B-INTV
group NN O
, , O
a DT O
risk NN B-OC
reduction NN I-OC
of IN O
24 CD O
% NN O
( ( O
P NNP O
= NNP O
0.026 CD O
) ) O
. . O

Considering VBG O
patients NNS O
on IN O
treatment NN O
or CC O
within IN O
28 CD O
days NNS O
after IN O
discontinuing VBG O
the DT O
test NN O
medication NN O
, , O
92 CD O
in IN O
the DT O
placebo NN O
group NN O
died VBD B-OC
, , O
as IN O
compared VBN O
with IN O
60 CD O
of IN O
the DT O
warfarin-treated JJ B-INTV
patients NNS O
, , O
a DT O
risk NN B-OC
reduction NN I-OC
of IN O
35 CD O
% NN O
( ( O
P NNP O
= NNP O
0.005 CD O
) ) O
. . O

Relapsing VBG B-OC
myocardial JJ I-OC
infarction NN I-OC
( ( I-OC
fatal JJ I-OC
and CC I-OC
nonfatal JJ I-OC
) ) I-OC
was VBD O
reduced VBN O
by IN O
43 CD O
% NN O
( ( O
P NNP O
= NNP O
0.0001 CD O
) ) O
. . O

The DT O
incidence NN B-OC
of IN I-OC
cerebrovascular JJ I-OC
attacks NNS I-OC
was VBD O
lower RBR O
in IN O
the DT O
warfarin NN B-INTV
group NN O
( ( O
16 CD O
patients NNS O
) ) O
than IN O
the DT O
placebo NN B-INTV
group NN O
( ( O
41 CD O
patients NNS O
) ) O
, , O
a DT O
highly RB O
significant JJ O
reduction NN O
of IN O
61 CD O
% NN O
( ( O
P NNP O
= NNP O
0.0003 CD O
) ) O
. . O

Serious JJ B-OC
bleeding NN I-OC
occurred VBD O
in IN O
11 CD O
patients NNS O
taking VBG O
warfarin NN B-INTV
, , O
an DT O
incidence NN O
of IN O
0.6 CD O
% NN O
per IN O
year NN O
. . O

In IN O
conclusion NN O
, , O
long-term JJ O
anticoagulant JJ B-INTV
therapy NN I-INTV
may MD O
be VB O
recommended VBN O
after IN O
acute JJ O
myocardial JJ O
infarction NN O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
enalapril NN B-INTV
on IN O
myocardial JJ O
infarction NN O
and CC O
unstable JJ O
angina NN O
in IN O
patients NNS B-POPU
with IN I-POPU
low JJ I-POPU
ejection NN I-POPU
fractions NNS I-POPU
. . O

An DT O
association NN O
between IN O
raised VBN O
renin NN O
levels NNS O
and CC O
myocardial JJ O
infarction NN O
has VBZ O
been VBN O
reported VBN O
. . O

We PRP O
studied VBD O
the DT O
effects NNS O
of IN O
enalapril NN B-INTV
, , O
an DT O
angiotensin-converting JJ O
enzyme NN O
( ( O
ACE NNP O
) ) O
inhibitor NN O
, , O
on IN O
the DT O
development NN O
of IN O
myocardial JJ O
infarction NN O
and CC O
unstable JJ O
angina NN O
in IN O
6797 CD B-POPU
patients NNS I-POPU
with IN I-POPU
ejection NN I-POPU
fractions NNS I-POPU
< VBP I-POPU
or CC I-POPU
= VBP I-POPU
0.35 CD I-POPU
enrolled VBN I-POPU
into IN I-POPU
the DT I-POPU
two CD I-POPU
Studies NNS I-POPU
of IN I-POPU
Left NNP I-POPU
Ventricular NNP I-POPU
Dysfunction NNP I-POPU
( ( I-POPU
SOLVD NNP I-POPU
) ) I-POPU
trials NNS I-POPU
. . O

Patients NNS O
were VBD O
randomly RB O
assigned VBN O
to TO O
placebo VB B-INTV
( ( O
n JJ O
= NN O
3401 CD O
) ) O
or CC O
enalapril $ B-INTV
( ( O
n JJ O
= NN O
3396 CD O
) ) O
at IN O
doses NNS O
of IN O
2.5-20 JJ O
mg NNS O
per IN O
day NN O
in IN O
two CD O
concurrent JJ O
double-blind JJ O
trials NNS O
with IN O
the DT O
same JJ O
protocol NN O
. . O

Patients NNS B-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
entered VBD I-POPU
the DT I-POPU
treatment NN I-POPU
trial NN I-POPU
( ( I-POPU
n JJ I-POPU
= NN I-POPU
2569 CD I-POPU
) ) I-POPU
and CC I-POPU
those DT I-POPU
without IN I-POPU
heart NN I-POPU
failure NN I-POPU
entered VBD I-POPU
the DT I-POPU
prevention NN I-POPU
trial NN I-POPU
( ( I-POPU
n JJ I-POPU
= NN I-POPU
4228 CD I-POPU
) ) I-POPU
. . O

Follow-up NNP O
averaged VBD O
40 CD O
months NNS O
. . O

In IN O
each DT O
trial NN O
there EX O
were VBD O
significant JJ O
reductions NNS O
in IN O
the DT O
number NN O
of IN O
patients NNS O
developing VBG O
myocardial JJ O
infarction NN O
( ( O
treatment NN O
trial NN O
: : O
158 CD O
placebo NN B-INTV
vs NN O
127 CD O
enalapril NN B-INTV
, , O
p NN O
< VBD O
0.02 CD O
; : O
prevention NN O
trial NN O
: : O
204 CD O
vs NN O
161 CD O
p NN O
< NNP O
0.01 CD O
) ) O
or CC O
unstable JJ O
angina NN O
( ( O
240 CD O
vs RB O
187 CD O
p NN O
< NN O
0.001 CD O
; : O
355 CD O
vs NN O
312 CD O
, , O
p NN O
< NNP O
0.05 CD O
) ) O
. . O

Combined VBN O
, , O
there EX O
were VBD O
362 CD B-POPU
placebo NNS I-POPU
group NN I-POPU
patients NNS O
with IN O
myocardial JJ O
infarction NN O
compared VBN O
with IN O
288 CD O
in IN O
the DT O
enalapril NN B-INTV
group NN O
( ( O
risk NN O
reduction NN O
23 CD O
% NN O
, , O
95 CD O
% NN O
CI NNP O
11-34 CD O
% NN O
; : O
p CC O
< VB O
0.001 CD O
) ) O
. . O

595 CD B-POPU
placebo NN I-POPU
group NN I-POPU
patients NNS O
developed VBD O
unstable JJ B-OC
angina NNS I-OC
compared VBN O
with IN O
499 CD O
in IN O
the DT O
enalapril NN B-INTV
group NN O
( ( O
risk NN O
reduction NN O
20 CD O
% NN O
, , O
95 CD O
% NN O
CI NNP O
9-29 CD O
% NN O
, , O
p NN O
< NNP O
0.001 CD O
) ) O
. . O

There EX O
was VBD O
also RB O
a DT O
reduction NN B-OC
in IN I-OC
cardiac JJ I-OC
deaths NNS I-OC
( ( O
711 CD O
placebo NN B-INTV
, , O
615 CD O
enalapril NN B-INTV
; : I-INTV
p CC O
< VB O
0.003 CD O
) ) O
, , O
so RB O
that IN O
the DT O
reduction NN O
in IN O
the DT O
combined JJ B-OC
endpoint NN I-OC
of IN I-OC
deaths NNS I-OC
, , I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
and CC I-OC
unstable JJ I-OC
angina NN I-OC
was VBD O
highly RB O
significant JJ O
( ( O
20 CD O
% NN O
risk NN O
reduction NN O
, , O
95 CD O
% NN O
CI NNP O
14-26 CD O
% NN O
; : O
p CC O
< VB O
0.0001 CD O
) ) O
. . O

Enalapril NNP B-INTV
treatment NN O
significantly RB O
reduced VBN O
myocardial JJ B-OC
infarction NN I-OC
, , I-OC
unstable JJ I-OC
angina NN I-OC
, , I-OC
and CC I-OC
cardiac JJ I-OC
mortality NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
low JJ I-POPU
ejection NN I-POPU
fractions NNS I-POPU
. . O

-DOCSTART- -X- O O

Controlled VBN O
study NN O
on IN O
the DT O
therapeutic JJ B-OC
efficacy NN I-OC
of IN O
propionyl-L-carnitine NN O
in IN O
patients NNS B-POPU
with IN I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

A DT O
double-blind JJ O
phase NN O
II NNP O
study NN O
of IN O
propionyl-L-carnitine NN O
( ( O
CAS NNP O
17298-37-2 CD O
) ) O
versus NN O
placebo NN O
was VBD O
carried VBN O
out RP O
on IN O
a DT O
group NN O
of IN O
60 CD B-POPU
patients NNS I-POPU
with IN I-POPU
mild JJ I-POPU
to TO I-POPU
moderate VB I-POPU
( ( I-POPU
II NNP I-POPU
and CC I-POPU
III NNP I-POPU
NYHA NNP I-POPU
class NN I-POPU
) ) I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

The DT B-POPU
group NN I-POPU
was VBD I-POPU
made VBN I-POPU
up IN I-POPU
of IN I-POPU
men NNS I-POPU
and CC I-POPU
women NNS I-POPU
aged VBD I-POPU
between IN I-POPU
48 CD I-POPU
and CC I-POPU
73 CD I-POPU
years NNS I-POPU
in IN I-POPU
chronic JJ I-POPU
treatment NN I-POPU
with IN I-POPU
digitalis NN I-POPU
and CC I-POPU
diuretics NNS I-POPU
for IN I-POPU
at IN I-POPU
least JJS I-POPU
3 CD I-POPU
months NNS I-POPU
and CC I-POPU
who WP I-POPU
still RB I-POPU
displayed VBD I-POPU
symptoms NNS I-POPU
. . O

Thirty NN O
of IN O
these DT O
patients NNS O
were VBD O
chosen VBN B-INTV
randomly RB I-INTV
and CC I-INTV
for IN I-INTV
180 CD I-INTV
days NNS I-INTV
, , I-INTV
500 CD I-INTV
mg NN I-INTV
of IN I-INTV
propionyl-L-carnitine NN I-INTV
was VBD I-INTV
orally RB I-INTV
administered VBN I-INTV
, , I-INTV
3 CD I-INTV
times NNS I-INTV
a DT I-INTV
day NN I-INTV
in IN I-INTV
addition NN I-INTV
to TO I-INTV
their PRP$ I-INTV
usual JJ I-INTV
treatment NN I-INTV
. . O

At IN B-INTV
basal JJ I-INTV
conditions NNS I-INTV
and CC I-INTV
after IN I-INTV
30 CD I-INTV
, , I-INTV
90 CD I-INTV
and CC I-INTV
180 CD I-INTV
days NNS I-INTV
the DT I-INTV
maximum JJ I-INTV
exercise NN I-INTV
time NN I-INTV
was VBD I-INTV
evaluated VBN I-INTV
using VBG I-INTV
an DT I-INTV
exercise NN I-INTV
tolerance NN I-INTV
test NN I-INTV
performed VBD I-INTV
on IN I-INTV
an DT I-INTV
ergometer NN I-INTV
bicycle NN I-INTV
and CC I-INTV
the DT I-INTV
left JJ I-INTV
ventricular JJ I-INTV
ejection NN I-INTV
fraction NN I-INTV
was VBD I-INTV
tested VBN I-INTV
by IN I-INTV
means NNS I-INTV
of IN I-INTV
bidimensional JJ I-INTV
echocardiography NN I-INTV
. . O

After IN O
one CD O
month NN O
of IN O
treatment NN O
, , O
the DT O
patients NNS O
treated VBN O
with IN O
propionyl-L-carnitine NN O
, , O
compared VBN O
to TO O
the DT O
control NN O
group NN O
, , O
showed VBD O
significant JJ O
increases NNS O
in IN O
the DT O
values NNS B-OC
of IN I-OC
both DT I-OC
tests NNS I-OC
, , O
increases NNS O
which WDT O
became VBD O
even RB O
more RBR O
evident JJ O
after IN O
90 CD O
and CC O
180 CD O
days NNS O
. . O

At IN O
the DT O
stated VBN O
times NNS O
the DT O
increases NNS O
in IN O
the DT O
maximum JJ B-OC
exercise NN I-OC
time NN I-OC
were VBD O
16.4 CD O
% NN O
, , O
22.9 CD O
% NN O
, , O
and CC O
25.9 CD O
% NN O
, , O
respectively RB O
. . O

The DT O
ventricular JJ B-OC
ejection NN I-OC
fraction NN I-OC
increased VBN O
by IN O
8.4 CD O
% NN O
, , O
11.6 CD O
% NN O
and CC O
13.6 CD O
% NN O
, , O
respectively RB O
. . O

On IN O
the DT O
basis NN O
of IN O
these DT O
results NNS O
, , O
having VBG O
studied VBN O
the DT O
particular JJ O
mechanism NN O
of IN O
action NN O
of IN O
propionyl-L-carnitine NN O
the DT O
authors NNS O
conclude VBP O
that IN O
it PRP O
represents VBZ O
a DT O
drug NN O
of IN O
undoubted JJ O
therapeutic JJ O
interest NN O
in IN O
patients NNS B-POPU
with IN I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
, , O
in IN O
whom WP O
it PRP O
could MD O
be VB O
efficaciously RB B-OC
administered VBN O
along IN O
with IN O
a DT O
standard JJ O
pharmacological JJ O
therapy NN O
. . O

-DOCSTART- -X- O O

A DT O
prospective JJ O
, , O
placebo-controlled JJ B-INTV
, , O
randomized JJ O
trial NN O
of IN O
intravenous JJ O
streptokinase NN B-INTV
and CC O
angioplasty JJ B-INTV
versus NN I-INTV
lone NN I-INTV
angioplasty JJ I-INTV
therapy NN I-INTV
of IN O
acute JJ O
myocardial JJ O
infarction NN O
. . O

BACKGROUND IN O
The DT O
value NN O
of IN O
routine JJ O
administration NN O
of IN O
intravenous JJ O
thrombolytic JJ B-INTV
agents NNS I-INTV
during IN O
percutaneous JJ B-INTV
transluminal JJ I-INTV
coronary NN I-INTV
angioplasty NN I-INTV
( ( I-INTV
PTCA NNP I-INTV
) ) I-INTV
therapy NN I-INTV
of IN O
acute JJ O
myocardial JJ O
infarction NN O
( ( O
MI NNP O
) ) O
has VBZ O
not RB O
been VBN O
determined VBN O
. . O

Therefore RB O
, , O
we PRP O
prospectively RB O
randomized VBD O
122 CD B-POPU
patients NNS I-POPU
with IN I-POPU
evolving VBG I-POPU
MI NNP I-POPU
to TO I-POPU
PTCA NNP I-POPU
therapy NN I-POPU
with IN I-POPU
or CC I-POPU
without IN I-POPU
adjunctive JJ I-POPU
intravenous JJ I-POPU
streptokinase NN I-POPU
therapy NN I-POPU
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
Patients NNP B-POPU
with IN I-POPU
ECG NNP I-POPU
ST NNP I-POPU
segment NN I-POPU
elevation NN I-POPU
who WP I-POPU
presented VBD I-POPU
within IN I-POPU
4 CD I-POPU
hours NNS I-POPU
of IN I-POPU
symptom JJ I-POPU
onset NN I-POPU
, , I-POPU
had VBD I-POPU
no DT I-POPU
contraindication NN I-POPU
to TO I-POPU
thrombolytic JJ I-POPU
therapy NN I-POPU
, , I-POPU
and CC I-POPU
were VBD I-POPU
not RB I-POPU
in IN I-POPU
cardiogenic JJ I-POPU
shock NN I-POPU
were VBD I-POPU
enrolled VBN I-POPU
. . O

They PRP O
were VBD O
treated VBN O
immediately RB O
with IN O
intravenous JJ B-INTV
heparin NNS I-INTV
( ( O
10,000 CD O
units NNS O
) ) O
and CC O
oral JJ B-INTV
aspirin NN I-INTV
( ( O
325 CD O
mg NN O
) ) O
and CC O
randomized VBN O
to TO O
treatment NN O
with IN O
placebo NN B-INTV
or CC I-INTV
streptokinase NN I-INTV
( ( O
1.5 CD O
M NNP O
units NNS O
) ) O
administered VBD O
intravenously RB O
over IN O
30 CD O
minutes NNS O
. . O

Patients NNS O
then RB O
were VBD O
taken VBN O
immediately RB O
to TO O
the DT O
catheterization NN O
laboratory NN O
, , O
and CC O
those DT O
with IN O
suitable JJ O
coronary JJ O
anatomy NN O
underwent JJ O
immediate JJ O
PTCA NNP B-INTV
. . O

Subsequent NNP O
clinical JJ O
course NN O
, , O
serial JJ O
radionuclide NN O
ventriculography NN O
, , O
and CC O
6-month JJ O
repeat NN O
angiography NN O
were VBD O
analyzed VBN O
. . O

A DT O
total NN O
of IN O
106 CD B-POPU
patients NNS I-POPU
were VBD I-POPU
treated VBN I-POPU
with IN I-POPU
PTCA NNP I-POPU
. . O

Use NNP O
of IN O
PTCA NNP B-INTV
was VBD O
similar JJ O
for IN O
placebo NN B-INTV
( ( O
92 CD O
% NN O
) ) O
and CC O
streptokinase NNP B-INTV
( ( O
83 CD O
% NN O
) ) O
groups NNS O
. . O

Angioplasty NNP B-INTV
was VBD O
successful JJ O
in IN O
95 CD O
% NN O
of IN O
patients NNS O
, , O
with IN O
no DT O
difference NN O
in IN O
placebo NN B-INTV
( ( O
93 CD O
% NN O
) ) O
and CC O
streptokinase NNP B-INTV
( ( O
98 CD O
% NN O
) ) O
groups NNS O
. . O

Serial JJ O
radionuclide NN O
ventriculography NN O
demonstrated VBD O
no DT O
difference NN O
in IN O
24-hour JJ O
( ( O
52 CD O
+/- JJ O
12 CD O
% NN O
versus NN O
50 CD O
+/- JJ O
12 CD O
% NN O
) ) O
or CC O
6-week JJ O
( ( O
51 CD O
+/- JJ O
12 CD O
% NN O
versus NN O
51 CD O
+/- JJ O
13 CD O
% NN O
) ) O
ejection NN B-OC
fraction NN I-OC
values NNS I-OC
for IN O
placebo NN B-INTV
and CC I-INTV
streptokinase NN I-INTV
groups NNS O
, , O
respectively RB O
. . O

Contrast NNP B-OC
ventriculography NN I-OC
demonstrated VBD O
improvement NN O
in IN O
immediate NN O
( ( O
54 CD O
+/- JJ O
12 CD O
% NN O
) ) O
versus NN O
6-month JJ O
( ( O
60 CD O
+/- JJ O
15 CD O
% NN O
, , O
p NN O
< NNP O
0.05 CD O
) ) O
values NNS O
for IN O
the DT O
overall JJ O
group NN O
. . O

No DT O
differences NNS O
in IN O
6-month JJ B-OC
values NNS I-OC
were VBD O
present JJ O
( ( O
58 CD O
+/- JJ O
15 CD O
% NN O
versus NN O
62 CD O
+/- JJ O
15 CD O
% NN O
, , O
p NN O
= NNP O
NS NNP O
) ) O
for IN O
placebo NN B-INTV
and CC I-INTV
streptokinase NN I-INTV
groups NNS O
, , O
respectively RB O
. . O

Coronary JJ B-INTV
angiography NN I-INTV
was VBD O
performed VBN O
in IN O
75 CD O
% NN O
of IN O
the DT O
90 CD O
patients NNS O
eligible JJ O
for IN O
restudy NN O
. . O

Arterial JJ B-OC
patency NN I-OC
was VBD O
87 CD O
% NN O
at IN O
6 CD O
months NNS O
, , O
and CC O
coronary JJ B-OC
restenosis NN I-OC
was VBD O
present JJ O
in IN O
38 CD O
% NN O
of IN O
patients NNS O
. . O

No DT O
differences NNS O
in IN O
chronic JJ B-OC
patency NN I-OC
or CC I-OC
restenosis NN I-OC
were VBD O
detected VBN O
for IN O
the DT O
two CD O
treatment NN O
groups NNS O
. . O

Although IN O
adjunctive JJ O
intravenous JJ O
streptokinase NN B-INTV
therapy NN O
did VBD O
not RB O
improve VB O
outcome NN O
, , O
it PRP O
did VBD O
complicate VB O
the DT O
hospital NN O
course NN O
. . O

Hospitalization NNP B-OC
was VBD O
longer JJR O
( ( O
9.3 CD O
+/- JJ O
5.0 CD O
versus NN O
7.7 CD O
+/- JJ O
4.4 CD O
days NNS O
, , O
p VBP O
= RB O
0.046 CD O
) ) O
and CC O
more RBR O
costly JJ B-OC
( ( O
$ $ O
25,191 CD O
+/- JJ O
15,368 CD O
versus IN O
$ $ O
19,643 CD O
+/- JJ O
7,250 CD O
, , O
p NN O
< NNP O
0.02 CD O
) ) O
. . O

Transfusion NN B-OC
rate NN I-OC
was VBD O
higher JJR O
( ( O
39 CD O
% NN O
versus IN O
8 CD O
% NN O
, , O
p NN O
= NNP O
0.0001 CD O
) ) O
and CC O
need VBP O
for IN O
emergency NN O
coronary JJ O
bypass NN O
surgery NN O
was VBD O
greater JJR O
( ( O
10.3 CD O
% NN O
versus IN O
1.6 CD O
% NN O
, , O
p NN O
= NNP O
0.03 CD O
) ) O
for IN O
the DT O
streptokinase-treated JJ O
patients NNS O
. . O

CONCLUSIONS NNP O
Adjunctive NNP O
intravenous JJ O
streptokinase NN B-INTV
therapy NN I-INTV
does VBZ O
not RB O
enhance VB O
early JJ O
preservation NN O
of IN O
ventricular JJ B-OC
function NN I-OC
, , O
improve VB O
arterial JJ B-OC
patency NN I-OC
rates NNS I-OC
, , O
or CC O
lower JJR O
restenosis NN B-OC
rates NNS I-OC
after IN O
PTCA NNP B-INTV
therapy NN I-INTV
of IN O
acute JJ O
MI NNP O
. . O

Hospital NNP O
course NN O
is VBZ O
longer JJR O
, , O
more RBR O
expensive JJ O
, , O
and CC O
more RBR O
complicated JJ O
. . O

For IN O
these DT O
reasons NNS O
, , O
PTCA NNP B-INTV
therapy NN I-INTV
of IN O
acute JJ O
MI NNP O
should MD O
not RB O
be VB O
routinely RB O
performed VBN O
with IN O
adjunctive JJ O
intravenous JJ O
streptokinase NN B-INTV
therapy NN I-INTV
. . O

-DOCSTART- -X- O O

EEG NNP O
mapping NN O
and CC O
psychopharmacological JJ O
studies NNS O
with IN O
denbufylline NN B-INTV
in IN O
SDAT NNP B-POPU
and CC I-POPU
MID NNP I-POPU
. . O

Computed VBN O
tomography NN O
( ( O
CT NNP O
) ) O
, , O
electroencephalograms FW O
( ( O
EEG NNP O
) ) O
, , O
clinical JJ O
and CC O
psychometric JJ O
data NNS O
were VBD O
obtained VBN O
in IN O
96 CD B-POPU
mildly RB I-POPU
to TO I-POPU
moderately RB I-POPU
demented JJ I-POPU
patients NNS I-POPU
( ( I-POPU
72 CD I-POPU
women NNS I-POPU
, , I-POPU
24 CD I-POPU
men NNS I-POPU
) ) I-POPU
, , I-POPU
aged VBN I-POPU
61-96 CD I-POPU
years NNS I-POPU
( ( I-POPU
mean VB I-POPU
82 CD I-POPU
) ) I-POPU
, , I-POPU
diagnosed VBD I-POPU
according VBG I-POPU
to TO I-POPU
DSM-III NNP I-POPU
criteria NNS I-POPU
. . O

Patients NNS B-POPU
were VBD I-POPU
off RP I-POPU
drugs NNS I-POPU
for IN I-POPU
at IN I-POPU
least JJS I-POPU
2 CD I-POPU
weeks NNS I-POPU
and CC I-POPU
subdiagnosed VBD I-POPU
according VBG I-POPU
to TO I-POPU
the DT I-POPU
modified VBN I-POPU
Marshall-Hachinski NNP I-POPU
ischemic JJ I-POPU
score NN I-POPU
and CC I-POPU
CT NNP I-POPU
in IN I-POPU
45 CD I-POPU
senile JJ I-POPU
dementia NN I-POPU
of IN I-POPU
the DT I-POPU
Alzheimer NNP I-POPU
type NN I-POPU
( ( I-POPU
SDAT NNP I-POPU
) ) I-POPU
and CC I-POPU
51 CD I-POPU
multiinfarct NN I-POPU
dementia NN I-POPU
( ( I-POPU
MID NNP I-POPU
) ) I-POPU
patients NNS I-POPU
. . O

Evaluations NNS O
were VBD O
carried VBN O
out RP O
before IN O
and CC O
12 CD O
weeks NNS O
after IN O
treatment NN O
with IN O
either DT O
100 CD O
mg NNS O
denbufylline JJ B-INTV
BID NNP O
or CC O
placebo NN B-INTV
and CC O
included VBD O
EEG NNP O
mapping NN O
, , O
the DT O
Sandoz NNP O
Clinical NNP O
Assessment NNP O
Geriatric NNP O
( ( O
SCAG NNP O
) ) O
score/factors NNS O
, , O
the DT O
Clinical NNP O
Global NNP O
Impression NNP O
( ( O
CGI NNP O
) ) O
, , O
the DT O
Digit NNP O
Symbol NNP O
Substitution NNP O
Test NNP O
( ( O
DSST NNP O
) ) O
, , O
the DT O
Trail-Making JJ O
Test NNP O
( ( O
TMT NNP O
) ) O
and CC O
the DT O
Digit NNP O
Span NNP O
Test NNP O
( ( O
DS NNP O
) ) O
. . O

Descriptive NNP O
data NNS O
analysis NN O
including VBG O
confirmatory JJ O
statements NNS O
found VBN O
delta/theta JJ B-OC
activity NN I-OC
enhanced VBD O
, , O
alpha NN B-OC
and CC I-OC
beta NN I-OC
activity NN I-OC
reduced VBN O
, , O
total JJ B-OC
power NN I-OC
augmented VBN O
, , O
and CC O
the DT O
centroid NN B-OC
slowed VBD O
down RB O
over RB O
various JJ O
brain NN O
regions NNS O
in IN O
patients NNS O
as IN O
compared VBN O
with IN O
controls NNS O
. . O

The DT O
two CD O
subtypes NNS O
of IN O
dementia NN O
could MD O
be VB O
differentiated VBN O
in IN O
some DT O
conventional JJ O
EEG NNP O
variables NNS O
but CC O
mostly RB O
by IN O
means NNS O
of IN O
power NN O
asymmetry NN O
indices NNS O
. . O

Denbufylline NNP B-INTV
induced VBD O
a DT O
statistically RB O
significant JJ O
and CC O
clinically RB O
relevant JJ O
improvement NN B-OC
in IN I-OC
both DT I-OC
SDAT NNP I-OC
and CC I-OC
MID NNP I-OC
patients NNS O
, , O
whereas NNS O
after IN O
placebo NN B-INTV
this DT O
was VBD O
not RB O
the DT O
case NN O
in IN O
CGI NNP O
, , O
the DT O
TMT NNP O
, , O
and CC O
the DT O
DS NNP O
, , O
with IN O
interdrug JJ O
differences NNS O
being VBG O
significant JJ O
in IN O
all DT O
primary JJ O
target NN O
variables NNS O
such JJ O
as IN O
the DT O
CGI NNP B-OC
, , I-OC
MMS NNP I-OC
, , I-OC
SCAG NNP I-OC
, , I-OC
and CC I-OC
DSST NNP I-OC
. . O

Thus RB O
, , O
both DT O
the DT O
degenerative NN O
and CC O
vascular JJ O
type NN O
of IN O
dementia NN O
exhibited VBD O
a DT O
therapeutic JJ O
benefit NN O
that WDT O
could MD O
be VB O
objectified VBN O
at IN O
the DT O
neurophysiological JJ O
level NN O
by IN O
EEG NNP O
mapping NN O
in IN O
an DT O
improvement NN O
of IN O
vigilance NN O
. . O

-DOCSTART- -X- O O

Future NNP O
therapeutic JJ O
directions NNS O
for IN O
factor NN O
Xa NNP O
inhibition NN O
in IN O
the DT O
prophylaxis NN O
and CC O
treatment NN O
of IN O
thrombotic JJ B-POPU
disorders NNS I-POPU
. . O

The DT O
targeted JJ O
mechanism NN O
of IN O
factor NN O
Xa NNP O
inhibition NN O
has VBZ O
been VBN O
studied VBN O
extensively RB O
, , O
initially RB O
as IN O
prophylaxis NN O
for IN O
venous JJ B-POPU
thromboembolism NN I-POPU
( ( I-POPU
VTE NNP I-POPU
) ) I-POPU
in IN I-POPU
the DT I-POPU
orthopedic JJ I-POPU
surgical JJ I-POPU
setting NN I-POPU
. . O

Future NNP O
therapeutic JJ O
directions NNS O
for IN O
selective JJ O
factor NN O
Xa NNP O
inhibition NN O
in IN O
the DT O
management NN O
of IN O
other JJ O
thrombotic JJ O
diseases NNS O
are VBP O
discussed VBN O
. . O

Thromboembolic JJ O
diseases NNS O
can MD O
occur VB O
in IN O
the DT O
venous JJ O
or CC O
arterial JJ O
sides NNS O
of IN O
the DT O
circulatory NN O
system NN O
. . O

Factor NNP O
Xa NNP O
inhibition NN O
is VBZ O
a DT O
targeted JJ O
approach NN O
to TO O
anticoagulation VB O
that IN O
resulted VBD O
from IN O
significant JJ O
advances NNS O
in IN O
our PRP$ O
understanding NN O
of IN O
the DT O
coagulation NN O
cascade NN O
. . O

The DT O
factor NN B-INTV
Xa NNP I-INTV
inhibitor NN I-INTV
fondaparinux NN I-INTV
has VBZ O
been VBN O
studied VBN O
extensively RB O
in IN O
the DT O
orthopedic JJ O
surgical JJ O
setting NN O
for IN O
the DT O
prophylaxis NN O
of IN O
VTE NNP O
. . O

Current NNP O
investigations NNS O
that WDT O
are VBP O
under IN O
way NN O
or CC O
completed VBN O
evaluate VBP O
the DT O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
fondaparinux NN O
for IN O
the DT O
management NN O
of IN O
various JJ O
thrombotic JJ O
diseases NNS O
. . O

The DT O
future NN O
development NN O
of IN O
fondaparinux NN O
resides NNS O
primarily RB O
in IN O
three CD O
therapeutic JJ O
areas NNS O
: : O
prevention NN O
of IN O
VTE NNP O
, , O
treatment NN O
of IN O
VTE NNP O
, , O
and CC O
treatment NN O
of IN O
acute JJ B-OC
coronary JJ I-OC
syndromes NNS I-OC
. . O

For IN O
the DT O
prevention NN O
of IN O
VTE NNP O
, , O
fondaparinux NN B-INTV
has VBZ O
been VBN O
studied VBN O
as IN O
extended JJ O
prophylaxis NN O
following VBG O
hip NN O
fracture NN O
surgery NN O
( ( O
PENTHIFRA NNP O
Plus NNP O
) ) O
, , O
for IN O
use NN O
in IN O
high-risk JJ O
abdominal JJ O
surgical JJ O
patients NNS O
( ( O
PEGASUS NNP O
and CC O
APOLLO NNP O
) ) O
, , O
and CC O
for IN O
use NN O
in IN O
medical JJ O
patients NNS O
( ( O
ARTEMIS NNP O
) ) O
. . O

Studies NNPS O
evaluating VBG O
fondaparinux NN B-INTV
for IN O
the DT O
treatment NN O
of IN O
VTE NNP O
are VBP O
part NN O
of IN O
the DT O
large JJ O
MATISSE NNP O
clinical JJ O
program NN O
( ( O
MATISSE NNP O
DVT NNP O
and CC O
MATISSE NNP O
PE NNP O
) ) O
. . O

Fondaparinux NNP B-INTV
was VBD O
investigated VBN O
in IN O
phase NN O
2 CD O
studies NNS O
for IN O
the DT O
treatment NN O
of IN O
acute JJ B-POPU
coronary JJ I-POPU
syndromes NNS I-POPU
, , O
including VBG O
acute JJ B-OC
ST-segment JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
( ( I-OC
PENTALYSE NNP I-OC
) ) I-OC
and CC I-OC
unstable JJ I-OC
angina NN I-OC
( ( I-OC
PENTUA NNP I-OC
) ) I-OC
. . O

Encouraging VBG O
data NNS O
from IN O
these DT O
trials NNS O
are VBP O
the DT O
basis NN O
for IN O
phase NN O
3 CD O
programs NNS O
in IN O
this DT O
area NN O
( ( O
MICHELANGELO NNP O
) ) O
. . O

The DT O
orthopedic JJ O
prophylactic JJ O
and CC O
nonorthopedic JJ O
clinical JJ O
programs NNS O
for IN O
fondaparinux NN O
in IN O
the DT O
management NN O
of IN O
thrombosis NN O
support NN O
the DT O
concept NN O
that WDT O
targeted VBD B-OC
inhibition NN I-OC
of IN I-OC
coagulation NN I-OC
is VBZ O
an DT O
effective JJ B-OC
advance NN I-OC
in IN I-OC
antithrombotic JJ I-OC
therapy NN I-OC
. . O

-DOCSTART- -X- O O

Early JJ O
reperfusion NN B-INTV
and CC O
late JJ O
clinical JJ O
outcomes NNS O
in IN O
patients NNS B-POPU
presenting VBG I-POPU
with IN I-POPU
acute JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
randomly RB O
assigned VBN O
to TO O
primary VB B-INTV
percutaneous JJ I-INTV
coronary JJ I-INTV
intervention NN I-INTV
or CC O
streptokinase NN B-INTV
. . O

BACKGROUND NNP O
Primary NNP B-INTV
percutaneous JJ I-INTV
coronary JJ I-INTV
intervention NN I-INTV
( ( I-INTV
PCI NNP I-INTV
) ) I-INTV
has VBZ O
become VBN O
an DT O
alternative JJ O
to TO O
thrombolytic JJ B-INTV
therapy NN I-INTV
as IN O
a DT O
reperfusion NN O
strategy NN O
for IN O
ST-elevation NNP B-POPU
acute JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
( ( I-POPU
AMI NNP I-POPU
) ) I-POPU
. . O

METHODS PDT O
The DT O
main JJ O
goal NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
determine VB O
whether IN O
PCI NNP B-INTV
and CC O
thrombolytic JJ B-INTV
therapy NN I-INTV
achieve VBP O
comparable JJ O
reperfusion NN O
rates NNS O
, , O
as IN O
evidenced VBN O
by IN O
ST-segment JJ O
resolution NN O
. . O

Secondary JJ O
end NN O
points NNS O
included VBD O
infarct JJ B-OC
vessel NN I-OC
patency NN I-OC
rates NNS I-OC
before IN O
hospital JJ O
discharge NN O
and CC O
short- JJ B-OC
and CC I-OC
long-term JJ I-OC
outcomes NNS I-OC
. . O

Patients NNS B-POPU
with IN I-POPU
ischemic JJ I-POPU
chest NN I-POPU
pain NN I-POPU
with IN I-POPU
duration NN I-POPU
< NN I-POPU
or CC I-POPU
=12 NN I-POPU
hours NNS I-POPU
and CC I-POPU
no DT I-POPU
contraindication NN I-POPU
for IN I-POPU
thrombolytic JJ I-POPU
therapy NN I-POPU
were VBD I-POPU
included VBN I-POPU
. . O

RESULTS NNP O
Between NNP B-POPU
October NNP I-POPU
1993 CD I-POPU
and CC I-POPU
August NNP I-POPU
1995 CD I-POPU
, , I-POPU
58 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO I-POPU
streptokinase VB I-POPU
( ( I-POPU
SK NNP I-POPU
) ) I-POPU
and CC I-POPU
54 CD I-POPU
patients NNS I-POPU
to TO I-POPU
primary JJ I-POPU
PCI NNP I-POPU
. . O

Baseline NNP O
clinical JJ O
characteristics NNS O
and CC O
infarct JJ O
location NN O
were VBD O
well RB O
balanced VBN O
in IN O
both DT O
groups NNS O
. . O

Median JJ B-POPU
age NN I-POPU
( ( I-POPU
interquartile JJ I-POPU
range NN I-POPU
) ) I-POPU
was VBD I-POPU
68 CD I-POPU
( ( I-POPU
58 CD I-POPU
, , I-POPU
75 CD I-POPU
) ) I-POPU
years NNS I-POPU
, , I-POPU
29 CD I-POPU
% NN I-POPU
were VBD I-POPU
women NNS I-POPU
, , I-POPU
and CC I-POPU
78 CD I-POPU
% NN I-POPU
of IN I-POPU
the DT I-POPU
patients NNS I-POPU
met VBD I-POPU
at IN I-POPU
least JJS I-POPU
one CD I-POPU
criterion NN I-POPU
for IN I-POPU
" NNP I-POPU
not RB I-POPU
low JJ I-POPU
risk NN I-POPU
" NN I-POPU
AMI NNP I-POPU
( ( I-POPU
anterior JJ I-POPU
location NN I-POPU
, , I-POPU
age NN I-POPU
> VBD I-POPU
70 CD I-POPU
years NNS I-POPU
old JJ I-POPU
, , I-POPU
previous JJ I-POPU
MI NNP I-POPU
, , I-POPU
systolic JJ I-POPU
blood NN I-POPU
pressure NN I-POPU
< VBZ I-POPU
100 CD I-POPU
mm NN I-POPU
Hg NNP I-POPU
, , I-POPU
and/or JJ I-POPU
heart NN I-POPU
rate NN I-POPU
> VBD I-POPU
100 CD I-POPU
bpm NN I-POPU
) ) I-POPU
. . O

The DT O
median JJ B-OC
time NN I-OC
from IN I-OC
symptom JJ I-OC
onset VBN I-OC
to TO O
random VB O
assignment NN O
was VBD O
217 CD O
( ( O
139 CD O
, , O
335 CD O
) ) O
minutes NNS O
in IN O
the DT O
PCI NNP B-INTV
group NN O
and CC O
210 CD O
( ( O
145 CD O
, , O
334 CD O
) ) O
minutes NNS O
in IN O
the DT O
SK NNP B-INTV
group NN O
. . O

Median JJ O
random JJ O
assignment NN O
to TO O
balloon VB B-OC
time NN I-OC
was VBD O
82 CD O
( ( O
55 CD O
, , O
100 CD O
) ) O
minutes NNS O
, , O
and CC O
median JJ O
random NN O
assignment NN O
to TO O
needle JJ B-OC
time NN I-OC
was VBD O
15 CD O
( ( O
10 CD O
, , O
26 CD O
) ) O
minutes NNS O
( ( O
P NNP O
< NNP O
.0001 NNP O
) ) O
. . O

TIMI NNP B-OC
grade VBD I-OC
3 CD I-OC
flow NN I-OC
after IN O
primary JJ O
PCI NNP O
was VBD O
obtained VBN O
in IN O
85 CD O
% NN O
of IN O
patients NNS O
. . O

The DT O
proportion NN O
of IN O
patients NNS O
with IN O
ST-segment JJ B-INTV
resolution NN B-OC
> NN O
or CC O
=50 VB O
% NN O
at IN O
120 CD O
minutes NNS O
was VBD O
80 CD O
% NN O
in IN O
the DT O
PCI NNP O
group NN O
and CC O
50 CD O
% NN O
in IN O
the DT O
SK NNP O
group NN O
( ( O
P NNP O
=.001 NNP O
) ) O
. . O

The DT O
predischarge NN O
angiogram NN O
showed VBD O
the DT O
presence NN B-OC
of IN I-OC
TIMI NNP I-OC
3 CD I-OC
flow NN I-OC
in IN O
96 CD O
% NN O
of IN O
patients NNS O
who WP O
received VBD O
PCI NNP O
and CC O
65 CD O
% NN O
of IN O
patients NNS O
who WP O
received VBD O
SK NNP O
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
. . O

A DT O
composite JJ O
of IN O
in-hospital JJ B-OC
death NN I-OC
, , I-OC
reinfarction NN I-OC
, , I-OC
severe JJ I-OC
heart NN I-OC
failure NN I-OC
, , I-OC
stroke NN I-OC
, , I-OC
and CC I-OC
major JJ I-OC
bleeding NN I-OC
occurred VBD O
in IN O
15 CD O
% NN O
of IN O
patients NNS O
who WP O
received VBD O
PCI NNP O
and CC O
21 CD O
% NN O
of IN O
patients NNS O
who WP O
received VBD O
SK NNP O
( ( O
P NNP O
=.4 NNP O
) ) O
. . O

At IN O
3 CD O
years NNS O
, , O
freedom NN O
from IN O
the DT O
composite JJ B-OC
end NN I-OC
point NN I-OC
of IN I-OC
AMI NNP I-OC
, , I-OC
postdischarge NN I-OC
revascularization NN I-OC
, , I-OC
and CC I-OC
death NN I-OC
was VBD O
61 CD O
% NN O
in IN O
the DT O
PCI NNP O
group NN O
and CC O
40 CD O
% NN O
in IN O
the DT O
SK NNP O
group NN O
( ( O
P NNP O
=.025 NNP O
) ) O
. . O

CONCLUSIONS NNP O
Our PRP$ O
study NN O
shows VBZ O
that IN O
primary JJ O
PCI NNP O
, , O
as IN O
compared VBN O
with IN O
SK NNP O
, , O
is VBZ O
associated VBN O
with IN O
more RBR O
effective JJ O
ST-segment JJ B-OC
resolution NN I-OC
, , O
higher JJR O
patency NN B-OC
rates NNS I-OC
in IN O
the DT O
infarct JJ O
vessel NN O
at IN O
7 CD O
days NNS O
, , O
and CC O
more RBR O
favorable JJ O
clinical JJ O
outcomes NNS O
at IN O
3 CD O
years NNS O
of IN O
follow-up NN O
. . O

-DOCSTART- -X- O O

Determination NN O
of IN O
vital JJ O
status NN O
at IN O
the DT O
end NN O
of IN O
the DT O
DIG NNP O
trial NN O
. . O

The DT O
Digitalis NNP O
Investigation NNP O
Group NNP O
( ( O
DIG NNP O
) ) O
trial NN O
was VBD O
a DT O
randomized JJ O
, , O
double-blind JJ O
placebo-controlled JJ B-INTV
trial NN O
whose WP$ O
primary JJ O
objective NN O
was VBD O
to TO O
determine VB O
whether IN O
digoxin NN B-INTV
had VBD O
beneficial JJ O
, , O
harmful JJ O
, , O
or CC O
no DT O
effect NN O
on IN O
total JJ O
mortality NN O
in IN O
patients NNS B-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
who WP I-POPU
were VBD I-POPU
in IN I-POPU
sinus NN I-POPU
rhythm NN I-POPU
and CC I-POPU
whose WP$ I-POPU
ejection NN I-POPU
fraction NN I-POPU
was VBD I-POPU
< JJ I-POPU
/=0.45 NNP I-POPU
. . O

The DT O
study NN O
was VBD O
designed VBN O
as IN O
a DT O
large JJ O
simple JJ O
trial NN O
with IN O
a DT B-POPU
large JJ I-POPU
number NN I-POPU
of IN I-POPU
centers NNS I-POPU
( ( I-POPU
302 CD I-POPU
) ) I-POPU
in IN I-POPU
the DT I-POPU
United NNP I-POPU
States NNPS I-POPU
and CC I-POPU
Canada NNP I-POPU
, , I-POPU
many JJ I-POPU
of IN I-POPU
which WDT I-POPU
were VBD I-POPU
inexperienced VBN I-POPU
in IN I-POPU
research NN I-POPU
. . O

To TO O
ensure VB O
that IN O
the DT O
results NNS O
of IN O
the DT O
trial NN O
would MD O
be VB O
reported VBN O
accurately RB O
without IN O
possible JJ O
bias NN O
due JJ O
to TO O
missing VBG O
data NNS O
, , O
the DT O
study NN O
leadership NN O
decided VBD O
that IN O
no DT O
outcome NN O
results NNS O
would MD O
be VB O
reported VBN O
until IN O
the DT O
vital JJ O
status NN O
at IN O
the DT O
end NN O
of IN O
the DT O
study NN O
was VBD O
known VBN O
for IN O
at IN O
least JJS O
97 CD O
% NN O
of IN O
the DT O
study NN O
participants NNS O
. . O

Planning VBG O
for IN O
closeout NN O
of IN O
the DT O
study NN O
began VBD O
a DT O
year NN O
prior RB O
to TO O
the DT O
common JJ O
end NN O
date NN O
of IN O
December NNP O
31 CD O
, , O
1995 CD O
and CC O
included VBD O
plans NNS O
for IN O
obtaining VBG O
vital JJ O
status NN O
on IN O
December NNP O
31 CD O
, , O
1995 CD O
. . O

Participants NNS O
were VBD O
given VBN B-INTV
postcards NNS I-INTV
at IN I-INTV
their PRP$ I-INTV
final JJ I-INTV
study NN I-INTV
visit NN I-INTV
to TO I-INTV
be VB I-INTV
completed VBN I-INTV
and CC I-INTV
mailed VBN I-INTV
on IN I-INTV
or CC I-INTV
after IN I-INTV
January NNP I-INTV
1 CD I-INTV
, , I-INTV
1996 CD I-INTV
. . O

Of IN B-POPU
5602 CD I-POPU
postcards NNS I-POPU
distributed VBN I-POPU
, , I-POPU
5070 CD I-POPU
( ( I-POPU
90.5 CD I-POPU
% NN I-POPU
) ) I-POPU
were VBD I-POPU
completed VBN I-POPU
and CC I-POPU
returned VBN I-POPU
. . O

A DT O
contract NN O
search NN O
agency NN O
was VBD O
hired VBN O
to TO O
locate VB O
the DT O
remaining VBG O
participants NNS O
. . O

Of IN B-POPU
the DT I-POPU
total JJ I-POPU
7788 CD I-POPU
participants NNS I-POPU
entered VBD I-POPU
into IN I-POPU
the DT I-POPU
DIG NNP I-POPU
trial NN I-POPU
, , I-POPU
only RB I-POPU
97 CD I-POPU
participants NNS I-POPU
( ( I-POPU
1.2 CD I-POPU
% NN I-POPU
) ) I-POPU
could MD I-POPU
not RB I-POPU
have VB I-POPU
their PRP$ I-POPU
vital JJ I-POPU
status NN I-POPU
as IN I-POPU
of IN I-POPU
December NNP I-POPU
31 CD I-POPU
, , I-POPU
1995 CD I-POPU
determined VBD I-POPU
. . O

It PRP O
is VBZ O
recommended VBN O
that IN O
investigators NNS O
having VBG O
an DT O
outcome NN O
measure NN O
with IN O
a DT O
common JJ O
end NN O
date NN O
include VBP O
plans NNS O
in IN O
their PRP$ O
protocols NNS O
for IN O
obtaining VBG O
their PRP$ O
measures NNS O
and CC O
activate VBP O
those DT O
plans NNS O
as RB O
early RB O
as IN O
possible JJ O
during IN O
the DT O
course NN O
of IN O
the DT O
study NN O
. . O

-DOCSTART- -X- O O

Prediction NN O
of IN O
the DT O
response NN O
to TO O
citalopram VB B-INTV
and CC I-INTV
reboxetine VB I-INTV
in IN O
post-stroke NN B-POPU
depressed JJ I-POPU
patients NNS I-POPU
. . O

RATIONALE NNP O
AND NNP O
OBJECTIVE NNP O
Depression NNP O
is VBZ O
a DT O
significant JJ O
complication NN O
of IN O
stroke NN O
. . O

The DT O
effectiveness NN O
of IN O
antidepressant JJ O
drugs NNS O
in IN O
the DT O
management NN O
of IN O
post-stroke JJ O
depression NN O
( ( O
PSD NNP O
) ) O
has VBZ O
been VBN O
widely RB O
investigated VBN O
. . O

However RB O
, , O
the DT O
choice NN O
of IN O
antidepressant JJ O
drug NN O
is VBZ O
critically RB O
influenced VBN O
by IN O
its PRP$ O
safety NN B-OC
and CC O
tolerability NN B-OC
and CC O
by IN O
its PRP$ O
effect NN O
on IN O
concurrent NN O
pathologies NNS O
. . O

Here RB O
we PRP O
investigate VBP O
the DT O
efficacy NN O
and CC O
safety NN O
of IN O
a DT O
selective JJ O
serotonin NN B-INTV
reuptake NN I-INTV
inhibitor NN I-INTV
( ( I-INTV
SSRI NNP I-INTV
) ) I-INTV
, , I-INTV
citalopram NN I-INTV
, , I-INTV
and CC I-INTV
a DT I-INTV
noradrenaline JJ I-INTV
reuptake NN I-INTV
inhibitor NN I-INTV
( ( I-INTV
NARI NNP I-INTV
) ) I-INTV
, , I-INTV
reboxetine NN I-INTV
, , O
in IN O
post-stroke JJ B-POPU
patients NNS I-POPU
affected VBN I-POPU
by IN I-POPU
anxious JJ I-POPU
depression NN I-POPU
or CC I-POPU
retarded VBN I-POPU
depression NN I-POPU
. . O

METHODS NNP O
This DT O
was VBD O
a DT O
randomized JJ O
double-blind NN O
study NN O
. . O

Seventy-four JJ B-POPU
post-stroke NN I-POPU
depressed JJ I-POPU
patients NNS I-POPU
were VBD O
diagnosed VBN O
as IN O
affected VBN O
by IN O
anxious JJ O
or CC O
retarded VBN O
depression NN O
by IN O
using VBG O
a DT O
synoptic JJ O
table NN O
. . O

Randomisation NN O
was VBD O
planned VBN O
so RB O
that IN O
50 CD O
% NN O
of IN O
the DT O
patients NNS O
in IN O
each DT O
subgroup NN O
were VBD O
assigned VBN O
for IN O
16 CD O
weeks NNS O
to TO O
treatment NN O
with IN O
citalopram NN B-INTV
and CC O
the DT O
remaining VBG O
50 CD O
% NN O
were VBD O
assigned VBN O
to TO O
treatment NN O
with IN O
reboxetine NN B-INTV
. . O

The DT O
Beck NNP B-OC
Depression NNP I-OC
Inventory NNP I-OC
( ( I-OC
BDI NNP I-OC
) ) I-OC
, , I-OC
the DT I-OC
Hamilton NNP I-OC
Depression NNP I-OC
Rating NNP I-OC
Scale NNP I-OC
( ( I-OC
HDRS NNP I-OC
) ) I-OC
and CC O
a DT O
synoptic JJ O
table NN O
were VBD O
used VBN O
to TO O
score VB O
depressive JJ B-OC
symptoms NNS I-OC
. . O

RESULTS NNP O
Both NNP O
citalopram NN B-INTV
and CC O
reboxetine NN B-INTV
showed VBD O
good JJ O
safety NN B-OC
and CC I-OC
tolerability NN I-OC
. . O

Citalopram NNP O
exhibited VBD O
greater JJR B-OC
efficacy NN I-OC
in IN O
anxious JJ O
depressed JJ O
patients NNS B-POPU
, , O
while IN O
reboxetine NN B-INTV
was VBD O
more RBR O
effective JJ B-OC
in IN O
retarded JJ O
depressed JJ O
patients NNS O
. . O

CONCLUSIONS NNP O
Citalopram NNP B-INTV
or CC O
other JJ O
SSRIs NNP O
and CC O
reboxetine NN B-INTV
may MD O
be VB O
of IN O
first JJ O
choice NN O
treatment NN O
in IN O
PSD NNP O
because IN O
of IN O
their PRP$ O
good JJ O
efficacy NN B-OC
and CC I-OC
lack NN I-OC
of IN I-OC
severe JJ I-OC
side NN I-OC
effects NNS I-OC
. . O

In IN O
addition NN O
, , O
PSD NNP B-POPU
patients NNS I-POPU
should MD O
be VB O
classified VBN O
according VBG O
to TO O
their PRP$ O
clinical JJ O
profile NN O
( ( O
similarly RB O
to TO O
patients NNS O
affected VBN O
by IN O
primary JJ O
depression NN O
) ) O
for IN O
the DT O
selection NN O
of IN O
SSRIs NNP O
or CC O
reboxetine VB O
as IN O
drugs NNS O
of IN O
choice NN O
in IN O
particular JJ O
subgroups NNS O
of IN O
patients NNS O
. . O

-DOCSTART- -X- O O

Azimilide NNP B-INTV
decreases VBZ O
recurrent JJ B-OC
ventricular JJ I-OC
tachyarrhythmias NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
implantable JJ I-POPU
cardioverter NN I-POPU
defibrillators NNS I-POPU
. . O

OBJECTIVES VB O
This DT O
study NN O
evaluated VBD O
the DT O
effects NNS O
of IN O
azimilide JJ B-INTV
dihydrochloride NN I-INTV
( ( I-INTV
AZ NNP I-INTV
) ) I-INTV
on IN O
anti-tachycardia JJ B-OC
pacing NN I-OC
( ( I-OC
ATP NNP I-OC
) ) I-OC
and CC O
shock-terminated JJ B-OC
events NNS I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
implantable JJ I-POPU
cardioverter NN I-POPU
defibrillators NNS I-POPU
( ( I-POPU
ICDs NNP I-POPU
) ) I-POPU
. . O

BACKGROUND NNP O
Animal NNP O
studies NNS O
have VBP O
shown VBN O
the DT O
effectiveness NN O
of IN O
AZ NNP O
for IN O
therapy NN O
of IN O
supraventricular JJ O
and CC O
ventricular JJ O
tachycardia NN O
( ( O
VT NNP O
) ) O
. . O

Azimilide NNP B-INTV
dihydrochloride NN I-INTV
was VBD O
investigated VBN O
as IN O
adjunctive JJ O
treatment NN O
for IN O
reducing VBG O
the DT O
frequency NN O
of IN O
VT NNP O
and CC O
, , O
thus RB O
, , O
the DT O
need NN O
for IN O
ICD NNP O
therapies NNS O
, , O
including VBG O
ATP NNP O
and CC O
cardioversion/defibrillation NN O
( ( O
ICD NNP O
shocks NNS O
) ) O
in IN O
patients NNS O
with IN O
inducible JJ O
monomorphic JJ O
VT. NNP O
METHODS NNP O
A NNP O
total NN O
of IN O
172 CD B-POPU
patients NNS I-POPU
were VBD O
randomized VBN O
to TO O
daily VB O
treatment NN O
with IN O
placebo NN B-INTV
, , O
35 CD O
mg NN O
, , O
75 CD O
mg NN O
, , O
or CC O
125 CD O
mg NN O
of IN O
oral JJ B-INTV
AZ NNP I-INTV
in IN O
this DT O
dose-ranging JJ O
pilot NN O
study NN O
of IN O
patients NNS B-POPU
with IN I-POPU
ICDs NNP I-POPU
. . O

The DT B-POPU
majority NN I-POPU
of IN I-POPU
patients NNS I-POPU
had VBD I-POPU
a DT I-POPU
history NN I-POPU
of IN I-POPU
documented JJ I-POPU
remote JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
and CC I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
New NNP I-POPU
York NNP I-POPU
Heart NNP I-POPU
Association NNP I-POPU
class NN I-POPU
II NNP I-POPU
or CC I-POPU
III NNP I-POPU
. . O

RESULTS VB O
The DT O
frequency NN B-OC
of IN I-OC
appropriate JJ I-OC
shocks NNS I-OC
and CC I-OC
ATP NNP I-OC
were VBD O
significantly RB O
decreased VBN O
among IN O
AZ-treated JJ O
patients NNS O
compared VBN O
with IN O
placebo NN O
patients NNS O
. . O

The DT O
incidence NN B-OC
of IN I-OC
ICD NNP I-OC
therapies NNS I-OC
per IN I-OC
patient-year NN I-OC
among IN O
the DT O
placebo NN O
group NN O
was VBD O
36 CD O
, , O
and CC O
it PRP O
was VBD O
10 CD O
, , O
12 CD O
, , O
and CC O
9 CD O
among IN O
35 CD O
mg NNS O
, , O
75 CD O
mg NN O
, , O
and CC O
125 CD O
mg NNS O
AZ NNP O
patients NNS O
, , O
respectively RB O
( ( O
hazard JJ O
ratio NN O
= VBD O
0.31 CD O
, , O
p NN O
= NNP O
0.0001 CD O
) ) O
. . O

Azimilide NNP O
dihydrochloride NN O
was VBD O
generally RB O
well RB B-OC
tolerated VBN I-OC
and CC O
did VBD O
not RB O
affect VB B-OC
left VBD I-OC
ventricular JJ I-OC
ejection NN I-OC
fraction NN I-OC
or CC I-OC
minimal JJ I-OC
energy NN I-OC
requirements NNS I-OC
for IN I-OC
defibrillation NN I-OC
or CC I-OC
pacing NN I-OC
. . O

CONCLUSIONS NNP O
Azimilide NNP B-INTV
dihydrochloride NN I-INTV
may MD O
be VB O
a DT O
safe JJ O
and CC O
effective JJ O
drug NN O
for IN O
reducing VBG O
the DT O
frequency NN B-OC
of IN I-OC
VT NNP I-OC
and CC I-OC
ventricular JJ I-OC
fibrillation NN I-OC
in IN O
patients NNS O
with IN O
implanted JJ O
ICDs NNP O
. . O

-DOCSTART- -X- O O

Outcomes NNS B-POPU
in IN I-POPU
patients NNS I-POPU
with IN I-POPU
diabetes NNS I-POPU
mellitus VBP I-POPU
undergoing VBG I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
in IN I-POPU
the DT I-POPU
current JJ I-POPU
era NN I-POPU
: : I-POPU
a DT O
report NN O
from IN O
the DT O
Prevention NNP O
of IN O
REStenosis NNP O
with IN O
Tranilast NNP O
and CC O
its PRP$ O
Outcomes NNP O
( ( O
PRESTO NNP O
) ) O
trial NN O
. . O

BACKGROUND NNP O
Diabetes NNP O
portends VBZ O
an DT O
adverse JJ O
prognosis NN O
in IN O
patients NNS B-POPU
undergoing VBG I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
( ( I-POPU
PCI NNP I-POPU
) ) I-POPU
. . O

Whether PRP$ O
improvements NNS O
in IN O
current JJ O
clinical JJ O
practice NN O
( ( O
stents NNS O
, , O
IIb/IIIa NNP O
antagonists VBZ O
) ) O
have VBP O
resulted VBN O
in IN O
substantial JJ O
improvement NN O
of IN O
these DT O
outcomes NNS O
remains VBZ O
an DT O
issue NN O
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
determine VB O
the DT O
influence NN O
of IN O
diabetes NNS O
on IN O
9-month JJ O
outcomes NNS O
of IN O
patients NNS B-POPU
undergoing VBG I-POPU
PCI NNP I-POPU
in IN I-POPU
the DT I-POPU
current JJ I-POPU
era NN I-POPU
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
The DT B-POPU
11 CD I-POPU
482 CD I-POPU
patients NNS I-POPU
enrolled VBN I-POPU
in IN I-POPU
the DT I-POPU
Prevention NNP I-POPU
of IN I-POPU
REStenosis NNP I-POPU
with IN I-POPU
Tranilast NNP I-POPU
and CC I-POPU
its PRP$ I-POPU
Outcomes NNP I-POPU
( ( I-POPU
PRESTO NNP I-POPU
) ) I-POPU
Trial NNP I-POPU
were VBD O
stratified VBN O
according VBG O
to TO O
the DT O
presence NN O
( ( O
n=2694 JJ O
) ) O
or CC O
absence NN O
( ( O
n=8798 JJ O
) ) O
of IN O
diabetes NNS O
. . O

Diabetic JJ O
patients NNS O
were VBD O
older JJR O
; : O
were VBD O
more RBR O
likely JJ O
to TO O
be VB O
female JJ O
; : O
had VBD O
a DT O
higher JJR O
proportion NN O
of IN O
congestive JJ B-OC
failure NN I-OC
, , I-OC
hypertension NN I-OC
, , I-OC
prior JJ I-OC
CABG NNP I-OC
, , I-OC
and CC I-OC
unstable JJ I-OC
angina NN I-OC
; : I-OC
and CC O
had VBD O
higher JJR O
body NN B-OC
mass NN I-OC
index NN I-OC
and CC O
lower JJR O
ejection NN B-OC
fraction NN I-OC
than IN O
nondiabetic JJ O
patients NNS O
( ( O
P NNP O
< VBZ O
0.01 CD O
for IN O
all DT O
comparisons NNS O
) ) O
. . O

The DT O
degree NN B-OC
of IN I-OC
multivessel NN I-OC
disease NN I-OC
was VBD O
similar JJ O
between IN O
the DT O
two CD O
groups NNS O
. . O

American JJ O
College NNP O
of IN O
Cardiology/American NNP O
Heart NNP O
Association NNP O
type VBD B-OC
C NNP I-OC
lesions NNS I-OC
were VBD O
more JJR O
common JJ O
in IN O
diabetic JJ O
patients NNS O
( ( O
17 CD O
% NN O
versus IN O
15 CD O
% NN O
, , O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

Angiographic NNP B-OC
and CC I-OC
procedural JJ I-OC
success NN I-OC
rates NNS I-OC
and CC O
in-hospital JJ B-OC
events NNS I-OC
were VBD O
similar JJ O
between IN O
the DT O
two CD O
groups NNS O
. . O

The DT O
primary JJ O
end NN O
point NN O
of IN O
death NN B-OC
, , I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
or CC I-OC
target VB I-OC
vessel JJ I-OC
revascularization NN I-OC
( ( I-OC
TVR NNP I-OC
) ) I-OC
was VBD O
analyzed VBN O
as IN O
time-to-first JJ O
event NN O
within IN O
9 CD O
months NNS O
of IN O
the DT O
index NN O
PCI NNP B-INTV
. . O

After IN O
adjusting VBG O
for IN O
certain JJ O
baseline NN O
characteristics NNS O
, , O
diabetes NNS O
was VBD O
independently RB O
associated VBN O
with IN O
death NN B-OC
at IN O
9 CD O
months NNS O
( ( O
relative JJ O
risk NN O
[ NNP O
RR NNP O
] NNP O
, , O
1.87 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.31 CD O
to TO O
2.68 CD O
, , O
P NNP O
< NNP O
0.01 CD O
) ) O
and CC O
with IN O
an DT O
increased VBN O
likelihood NN O
of IN O
TVR NNP B-OC
( ( O
RR NNP O
, , O
1.27 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.14 CD O
to TO O
1.42 CD O
, , O
P NNP O
< NNP O
0.01 CD O
) ) O
, , O
as RB O
well RB O
as IN O
the DT O
composite JJ O
end NN O
point NN O
of IN O
death/myocardial JJ B-OC
infarction/TVR NN I-OC
( ( O
RR NNP O
, , O
1.26 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.13 CD O
to TO O
1.40 CD O
, , O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

CONCLUSIONS NNP O
Despite IN O
advances NNS O
in IN O
interventional JJ O
techniques NNS O
, , O
diabetes VBZ O
remains VBZ O
a DT O
significant JJ O
independent JJ O
predictor NN O
of IN O
adverse JJ O
events NNS O
in IN O
the DT O
intermediate JJ O
term NN O
after IN O
PCI NNP B-INTV
. . O

-DOCSTART- -X- O O

Single-needle JJ B-INTV
acupuncture NN I-INTV
alleviates VBZ O
gag JJ O
reflex NN O
during IN B-POPU
transesophageal JJ I-POPU
echocardiography NN I-POPU
: : I-POPU
a DT O
blinded VBN O
, , O
randomized VBN O
, , O
controlled VBD O
pilot NN O
trial NN O
. . O

OBJECTIVES UH O
To TO O
study VB O
the DT O
effect NN O
of IN O
single-needle JJ B-INTV
acupuncture NN I-INTV
in IN O
suppressing VBG O
gag-reflex JJ O
in IN O
transesophageal JJ O
echocardiography NN O
( ( O
TEE NNP O
) ) O
. . O

DESIGN NNP O
Prospective NNP O
, , O
blinded VBD O
trial NN O
. . O

Settings/locations NNS O
: : O
Patients NNS B-POPU
with IN I-POPU
ischemic JJ I-POPU
stroke NN I-POPU
or CC I-POPU
transient JJ I-POPU
ischemic JJ I-POPU
attack NN I-POPU
undergoing JJ I-POPU
TEE NNP I-POPU
because IN I-POPU
of IN I-POPU
presumed JJ I-POPU
cardioembolic JJ I-POPU
origin NN I-POPU
in IN I-POPU
a DT I-POPU
specialized JJ I-POPU
stroke NN I-POPU
unit NN I-POPU
of IN I-POPU
the DT I-POPU
Johann NNP I-POPU
Wolfgang NNP I-POPU
Goethe-University NNP I-POPU
, , I-POPU
Frankfurt/Main NNP I-POPU
, , I-POPU
Germany NNP I-POPU
. . O

Subjects/Study NNP O
interventions NNS O
: : O
Forty-one CD B-POPU
( ( I-POPU
41 CD I-POPU
) ) I-POPU
patients NNS I-POPU
were VBD I-POPU
studied VBN I-POPU
. . O

Patients NNS O
received VBD O
single-needle JJ B-INTV
acupuncture NN I-INTV
with IN O
a DT O
0.2 CD O
x NN O
13 CD O
mm NN O
disposable JJ O
acupuncture NN O
needle NN O
( ( O
Suzhou NNP O
Medical NNP O
Appliances NNP O
, , O
China NNP O
) ) O
, , O
10-mm JJ O
deep NN O
either NN O
at IN O
Chengjiang NNP O
( ( O
midline NN O
between IN O
lower JJR O
lip NN O
and CC O
chin NN O
) ) O
or CC O
superficially RB O
at IN O
a DT O
sham NN O
point NN O
( ( O
tip NN O
of IN O
the DT O
chin NN O
) ) O
during IN O
TEE NNP O
or CC O
no DT B-INTV
acupuncture NN I-INTV
for IN O
alleviating VBG O
gag NN O
reflex NN O
. . O

OUTCOME NNP O
MEASURES NNP O
Severity NNP B-OC
of IN I-OC
gagging NN I-OC
was VBD O
rated VBN O
on IN O
a DT O
visual-analogue JJ O
scale NN O
. . O

RESULTS VB O
The DT O
acupuncture NN O
group NN O
experienced VBD O
significantly RB O
less RBR B-OC
gagging VBG I-OC
than IN O
the DT O
sham NN O
group NN O
( ( O
p JJ O
= NNP O
0.037 CD O
) ) O
or CC O
the DT O
nonacupuncture NN O
group NN O
( ( O
p JJ O
= NNP O
0.013 CD O
) ) O
. . O

CONCLUSIONS NNP O
Acupuncture NNP B-INTV
of IN I-INTV
CV24 NNP I-INTV
is VBZ O
an DT O
easy JJ O
to TO O
apply VB O
and CC O
effective JJ O
method NN O
to TO O
reduce VB O
gag NN B-OC
reflex NN I-OC
during IN O
TEE NNP O
. . O

-DOCSTART- -X- O O

Reliance NN O
on IN O
visual JJ B-OC
information NN I-OC
after IN O
stroke NN O
. . O

Part NNP O
II NNP O
: : O
Effectiveness NN O
of IN O
a DT O
balance NN O
rehabilitation NN B-INTV
program NN I-INTV
with IN O
visual JJ B-INTV
cue NN I-INTV
deprivation NN I-INTV
after IN B-POPU
stroke NN I-POPU
: : I-POPU
a DT O
randomized NN O
controlled VBN O
trial NN O
. . O

OBJECTIVE UH O
To TO O
test VB O
the DT O
hypothesis NN O
that WDT O
balance NN O
rehabilitation NN B-INTV
with IN I-INTV
visual JJ I-INTV
cue NN I-INTV
deprivation NN I-INTV
improves VBZ O
balance NN B-OC
more RBR O
effectively RB O
than IN O
rehabilitation NN B-INTV
with IN I-INTV
free JJ I-INTV
vision NN I-INTV
. . O

DESIGN NNP O
Single-blind NNP O
, , O
randomized VBD O
controlled VBN O
trial NN O
. . O

SETTING NNP O
Public NNP B-POPU
rehabilitation NN I-POPU
center NN I-POPU
in IN I-POPU
France NNP I-POPU
. . O

PARTICIPANTS NNP O
Twenty NNP B-POPU
patients NNS I-POPU
with IN I-POPU
hemiplegia NN I-POPU
after IN I-POPU
a DT I-POPU
single-hemisphere JJ I-POPU
stroke NN I-POPU
that WDT I-POPU
occurred VBD I-POPU
at IN I-POPU
least JJS I-POPU
12 CD I-POPU
months NNS I-POPU
before IN I-POPU
the DT I-POPU
study NN I-POPU
. . O

INTERVENTION NNP O
Patients NNPS B-INTV
were VBD I-INTV
randomly RB I-INTV
assigned VBN I-INTV
to TO I-INTV
1 CD I-INTV
of IN I-INTV
2 CD I-INTV
balance NN I-INTV
rehabilitation NN I-INTV
programs-with NN I-INTV
and CC I-INTV
without IN I-INTV
visual JJ I-INTV
cue NN I-INTV
deprivation NN I-INTV
. . O

In IN B-INTV
all DT I-INTV
other JJ I-INTV
respects NNS I-INTV
, , I-INTV
the DT I-INTV
programs NNS I-INTV
were VBD I-INTV
identical JJ I-INTV
. . O

Each DT O
lasted VBD O
for IN O
1 CD O
hour NN O
and CC O
was VBD O
implemented VBN O
5 CD O
days NNS O
a DT O
week NN O
for IN O
4 CD O
weeks NNS O
. . O

All DT B-POPU
patients NNS I-POPU
completed VBD I-POPU
the DT I-POPU
program NN I-POPU
. . O

Mean NNP O
outcome JJ O
measures NNS O
Balance NNP B-OC
under IN O
6 CD O
sensory JJ O
conditions NNS O
was VBD O
assessed VBN O
by IN O
computerized JJ O
dynamic JJ B-OC
posturography NN I-OC
( ( I-OC
EquiTest NNP I-OC
) ) I-OC
, , I-OC
gait JJ I-OC
velocity NN I-OC
, , I-OC
timed VBD I-OC
stair NN I-OC
climbing NN I-OC
, , I-OC
and CC I-OC
self-assessment NN I-OC
of IN I-OC
ease NN I-OC
of IN I-OC
gait NN I-OC
before IN I-OC
and CC I-OC
after IN I-OC
program NN I-OC
completion NN I-OC
. . O

RESULTS NNP O
After IN O
completing VBG O
the DT O
program NN O
, , O
balance NN B-OC
, , I-OC
gait JJ I-OC
velocity NN I-OC
, , I-OC
and CC I-OC
self-assessment NN I-OC
of IN I-OC
gait NN I-OC
improved VBN O
significantly RB O
in IN O
all DT O
patients NNS O
. . O

The DT O
improvements NNS O
in IN O
gait NN B-OC
velocity NN I-OC
( ( O
P= NNP O
.03 NNP O
) ) O
and CC O
timed VBD B-OC
stair NN I-OC
climbing VBG I-OC
( ( O
P= NNP O
.01 NNP O
) ) O
correlated VBD O
significantly RB O
with IN O
improved JJ O
balance NN O
. . O

Balance NNP B-OC
improved VBD O
more RBR O
in IN O
the DT O
vision-deprived JJ O
group NN O
than IN O
in IN O
the DT O
free-vision NN O
group NN O
. . O

CONCLUSIONS NNP O
Balance NNP B-OC
improved VBD O
more RBR O
after IN O
rehabilitation NN O
with IN O
visual JJ B-INTV
deprivation NN I-INTV
than IN O
with IN O
free JJ B-INTV
vision NN I-INTV
. . O

Visual JJ O
overuse NN O
may MD O
be VB O
a DT O
compensatory NN O
strategy NN O
for IN O
coping VBG O
with IN O
initial JJ O
imbalance NN O
exacerbated VBN O
by IN O
traditional JJ O
rehabilitation NN O
. . O

-DOCSTART- -X- O O

Does NNP O
aerobic VB B-INTV
training VBG I-INTV
lead NN O
to TO O
a DT O
more RBR O
active JJ B-OC
lifestyle NN I-OC
and CC I-OC
improved JJ I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
? . O
BACKGROUND NNP O
Due NNP O
to TO O
dyspnea VB O
and CC O
fatigue VB O
, , O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
( ( I-POPU
CHF NNP I-POPU
) ) I-POPU
are VBP O
often RB O
restricted VBN O
in IN O
the DT O
performance NN O
of IN O
everyday JJ O
activities NNS O
, , O
which WDT O
gradually RB O
may MD O
lead VB O
to TO O
hypoactivity NN O
. . O

AIMS NNP O
To TO O
assess VB O
whether IN O
aerobic JJ B-INTV
training VBG I-INTV
leads NNS O
to TO O
a DT O
more RBR O
active JJ B-OC
lifestyle NN I-OC
and CC I-OC
improved JJ I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
( ( I-OC
QoL NNP I-OC
) ) I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
CHF NNP I-POPU
. . O

METHODS NNP O
Patients NNPS B-POPU
with IN I-POPU
stable JJ I-POPU
CHF NNP I-POPU
( ( I-POPU
NYHA NNP I-POPU
II/III NNP I-POPU
; : I-POPU
59 CD I-POPU
( ( I-POPU
11 CD I-POPU
) ) I-POPU
years NNS I-POPU
) ) I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
a DT O
training NN B-INTV
group NN O
( ( O
n=18 JJ O
; : O
3-month JJ O
aerobic JJ B-INTV
program NN I-INTV
above IN I-INTV
standard JJ I-INTV
treatment NN I-INTV
) ) I-INTV
or CC O
control VB B-INTV
group NN I-INTV
( ( O
n=16 RB O
; : O
standard JJ B-INTV
treatment NN I-INTV
without IN I-INTV
special JJ I-INTV
advice NN I-INTV
for IN I-INTV
exercise NN I-INTV
) ) I-INTV
. . O

Measurements NNS O
were VBD O
performed VBN O
on IN O
level NN O
of IN O
everyday JJ B-OC
physical JJ I-OC
activity NN I-OC
( ( I-OC
PA NNP I-OC
, , I-OC
novel JJ I-OC
accelerometry-based JJ I-OC
activity NN I-OC
monitor NN I-OC
) ) I-OC
and CC I-OC
QoL NNP I-OC
, , O
and CC O
on IN O
several JJ B-OC
related JJ I-OC
parameters NNS I-OC
. . O

RESULTS NNP O
Training VBG O
did VBD O
not RB O
result VB O
in IN O
a DT O
more RBR O
active JJ B-OC
lifestyle NN I-OC
or CC I-OC
improved VBN I-OC
QoL NNP I-OC
, , O
but CC O
improved VBD O
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
peak NN B-OC
power NN I-OC
( ( O
17 CD O
% NN O
) ) O
, , O
6-min JJ B-OC
walk NN I-OC
distance NN I-OC
( ( O
10 CD O
% NN O
) ) O
, , O
muscle NN B-OC
strength NN I-OC
( ( O
13-15 CD O
% NN O
) ) O
and CC O
depression NN B-OC
( ( O
-1.3 JJ O
unit NN O
) ) O
. . O

Changes NNS O
in IN O
level NN O
of IN O
everyday JJ O
PA NNP O
were VBD O
related VBN O
to TO O
changes NNS O
in IN O
peak NN B-OC
Vo NNP I-OC
( ( I-OC
2 CD I-OC
) ) I-OC
( ( O
r=0.58 NN O
, , O
P=0.01 NNP O
) ) O
and CC O
knee $ B-OC
extension NN I-OC
strength NN I-OC
( ( O
r=0.48 NN O
, , O
P=0.05 NNP O
) ) O
. . O

CONCLUSIONS NNP O
At IN O
group NN O
level NN O
training NN O
did VBD O
not RB O
result VB O
in IN O
a DT O
more RBR O
active JJ B-OC
lifestyle NN I-OC
or CC I-OC
improved VBN I-OC
QoL NNP I-OC
. . O

However RB O
, , O
correlations NNS O
between IN O
training-related JJ O
changes NNS O
in IN O
parameters NNS O
suggest VBP O
that IN O
aerobic JJ O
training NN O
has VBZ O
the DT O
potential JJ O
to TO O
increase VB O
levels NNS O
of IN O
everyday JJ B-OC
PA NNP I-OC
in IN O
CHF NNP O
. . O

-DOCSTART- -X- O O

Metoprolol NNP B-INTV
CR/XL NNP I-INTV
improves VBZ O
systolic JJ B-OC
and CC I-OC
diastolic JJ I-OC
left VBD I-OC
ventricular JJ I-OC
function NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

AIMS NNP O
To TO O
investigate VB O
whether IN O
metoprolol NN B-INTV
controlled VBN I-INTV
release/extended VBD I-INTV
release NN I-INTV
( ( I-INTV
CR/XL NNP I-INTV
) ) I-INTV
once RB O
daily RB O
would MD O
improve VB O
diastolic NN B-OC
and CC I-OC
systolic JJ I-OC
left VBD I-OC
ventricular JJ I-OC
function NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
and CC I-POPU
decreased JJ I-POPU
ejection NN I-POPU
fraction NN I-POPU
. . O

METHODS NNP O
In IN O
an DT O
echocardiographic JJ O
substudy NN O
to TO O
the DT O
Metoprolol NNP B-INTV
CR/XL NNP I-INTV
Randomized NNP O
Intervention NNP O
Trial NNP O
in IN O
Heart NNP O
Failure NNP O
( ( O
MERIT-HF NNP O
) ) O
, , O
66 CD B-POPU
patients NNS I-POPU
were VBD I-POPU
examined VBN I-POPU
three CD O
times NNS O
during IN O
a DT O
12-month JJ O
period NN O
blinded VBD O
to TO O
treatment NN O
group NN O
, , O
assessing VBG O
left VBD B-OC
ventricular JJ I-OC
dimensions NNS I-OC
and CC I-OC
ejection NN I-OC
fraction NN I-OC
, , I-OC
and CC I-OC
Doppler NNP I-OC
mitral JJ I-OC
inflow NN I-OC
parameters NNS I-OC
, , O
all DT O
measured VBN O
in IN O
a DT O
core NN O
laboratory NN O
. . O

RESULTS NNP O
In IN O
the DT O
metoprolol NN B-INTV
CR/XL NNP I-INTV
group NN O
left VBD B-OC
ventricular JJ I-OC
ejection NN I-OC
fraction NN I-OC
increased VBD O
from IN O
0.26 CD O
to TO O
0.31 CD O
( ( O
P NNP O
= NNP O
0.009 CD O
) ) O
after IN O
a DT O
mean JJ O
observation NN O
period NN O
of IN O
10.6 CD O
months NNS O
, , O
and CC O
deceleration NN O
time NN B-OC
of IN I-OC
the DT I-OC
early JJ I-OC
mitral JJ I-OC
filling NN I-OC
wave NN I-OC
( ( O
E NNP O
) ) O
increased VBD O
from IN O
189 CD O
to TO O
246 CD O
ms NN O
( ( O
P NNP O
= NNP O
0.0012 CD O
) ) O
, , O
time NN B-OC
velocity JJ I-OC
integral JJ I-OC
of IN I-OC
E-wave NNP I-OC
increased VBD O
from IN O
8.7 CD O
to TO O
11.2 CD O
cm NN O
( ( O
P NNP O
= NNP O
0.018 CD O
) ) O
, , O
and CC O
the DT O
duration NN B-OC
of IN I-OC
the DT I-OC
late JJ I-OC
mitral JJ I-OC
filling NN I-OC
wave NN I-OC
( ( O
A NNP O
) ) O
increased VBD O
from IN O
122 CD O
to TO O
145 CD O
ms NN O
( ( O
P NNP O
= NNP O
0.014 CD O
) ) O
. . O

No DT O
significant JJ O
changes NNS O
were VBD O
seen VBN O
in IN O
the DT O
placebo NN B-INTV
group NN O
regarding VBG O
any DT O
of IN O
these DT O
variables NNS O
. . O

CONCLUSION NNP O
Metoprolol NNP B-INTV
CR/XL NNP I-INTV
once RB O
daily RB O
in IN O
addition NN O
to TO O
standard VB O
therapy NN O
improved VBN O
both DT O
diastolic JJ B-OC
and CC I-OC
systolic JJ I-OC
function NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
and CC I-POPU
decreased JJ I-POPU
ejection NN I-POPU
fraction NN I-POPU
. . O

-DOCSTART- -X- O O

The DT O
reversibility NN O
of IN O
increased JJ O
airways NNS O
resistance NN O
in IN O
chronic JJ B-POPU
heart NN I-POPU
failure NN I-POPU
measured VBN O
by IN O
impulse JJ O
oscillometry NN O
. . O

BACKGROUND NNP O
Patients NNPS B-POPU
with IN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
complain NN O
of IN O
breathlessness NN O
and CC O
fatigue NN O
on IN O
exercise NN O
. . O

Airways NNS O
resistance NN O
is VBZ O
increased VBN O
and CC O
lung JJ O
compliance NN O
is VBZ O
reduced VBN O
in IN O
chronic JJ B-POPU
heart NN I-POPU
failure NN I-POPU
patients NNS I-POPU
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
determine VB O
whether IN O
the DT O
pulmonary JJ O
abnormalities NNS O
are VBP O
reversible JJ O
and CC O
whether IN O
any DT O
improvements NNS O
lead VBP O
to TO O
changes NNS O
to TO O
exercise VB O
capacity NN O
or CC O
symptoms NNS O
. . O

METHODS NNP O
Twelve NNP B-POPU
patients NNS I-POPU
with IN I-POPU
stable JJ I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
and CC I-POPU
10 CD I-POPU
matched VBD I-POPU
controls NNS I-POPU
underwent JJ O
repeated VBD O
assessment NN O
of IN O
airways NNS O
resistance NN O
using VBG O
impulse JJ O
oscillometry NN B-INTV
and CC I-INTV
peak NN I-INTV
exercise NN I-INTV
testing VBG I-INTV
with IN I-INTV
metabolic NNP I-INTV
gas NN I-INTV
exchange NN I-INTV
after IN O
receiving VBG O
nebulized JJ B-INTV
saline NN I-INTV
as IN I-INTV
placebo NN I-INTV
or CC O
combined VBN B-INTV
salbutamol NNS I-INTV
and CC I-INTV
ipratropium NN I-INTV
bromide NN I-INTV
in IN O
a DT O
double-blind JJ O
crossover NN O
randomized VBN O
fashion NN O
. . O

RESULTS JJ O
Patients NNS O
had VBD O
lower JJR O
peak NN B-OC
oxygen NN I-OC
consumption NN I-OC
and CC O
a DT O
steeper JJ O
slope NN O
relating VBG O
ventilation NN O
to TO O
carbon VB O
dioxide NN O
production NN O
than IN O
controls NNS O
. . O

Bronchodilators NNS O
reduced VBD O
peripheral JJ O
airways NNS O
resistance NN O
in IN O
patients NNS O
( ( O
0.53 CD O
versus NN O
0.38 CD O
, , O
P NNP O
< NNP O
.02 NNP O
) ) O
and CC O
controls NNS O
( ( O
0.21 CD O
versus NN O
0.19 CD O
, , O
P NNP O
< NNP O
.005 NNP O
) ) O
and CC O
increased JJ O
measures NNS O
of IN O
compliance NN O
in IN O
both DT O
groups NNS O
. . O

There EX O
was VBD O
no DT O
effect NN O
on IN O
the DT O
peak NN B-OC
oxygen NN I-OC
consumption NN I-OC
, , I-OC
exercise NN I-OC
time NN I-OC
, , I-OC
ventilation NN I-OC
to TO I-OC
carbon VB I-OC
dioxide NN I-OC
slope NN I-OC
, , I-OC
or CC I-OC
anaerobic JJ I-OC
threshold NN I-OC
. . O

There EX O
was VBD O
an DT O
increase NN O
in IN O
peak JJ B-OC
tidal JJ I-OC
volume NN I-OC
( ( I-OC
VT NNP I-OC
) ) I-OC
in IN O
both DT O
groups NNS O
but CC O
this DT O
did VBD O
not RB O
lead VB O
to TO O
an DT O
increase NN O
in IN O
peak JJ B-OC
ventilation NN I-OC
. . O

The DT O
slope NN O
relating VBG O
symptoms NNS O
to TO O
ventilation NN B-OC
( ( O
ie JJ O
, , O
Borg/VE NNP O
) ) O
was VBD O
significantly RB O
reduced VBN O
in IN O
the DT O
patients NNS O
after IN O
bronchodilators NNS O
( ( O
17 CD O
% NN O
+/-8 JJ O
% NN O
, , O
P NNP O
< NNP O
.05 NNP O
) ) O
. . O

The DT O
relationship NN O
between IN O
the DT O
improvement NN O
in IN O
VT NNP O
and CC O
reduction NN O
in IN O
gradient NN O
of IN O
the DT O
Borg/VE NNP B-OC
slope NN I-OC
was VBD O
significant JJ O
( ( O
r=.40 NN O
, , O
P NNP O
< NNP O
.05 NNP O
) ) O
. . O

CONCLUSIONS NNP O
Nebulized NNP O
bronchodilators NNS O
improve VBP O
airways NNS B-OC
resistance NN I-OC
, , I-OC
lung NN I-OC
reactance NN I-OC
, , I-OC
and CC I-OC
peak JJ I-OC
tidal JJ I-OC
volume NN I-OC
during IN O
exercise NN O
in IN O
chronic JJ O
heart NN O
failure NN O
but CC O
do VBP O
not RB O
increase VB O
peak NN O
exercise NN O
capacity NN O
. . O

They PRP O
do VBP O
, , O
however RB O
, , O
reduce VB O
the DT O
symptom NN B-OC
of IN I-OC
breathlessness NN I-OC
. . O

-DOCSTART- -X- O O

A DT O
description NN O
of IN O
the DT O
clinical JJ O
characteristics NNS O
at IN O
baseline NN O
of IN O
patients NNS B-POPU
recruited VBN I-POPU
into IN I-POPU
the DT I-POPU
Carvedilol NNP I-POPU
or CC I-POPU
Metoprolol NNP I-POPU
European JJ I-POPU
Trial NNP I-POPU
( ( I-POPU
COMET NNP I-POPU
) ) I-POPU
. . O

BACKGROUND NNP O
& CC O
AIMS NNP O
The DT O
COMET NNP B-INTV
trial NN O
was VBD O
a DT O
prospective JJ O
, , O
double-blind JJ O
, , O
randomised JJ O
trial NN O
comparing VBG O
carvedilol NN B-INTV
, , O
a DT O
comprehensive JJ O
adrenergic NN O
receptor NN O
antagonist NN B-INTV
, , O
with IN O
metoprolol NN B-INTV
, , I-INTV
a DT I-INTV
beta-1-selective JJ I-INTV
agent NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
and CC I-POPU
left VBD I-POPU
ventricular JJ I-POPU
systolic JJ I-POPU
dysfunction NN I-POPU
. . O

The DT O
trial NN O
showed VBD O
a DT O
reduction NN O
in IN O
mortality NN B-OC
with IN O
carvedilol NN B-INTV
that WDT O
was VBD O
consistent JJ O
across IN O
subgroups NNS O
. . O

The DT O
purpose NN O
of IN O
this DT O
report NN O
is VBZ O
to TO O
describe VB O
in IN O
greater JJR O
detail NN O
the DT O
heterogeneity NN O
of IN O
this DT O
population NN O
at IN O
baseline NN O
with IN O
particular JJ O
reference NN O
to TO O
the DT O
impact NN O
of IN O
symptomatic JJ O
severity NN O
, , O
age NN O
and CC O
gender NN O
on IN O
patient JJ O
characteristics NNS O
. . O

METHODS NNP O
A NNP O
descriptive JJ O
report NN O
using VBG O
data NNS O
entered VBN O
in IN O
the DT O
COMET NNP B-INTV
study NN O
data-base NN O
. . O

RESULTS VB O
The DT O
characteristics NNS O
of IN O
the DT O
population NN O
studied VBN O
were VBD O
similar JJ O
to TO O
those DT O
reported VBN O
in IN O
previous JJ O
trials NNS O
of IN O
beta-blockers NNS O
. . O

Almost NNP B-POPU
all DT I-POPU
patients NNS I-POPU
were VBD I-POPU
receiving VBG I-POPU
diuretics NNS I-POPU
and CC I-POPU
ACE NNP I-POPU
inhibitors NNS I-POPU
with IN I-POPU
few JJ I-POPU
patients NNS I-POPU
taking VBG I-POPU
angiotensin JJ I-POPU
receptor NN I-POPU
blockers NNS I-POPU
. . O

As IN O
expected VBN O
, , O
older JJR O
patients NNS O
had VBD O
more RBR O
co-morbidity JJ B-OC
. . O

Older JJR O
patients NNS O
and CC O
women NNS O
reported VBD O
worse JJR O
symptoms NNS B-OC
and CC I-OC
poorer JJR I-OC
well-being JJ I-OC
despite IN O
similar JJ O
ventricular JJ B-OC
dimensions NNS I-OC
and CC I-OC
systolic JJ I-OC
dysfunction NN I-OC
. . O

NT-proBNP NNP B-OC
was VBD O
higher RBR O
in IN O
patients NNS O
with IN O
more RBR O
severe JJ B-OC
symptoms NNS I-OC
and CC O
older JJR O
patients NNS O
but CC O
not RB O
in IN O
women NNS O
, , O
although IN O
differences NNS O
in IN O
NT-proBNP NNP O
may MD O
have VB O
been VBN O
confounded VBN O
by IN O
differences NNS O
in IN O
renal JJ B-OC
function NN I-OC
. . O

CONCLUSION NNP O
Age NNP O
and CC O
gender NN O
, , O
as RB O
well RB O
as IN O
the DT O
severity NN O
of IN O
cardiac JJ O
dysfunction NN O
, , O
appear VBP O
to TO O
have VB O
an DT O
important JJ O
effect NN O
on IN O
the DT O
severity NN O
of IN O
heart NN B-OC
failure NN I-OC
symptoms NNS I-OC
and CC O
patient JJ B-OC
'well-being NN I-OC
' POS I-OC
. . O

This DT O
could MD O
have VB O
important JJ O
implications NNS O
for IN O
the DT O
relationship NN O
between IN O
symptoms NNS O
and CC O
prognosis NN O
and CC O
therefore RB O
the DT O
way NN O
in IN O
which WDT O
patients NNS O
are VBP O
selected VBN O
for IN O
clinical JJ O
trials NNS O
and CC O
the DT O
goals NNS O
of IN O
treatment NN O
. . O

This DT O
will MD O
be VB O
the DT O
subject NN O
of IN O
further JJ O
analyses NNS O
. . O

-DOCSTART- -X- O O

Is VBZ O
individual JJ B-INTV
peer NN I-INTV
support NN I-INTV
a DT O
promising NN O
intervention NN O
for IN O
persons NNS B-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
? . O
Peer NNP B-INTV
support NN I-INTV
has VBZ O
been VBN O
used VBN O
effectively RB O
in IN O
a DT O
variety NN O
of IN O
patient JJ O
populations NNS O
, , O
but CC O
its PRP$ O
effectiveness NN O
in IN O
improving VBG O
outcomes NNS O
in IN O
persons NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
has VBZ O
not RB O
been VBN O
explored VBN O
. . O

We PRP O
trained VBD O
9 CD B-POPU
persons NNS I-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
to TO I-POPU
mentor VB I-POPU
other JJ I-POPU
heart NN I-POPU
failure NN I-POPU
patients NNS I-POPU
and CC O
tested VBD O
the DT O
effectiveness NN O
of IN O
this DT O
approach NN O
in IN O
a DT O
randomized NN O
controlled VBD O
clinical JJ O
trial NN O
. . O

A DT O
low JJ O
proportion NN O
( ( B-POPU
37 CD I-POPU
% NN I-POPU
) ) I-POPU
of IN I-POPU
the DT I-POPU
eligible JJ I-POPU
population NN I-POPU
of IN I-POPU
hospitalized JJ I-POPU
patients NNS I-POPU
agreed VBD I-POPU
to TO I-POPU
participate VB I-POPU
. . O

At IN O
the DT O
end NN O
of IN O
the DT O
3-month JJ O
trial NN O
, , O
there EX O
was VBD O
significantly RB O
higher JJR O
heart NN B-OC
failure NN I-OC
self-care NN I-OC
in IN O
the DT O
intervention NN O
group NN O
( ( O
P NNP O
< NNP O
.05 NNP O
) ) O
. . O

The DT O
only JJ O
difference NN O
in IN O
social JJ O
support NN O
was VBD O
a DT O
significant JJ O
decline NN O
in IN O
perceived JJ O
support NN B-OC
reciprocity NN I-OC
in IN O
the DT O
intervention NN O
group NN O
( ( O
F NNP O
= NNP O
5.94 CD O
, , O
P NNP O
= NNP O
.004 NNP O
) ) O
. . O

No DT O
significant JJ O
group NN O
differences NNS O
in IN O
heart NN B-OC
failure NN I-OC
readmissions NNS I-OC
, , I-OC
length NN I-OC
of IN I-OC
stay NN I-OC
, , I-OC
or CC I-OC
cost NN I-OC
were VBD O
evident JJ O
at IN O
90-days CD O
, , O
although IN O
the DT O
heart NN B-OC
failure NN I-OC
readmission NN I-OC
rate NN I-OC
was VBD O
96 CD O
% NN O
higher JJR O
in IN O
the DT O
intervention NN O
group NN O
when WRB O
compared VBN O
to TO O
that DT O
in IN O
the DT O
control NN O
group NN O
. . O

The DT O
reasons NNS O
for IN O
low JJ B-OC
overall JJ I-OC
enrollment NN I-OC
and CC I-OC
high JJ I-OC
readmission NN I-OC
rates NNS I-OC
in IN O
the DT O
intervention NN O
group NN O
require VBP O
further JJ O
study NN O
. . O

Including VBG O
additional JJ O
self-care JJ O
education NN O
by IN O
a DT O
professional JJ O
, , O
rather RB O
than IN O
leaving VBG O
all PDT O
the DT O
education NN O
to TO O
the DT O
mentor NN O
, , O
could MD O
strengthen VB O
the DT O
peer NN O
support NN O
intervention NN O
trialed VBN O
in IN O
this DT O
study NN O
. . O

Small NNP O
group NN O
meetings NNS O
may MD O
be VB O
less JJR O
intrusive JJ O
and CC O
more RBR O
desirable JJ O
for IN O
this DT O
patient JJ O
population NN O
. . O

-DOCSTART- -X- O O

The DT O
A-V NNP B-INTV
Impulse NNP I-INTV
System NNP I-INTV
reduces VBZ O
deep-vein JJ B-POPU
thrombosis NN I-POPU
and CC I-POPU
swelling NN I-POPU
after IN I-POPU
hemiarthroplasty NN I-POPU
for IN I-POPU
hip NN I-POPU
fracture NN I-POPU
. . O

We PRP O
performed VBD O
a DT O
prospective JJ O
randomised VBN O
controlled JJ O
trial NN O
of IN O
the DT O
A-V NNP B-INTV
Impulse NNP I-INTV
System NNP I-INTV
in IN O
82 CD B-POPU
patients NNS I-POPU
treated VBN I-POPU
by IN I-POPU
hemiarthroplasty NN I-POPU
for IN I-POPU
subcapital JJ I-POPU
fracture NN I-POPU
of IN I-POPU
the DT I-POPU
femoral JJ I-POPU
neck NN I-POPU
. . O

The DT O
incidence NN O
of IN O
proximal JJ O
deep-vein JJ O
thrombosis NN O
as IN O
assessed VBN O
by IN O
Doppler NNP B-INTV
ultrasonography NN I-INTV
was VBD O
23 CD O
% NN O
in IN O
the DT O
control NN O
group NN O
and CC O
0 CD O
% NN O
in IN O
those DT O
using VBG O
the DT O
device NN O
( ( O
p NN O
less JJR O
than IN O
0.01 CD O
) ) O
. . O

Calf NNP O
and CC O
thigh JJ O
circumferences NNS O
were VBD O
measured VBN O
in IN O
both DT O
groups NNS O
at IN O
seven CD O
to TO O
ten VB O
days NNS O
after IN O
operation NN O
. . O

In IN O
the DT O
treatment NN O
group NN O
there EX O
was VBD O
a DT O
mean JJ B-OC
relative JJ I-OC
reduction NN I-OC
of IN I-OC
postoperative JJ I-OC
swelling NN I-OC
of IN I-OC
the DT I-OC
thigh NN I-OC
by IN O
3.27 CD O
cm NN O
( ( O
p NN O
less JJR O
than IN O
0.001 CD O
) ) O
and CC O
of IN O
the DT O
calf NN O
by IN O
1.55 CD O
cm NN O
( ( O
p NN O
less JJR O
than IN O
0.001 CD O
) ) O
. . O

The DT O
A-V NNP O
Impulse NNP O
System NNP O
appears VBZ O
to TO O
be VB O
a DT O
safe JJ B-OC
and CC O
effective JJ O
method NN O
of IN O
reducing VBG O
the DT O
incidence NN B-OC
of IN I-OC
proximal JJ I-OC
deep-vein JJ I-OC
thrombosis NN I-OC
, , I-OC
and CC I-OC
of IN I-OC
postoperative JJ I-OC
swelling NN I-OC
. . O

-DOCSTART- -X- O O

Randomized VBN O
, , O
double-blind JJ O
, , O
placebo-controlled JJ B-INTV
trial NN O
of IN O
oral JJ O
sirolimus NN O
for IN O
restenosis NN B-OC
prevention NN O
in IN O
patients NNS B-POPU
with IN I-POPU
in-stent JJ I-POPU
restenosis NN I-POPU
: : I-POPU
the DT O
Oral NNP O
Sirolimus NNP B-INTV
to TO O
Inhibit NNP O
Recurrent NNP O
In-stent JJ O
Stenosis NNP O
( ( O
OSIRIS NNP O
) ) O
trial NN O
. . O

BACKGROUND NNP O
Despite IN O
recent JJ O
advances NNS O
in IN O
interventional JJ O
cardiology NN O
, , O
including VBG O
the DT O
introduction NN O
of IN O
drug-eluting JJ O
stents NNS O
for IN O
de FW O
novo FW O
coronary JJ O
lesions NNS O
, , O
the DT O
treatment NN O
of IN O
in-stent JJ O
restenosis NN O
( ( O
ISR NNP O
) ) O
remains VBZ O
a DT O
challenging JJ O
clinical JJ O
issue NN O
. . O

Given VBN O
the DT O
efficacy NN O
of IN O
systemic JJ O
sirolimus JJ O
administration NN O
to TO O
prevent VB O
neointimal JJ B-OC
hyperplasia NN I-OC
in IN O
animal JJ O
models NNS O
and CC O
to TO O
halt VB O
and CC O
even RB O
reverse VB O
the DT O
progression NN O
of IN O
allograft NN O
vasculopathy NN O
, , O
the DT O
aim NN O
of IN O
the DT O
present JJ O
double-blind NN O
, , O
placebo-controlled JJ O
study NN O
was VBD O
to TO O
evaluate VB O
the DT O
efficacy NN O
of IN O
a DT O
10-day JJ O
oral JJ O
sirolimus NN O
treatment NN O
with IN O
2 CD O
different JJ O
loading VBG O
regimens NNS O
for IN O
the DT O
prevention NN O
of IN O
recurrent JJ O
restenosis NN O
in IN O
patients NNS B-POPU
with IN I-POPU
ISR NNP I-POPU
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
Three NNP B-POPU
hundred VBD I-POPU
symptomatic JJ I-POPU
patients NNS I-POPU
with IN I-POPU
ISR NNP I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
1 CD O
of IN O
3 CD O
treatment NN O
arms NNS O
: : O
placebo NN B-INTV
or CC I-INTV
usual-dose JJ I-INTV
or CC I-INTV
high-dose JJ I-INTV
sirolimus NN I-INTV
. . O

Patients NNS O
received VBD O
a DT O
cumulative JJ O
loading NN O
dose NN O
of IN O
0 CD O
, , O
8 CD O
, , O
or CC O
24 CD O
mg NN O
of IN O
sirolimus JJ O
2 CD O
days NNS O
before IN O
and CC O
the DT O
day NN O
of IN O
repeat NN O
intervention NN O
followed VBN O
by IN O
maintenance NN O
therapy NN O
of IN O
2 CD O
mg/d NN O
for IN O
7 CD O
days NNS O
. . O

Angiographic JJ B-OC
restenosis NN I-OC
at IN I-OC
6-month JJ B-INTV
angiography NN I-INTV
was VBD O
the DT O
primary JJ O
end NN O
point NN O
of IN O
the DT O
study NN O
. . O

Restenosis NNP B-OC
was VBD O
significantly RB O
reduced VBN O
from IN O
42.2 CD O
% NN O
to TO O
38.6 CD O
% NN O
and CC O
to TO O
22.1 CD O
% NN O
in IN O
the DT O
placebo NN O
, , O
usual-dose JJ O
, , O
and CC O
high-dose JJ O
sirolimus NN O
groups NNS O
, , O
respectively RB O
( ( O
P=0.005 NNP O
) ) O
. . O

Similarly RB O
, , O
the DT O
need NN B-OC
for IN I-OC
target NN I-OC
vessel JJ I-OC
revascularization NN I-OC
was VBD O
reduced VBN O
from IN O
25.5 CD O
% NN O
to TO O
24.2 CD O
% NN O
and CC O
to TO O
15.2 CD O
% NN O
in IN O
the DT O
placebo NN O
, , O
usual-dose JJ O
, , O
and CC O
high-dose JJ O
groups NNS O
, , O
respectively RB O
( ( O
P=0.08 NNP O
) ) O
. . O

The DT B-OC
sirolimus JJ I-OC
blood NN I-OC
concentration NN I-OC
on IN O
the DT O
day NN O
of IN O
the DT O
procedure NN O
correlated VBD O
significantly RB O
with IN O
the DT O
late JJ O
lumen NNS O
loss NN O
at IN O
follow-up JJ O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

CONCLUSIONS NNP O
In IN O
patients NNS O
with IN O
ISR NNP O
, , O
an DT O
oral JJ O
adjunctive JJ O
sirolimus NN O
treatment NN O
with IN O
an DT O
intensified JJ O
loading NN O
regimen NNS O
before IN O
coronary JJ O
intervention NN O
resulted VBD O
in IN O
a DT O
significant JJ O
improvement NN O
in IN O
the DT O
angiographic JJ B-OC
parameters NNS I-OC
of IN I-OC
restenosis NN I-OC
. . O

-DOCSTART- -X- O O

Impact NN O
of IN O
angiotensin-converting JJ O
enzyme JJ O
gene NN O
polymorphism NN O
on IN O
neurohormonal JJ B-OC
responses NNS I-OC
to TO O
high- JJ O
versus NN O
low-dose JJ O
enalapril NN O
in IN O
advanced JJ B-POPU
heart NN I-POPU
failure NN I-POPU
. . O

BACKGROUND CC O
The DT O
impact NN O
of IN O
angiotensin-converting JJ O
enzyme NN O
( ( O
ACE NNP O
) ) O
gene NN O
polymorphism NN O
on IN O
neurohormonal JJ O
dose JJ O
response NN O
to TO O
ACE NNP B-INTV
inhibitor NN O
therapy NN O
is VBZ O
unclear JJ O
. . O

METHODS NNP O
ACE NNP O
Insertion NNP O
( ( O
I PRP O
) ) O
or CC O
Deletion NNP O
( ( O
D NNP O
) ) O
genotype NN O
was VBD O
determined VBN O
in IN O
74 CD B-POPU
patients NNS I-POPU
with IN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
who WP O
were VBD O
randomly RB B-INTV
assigned VBN I-INTV
to TO I-INTV
receive VB I-INTV
either DT I-INTV
high-dose JJ I-INTV
or CC I-INTV
low-dose JJ I-INTV
enalapril NN I-INTV
over IN I-INTV
a DT I-INTV
period NN I-INTV
of IN I-INTV
6 CD I-INTV
months NNS I-INTV
. . O

Monthly JJ B-INTV
pre-enalapril JJ I-INTV
and CC I-INTV
post-enalapril JJ I-INTV
neurohormone NN I-INTV
levels NNS I-INTV
( ( I-INTV
serum JJ I-INTV
ACE NNP I-INTV
activity NN I-INTV
( ( I-INTV
sACE NN I-INTV
) ) I-INTV
, , I-INTV
plasma JJ I-INTV
angiotensin NN I-INTV
II NNP I-INTV
( ( I-INTV
A-II NNP I-INTV
) ) I-INTV
, , I-INTV
plasma JJ I-INTV
renin NN I-INTV
activity NN I-INTV
( ( I-INTV
PRA NNP I-INTV
) ) I-INTV
, , I-INTV
and CC I-INTV
serum VB I-INTV
aldosterone NN I-INTV
( ( I-INTV
ALDO NNP I-INTV
) ) I-INTV
were VBD O
compared VBN O
between IN O
genotype NN O
subgroups NNS O
and CC O
between IN O
patients NNS O
who WP O
received VBD O
high- JJ O
or CC O
low-dose JJ O
enalapril NN B-INTV
within IN O
each DT O
genotype NN O
subgroup NN O
. . O

RESULTS NNP O
At IN O
baseline NN O
, , O
predose/postdose JJ B-OC
sACE NN I-OC
and CC I-OC
postdose JJ I-OC
PRA NNP I-OC
were VBD O
significantly RB O
higher JJR O
in IN O
the DT O
DD NNP B-POPU
genotype NN I-POPU
. . O

At IN O
6-month JJ O
follow-up NN O
, , O
postdose JJ B-OC
sACE NN I-OC
was VBD O
reduced VBN O
in IN O
a DT O
dose-dependent JJ O
fashion NN O
in IN O
all DT O
three CD O
genotypes NNS O
( ( O
P NNP O
< NNP O
.05 NNP O
) ) O
. . O

However RB O
, , O
predose JJ B-OC
and CC I-OC
postdose JJ I-OC
ALDO NNP I-OC
and CC I-OC
A-II NNP I-OC
levels NNS I-OC
did VBD O
not RB O
differ VB O
between IN O
each DT O
genotype NN O
subgroup NN O
at IN O
baseline NN O
or CC O
by IN O
enalapril JJ O
dose NN O
within IN O
each DT O
genotype NN O
subgroup NN O
. . O

ALDO NNP B-OC
escape NN I-OC
and CC I-OC
A-II JJ I-OC
reactivation NN I-OC
were VBD O
not RB O
affected VBN O
by IN O
ACE NNP B-POPU
genotype NN I-POPU
or CC O
enalapril JJ O
dosage NN O
. . O

CONCLUSIONS NNP O
Predose NNP B-OC
sACE NN I-OC
were VBD O
consistently RB O
higher JJR O
in IN O
the DT O
DD NNP O
genotype NN O
when WRB O
compared VBN O
with IN O
ID NNP B-POPU
or CC I-POPU
II NNP I-POPU
subgroups NNS I-POPU
. . O

Despite IN O
a DT O
dose-dependent JJ O
suppression NN B-OC
of IN I-OC
sACE NN I-OC
, , O
there EX O
were VBD O
no DT O
observed VBN O
statistically RB O
significant JJ O
differences NNS O
in IN O
ALDO NNP B-OC
and CC I-OC
A-II NNP I-OC
suppression NN I-OC
or CC O
escape NN O
with IN O
escalating VBG O
doses NNS O
of IN O
enalapril NN O
within IN O
each DT O
subgroup NN O
. . O

-DOCSTART- -X- O O

Folate NN O
levels NNS O
determine VBP O
effect NN O
of IN O
antioxidant JJ B-INTV
supplementation NN I-INTV
on IN O
micronuclei NN B-OC
in IN O
subjects NNS B-POPU
with IN I-POPU
cardiovascular JJ I-POPU
risk NN I-POPU
. . O

We PRP O
have VBP O
investigated VBN O
the DT O
effect NN O
of IN O
modest JJ O
supplementation NN B-INTV
with IN I-INTV
alpha-tocopherol NN I-INTV
( ( O
100 CD O
mg/day NN O
) ) O
, , O
beta-carotene JJ B-INTV
( ( O
6 CD O
mg/day NN O
) ) O
, , O
vitamin FW B-INTV
C NNP I-INTV
( ( O
100 CD O
mg/day NN O
) ) O
and CC O
selenium NN B-INTV
( ( O
50 CD O
microg/day NN O
) ) O
on IN O
oxidative JJ O
stress NN O
and CC O
chromosomal JJ O
damage NN O
, , O
and CC O
the DT O
influence NN O
of IN O
methylenetetrahydrofolate NN O
reductase NN O
( ( O
MTHFR NNP O
) ) O
genotype NN O
on IN O
these DT O
end-points NNS O
. . O

Subjects NNS O
were VBD O
two CD B-POPU
groups NNS I-POPU
of IN I-POPU
middle-aged JJ I-POPU
men NNS I-POPU
differing VBG I-POPU
in IN I-POPU
cardiovascular JJ I-POPU
risk NN I-POPU
; : I-POPU
46 CD I-POPU
survivors NNS I-POPU
of IN I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
before IN I-POPU
age NN I-POPU
50 CD I-POPU
and CC I-POPU
60 CD I-POPU
healthy JJ I-POPU
controls NNS I-POPU
. . O

They PRP O
were VBD O
randomly RB O
divided VBN O
into IN O
equal JJ O
groups NNS O
to TO O
receive VB O
antioxidants NNS B-INTV
or CC O
placebo NN B-INTV
for IN O
12 CD O
weeks NNS O
. . O

Twenty-eight JJ B-POPU
patients NNS I-POPU
and CC I-POPU
58 CD I-POPU
controls NNS I-POPU
completed VBD I-POPU
the DT I-POPU
intervention NN I-POPU
. . O

Micronucleus NNP B-OC
levels NNS I-OC
in IN I-OC
peripheral JJ I-OC
lymphocytes NNS I-OC
and CC I-OC
changes NNS I-OC
seen VBN I-OC
after IN I-OC
intervention NN I-OC
were VBD I-OC
studied VBN I-OC
in IN I-OC
relation NN I-OC
to TO I-OC
the DT I-OC
MTHFR NNP I-OC
C677T NNP I-OC
genotype NN I-OC
, , I-OC
basal JJ I-OC
homocysteine NN I-OC
and CC I-OC
plasma JJ I-OC
folate NN I-OC
levels NNS I-OC
. . O

Ferric NNP B-OC
reducing VBG I-OC
ability NN I-OC
of IN I-OC
plasma NN I-OC
and CC I-OC
concentration NN I-OC
of IN I-OC
malondialdehyde NNS I-OC
were VBD I-OC
measured VBN I-OC
to TO I-OC
assess VB I-OC
the DT I-OC
antioxidant JJ I-OC
effect NN I-OC
of IN I-OC
supplementation NN B-INTV
. . O

There EX O
was VBD O
no DT O
association NN O
of IN O
micronuclei NN O
with IN O
folate NN O
, , O
homocysteine NN O
or CC O
malondialdehyde NN O
levels NNS O
before IN O
supplementation NN O
. . O

Micronucleus NNP B-OC
frequencies NNS I-OC
and CC I-OC
plasma JJ I-OC
folate NN I-OC
levels NNS I-OC
did VBD O
not RB O
vary JJ O
significantly RB O
with IN O
MTHFR NNP O
genotype NN O
. . O

Homocysteine NNP B-OC
levels NNS I-OC
in IN O
subjects NNS B-POPU
with IN I-POPU
the DT I-POPU
TT NNP I-POPU
variant NN I-POPU
genotype NN I-POPU
were VBD O
significantly RB O
higher JJR O
compared VBN O
with IN O
CT NNP O
or CC O
CC NNP O
( ( O
P NNP O
= NNP O
0.001 CD O
) ) O
, , O
especially RB O
in IN O
subjects NNS B-POPU
with IN I-POPU
low JJ I-POPU
folate NN I-POPU
( ( O
P NNP O
= NNP O
0.012 CD O
) ) O
. . O

In IN O
the DT O
placebo NN O
control NN O
group NN O
an DT O
increase NN O
in IN O
micronuclei NN B-OC
( ( O
P NNP O
= NNP O
0.04 CD O
) ) O
was VBD O
detected VBN O
at IN O
the DT O
end NN O
of IN O
the DT O
intervention NN O
period NN O
. . O

This DT O
effect NN O
was VBD O
not RB O
seen VBN O
in IN O
the DT O
supplemented JJ O
group NN O
. . O

In IN O
antioxidant-supplemented JJ O
myocardial JJ B-POPU
infarction NN I-POPU
survivors NNS I-POPU
we PRP O
found VBD O
an DT O
increase NN O
in IN O
the DT O
ferric JJ B-OC
reducing VBG I-OC
ability NN I-OC
of IN I-OC
plasma NN I-OC
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
and CC O
a DT O
decrease NN B-OC
in IN I-OC
malondialdehyde NN I-OC
( ( O
P NNP O
= NNP O
0.001 CD O
) ) O
. . O

Micronucleus NNP B-OC
frequency NN I-OC
showed VBD O
a DT O
decrease NN O
, , O
strongest JJS O
in IN O
subjects NNS B-POPU
with IN I-POPU
normal JJ I-POPU
folate NN I-POPU
levels NNS I-POPU
( ( O
P NNP O
= NNP O
0.015 CD O
) ) O
. . O

In IN O
subjects NNS B-POPU
with IN I-POPU
low JJ I-POPU
folate NN I-POPU
levels NNS I-POPU
, , O
a DT O
high JJ O
correlation NN O
was VBD O
found VBN O
between IN O
micronuclei NN B-OC
after IN O
supplementation NN O
and CC O
homocysteine NN O
, , O
both DT O
before IN O
( ( O
r NN O
= VBZ O
0.979 CD O
, , O
P NNP O
= NNP O
0.002 CD O
) ) O
and CC O
after IN O
supplementation NN O
( ( O
r JJ O
= NN O
0.922 CD O
, , O
P NNP O
= NNP O
0.009 CD O
) ) O
. . O

Thus RB O
, , O
folate JJ O
deficiency NN O
may MD O
amplify VB O
the DT O
effect NN O
of IN O
other JJ O
risk NN O
factors NNS O
such JJ O
as IN O
elevated JJ O
homocysteine NN O
levels NNS O
or CC O
variant JJ O
MTHFR NNP O
genotype NN O
, , O
as RB O
well RB O
as IN O
influencing VBG O
the DT O
ability NN O
of IN O
antioxidant JJ B-INTV
supplementation NN I-INTV
to TO O
protect VB O
against IN O
genetic JJ O
damage NN O
. . O

-DOCSTART- -X- O O

Use NNP O
of IN O
abciximab NN B-INTV
prior RB O
to TO O
primary JJ B-INTV
angioplasty NN I-INTV
in IN O
STEMI NNP B-POPU
results NNS O
in IN O
early JJ O
recanalization NN B-OC
of IN I-OC
the DT I-OC
infarct-related JJ I-OC
artery NN I-OC
and CC O
improved VBN O
myocardial JJ B-OC
tissue NN I-OC
reperfusion NN I-OC
- : O
results NNS O
of IN O
the DT O
Austrian JJ B-POPU
multi-centre JJ I-POPU
randomized VBN I-POPU
ReoPro-BRIDGING NN I-POPU
Study NNP I-POPU
. . O

AIMS NNP O
The DT O
aim NN O
of IN O
the DT O
ReoPro-BRIDGING JJ B-POPU
Austrian JJ I-POPU
multi-centre NN I-POPU
study NN I-POPU
was VBD O
to TO O
investigate VB O
the DT O
effects NNS O
of IN O
abciximab NN B-INTV
( ( I-INTV
ReoPro NNP I-INTV
) ) I-INTV
on IN O
early JJ B-OC
reperfusion NN I-OC
in IN I-OC
ST-elevation NNP I-OC
myocardial JJ I-OC
infarction NN I-OC
prior RB O
to TO O
or CC O
during IN O
primary JJ O
percutaneous JJ B-INTV
coronary JJ I-INTV
angioplasty NN I-INTV
( ( I-INTV
pPCI NN I-INTV
) ) I-INTV
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
Fifty-five JJ B-POPU
patients NNS I-POPU
with IN I-POPU
STEMI NNP I-POPU
were VBD I-POPU
randomized VBN I-POPU
either RB I-POPU
to TO I-POPU
start VB I-POPU
abciximab NN I-POPU
( ( I-POPU
0.25 CD I-POPU
mg/kg NN I-POPU
bolus NN I-POPU
followed VBN I-POPU
by IN I-POPU
10 CD I-POPU
microg/min NNS I-POPU
infusion NN I-POPU
) ) I-POPU
during IN I-POPU
the DT I-POPU
organization NN I-POPU
phase NN I-POPU
for IN I-POPU
pPCI NN I-POPU
( ( I-POPU
Group NNP I-POPU
1 CD I-POPU
, , I-POPU
n=28 NN I-POPU
) ) I-POPU
or CC I-POPU
immediately RB I-POPU
before IN I-POPU
pPCI NN I-POPU
( ( I-POPU
Group NNP I-POPU
2 CD I-POPU
, , I-POPU
n=27 NN I-POPU
) ) I-POPU
. . O

The DT O
time NN O
between IN O
first JJ O
bolus NN O
of IN O
abciximab NN B-INTV
and CC O
first JJ O
balloon NN O
inflation NN O
of IN O
pPCI NN O
was VBD O
83+/-18 JJ O
vs JJ O
21+/-13 JJ O
min NN O
in IN O
Group NNP O
1 CD O
vs NN O
2 CD O
. . O

The DT O
pre-pPCI JJ B-OC
ST-segment JJ I-OC
resolution NN I-OC
( ( O
55+/-21.4 CD O
% NN O
vs JJ O
42.4+/-18.2 CD O
% NN O
, , O
p=0.005 NN O
) ) O
, , O
TIMI NNP B-OC
flow NN I-OC
grade VBD I-OC
3 CD I-OC
( ( O
29 CD O
% NN O
vs JJ O
7 CD O
% NN O
, , O
p=0.042 NN O
) ) O
, , O
corrected VBN O
TIMI NNP B-OC
frame NN I-OC
count NN I-OC
( ( O
58.4+/-32.7 JJ O
vs NN O
78.9+/-28.4 JJ O
frame NN O
, , O
p=0.018 NN O
) ) O
% NN B-OC
diameter JJ I-OC
stenosis NN I-OC
( ( O
76.3 CD O
/63.5-100/ JJ O
vs NN O
100 CD O
/73.5-100/ NN O
; : O
median JJ O
/interquartile NN O
range/ NN O
, , O
p=0.023 NN O
) ) O
, , O
were VBD O
significantly RB O
higher JJR O
in IN O
Group NNP O
1 CD O
vs NN O
Group NNP O
2 CD O
. . O

Quantitative JJ O
myocardial JJ O
dye NN O
intensity NN O
measurement NN O
revealed VBD O
a DT O
significantly RB O
higher JJR O
grade NN O
of IN O
myocardial JJ B-OC
tissue NN I-OC
perfusion NN I-OC
( ( O
1 CD O
/0-9.25/ JJ O
vs NN O
0 CD O
/0-3.0/ JJ O
grey NNS O
pixel JJ O
unit NN O
, , O
p=0.048 NN O
) ) O
in IN O
Group NNP O
1 CD O
before IN O
pPCI NN O
. . O

Rapid JJ O
release NN O
of IN O
cardiac JJ B-OC
enzymes NNS I-OC
was VBD O
observed VBN O
in IN O
Group NNP O
1 CD O
as IN O
compared VBN O
with IN O
Group NNP O
2 CD O
: : O
rate NN O
of IN O
rise NN B-OC
of IN I-OC
CK NNP I-OC
was VBD O
210+/-209 JJ O
vs JJ O
97+/-95 CD O
U/l/h NNP O
( ( O
p=0.015 NN O
) ) O
. . O

QRS NNP B-OC
score RB I-OC
indicated VBD O
a DT O
smaller JJR O
infarct NN B-OC
size NN I-OC
in IN O
Group NNP O
1 CD O
( ( O
4.8+/-3.8 JJ O
vs NN O
7.6+/-3.5 CD O
, , O
p=0.011 NN O
) ) O
on IN O
day NN O
7 CD O
. . O

CONCLUSION VB O
The DT O
use NN O
of IN O
abciximab NN O
in IN O
the DT O
organization NN O
phase NN O
for IN O
pPCI JJ O
results NNS O
in IN O
signs NNS B-OC
of IN I-OC
early JJ I-OC
recanalization NN I-OC
of IN I-OC
the DT I-OC
infarct-related JJ I-OC
artery NN I-OC
and CC O
a DT O
subsequent JJ O
improved VBN O
myocardial JJ B-OC
tissue NN I-OC
reperfusion NN I-OC
. . O

-DOCSTART- -X- O O

B-type JJ B-INTV
natriuretic JJ I-INTV
peptide NN I-INTV
for IN O
acute JJ O
dyspnea NN O
in IN O
patients NNS B-POPU
with IN I-POPU
kidney JJ I-POPU
disease NN I-POPU
: : I-POPU
insights NNS O
from IN O
a DT O
randomized JJ O
comparison NN O
. . O

BACKGROUND NNP O
B-type NNP B-INTV
natriuretic JJ I-INTV
peptide NN I-INTV
( ( I-INTV
BNP NNP I-INTV
) ) I-INTV
levels NNS I-INTV
are VBP O
reliably RB O
elevated VBN O
in IN O
patients NNS B-POPU
with IN I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
( ( I-POPU
CHF NNP I-POPU
) ) I-POPU
and CC O
therefore RB O
helpful JJ O
in IN O
its PRP$ O
diagnosis NN O
. . O

However RB O
, , O
kidney FW O
disease NN O
results NNS O
in IN O
elevated JJ O
BNP NNP O
levels NNS O
independently RB O
of IN O
CHF NNP O
. . O

Accordingly RB O
, , O
the DT O
impact NN O
of IN O
kidney NN O
disease NN O
on IN O
the DT O
benefit NN O
of IN O
BNP NNP B-INTV
testing VBG O
needs NNS O
to TO O
be VB O
scrutinized VBN O
. . O

METHODS NNP O
This DT O
study NN O
evaluated VBD O
patients NNS B-POPU
with IN I-POPU
and CC I-POPU
without IN I-POPU
kidney NN I-POPU
disease NN I-POPU
[ NNP I-POPU
glomerular JJ I-POPU
filtration NN I-POPU
rate NN I-POPU
( ( I-POPU
GFR NNP I-POPU
) ) I-POPU
less JJR I-POPU
than IN I-POPU
60 CD I-POPU
mL/min/1.73 JJ I-POPU
m NN I-POPU
( ( I-POPU
2 CD I-POPU
) ) I-POPU
) ) I-POPU
presenting VBG I-POPU
with IN I-POPU
acute JJ I-POPU
dyspnea NN I-POPU
. . O

A DT O
total NN O
of IN O
452 CD B-POPU
consecutive JJ I-POPU
patients NNS I-POPU
( ( I-POPU
240 CD I-POPU
with IN I-POPU
kidney NN I-POPU
disease NN I-POPU
and CC I-POPU
212 CD I-POPU
without IN I-POPU
kidney NN I-POPU
disease NN I-POPU
) ) I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
a DT O
diagnostic JJ B-INTV
strategy NN I-INTV
with IN I-INTV
( ( I-INTV
BNP NNP I-INTV
group NN I-INTV
) ) I-INTV
or CC I-INTV
without IN I-INTV
( ( I-INTV
control NN I-INTV
group NN I-INTV
) ) I-INTV
the DT I-INTV
use NN I-INTV
of IN I-INTV
BNP NNP I-INTV
levels NNS I-INTV
provided VBN I-INTV
by IN I-INTV
a DT I-INTV
rapid JJ I-INTV
bedside NN I-INTV
assay NN I-INTV
. . O

RESULTS JJ O
Patients NNS B-POPU
with IN I-POPU
kidney JJ I-POPU
disease NN I-POPU
were VBD I-POPU
older JJR I-POPU
, , I-POPU
more RBR I-POPU
often RB I-POPU
had VBD I-POPU
CHF NNP I-POPU
as IN I-POPU
the DT I-POPU
cause NN I-POPU
of IN I-POPU
acute JJ I-POPU
dyspnea NN I-POPU
, , I-POPU
and CC I-POPU
more RBR I-POPU
often RB I-POPU
died JJ I-POPU
in-hospital JJ I-POPU
or CC I-POPU
within IN I-POPU
30 CD I-POPU
days NNS I-POPU
as RB I-POPU
compared VBN I-POPU
to TO I-POPU
patients NNS I-POPU
without IN I-POPU
kidney NN I-POPU
disease NN I-POPU
. . O

In IN O
patients NNS O
without IN O
kidney NN O
disease NN O
, , O
BNP NNP B-INTV
testing VBG I-INTV
significantly RB O
reduced VBN O
median JJ B-OC
time NN I-OC
to TO I-OC
discharge VB I-OC
( ( O
from IN O
9.5 CD O
days NNS O
to TO O
2.5 CD O
days NNS O
) ) O
( ( O
P= NNP O
0.003 CD O
) ) O
and CC O
total JJ B-OC
cost NN I-OC
of IN I-OC
treatment NN I-OC
( ( O
from IN O
7184 CD O
dollars NNS O
to TO O
4151 CD O
dollars NNS O
) ) O
( ( O
P= NNP O
0.004 CD O
) ) O
. . O

In IN O
contrast NN O
, , O
in IN O
patients NNS O
with IN O
kidney NN O
disease NN O
, , O
time NN O
to TO O
discharge VB O
and CC O
total JJ O
cost NN O
of IN O
treatment NN O
were VBD O
similar JJ O
in IN O
both DT O
groups NNS O
. . O

CONCLUSION NNP O
When WRB O
applying VBG O
BNP NNP B-INTV
cut-off NN O
values NNS O
without IN O
adjustment NN O
for IN O
the DT O
presence NN O
of IN O
kidney NN O
disease NN O
, , O
the DT O
use NN O
of IN O
BNP NNP B-INTV
levels NNS I-INTV
does VBZ O
significantly RB O
improve VB O
the DT O
management NN O
of IN O
patients NNS O
without IN O
kidney NN O
disease NN O
, , O
but CC O
not RB O
of IN O
those DT O
with IN O
kidney JJ O
disease NN O
. . O

-DOCSTART- -X- O O

Multi-institutional JJ O
randomized JJ O
phase NN O
II NNP O
trial NN O
of IN O
the DT O
epothilone NN B-INTV
B NNP I-INTV
analog NN I-INTV
ixabepilone NN I-INTV
( ( I-INTV
BMS-247550 NNP I-INTV
) ) I-INTV
with IN I-INTV
or CC I-INTV
without IN I-INTV
estramustine JJ I-INTV
phosphate NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
progressive JJ I-POPU
castrate NN I-POPU
metastatic JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

PURPOSE NNP O
To TO O
evaluate VB O
the DT O
antitumor NN B-OC
activity NN I-OC
and CC O
safety NN B-OC
of IN O
the DT O
epothilone NN B-INTV
B NNP I-INTV
analog NN I-INTV
, , I-INTV
ixabepilone NN I-INTV
, , I-INTV
with IN I-INTV
or CC I-INTV
without IN I-INTV
estramustine JJ I-INTV
phosphate NN I-INTV
( ( I-INTV
EMP NNP I-INTV
) ) I-INTV
, , O
in IN O
chemotherapy-naive JJ B-POPU
patients NNS I-POPU
with IN I-POPU
progressive JJ I-POPU
castrate NN I-POPU
metastatic JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Patients NNPS O
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
ixabepilone NN B-INTV
( ( O
35 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
by IN O
intravenous JJ B-INTV
infusion NN I-INTV
every DT I-INTV
3 CD I-INTV
weeks NNS I-INTV
with IN I-INTV
or CC I-INTV
without IN I-INTV
EMP NNP I-INTV
280 CD I-INTV
mg NN I-INTV
orally RB I-INTV
three CD O
times NNS O
daily RB O
on IN O
days NNS O
1 CD O
to TO O
5 CD O
. . O

RESULTS NN O
Between NNP B-POPU
December NNP I-POPU
2001 CD I-POPU
and CC I-POPU
October NNP I-POPU
2003 CD I-POPU
, , I-POPU
92 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
enrolled VBN I-POPU
and CC I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO O
treatment NN B-POPU
with IN I-POPU
ixabepilone NN I-POPU
alone RB I-POPU
( ( I-POPU
45 CD I-POPU
patients NNS I-POPU
) ) I-POPU
or CC I-POPU
in IN I-POPU
combination NN I-POPU
with IN I-POPU
EMP NNP I-POPU
( ( I-POPU
47 CD I-POPU
patients NNS I-POPU
) ) I-POPU
. . O

Grades $ B-OC
3 CD I-OC
and CC I-OC
4 CD I-OC
toxicities NNS I-OC
experienced VBN O
by IN O
more JJR O
than IN O
5 CD O
% NN O
of IN O
patients NNS O
included VBN O
neutropenia RB B-OC
( ( O
22 CD O
% NN O
) ) O
, , O
fatigue NN B-OC
( ( O
9 CD O
% NN O
) ) O
, , O
and CC O
neuropathy JJ B-OC
( ( O
13 CD O
% NN O
) ) O
on IN O
the DT O
ixabepilone NN B-OC
arm NN I-OC
, , I-OC
and CC I-OC
neutropenia NN I-OC
( ( O
29 CD O
% NN O
) ) O
, , O
febrile JJ B-OC
neutropenia NN I-OC
( ( O
9 CD O
% NN O
) ) O
, , O
fatigue NN B-OC
( ( O
9 CD O
% NN O
) ) O
, , O
neuropathy JJ B-OC
( ( O
7 CD O
% NN O
) ) O
, , O
and CC O
thrombosis NN B-OC
( ( O
6 CD O
% NN O
) ) O
on IN O
the DT O
ixabepilone NN O
+ NNP O
EMP NNP O
arm NN O
. . O

Post-treatment JJ O
declines NNS O
in IN O
prostate-specific JJ B-OC
antigen NN I-OC
of IN O
> NN O
or CC O
= VB O
50 CD O
% NN O
were VBD O
achieved VBN O
in IN O
21 CD O
of IN O
44 CD O
patients NNS O
( ( O
48 CD O
% NN O
; : O
95 CD O
% NN O
CI NNP O
, , O
33 CD O
% NN O
to TO O
64 CD O
% NN O
) ) O
on IN O
the DT O
ixabepilone NN O
arm NN O
, , O
and CC O
31 CD O
of IN O
45 CD O
patients NNS O
( ( O
69 CD O
% NN O
; : O
95 CD O
% NN O
CI NNP O
, , O
55 CD O
% NN O
to TO O
82 CD O
% NN O
) ) O
on IN O
the DT O
ixabepilone NN O
+ NNP O
EMP NNP O
arm NN O
. . O

In IN O
patients NNS O
with IN O
measurable JJ O
disease NN O
, , O
partial JJ B-OC
responses NNS I-OC
were VBD O
observed VBN O
in IN O
eight CD O
of IN O
25 CD O
patients NNS O
( ( O
32 CD O
% NN O
; : O
95 CD O
% NN O
CI NNP O
, , O
14 CD O
% NN O
to TO O
50 CD O
% NN O
) ) O
on IN O
the DT O
ixabepilone NN O
arm NN O
, , O
and CC O
11 CD O
of IN O
23 CD O
( ( O
48 CD O
% NN O
; : O
95 CD O
% NN O
CI NNP O
, , O
27 CD O
% NN O
to TO O
68 CD O
% NN O
) ) O
on IN O
the DT O
ixabepilone NN O
+ NNP O
EMP NNP O
arm NN O
. . O

Time NN B-OC
to TO I-OC
prostate-specific JJ I-OC
antigen NN I-OC
progression NN I-OC
was VBD O
4.4 CD O
months NNS O
( ( O
95 CD O
% NN O
CI NNP O
, , O
3.1 CD O
to TO O
6.9 CD O
months NNS O
) ) O
on IN O
the DT O
ixabepilone-alone JJ O
arm NN O
and CC O
5.2 CD O
months NNS O
( ( O
95 CD O
% NN O
CI NNP O
, , O
4.5 CD O
to TO O
6.8 CD O
months NNS O
) ) O
on IN O
the DT O
combination NN O
arm NN O
. . O

CONCLUSION NNP O
Ixabepilone NNP B-INTV
, , O
with IN O
or CC O
without IN O
estramustine JJ B-INTV
phosphate NN I-INTV
, , O
is VBZ O
well RB B-OC
tolerated VBN I-OC
and CC O
has VBZ O
antitumor VBN B-OC
activity NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
castrate JJ I-POPU
metastatic JJ I-POPU
prostate NN I-POPU
cancer NN I-POPU
. . O

-DOCSTART- -X- O O

Magnesium NN B-INTV
sulphate NN I-INTV
only RB O
slightly RB O
reduces VBZ O
the DT O
shivering VBG B-POPU
threshold NN I-POPU
in IN I-POPU
humans NNS I-POPU
. . O

BACKGROUND NNP O
Hypothermia NNP B-INTV
may MD O
be VB O
an DT O
effective JJ O
treatment NN O
for IN O
stroke NN O
or CC O
acute JJ O
myocardial JJ O
infarction NN O
; : O
however RB O
, , O
it PRP O
provokes VBZ O
vigorous JJ O
shivering NN O
, , O
which WDT O
causes VBZ O
potentially RB O
dangerous JJ O
haemodynamic JJ O
responses NNS O
and CC O
prevents NNS O
further RBR O
hypothermia NN O
. . O

Magnesium NNP B-INTV
is VBZ O
an DT O
attractive JJ O
anti-shivering NN O
agent NN O
because IN O
it PRP O
is VBZ O
used VBN O
for IN O
treatment NN O
of IN O
postoperative JJ O
shivering NN O
and CC O
provides VBZ O
protection NN O
against IN O
ischaemic JJ O
injury NN O
in IN O
animal JJ O
models NNS O
. . O

We PRP O
tested VBD O
the DT O
hypothesis NN O
that WDT O
magnesium NN B-INTV
reduces VBZ O
the DT O
threshold NN O
( ( O
triggering VBG O
core RB O
temperature NN O
) ) O
and CC O
gain NN O
of IN O
shivering VBG B-OC
without IN O
substantial JJ O
sedation NN B-OC
or CC O
muscle NN O
weakness NN O
. . O

METHODS NNP O
We PRP O
studied VBD O
nine CD B-POPU
healthy JJ I-POPU
male NN I-POPU
volunteers NNS I-POPU
( ( I-POPU
18-40 JJ I-POPU
yr NN I-POPU
) ) I-POPU
on IN I-POPU
two CD I-POPU
randomly NNS I-POPU
assigned VBN I-POPU
treatment NN I-POPU
days NNS I-POPU
: : I-POPU
( ( O
1 CD O
) ) O
control NN B-INTV
and CC O
( ( O
2 CD O
) ) O
magnesium NN B-INTV
( ( O
80 CD O
mg NN O
kg NN O
( ( O
-1 NNP O
) ) O
followed VBN O
by IN O
infusion NN O
at IN O
2 CD O
g NN O
h NN O
( ( O
-1 NNP O
) ) O
) ) O
. . O

Lactated VBN B-INTV
Ringer NNP I-INTV
's POS I-INTV
solution NN I-INTV
( ( O
4 CD O
degrees NNS O
C NNP O
) ) O
was VBD O
infused VBN O
via IN O
a DT O
central JJ O
venous JJ O
catheter NN O
over IN O
a DT O
period NN O
of IN O
approximately RB O
2 CD O
h NN O
to TO O
decrease VB O
tympanic JJ B-OC
membrane NN I-OC
temperature NN I-OC
by IN O
approximately RB O
1.5 CD O
degrees NNS O
C NNP O
h NN O
( ( O
-1 NNP O
) ) O
. . O

A DT O
significant JJ O
and CC O
persistent JJ O
increase NN O
in IN O
oxygen JJ B-OC
consumption NN O
identified VBD O
the DT O
threshold NN O
. . O

The DT O
gain NN B-OC
of IN I-OC
shivering NN I-OC
was VBD O
determined VBN O
by IN O
the DT O
slope NN O
of IN O
oxygen NN O
consumption NN O
vs NN O
core NN B-OC
temperature NN I-OC
regression NN O
. . O

Sedation NN B-OC
was VBD O
evaluated VBN O
using VBG O
a DT O
verbal JJ B-OC
rating NN I-OC
score NN I-OC
( ( I-OC
VRS NNP I-OC
) ) I-OC
from IN O
0 CD O
to TO O
10 CD O
and CC O
bispectral JJ B-OC
index NN I-OC
( ( I-OC
BIS NNP I-OC
) ) I-OC
of IN I-OC
the DT I-OC
EEG NNP I-OC
. . O

Peripheral NNP B-OC
muscle NN I-OC
strength NN I-OC
was VBD O
evaluated VBN O
using VBG O
dynamometry NN O
and CC O
spirometry NN O
. . O

Data NNS O
were VBD O
analysed VBN O
using VBG O
repeated JJ O
measures NNS O
anova VBP O
; : O
P NNP O
< VBD O
0.05 CD O
was VBD O
statistically RB O
significant JJ O
. . O

RESULTS NNP O
Magnesium NNP B-INTV
reduced VBD O
the DT O
shivering NN B-OC
threshold NN I-OC
( ( O
36.3 CD O
[ NNP O
SD NNP O
0.4 CD O
] NNP O
degrees NNS O
C NNP O
vs VBD O
36.6 CD O
[ JJ O
0.3 CD O
] NN O
degrees NNS O
C NNP O
, , O
P NNP O
= NNP O
0.040 CD O
) ) O
. . O

It PRP O
did VBD O
not RB O
affect VB O
the DT O
gain NN B-OC
of IN I-OC
shivering VBG I-OC
( ( O
control NN O
, , O
437 CD O
[ NN O
289 CD O
] NN O
ml NN O
min NN O
( ( O
-1 NNP O
) ) O
degrees VBZ O
C NNP O
( ( O
-1 NNP O
) ) O
; : O
magnesium NN O
, , O
573 CD O
[ NN O
370 CD O
] NN O
ml NN O
min NN O
( ( O
-1 NNP O
) ) O
degrees VBZ O
C NNP O
( ( O
-1 NNP O
) ) O
; : O
P=0.344 NNP O
) ) O
. . O

The DT O
magnesium NN B-INTV
bolus NN O
did VBD O
not RB O
produce VB O
significant JJ O
sedation NN B-OC
or CC O
appreciably RB O
reduce VB O
muscle NN B-OC
strength NN I-OC
. . O

CONCLUSIONS NNP O
Magnesium NNP B-INTV
significantly RB O
reduced VBD O
the DT O
shivering NN B-OC
threshold NN I-OC
. . O

However RB O
, , O
in IN O
view NN O
of IN O
the DT O
modest JJ O
absolute NN O
reduction NN O
, , O
this DT O
finding NN O
is VBZ O
considered VBN O
to TO O
be VB O
clinically RB O
unimportant JJ O
for IN O
induction NN O
of IN O
therapeutic JJ O
hypothermia NN O
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
long-term JJ B-INTV
vitamin NN I-INTV
E NNP I-INTV
supplementation NN I-INTV
on IN O
cardiovascular JJ B-POPU
events NNS I-POPU
and CC I-POPU
cancer NN I-POPU
: : I-POPU
a DT O
randomized NN O
controlled VBN O
trial NN O
. . O

CONTEXT NNP O
Experimental NNP O
and CC O
epidemiological JJ O
data NNS O
suggest VBP O
that IN O
vitamin NN B-INTV
E NNP I-INTV
supplementation NN I-INTV
may MD O
prevent VB O
cancer NN B-POPU
and CC I-POPU
cardiovascular JJ I-POPU
events NNS I-POPU
. . O

Clinical JJ O
trials NNS O
have VBP O
generally RB O
failed VBN O
to TO O
confirm VB O
benefits NNS O
, , O
possibly RB O
due JJ O
to TO O
their PRP$ O
relatively RB O
short JJ O
duration NN O
. . O

OBJECTIVE UH O
To TO O
evaluate VB O
whether IN O
long-term JJ B-INTV
supplementation NN I-INTV
with IN I-INTV
vitamin JJ I-INTV
E NN I-INTV
decreases VBZ O
the DT O
risk NN B-OC
of IN I-OC
cancer NN B-POPU
, , I-POPU
cancer NN I-POPU
death NN I-POPU
, , I-POPU
and CC I-POPU
major JJ I-POPU
cardiovascular JJ I-POPU
events NNS I-POPU
. . O

DESIGN NNP O
, , O
SETTING NNP O
, , O
AND NNP O
PATIENTS NNP O
A NNP O
randomized JJ O
, , O
double-blind JJ O
, , O
placebo-controlled JJ O
international JJ B-POPU
trial NN O
( ( O
the DT O
initial JJ O
Heart NNP O
Outcomes NNP O
Prevention NNP O
Evaluation NNP O
[ NNP O
HOPE NNP O
] NNP O
trial NN O
conducted VBD O
between IN O
December NNP O
21 CD O
, , O
1993 CD O
, , O
and CC O
April NNP O
15 CD O
, , O
1999 CD O
) ) O
of IN O
patients NNS B-POPU
at IN I-POPU
least JJS I-POPU
55 CD I-POPU
years NNS I-POPU
old JJ I-POPU
with IN I-POPU
vascular JJ I-POPU
disease NN I-POPU
or CC I-POPU
diabetes VBZ I-POPU
mellitus NN I-POPU
was VBD I-POPU
extended VBN I-POPU
( ( I-POPU
HOPE-The NNP I-POPU
Ongoing NNP I-POPU
Outcomes NNP I-POPU
[ NNP I-POPU
HOPE-TOO NNP I-POPU
] NNP I-POPU
) ) I-POPU
between IN I-POPU
April NNP I-POPU
16 CD I-POPU
, , I-POPU
1999 CD I-POPU
, , I-POPU
and CC I-POPU
May NNP I-POPU
26 CD I-POPU
, , I-POPU
2003 CD I-POPU
. . O

Of IN O
the DT O
initial JJ O
267 CD B-POPU
HOPE NNP I-POPU
centers NNS I-POPU
that WDT I-POPU
had VBD I-POPU
enrolled VBN I-POPU
9541 CD I-POPU
patients NNS I-POPU
, , I-POPU
174 CD I-POPU
centers NNS I-POPU
participated VBN I-POPU
in IN I-POPU
the DT I-POPU
HOPE-TOO NNP I-POPU
trial NN I-POPU
. . O

Of IN O
7030 CD B-POPU
patients NNS I-POPU
enrolled VBN I-POPU
at IN I-POPU
these DT I-POPU
centers NNS I-POPU
, , I-POPU
916 CD I-POPU
were VBD I-POPU
deceased VBN I-POPU
at IN I-POPU
the DT I-POPU
beginning NN I-POPU
of IN I-POPU
the DT I-POPU
extension NN I-POPU
, , I-POPU
1382 CD I-POPU
refused VBD I-POPU
participation NN I-POPU
, , I-POPU
3994 CD I-POPU
continued VBD I-POPU
to TO I-POPU
take VB I-POPU
the DT I-POPU
study NN I-POPU
intervention NN I-POPU
, , I-POPU
and CC I-POPU
738 CD I-POPU
agreed VBD I-POPU
to TO I-POPU
passive VB I-POPU
follow-up NN I-POPU
. . O

Median JJ O
duration NN O
of IN O
follow-up NN O
was VBD O
7.0 CD O
years NNS O
. . O

INTERVENTION NNP O
Daily NNP B-INTV
dose NN I-INTV
of IN I-INTV
natural JJ I-INTV
source NN I-INTV
vitamin NN I-INTV
E NNP I-INTV
( ( I-INTV
400 CD I-INTV
IU NNP I-INTV
) ) I-INTV
or CC I-INTV
matching VBG I-INTV
placebo NN I-INTV
. . O

MAIN NNP O
OUTCOME NNP O
MEASURES NNP O
Primary NNP O
outcomes NNS O
included VBD O
cancer NN B-OC
incidence NN I-OC
, , I-OC
cancer NN I-OC
deaths NNS I-OC
, , I-OC
and CC I-OC
major JJ I-OC
cardiovascular JJ I-OC
events NNS I-OC
( ( I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
stroke NN I-OC
, , I-OC
and CC I-OC
cardiovascular JJ I-OC
death NN I-OC
) ) I-OC
. . O

Secondary JJ O
outcomes NNS O
included VBD O
heart NN B-OC
failure NN I-OC
, , I-OC
unstable JJ I-OC
angina NN I-OC
, , I-OC
and CC I-OC
revascularizations NNS I-OC
. . O

RESULTS NNP O
Among IN O
all DT O
HOPE NNP O
patients NNS O
, , O
there EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
the DT O
primary JJ O
analysis NN O
: : O
for IN O
cancer NN B-OC
incidence NN I-OC
, , O
there EX O
were VBD O
552 CD O
patients NNS O
( ( O
11.6 CD O
% NN O
) ) O
in IN O
the DT O
vitamin NN B-INTV
E NNP I-INTV
group NN O
vs VBD O
586 CD O
( ( O
12.3 CD O
% NN O
) ) O
in IN O
the DT O
placebo NN B-INTV
group NN O
( ( O
relative JJ O
risk NN O
[ NNP O
RR NNP O
] NNP O
, , O
0.94 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
[ NNP O
CI NNP O
] NNP O
, , O
0.84-1.06 NNP O
; : O
P NNP O
= NNP O
.30 NNP O
) ) O
; : O
for IN O
cancer NN B-OC
deaths NNS I-OC
, , O
156 CD O
( ( O
3.3 CD O
% NN O
) ) O
vs NN O
178 CD O
( ( O
3.7 CD O
% NN O
) ) O
, , O
respectively RB O
( ( O
RR NNP O
, , O
0.88 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.71-1.09 NNP O
; : O
P NNP O
= NNP O
.24 NNP O
) ) O
; : O
and CC O
for IN O
major JJ B-OC
cardiovascular JJ I-OC
events NNS I-OC
, , O
1022 CD O
( ( O
21.5 CD O
% NN O
) ) O
vs NN O
985 CD O
( ( O
20.6 CD O
% NN O
) ) O
, , O
respectively RB O
( ( O
RR NNP O
, , O
1.04 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.96-1.14 NNP O
; : O
P NNP O
= NNP O
.34 NNP O
) ) O
. . O

Patients NNS O
in IN O
the DT O
vitamin NN B-INTV
E NNP I-INTV
group NN O
had VBD O
a DT O
higher JJR O
risk NN B-OC
of IN I-OC
heart NN I-OC
failure NN I-OC
( ( O
RR NNP O
, , O
1.13 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.01-1.26 JJ O
; : O
P NNP O
= NNP O
.03 NNP O
) ) O
and CC O
hospitalization NN B-OC
for IN I-OC
heart NN I-OC
failure NN I-OC
( ( O
RR NNP O
, , O
1.21 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.00-1.47 JJ O
; : O
P NNP O
= NNP O
.045 NNP O
) ) O
. . O

Similarly RB O
, , O
among IN O
patients NNS O
enrolled VBN O
at IN O
the DT O
centers NNS O
participating VBG O
in IN O
the DT O
HOPE-TOO NNP O
trial NN O
, , O
there EX O
were VBD O
no DT O
differences NNS O
in IN O
cancer NN B-OC
incidence NN I-OC
, , I-OC
cancer NN I-OC
deaths NNS I-OC
, , I-OC
and CC I-OC
major JJ I-OC
cardiovascular JJ I-OC
events NNS I-OC
, , O
but CC O
higher JJR O
rates NNS B-OC
of IN I-OC
heart NN I-OC
failure NN I-OC
and CC I-OC
hospitalizations NNS I-OC
for IN I-OC
heart NN I-OC
failure NN I-OC
. . O

CONCLUSION NNP O
In IN O
patients NNS B-POPU
with IN I-POPU
vascular JJ I-POPU
disease NN I-POPU
or CC I-POPU
diabetes VBZ I-POPU
mellitus NNS I-POPU
, , O
long-term JJ B-INTV
vitamin NN I-INTV
E NNP I-INTV
supplementation NN I-INTV
does VBZ O
not RB O
prevent VB O
cancer NN B-OC
or CC I-OC
major JJ I-OC
cardiovascular JJ I-OC
events NNS I-OC
and CC O
may MD O
increase VB O
the DT O
risk NN B-OC
for IN I-OC
heart NN I-OC
failure NN I-OC
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
intravenous JJ O
and CC O
intra-arterial JJ O
urokinase JJ O
thrombolysis NN O
for IN O
acute JJ B-POPU
ischaemic JJ I-POPU
stroke NN I-POPU
. . O

Intravenous JJ B-INTV
fibrinolysis NN I-INTV
( ( I-INTV
IVF NNP I-INTV
) ) I-INTV
with IN I-INTV
rt-PA NN I-INTV
( ( I-INTV
alteplase NN I-INTV
) ) I-INTV
provides VBZ O
significant JJ O
benefits NNS O
in IN O
acute JJ O
ischaemic JJ O
stroke NN O
when WRB O
it PRP O
is VBZ O
given VBN O
within IN O
the DT O
first JJ O
three CD O
hours NNS O
following VBG O
stroke NN O
onset VBN O
. . O

Intra-arterial JJ B-INTV
fibrinolysis NN I-INTV
( ( I-INTV
IAF NNP I-INTV
) ) I-INTV
with IN I-INTV
pro-urokinase NN I-INTV
in IN O
PROACT NNP O
II NNP O
study NN O
provides VBZ O
quite RB O
the DT O
same JJ O
benefit NN O
in IN O
the DT O
first JJ O
6 CD O
hours NNS O
. . O

IVF NNP B-INTV
and CC O
IAF NNP B-INTV
have VBP O
never RB O
been VBN O
compared VBN O
. . O

To TO O
compare VB O
the DT O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
IVF NNP B-INTV
and CC O
IAF NNP B-INTV
with IN O
urokinase JJ O
given VBN O
within IN B-POPU
the DT I-POPU
first JJ I-POPU
6 CD I-POPU
hours NNS I-POPU
of IN I-POPU
acute JJ I-POPU
ischaemic JJ I-POPU
stroke NN I-POPU
. . O

Patients NNS B-POPU
fulfilling VBG I-POPU
the DT I-POPU
selection NN I-POPU
criteria NNS I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
urokinase JJ B-INTV
900,000 CD O
units NNS O
via IN O
intravenous JJ O
or CC O
intra-arterial JJ O
routes NNS O
. . O

This DT O
randomised VBD O
monocentre NN O
study NN O
was VBD O
done VBN O
between IN O
December NNP O
1995 CD O
and CC O
August NNP O
1997 CD O
. . O

The DT O
primary JJ O
outcome NN O
was VBD O
defined VBN O
as IN O
the DT O
number NN B-OC
of IN I-OC
patients NNS I-OC
with IN I-OC
a DT I-OC
modified JJ I-OC
Rankin NNP I-OC
score NN I-OC
of IN I-OC
2 CD I-OC
or CC I-OC
less JJR I-OC
. . O

Secondary JJ O
outcomes NNS O
included VBD O
mortality NN B-OC
, , I-OC
frequency NN I-OC
of IN I-OC
symptomatic JJ I-OC
intracranial JJ I-OC
haemorrhage NN I-OC
( ( I-OC
SIH NNP I-OC
) ) I-OC
, , I-OC
neurological JJ I-OC
and CC I-OC
functional JJ I-OC
scores NNS I-OC
. . O

Fourteen CD B-POPU
patients NNS I-POPU
were VBD I-POPU
given VBN I-POPU
IVF NNP I-POPU
and CC I-POPU
13 CD I-POPU
IAF NNP I-POPU
. . O

The DT O
study NN O
was VBD O
terminated VBN O
by IN O
the DT O
National NNP O
Health NNP O
Authorities NNP O
when WRB O
27 CD B-POPU
patients NNS I-POPU
had VBD I-POPU
been VBN I-POPU
included VBN I-POPU
because IN I-POPU
of IN I-POPU
the DT I-POPU
mortality NN I-POPU
rate NN I-POPU
. . O

Seven CD O
patients NNS O
( ( O
26 CD O
% NN O
) ) O
died VBD O
, , O
4 CD O
in IN O
the DT O
IV NNP O
group NN O
( ( O
oedematous JJ O
infarct NN O
in IN O
3 CD O
and CC O
recurrence NN O
in IN O
1 CD O
) ) O
, , O
3 CD O
in IN O
the DT O
IA NNP O
group NN O
( ( O
SIH NNP O
in IN O
2 CD O
, , O
and CC O
oedematous JJ O
infarct NN O
in IN O
1 CD O
) ) O
. . O

Patients NNS O
given VBN O
IVF NNP B-INTV
were VBD O
treated VBN O
significantly RB O
earlier RBR O
( ( O
4:16 CD O
h NN O
vs NN O
5:24 CD O
h NN O
; : O
p=.007 NN O
) ) O
. . O

Although IN O
IA NNP O
patients NNS O
showed VBD O
greater JJR O
and CC O
earlier RBR O
improvement NN O
there EX O
was VBD O
no DT O
significant JJ O
difference NN O
in IN O
primary JJ O
and CC O
secondary JJ O
outcomes NNS O
. . O

Because IN O
of IN O
premature NN O
termination NN O
, , O
the DT O
trial NN O
was VBD O
too RB O
small JJ O
to TO O
provide VB O
any DT O
reliable JJ O
and CC O
conclusive JJ O
results NNS O
. . O

Intra-arterial JJ O
fibrinolysis NN O
began VBD O
significantly RB O
later RBR O
than IN O
IV NNP O
fibrinolysis NN O
but CC O
it PRP O
gave VBD O
non-significantly RB O
better JJ O
results NNS O
in IN O
this DT O
prematurely RB O
terminated VBN O
study NN O
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
warfarin NN B-INTV
and CC O
aspirin NN B-INTV
for IN O
symptomatic JJ O
intracranial JJ O
arterial JJ O
stenosis NN O
. . O

BACKGROUND NNP O
Atherosclerotic NNP O
intracranial JJ O
arterial JJ O
stenosis NN O
is VBZ O
an DT O
important JJ O
cause NN O
of IN O
stroke NN O
. . O

Warfarin NNP O
is VBZ O
commonly RB O
used VBN O
in IN O
preference NN O
to TO O
aspirin VB O
for IN O
this DT O
disorder NN O
, , O
but CC O
these DT O
therapies NNS O
have VBP O
not RB O
been VBN O
compared VBN O
in IN O
a DT O
randomized JJ O
trial NN O
. . O

METHODS NNP O
We PRP O
randomly VBP O
assigned VBN O
patients NNS B-POPU
with IN I-POPU
transient JJ I-POPU
ischemic JJ I-POPU
attack NN I-POPU
or CC I-POPU
stroke NN I-POPU
caused VBN I-POPU
by IN I-POPU
angiographically RB I-POPU
verified VBN I-POPU
50 CD I-POPU
to TO I-POPU
99 CD I-POPU
percent NN I-POPU
stenosis NN I-POPU
of IN I-POPU
a DT I-POPU
major JJ I-POPU
intracranial JJ I-POPU
artery NN I-POPU
to TO O
receive VB B-INTV
warfarin NN I-INTV
( ( I-INTV
target VB I-INTV
international JJ I-INTV
normalized JJ I-INTV
ratio NN I-INTV
, , I-INTV
2.0 CD I-INTV
to TO I-INTV
3.0 CD I-INTV
) ) I-INTV
or CC I-INTV
aspirin NN I-INTV
( ( I-INTV
1300 CD I-INTV
mg NN I-INTV
per IN I-INTV
day NN I-INTV
) ) I-INTV
in IN I-INTV
a DT I-INTV
double-blind NN I-INTV
, , I-INTV
multicenter RB I-INTV
clinical JJ I-INTV
trial NN I-INTV
. . O

The DT O
primary JJ O
end NN O
point NN O
was VBD O
ischemic JJ B-OC
stroke NN I-OC
, , I-OC
brain NN I-OC
hemorrhage NN I-OC
, , I-OC
or CC I-OC
death NN I-OC
from IN O
vascular JJ O
causes NNS O
other JJ O
than IN O
stroke NN B-OC
. . O

RESULTS NNP O
After IN B-POPU
569 CD I-POPU
patients NNS I-POPU
had VBD I-POPU
undergone JJ I-POPU
randomization NN I-POPU
, , I-POPU
enrollment NN I-POPU
was VBD I-POPU
stopped VBN I-POPU
because IN I-POPU
of IN I-POPU
concerns NNS I-POPU
about IN I-POPU
the DT I-POPU
safety NN I-POPU
of IN I-POPU
the DT I-POPU
patients NNS I-POPU
who WP I-POPU
had VBD I-POPU
been VBN I-POPU
assigned VBN I-POPU
to TO I-POPU
receive VB I-POPU
warfarin NN I-POPU
. . O

During IN O
a DT O
mean JJ O
follow-up JJ O
period NN O
of IN O
1.8 CD O
years NNS O
, , O
adverse JJ B-OC
events NNS I-OC
in IN O
the DT O
two CD O
groups NNS O
included VBD O
death NN B-OC
( ( O
4.3 CD O
percent NN O
in IN O
the DT O
aspirin NN B-INTV
group NN O
vs. FW O
9.7 CD O
percent NN O
in IN O
the DT O
warfarin NN O
group NN O
; : O
hazard CC O
ratio NN O
for IN O
aspirin JJ B-INTV
relative JJ O
to TO O
warfarin VB B-INTV
, , O
0.46 CD O
; : O
95 CD O
percent NN O
confidence NN O
interval NN O
, , O
0.23 CD O
to TO O
0.90 CD O
; : O
P=0.02 NNP O
) ) O
, , O
major JJ B-OC
hemorrhage NN I-OC
( ( O
3.2 CD O
percent NN O
vs. FW O
8.3 CD O
percent NN O
, , O
respectively RB O
; : O
hazard NN O
ratio NN O
, , O
0.39 CD O
; : O
95 CD O
percent NN O
confidence NN O
interval NN O
, , O
0.18 CD O
to TO O
0.84 CD O
; : O
P=0.01 NNP O
) ) O
, , O
and CC O
myocardial JJ B-OC
infarction NN I-OC
or CC I-OC
sudden JJ I-OC
death NN I-OC
( ( O
2.9 CD O
percent NN O
vs. FW O
7.3 CD O
percent NN O
, , O
respectively RB O
; : O
hazard NN O
ratio NN O
, , O
0.40 CD O
; : O
95 CD O
percent NN O
confidence NN O
interval NN O
, , O
0.18 CD O
to TO O
0.91 CD O
; : O
P=0.02 NNP O
) ) O
. . O

The DT O
rate NN B-OC
of IN I-OC
death NN I-OC
from IN O
vascular JJ O
causes NNS O
was VBD O
3.2 CD O
percent NN O
in IN O
the DT O
aspirin NN O
group NN O
and CC O
5.9 CD O
percent NN O
in IN O
the DT O
warfarin NN O
group NN O
( ( O
P=0.16 NNP O
) ) O
; : O
the DT O
rate NN B-OC
of IN I-OC
death NN I-OC
from IN O
nonvascular JJ O
causes NNS O
was VBD O
1.1 CD O
percent NN O
and CC O
3.8 CD O
percent NN O
, , O
respectively RB O
( ( O
P=0.05 NNP O
) ) O
. . O

The DT O
primary JJ O
end NN O
point NN O
occurred VBD O
in IN O
22.1 CD O
percent NN O
of IN O
the DT O
patients NNS O
in IN O
the DT O
aspirin NN O
group NN O
and CC O
21.8 CD O
percent NN O
of IN O
those DT O
in IN O
the DT O
warfarin NN O
group NN O
( ( O
hazard JJ O
ratio NN O
, , O
1.04 CD O
; : O
95 CD O
percent NN O
confidence NN O
interval NN O
, , O
0.73 CD O
to TO O
1.48 CD O
; : O
P=0.83 NNP O
) ) O
. . O

CONCLUSIONS NNP O
Warfarin NNP B-INTV
was VBD O
associated VBN O
with IN O
significantly RB O
higher JJR O
rates NNS O
of IN O
adverse JJ O
events NNS O
and CC O
provided VBD O
no DT O
benefit NN O
over IN O
aspirin NN O
in IN O
this DT O
trial NN O
. . O

Aspirin NNP B-INTV
should MD O
be VB O
used VBN O
in IN O
preference NN O
to TO O
warfarin VB O
for IN O
patients NNS B-POPU
with IN I-POPU
intracranial JJ I-POPU
arterial JJ I-POPU
stenosis NN I-POPU
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
congestive JJ O
heart NN O
failure NN O
on IN O
plasma NN B-OC
von NN I-OC
Willebrand NNP I-OC
factor NN I-OC
and CC O
soluble JJ B-OC
P-selectin JJ I-OC
concentrations NNS I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
non-valvar JJ I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
. . O

OBJECTIVE UH O
To TO O
examine VB O
further RB O
the DT O
relations NNS O
of IN O
plasma NN B-OC
von NN I-OC
Willebrand NNP B-INTV
factor NN I-INTV
( ( B-OC
vWf NN I-OC
, , I-OC
an DT I-OC
index NN I-OC
of IN I-OC
endothelial JJ I-OC
damage NN I-OC
and CC I-OC
dysfunction NN I-OC
) ) I-OC
and CC O
soluble JJ B-OC
P-selectin NNP B-INTV
( ( B-OC
sP-sel NN I-OC
, , I-OC
an DT I-OC
index NN I-OC
of IN I-OC
platelet NN I-OC
activation NN I-OC
) ) I-OC
concentrations NNS O
to TO O
the DT O
presence NN O
and CC O
onset NN O
of IN O
clinical JJ O
congestive JJ O
heart NN O
failure NN O
( ( O
CHF NNP O
) ) O
and CC O
the DT O
degree NN O
of IN O
left NN O
ventricular NN O
( ( O
LV NNP O
) ) O
dysfunction NN O
in IN O
patients NNS B-POPU
taking VBG I-POPU
part NN I-POPU
in IN I-POPU
the DT I-POPU
SPAF NNP I-POPU
( ( I-POPU
stroke JJ I-POPU
prevention NN I-POPU
in IN I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
) ) I-POPU
study NN I-POPU
. . O

METHODS NNP O
Plasma NNP B-OC
concentrations NNS I-OC
of IN I-OC
vWf NN B-INTV
and CC I-INTV
sP-sel NN I-INTV
were VBD O
measured VBN O
by IN O
enzyme NN O
linked VBN O
immunosorbent JJ O
assay NN O
( ( O
ELISA NNP O
) ) O
in IN O
1321 CD B-POPU
participants NNS I-POPU
in IN I-POPU
the DT I-POPU
SPAF NNP I-POPU
III NNP I-POPU
study NN I-POPU
and CC O
related VBN O
to TO O
the DT O
presence NN O
and CC O
onset NN O
of IN O
clinical JJ O
CHF NNP O
, , O
as RB O
well RB O
as IN O
echocardiographic JJ O
findings NNS O
. . O

Of IN O
the DT O
1321 CD B-POPU
patients NNS I-POPU
with IN I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
( ( I-POPU
AF NNP I-POPU
) ) I-POPU
, , I-POPU
331 CD I-POPU
( ( I-POPU
25 CD I-POPU
% NN I-POPU
) ) I-POPU
had VBD I-POPU
a DT I-POPU
documented JJ I-POPU
history NN I-POPU
of IN I-POPU
clinical JJ I-POPU
heart NN I-POPU
failure NN I-POPU
, , I-POPU
of IN I-POPU
which WDT I-POPU
168 CD I-POPU
cases NNS I-POPU
were VBD I-POPU
related VBN I-POPU
to TO I-POPU
a DT I-POPU
new JJ I-POPU
or CC I-POPU
recurrent JJ I-POPU
episode NN I-POPU
of IN I-POPU
acute NN I-POPU
decompensated VBN I-POPU
heart NN I-POPU
failure NN I-POPU
occurring VBG I-POPU
within IN I-POPU
the DT I-POPU
preceding VBG I-POPU
three CD I-POPU
months NNS I-POPU
. . O

RESULTS NNP O
Mean NNP B-OC
plasma NN I-OC
vWf NN I-OC
was VBD O
higher JJR O
among IN O
patients NNS O
with IN O
AF NNP O
and CC O
CHF NNP O
( ( O
154 CD O
( ( O
29 CD O
) ) O
v NN O
144 CD O
( ( O
31 CD O
) ) O
IU/dl NNP O
, , O
p NN O
< NNP O
0.001 CD O
) ) O
, , O
particularly RB O
those DT O
with IN O
acute NN O
or CC O
recent JJ O
decompensated VBN O
symptoms NNS O
. . O

Patients NNS B-POPU
with IN I-POPU
severe JJ I-POPU
LV NNP I-POPU
dysfunction NN I-POPU
on IN I-POPU
two CD I-POPU
dimensional JJ I-POPU
echocardiography NN I-POPU
and CC I-POPU
low JJ I-POPU
fractional JJ I-POPU
shortening NN I-POPU
also RB O
had VBD O
significantly RB O
higher JJR O
vWf NN B-OC
concentrations NNS I-OC
than IN O
those DT O
with IN O
no DT O
LV NNP O
dysfunction NN O
. . O

CHF NNP O
patients NNS O
with IN O
clinical JJ O
features NNS O
-- : O
with IN O
( ( O
156 CD O
( ( O
28 CD O
) ) O
IU/dl NNP O
) ) O
and CC O
without IN O
( ( O
152 CD O
( ( O
31 CD O
) ) O
IU/dl NNP O
) ) O
LV NNP O
dysfunction NN O
-- : O
also RB O
had VBD O
higher JJR O
mean JJ B-OC
vWf NN I-OC
concentrations NNS I-OC
than IN O
patients NNS O
with IN O
asymptomatic JJ O
LV NNP O
dysfunction NN O
( ( O
146 CD O
( ( O
31 CD O
) ) O
IU/dl NNP O
, , O
p NN O
< NNP O
0.001 CD O
) ) O
. . O

The DT O
presence NN O
of IN O
mitral JJ B-OC
regurgitation NN I-OC
in IN I-OC
CHF NNP I-OC
was VBD O
associated VBN O
with IN O
lower JJR O
vWf NN O
concentrations NNS O
. . O

Plasma NNP B-OC
sP-sel JJ I-OC
concentrations NNS I-OC
were VBD O
not RB O
affected VBN O
by IN O
presence NN O
, , O
onset NN O
, , O
or CC O
severity NN O
of IN O
heart NN O
failure NN O
. . O

CONCLUSIONS NNP O
CHF NNP O
may MD O
contribute VB O
to TO O
hypercoagulability NN O
and CC O
thrombotic JJ O
risk NN O
in IN O
AF NNP O
through IN O
increased VBN O
endothelial JJ B-OC
damage NN I-OC
and CC I-OC
dysfunction NN I-OC
. . O

Patients NNS B-POPU
with IN I-POPU
acute NN I-POPU
or CC I-POPU
recent JJ I-POPU
decompensated VBN I-POPU
features NNS I-POPU
have VBP O
the DT O
highest JJS O
degree NN O
of IN O
endothelial JJ B-OC
damage NN I-OC
and CC I-OC
dysfunction NN I-OC
. . O

The DT O
presence NN O
of IN O
CHF NNP O
clinical JJ O
features NNS O
was VBD O
an DT O
important JJ O
determinant NN O
of IN O
plasma NN O
vWf NN O
concentrations NNS O
. . O

-DOCSTART- -X- O O

Association NNP O
between IN O
platelet NN O
activation NN O
and CC O
fibrinolysis NN O
in IN O
acute JJ B-POPU
stroke NN I-POPU
patients NNS I-POPU
. . O

We PRP O
aimed VBD O
to TO O
evaluate VB O
platelet NN O
activation NN O
and CC O
fibrinolyis NN O
in IN O
acute JJ B-POPU
atherosclerotic JJ I-POPU
ischemic JJ I-POPU
stroke NN I-POPU
patients NNS I-POPU
to TO O
clarify VB O
the DT O
relationship NN O
between IN O
them PRP O
. . O

Plasma VB B-INTV
P-selectin NNP I-INTV
antigen NN I-INTV
, , I-INTV
tissue NN I-INTV
plasminogen NN I-INTV
activator NN I-INTV
( ( I-INTV
tPA NN I-INTV
) ) I-INTV
antigen NN I-INTV
and CC I-INTV
activity NN I-INTV
, , I-INTV
and CC I-INTV
plasminogen NN I-INTV
activator NN I-INTV
inhibitor-1 JJ I-INTV
( ( I-INTV
PAI-1 NNP I-INTV
) ) I-INTV
activity NN I-INTV
were VBD O
determined VBN O
in IN O
60 CD B-POPU
acute JJ I-POPU
atherosclerotic JJ I-POPU
stroke NN I-POPU
patients NNS I-POPU
and CC I-POPU
matched VBN I-POPU
control NN I-POPU
subjects NNS I-POPU
. . O

All DT B-POPU
patients NNS I-POPU
were VBD I-POPU
examined VBN I-POPU
within IN I-POPU
72 CD I-POPU
h NN I-POPU
after IN I-POPU
stroke NN I-POPU
onset NN I-POPU
. . O

The DT O
levels NNS B-OC
of IN I-OC
P-selectin NNP B-INTV
, , I-INTV
tPA NN I-INTV
antigen NN I-INTV
, , B-OC
and CC I-OC
PAI-1 JJ B-INTV
activity NN B-OC
were VBD O
all DT O
significantly RB B-OC
higher JJR I-OC
in IN O
stroke NN O
patients NNS O
compared VBN O
with IN O
controls NNS O
( ( O
all DT O
p VBP O
< $ O
0.0001 CD O
) ) O
; : O
the DT O
level NN B-OC
of IN I-OC
tPA JJ I-OC
activity NN I-OC
was VBD O
significantly RB O
lower JJR O
in IN O
patients NNS O
than IN O
that DT O
in IN O
controls NNS O
( ( O
p VB O
< RB O
0.0001 CD O
) ) O
. . O

These DT O
markers NNS O
did VBD O
not RB O
change VB O
much RB O
at IN O
different JJ O
time NN O
points NNS O
within IN O
72 CD O
h. NN O
In IN O
stroke NN O
group NN O
, , O
P-selectin NNP B-INTV
concentration NN B-OC
was VBD O
highly RB O
correlated VBN O
to TO O
PAI-1 NNP B-OC
activity NN I-OC
( ( O
r NN O
= VBZ O
0.8433 CD O
, , O
p NN O
< NNP O
0.001 CD O
) ) O
, , O
but CC O
not RB O
to TO O
tPA VB B-INTV
antigen NN B-OC
( ( O
r JJ O
= NNP O
-0.1752 NNP O
, , O
p NN O
> NNP O
0.05 CD O
) ) O
, , O
and CC O
tPA NN B-INTV
activity NN B-OC
( ( O
r NN O
= VBZ O
0.2465 CD O
, , O
p NN O
> NNP O
0.05 CD O
) ) O
, , O
which WDT O
was VBD O
further RBR O
confirmed VBN O
in IN O
the DT O
multiple JJ O
linear JJ O
regression NN O
analysis NN O
( ( O
F NNP O
= NNP O
47.052 CD O
, , O
p NN O
< NNP O
0.0001 CD O
) ) O
. . O

Our PRP$ O
results NNS O
indicate VBP O
increased JJ B-OC
platelet NN I-OC
activation NN I-OC
and CC O
decreased JJ B-OC
fibrinolysis NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
acute JJ I-POPU
atherosclerotic JJ I-POPU
ischemic JJ I-POPU
stroke NN I-POPU
. . O

Increased VBN O
platelet NN B-OC
activation NN I-OC
may MD O
be VB O
correlated VBN O
with IN O
decreased JJ O
fibrinolysis NN O
. . O

-DOCSTART- -X- O O

[ VB O
A DT O
multicenter NN O
, , O
randomized VBD O
clinical JJ O
trial NN O
of IN O
intravenous JJ O
diltiazem NNS B-INTV
in IN O
treatment NN O
of IN O
unstable JJ B-POPU
angina NN I-POPU
] NNP I-POPU
. . O

OBJECTIVE NNP O
To TO O
investigate VB O
the DT O
clinical JJ O
efficacy NN O
and CC O
safety NN O
of IN O
intravenous JJ O
diltiazem NNS B-INTV
compared VBN O
with IN O
nitroglycerin NN B-INTV
in IN O
the DT O
patients NNS B-POPU
with IN I-POPU
unstable JJ I-POPU
angina JJ I-POPU
pectoris NN I-POPU
. . O

METHODS NNP O
A NNP O
multicenter NN O
, , O
randomized VBN O
, , O
open-label JJ O
, , O
parallel JJ O
group NN O
trial NN O
was VBD O
conducted VBN O
. . O

A DT O
total NN B-POPU
of IN I-POPU
213 CD I-POPU
eligible JJ I-POPU
patients NNS I-POPU
were VBD I-POPU
enrolled VBN I-POPU
. . O

They PRP O
were VBD O
randomized VBN O
either RB O
to TO O
diltiazem VB B-INTV
or CC I-INTV
nitroglycerin VB I-INTV
treatment NN O
. . O

The DT O
diltiazem NN B-INTV
was VBD O
administered VBN O
from IN O
100 CD O
microg/min NN O
at IN O
the DT O
initiation NN O
of IN O
treatment NN O
, , O
the DT O
largest JJS O
dosage NN O
was VBD O
200 CD O
- : O
300 CD O
microg/min NN O
; : O
the DT O
nitroglycerin NN B-INTV
was VBD O
administered VBN O
from IN O
20 CD O
microg/min NN O
at IN O
the DT O
initiation NN O
of IN O
treatment NN O
. . O

The DT O
largest JJS O
dosage NN O
was VBD O
80 CD O
- : O
100 CD O
microg/min NN O
. . O

Intravenous JJ O
infusion NN O
was VBD O
kept VBN O
over IN O
48 CD O
hours NNS O
. . O

The DT O
endpoints NNS O
included VBD O
refractory JJ B-OC
angina NN I-OC
pectoris NN I-OC
, , I-OC
acute JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
death NN I-OC
, , I-OC
emergency NN I-OC
PTCA NNP I-OC
and CC I-OC
CABG NNP I-OC
. . O

RESULTS NNP O
( ( O
1 CD O
) ) O
Intravenous NNP O
diltiazem NN O
was VBD O
effective JJ O
on IN O
the DT O
improvement NN O
of IN O
symptom NN B-OC
and CC I-OC
electrocardiogram NN I-OC
, , O
and CC O
its PRP$ O
effects NNS O
were VBD O
similar JJ O
to TO O
intravenous JJ O
nitroglycerin NN O
. . O

( ( O
2 CD O
) ) O
Compared VBN O
with IN O
nitroglycerin NN B-INTV
, , O
intravenous JJ O
diltiazem NN B-INTV
lowered VBD B-OC
heart NN I-OC
rate NN I-OC
and CC I-OC
myocardial JJ I-OC
oxygen NN I-OC
consumption NN I-OC
index NN I-OC
( ( O
systolic JJ O
pressure NN O
x JJ O
heart NN O
rate NN O
) ) O
to TO O
more RBR O
extent JJ O
significantly RB O
. . O

( ( O
3 CD O
) ) O
After IN O
treatment NN O
, , O
the DT O
onsets NNS B-OC
of IN I-OC
refractory JJ I-OC
angina NNS I-OC
pectoris NN I-OC
were VBD O
reduced VBN B-OC
more RBR I-OC
significantly RB I-OC
in IN O
the DT O
diltiazem NN B-INTV
group NN O
than IN O
in IN O
nitroglycerin JJ O
group NN O
[ VBD O
4 CD O
( ( O
3.8 CD O
% NN O
) ) O
vs NN O
13 CD O
( ( O
11.9 CD O
% NN O
) ) O
, , O
RR NNP O
0.32 CD O
( ( O
95 CD O
% NN O
CI NNP O
0.11 CD O
- : O
0.96 CD O
) ) O
, , O
P NNP O
< VBZ O
0.05 CD O
] NN O
. . O

( ( O
4 CD O
) ) O
The DT O
patients NNS O
whose WP$ O
heart NN B-OC
rate NN I-OC
were VBD O
reduced VBN B-OC
significantly RB I-OC
( ( O
< JJ O
or= RB O
50 CD O
beats NNS O
per IN O
minute NN O
) ) O
in IN O
the DT O
diltiazem NN O
group NN O
were VBD O
more JJR O
than IN O
in IN O
the DT O
nitroglycerin JJ O
group NN O
[ VBD O
8 CD O
( ( O
7.7 CD O
% NN O
) ) O
vs NN O
0 CD O
( ( O
0 CD O
% NN O
) ) O
, , O
P NNP O
< VBZ O
0.01 CD O
] NN O
. . O

But CC O
these DT O
patients NNS O
could MD O
tolerate VB O
the DT O
lower JJR O
heart NN B-OC
rate NN I-OC
very RB O
well RB O
in IN O
the DT O
diltiazem NN O
group NN O
. . O

( ( O
5 CD O
) ) O
The DT O
needs NNS O
of IN O
beta NN O
receptor NN O
blocker NN O
or CC O
calcium NN O
antagonists NNS O
were VBD O
reduced VBN O
more RBR O
significantly RB O
in IN O
the DT O
diltiazem NN B-INTV
group NN O
compared VBN O
with IN O
those DT O
in IN O
the DT O
nitroglycerin JJ O
group NN O
[ VBD O
2 CD O
( ( O
1.9 CD O
% NN O
) ) O
vs NN O
13 CD O
( ( O
11.9 CD O
% NN O
) ) O
, , O
P NNP O
< VBZ O
0.01 CD O
] NN O
. . O

CONCLUSION NNP O
Intravenous NNP O
diltiazem NN B-INTV
therapy NN O
is VBZ O
effective JJ O
and CC O
safe JJ O
for IN O
patients NNS B-POPU
with IN I-POPU
unstable JJ I-POPU
angina JJ I-POPU
pectoris NN I-POPU
. . O

It PRP O
may MD O
significantly RB O
lower VB O
the DT O
risk NN O
of IN O
refractory JJ O
angina JJ O
pectoris NNS O
compared VBN O
with IN O
intravenous JJ O
nitroglycerin NNS O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
Orlistat NNP B-INTV
in IN O
obese JJ B-POPU
patients NNS I-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
: : I-POPU
a DT O
pilot NN O
study NN O
. . O

Heart NNP O
failure NN O
is VBZ O
the DT O
leading VBG O
cause NN O
of IN O
hospitalization NN O
. . O

Obesity NNP O
is VBZ O
increasingly RB O
common JJ O
and CC O
is VBZ O
a DT O
major JJ O
public JJ O
health NN O
problem NN O
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
is VBZ O
to TO O
assess VB O
whether IN O
obese JJ B-POPU
patients NNS I-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
can MD O
benefit VB O
from IN O
losing VBG O
weight NN O
via IN O
an DT O
orlistat-assisted JJ B-INTV
diet NN I-INTV
. . O

This DT O
randomized JJ O
clinical JJ O
trial NN O
included VBD O
obese JJ B-POPU
patients NNS I-POPU
with IN I-POPU
ejection NN I-POPU
fractions NNS I-POPU
< VBP I-POPU
or CC I-POPU
=40 CD I-POPU
% NN I-POPU
. . O

Orlistat NNP B-INTV
and CC I-INTV
diet JJ I-INTV
counseling NN I-INTV
were VBD I-INTV
compared VBN I-INTV
with IN I-INTV
diet JJ I-INTV
counseling VBG I-INTV
alone RB I-INTV
. . O

Twenty-one JJ B-POPU
consecutive JJ I-POPU
obese JJ I-POPU
patients NNS I-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
were VBD I-POPU
recruited VBN I-POPU
. . O

Significant JJ O
improvement NN O
in IN O
6-minute JJ B-OC
walk NN I-OC
test NN I-OC
( ( O
45.8 CD O
m NN O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
5.2-86.4 JJ O
m NN O
; : O
p=0.031 NN O
) ) O
, , O
functional JJ B-OC
class NN I-OC
( ( O
-0.6+/-0.5 UH O
, , O
p=0.014 NN O
) ) O
, , O
weight JJ B-OC
loss NN I-OC
( ( O
-8.55 JJ O
kg NN O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
-13.0 NN O
to TO O
-4.1 VB O
kg NN O
; : O
p CC O
< VB O
0.001 CD O
) ) O
and CC O
also RB O
significant JJ O
decreases NNS O
in IN O
total JJ B-OC
cholesterol NN I-OC
( ( O
p=0.017 NN O
) ) O
, , O
low-density JJ B-OC
lipoprotein NN I-OC
cholesterol NN I-OC
( ( O
p=0.03 NN O
) ) O
, , O
and CC O
triglycerides NNS B-OC
( ( O
p=0.036 NN O
) ) O
were VBD O
observed VBN O
in IN O
the DT O
orlistat NN O
group NN O
. . O

Orlistat CC B-INTV
can MD O
promote VB O
significant JJ O
weight JJ B-OC
loss NN I-OC
and CC I-OC
symptoms NNS I-OC
of IN I-OC
relief NN I-OC
in IN O
obese JJ O
patients NNS O
with IN O
heart NN O
failure NN O
, , O
as IN O
measured VBN O
by IN O
6-minute JJ O
walk NN O
test NN O
and CC O
functional JJ O
capacity NN O
. . O

The DT O
lipid JJ O
profile NN O
improved VBN O
. . O

Orlistat NNP B-INTV
was VBD O
safe JJ O
and CC O
well RB O
tolerated VBN O
. . O

-DOCSTART- -X- O O

Just-in-time JJ O
evidence-based JJ O
e-mail JJ O
" NN O
reminders NNS O
" VBP O
in IN O
home NN O
health NN O
care NN O
: : O
impact NN B-POPU
on IN I-POPU
nurse JJ I-POPU
practices NNS I-POPU
. . O

OBJECTIVE NNP O
To TO O
test VB O
the DT O
effectiveness NN O
of IN O
two CD O
interventions NNS O
designed VBN O
to TO O
improve VB O
the DT O
adoption NN O
of IN O
evidence-based JJ O
practices NNS O
by IN O
home NN B-POPU
health NN I-POPU
nurses NNS I-POPU
caring VBG I-POPU
for IN I-POPU
heart NN I-POPU
failure NN I-POPU
( ( I-POPU
HF NNP I-POPU
) ) I-POPU
patients NNS I-POPU
. . O

DATA NNP O
SOURCES/STUDY NNP O
SETTING NNP O
Information NNP B-POPU
on IN I-POPU
nurse NN I-POPU
practices NNS I-POPU
was VBD I-POPU
abstracted VBN I-POPU
from IN I-POPU
the DT I-POPU
clinical JJ I-POPU
records NNS I-POPU
of IN I-POPU
patients NNS I-POPU
admitted VBN I-POPU
between IN I-POPU
June NNP I-POPU
2000 CD I-POPU
and CC I-POPU
November NNP I-POPU
2001 CD I-POPU
to TO I-POPU
the DT I-POPU
care NN I-POPU
of IN I-POPU
354 CD I-POPU
study NN I-POPU
nurses NNS I-POPU
at IN I-POPU
a DT I-POPU
large JJ I-POPU
, , I-POPU
urban JJ I-POPU
, , I-POPU
nonprofit JJ I-POPU
home NN I-POPU
care NN I-POPU
agency NN I-POPU
. . O

STUDY NNP O
DESIGN NNP O
The DT O
study NN O
employed VBD O
a DT O
randomized JJ O
design NN O
with IN O
nurses NNS O
assigned VBN O
to TO O
usual JJ O
care NN O
or CC O
one CD O
of IN O
two CD O
intervention NN O
groups NNS O
upon IN O
identification NN O
of IN O
an DT O
eligible JJ O
patient NN O
. . O

The DT O
basic JJ O
intervention NN O
was VBD O
a DT O
one-time JJ B-INTV
e-mail JJ I-INTV
reminder NN I-INTV
highlighting VBG I-INTV
six CD I-INTV
HF-specific JJ I-INTV
clinical JJ I-INTV
recommendations NNS I-INTV
. . O

The DT O
augmented JJ O
intervention NN O
consisted VBN O
of IN O
the DT O
initial JJ B-INTV
e-mail JJ I-INTV
reminder NN I-INTV
supplemented VBN I-INTV
by IN I-INTV
provider NN I-INTV
prompts NNS I-INTV
, , I-INTV
patient JJ I-INTV
education NN I-INTV
material NN I-INTV
, , I-INTV
and CC I-INTV
clinical JJ I-INTV
nurse NN I-INTV
specialist NN I-INTV
outreach NN I-INTV
. . O

DATA NNP O
COLLECTION NNP O
At IN O
each DT O
home NN O
health NN O
visit NN O
provided VBN O
by IN O
a DT O
study NN O
nurse NN O
to TO O
an DT O
eligible JJ O
HF NNP O
patient NN O
during IN O
the DT O
45-day JJ O
follow-up JJ O
period NN O
, , O
a DT O
structured JJ O
chart NN O
abstraction NN O
tool NN O
was VBD O
used VBN O
to TO O
collect VB O
information NN O
on IN O
whether IN O
the DT O
nurse NN O
provided VBD O
the DT O
care NN O
practices NNS O
highlighted VBN O
in IN O
the DT O
e-mail JJ O
reminder NN O
. . O

PRINCIPAL NNP O
FINDINGS NNP O
Both NNP O
the DT O
basic JJ O
and CC O
the DT O
augmented JJ O
interventions NNS O
greatly RB O
increased VBD O
the DT O
practice NN B-OC
of IN I-OC
evidence-based JJ I-OC
care NN I-OC
, , O
according VBG O
to TO O
patient NN O
records NNS O
, , O
in IN O
the DT O
areas NNS O
of IN O
patient JJ O
assessment NN O
and CC O
instructions NNS O
about IN O
HF NNP O
disease NN O
management NN O
. . O

While IN O
not RB O
all DT O
results NNS O
were VBD O
statistically RB O
significant JJ O
at IN O
conventional JJ O
levels NNS O
, , O
intervention NN B-OC
effects NNS I-OC
were VBD O
positive JJ O
in IN O
virtually RB O
all DT O
cases NNS O
and CC O
effect NN B-OC
magnitudes NNS I-OC
frequently RB I-OC
were VBD O
large JJ O
. . O

CONCLUSIONS VB O
The DT O
results NNS O
of IN O
this DT O
randomized JJ O
trial NN O
strongly RB O
support VB O
the DT O
efficacy NN B-OC
of IN O
just-in-time JJ B-OC
evidence-based JJ I-OC
reminders NNS I-OC
as IN O
a DT O
means NN O
of IN O
changing VBG O
clinical JJ O
practice NN O
among IN O
home NN B-POPU
health NN I-POPU
nurses NNS I-POPU
who WP O
are VBP O
geographically RB O
dispersed VBN O
and CC O
spend VBP O
much RB O
of IN O
their PRP$ O
time NN O
in IN O
the DT O
field NN O
. . O

-DOCSTART- -X- O O

Inhibition NN O
of IN O
awake JJ O
sympathetic JJ O
nerve NN O
activity NN O
of IN O
heart NN B-POPU
failure NN I-POPU
patients NNS I-POPU
with IN I-POPU
obstructive JJ I-POPU
sleep NN I-POPU
apnea NN I-POPU
by IN O
nocturnal JJ B-INTV
continuous JJ I-INTV
positive JJ I-INTV
airway NN I-INTV
pressure NN I-INTV
. . O

OBJECTIVES CC O
This DT O
study NN O
was VBD O
designed VBN O
to TO O
determine VB O
whether IN O
reductions NNS O
in IN O
morning NN B-OC
systolic JJ I-OC
blood NN I-OC
pressure NN I-OC
( ( I-OC
BP NNP I-OC
) ) I-OC
elicited VBN O
by IN O
treatment NN O
of IN O
moderate JJ O
to TO O
severe VB O
obstructive JJ B-OC
sleep JJ I-OC
apnea NN I-OC
( ( O
OSA NNP O
) ) O
in IN O
heart NN B-POPU
failure NN I-POPU
( ( I-POPU
HF NNP I-POPU
) ) I-POPU
patients NNS I-POPU
are VBP O
associated VBN O
with IN O
a DT O
reduction NN O
in IN O
sympathetic JJ B-OC
vasoconstrictor NN I-OC
tone NN I-OC
. . O

BACKGROUND NNP O
Daytime NNP B-OC
muscle NN I-OC
sympathetic JJ I-OC
nerve NN I-OC
activity NN I-OC
( ( I-OC
MSNA NNP I-OC
) ) I-OC
is VBZ O
elevated VBN O
in IN O
HF NNP B-POPU
patients NNS I-POPU
with IN I-POPU
coexisting VBG I-POPU
OSA NNP I-POPU
. . O

In IN O
our PRP$ O
recent JJ O
randomized VBN O
trial NN O
in IN O
HF NNP O
, , O
abolition NN O
of IN O
OSA NNP O
by IN O
continuous JJ B-INTV
positive JJ I-INTV
airway NN I-INTV
pressure NN I-INTV
( ( I-INTV
CPAP NNP I-INTV
) ) I-INTV
increased VBD O
left JJ B-OC
ventricular JJ I-OC
ejection NN I-OC
fraction NN I-OC
( ( I-OC
LVEF NNP I-OC
) ) I-OC
and CC I-OC
lowered VBD O
morning NN B-OC
systolic JJ I-OC
BP NNP I-OC
. . O

METHODS NNP O
Muscle NNP B-INTV
sympathetic JJ I-INTV
nerve NN I-INTV
activity NN I-INTV
, , I-INTV
BP NNP I-INTV
, , I-INTV
and CC I-INTV
heart NN I-INTV
rate NN I-INTV
( ( I-INTV
HR NNP I-INTV
) ) I-INTV
of IN I-INTV
medically RB B-POPU
treated VBN I-POPU
HF NNP I-POPU
patients NNS I-POPU
( ( I-POPU
EF NNP I-POPU
< RB I-POPU
45 CD I-POPU
% NN I-POPU
) ) I-POPU
and CC I-POPU
OSA NNP I-POPU
( ( I-POPU
apnea-hypopnea JJ I-POPU
index NN I-POPU
> VBD I-POPU
or CC I-POPU
=20/h CD I-POPU
of IN I-POPU
sleep NN I-POPU
) ) I-POPU
were VBD B-INTV
recorded VBN I-INTV
on IN I-INTV
the DT I-INTV
morning NN I-INTV
after IN I-INTV
overnight JJ I-INTV
polysomnography NN I-INTV
, , I-INTV
and CC I-INTV
again RB I-INTV
one CD I-INTV
month NN I-INTV
after IN I-INTV
patients NNS I-INTV
were VBD I-INTV
randomly RB I-INTV
allocated VBN I-INTV
nocturnal JJ I-INTV
CPAP NNP I-INTV
treatment NN I-INTV
or CC I-INTV
no DT I-INTV
CPAP NNP I-INTV
( ( I-INTV
control NN I-INTV
) ) I-INTV
. . O

RESULTS NNP O
In IN B-POPU
nine CD I-POPU
control NN I-POPU
patients NNS I-POPU
, , O
there EX O
were VBD O
no DT O
significant JJ O
changes NNS O
in IN O
the DT O
severity NN O
of IN O
OSA NNP B-OC
, , I-OC
MSNA NNP I-OC
, , I-OC
systolic JJ I-OC
BP NNP I-OC
, , I-OC
or CC I-OC
HR NNP I-OC
. . O

In IN O
contrast NN O
, , O
in IN O
the DT O
8 CD B-POPU
CPAP-treated JJ I-POPU
patients NNS I-POPU
, , O
OSA NNP B-OC
was VBD O
attenuated VBN O
, , O
and CC O
there EX O
were VBD O
significant JJ O
reductions NNS O
in IN O
daytime JJ B-OC
MSNA NNP I-OC
( ( O
from IN O
58 CD O
+/- JJ O
4 CD O
bursts/min NN O
to TO O
48 CD O
+/- JJ O
5 CD O
bursts/min NN O
; : O
84 CD O
+/- JJ O
4 CD O
bursts/100 JJ O
heart NN O
beats VBZ O
to TO O
72 CD O
+/- JJ O
5 CD O
bursts/100 JJ O
heart NN O
beats VBZ O
; : O
p NN O
< VBZ O
0.001 CD O
and CC O
p VB O
= JJ O
0.003 CD O
, , O
respectively RB O
) ) O
, , O
systolic JJ B-OC
BP NNP I-OC
( ( O
from IN O
135 CD O
+/- JJ O
5 CD O
mm NN O
Hg NNP O
to TO O
120 CD O
+/- JJ O
6 CD O
mm NN O
Hg NNP O
, , O
p NN O
= NNP O
0.03 CD O
) ) O
, , O
and CC O
HR NNP B-OC
( ( O
from IN O
69 CD O
+/- JJ O
2 CD O
min NN O
( ( O
-1 NN O
) ) O
to TO O
66 CD O
+/- JJ O
2 CD O
min NN O
( ( O
-1 NNP O
) ) O
; : O
p CC O
= VB O
0.013 CD O
) ) O
. . O

CONCLUSIONS NNP O
Treatment NNP B-POPU
of IN I-POPU
coexisting VBG I-POPU
OSA NNP I-POPU
by IN I-POPU
CPAP NNP I-POPU
in IN I-POPU
HF NNP I-POPU
patients NNS I-POPU
lowers NNS O
daytime JJ B-OC
MSNA NNP I-OC
, , I-OC
systolic JJ I-OC
BP NNP I-OC
, , I-OC
and CC I-OC
HR NNP I-OC
. . O

Inhibition NNP O
of IN O
increased JJ O
central JJ O
sympathetic JJ O
vasoconstrictor NN O
outflow NN O
is VBZ O
one CD O
mechanism NN O
by IN O
which WDT O
nocturnal JJ B-INTV
CPAP NNP I-INTV
reduces NNS O
awake VBP O
BP NNP B-OC
in IN O
HF NNP B-POPU
patients NNS I-POPU
with IN I-POPU
moderate JJ I-POPU
to TO I-POPU
severe VB I-POPU
OSA NNP I-POPU
. . O

-DOCSTART- -X- O O

Stapled VBN B-INTV
hemorrhoidopexy JJ I-INTV
versus NN I-INTV
milligan-morgan JJ I-INTV
hemorrhoidectomy NN B-POPU
: : I-POPU
a DT O
prospective JJ O
, , O
randomized VBN O
, , O
multicenter RBR O
trial NN O
with IN O
2-year JJ O
postoperative NN O
follow VB O
up RP O
. . O

PURPOSE VB O
The DT O
purpose NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
compare VB B-OC
the DT I-OC
outcome NN I-OC
of IN I-OC
stapled JJ B-INTV
hemorrhoidopexy NN I-INTV
( ( I-INTV
SH NNP I-INTV
group NN I-INTV
) ) I-INTV
performed VBD O
using VBG O
a DT O
circular JJ O
stapler NN O
with IN O
that DT O
of IN O
the DT O
Milligan-Morgan NNP B-INTV
technique NN I-INTV
( ( I-INTV
MM NNP I-INTV
group NN I-INTV
) ) I-INTV
. . O

The DT O
goals NNS O
of IN O
the DT O
study NN O
were VBD O
to TO O
evaluate VB O
the DT O
efficacy NN B-OC
and CC I-OC
reproducibility NN I-OC
of IN O
stapled JJ B-INTV
hemorrhoidopexy NN I-INTV
and CC O
define VB O
its PRP$ O
place NN O
among IN O
conventional JJ O
techniques NNS O
. . O

METHODS VB O
A NNP O
series NN O
of IN O
134 CD B-POPU
patients NNS I-POPU
were VBD I-POPU
included VBN I-POPU
at IN I-POPU
7 CD I-POPU
hospital NN I-POPU
centers NNS I-POPU
. . O

They PRP O
were VBD O
randomized VBN O
according VBG O
to TO O
a DT O
single-masked JJ O
design NN O
and CC O
stratified VBN O
by IN O
center NN O
( ( O
with IN O
balancing VBG O
every DT O
4 CD O
patients NNS O
) ) O
. . O

Patients NNS O
were VBD O
clinically RB O
evaluated VBN O
preoperatively RB O
and CC O
at IN O
6 CD O
weeks NNS O
, , O
1 CD O
year NN O
, , O
and CC O
a DT O
minimum NN O
of IN O
2 CD O
years NNS O
after IN O
treatment NN O
. . O

Patients NNS O
completed VBD O
a DT O
questionnaire NN B-INTV
before IN O
and CC O
1 CD O
year NN O
after IN O
surgery NN O
to TO O
evaluate VB O
symptoms NNS O
, , O
function NN O
, , O
and CC O
overall JJ O
satisfaction NN O
. . O

RESULTS VB O
The DT O
mean JJ O
follow-up JJ O
period NN O
was VBD O
2.21 CD O
years NNS O
+/- JJ O
0.26 CD O
( ( O
1.89-3.07 JJ O
) ) O
. . O

Nine JJ O
patients NNS O
( ( O
7 CD O
% NN O
) ) O
could MD O
not RB O
be VB O
monitored VBN O
at IN O
1 CD O
or CC O
2 CD O
years NNS O
, , O
but CC O
4 CD O
of IN O
these DT O
9 CD O
nevertheless RB O
filled VBN O
in IN O
the DT O
1-year JJ O
questionnaire NN O
. . O

The DT O
patients NNS O
in IN O
the DT O
SH NNP B-INTV
group NN O
experienced VBD O
less RBR O
postoperative JJ B-OC
pain/discomfort NN I-OC
as IN O
scored VBN O
by IN O
pain NN B-OC
during IN I-OC
bowel NN I-OC
movement NN I-OC
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
, , O
total JJ B-OC
analgesic JJ I-OC
requirement NN I-OC
over IN I-OC
the DT I-OC
first JJ I-OC
3 CD I-OC
days NNS I-OC
( ( O
according VBG O
to TO O
the DT O
World NNP O
Health NNP O
Organization NNP O
[ NNP O
WHO NNP O
] NNP O
class NN O
II NNP O
analgesics NNS O
[ VBP O
P NNP O
= NNP O
0.002 CD O
] NNP O
; : O
class NN O
III NNP O
[ NNP O
P NNP O
= VBD O
0.066 CD O
] NN O
) ) O
, , O
and CC O
per-patient JJ O
consumption NN O
frequency NN O
of IN O
class NN O
III NNP O
analgesics NNS O
( ( O
P NNP O
= NNP O
0.089 CD O
) ) O
. . O

A DT O
clear JJ O
difference NN O
in IN O
morphine JJ B-OC
requirement NN I-OC
became VBD O
evident JJ O
after IN O
24 CD O
hours NNS O
( ( O
P NNP O
= NNP O
0.010 CD O
) ) O
. . O

Hospital NNP B-OC
stay NN I-OC
was VBD O
significantly RB O
shorter JJR O
in IN O
the DT O
SH NNP B-INTV
group NN O
( ( O
SH NNP O
2.2 CD O
+/- JJ O
1.2 CD O
[ JJ O
0 CD O
; : O
5.0 CD O
] NNP O
versus NN O
MM NNP B-INTV
3.1 CD O
+/- JJ O
1.7 CD O
[ JJ O
1 CD O
; : O
8.0 CD O
] NN O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

At IN O
1 CD O
year NN O
, , O
no DT O
differences NNS B-OC
in IN O
the DT O
resolution NN B-OC
of IN I-OC
symptoms NNS I-OC
were VBD O
observed VBN O
between IN O
the DT O
2 CD O
groups NNS O
, , O
and CC O
over IN O
2 CD O
years NNS O
, , O
the DT O
overall JJ B-OC
incidence NN I-OC
of IN I-OC
complications NNS I-OC
was VBD O
the DT O
same JJ O
, , O
specifically RB O
fecaloma JJ B-OC
( ( O
P NNP O
= NNP O
0.003 CD O
) ) O
in IN O
the DT O
MM NNP B-INTV
group NN O
and CC O
external JJ B-OC
hemorrhoidal NN I-OC
thrombosis NN I-OC
( ( O
P NNP O
= NNP O
0.006 CD O
) ) O
in IN O
the DT O
SH NNP B-INTV
group NN O
. . O

Impaired NNP B-OC
sphincter NN I-OC
function NN I-OC
was VBD O
observed VBN O
at IN O
1 CD O
year NN O
with IN O
no DT O
significant JJ O
difference NN O
between IN O
the DT O
groups NNS O
for IN O
urgency NN O
( ( O
12 CD O
% NN O
) ) O
, , O
continence NN O
problems NNS O
( ( O
10 CD O
% NN O
) ) O
, , O
or CC O
tenesmus NN O
( ( O
3 CD O
% NN O
) ) O
. . O

No DT O
patient NN O
needed VBD O
a DT O
second JJ B-OC
procedure NN I-OC
for IN O
recurrence NN O
within IN O
2 CD O
years NNS O
, , O
although IN O
partial JJ B-OC
residual JJ I-OC
prolapse NN I-OC
was VBD O
detected VBN O
in IN O
4 CD O
SH JJ B-INTV
patients NNS O
( ( O
7.5 CD O
% NN O
) ) O
versus NN O
1 CD O
MM NNP B-INTV
patient NN O
( ( O
1.8 CD O
% NN O
) ) O
( ( O
P NNP O
= NNP O
0.194 CD O
) ) O
. . O

CONCLUSION NNP O
Stapled VBD B-INTV
hemorrhoidopexy JJ I-INTV
causes NNS O
significantly RB O
less RBR O
postoperative JJ B-OC
pain NN I-OC
. . O

The DT O
technique NN O
is VBZ O
reproducible JJ O
and CC O
can MD O
achieve VB O
comparable JJ O
outcomes NNS B-OC
as IN O
those DT O
of IN O
the DT O
MM NNP B-INTV
technique NN O
as RB O
long RB O
as IN O
the DT O
well-described JJ O
steps NNS O
of IN O
the DT O
technique NN O
are VBP O
followed VBN O
. . O

Like IN O
with IN O
conventional JJ O
surgery NN B-INTV
, , O
anorectal JJ B-OC
dysfunction NN I-OC
can MD O
occur VB O
after IN O
stapled JJ B-INTV
hemorrhoidopexy NN I-INTV
in IN O
some DT O
patients NNS O
. . O

Its PRP$ O
effectiveness NN B-OC
in IN O
relieving VBG O
symptoms NNS O
is VBZ O
equivalent JJ O
to TO O
conventional JJ O
surgery NN O
, , O
and CC O
the DT O
number NN B-OC
of IN I-OC
hemorrhoidal JJ I-OC
prolapse NN I-OC
recurrences NNS I-OC
at IN I-OC
2 CD I-OC
years NNS I-OC
is VBZ O
not RB O
significantly RB O
different JJ O
. . O

Hemorroidopexy NNP B-INTV
is VBZ O
applicable JJ O
for IN O
treating VBG O
reducible JJ O
hemorrhoidal JJ O
prolapse NN O
. . O

-DOCSTART- -X- O O

Administrative JJ O
Data NNP O
Feedback NNP O
for IN O
Effective NNP B-INTV
Cardiac NNP I-INTV
Treatment NNP I-INTV
: : I-INTV
AFFECT NNP O
, , O
a DT O
cluster NN O
randomized VBN O
trial NN O
. . O

CONTEXT NNP O
Hospital NNP O
report NN O
cards NNS O
are VBP O
increasingly RB O
being VBG O
implemented VBN O
for IN O
quality NN O
improvement NN O
despite IN O
lack NN O
of IN O
strong JJ O
evidence NN O
to TO O
support VB O
their PRP$ O
use NN O
. . O

OBJECTIVE NN O
To TO O
determine VB O
whether IN O
hospital JJ B-INTV
report NN I-INTV
cards NNS I-INTV
constructed VBN I-INTV
using VBG I-INTV
linked VBN I-INTV
hospital NN I-INTV
and CC I-INTV
prescription NN I-INTV
administrative JJ I-INTV
databases NNS I-INTV
are VBP O
effective JJ O
for IN O
improving VBG O
quality NN B-OC
of IN I-OC
care NN I-OC
for IN O
acute JJ B-POPU
myocardial JJ I-POPU
infarction NN I-POPU
( ( O
AMI NNP O
) ) O
. . O

DESIGN VB O
The DT O
Administrative NNP B-INTV
Data NNP I-INTV
Feedback NNP I-INTV
for IN I-INTV
Effective NNP I-INTV
Cardiac NNP I-INTV
Treatment NNP I-INTV
( ( O
AFFECT NNP O
) ) O
study NN O
, , O
a DT O
cluster NN O
randomized VBN O
trial NN O
. . O

SETTING NN O
AND CC O
PATIENTS NNP O
Patients NNPS B-POPU
with IN I-POPU
AMI NNP I-POPU
who WP I-POPU
were VBD I-POPU
admitted VBN I-POPU
to TO I-POPU
76 CD I-POPU
acute NN I-POPU
care NN I-POPU
hospitals NNS I-POPU
in IN I-POPU
Quebec NNP I-POPU
that WDT I-POPU
treated VBD I-POPU
at IN I-POPU
least JJS I-POPU
30 CD I-POPU
AMI NNP I-POPU
patients NNS I-POPU
per IN I-POPU
year NN I-POPU
between IN I-POPU
April NNP I-POPU
1 CD I-POPU
, , I-POPU
1999 CD I-POPU
, , I-POPU
and CC I-POPU
March NNP I-POPU
31 CD I-POPU
, , I-POPU
2003 CD I-POPU
. . O

INTERVENTION NN O
Hospitals NNS O
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
rapid JJ B-POPU
( ( I-POPU
immediate JJ I-POPU
; : I-POPU
n CC I-POPU
= $ I-POPU
38 CD I-POPU
hospitals NNS I-POPU
and CC I-POPU
2533 CD I-POPU
patients NNS I-POPU
) ) I-POPU
or CC I-POPU
delayed VBN I-POPU
( ( I-POPU
14 CD I-POPU
months NNS I-POPU
; : I-POPU
n CC I-POPU
= $ I-POPU
38 CD I-POPU
hospitals NNS I-POPU
and CC I-POPU
3142 CD I-POPU
patients NNS I-POPU
) ) I-POPU
confidential JJ B-INTV
feedback NN I-INTV
on IN I-INTV
quality NN I-INTV
indicators NNS I-INTV
constructed VBD I-INTV
using VBG I-INTV
administrative JJ I-INTV
data NNS I-INTV
. . O

MAIN NNP O
OUTCOME NNP O
MEASURES NNP O
Quality NNP O
indicators NNS O
pertaining VBG O
to TO O
processes NNS O
of IN O
care NN O
and CC O
outcomes NNS O
of IN O
patients NNS O
admitted VBN O
between IN O
4 CD O
and CC O
10 CD O
months NNS O
after IN O
randomization NN O
. . O

The DT O
primary JJ O
indicator NN O
was VBD O
the DT O
proportion NN O
of IN O
elderly JJ O
survivors NNS O
of IN O
AMI NNP O
at IN O
each DT O
study NN O
hospital NN O
who WP O
filled VBD O
a DT O
prescription NN O
for IN O
a DT O
beta-blocker NN O
within IN O
30 CD O
days NNS O
after IN O
discharge NN O
. . O

RESULTS VB O
At IN O
follow-up JJ O
, , O
adjusted JJ O
prescription NN O
rates NNS O
within IN O
30 CD O
days NNS O
after IN O
discharge NN O
were VBD O
similar JJ O
in IN O
the DT O
early JJ O
vs NN O
late JJ O
groups NNS O
( ( O
for IN O
beta-blockers NNS O
, , O
odds NNS O
ratio VBP O
[ CD O
OR NNP O
] NNP O
, , O
1.06 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
[ NNP O
CI NNP O
] NNP O
, , O
0.82-1.37 NNP O
; : O
for IN O
angiotensin-converting JJ O
enzyme NN O
inhibitors NNS O
, , O
OR NNP O
, , O
1.17 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.90-1.52 NNP O
; : O
for IN O
lipid-lowering NN O
drugs NNS O
, , O
OR NNP O
, , O
1.14 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.86-1.50 NNP O
; : O
and CC O
for IN O
aspirin NN O
, , O
OR NNP O
, , O
1.05 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.84-1.33 NN O
) ) O
. . O

In IN O
addition NN O
, , O
adjusted VBN B-OC
mortality NN I-OC
was VBD O
similar JJ O
in IN O
both DT O
groups NNS O
, , O
as IN O
were VBD O
length NN B-OC
of IN I-OC
in-hospital JJ I-OC
stay NN I-OC
, , I-OC
physician JJ I-OC
visits NNS I-OC
after IN I-OC
discharge NN I-OC
, , I-OC
waiting VBG I-OC
times NNS I-OC
for IN I-OC
invasive JJ I-OC
cardiac NN I-OC
procedures NNS I-OC
, , I-OC
and CC I-OC
readmissions NNS I-OC
for IN I-OC
cardiac JJ I-OC
complications NNS I-OC
. . O

CONCLUSIONS NNP O
Feedback NNP O
based VBN O
on IN O
one-time JJ O
, , O
confidential JJ O
report NN O
cards NNS O
constructed VBN O
using VBG O
administrative JJ O
data NNS O
is VBZ O
not RB O
an DT O
effective JJ O
strategy NN O
for IN O
quality NN B-OC
improvement NN I-OC
regarding VBG O
care NN O
of IN O
patients NNS B-POPU
with IN I-POPU
AMI NNP I-POPU
. . O

A NNP O
need NN O
exists VBZ O
for IN O
further JJ O
studies NNS O
to TO O
rigorously VB O
evaluate VB O
the DT O
effectiveness NN B-OC
of IN O
more RBR O
intensive JJ O
report NN B-INTV
card NN I-INTV
interventions NNS I-INTV
. . O

-DOCSTART- -X- O O

Superior JJ O
efficacy NN O
of IN O
clopidogrel NN B-INTV
plus CC I-INTV
acetylsalicylic JJ I-INTV
acid NNS I-INTV
compared VBN O
with IN O
extended-release JJ B-INTV
dipyridamole JJ I-INTV
plus CC I-INTV
acetylsalicylic JJ I-INTV
acid NN I-INTV
in IN O
preventing VBG O
arterial JJ O
thrombogenesis NN O
in IN O
healthy JJ B-POPU
volunteers NNS I-POPU
. . O

INTRODUCTION NNP O
Recent NNP O
ex NN O
vivo NN O
platelet NN O
aggregometry NN O
data NNS O
indicate VBP O
that IN O
clopidogrel NN B-INTV
75 CD O
mg/day JJ O
plus CC B-INTV
acetylsalicylic JJ I-INTV
acid NN I-INTV
( ( I-INTV
ASA NNP I-INTV
) ) I-INTV
75 CD O
mg/day NN O
is VBZ O
a DT O
more RBR O
potent JJ O
antiplatelet NN O
regimen NNS O
than IN O
the DT O
marketed JJ O
combination NN O
of IN O
dipyridamole+ASA NN B-INTV
. . O

The DT O
present JJ O
study NN O
was VBD O
designed VBN O
to TO O
assess VB O
the DT O
antithrombotic JJ O
effect NN O
of IN O
both DT O
dual JJ B-INTV
antiplatelet NN I-INTV
regimens NNS I-INTV
using VBG O
a DT O
human JJ O
ex NN O
vivo NN O
model NN O
of IN O
arterial JJ O
thrombosis NN O
. . O

MATERIALS NNP O
AND CC O
METHODS NNP O
This DT O
was VBD O
a DT O
randomized JJ O
, , O
double-blind JJ O
, , O
placebo-controlled JJ O
, , O
crossover NN O
study NN O
. . O

During IN O
two CD O
10-day JJ O
treatment NN O
periods NNS O
separated VBN O
by IN O
a DT O
14-day JJ O
washout NN O
period NN O
, , O
23 CD B-POPU
healthy JJ I-POPU
male NN I-POPU
volunteers NNS I-POPU
received VBD O
once-daily RB O
clopidogrel JJ B-INTV
75 CD I-INTV
mg NN I-INTV
plus CC I-INTV
acetylsalicylic JJ I-INTV
acid NN I-INTV
75 CD O
mg NN O
, , O
or CC O
twice-daily RB O
extended-release JJ B-INTV
dipyridamole NN I-INTV
200 CD I-INTV
mg NN I-INTV
plus CC I-INTV
acetylsalicylic JJ I-INTV
acid NN I-INTV
25 CD O
mg NN O
. . O

Assessments NNS O
were VBD O
made VBN O
at IN O
baseline NN O
and CC O
on IN O
Day NNP O
10 CD O
of IN O
each DT O
period NN O
. . O

Arterial JJ O
thrombus NN O
formation NN O
was VBD O
induced VBN O
ex JJ O
vivo NN O
by IN O
exposing VBG O
a DT O
collagen-coated JJ O
surface NN O
in IN O
a DT O
parallel-plate JJ O
perfusion NN O
chamber NN O
to TO O
native JJ O
blood NN O
for IN O
3 CD O
min NN O
( ( O
arterial JJ O
wall NN O
shear NN O
rate NN O
2600 CD O
s NN O
( ( O
-1 NNP O
) ) O
) ) O
. . O

Total JJ B-OC
platelet NN I-OC
and CC I-OC
fibrin JJ I-OC
deposition NN I-OC
was VBD O
determined VBN O
by IN O
immunoenzymatic JJ O
methods NNS O
. . O

RESULTS NNP O
Compared VBD O
with IN O
baseline NN O
values NNS O
, , O
the DT O
mean JJ B-OC
inhibition NN I-OC
of IN I-OC
total JJ I-OC
platelet NN I-OC
deposition NN I-OC
was VBD O
63.9+/-5.9 JJ O
% NN O
with IN O
clopidogrel JJ B-INTV
plus CC I-INTV
acetylsalicylic JJ I-INTV
acid NN I-INTV
, , O
compared VBN O
with IN O
18.4+/-5.6 CD O
% NN O
for IN O
extended-release JJ B-INTV
dipyridamole JJ I-INTV
plus CC I-INTV
acetylsalicylic JJ I-INTV
acid NN I-INTV
( ( O
67 CD O
% NN O
reduction NN O
; : O
95 CD O
% NN O
CI NNP O
, , O
49-79 JJ O
% NN O
; : O
p CC O
< VB O
0.0001 CD O
) ) O
. . O

Corresponding VBG O
figures NNS O
for IN O
fibrin JJ B-OC
deposition NN I-OC
were VBD O
64.9+/-4.8 CD O
% NN O
and CC O
18.3+/-9.7 CD O
% NN O
, , O
respectively RB O
( ( O
58 CD O
% NN O
reduction NN O
; : O
95 CD O
% NN O
CI NNP O
, , O
45-67 JJ O
% NN O
; : O
p CC O
< VB O
0.0001 CD O
) ) O
. . O

Both DT O
treatments NNS O
were VBD O
well RB O
tolerated VBN B-OC
. . O

CONCLUSIONS NNP O
Clopidogrel NNP B-INTV
plus CC I-INTV
acetylsalicylic JJ I-INTV
acid NN I-INTV
showed VBD O
significantly RB O
superior JJ O
antithrombotic JJ O
efficacy NN O
compared VBN O
with IN O
extended-release JJ B-INTV
dipyridamole JJ I-INTV
plus CC I-INTV
acetylsalicylic JJ I-INTV
acid NN I-INTV
in IN O
preventing VBG O
arterial JJ O
thrombogenesis NN O
in IN O
humans NNS O
. . O

-DOCSTART- -X- O O

Reactivation NN B-OC
of IN I-OC
unstable JJ B-POPU
angina NN I-POPU
after IN O
the DT O
discontinuation NN O
of IN O
heparin NN B-INTV
. . O

BACKGROUND NNP O
Heparin NNP B-INTV
is VBZ O
an DT O
effective JJ O
, , O
widely RB O
used VBN O
treatment NN O
for IN O
unstable JJ B-POPU
angina NNS I-POPU
. . O

Among IN O
patients NNS B-POPU
enrolled VBN O
in IN O
a DT O
double-blind NN O
, , O
randomized VBN O
, , O
placebo-controlled JJ B-INTV
trial NN I-INTV
comparing VBG O
intravenous JJ B-INTV
heparin NN I-INTV
, , I-INTV
aspirin NN I-INTV
, , I-INTV
both DT I-INTV
treatments NNS I-INTV
, , I-INTV
and CC I-INTV
neither RB I-INTV
during IN O
the DT O
acute JJ O
phase NN O
of IN O
unstable JJ O
angina NNS O
, , O
we PRP O
encountered VBD O
patients NNS O
in IN O
whom WP O
unstable JJ O
angina NN O
was VBD O
reactivated VBN O
after IN O
heparin NN B-INTV
was VBD O
discontinued VBN O
. . O

METHODS NNP O
The DT B-POPU
study NN I-POPU
population NN I-POPU
included VBD I-POPU
403 CD I-POPU
of IN I-POPU
the DT I-POPU
original JJ I-POPU
479 CD I-POPU
patients NNS I-POPU
in IN I-POPU
the DT I-POPU
trial NN I-POPU
who WP I-POPU
had VBD I-POPU
completed VBN I-POPU
six CD I-POPU
days NNS I-POPU
of IN I-POPU
blinded JJ I-POPU
therapy NN I-POPU
without IN I-POPU
refractory JJ I-POPU
angina NN I-POPU
or CC I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
. . O

After IN O
the DT O
discontinuation NN O
of IN O
therapy NN O
, , O
clinical JJ B-OC
events NNS I-OC
, , I-OC
including VBG I-OC
reactivation NN I-OC
of IN I-OC
unstable JJ I-OC
angina NN I-OC
and CC I-OC
myocardial JJ I-OC
infarction NN I-OC
occurring VBG I-OC
within IN I-OC
96 CD I-OC
hours NNS I-OC
after IN I-OC
hospitalization NN I-OC
, , O
were VBD O
closely RB O
monitored VBN O
. . O

RESULTS NNP O
Early JJ B-OC
reactivation NN I-OC
occurred VBD O
in IN O
14 CD O
of IN O
the DT O
107 CD O
patients NNS O
who WP O
received VBD O
heparin NN B-INTV
alone RB O
, , O
as IN O
compared VBN O
with IN O
only RB O
5 CD O
patients NNS O
in IN O
each DT O
of IN O
the DT O
other JJ O
three CD O
study NN O
groups NNS O
( ( O
P NNP O
less JJR O
than IN O
0.01 CD O
) ) O
. . O

These DT O
reactivations NNS B-OC
required VBD O
urgent JJ O
intervention NN O
( ( O
thrombolysis NN O
, , O
angioplasty JJ O
, , O
or CC O
coronary-bypass NN O
surgery NN O
) ) O
in IN O
11 CD O
patients NNS O
treated VBN O
with IN O
heparin NN B-INTV
alone RB O
, , O
but CC O
in IN O
only RB O
2 CD O
patients NNS O
in IN O
the DT O
other JJ O
groups NNS O
combined VBN O
( ( O
P NNP O
less JJR O
than IN O
0.01 CD O
) ) O
. . O

Four CD O
of IN O
the DT O
six CD O
patients NNS O
who WP O
had VBD O
a DT O
myocardial JJ B-OC
infarction NN I-OC
during IN O
a DT O
reactivation NN O
of IN O
their PRP$ O
disease NN O
were VBD O
in IN O
the DT O
heparin NN O
group NN O
. . O

Reactivations NNS B-OC
in IN O
this DT O
group NN O
occurred VBD O
in IN O
a DT O
cluster NN O
a DT O
mean NN O
( ( O
+/- JJ O
SD NNP O
) ) O
of IN O
9.5 CD O
+/- JJ O
5 CD O
hours NNS O
after IN O
the DT O
discontinuation NN O
of IN O
the DT O
study NN O
drug NN O
but CC O
were VBD O
randomly RB O
distributed VBN O
over IN O
the DT O
initial JJ O
96 CD O
hours NNS O
in IN O
the DT O
other JJ O
three CD O
groups NNS O
. . O

CONCLUSIONS NNP O
Although IN O
heparin NN B-INTV
is VBZ O
beneficial JJ O
in IN O
treating VBG O
unstable JJ O
angina NN O
, , O
the DT O
disease NN O
process NN O
may MD O
be VB O
reactivated VBN B-OC
within IN O
hours NNS O
of IN O
the DT O
discontinuation NN O
of IN O
this DT O
drug NN O
. . O

Concomitant JJ O
therapy NN O
with IN O
aspirin NN O
may MD O
prevent VB O
this DT O
withdrawal NN O
phenomenon NN O
. . O

-DOCSTART- -X- O O

Impact NN O
of IN O
a DT O
single JJ O
intravenous JJ O
administration NN O
of IN O
nicorandil JJ B-INTV
before IN O
reperfusion NN O
in IN O
patients NNS B-POPU
with IN I-POPU
ST-segment-elevation NNP I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
. . O

BACKGROUND NNP O
Intravenous NNP O
nicorandil NN B-INTV
, , O
a DT O
hybrid JJ O
compound NN O
of IN O
ATP-sensitive JJ O
potassium NN O
channel NN O
opener NN O
and CC O
nitric JJ O
oxide NN O
donor NN O
, , O
has VBZ O
been VBN O
reported VBN O
to TO O
ameliorate VB O
early JJ O
functional NN O
and CC O
clinical JJ O
problems NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
acute JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
. . O

However RB O
, , O
its PRP$ O
effects NNS O
on IN O
the DT O
late JJ O
phase NN O
remain VBP O
unclear JJ O
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
This DT O
follow-up JJ O
study NN O
to TO O
5 CD O
years NNS O
of IN O
a DT O
randomized JJ O
, , O
double-blinded JJ O
trial NN O
was VBD O
conducted VBN O
among IN O
368 CD B-POPU
patients NNS I-POPU
with IN I-POPU
first JJ I-POPU
ST-segment-elevation NNP I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
undergoing VBG I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
( ( I-POPU
PCI NNP I-POPU
) ) I-POPU
. . O

They PRP O
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
12 CD O
mg NN O
of IN O
nicorandil NN B-INTV
or CC I-INTV
a DT I-INTV
placebo NN I-INTV
intravenously RB O
just RB O
before IN O
reperfusion NN O
. . O

We PRP O
analyzed VBD O
incidence NN O
of IN O
cardiovascular JJ B-OC
death NN I-OC
or CC I-OC
rehospitalization NN I-OC
for IN O
congestive JJ B-OC
heart NN I-OC
failure NN I-OC
after IN O
PCI NNP O
as RB O
well RB O
as IN O
various JJ O
aspects NNS O
of IN O
epicardial JJ O
flow NN O
and CC O
microvascular JJ O
function NN O
. . O

Mean JJ O
follow-up NN O
was VBD O
2.4 CD O
years NNS O
( ( O
SD NNP O
, , O
1.4 CD O
) ) O
. . O

A DT O
total NN O
of IN O
12 CD O
( ( O
6.5 CD O
% NN O
) ) O
patients NNS O
receiving VBG O
nicorandil JJ B-INTV
and CC O
30 CD O
( ( O
16.4 CD O
% NN O
) ) O
receiving NN O
placebo NN B-INTV
had VBD O
cardiovascular JJ B-OC
death NN I-OC
or CC I-OC
hospital NN I-OC
admission NN I-OC
for IN I-OC
congestive JJ I-OC
heart NN I-OC
failure NN I-OC
( ( O
hazard JJ O
ratio NN O
, , O
0.39 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.20 CD O
to TO O
0.76 CD O
; : O
P=0.0058 NNP O
) ) O
. . O

Postprocedural NNP B-OC
TIMI NNP I-OC
3 CD I-OC
flow NN I-OC
was VBD O
obtained VBN O
in IN O
89.7 CD O
% NN O
of IN O
the DT O
nicorandil JJ B-INTV
group NN O
and CC O
in IN O
81.4 CD O
% NN O
of IN O
the DT O
placebo NN B-INTV
( ( O
hazard JJ O
ratio NN O
, , O
1.99 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.09 CD O
to TO O
3.65 CD O
; : O
P=0.025 NNP O
) ) O
. . O

Corrected VBN B-OC
TIMI NNP I-OC
frame NN I-OC
count NN I-OC
was VBD O
furthermore RB O
lower JJR O
in IN O
the DT O
nicorandil NN B-INTV
group NN O
( ( O
21.0+/-9.1 JJ O
versus NN O
25.1+/-14.1 CD O
; : O
P=0.0009 NNP O
) ) O
. . O

ST-segment JJ B-OC
resolution NN I-OC
> VBD I-OC
50 CD I-OC
% NN I-OC
was VBD O
observed VBN O
in IN O
79.5 CD O
% NN O
and CC O
61.2 CD O
% NN O
of IN O
the DT O
nicorandil NN B-INTV
and CC O
placebo NN B-INTV
groups NNS O
, , O
respectively RB O
( ( O
hazard JJ O
ratio NN O
, , O
2.45 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.54 CD O
to TO O
3.90 CD O
; : O
P=0.0002 NNP O
) ) O
. . O

CONCLUSIONS VB O
The DT O
addition NN O
of IN O
intravenous JJ O
nicorandil NNS B-INTV
to TO O
PCI NNP O
leads VBZ O
to TO O
beneficial JJ O
clinical JJ B-OC
outcomes NNS I-OC
and CC O
prevents NNS O
cardiovascular JJ B-OC
events NNS I-OC
of IN I-OC
long JJ I-OC
duration NN I-OC
and CC I-OC
death NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
ST-segment-elevation NNP I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
. . O

-DOCSTART- -X- O O

Usefulness NN O
of IN O
temporal JJ O
changes NNS O
in IN O
neurohormones NNS B-INTV
as IN O
markers NNS O
of IN O
ventricular JJ O
remodeling NN O
and CC O
prognosis NN O
in IN O
patients NNS B-POPU
with IN I-POPU
left JJ I-POPU
ventricular JJ I-POPU
systolic JJ I-POPU
dysfunction NN I-POPU
and CC I-POPU
heart NN I-POPU
failure NN I-POPU
receiving VBG I-POPU
either CC I-POPU
candesartan NN I-POPU
or CC I-POPU
enalapril NN I-POPU
or CC I-POPU
both DT I-POPU
. . O

Although IN O
various JJ O
neurohormones NNS O
at IN O
initial JJ O
measurement NN O
confer NN O
prognostic JJ O
value NN O
in IN O
heart NN O
failure NN O
and CC O
correlate NN O
with IN O
the DT O
left NN B-OC
ventricular JJ I-OC
ejection NN I-OC
fraction NN I-OC
( ( I-OC
EF NNP I-OC
) ) I-OC
and CC O
cardiac JJ B-OC
volumes NNS I-OC
, , O
the DT O
significance NN O
of IN O
their PRP$ O
temporal JJ O
changes NNS O
( ( O
Delta NNP O
) ) O
remains VBZ O
undetermined JJ O
. . O

This DT O
study NN O
examined VBD O
temporal JJ O
changes NNS B-OC
in IN I-OC
neurohormones NNS I-OC
related VBN O
to TO O
cardiac VB O
remodeling NN O
and CC O
prognosis NN O
in IN O
patients NNS B-POPU
with IN I-POPU
systolic JJ I-POPU
dysfunction NN I-POPU
and CC I-POPU
heart NN I-POPU
failure NN I-POPU
receiving VBG I-POPU
therapeutic JJ I-POPU
inhibition NN I-POPU
of IN I-POPU
the DT I-POPU
renin-angiotensin-aldosterone NN I-POPU
system NN I-POPU
. . O

Temporal JJ B-OC
changes NNS I-OC
in IN I-OC
plasma NN I-OC
renin NN I-OC
, , I-OC
angiotensin-II JJ I-OC
, , I-OC
aldosterone NN I-OC
, , I-OC
epinephrine NN I-OC
, , I-OC
norepinephrine JJ I-OC
, , I-OC
B-type JJ I-OC
natriuretic JJ I-OC
peptide NN I-OC
( ( I-OC
BNP NNP I-OC
) ) I-OC
, , I-OC
and CC I-OC
N-terminal JJ I-OC
atrial JJ I-OC
natriuretic JJ I-OC
peptide NN I-OC
( ( I-OC
NT-ANP NNP I-OC
) ) I-OC
in IN O
768 CD B-POPU
treated JJ I-POPU
patients NNS I-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
measured VBN I-POPU
at IN I-POPU
baseline NN I-POPU
and CC O
17 CD O
and CC O
43 CD O
weeks NNS O
after IN O
randomization NN O
were VBD O
examined VBN O
for IN O
their PRP$ O
relations NNS O
with IN O
concurrent NN O
changes NNS O
in IN O
the DT O
EF NNP B-OC
, , I-OC
cardiac JJ I-OC
volumes NNS I-OC
, , I-OC
and CC I-OC
risk NN I-OC
for IN I-OC
subsequent JJ I-OC
adverse JJ I-OC
clinical JJ I-OC
outcomes NNS I-OC
. . O

Increasing VBG O
BNP NNP B-OC
( ( O
p JJ O
< NNP O
0.0001 CD O
) ) O
and CC O
NT-ANP NNP B-OC
( ( O
p JJ O
= NNP O
0.01 CD O
) ) O
over IN O
time NN O
were VBD O
associated VBN O
with IN O
a DT O
concurrent NN O
decreasing VBG O
EF NNP B-OC
, , O
increasing VBG O
end-diastolic JJ B-OC
volume NN I-OC
( ( I-OC
EDV NNP I-OC
) ) I-OC
, , O
and CC O
increasing VBG O
end-systolic JJ B-OC
volume NN I-OC
( ( O
ESV NNP O
; : O
all DT O
p VBP O
< $ O
0.0001 CD O
) ) O
. . O

In IN O
multivariable JJ O
analysis NN O
, , O
DeltaBNP NNP O
and CC O
DeltaNT-ANP NNP O
were VBD O
independent JJ O
predictors NNS O
of IN O
DeltaESV NNP O
and CC O
DeltaEDV NNP O
, , O
whereas JJ O
DeltaBNP NNP O
also RB O
predicted VBD O
DeltaEF NNP O
( ( O
all DT O
p VBP O
< $ O
0.0001 CD O
) ) O
. . O

Patients NNS O
who WP O
died VBD B-OC
or CC I-OC
experienced JJ I-OC
heart NN I-OC
failure NN I-OC
hospitalization NN I-OC
had VBD O
larger JJR O
antecedent NN O
increases NNS O
in IN O
NT-ANP NNP B-OC
( ( O
+293.7 NNP O
vs RB O
-21.5 NNP O
pmol/ml NN O
, , O
p NN O
= NNP O
0.006 CD O
) ) O
and CC O
lesser JJR O
decreases NNS O
in IN O
norepinephrine NN B-OC
( ( O
-22.3 JJ O
vs NN O
-48.5 NNP O
pg/ml NN O
, , O
p NN O
= NNP O
0.04 CD O
) ) O
. . O

Increasing VBG O
NT-ANP NNP B-OC
( ( O
hazard JJ O
ratio NN O
[ NNP O
HR NNP O
] NNP O
3.45 CD O
, , O
p NN O
= NNP O
0.009 CD O
) ) O
and CC O
norepinephrine JJ O
( ( O
HR NNP O
2.04 CD O
, , O
p NN O
= NNP O
0.02 CD O
) ) O
over IN O
time NN O
independently RB O
predicted VBD O
increased VBN O
risk NN O
for IN O
subsequent JJ O
death NN B-OC
or CC I-OC
heart NN I-OC
failure NN I-OC
hospitalization NN I-OC
. . O

In IN O
conclusion NN O
, , O
in IN O
treated JJ B-POPU
patients NNS I-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
, , O
increasing VBG O
NT-ANP NNP O
and CC O
BNP NNP O
over IN O
time NN O
predict VBP O
a DT O
decreasing NN O
EF NNP B-OC
and CC O
ventricular JJ B-OC
dilatation NN I-OC
, , O
while IN O
increasing VBG O
NT-ANP NNP O
and CC O
norepinephrine VB O
independently RB O
predict VBP O
greater JJR O
mortality NN B-OC
and CC I-OC
morbidity NN I-OC
. . O

Serial JJ O
measurements NNS O
of IN O
these DT O
neurohormones NNS O
may MD O
serve VB O
as IN O
useful JJ O
surrogate JJ O
markers NNS O
of IN O
ventricular JJ B-OC
remodeling NN I-OC
and CC O
prognosticators NNS O
for IN O
clinical JJ O
risk NN O
stratification NN O
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
glucose-insulin-potassium JJ B-INTV
infusion NN I-INTV
on IN O
ST-elevation NNP B-POPU
myocardial JJ I-POPU
infarction NN I-POPU
in IN I-POPU
patients NNS I-POPU
treated VBN I-POPU
with IN I-POPU
thrombolytic JJ I-POPU
therapy NN I-POPU
. . O

The DT O
role NN O
of IN O
glucose-insulin-potassium NN B-INTV
( ( I-INTV
GIK NNP I-INTV
) ) I-INTV
infusion NN I-INTV
in IN O
the DT O
management NN O
of IN O
acute JJ B-OC
myocardial JJ I-OC
infarction NN I-OC
is VBZ O
not RB O
well RB O
established VBN O
. . O

This DT O
prospective JJ O
, , O
randomized VBN O
study NN O
comprised VBD O
120 CD B-POPU
patients NNS I-POPU
who WP I-POPU
had VBD I-POPU
ST-elevation NNP I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
that WDT I-POPU
was VBD I-POPU
treated VBN I-POPU
within IN I-POPU
12 CD I-POPU
hours NNS I-POPU
from IN I-POPU
symptom JJ I-POPU
onset VBN I-POPU
with IN O
a DT O
high JJ O
dose NN O
of IN O
GIK NNP B-INTV
( ( I-INTV
25 CD I-INTV
% NN I-INTV
glucose NN I-INTV
, , I-INTV
50 CD I-INTV
IU NNP I-INTV
of IN I-INTV
soluble JJ I-INTV
insulin NN I-INTV
per IN I-INTV
liter NN I-INTV
, , I-INTV
and CC I-INTV
80 CD I-INTV
mmol NN I-INTV
of IN I-INTV
potassium NN I-INTV
chloride NN I-INTV
per IN I-INTV
liter NN I-INTV
at IN I-INTV
1 CD I-INTV
ml/kg/hour NN I-INTV
over IN I-INTV
24 CD I-INTV
hours NNS I-INTV
) ) I-INTV
as IN I-INTV
adjunct NN I-INTV
to TO I-INTV
thrombolytic JJ I-INTV
therapy NN I-INTV
( ( I-INTV
1.5 CD I-INTV
MU NNP I-INTV
of IN I-INTV
streptokinase/30 NN I-INTV
to TO I-INTV
60 CD I-INTV
minutes NNS I-INTV
; : I-INTV
GIK NNP I-INTV
group NN I-INTV
) ) I-INTV
or CC O
thrombolytic JJ B-INTV
therapy NN I-INTV
alone RB I-INTV
( ( I-INTV
control VB I-INTV
group NN I-INTV
) ) I-INTV
. . O

The DT O
primary JJ O
end NN O
point NN O
of IN O
the DT O
study NN O
was VBD O
the DT O
rate NN B-OC
of IN I-OC
major JJ I-OC
adverse JJ I-OC
cardiac NN I-OC
events NNS I-OC
( ( I-OC
MACEs NNP I-OC
) ) I-OC
at IN I-OC
1 CD I-OC
month NN I-OC
, , O
defined VBD O
as IN O
a DT B-OC
composite NN I-OC
of IN I-OC
cardiac JJ I-OC
death NN I-OC
, , I-OC
reinfarction NN I-OC
, , I-OC
serious JJ I-OC
arrhythmias NN I-OC
( ( I-OC
ventricular JJ I-OC
fibrillation NN I-OC
and/or IN I-OC
tachycardia NN I-OC
) ) I-OC
, , I-OC
and CC I-OC
severe JJ I-OC
heart NN I-OC
failure NN I-OC
. . O

The DT O
secondary JJ O
end NN O
points NNS O
were VBD O
the DT O
rate NN B-OC
of IN I-OC
MACEs NNP I-OC
at IN I-OC
1 CD I-OC
year NN I-OC
and CC I-OC
improvement NN I-OC
in IN I-OC
left JJ I-OC
ventricular JJ I-OC
systolic JJ I-OC
function NN I-OC
. . O

The DT O
incidence NN B-OC
of IN I-OC
MACEs NNP I-OC
at IN I-OC
1 CD I-OC
month NN I-OC
was VBD O
significantly RB O
lower JJR O
in IN O
the DT O
GIK NNP B-INTV
group NN I-INTV
( ( O
10 CD O
% NN O
vs JJ O
32.5 CD O
% NN O
, , O
relative JJ O
risk NN O
0.24 CD O
, , O
95 CD O
% NN O
confidence NN O
interval NN O
0.09 CD O
to TO O
0.63 CD O
, , O
p NN O
= NNP O
0.0043 CD O
) ) O
. . O

Patients NNS O
in IN O
the DT O
GIK NNP B-INTV
group NN O
had VBD O
significant JJ O
decreases NNS O
in IN O
ventricular JJ B-OC
tachycardia NN I-OC
and/or NN I-OC
fibrillation NN I-OC
( ( O
1.3 CD O
% NN O
vs JJ O
15.0 CD O
% NN O
, , O
p NN O
= NNP O
0.003 CD O
) ) O
and CC O
severe JJ O
heart NN B-OC
failure NN I-OC
( ( O
3 CD O
% NN O
vs JJ O
12.5 CD O
% NN O
, , O
p NN O
= NNP O
0.031 CD O
) ) O
. . O

The DT O
rate NN B-OC
of IN I-OC
MACEs NNP I-OC
at IN I-OC
1 CD I-OC
year NN I-OC
was VBD O
also RB O
significantly RB O
lower JJR O
in IN O
the DT O
GIK NNP B-INTV
group NN I-INTV
( ( O
13 CD O
% NN O
vs JJ O
40.0 CD O
% NN O
, , O
relative JJ O
risk NN O
0.22 CD O
, , O
95 CD O
% NN O
confidence NN O
interval NN O
0.09 CD O
to TO O
0.55 CD O
, , O
p NN O
= NNP O
0.0012 CD O
) ) O
. . O

After IN O
1 CD O
year NN O
, , O
there EX O
was VBD O
a DT O
significant JJ O
improvement NN O
in IN O
left JJ B-OC
ventricular JJ I-OC
ejection NN I-OC
fraction NN I-OC
in IN O
the DT O
GIK NNP B-INTV
group NN I-INTV
( ( O
from IN O
48 CD O
+/- JJ O
8 CD O
% NN O
to TO O
51 CD O
+/- JJ O
10 CD O
% NN O
, , O
p NN O
< NNP O
0.01 CD O
) ) O
, , O
which WDT O
was VBD O
not RB O
observed VBN O
in IN O
the DT O
control NN B-INTV
group NN O
. . O

In IN O
conclusion NN O
, , O
high-dose JJ O
GIK NNP B-INTV
, , O
used VBD O
as IN O
an DT O
adjunct NN O
to TO O
thrombolytic JJ B-INTV
therapy NN I-INTV
, , O
was VBD O
safe JJ B-OC
and CC O
improved JJ O
clinical JJ B-OC
outcome NN I-OC
at IN O
1 CD O
month NN O
. . O

The DT O
beneficial JJ O
effect NN O
of IN O
GIK NNP B-INTV
infusion NN O
was VBD O
maintained VBN O
up RP O
to TO O
1 CD O
year NN O
. . O

-DOCSTART- -X- O O

Secondary JJ O
prevention NN O
of IN O
macrovascular JJ B-OC
events NNS I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
in IN I-POPU
the DT I-POPU
PROactive NNP I-POPU
Study NNP I-POPU
( ( O
PROspective NNP O
pioglitAzone RB O
Clinical JJ O
Trial NNP O
In IN O
macroVascular JJ O
Events NNS O
) ) O
: : O
a DT O
randomised JJ O
controlled VBN O
trial NN O
. . O

BACKGROUND NNP O
Patients NNPS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
are VBP O
at IN O
high JJ O
risk NN O
of IN O
fatal JJ O
and CC O
non-fatal JJ O
myocardial JJ B-OC
infarction NN I-OC
and CC O
stroke NN B-OC
. . O

There EX O
is VBZ O
indirect JJ O
evidence NN O
that IN O
agonists NNS O
of IN O
peroxisome JJ O
proliferator-activated JJ O
receptor NN O
gamma NN O
( ( O
PPAR NNP O
gamma NN O
) ) O
could MD O
reduce VB O
macrovascular JJ B-OC
complications NNS I-OC
. . O

Our PRP$ O
aim NN O
, , O
therefore RB O
, , O
was VBD O
to TO O
ascertain VB O
whether IN O
pioglitazone NN B-INTV
reduces NNS O
macrovascular JJ B-OC
morbidity NN I-OC
and CC O
mortality NN B-OC
in IN O
high-risk JJ B-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
. . O

METHODS NNP O
We PRP O
did VBD O
a DT O
prospective NN O
, , O
randomised VBD O
controlled VBN O
trial NN O
in IN O
5238 CD B-POPU
patients NNS I-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
who WP I-POPU
had VBD I-POPU
evidence NN I-POPU
of IN I-POPU
macrovascular JJ I-POPU
disease NN I-POPU
. . O

We PRP O
recruited VBD O
patients NNS B-POPU
from IN I-POPU
primary-care JJ I-POPU
practices NNS I-POPU
and CC I-POPU
hospitals NNS I-POPU
. . O

We PRP O
assigned VBD O
patients NNS O
to TO O
oral JJ B-INTV
pioglitazone NN I-INTV
titrated VBD I-INTV
from IN I-INTV
15 CD I-INTV
mg NNS I-INTV
to TO I-INTV
45 CD I-INTV
mg NN I-INTV
( ( O
n=2605 JJ O
) ) O
or CC B-INTV
matching VBG I-INTV
placebo NN I-INTV
( ( O
n=2633 JJ O
) ) O
, , O
to TO O
be VB O
taken VBN O
in IN B-INTV
addition NN I-INTV
to TO I-INTV
their PRP$ I-INTV
glucose-lowering JJ I-INTV
drugs NNS I-INTV
and CC I-INTV
other JJ I-INTV
medications NNS I-INTV
. . O

Our PRP$ O
primary JJ O
endpoint NN O
was VBD O
the DT O
composite NN B-OC
of IN I-OC
all-cause JJ I-OC
mortality NN I-OC
, , I-OC
non JJ I-OC
fatal JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
( ( I-OC
including VBG I-OC
silent JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
) ) I-OC
, , I-OC
stroke VBD I-OC
, , I-OC
acute JJ I-OC
coronary JJ I-OC
syndrome NN I-OC
, , I-OC
endovascular JJ I-OC
or CC I-OC
surgical JJ I-OC
intervention NN I-OC
in IN I-OC
the DT I-OC
coronary NN I-OC
or CC I-OC
leg NN I-OC
arteries NNS I-OC
, , I-OC
and CC I-OC
amputation NN I-OC
above IN I-OC
the DT I-OC
ankle NN I-OC
. . O

Analysis NN O
was VBD O
by IN O
intention NN O
to TO O
treat VB O
. . O

This DT O
study NN O
is VBZ O
registered VBN O
as IN O
an DT O
International NNP O
Standard NNP O
Randomised VBD O
Controlled NNP O
Trial NNP O
, , O
number NN O
ISRCTN NNP O
NCT00174993 NNP O
. . O

FINDINGS NNP O
Two CD O
patients NNS O
were VBD O
lost VBN O
to TO O
follow-up JJ O
, , O
but CC O
were VBD O
included VBN O
in IN O
analyses NNS O
. . O

The DT O
average JJ O
time NN O
of IN O
observation NN O
was VBD O
34.5 CD O
months NNS O
. . O

514 CD B-POPU
of IN I-POPU
2605 CD I-POPU
patients NNS I-POPU
in IN O
the DT O
pioglitazone NN O
group NN O
and CC O
572 CD O
of IN O
2633 CD O
patients NNS O
in IN O
the DT O
placebo NN O
group NN O
had VBD O
at IN O
least JJS O
one CD O
event NN O
in IN O
the DT O
primary JJ B-OC
composite JJ I-OC
endpoint NN I-OC
( ( O
HR NNP O
0.90 CD O
, , O
95 CD O
% NN O
CI NNP O
0.80-1.02 CD O
, , O
p=0.095 NN O
) ) O
. . O

The DT O
main JJ O
secondary JJ O
endpoint NN O
was VBD O
the DT O
composite NN B-OC
of IN I-OC
all-cause JJ I-OC
mortality NN I-OC
, , I-OC
non-fatal JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
and CC I-OC
stroke VBD I-OC
. . O

301 CD O
patients NNS O
in IN O
the DT O
pioglitazone NN O
group NN O
and CC O
358 CD O
in IN O
the DT O
placebo NN O
group NN O
reached VBD O
this DT O
endpoint NN B-OC
( ( O
0.84 CD O
, , O
0.72-0.98 CD O
, , O
p=0.027 NN O
) ) O
. . O

Overall JJ B-OC
safety NN I-OC
and CC I-OC
tolerability NN I-OC
was VBD O
good JJ O
with IN O
no DT O
change NN O
in IN O
the DT O
safety NN B-OC
profile NN I-OC
of IN O
pioglitazone NN O
identified VBN O
. . O

6 CD O
% NN O
( ( O
149 CD O
of IN O
2065 CD O
) ) O
and CC O
4 CD O
% NN O
( ( O
108 CD O
of IN O
2633 CD O
) ) O
of IN O
those DT O
in IN O
the DT O
pioglitazone NN O
and CC O
placebo NN O
groups NNS O
, , O
respectively RB O
, , O
were VBD O
admitted VBN O
to TO O
hospital VB O
with IN O
heart NN B-OC
failure NN I-OC
; : I-OC
mortality NN I-OC
rates NNS I-OC
from IN I-OC
heart NN I-OC
failure NN I-OC
did VBD O
not RB O
differ VB O
between IN O
groups NNS O
. . O

INTERPRETATION NNP O
Pioglitazone NNP O
reduces VBZ O
the DT O
composite NN O
of IN O
all-cause JJ O
mortality NN B-OC
, , I-OC
non-fatal JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
, , O
and CC O
stroke VBD B-OC
in IN O
patients NNS B-POPU
with IN I-POPU
type JJ I-POPU
2 CD I-POPU
diabetes NNS I-POPU
who WP I-POPU
have VBP I-POPU
a DT I-POPU
high JJ I-POPU
risk NN I-POPU
of IN I-POPU
macrovascular JJ I-POPU
events NNS I-POPU
. . O

-DOCSTART- -X- O O

The DT O
evaluation NN O
of IN O
pulmonary JJ O
hypertension NN O
using VBG O
right JJ B-INTV
ventricular JJ I-INTV
myocardial JJ I-INTV
isovolumic JJ I-INTV
relaxation NN I-INTV
time NN I-INTV
. . O

Right JJ O
ventricular NN O
( ( O
RV NNP O
) ) O
blood VBD O
pool-derived JJ O
isovolumic JJ O
relaxation NN O
time NN O
( ( O
IVRT NNP O
) ) O
correlates VBZ O
well RB O
with IN O
systolic JJ O
pulmonary JJ O
arterial JJ O
pressure NN O
( ( O
PAP NNP O
) ) O
. . O

However RB O
, , O
because IN O
of IN O
complex JJ O
parameter NN O
derivation NN O
, , O
the DT O
method NN O
is VBZ O
rarely RB O
used VBN O
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
validate VB O
the DT O
measurement NN O
of IN O
myocardial JJ O
velocity NN O
imaging-derived JJ O
RV NNP B-INTV
IVRT NNP I-INTV
( ( I-INTV
IVRT NNP I-INTV
' POS I-INTV
) ) I-INTV
against IN O
invasively RB B-INTV
measured VBN I-INTV
PAP NNP I-INTV
. . O

Transthoracic NNP B-INTV
echocardiography NN I-INTV
with IN I-INTV
myocardial JJ I-INTV
velocity NN I-INTV
imaging NN I-INTV
and CC I-INTV
right JJ I-INTV
heart NN I-INTV
catheterization NN I-INTV
were VBD O
performed VBN O
in IN O
33 CD B-POPU
patients NNS I-POPU
with IN I-POPU
pulmonary JJ I-POPU
hypertension NN I-POPU
. . O

Blood NNP B-OC
pool NN I-OC
IVRT NNP I-OC
and CC I-OC
myocardial JJ I-OC
IVRTs NNP I-OC
for IN I-OC
the DT I-OC
tricuspid JJ I-OC
valve NN I-OC
annulus NN I-OC
ring NN I-OC
, , I-OC
basal NN I-OC
and CC I-OC
apical JJ I-OC
RV NNP I-OC
free JJ I-OC
wall NN I-OC
segments NNS I-OC
were VBD O
measured VBN O
and CC O
compared VBN O
with IN O
data NNS O
from IN O
33 CD B-POPU
age- JJ I-POPU
and CC I-POPU
sex-matched JJ I-POPU
control NN I-POPU
subjects NNS I-POPU
. . O

Measured VBN B-OC
IVRTs NNP I-OC
were VBD O
significantly RB B-OC
longer RBR I-OC
in IN O
patients NNS O
with IN O
pulmonary JJ O
hypertension NN O
than IN O
in IN O
control NN O
subjects NNS O
. . O

The DT O
strongest JJS O
correlation NN O
( ( O
R NNP O
= NNP O
0.74 CD O
, , O
P NNP O
< NNP O
.0001 NNP O
) ) O
was VBD O
found VBN O
between IN O
systolic JJ B-OC
PAP NNP I-OC
and CC I-OC
the DT I-OC
heart NN I-OC
rate-corrected JJ I-OC
IVRT NNP I-OC
' POS I-OC
derived VBN O
from IN O
the DT O
basal NN O
RV NNP O
free JJ O
wall NN O
segment NN O
. . O

The DT O
basal NN B-OC
segment NN I-OC
IVRT NNP I-OC
' POS I-OC
corrected VBN O
for IN O
heart NN B-OC
rate NN I-OC
correlates NNS O
well RB O
with IN O
the DT O
invasive JJ O
PAP NNP O
measurement NN O
and CC O
, , O
therefore RB O
, , O
can MD O
be VB O
used VBN O
to TO O
predict VB O
systolic JJ B-OC
PAP NNP I-OC
. . O

It PRP O
can MD O
even RB O
be VB O
considered VBN O
as IN O
an DT O
alternative NN O
to TO O
tricuspid VB O
regurgitation-derived JJ O
PAP NNP O
systolic NN O
when WRB O
tricuspid JJ O
regurgitation NN O
is VBZ O
nonrecordable JJ O
. . O

A DT O
proposed VBN O
method NN O
to TO O
derive VB O
systolic JJ O
PAP NNP O
should MD O
be VB O
used VBN O
while IN O
screening VBG O
the DT O
patients NNS O
at IN O
risk NN O
for IN O
pulmonary JJ O
hypertension NN O
, , O
monitoring VBG O
the DT O
disease NN O
progression NN O
and CC O
the DT O
effect NN O
of IN O
treatment NN O
. . O

-DOCSTART- -X- O O

Mending VBG O
the DT O
rhythm NN O
does VBZ O
not RB O
improve VB O
prognosis NN O
in IN O
patients NNS B-POPU
with IN I-POPU
persistent JJ I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
: : I-POPU
a DT O
subanalysis NN O
of IN O
the DT O
RACE NNP O
study NN O
. . O

AIMS NNP O
To TO O
compare VB O
outcome NN O
of IN O
AF NNP B-POPU
patients NNS I-POPU
with IN I-POPU
effective JJ I-POPU
rhythm NNS I-POPU
control NN I-POPU
with IN O
patients NNS B-POPU
treated VBN I-POPU
with IN I-POPU
rate NN I-POPU
control NN I-POPU
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
Out NNP O
of IN O
the DT O
266 CD B-POPU
AF NNP I-POPU
patients NNS I-POPU
randomized VBD I-POPU
to TO I-POPU
rhythm VB I-POPU
control NN I-POPU
in IN I-POPU
the DT I-POPU
RACE NNP I-POPU
study NN I-POPU
, , I-POPU
49 CD I-POPU
patients NNS I-POPU
turned VBD I-POPU
to TO I-POPU
long-term JJ I-POPU
sinus NN I-POPU
rhythm NN I-POPU
and CC I-POPU
were VBD I-POPU
continuously RB I-POPU
treated VBN I-POPU
with IN I-POPU
oral JJ I-POPU
anticoagulation NN I-POPU
. . O

The DT O
incidence NN O
of IN O
the DT O
primary JJ O
endpoint NN O
in IN O
these DT O
patients NNS O
was VBD O
compared VBN O
to TO O
that DT O
in IN O
178 CD O
patients NNS O
out IN O
of IN O
the DT O
initial JJ O
256 CD B-POPU
rate-control JJ I-POPU
patients NNS I-POPU
of IN I-POPU
RACE NNP I-POPU
who WP O
were VBD O
in IN O
AF NNP O
and CC O
using VBG O
oral JJ O
anticoagulation NN O
continuously RB O
. . O

Baseline NNP O
characteristics NNS O
of IN O
both DT O
groups NNS O
were VBD O
not RB O
different JJ O
. . O

After IN O
a DT O
mean JJ O
follow-up NN O
of IN O
2.3+/-0.6 CD O
years NNS O
, , O
the DT O
primary JJ O
endpoint NN O
( ( O
a DT O
composite NN B-OC
of IN I-OC
cardiovascular JJ I-OC
mortality NN I-OC
, , I-OC
heart NN I-OC
failure NN I-OC
, , I-OC
thrombo-embolic JJ I-OC
complications NNS I-OC
( ( I-OC
TECs NNP I-OC
) ) I-OC
, , I-OC
bleeding VBG I-OC
, , I-OC
serious JJ I-OC
adverse JJ I-OC
effects NNS I-OC
of IN I-OC
antiarrhythmic JJ I-OC
drugs NNS I-OC
and CC I-OC
pacemaker NN I-OC
implants NNS I-OC
) ) I-OC
was VBD O
22.4 CD O
% NN O
in IN O
the DT O
rhythm-control NN O
group NN O
vs. FW O
15.2 CD O
% NN O
in IN O
the DT O
rate-control NN O
group NN O
. . O

Multivariable JJ O
regression NN O
analysis NN O
indicated VBD O
coronary JJ B-OC
artery NN I-OC
disease NN I-OC
, , I-OC
heart NN I-OC
failure NN I-OC
, , I-OC
and CC I-OC
digitalis RB I-OC
as IN O
independent JJ O
risk NN O
indicators NNS O
of IN O
cardiovascular JJ O
morbidity NN O
and CC O
mortality NN O
. . O

Chronic NNP B-OC
sinus NN I-OC
rhythm NN I-OC
did VBD O
not RB O
matter NN O
. . O

CONCLUSION NNP O
Among IN O
patients NNS B-POPU
who WP I-POPU
remained VBD I-POPU
on IN I-POPU
warfarin NN I-POPU
, , O
those DT O
who WP O
mostly RB O
were VBD O
maintained VBN O
in IN O
sinus NN O
rhythm NN O
under IN O
a DT O
rhythm-control JJ O
strategy NN O
did VBD O
not RB O
have VB O
a DT O
superior JJ O
prognosis NN O
compared VBN O
to TO O
those DT O
who WP O
remained VBD O
in IN O
AF NNP O
under IN O
a DT O
rate-control JJ O
strategy NN O
. . O

-DOCSTART- -X- O O

Biochemical NNP O
and CC O
functional JJ O
effects NNS O
of IN O
creatine NN B-INTV
phosphate NN I-INTV
in IN O
cardioplegic JJ O
solution NN O
during IN O
aortic JJ B-POPU
valve NN I-POPU
surgery NN I-POPU
-- : I-POPU
a DT I-POPU
clinical JJ O
study NN O
. . O

During IN O
myocardial JJ O
ischemia NN O
there EX O
is VBZ O
a DT O
drop NN B-OC
in IN I-OC
high-energy JJ I-OC
phosphates NNS I-OC
in IN O
the DT O
myocardium NN O
. . O

Cold NNP O
potassium NN O
cardioplegia NN O
decreases NNS O
but CC O
does VBZ O
not RB O
altogether RB O
prevent VB O
this DT O
reduction NN O
. . O

Supplementation NN O
of IN O
cardioplegic JJ O
solutions NNS O
with IN O
the DT O
high-energy JJ O
compound NN O
creatine NN B-INTV
phosphate NN I-INTV
( ( O
10 CD O
mmol/L NN O
) ) O
compared VBN O
to TO O
plain VB B-INTV
cardioplegic JJ I-INTV
solutions NNS I-INTV
was VBD O
investigated VBN O
in IN O
this DT O
study NN O
. . O

Thirty NNP B-POPU
patients NNS I-POPU
scheduled VBN I-POPU
for IN I-POPU
aortic JJ I-POPU
valve NNS I-POPU
replacement NN I-POPU
were VBD I-POPU
included VBN I-POPU
. . O

The DT O
patients NNS O
were VBD O
randomized VBN O
to TO O
group NN O
I PRP O
( ( B-INTV
creatine VB I-INTV
phosphate NN I-INTV
) ) I-INTV
or CC O
group NN O
II NNP O
( ( B-INTV
control NN I-INTV
) ) I-INTV
. . O

Postoperative JJ O
hemodynamic JJ B-OC
evaluation NN I-OC
revealed VBD O
no DT O
significant JJ O
differences NNS O
between IN O
the DT O
groups NNS O
. . O

However RB O
, , O
group NN O
I PRP O
exhibited VBD O
a DT O
tendency NN O
toward IN O
a DT O
better JJR O
stroke-work NN B-OC
index NN I-OC
( ( O
135 CD O
+/- JJ O
18 CD O
% NN O
vs. FW O
102 CD O
+/- JJ O
5 CD O
% NN O
recovery NN O
15 CD O
minutes NNS O
after IN O
bypass NN O
and CC O
145 CD O
+/- JJ O
16 CD O
% NN O
vs. FW O
119 CD O
+/- JJ O
11 CD O
% NN O
recovery NN O
105 CD O
min NN O
after IN O
bypass NN O
) ) O
. . O

There EX O
were VBD O
fewer JJR O
patients NNS O
in IN O
group NN O
I PRP O
( ( O
5/15 CD O
) ) O
needing VBG B-OC
inotropic JJ I-OC
support NN I-OC
compared VBN O
to TO O
group NN O
II NNP O
( ( O
9/14 CD O
) ) O
. . O

The DT O
myocardial JJ B-OC
content NN I-OC
of IN I-OC
ATP NNP I-OC
and CC I-OC
creatine NN B-INTV
phosphate NN I-INTV
showed VBD O
no DT O
significant JJ O
differences NNS O
during IN O
ischemia NN O
and CC O
reperfusion NN O
. . O

It PRP O
is VBZ O
concluded VBN O
that IN O
the DT O
myocardial JJ O
protection NN O
during IN O
ischemia NN O
was VBD O
sufficient JJ O
to TO O
prevent VB O
significant JJ O
reductions NNS O
of IN O
myocardial JJ B-OC
ATP NNP I-OC
and CC I-OC
creatine VB I-OC
phosphate JJ I-OC
irrespective NN O
of IN O
supplementation NN O
with IN O
CP NNP O
. . O

-DOCSTART- -X- O O

XS0601 NN B-INTV
reduces VBZ O
the DT O
incidence NN O
of IN O
restenosis NN O
: : O
a DT O
prospective JJ O
study NN O
of IN O
335 CD B-POPU
patients NNS I-POPU
undergoing VBG I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
in IN I-POPU
China NNP I-POPU
. . O

BACKGROUND NNP O
XS0601 NNP B-INTV
, , O
consisting VBG O
of IN O
active JJ O
ingredients NNS O
( ( O
Chuangxiongol NNP O
and CC O
paeoniflorin NN O
) ) O
, , O
has VBZ O
been VBN O
shown VBN O
to TO O
inhibit VB O
arterial JJ O
neointimal JJ O
hyperplasia NN O
in IN O
animal JJ O
models NNS O
and CC O
in IN O
preliminary JJ O
human JJ O
studies NNS O
. . O

The DT O
objective NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
evaluate VB O
the DT O
safety NN O
and CC O
efficacy NN O
of IN O
XS0601 NNP B-INTV
in IN O
preventing VBG O
restenosis NN O
following VBG O
percutaneous JJ B-INTV
coronary JJ I-INTV
intervention NN I-INTV
( ( O
PCI NNP O
) ) O
. . O

METHODS VB O
A DT O
multi-center NN O
, , O
randomized VBN O
, , O
double-blind JJ O
, , O
placebo-controlled JJ O
trial NN O
was VBD O
conducted VBN O
. . O

A DT B-POPU
total NN I-POPU
of IN I-POPU
335 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
randomized VBN I-POPU
into IN O
treatment NN O
with IN O
the DT O
oral JJ B-INTV
administration NN I-INTV
of IN I-INTV
XS0601 NNP I-INTV
, , I-INTV
or CC I-INTV
a DT I-INTV
placebo NN I-INTV
for IN O
6 CD O
months NNS O
after IN O
successful JJ O
PCI NNP O
. . O

Angiographic NNP O
follow-up NN O
was VBD O
scheduled VBN O
at IN O
6 CD O
months NNS O
, , O
and CC O
clinical JJ O
follow-ups NNS O
performed VBN O
at IN O
1 CD O
, , O
3 CD O
and CC O
6 CD O
months NNS O
after IN O
PCI NNP O
. . O

The DT O
primary JJ O
end NN O
point NN O
was VBD O
angiographic JJ B-OC
restenosis NN I-OC
. . O

The DT O
secondary JJ O
end NN O
points NNS O
were VBD O
the DT O
combined JJ B-OC
incidence NN I-OC
of IN I-OC
death NN I-OC
, , I-OC
target NN I-OC
lesion NN I-OC
nonfatal JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
repeat NN I-OC
angioplasty NN I-OC
, , I-OC
and CC I-OC
coronary JJ B-INTV
artery NN I-INTV
bypass NN I-INTV
graft NN I-INTV
surgery NN I-INTV
. . O

RESULTS VB O
A DT B-POPU
total NN I-POPU
of IN I-POPU
308 CD I-POPU
patients NNS I-POPU
( ( I-POPU
91.9 CD I-POPU
% NN I-POPU
) ) I-POPU
completed VBD I-POPU
the DT I-POPU
study NN I-POPU
and CC I-POPU
145 CD I-POPU
cases NNS I-POPU
( ( I-POPU
47.1 CD I-POPU
% NN I-POPU
) ) I-POPU
received VBD I-POPU
angiographic JJ I-POPU
follow-up NN I-POPU
. . O

The DT O
restenosis NN B-OC
rates NNS I-OC
were VBD O
significantly RB O
reduced VBN O
in IN O
the DT O
XS0601 NNP B-INTV
group NN O
as IN O
compared VBN O
with IN O
the DT O
placebo NN B-INTV
group NN O
( ( O
26.0 CD O
% NN O
vs. FW O
47.2 CD O
% NN O
, , O
P NNP O
< NNP O
0.05 CD O
) ) O
, , O
and CC O
the DT O
minimum JJ B-OC
lumen NNS I-OC
diameter NN I-OC
( ( I-OC
MLD NNP I-OC
) ) I-OC
was VBD O
greater JJR O
[ NNP O
( ( O
2.08 CD O
+/- JJ O
0.89 CD O
) ) O
mm NN O
for IN O
XS0601 NNP B-INTV
vs. FW O
( ( O
1.73 CD O
+/- JJ O
0.94 CD O
) ) O
mm NN O
for IN O
placebo NN B-INTV
, , O
P NNP O
< VBZ O
0.05 CD O
] NN O
. . O

XS0601 NN B-INTV
also RB O
significantly RB O
reduced VBD O
the DT O
combined JJ B-OC
incidence NN I-OC
of IN I-OC
major JJ I-OC
adverse JJ I-OC
cardiac NN I-OC
event NN I-OC
( ( O
10.4 CD O
% NN O
in IN O
the DT O
XS0601 NNP O
group NN O
vs. FW O
22.7 CD O
% NN O
in IN O
the DT O
placebo NN B-INTV
group NN O
, , O
P NNP O
< NNP O
0.05 CD O
) ) O
. . O

The DT O
incidence NN B-OC
of IN I-OC
recurrent JJ I-OC
angina NN I-OC
at IN O
3 CD O
and CC O
6 CD O
months NNS O
after IN O
PCI NNP O
was VBD O
also RB O
significantly RB O
reduced VBN O
in IN O
XS0601 NNP B-INTV
group NN O
( ( O
7.1 CD O
% NN O
and CC O
11.0 CD O
% NN O
) ) O
as IN O
compared VBN O
with IN O
those DT O
in IN O
placebo JJ B-INTV
group NN O
( ( O
19.5 CD O
% NN O
and CC O
42.9 CD O
% NN O
) ) O
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
. . O

No DT O
significant JJ O
side NN O
effects NNS O
occurred VBD O
within IN O
the DT O
6-month JJ O
follow-up JJ O
period NN O
in IN O
the DT O
XS0601 NNP B-INTV
group NN O
. . O

CONCLUSION NNP O
Administration NNP O
of IN O
XS0601 NNP B-INTV
for IN O
6 CD O
months NNS O
is VBZ O
demonstrated VBN O
to TO O
be VB O
safe JJ O
and CC O
effective JJ O
in IN O
reducing VBG O
restenosis NN O
in IN O
post-PCI JJ B-POPU
patients NNS I-POPU
. . O

-DOCSTART- -X- O O

Prolonged JJ O
effects NNS O
of IN O
a DT O
home-based JJ B-INTV
intervention NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
illness NN I-POPU
. . O

BACKGROUND NNP O
Data NNP O
on IN O
the DT O
long-term JJ O
benefits NNS O
of IN O
nonspecific JJ O
disease NN O
management NN O
programs NNS O
are VBP O
limited JJ O
. . O

We PRP O
performed VBD O
a DT O
long-term JJ O
follow-up NN O
of IN O
a DT O
previously RB O
published VBN O
randomized VBN O
trial NN O
. . O

METHODS NNP O
We PRP O
compared VBN O
all-cause JJ B-OC
mortality NN I-OC
and CC I-OC
recurrent JJ I-OC
hospitalization NN I-OC
during IN O
median JJ O
follow-up NN O
of IN O
7.5 CD O
years NNS O
in IN O
a DT O
heterogeneous JJ B-POPU
cohort NN I-POPU
of IN I-POPU
patients NNS I-POPU
with IN I-POPU
chronic JJ I-POPU
illness NN I-POPU
initially RB I-POPU
exposed VBD I-POPU
to TO I-POPU
a DT I-POPU
multidisciplinary JJ I-POPU
, , I-POPU
home-based JJ I-POPU
intervention NN I-POPU
( ( I-POPU
HBI NNP I-POPU
) ) I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
260 CD I-POPU
) ) I-POPU
or CC I-POPU
to TO I-POPU
usual JJ I-POPU
postdischarge NN I-POPU
care NN I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
268 CD I-POPU
) ) I-POPU
. . O

RESULTS NNP O
During IN O
follow-up JJ O
, , O
HBI NNP B-INTV
had VBD O
no DT O
impact NN O
on IN O
all-cause JJ B-OC
mortality NN I-OC
( ( O
relative JJ O
risk NN O
, , O
1.04 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
0.80-1.35 JJ O
) ) O
or CC O
event-free JJ B-OC
survival NN I-OC
from IN I-OC
death NN I-OC
or CC I-OC
unplanned JJ I-OC
hospitalization NN I-OC
( ( O
relative JJ O
risk NN O
, , O
1.03 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
0.86-1.24 JJ O
) ) O
. . O

Initial JJ O
analysis NN O
suggested VBD O
that IN O
HBI NNP B-INTV
had VBD O
only RB O
a DT O
marginal JJ O
impact NN O
in IN O
reducing VBG O
unplanned JJ B-OC
hospitalization NN I-OC
, , O
with IN O
677 CD O
readmissions NNS O
vs VBP O
824 CD O
for IN O
the DT O
usual JJ O
care NN O
group NN O
( ( O
mean JJ O
+/- JJ O
SD NNP O
rate NN O
, , O
0.72 CD O
+/- JJ O
0.96 CD O
vs JJ O
0.84 CD O
+/- JJ O
1.20 CD O
readmissions/patient NN O
per IN O
year NN O
; : O
P NNP O
= NNP O
.08 NNP O
) ) O
. . O

When WRB O
accounting VBG O
for IN O
increased JJ O
hospital NN B-OC
activity NN I-OC
in IN O
HBI NNP O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
obstructive JJ I-POPU
pulmonary JJ I-POPU
disease NN I-POPU
during IN O
follow-up NN O
for IN O
2 CD O
years NNS O
, , O
post NN O
hoc NN O
analyses VBZ O
showed VBD O
that IN O
HBI NNP B-INTV
reduced VBD O
readmissions NNS B-OC
by IN O
14 CD O
% NN O
within IN O
2 CD O
years NNS O
in IN O
patients NNS O
without IN O
this DT O
condition NN O
( ( O
mean JJ O
+/- JJ O
SD NNP O
rate NN O
, , O
0.54 CD O
+/- JJ O
0.72 CD O
vs JJ O
0.63 CD O
+/- JJ O
0.88 CD O
readmission/patient NN O
per IN O
year NN O
; : O
P NNP O
= NNP O
.04 NNP O
) ) O
and CC O
by IN O
21 CD O
% NN O
in IN O
all DT O
surviving VBG O
patients NNS O
within IN O
3 CD O
to TO O
8 CD O
years NNS O
( ( O
mean JJ O
+/- JJ O
SD NNP O
rate NN O
, , O
0.64 CD O
+/- JJ O
1.26 CD O
vs JJ O
0.81 CD O
+/- JJ O
1.61 CD O
readmissions/patient NN O
per IN O
year NN O
; : O
P NNP O
= NNP O
.03 NNP O
) ) O
. . O

Overall JJ O
, , O
recurrent JJ B-OC
hospital NN I-OC
costs NNS I-OC
were VBD O
significantly RB O
lower JJR O
( ( O
14 CD O
% NN O
) ) O
in IN O
the DT O
HBI NNP B-INTV
group NN O
( ( O
mean JJ O
+/- JJ O
SD NNP O
, , O
823 CD O
dollars NNS O
+/- JJ O
1642 CD O
dollars NNS O
vs JJ O
960 CD O
dollars NNS O
+/- JJ O
1376 CD O
dollars NNS O
per IN O
patient NN O
per IN O
year NN O
; : O
P NNP O
= NNP O
.045 NNP O
) ) O
. . O

CONCLUSION VB O
This DT O
unique JJ O
study NN O
suggests VBZ O
that IN O
a DT O
nonspecific JJ O
HBI NNP B-INTV
provides VBZ O
long-term JJ O
cost NN O
benefits NNS O
in IN O
a DT O
range NN O
of IN O
chronic JJ O
illnesses NNS O
, , O
except IN O
for IN O
chronic JJ O
obstructive JJ O
pulmonary JJ O
disease NN O
. . O

-DOCSTART- -X- O O

Thromboprophylaxis VBN O
by IN O
low-molecular-weight JJ B-INTV
heparin NN I-INTV
in IN O
elective JJ B-POPU
hip NN I-POPU
surgery NN I-POPU
. . O

A DT O
placebo NN B-INTV
controlled VBN O
study NN O
. . O

In IN O
a DT O
double-blind NN O
, , O
randomised VBD O
study NN O
of IN O
thromboprophylaxis NN O
in IN O
patients NNS B-POPU
undergoing JJ I-POPU
total JJ I-POPU
hip NN I-POPU
replacement NN I-POPU
, , O
we PRP O
compared VBN O
a DT O
low-molecular-weight JJ B-INTV
heparin NN I-INTV
with IN I-INTV
a DT I-INTV
placebo NN I-INTV
. . O

Of IN O
the DT O
120 CD B-POPU
patients NNS I-POPU
enrolled VBD I-POPU
, , I-POPU
112 CD I-POPU
completed VBD I-POPU
the DT O
trial NN O
; : O
58 CD O
in IN O
the DT O
treatment NN O
group NN O
and CC O
54 CD O
in IN O
the DT O
placebo NN O
group NN O
. . O

Nine NNP O
( ( O
16 CD O
% NN O
) ) O
patients NNS O
in IN O
the DT O
treatment NN O
group NN O
and CC O
19 CD O
( ( O
35 CD O
% NN O
) ) O
in IN O
the DT O
placebo NN B-INTV
group NN O
developed VBD O
deep RB B-OC
venous JJ I-OC
thrombosis NN I-OC
, , O
diagnosed VBN O
by IN O
the DT O
125I-fibrinogen JJ O
uptake JJ O
test NN O
( ( O
p JJ O
< NNP O
0.02 CD O
) ) O
. . O

Verification NN O
was VBD O
obtained VBN O
by IN O
phlebography NN O
in IN O
86 CD O
% NN O
of IN O
the DT O
patients NNS O
. . O

Prolonged JJ O
surgery NN O
increased VBD O
the DT O
risk NN B-OC
of IN I-OC
thrombosis NN I-OC
in IN O
the DT O
placebo NN O
group NN O
but CC O
not RB O
in IN O
the DT O
treatment NN O
group NN O
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
. . O

There EX O
were VBD O
significantly RB O
more JJR O
cases NNS B-OC
of IN I-OC
deep JJ I-OC
venous JJ I-OC
thrombosis NN I-OC
in IN O
the DT O
placebo NN O
group NN O
during IN O
the DT O
first JJ O
four CD O
postoperative JJ O
days NNS O
( ( O
p JJ O
< NNP O
0.02 CD O
) ) O
. . O

The DT O
groups NNS O
did VBD O
not RB O
differ VB O
with IN O
respect NN O
to TO O
peroperative VB B-OC
and CC I-OC
postoperative JJ I-OC
bleeding NN I-OC
. . O

Low-molecular-weight JJ B-INTV
heparin NN I-INTV
offers NNS O
safe JJ O
and CC O
easily RB O
administered VBN O
thromboprophylaxis NN O
in IN O
total JJ O
hip NN O
replacement NN O
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
levosimendan JJ B-INTV
versus FW O
dobutamine NN B-INTV
on IN O
inflammatory NN O
and CC O
apoptotic JJ O
pathways NNS O
in IN O
acutely RB B-POPU
decompensated VBN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

A DT O
single JJ O
levosimendan NN B-INTV
administration NN O
has VBZ O
recently RB O
been VBN O
shown VBN O
to TO O
result VB O
in IN O
clinical JJ O
and CC O
hemodynamic JJ O
improvement NN O
in IN O
patients NNS B-POPU
with IN I-POPU
decompensated JJ I-POPU
heart NN I-POPU
failure NN I-POPU
( ( I-POPU
HF NNP I-POPU
) ) I-POPU
, , I-POPU
but CC I-POPU
without IN I-POPU
survival JJ I-POPU
benefits NNS I-POPU
. . O

In IN O
this DT O
study NN O
, , O
the DT O
effects NNS O
of IN O
levosimendan NN B-INTV
and CC O
dobutamine NN B-INTV
on IN O
plasma NN O
levels NNS O
of IN O
proinflammatory NN O
and CC O
proapoptotic JJ O
mediators NNS O
in IN O
decompensated JJ O
HF NNP O
were VBD O
compared VBN O
and CC O
correlated VBN O
with IN O
the DT O
concomitant JJ O
effects NNS O
on IN O
cardiac JJ O
function NN O
and CC O
prognosis NN O
. . O

Sixty-nine JJ B-POPU
patients NNS I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO O
received VB O
24-hour JJ O
intravenous JJ O
infusions NNS O
of IN O
levosimendan NN B-INTV
( ( O
n JJ O
= NNP O
23 CD O
) ) O
, , O
dobutamine NN B-INTV
( ( O
n JJ O
= NNP O
23 CD O
) ) O
, , O
or CC O
placebo NN B-INTV
( ( O
n JJ O
= NNP O
23 CD O
) ) O
. . O

Echocardiographic NNP B-OC
, , I-OC
hemodynamic JJ I-OC
, , I-OC
and CC I-OC
biochemical JJ I-OC
assessments NNS I-OC
were VBD O
performed VBN O
at IN O
baseline NN O
, , O
immediately RB O
after IN O
treatment NN O
, , O
and CC O
48 CD O
hours NNS O
later RB O
. . O

Patients NNS O
were VBD O
subsequently RB O
followed VBN O
for IN O
4 CD O
months NNS O
for IN O
disease NN O
progression NN O
. . O

End-systolic JJ B-OC
wall NN I-OC
stress NN I-OC
, , I-OC
the DT I-OC
left NN I-OC
ventricular JJ I-OC
ejection NN I-OC
fraction NN I-OC
, , I-OC
pulmonary JJ I-OC
capillary JJ I-OC
wedge NN I-OC
pressure NN I-OC
, , I-OC
and CC I-OC
cardiac JJ I-OC
index NN I-OC
were VBD O
significantly RB O
improved VBN O
in IN O
the DT O
levosimendan NN O
group NN O
but CC O
remained VBD O
practically RB O
unaffected VBN O
in IN O
the DT O
other JJ O
groups NNS O
. . O

Plasma NNP B-OC
N-terminal-pro-B-type JJ I-OC
natriuretic JJ I-OC
peptide NN I-OC
, , I-OC
tumor NN I-OC
necrosis NN I-OC
factor-alpha NN I-OC
, , I-OC
and CC I-OC
soluble JJ I-OC
Fas NNP I-OC
ligand NN I-OC
levels NNS I-OC
were VBD O
significantly RB O
decreased VBN O
only RB O
in IN O
the DT O
levosimendan NN B-INTV
group NN O
( ( O
from IN O
1,900 CD O
+/- JJ O
223 CD O
to TO O
1,378 CD O
+/- JJ O
170 CD O
pg/ml NN O
, , O
13.4 CD O
+/- JJ O
1.0 CD O
to TO O
12.3 CD O
+/- JJ O
1.2 CD O
pg/ml NN O
, , O
and CC O
68.2 CD O
+/- JJ O
3.7 CD O
to TO O
59.8 CD O
+/- JJ O
3.6 CD O
pg/ml NN O
, , O
respectively RB O
; : O
p VB O
< $ O
0.05 CD O
for IN O
all DT O
) ) O
; : O
interleukin-6 NN B-OC
was VBD O
also RB O
borderline JJ O
reduced VBN O
( ( O
p JJ O
= NNP O
0.051 CD O
) ) O
. . O

Levosimendan-induced JJ B-OC
reduction NN I-OC
in IN I-OC
end-systolic JJ I-OC
wall NN I-OC
stress NN I-OC
was VBD O
significantly RB O
correlated VBN O
with IN O
respective JJ O
decreases NNS O
in IN O
N-terminal-pro-B-type NNP B-OC
natriuretic JJ I-OC
peptide NN I-OC
( ( O
r JJ O
= NN O
0.671 CD O
, , O
p NN O
< NNP O
0.01 CD O
) ) O
, , O
tumor JJ B-OC
necrosis NN I-OC
factor-alpha NN I-OC
( ( O
r JJ O
= NN O
0.586 CD O
, , O
p NN O
< NNP O
0.01 CD O
) ) O
, , O
soluble JJ B-OC
Fas NNP I-OC
( ( O
r VB O
= RB O
0.441 CD O
, , O
p NN O
< NNP O
0.05 CD O
) ) O
, , O
and CC O
soluble JJ B-OC
Fas NNP I-OC
ligand NN I-OC
( ( O
r JJ O
= NN O
0.614 CD O
, , O
p NN O
< NNP O
0.01 CD O
) ) O
. . O

Event-free JJ B-OC
survival NN I-OC
was VBD O
significantly RB O
longer RBR O
in IN O
the DT O
levosimendan NN B-INTV
group NN O
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
. . O

In IN O
conclusion NN O
, , O
the DT O
superiority NN O
of IN O
levosimendan NN B-INTV
over IN O
dobutamine NN B-INTV
in IN O
improving VBG O
central JJ B-OC
hemodynamics NNS I-OC
and CC O
left VBD B-OC
ventricular JJ I-OC
performance NN I-OC
in IN O
decompensated JJ B-POPU
HF NNP I-POPU
seems VBZ O
to TO O
be VB O
related VBN O
to TO O
its PRP$ O
anti-inflammatory JJ O
and CC O
antiapoptotic JJ O
effects NNS O
. . O

-DOCSTART- -X- O O

The DT O
efficacy NN O
of IN O
early RB O
continuous JJ O
positive JJ O
airway NN O
pressure NN O
therapy NN O
in IN O
patients NNS B-POPU
with IN I-POPU
acute JJ I-POPU
cardiogenic JJ I-POPU
pulmonary JJ I-POPU
edema NN I-POPU
. . O

Although IN O
continuous JJ O
positive JJ O
airway NN O
pressure NN O
( ( O
CPAP NNP O
) ) O
therapy NN O
using VBG O
a DT O
face NN O
mask NN O
is VBZ O
known VBN O
to TO O
improve VB O
oxygenation NN O
, , O
the DT O
intrapulmonary JJ O
shunt NN O
reduction NN O
remains VBZ O
unsettled JJ O
. . O

Our PRP$ O
study NN O
was VBD O
designed VBN O
to TO O
explore VB O
this DT O
issue NN O
. . O

From IN B-POPU
1985 CD I-POPU
to TO I-POPU
1987 CD I-POPU
80 CD I-POPU
patients NNS I-POPU
with IN I-POPU
acute JJ I-POPU
cardiogenic JJ I-POPU
pulmonary JJ I-POPU
edema NN I-POPU
were VBD O
randomly RB O
chosen VBN O
to TO O
receive VB O
either DT O
serial JJ B-INTV
CPAP NNP I-INTV
therapy NN I-INTV
or CC I-INTV
high-flow JJ I-INTV
face NN I-INTV
mask NN I-INTV
oxygen NN I-INTV
therapy NN I-INTV
without IN I-INTV
CPAP NNP I-INTV
( ( I-INTV
control NN I-INTV
) ) I-INTV
for IN O
the DT O
purpose NN O
of IN O
evaluating VBG O
the DT O
efficacy NN O
of IN O
CPAP NNP O
therapy NN O
. . O

After IN O
screening VBG O
for IN O
exclusion NN O
, , O
only RB B-POPU
55 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
included VBN I-POPU
in IN O
the DT O
first JJ O
3-hour JJ O
investigation NN O
period NN O
. . O

PaO2 NNP B-OC
in IN O
the DT O
CPAP NNP O
group NN O
showed VBD O
a DT O
significant JJ O
increase NN O
by IN O
the DT O
end NN O
of IN O
the DT O
initial JJ O
study NN O
; : O
whereas CC O
intrapulmonary JJ B-OC
shunt NN I-OC
and CC O
alveolar-arterial JJ B-OC
oxygen NN I-OC
tension NN I-OC
gradient NN I-OC
AaDO2 NNP I-OC
revealed VBD O
simultaneously RB O
a DT O
significant JJ O
reduction NN O
. . O

Conversely RB O
, , O
neither DT O
PaO2 NNP B-OC
nor CC I-OC
intrapulmonary JJ I-OC
shunt NN I-OC
( ( I-OC
or CC I-OC
AaDO2 NNP I-OC
) ) I-OC
in IN O
the DT O
control NN O
group NN O
demonstrated VBD O
any DT O
significant JJ O
beneficial JJ O
changes NNS O
. . O

As IN O
for IN O
cardiovascular JJ O
function NN O
, , O
only RB O
the DT O
CPAP NNP O
therapy NN O
achieved VBD O
a DT O
significant JJ O
reduction NN O
in IN O
rate NN B-OC
pressure NN I-OC
product NN I-OC
in IN O
contrast NN O
to TO O
the DT O
control NN O
( ( O
face NN O
mask NN O
) ) O
therapy NN O
alone RB O
. . O

In IN O
terms NNS O
of IN O
therapeutic JJ B-OC
failure NN I-OC
, , O
10 CD O
patients NNS O
in IN O
the DT O
control NN O
group NN O
failed VBD O
. . O

However RB O
, , O
in IN O
the DT O
CPAP NNP O
group NN O
only RB O
5 CD O
patients NNS O
had VBD O
failed VBN O
at IN O
the DT O
end NN O
of IN O
the DT O
first JJ O
3-hour JJ O
study NN O
period NN O
. . O

Overall JJ O
, , O
the DT O
cumulative JJ B-OC
therapeutic JJ I-OC
failure NN I-OC
rate NN I-OC
was VBD O
28 CD O
% NN O
in IN O
the DT O
CPAP NNP O
group NN O
and CC O
60 CD O
% NN O
in IN O
the DT O
control NN O
group NN O
during IN O
a DT O
6-hour JJ O
observation NN O
study NN O
. . O

However RB O
, , O
there EX O
was VBD O
no DT O
significant JJ O
difference NN O
between IN O
the DT O
two CD O
groups NNS O
in IN O
24-hour JJ O
hospital NN O
mortality NN O
. . O

( ( O
ABSTRACT NNP O
TRUNCATED NNP O
AT NNP O
250 CD O
WORDS NNP O
) ) O
-DOCSTART- -X- O O

Coenzyme NNP B-INTV
Q10 NNP I-INTV
and CC O
exercise NN O
training NN O
in IN O
chronic JJ B-POPU
heart NN I-POPU
failure NN I-POPU
. . O

AIMS NNP O
There EX O
is VBZ O
evidence NN O
that IN O
plasma NN O
coenzyme NN B-OC
Q NNP I-OC
( ( I-OC
10 CD I-OC
) ) I-OC
( ( B-INTV
CoQ NNP I-INTV
( ( I-INTV
10 CD I-INTV
) ) I-INTV
) ) I-INTV
levels NNS B-OC
decrease NN O
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
( ( I-POPU
CHF NNP I-POPU
) ) I-POPU
. . O

However RB O
, , O
it PRP O
is VBZ O
not RB O
known VBN O
whether IN O
oral JJ O
CoQ NNP B-INTV
( ( I-INTV
10 CD I-INTV
) ) I-INTV
supplementation NN O
may MD O
improve VB O
cardiocirculatory NN B-OC
efficiency NN I-OC
and CC I-OC
endothelial JJ I-OC
function NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
CHF NNP I-POPU
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
We PRP O
studied VBD O
23 CD B-POPU
patients NNS I-POPU
in IN I-POPU
NYHA NNP I-POPU
class NN I-POPU
II NNP I-POPU
and CC I-POPU
III NNP I-POPU
( ( I-POPU
20 CD I-POPU
men NNS I-POPU
, , I-POPU
three CD I-POPU
women NNS I-POPU
, , I-POPU
mean JJ I-POPU
age NN I-POPU
59+/-9 CD I-POPU
years NNS I-POPU
) ) I-POPU
with IN I-POPU
stable JJ I-POPU
CHF NNP I-POPU
secondary JJ I-POPU
to TO I-POPU
ischaemic VB I-POPU
heart NN I-POPU
disease NN I-POPU
[ NNP I-POPU
ejection NN I-POPU
fraction NN I-POPU
37+/-7 CD I-POPU
% NN I-POPU
] NN I-POPU
, , O
using VBG O
a DT O
double-blind JJ O
, , O
placebo-controlled JJ O
cross-over NN O
design NN O
. . O

Patients NNS B-POPU
were VBD O
assigned VBN O
to TO O
each DT O
of IN O
the DT O
following JJ O
treatments NNS O
: : O
oral JJ B-INTV
CoQ NNP B-POPU
( ( I-POPU
10 CD I-POPU
) ) I-POPU
( ( B-INTV
100 CD I-INTV
mg RB I-INTV
tid NN I-INTV
) ) I-INTV
, , I-INTV
CoQ NNP B-POPU
( ( I-POPU
10 CD I-POPU
) ) I-POPU
plus CC I-POPU
supervised JJ I-POPU
exercise NN I-POPU
training NN I-POPU
( ( B-INTV
ET NNP I-INTV
) ) I-INTV
( ( O
60 CD O
% NN O
of IN O
peak NN O
VO NNP O
( ( O
2 CD O
) ) O
, , O
five CD O
times NNS O
a DT O
week NN O
) ) O
, , O
placebo NN B-INTV
, , I-INTV
and CC I-INTV
placebo NN I-INTV
plus CC I-INTV
ET NNP I-INTV
. . O

Each DT O
phase NN O
lasted VBD O
4 CD O
weeks NNS O
. . O

Both DT O
peak JJ B-OC
VO NNP I-OC
( ( I-OC
2 CD I-OC
) ) I-OC
and CC I-OC
endothelium-dependent JJ I-OC
dilation NN I-OC
of IN I-OC
the DT I-OC
brachial JJ I-OC
artery NN I-OC
( ( I-OC
EDDBA NNP I-OC
) ) I-OC
improved VBD O
significantly RB O
after IN O
CoQ NNP B-INTV
( ( I-INTV
10 CD I-INTV
) ) I-INTV
and CC O
after IN O
ET NNP B-INTV
as IN O
compared VBN O
with IN O
placebo NN B-INTV
. . O

CoQ NNP B-INTV
( ( I-INTV
10 CD I-INTV
) ) I-INTV
main JJ O
effect NN O
was VBD O
: : O
peak NN B-OC
VO NNP I-OC
( ( I-OC
2 CD I-OC
) ) I-OC
+9 CD I-OC
% NN I-OC
, , I-OC
EDDBA NNP I-OC
+38 NNP O
% NN O
, , O
systolic JJ B-OC
wall NN I-OC
thickening VBG I-OC
score NN I-OC
index NN I-OC
( ( I-OC
SWTI NNP I-OC
) ) I-OC
-12 CD O
% NN O
; : O
ET NNP B-INTV
produced VBD O
comparable JJ O
effects NNS O
. . O

CoQ NNP B-INTV
( ( I-INTV
10 CD I-INTV
) ) I-INTV
supplementation NN O
resulted VBD O
in IN O
a DT O
four-fold JJ O
increase NN O
in IN O
plasma JJ B-OC
CoQ NNP B-INTV
( ( I-INTV
10 CD I-INTV
) ) I-INTV
level NN B-OC
, , O
whereas IN O
the DT O
combination NN O
with IN O
ET NNP B-INTV
further RB O
increased VBD O
it PRP O
. . O

No DT O
side NN O
effects NNS O
were VBD O
reported VBN O
with IN O
CoQ NNP B-INTV
( ( I-INTV
10 CD I-INTV
) ) I-INTV
. . O

CONCLUSIONS NNP O
Oral NNP B-INTV
CoQ NNP I-INTV
( ( I-INTV
10 CD I-INTV
) ) I-INTV
improves VBZ O
functional JJ B-OC
capacity NN I-OC
, , I-OC
endothelial JJ I-OC
function NN I-OC
, , I-OC
and CC I-OC
LV NNP I-OC
contractility NN I-OC
in IN O
CHF NNP O
without IN O
any DT O
side NN B-OC
effects NNS I-OC
. . O

The DT O
combination NN O
of IN O
CoQ NNP B-INTV
( ( I-INTV
10 CD I-INTV
) ) I-INTV
and CC O
ET NNP B-INTV
resulted VBD O
in IN O
higher JJR O
plasma NN B-OC
CoQ NNP B-INTV
( ( I-INTV
10 CD I-INTV
) ) I-INTV
levels NNS B-OC
and CC O
more JJR O
pronounced JJ O
effects NNS O
on IN O
all PDT O
the DT O
abovementioned JJ O
parameters NNS O
. . O

However RB O
, , O
significant JJ O
synergistic JJ O
effect NN O
of IN O
CoQ NNP B-INTV
( ( I-INTV
10 CD I-INTV
) ) I-INTV
with IN O
ET NNP B-INTV
was VBD O
observed VBN O
only RB O
for IN O
peak NN O
SWTI NNP B-OC
suggesting VBG O
that IN O
ET NNP B-INTV
amplifies VBZ O
the DT O
already RB O
described JJ O
effect NN O
of IN O
CoQ NNP B-INTV
( ( I-INTV
10 CD I-INTV
) ) I-INTV
on IN O
contractility NN B-OC
of IN I-OC
dysfunctional JJ I-OC
myocardium NN I-OC
. . O

-DOCSTART- -X- O O

Dietary NNP B-INTV
sodium NN I-INTV
intake NN I-INTV
modulates VBZ O
myocardial JJ B-POPU
relaxation NN I-POPU
responsiveness NN B-OC
to TO O
angiotensin VB O
II NNP O
. . O

Dietary NNP B-INTV
sodium NN I-INTV
alters NNS O
renovascular JJ O
responsiveness NN O
to TO O
angiotensin VB O
II NNP O
( ( O
Ang NNP O
II NNP O
) ) O
in IN O
normal JJ B-POPU
subjects NNS I-POPU
. . O

Evidence NN O
supports VBZ O
a DT O
connection NN O
among IN O
dietary JJ B-INTV
sodium NN I-INTV
, , O
the DT O
rennin-angiotensin NN O
system NN O
, , O
and CC O
myocardial JJ O
function NN O
. . O

The DT O
authors NNS O
hypothesized VBD O
that IN O
a DT O
similar JJ O
relationship NN O
would MD O
exist VB O
in IN O
the DT O
heart NN O
, , O
and CC O
that IN O
the DT O
pattern NN O
of IN O
responses NNS O
would MD O
be VB O
qualitatively RB O
similar JJ O
to TO O
the DT O
renal JJ O
vasculature NN O
. . O

Thirteen NNP B-POPU
healthy JJ I-POPU
volunteers NNS I-POPU
( ( I-POPU
aged VBN I-POPU
38.6 CD I-POPU
+/- JJ I-POPU
4 CD I-POPU
years NNS I-POPU
) ) I-POPU
entered VBD O
a DT O
2 CD O
week NN O
crossover NN O
design NN O
study NN O
( ( O
week NN O
1 CD O
, , O
high JJ B-INTV
sodium NN I-INTV
diet JJ I-INTV
[ NNP I-INTV
HS NNP I-INTV
] NNP I-INTV
> VBD O
200 CD O
mmol NN O
Na/day NNP O
; : O
week NN O
2 CD O
, , O
low JJ B-INTV
sodium NN I-INTV
diet JJ I-INTV
[ NNP I-INTV
LS NNP I-INTV
] NNP I-INTV
, , O
< VBD O
10 CD O
mmol NNS O
Na/day NNP O
) ) O
to TO O
investigate VB O
the DT O
influence NN O
of IN O
dietary JJ O
sodium NN O
and CC O
Ang NNP O
II NNP O
on IN O
myocardial JJ O
relaxation NN O
and CC O
renal JJ B-OC
blood NN I-OC
flow NN I-OC
( ( I-OC
RBF NNP I-OC
) ) I-OC
. . O

At IN O
the DT O
end NN O
of IN O
each DT O
study NN O
week NN O
, , O
the DT O
authors NNS O
assessed VBD O
diastolic JJ B-OC
function NN I-OC
( ( I-OC
myocardial JJ I-OC
relaxation NN I-OC
velocities NNS I-OC
[ VBP I-OC
E NNP I-OC
' POS I-OC
] NN I-OC
using VBG O
tissue NN O
Doppler NNP O
imaging NN O
) ) O
and CC O
RBF NNP B-OC
( ( I-OC
para-aminohippurate JJ I-OC
clearance NN I-OC
) ) I-OC
at IN O
baseline NN O
and CC O
after IN O
infusion NN O
of IN O
Ang NNP O
II NNP O
( ( O
3 CD O
ng/kg/min RB O
x JJ O
45 CD O
min NN O
) ) O
. . O

On IN O
HS NNP O
diet NN O
, , O
E NNP O
' POS O
and CC O
RBF NNP B-OC
were VBD O
higher JJR O
than IN O
on IN O
LS NNP O
diet NN O
( ( O
E NNP O
' POS O
14.0 CD O
+/- JJ O
1.2 CD O
vs JJ O
12.6 CD O
+/- JJ O
1.0 CD O
cm/s NN O
, , O
P NNP O
= NNP O
0.02 CD O
; : O
RBF NNP O
596 CD O
+/- JJ O
24 CD O
vs JJ O
563 CD O
+/- JJ O
26 CD O
mL/min NN O
, , O
P NNP O
= NNP O
0.02 CD O
) ) O
. . O

Dietary JJ B-INTV
sodium NN I-INTV
significantly RB O
modulated VBD O
E NNP B-OC
' POS I-OC
and CC I-OC
RBF NNP I-OC
responsiveness NN I-OC
to TO O
Ang NNP O
II NNP O
infusion NN O
in IN O
like JJ O
manner NN O
. . O

HS NNP O
was VBD O
associated VBN O
with IN O
increased JJ O
responsiveness NN O
compared VBN O
with IN O
a DT O
blunted JJ O
LS NNP B-OC
response NN I-OC
( ( O
HS NNP O
DeltaE NNP O
' POS O
-1.4 JJ O
+/- JJ O
0.4 CD O
cm/s NN O
vs NN O
LS NNP O
DeltaE NNP O
' POS O
-0.1 JJ O
+/- JJ O
0.3 CD O
cm/s NN O
, , O
P NNP O
= NNP O
0.02 CD O
; : O
HS NNP O
DeltaRBF NNP O
-135.2 NNP O
+/- JJ O
13.2 CD O
vs NN O
LS NNP O
DeltaRBF NNP O
-62.5 NNP O
+/- JJ O
10.1 CD O
mL/min NN O
, , O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

The DT O
authors NNS O
describe VBP O
for IN O
the DT O
first JJ O
time NN O
that WDT O
dietary JJ B-INTV
sodium NN I-INTV
modulates VBZ O
myocardial JJ B-OC
relaxation NN I-OC
and CC I-OC
responsiveness NN I-OC
to TO O
Ang NNP O
II NNP O
. . O

It PRP O
is VBZ O
important JJ O
to TO O
consider VB O
dietary JJ B-INTV
sodium NN I-INTV
intake NN O
when WRB O
assessing VBG O
diastolic JJ B-OC
function NN I-OC
. . O

Ang NNP O
II NNP O
may MD O
play VB O
a DT O
role NN O
in IN O
the DT O
interaction NN O
between IN O
dietary JJ B-INTV
sodium NN I-INTV
and CC O
myocardial JJ B-OC
relaxation NN I-OC
. . O

Future NNP O
research NN O
will MD O
investigate VB O
whether IN O
abnormalities NNS O
in IN O
these DT O
mechanisms NNS O
play VBP O
a DT O
role NN O
in IN O
disorders NNS O
of IN O
diastolic JJ O
function NN O
. . O

-DOCSTART- -X- O O

Atorvastatin NNP B-INTV
and CC I-INTV
quinapril JJ I-INTV
inhibit NN O
blood NN O
coagulation NN O
in IN O
patients NNS B-POPU
with IN I-POPU
coronary JJ I-POPU
artery NN I-POPU
disease NN I-POPU
following VBG O
28 CD O
days NNS O
of IN O
therapy NN O
. . O

BACKGROUND IN O
We PRP O
evaluated VBD O
the DT O
antithrombotic JJ O
effects NNS O
of IN O
statins NNS B-INTV
and CC O
angiotensin-converting JJ B-INTV
enzyme NN I-INTV
inhibitor NN I-INTV
( ( I-INTV
ACEI NNP I-INTV
) ) I-INTV
drugs NNS I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
coronary JJ I-POPU
artery NN I-POPU
disease NN I-POPU
( ( I-POPU
CAD NNP I-POPU
) ) I-POPU
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
Blood NNP O
coagulation NN O
at IN O
the DT O
site NN O
of IN O
microvascular JJ O
injury NN O
was VBD O
assessed VBN O
in IN O
26 CD B-POPU
males NNS I-POPU
with IN I-POPU
CAD NNP I-POPU
before IN I-POPU
and CC I-POPU
after IN I-POPU
treatment NN I-POPU
with IN I-POPU
quinapril NN I-POPU
( ( I-POPU
10 CD I-POPU
mg RB I-POPU
day-1 NN I-POPU
; : I-POPU
n=13 CC I-POPU
) ) I-POPU
or CC I-POPU
atorvastatin NN I-POPU
( ( I-POPU
40 CD I-POPU
mg RB I-POPU
day-1 NN I-POPU
; : I-POPU
n=13 CC I-POPU
) ) I-POPU
for IN I-POPU
4 CD I-POPU
weeks NNS I-POPU
and CC I-POPU
an DT I-POPU
additional JJ I-POPU
4 CD I-POPU
weeks NNS I-POPU
of IN I-POPU
combined JJ I-POPU
therapy NN I-POPU
( ( O
quinapril+atorvastatin NN O
) ) O
. . O

Rates NNS B-OC
of IN I-OC
prothrombin NN I-OC
and CC I-OC
factor NN I-OC
V NNP I-OC
activation NN I-OC
( ( I-OC
FVa NNP I-OC
) ) I-OC
, , I-OC
fibrinogen NN I-OC
( ( I-OC
Fbg NNP I-OC
) ) I-OC
cleavage NN I-OC
and CC I-OC
FVa NNP I-OC
inactivation NN I-OC
showed VBD O
that IN O
both DT O
quinapril NNS O
and CC O
atorvastatin NN O
decreased VBD O
the DT O
rates NNS O
of IN O
: : O
formation NN B-OC
of IN I-OC
thrombin JJ I-OC
B-chain NNP I-OC
( ( O
by IN O
30.6 CD O
% NN O
, , O
P=0.007 NNP O
; : O
and CC O
by IN O
34.3 CD O
% NN O
, , O
P=0.003 NNP O
) ) O
, , O
formation NN B-OC
of IN I-OC
thrombin-antithrombin NN I-OC
complexes NNS I-OC
( ( O
by IN O
30.4 CD O
% NN O
, , O
P=0.0002 NNP O
; : O
and CC O
by IN O
40 CD O
% NN O
, , O
P=0.001 NNP O
) ) O
, , O
FV NNP B-OC
activation NN I-OC
( ( O
by IN O
19.1 CD O
% NN O
, , O
P=0.03 NNP O
; : O
and CC O
by IN O
21.8 CD O
% NN O
, , O
P=0.005 NNP O
) ) O
and CC O
Fbg NNP B-OC
depletion NN I-OC
( ( O
by IN O
29.2 CD O
% NN O
, , O
P=0.004 NNP O
; : O
and CC O
by IN O
32.7 CD O
% NN O
, , O
P=0.001 NNP O
) ) O
. . O

Atorvastatin NNP O
alone RB O
accelerated VBD O
FVa NNP B-OC
inactivation NN I-OC
( ( O
P=0.005 NNP O
) ) O
. . O

A DT O
further JJ O
4 CD O
weeks NNS O
of IN O
combined JJ O
therapy NN O
enhanced VBD O
most RBS O
anticoagulant JJ B-OC
effects NNS I-OC
only RB O
when WRB O
atorvastatin NN O
was VBD O
added VBN O
to TO O
quinapril VB O
. . O

CONCLUSIONS NNP O
In IN O
CAD NNP B-POPU
patients NNS I-POPU
, , O
atorvastatin NN O
and CC O
quinapril NN O
slowed VBD O
blood NN O
clotting NN O
at IN O
the DT O
site NN O
of IN O
microvascular JJ O
injury NN O
after IN O
28 CD O
days NNS O
of IN O
therapy NN O
. . O

Addition NN O
of IN O
atorvastatin NN B-INTV
to TO O
quinapril VB B-INTV
, , O
but CC O
not RB O
quinapril VB B-INTV
to TO O
the DT O
statin NN B-INTV
, , O
enhanced VBD O
the DT O
anticoagulant JJ O
effects NNS O
. . O

Our PRP$ O
findings NNS O
might MD O
help VB O
explain VB O
the DT O
reduced JJ O
risk NN O
of IN O
myocardial JJ O
infarction NN O
or CC O
stroke NN O
in IN O
patients NNS O
treated VBN O
with IN O
statins NNS B-INTV
and/or VBP O
ACEIs NNP O
and CC O
the DT O
lack NN O
of IN O
clinical JJ O
benefits NNS O
from IN O
ACEI NNP O
added VBD O
to TO O
prior VB O
statin JJ O
therapy NN O
in IN O
patients NNS O
at IN O
cardiovascular JJ O
risk NN O
. . O

-DOCSTART- -X- O O

Cardiac NNP B-OC
safety NN O
of IN O
formoterol NN B-INTV
12 CD O
microg NN O
twice RB O
daily RB O
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
obstructive JJ I-POPU
pulmonary JJ I-POPU
disease NN I-POPU
. . O

BACKGROUND CC O
Some DT O
evidence NN O
suggests VBZ O
an DT O
increased VBN O
risk NN O
of IN O
myocardial JJ B-OC
infarction NN I-OC
and CC I-OC
dysrhythmia NN I-OC
events NNS I-OC
associated VBN O
with IN O
beta NN O
( ( O
2 CD O
) ) O
-agonist NN O
use NN O
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
obstructive JJ I-POPU
pulmonary JJ I-POPU
disease NN I-POPU
( ( I-POPU
COPD NNP I-POPU
) ) I-POPU
. . O

This DT O
prospective JJ O
, , O
multicenter NN O
, , O
randomized VBN O
, , O
double-blind JJ O
, , O
placebo-controlled JJ O
study NN O
compared VBN O
the DT O
cardiac JJ O
safety NN O
of IN O
formoterol NN B-INTV
and CC O
placebo NN B-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
COPD NNP I-POPU
. . O

METHODS NNP O
After IN O
a DT O
3-14-day JJ O
run-in NN O
, , O
204 CD B-POPU
patients NNS I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
formoterol NN B-INTV
12 CD I-INTV
microg NN I-INTV
dry JJ I-INTV
powder NN I-INTV
inhalation NN I-INTV
or CC I-INTV
matching VBG I-INTV
placebo JJ I-INTV
twice RB I-INTV
daily RB I-INTV
for IN I-INTV
8 CD I-INTV
weeks NNS I-INTV
. . O

Twenty CD B-INTV
four-hour JJ I-INTV
continuous JJ I-INTV
electrocardiography NN I-INTV
( ( I-INTV
Holter NNP I-INTV
monitoring NN I-INTV
) ) I-INTV
was VBD O
performed VBN O
at IN O
screening NN O
and CC O
after IN O
2 CD O
and CC O
8 CD O
weeks NNS O
of IN O
treatment NN O
. . O

RESULTS NNP O
Only RB O
a DT O
small JJ O
number NN O
of IN O
patients NNS O
met VBD O
the DT O
predefined JJ O
criteria NNS O
for IN O
a DT O
proarrhythmic JJ B-OC
event NN I-OC
( ( O
4 CD O
formoterol NN B-INTV
and CC O
2 CD O
placebo NN B-INTV
patients NNS O
) ) O
. . O

No UH O
patients NNS O
had VBD O
sustained VBN O
postbaseline JJ B-OC
ventricular JJ I-OC
tachycardia NN I-OC
events NNS I-OC
, , I-OC
postbaseline JJ I-OC
run NN I-OC
of IN I-OC
ventricular JJ I-OC
ectopic NN I-OC
beats NNS I-OC
associated VBN O
with IN O
relevant JJ B-OC
symptoms NNS I-OC
( ( I-OC
e.g NN I-OC
. . O

hypotension NN B-OC
, , I-OC
syncope NN I-OC
) ) I-OC
, , O
or CC O
an DT O
episode NN B-OC
of IN I-OC
ventricular JJ I-OC
flutter NN I-OC
or CC I-OC
fibrillation NN I-OC
. . O

Holter NNP O
monitoring VBG O
data NNS O
were VBD O
variable JJ O
but CC O
showed VBD O
no DT O
clinically RB O
meaningful JJ O
differences NNS O
between IN O
the DT O
formoterol NN O
and CC O
placebo NN O
groups NNS O
, , O
respectively RB O
, , O
for IN O
variables NNS O
such JJ O
as IN O
( ( O
mean+/-SD NN O
at IN O
end NN O
of IN O
treatment NN O
) ) O
: : O
heart NN B-OC
rate NN I-OC
( ( O
80+/-8.6 JJ O
vs. IN O
80+/-10.6 JJ O
bpm NN O
) ) O
, , O
number NN B-OC
and CC I-OC
rate NN I-OC
of IN I-OC
ventricular JJ I-OC
premature NN I-OC
beats NNS I-OC
( ( O
total JJ O
732+/-2685.4 JJ O
vs. IN O
650+/-2090.6 JJ O
; : O
rate NN O
35+/-131.0 JJ O
vs. IN O
30+/-101.3 JJ O
per IN O
h NN O
) ) O
, , O
ventricular JJ B-OC
tachycardia NN I-OC
events NNS I-OC
( ( O
total JJ O
0.4+/-1.70 JJ O
vs. IN O
1.0+/-9.23 JJ O
; : O
rate NN O
0.02+/-0.082 JJ O
vs. IN O
0.05+/-0.479 JJ O
per IN O
h NN O
) ) O
, , O
and CC O
supraventricular JJ B-OC
premature NN I-OC
beats NNS I-OC
( ( O
total JJ O
504+/-1844.1 JJ O
vs. IN O
823+/-2961.8 JJ O
; : O
rate NN O
22+/-80.6 JJ O
vs. IN O
37+/-129.6 JJ O
per IN O
h NN O
) ) O
. . O

Vital JJ B-OC
signs NNS I-OC
and CC I-OC
electrocardiogram NN I-OC
data NNS I-OC
, , I-OC
including VBG I-OC
corrected VBN I-OC
QT NNP I-OC
intervals NNS I-OC
( ( O
Bazett NNP O
and CC O
Fridericia NNP O
) ) O
, , O
were VBD O
similar JJ O
across IN O
treatment NN O
groups NNS O
. . O

The DT O
overall JJ B-OC
adverse JJ I-OC
event NN I-OC
experience NN I-OC
was VBD O
similar JJ O
in IN O
the DT O
formoterol NN O
( ( O
n=26 JJ O
[ RB O
27 CD O
% NN O
] NN O
) ) O
and CC O
placebo NN O
( ( O
n=33 JJ O
[ RB O
31 CD O
% NN O
] NN O
) ) O
groups NNS O
. . O

The DT O
most RBS O
common JJ O
adverse JJ B-OC
events NNS I-OC
, , I-OC
infections NNS I-OC
and CC I-OC
respiratory JJ I-OC
events NNS I-OC
, , O
were VBD O
expected VBN O
for IN O
this DT O
patient JJ O
population NN O
. . O

The DT O
incidence NN O
of IN O
cardiac JJ B-OC
adverse JJ I-OC
events NNS I-OC
was VBD O
low JJ O
( ( O
1 CD O
formoterol NN O
and CC O
4 CD O
placebo NN O
patients NNS O
) ) O
. . O

CONCLUSIONS VB O
The DT O
results NNS O
of IN O
this DT O
study NN O
confirm VBD O
the DT O
good JJ B-OC
cardiovascular JJ I-OC
safety NN I-OC
profile NN O
of IN O
formoterol NN O
in IN O
patients NNS B-POPU
with IN I-POPU
COPD NNP I-POPU
. . O

-DOCSTART- -X- O O

Rationale NNP O
and CC O
design NN O
of IN O
the DT O
Folic NNP B-INTV
Acid NNP I-INTV
for IN O
Vascular NNP B-OC
Outcome NNP I-OC
Reduction NNP O
In IN O
Transplantation NNP O
( ( O
FAVORIT NNP O
) ) O
trial NN O
. . O

BACKGROUND NNP O
Patients NNPS B-POPU
with IN I-POPU
chronic JJ I-POPU
kidney NN I-POPU
disease NN I-POPU
, , I-POPU
including VBG I-POPU
kidney NN I-POPU
transplant NN I-POPU
recipients NNS I-POPU
, , O
are VBP O
at IN O
high JJ O
risk NN O
for IN O
cardiovascular JJ B-OC
disease NN I-OC
( ( I-OC
CVD NNP I-OC
) ) I-OC
. . O

In IN O
addition NN O
to TO O
the DT O
constellation NN O
of IN O
traditional JJ O
CVD NNP O
risk NN O
factors NNS O
in IN O
chronic JJ O
kidney NN O
disease NN O
, , O
elevated VBD O
total JJ B-OC
homocysteine NN I-OC
( ( I-OC
tHcy NN I-OC
) ) I-OC
is VBZ O
notably RB O
more RBR O
prevalent JJ O
among IN O
the DT O
general JJ O
population NN O
. . O

The DT B-INTV
Folic NNP I-INTV
Acid NNP I-INTV
for IN O
Vascular NNP O
Outcome NNP O
Reduction NNP O
In IN O
Transplantation NNP O
( ( O
FAVORIT NNP O
) ) O
trial NN O
is VBZ O
designed VBN O
to TO O
evaluate VB O
whether IN O
lowering VBG O
tHcy NN B-OC
using VBG O
vitamin JJ B-INTV
supplementation NN I-INTV
reduces NNS O
CVD NNP B-OC
events NNS I-OC
in IN O
renal JJ B-POPU
transplant NN I-POPU
recipients NNS I-POPU
. . O

METHODS NNP O
FAVORIT NNP O
is VBZ O
a DT O
multicenter JJ O
double-blind NN O
randomized VBD O
controlled JJ O
clinical JJ O
trial NN O
. . O

Participants NNS B-POPU
are VBP I-POPU
clinically RB I-POPU
stable JJ I-POPU
renal JJ I-POPU
transplant NN I-POPU
recipients NNS I-POPU
who WP I-POPU
are VBP I-POPU
6 CD I-POPU
months NNS I-POPU
or CC I-POPU
longer JJR I-POPU
posttransplant NN I-POPU
with IN I-POPU
elevated JJ I-POPU
tHcy NN I-POPU
. . O

Patients NNS O
are VBP O
randomized VBN O
to TO O
a DT O
multivitamin NN B-INTV
that WDT I-INTV
includes VBZ I-INTV
either CC I-INTV
a DT I-INTV
high-dose JJ I-INTV
or CC I-INTV
low-dose JJ I-INTV
of IN I-INTV
folic JJ I-INTV
acid NN I-INTV
( ( O
5 CD O
or CC O
0 CD O
mg NN O
) ) O
, , O
vitamin FW B-INTV
B6 NNP I-INTV
( ( O
50 CD O
or CC O
1.4 CD O
mg NN O
) ) O
, , O
and CC B-INTV
vitamin NN I-INTV
B12 NNP I-INTV
( ( O
1000 CD O
or CC O
2 CD O
microg NN O
) ) O
. . O

The DT O
primary JJ O
end NN O
point NN O
is VBZ O
a DT O
composite NN B-OC
of IN I-OC
incident NN I-OC
or CC I-OC
recurrent NN I-OC
CVD NNP I-OC
outcomes RB I-OC
, , I-OC
that DT I-OC
is VBZ I-OC
, , I-OC
coronary JJ I-OC
heart NN I-OC
, , I-OC
cerebrovascular JJ I-OC
, , I-OC
or CC I-OC
abdominal JJ I-OC
aortic/lower NN I-OC
extremity NN I-OC
arterial JJ I-OC
events NNS I-OC
. . O

A DT O
sample JJ O
size NN O
of IN O
4000 CD O
is VBZ O
estimated VBN O
to TO O
provide VB O
87 CD O
% NN O
power NN O
to TO O
detect VB O
a DT O
20 CD O
% NN O
treatment NN O
effect NN O
. . O

Recruitment NN B-POPU
is VBZ I-POPU
expected VBN I-POPU
to TO I-POPU
continue VB I-POPU
until IN I-POPU
July NNP I-POPU
2006 CD I-POPU
, , O
with IN O
follow-up JJ O
through IN O
June NNP O
2010 CD O
. . O

RESULTS VB O
From IN B-POPU
August NNP I-POPU
2002 CD I-POPU
through IN I-POPU
December NNP I-POPU
2004 CD I-POPU
, , I-POPU
2234 CD I-POPU
of IN I-POPU
the DT I-POPU
target NN I-POPU
4000 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
enrolled VBN I-POPU
. . O

In IN O
accordance NN O
with IN O
trial NN O
design NN O
, , O
mean NN B-OC
( ( I-OC
SD NNP I-OC
) ) I-OC
screening VBG I-OC
tHcy NN I-OC
was VBD O
elevated VBN O
( ( O
17.4 CD O
+/- JJ O
6.2 CD O
micromol/L NN O
) ) O
, , O
and CC O
mean NN B-OC
( ( I-OC
SD NNP I-OC
) ) I-OC
estimated VBD I-OC
creatinine JJ I-OC
clearance NN I-OC
was VBD O
consistent JJ O
with IN O
stable JJ O
renal JJ O
function NN O
( ( O
58.0 CD O
+/- JJ O
18.6 CD O
mL/min NN O
) ) O
. . O

Evaluating VBG O
baseline JJ O
results NNS O
to TO O
date NN O
, , O
42 CD O
% NN O
of IN O
the DT O
randomized JJ O
participants NNS O
had VBD O
a DT O
history NN B-OC
of IN I-OC
diabetes NNS I-OC
mellitus NNS I-OC
, , O
and CC O
21 CD O
% NN O
had VBD O
prevalent JJ O
CVD NNP O
. . O

CONCLUSIONS NNP O
The DT O
FAVORIT NNP O
trial NN O
is VBZ O
designed VBN O
with IN O
sufficient JJ O
power NN O
and CC O
follow-up JJ O
time NN O
to TO O
detect VB O
a DT O
clinically RB O
relevant JJ O
change NN O
in IN O
CVD NNP O
risk NN O
between IN O
renal JJ B-POPU
transplant NN I-POPU
recipients NNS I-POPU
receiving VBG O
a DT O
high JJ O
or CC O
low JJ O
tHcy-lowering JJ O
folic JJ B-INTV
acid NN I-INTV
multivitamin NN I-INTV
. . O

Preliminary JJ O
screening NN O
and CC O
baseline NN O
data NNS O
support NN O
the DT O
trial NN O
's POS O
objectives NNS O
. . O

-DOCSTART- -X- O O

Albumin-glutaraldehyde JJ B-INTV
bioadhesive NN I-INTV
( ( I-INTV
" JJ I-INTV
Bioglue NNP I-INTV
" NNP I-INTV
) ) I-INTV
for IN O
prevention NN O
of IN O
postoperative JJ B-OC
complications NNS I-OC
after IN O
stapled VBN O
hemorrhoidopexy NN O
: : O
A DT O
randomized NN O
controlled VBN O
trial NN O
. . O

BACKGROUND NNP O
Hemorrhoidopexy NNP O
using VBG O
the DT O
circumferential JJ O
stapler NN O
is VBZ O
an DT O
established JJ O
method NN O
for IN O
surgical JJ O
treatment NN O
of IN O
patients NNS B-POPU
with IN I-POPU
prolapsing JJ I-POPU
hemorrhoids NNS I-POPU
. . O

Despite IN O
its PRP$ O
advantages NNS O
, , O
complications NNS O
such JJ O
as IN O
anal JJ O
canal JJ O
stenosis NN O
, , O
hemorrhage NN O
and CC O
anastomosis NN O
leak NN O
with IN O
eventual JJ O
intrapelvic JJ O
sepsis NN O
can MD O
cause VB O
serious JJ O
postoperative JJ O
problems NNS O
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
evaluate VB O
the DT O
utility NN O
of IN O
a DT O
surgical JJ O
adhesive NN O
, , O
the DT O
biological JJ B-INTV
albumin-glutaraldehyde JJ I-INTV
glue NN I-INTV
" NNP I-INTV
Bioglue NNP I-INTV
" NNP I-INTV
, , O
in IN O
reduction NN O
of IN O
these DT O
postoperative JJ O
complications NNS O
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Between NNP B-POPU
January NNP I-POPU
2002 CD I-POPU
and CC I-POPU
November NNP I-POPU
2004 CD I-POPU
, , I-POPU
200 CD I-POPU
patients NNS I-POPU
undergoing VBG I-POPU
stapled JJ I-POPU
hemorrhoidopexy NN I-POPU
were VBD I-POPU
enrolled VBN I-POPU
in IN O
a DT O
prospective JJ O
, , O
randomized JJ O
clinical JJ O
trial NN O
. . O

One CD B-POPU
hundred VBD I-POPU
patients NNS I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO I-POPU
the DT I-POPU
control NN I-POPU
group NN I-POPU
; : I-POPU
the DT I-POPU
study NN I-POPU
group NN I-POPU
consisted VBD I-POPU
of IN I-POPU
100 CD I-POPU
patients NNS I-POPU
who WP O
received VBD O
Bioglue NNP B-INTV
in IN I-INTV
the DT I-INTV
mucosa NN I-INTV
anastomosis NN I-INTV
area NN I-INTV
. . O

All DT O
patients NNS O
received VBD O
standardized JJ B-INTV
postoperative JJ I-INTV
analgesic NN I-INTV
, , I-INTV
laxative JJ I-INTV
and CC I-INTV
antibiotic JJ I-INTV
treatment NN I-INTV
. . O

We PRP O
then RB O
evaluated VBD O
the DT O
two CD O
groups NNS O
for IN O
postoperative JJ B-OC
complications NNS I-OC
( ( O
after IN O
surgery NN O
and CC O
6 CD O
months NNS O
postoperatively RB O
) ) O
. . O

RESULTS CC O
From IN O
the DT O
control NN O
group NN O
( ( O
no DT O
Bioglue NNP O
application NN O
) ) O
, , O
two CD O
patients NNS O
presented VBN O
with IN O
anal JJ B-OC
stenosis NN I-OC
, , O
two CD O
with IN O
hemorrhage NN B-OC
, , O
three CD O
had VBD O
anastomosis VBN B-OC
leak NN I-OC
and CC O
one CD O
had VBD O
thrombosis NN B-OC
, , O
whereas IN O
none NN O
of IN O
the DT O
patients NNS O
from IN O
the DT O
Bioglue NNP O
group NN O
had VBD O
any DT O
of IN O
these DT O
complications NNS B-OC
. . O

Both DT O
groups NNS O
had VBD O
patients NNS O
with IN O
severe JJ B-OC
postoperative JJ I-OC
pain NN I-OC
( ( O
3 CD O
each DT O
) ) O
and CC O
fecal JJ B-OC
incontinence NN I-OC
( ( O
1 CD O
patient NN O
each DT O
) ) O
. . O

The DT O
overall JJ B-OC
difference NN I-OC
in IN O
the DT O
number NN B-OC
of IN I-OC
complications NNS I-OC
in IN O
the DT O
two CD O
groups NNS O
was VBD O
statistically RB O
significant JJ O
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
. . O

CONCLUSION NN O
In IN O
this DT O
first JJ O
study NN O
using VBG O
Bioglue NNP O
in IN O
patients NNS O
undergoing VBG O
circumferential JJ O
stapled JJ O
hemorrhoidopexy NN O
we PRP O
have VBP O
shown VBN O
that IN O
application NN O
of IN O
the DT O
glue NN O
is VBZ O
effective JJ B-OC
in IN O
reducing VBG B-OC
postoperative JJ I-OC
complications NNS I-OC
. . O

-DOCSTART- -X- O O

Effectiveness NN B-OC
of IN O
written VBN O
guidelines NNS O
on IN O
the DT O
appropriateness NN O
of IN O
thromboprophylaxis JJ B-POPU
prescriptions NNS I-POPU
for IN I-POPU
medical JJ I-POPU
patients NNS I-POPU
: : I-POPU
a DT O
prospective JJ O
randomized NN O
study NN O
. . O

OBJECTIVE NNP O
To TO O
assess VB O
the DT O
effectiveness NN B-OC
of IN O
providing VBG O
doctors NNS O
with IN O
written VBN O
thromboprophylaxis JJ B-INTV
prescription NN I-INTV
aids NNS I-INTV
based VBN O
on IN O
current JJ O
recommendations NNS O
. . O

DESIGN VB O
A DT O
prospective JJ O
trial NN O
of IN O
specific JJ O
anticoagulant JJ O
prescription NN O
forms NNS O
: : O
a DT O
1-day JJ O
survey NN O
before IN O
and CC O
after IN O
the DT O
intervention NN O
in IN O
each DT O
centre NN O
. . O

SETTING CC O
30 CD B-POPU
Internal NNP I-POPU
Medicine NNP I-POPU
departments NNS I-POPU
of IN I-POPU
Assistance NNP I-POPU
Publique-Hôpitaux NNP I-POPU
de IN I-POPU
Paris NNP I-POPU
. . O

SUBJECTS NNP B-POPU
All DT I-POPU
inpatients NNS I-POPU
were VBD I-POPU
included VBN I-POPU
, , I-POPU
except IN I-POPU
those DT I-POPU
who WP I-POPU
were VBD I-POPU
either RB I-POPU
admitted VBN I-POPU
or CC I-POPU
discharged VBN I-POPU
on IN I-POPU
the DT I-POPU
day NN I-POPU
of IN I-POPU
the DT I-POPU
survey NN I-POPU
, , I-POPU
and CC I-POPU
those DT I-POPU
receiving VBG I-POPU
curative JJ I-POPU
anticoagulant JJ I-POPU
treatment NN I-POPU
. . O

INTERVENTIONS VBZ O
The DT O
study NN O
included VBD O
three CD O
parts NNS O
: : O
( ( O
i NN O
) ) O
a DT O
1-day JJ O
baseline NN O
survey NN O
; : O
( ( O
ii NN O
) ) O
over IN O
the DT O
following JJ O
3-month JJ O
period NN O
, , O
departments NNS O
were VBD O
randomized VBN O
into IN O
two CD O
groups NNS O
: : O
all DT O
practitioners NNS O
in IN O
wards NNS O
allocated VBN O
to TO O
the DT O
intervention NN O
group NN O
were VBD O
required VBN O
to TO O
systematically RB O
use VB O
specific JJ B-INTV
anticoagulant JJ I-INTV
prescription NN O
forms NNS O
, , O
whilst NN O
doctors NNS O
in IN O
the DT O
control NN O
group NN O
continued VBD O
prescribing VBG O
according VBG O
to TO O
their PRP$ B-INTV
usual JJ I-INTV
practices NNS I-INTV
and CC O
( ( O
iii NN O
) ) O
a DT O
1-day JJ O
postintervention NN O
survey NN O
. . O

MAIN NNP O
OUTCOME NNP O
MEASURE NNP B-OC
The DT I-OC
proportion NN I-OC
of IN I-OC
prescriptions NNS I-OC
in IN I-OC
accordance NN I-OC
with IN I-OC
the DT I-OC
recommendations NNS I-OC
. . O

RESULTS VB B-POPU
1,469 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
included VBN I-POPU
. . O

The DT O
intervention NN O
produced VBD O
a DT B-OC
significant JJ I-OC
reduction NN I-OC
in IN O
the DT B-OC
frequency NN I-OC
of IN I-OC
over-prescriptions NNS I-OC
, , O
from IN O
25 CD O
% NN O
to TO O
14 CD O
% NN O
of IN O
the DT O
patients NNS O
who WP O
did VBD O
not RB O
meet VB O
the DT O
guideline NN O
criteria NNS O
( ( O
adjusted VBN O
OR NNP O
: : O
0.3 CD O
; : O
95 CD O
% NN O
CI NNP O
: : O
0.1-0.8 NN O
) ) O
. . O

Using VBG B-OC
specific JJ I-OC
forms NNS I-OC
did VBD O
not RB B-OC
improve VB I-OC
under-prescription NN I-OC
of IN B-INTV
anticoagulants NNS I-INTV
. . O

A DT O
little JJ O
over IN O
60 CD O
% NN O
of IN O
the DT O
patients NNS O
who WP O
met VBD O
guideline NN O
criteria NNS O
for IN O
thromboprophylaxis NN O
were VBD B-OC
prescribed JJ B-INTV
anticoagulants NNS I-INTV
in IN O
both DT O
intervention NN O
and CC O
control NN O
wards NNS O
, , O
either RB O
at IN O
baseline NN O
or CC O
after IN O
intervention NN O
. . O

CONCLUSIONS NNP B-INTV
Multitargeted VBD I-INTV
interventions NNS I-INTV
using VBG O
a DT O
variety NN O
of IN O
means NNS O
and CC O
strategies NNS O
should MD O
still RB O
be VB O
considered VBN O
to TO B-OC
improve VB I-OC
prescriptions NNS I-OC
that WDT O
may MD O
have VB O
a DT B-OC
significant JJ I-OC
impact NN I-OC
on IN I-OC
health NN I-OC
expenses NNS I-OC
and CC O
, , O
most RBS O
importantly RB O
, , O
on IN B-OC
patients NNS I-OC
outcomes NNS I-OC
. . O

-DOCSTART- -X- O O

Thrombus NNP O
aspiration NN O
reduces NNS O
microvascular JJ B-OC
obstruction NN I-OC
after IN O
primary JJ B-POPU
coronary JJ I-POPU
intervention NN I-POPU
: : I-POPU
a DT O
myocardial JJ O
contrast NN O
echocardiography NN O
substudy NN O
of IN O
the DT O
REMEDIA NNP O
Trial NNP O
. . O

OBJECTIVES CC O
The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
clarify VB O
the DT O
role NN O
of IN O
microembolization NN O
in IN O
the DT O
genesis NN O
of IN O
microvascular JJ B-OC
obstruction NN I-OC
( ( I-OC
MO NNP I-OC
) ) I-OC
after IN O
percutaneous JJ O
coronary JJ O
intervention NN O
( ( O
PCI NNP O
) ) O
. . O

BACKGROUND NNP O
Fifty NNP B-POPU
consecutive JJ I-POPU
patients NNS I-POPU
entered VBD I-POPU
the DT I-POPU
myocardial JJ I-POPU
contrast NN I-POPU
echocardiography NN I-POPU
( ( I-POPU
MCE NNP I-POPU
) ) I-POPU
substudy NN I-POPU
of IN I-POPU
the DT I-POPU
REMEDIA NNP I-POPU
( ( I-POPU
Randomized NNP I-POPU
Evaluation NNP I-POPU
of IN I-POPU
the DT I-POPU
Effect NNP I-POPU
of IN I-POPU
Mechanical NNP I-POPU
Reduction NNP I-POPU
of IN I-POPU
Distal NNP I-POPU
Embolization NNP I-POPU
by IN I-POPU
Thrombus NNP I-POPU
Aspiration NNP I-POPU
in IN I-POPU
Primary NNP I-POPU
and CC I-POPU
Rescue NNP I-POPU
Angioplasty NNP I-POPU
) ) I-POPU
trial NN I-POPU
, , O
which WDT O
defined VBD O
the DT O
role NN O
of IN O
a DT O
new JJ O
thrombus-aspirating JJ O
device NN O
in IN O
preventing VBG O
distal JJ O
microembolization NN B-OC
after IN O
PCI NNP O
. . O

METHODS NNP O
A NNP O
total NN B-POPU
of IN I-POPU
25 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO I-POPU
be VB I-POPU
pretreated VBN I-POPU
with IN I-POPU
thrombus JJ I-POPU
aspiration NN I-POPU
before IN I-POPU
PCI NNP I-POPU
of IN I-POPU
the DT I-POPU
culprit NN I-POPU
lesion NN I-POPU
and CC I-POPU
25 CD I-POPU
received JJ I-POPU
standard JJ I-POPU
PCI NNP I-POPU
. . O

At IN O
24 CD O
h NN O
, , O
1 CD O
week NN O
, , O
and CC O
6 CD O
months NNS O
after IN O
PCI NNP O
, , O
MCE NNP O
was VBD O
performed VBN O
by IN O
Sonovue NNP O
, , O
and CC O
real-time JJ O
imaging NN O
was VBD O
performed VBN O
by IN O
contrast NN O
pulse JJ O
sequencing VBG O
technology NN O
. . O

Regional NNP B-OC
wall NN I-OC
motion NN I-OC
score NN I-OC
index NN I-OC
( ( I-OC
WMSI NNP I-OC
) ) I-OC
, , I-OC
contrast RB I-OC
score NN I-OC
index NN I-OC
( ( I-OC
CSI NNP I-OC
) ) I-OC
, , I-OC
endocardial JJ I-OC
length NN I-OC
of IN I-OC
wall NN I-OC
motion NN I-OC
abnormality NN I-OC
( ( I-OC
WML NNP I-OC
) ) I-OC
and CC I-OC
contrast NN I-OC
defect NN I-OC
( ( I-OC
CDL NNP I-OC
) ) I-OC
, , I-OC
end-diastolic JJ I-OC
and CC I-OC
end-systolic JJ I-OC
left NN I-OC
ventricular NN I-OC
( ( I-OC
LV NNP I-OC
) ) I-OC
volumes NNS I-OC
, , I-OC
and CC I-OC
ejection NN I-OC
fraction NN I-OC
were VBD O
calculated VBN O
. . O

RESULTS NNP O
At IN O
each DT O
time NN O
point NN O
, , O
in IN O
patients NNS O
treated VBN O
with IN O
a DT O
thrombus-aspiration NN O
filter NN O
device NN O
, , O
WMSI NNP B-OC
, , I-OC
CSI NNP I-OC
, , I-OC
WML NNP I-OC
, , I-OC
and CC I-OC
CDL NNP I-OC
were VBD O
significantly RB O
lower JJR O
and CC O
ejection NN B-OC
fraction NN I-OC
higher JJR O
( ( O
p JJ O
< $ O
0.05 CD O
vs. FW O
control NN O
patients NNS O
) ) O
, , O
whereas JJ O
LV NNP B-OC
volumes NNS I-OC
were VBD O
slightly RB O
but CC O
not RB O
significantly RB O
smaller JJR O
compared VBN O
with IN O
control NN O
patients NNS O
. . O

In IN O
the DT O
overall JJ O
study NN O
population NN O
, , O
the DT O
extent NN B-OC
of IN I-OC
MO NNP I-OC
significantly RB O
correlated VBD O
with IN O
temporal JJ O
changes NNS O
in IN O
LV NNP B-OC
volumes NNS I-OC
. . O

CONCLUSIONS NNP O
Thrombus NNP O
aspiration NN O
used VBN O
at IN O
the DT O
time NN O
of IN O
PCI NNP O
significantly RB O
reduces VBZ O
the DT O
extent NN B-OC
of IN I-OC
MO NNP I-OC
and CC O
myocardial JJ B-OC
dysfunction NN I-OC
, , O
although IN O
it PRP O
does VBZ O
not RB O
have VB O
a DT O
significant JJ O
favorable JJ O
effect NN O
in IN O
preventing VBG O
LV NNP B-OC
remodeling VBG I-OC
. . O

Thus RB O
, , O
the DT O
beneficial JJ O
effect NN O
of IN O
thrombus NN O
aspiration NN O
occurs VBZ O
at IN O
the DT O
microvascular JJ O
level NN O
, , O
but CC O
additional JJ O
mechanisms NN O
may MD O
play VB O
a DT O
role NN O
in IN O
influencing VBG O
the DT O
final JJ O
extent NN O
of IN O
MO NNP B-OC
, , O
which WDT O
strictly RB O
correlates VBZ O
with IN O
post-infarct JJ O
LV NNP B-OC
remodeling NN I-OC
. . O

-DOCSTART- -X- O O

Enhanced NNP O
baroreceptor NN O
control NN O
of IN O
the DT O
cardiovascular JJ O
system NN O
by IN O
polyunsaturated JJ B-INTV
Fatty NNP I-INTV
acids NNS I-INTV
in IN O
heart NN B-POPU
failure NN I-POPU
patients NNS I-POPU
. . O

OBJECTIVES IN O
The DT O
intention NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
test VB O
the DT O
hypothesis NN O
that WDT O
, , O
in IN O
heart NN B-POPU
failure NN I-POPU
patients NNS I-POPU
, , O
dietary JJ B-INTV
supplementation NN I-INTV
of IN I-INTV
polyunsaturated JJ I-INTV
fatty JJ I-INTV
acids NNS I-INTV
( ( I-INTV
PUFA NNP I-INTV
) ) I-INTV
enhances VBZ O
arterial JJ O
baroreceptor NN O
control NN O
of IN O
the DT O
cardiovascular JJ O
system NN O
. . O

BACKGROUND NNP O
Administration NNP O
of IN O
PUFA NNP B-INTV
reduces VBZ O
the DT O
risk NN O
of IN O
life-threatening JJ O
arrhythmias NNS O
in IN O
patients NNS B-POPU
surviving VBG I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
. . O

This DT O
might MD O
result VB O
from IN O
potentiation NN O
of IN O
arterial JJ O
baroreflexes NNS O
, , O
but CC O
whether IN O
or CC O
not RB O
PUFA NNP B-INTV
enhance NN O
baroreflex NN O
function NN O
has VBZ O
never RB O
been VBN O
studied VBN O
in IN O
humans NNS B-POPU
. . O

METHODS NNP O
Patients NNPS B-POPU
with IN I-POPU
post-myocardial JJ I-POPU
infarction NN I-POPU
left VBD I-POPU
ventricular JJ I-POPU
dysfunction NN I-POPU
underwent JJ O
beat-to-beat JJ O
blood NN O
pressure NN O
( ( O
BP NNP O
) ) O
( ( O
Finapres NNP O
, , O
Ohmeda NNP O
Inc. NNP O
, , O
Englewood NNP O
, , O
Colorado NNP O
) ) O
and CC O
R-R JJ O
interval NN O
( ( O
electrocardiogram NN O
) ) O
recording NN O
; : O
baroreceptor NN O
reflexes NNS O
were VBD O
assessed VBN O
from IN O
the DT O
bradycardic NN O
and CC O
depressor NN O
responses NNS O
to TO O
graded VB O
neck NN O
suction NN O
( ( O
NS NNP O
) ) O
as RB O
well RB O
as IN O
by IN O
computation NN O
of IN O
the DT O
alpha NN O
" NNP O
spontaneous JJ O
" NNP O
baroreflex NN O
sensitivity NN O
index NN O
. . O

Assessments NNS O
were VBD O
repeated VBN O
after IN O
prolonged JJ O
treatment NN O
with IN O
PUFA NNP B-INTV
( ( O
2 CD O
g/die NN O
, , O
n JJ O
= NNP O
15 CD O
) ) O
or CC O
placebo NN B-INTV
( ( O
n JJ O
= NNP O
10 CD O
) ) O
. . O

RESULTS NNP O
Baseline NNP B-OC
BP NNP I-OC
and CC I-OC
R-R NNP I-OC
interval NN I-OC
were VBD O
unaffected VBN O
by IN O
PUFA NNP B-INTV
. . O

Both DT O
reflex JJ B-OC
depressor NN I-OC
and CC I-OC
bradycardic JJ I-OC
responses NNS I-OC
to TO I-OC
NS NNP I-OC
increased VBN O
after IN O
PUFA NNP B-INTV
( ( O
respectively RB O
from IN O
-0.09 JJ O
+/- JJ O
0.01 CD O
to TO O
-0.16 VB O
+/- JJ O
0.01 CD O
mm NN O
Hg NNP O
x NNP O
mm NN O
Hg NNP O
( ( O
-1 NNP O
) ) O
, , O
p JJ O
< NN O
0.01 CD O
, , O
and CC O
from IN O
1.25 CD O
+/- JJ O
0.9 CD O
to TO O
1.76 CD O
+/- JJ O
1.1 CD O
ms NN O
x NNP O
mm NN O
Hg NNP O
( ( O
-1 NNP O
) ) O
, , O
p JJ O
< NNP O
0.04 CD O
) ) O
but CC O
not RB O
after IN O
placebo NN B-INTV
. . O

The DT O
spontaneous JJ B-OC
baroreflex JJ I-OC
sensitivity NN I-OC
increased VBN O
in IN O
the DT O
PUFA NNP B-INTV
( ( O
from IN O
8.99 CD O
+/- JJ O
1.4 CD O
to TO O
12.2 CD O
+/- JJ O
1.2 CD O
ms NN O
x NNP O
mm NN O
Hg NNP O
( ( O
-1 NNP O
) ) O
, , O
p JJ O
< NNP O
0.02 CD O
) ) O
but CC O
not RB O
in IN O
the DT O
placebo NN B-INTV
group NN O
. . O

Polyunsaturated VBN B-INTV
fatty JJ I-INTV
acids NNS I-INTV
( ( O
but CC O
not RB O
placebo VB B-INTV
) ) I-INTV
treatment NN O
also RB O
significantly RB O
increased VBD O
R-R NNP B-OC
interval JJ I-OC
total JJ I-OC
variance NN I-OC
and CC O
low-frequency NN O
and CC O
high-frequency NN O
spectral JJ O
powers NNS O
. . O

CONCLUSIONS NNP O
Dietary NNP B-INTV
PUFA NNP I-INTV
supplementation NN I-INTV
markedly RB O
potentiates VBZ O
baroreflex JJ O
function NN O
and CC O
enhances NNS O
heart NN B-OC
rate NN I-OC
variability NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
stable JJ I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

-DOCSTART- -X- O O

[ IN O
The DT O
effects NNS O
of IN O
mexicor NN B-INTV
on IN O
thrombocyte JJ B-OC
aggregation NN I-OC
, , I-OC
blood NN I-OC
viscosity NN I-OC
, , I-OC
hemodynamics NNS I-OC
, , O
and CC O
the DT O
clinical JJ O
course NN O
of IN O
coronary JJ B-POPU
artery NN I-POPU
disease NN I-POPU
] NNP I-POPU
. . O

The DT O
authors NNS O
analyze VBP O
their PRP$ O
experience NN O
in IN O
the DT O
application NN O
of IN O
mexicor NN B-INTV
, , I-INTV
a DT I-INTV
Russian JJ I-INTV
cytoprotector NN I-INTV
, , O
in IN O
50patients CD B-POPU
with IN I-POPU
chronic JJ I-POPU
coronary JJ I-POPU
artery NN I-POPU
disease NN I-POPU
( ( I-POPU
CAD NNP I-POPU
) ) I-POPU
and CC I-POPU
51 CD I-POPU
patients NNS I-POPU
with IN I-POPU
acute JJ I-POPU
coronary JJ I-POPU
syndrome NN I-POPU
. . O

In IN O
additional JJ O
to TO O
cytoprotective JJ O
action NN O
, , O
the DT O
use NN O
of IN O
mexidor NN B-INTV
in IN O
complex JJ O
therapy NN O
of IN O
CAD NNP O
lowers VBZ O
the DT O
functional JJ B-OC
activity NN I-OC
of IN I-OC
thrombocytes NNS I-OC
, , O
eliminates VBZ O
high JJ B-OC
blood NN I-OC
viscosity NN I-OC
syndrome NN I-OC
, , O
and CC O
lowers NNS O
low JJ B-OC
density NN I-OC
lipoprotein NN I-OC
cholesterol NN I-OC
level NN I-OC
. . O

These DT O
favorable JJ O
changes NNS O
in IN O
hemorheological JJ O
parameters NNS O
improves VBZ O
myocardial JJ B-OC
perfusion NN I-OC
, , O
lowers VBZ O
the DT O
strength NN B-OC
and CC I-OC
frequency NN I-OC
of IN I-OC
coronary JJ I-OC
pain NN I-OC
attacks NNS I-OC
, , O
retards NNS O
postinfarction NN B-OC
left VBD I-OC
ventricular JJ I-OC
remodeling NN I-OC
, , O
and CC O
increases VBZ O
the DT O
quality NN B-OC
of IN I-OC
life NN I-OC
of IN I-OC
patients NNS B-POPU
with IN I-POPU
various JJ I-POPU
CAD NNP I-POPU
forms NNS I-POPU
. . O

-DOCSTART- -X- O O

Role NNP O
of IN O
diltiazem NN B-INTV
in IN O
the DT O
treatment NN O
of IN O
silent JJ O
myocardial JJ O
ischemia NN O
. . O

Silent JJ O
myocardial JJ O
ischemia NN O
is VBZ O
a DT O
frequent JJ O
finding NN O
when WRB O
Holter NNP O
monitoring NN O
is VBZ O
done VBN O
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
coronary JJ I-POPU
disease NN I-POPU
. . O

Silent JJ O
ischemia NN O
is VBZ O
associated VBN O
with IN O
a DT O
worse JJR O
prognosis NN O
in IN O
patients NNS O
with IN O
stable JJ O
or CC O
unstable JJ O
angina NN O
, , O
survivors NNS O
of IN O
myocardial JJ O
infarction NN O
, , O
and CC O
populations NNS O
at IN O
risk NN O
for IN O
coronary JJ O
disease NN O
. . O

Whether NNP O
medical JJ O
therapy NN O
for IN O
silent JJ O
ischemia NN O
improves VBZ O
prognosis NN O
is VBZ O
not RB O
known VBN O
. . O

In IN O
a DT O
randomized JJ O
, , O
placebo-controlled JJ B-INTV
, , O
multicenter JJ O
trial NN O
of IN O
60 CD B-POPU
patients NNS I-POPU
with IN I-POPU
documented JJ I-POPU
coronary JJ I-POPU
disease NN I-POPU
, , I-POPU
positive JJ I-POPU
exercise NN I-POPU
tests NNS I-POPU
, , I-POPU
and CC I-POPU
ischemic JJ I-POPU
episodes NNS I-POPU
on IN I-POPU
Holter NNP I-POPU
monitoring NN I-POPU
, , O
long-acting JJ O
diltiazem NN B-INTV
reduced VBD O
ischemic JJ B-OC
episodes NNS I-OC
by IN O
50 CD O
% NN O
compared VBN O
to TO O
placebo VB B-INTV
, , O
from IN O
a DT O
mean NN O
of IN O
5.6 CD O
to TO O
2.8 CD O
( ( O
p NN O
less JJR O
than IN O
0.0001 CD O
) ) O
. . O

Efficacy NN B-OC
was VBD O
maintained VBN O
over IN O
24 CD O
h NNS O
and CC O
diltiazem NN B-INTV
also RB O
significantly RB O
improved VBN O
exercise NN B-OC
test NN I-OC
parameters NNS I-OC
. . O

Three CD O
smaller JJR O
studies NNS O
also RB O
demonstrated VBD O
that IN O
diltiazem NN B-INTV
effectively RB O
reduces VBZ O
ambulatory JJ B-OC
ischemia NN I-OC
; : I-OC
however RB O
, , O
results NNS O
with IN O
nifedipine JJ O
are VBP O
conflicting VBG O
, , O
with IN O
several JJ O
studies NNS O
showing VBG O
no DT O
benefit NN O
. . O

In IN O
contrast NN O
, , O
beta-blockers NNS O
reliably RB O
reduce VB O
ischemic JJ B-OC
episodes NNS I-OC
. . O

The DT O
role NN O
of IN O
medical JJ O
therapy NN O
for IN O
silent JJ O
ischemia NN O
will MD O
be VB O
clarified VBN O
only RB O
when WRB O
its PRP$ O
effect NN O
upon IN O
morbidity NN O
and CC O
mortality NN O
are VBP O
determined VBN O
. . O

-DOCSTART- -X- O O

The DT O
NORwegian JJ O
study NN O
on IN O
DIstrict NNP O
treatment NN O
of IN O
ST-elevation NNP B-POPU
myocardial JJ I-POPU
infarction NN I-POPU
( ( O
NORDISTEMI NNP O
) ) O
. . O

OBJECTIVES NNP O
Thrombolysis NNP O
is VBZ O
the DT O
treatment NN O
of IN O
choice NN O
for IN O
patients NNS B-POPU
with IN I-POPU
ST-elevation NNP I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
( ( I-POPU
STEMI NNP I-POPU
) ) I-POPU
living NN I-POPU
in IN I-POPU
rural JJ I-POPU
areas NNS I-POPU
with IN I-POPU
long JJ I-POPU
transfer NN I-POPU
delays NNS I-POPU
to TO I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
( ( I-POPU
PCI NNP I-POPU
) ) I-POPU
. . O

This DT O
trial NN O
compares VBZ O
two CD O
different JJ O
strategies NNS O
following VBG O
thrombolysis NN O
: : O
to TO O
transfer VB O
all DT O
patients NNS O
for IN O
immediate JJ O
coronary JJ O
angiography NN O
and CC O
intervention NN O
, , O
or CC O
to TO O
manage VB O
the DT O
patients NNS O
more RBR O
conservatively RB O
. . O

DESIGN VB O
The DT B-POPU
NORwegian JJ I-POPU
study NN I-POPU
on IN I-POPU
DIstrict NNP I-POPU
treatment NN I-POPU
of IN I-POPU
STEMI NNP I-POPU
( ( I-POPU
NORDISTEMI NNP I-POPU
) ) I-POPU
is VBZ O
an DT O
open JJ O
, , O
prospective JJ O
, , O
randomized VBD B-INTV
controlled VBN I-INTV
trial NN I-INTV
in IN I-INTV
patients NNS B-POPU
with IN I-POPU
STEMI NNP I-POPU
of IN I-POPU
less JJR I-POPU
than IN I-POPU
6 CD I-POPU
hours NNS I-POPU
of IN I-POPU
duration NN I-POPU
and CC I-POPU
more JJR I-POPU
than IN I-POPU
90 CD I-POPU
minutes NNS I-POPU
expected VBD I-POPU
time NN I-POPU
delay NN I-POPU
to TO I-POPU
PCI NNP I-POPU
. . O

A NNP B-POPU
total NN I-POPU
of IN I-POPU
266 CD I-POPU
patients NNS I-POPU
will MD O
receive VB B-INTV
full-dose JJ I-INTV
thrombolysis NN I-INTV
, , I-INTV
preferably RB I-INTV
pre-hospital JJ I-INTV
, , I-INTV
and CC I-INTV
then RB I-INTV
be VB I-INTV
randomized VBN I-INTV
to TO I-INTV
either DT I-INTV
strategy NN I-INTV
. . O

Our PRP$ O
primary JJ O
endpoint NN O
is VBZ O
the DT O
one CD O
year NN O
combined VBN B-OC
incidence NN I-OC
of IN I-OC
death NN I-OC
, , I-OC
reinfarction NN I-OC
, , I-OC
stroke VBD I-OC
or CC I-OC
new JJ I-OC
myocardial JJ I-OC
ischaemia NN I-OC
. . O

The DT O
study NN O
is VBZ O
registered VBN O
with IN O
ClinicalTrials.gov NNP O
, , O
number NN O
NCT00161005 NNP O
. . O

RESULTS VBN O
By IN O
April NNP B-POPU
2006 CD I-POPU
, , I-POPU
109 CD I-POPU
patients NNS I-POPU
have VBP O
been VBN O
randomized VBN O
. . O

Thrombolysis NN O
has VBZ O
been VBN O
given VBN O
pre-hospital JJ O
to TO O
52 CD O
% NN O
of IN O
patients NNS O
. . O

The DT O
median JJ O
transport NN O
distance NN O
from IN O
first JJ O
medical JJ O
contact NN O
to TO O
catheterization NN O
laboratory NN O
was VBD O
155 CD O
km NN O
( ( O
range JJ O
90-396 CD O
km NN O
) ) O
. . O

Results NNS O
of IN O
the DT O
study NN O
are VBP O
expected VBN O
in IN O
2008 CD O
. . O

-DOCSTART- -X- O O

Enhanced NNP O
inotropic NN O
state NN O
of IN O
the DT O
failing NN O
left VBD O
ventricle NN O
by IN O
cardiac JJ B-INTV
contractility NN I-INTV
modulation NN I-INTV
electrical JJ I-INTV
signals NNS I-INTV
is VBZ O
not RB O
associated VBN O
with IN O
increased JJ O
myocardial JJ B-OC
oxygen NN I-OC
consumption NN I-OC
. . O

BACKGROUND NNP O
Previous NNP O
studies NNS O
in IN O
patients NNS B-POPU
and CC I-POPU
in IN I-POPU
dogs NNS I-POPU
with IN I-POPU
experimentally RB I-POPU
induced JJ I-POPU
heart NN I-POPU
failure NN I-POPU
( ( I-POPU
HF NNP I-POPU
) ) I-POPU
showed VBD O
that IN O
electrical JJ B-INTV
signals NNS I-INTV
applied VBN O
to TO O
the DT O
failing VBG O
myocardium NN O
during IN O
the DT O
absolute JJ O
refractory NN O
period NN O
improved VBD O
left JJ B-OC
ventricular NN I-OC
( ( I-OC
LV NNP I-OC
) ) I-OC
function NN I-OC
. . O

We PRP O
examined VBD O
the DT O
effects NNS O
these DT O
same JJ O
cardiac NN B-INTV
contractility NN I-INTV
modulating NN I-INTV
( ( I-INTV
CCM NNP I-INTV
) ) I-INTV
electrical JJ I-INTV
signals NNS I-INTV
on IN O
myocardial JJ B-OC
oxygen NN I-OC
consumption NN I-OC
( ( I-OC
MVO NNP I-OC
( ( I-OC
2 CD I-OC
) ) I-OC
) ) I-OC
in IN O
both DT B-POPU
patients NNS I-POPU
and CC I-POPU
dogs NNS I-POPU
with IN I-POPU
chronic JJ I-POPU
HF NNP I-POPU
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
Six NNP B-POPU
dogs NNS I-POPU
with IN I-POPU
microembolizations-induced JJ I-POPU
HF NNP I-POPU
and CC I-POPU
9 CD I-POPU
HF NNP I-POPU
patients NNS I-POPU
underwent JJ I-POPU
CCM NNP I-POPU
leads NNS I-POPU
and CC I-POPU
generator NN I-POPU
( ( I-POPU
OPTIMIZER NNP I-POPU
II NNP I-POPU
) ) I-POPU
implantation NN I-POPU
. . O

After IN O
baseline NN O
measurements NNS O
, , O
CCM NNP B-INTV
signals NNS I-INTV
were VBD O
delivered VBN O
continuously RB O
for IN O
2 CD O
hours NNS O
in IN O
dogs NNS O
and CC O
for IN O
30 CD O
minutes NNS O
in IN O
patients NNS O
. . O

MVO NNP B-OC
( ( I-OC
2 CD I-OC
) ) I-OC
was VBD O
measured VBN O
before IN O
and CC O
after IN O
CCM NNP B-INTV
therapy NN I-INTV
. . O

In IN O
dogs NNS O
, , O
CCM NNP B-INTV
therapy NN I-INTV
increased VBD O
LV NNP B-OC
ejection NN I-OC
fraction NN I-OC
at IN O
2 CD O
hours NNS O
( ( O
26 CD O
+/- JJ O
1 CD O
versus NN O
31 CD O
+/- JJ O
2 CD O
% NN O
, , O
P NNP O
= NNP O
.001 NNP O
) ) O
without IN O
increasing VBG O
MVO NNP B-OC
( ( I-OC
2 CD I-OC
) ) I-OC
( ( O
257 CD O
+/- JJ O
41 CD O
versus NN O
180 CD O
+/- JJ O
34 CD O
micromol/min NN O
) ) O
. . O

In IN O
patients NNS O
, , O
CCM NNP B-INTV
therapy NN I-INTV
increased VBD O
LV NNP B-OC
peak NN I-OC
+dP/dt NN I-OC
by IN O
10.1 CD O
+/- JJ O
1.5 CD O
% NN O
. . O

As IN O
with IN O
dogs NNS O
, , O
the DT O
increase NN O
in IN O
LV NNP B-OC
function NN I-OC
after IN O
30 CD O
minutes NNS O
of IN O
CCM NNP B-INTV
therapy NN I-INTV
was VBD O
not RB O
associated VBN O
with IN O
increased VBN O
MVO NNP B-OC
( ( I-OC
2 CD I-OC
) ) I-OC
( ( O
13.6 CD O
+/- JJ O
9.7 CD O
versus NN O
12.5 CD O
+/- JJ O
7.2 CD O
mL NN O
O NNP O
( ( O
2 CD O
) ) O
/min NN O
) ) O
. . O

CONCLUSIONS VB O
The DT O
study NN O
results NNS O
suggest VBP O
that IN O
unlike IN O
cAMP-dependent JJ O
positive JJ O
inotropic NN O
drugs NNS O
, , O
the DT O
increase NN O
in IN O
LV NNP B-OC
function NN I-OC
during IN O
CCM NNP B-INTV
therapy NN I-INTV
is VBZ O
elicited VBN O
without IN O
increasing VBG O
MVO NNP B-OC
( ( I-OC
2 CD I-OC
) ) I-OC
. . O

-DOCSTART- -X- O O

Clinical JJ O
evaluation NN O
of IN O
imidapril NN B-INTV
in IN O
congestive JJ B-POPU
heart NN I-POPU
failure NN I-POPU
in IN I-POPU
dogs NNS I-POPU
: : I-POPU
results NNS O
of IN O
the DT O
EFFIC NNP O
study NN O
. . O

OBJECTIVES CC O
The DT O
clinical JJ O
efficacy NN B-OC
and CC I-OC
safety NN I-OC
of IN O
imidapril NN B-INTV
were VBD O
evaluated VBN O
in IN O
dogs NNS B-POPU
that WDT I-POPU
presented VBD I-POPU
with IN I-POPU
mild NN I-POPU
to TO I-POPU
severe VB I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
( ( I-POPU
New NNP I-POPU
York NNP I-POPU
Heart NNP I-POPU
Association NNP I-POPU
stage NN I-POPU
II NNP I-POPU
to TO I-POPU
IV NNP I-POPU
) ) I-POPU
by IN O
comparing VBG O
the DT O
success NN O
rate NN O
of IN O
imidapril NN B-INTV
with IN O
a DT O
positive JJ O
control NN O
by IN O
a DT O
non-inferiority JJ O
approach NN O
. . O

METHODS NNP O
This DT O
good JJ O
, , O
clinical JJ O
practice NN O
compliant NN O
, , O
multicentre NN O
study NN O
( ( O
EFFIC NNP O
study NN O
) ) O
enrolled VBD B-POPU
142 CD I-POPU
client-owned JJ I-POPU
dogs NNS I-POPU
and CC I-POPU
was VBD I-POPU
conducted VBN I-POPU
in IN I-POPU
20 CD I-POPU
locations NNS I-POPU
in IN I-POPU
France NNP I-POPU
, , I-POPU
Belgium NNP I-POPU
and CC I-POPU
Germany NNP I-POPU
. . O

Dogs NNP B-POPU
of IN I-POPU
various JJ I-POPU
breed NN I-POPU
, , I-POPU
age NN I-POPU
and CC I-POPU
weight NN I-POPU
were VBD I-POPU
included VBN I-POPU
in IN I-POPU
the DT I-POPU
study NN I-POPU
. . O

These DT O
dogs NNS O
were VBD O
randomised VBN O
into IN O
two CD O
groups NNS O
that WDT O
were VBD O
treated VBN O
for IN O
84 CD O
days NNS O
with IN O
either DT O
the DT O
test NN O
product NN O
, , O
imidapril NN B-INTV
, , O
or CC O
the DT O
positive JJ O
control NN O
, , O
benazepril NN B-INTV
, , O
and CC O
followed VBD O
up RP O
in IN O
parallel NN O
over IN O
this DT O
period NN O
. . O

Both DT O
treatments NNS O
were VBD O
administered VBN O
at IN O
a DT O
dose NN O
of IN O
0.25 CD O
mg/kg NN O
once RB O
a DT O
day NN O
with IN O
the DT O
possibility NN O
of IN O
doubling VBG O
this DT O
dose NN O
to TO O
0.5 CD O
mg/kg NN O
if IN O
considered VBN O
necessary JJ O
from IN O
a DT O
clinical JJ O
point NN O
of IN O
view NN O
. . O

In IN O
addition NN O
, , O
concomitant JJ O
treatment NN O
was VBD O
given VBN O
to TO O
dogs NNS B-POPU
presenting VBG O
with IN O
pulmonary JJ O
oedema NN O
and/or NN O
ascites NNS O
, , O
supraventricular JJ O
tachyarrhythmia NN O
and/or NN O
dilated VBD O
cardiomyopathy NN O
. . O

The DT O
evolution NN B-OC
of IN I-OC
the DT I-OC
New NNP I-OC
York NNP I-OC
Heart NNP I-OC
Association NNP I-OC
stage NN I-OC
and CC O
the DT O
" NNP B-OC
functional JJ I-OC
signs NNS I-OC
" IN I-OC
score NN I-OC
were VBD O
evaluated VBN O
as IN O
primary JJ O
efficacy NN O
criteria NNS O
. . O

RESULTS VB O
The DT O
success NN B-OC
rate NN I-OC
in IN O
the DT O
imidapril NN B-INTV
group NN O
was VBD O
66 CD O
compared VBN O
with IN O
68 CD O
per IN O
cent NN O
in IN O
the DT O
benazepril NN B-INTV
group NN O
. . O

Regarding VBG O
safety NN O
, , O
35 CD O
dogs NNS O
in IN O
each DT O
group NN O
experienced VBD O
at IN O
least JJS O
one CD O
adverse JJ B-OC
event NN I-OC
. . O

Nine NNP O
dogs NNS O
in IN O
each DT O
group NN O
experienced VBD O
at IN O
least JJS O
one CD O
serious JJ B-OC
adverse JJ I-OC
event NN O
. . O

The DT O
difference NN O
between IN O
these DT O
results NNS O
was VBD O
not RB O
statistically RB O
significant JJ O
. . O

CLINICAL JJ O
SIGNIFICANCE NNP O
Imidapril NNP B-INTV
is VBZ O
as RB O
efficacious JJ B-OC
and CC I-OC
safe JJ I-OC
as IN O
the DT O
reference NN O
product NN O
, , O
benazepril NN B-INTV
. . O

-DOCSTART- -X- O O

Using VBG O
the DT O
demand-control JJ B-INTV
model NN I-INTV
of IN I-INTV
job NN I-INTV
strain NN I-INTV
to TO O
predict VB O
caregiver NN B-OC
burden NN I-OC
and CC O
caregiver JJ B-OC
satisfaction NN I-OC
in IN O
the DT O
informal JJ B-POPU
caregivers NNS I-POPU
of IN I-POPU
heart NN I-POPU
failure NN I-POPU
patients NNS I-POPU
. . O

OBJECTIVES IN O
The DT B-INTV
demand-control NN I-INTV
( ( I-INTV
D-C NNP I-INTV
) ) I-INTV
model NN I-INTV
of IN I-INTV
job NN I-INTV
strain NN I-INTV
has VBZ O
generated VBN O
a DT O
considerable JJ O
body NN O
of IN O
empirical JJ O
support NN O
in IN O
predicting VBG O
psychological JJ O
health NN O
outcomes NNS O
in IN O
the DT O
context NN O
of IN O
work NN O
. . O

This DT O
study NN O
aimed VBD O
to TO O
extend VB O
previous JJ O
work NN O
using VBG O
the DT O
D-C NNP B-INTV
model NN I-INTV
of IN I-INTV
job NN I-INTV
strain NN I-INTV
to TO O
predict VB O
caregiver NN B-OC
burden NN I-OC
and CC O
satisfaction NN B-OC
in IN O
the DT O
informal JJ B-POPU
caregivers NNS I-POPU
of IN I-POPU
patients NNS I-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

DESIGN NNP O
AND CC O
METHOD NNP O
Data NNP O
were VBD O
gathered VBN O
from IN O
60 CD B-POPU
caregiver/patient NN I-POPU
dyads NNS I-POPU
in IN I-POPU
a DT I-POPU
cross-sectional JJ I-POPU
design NN I-POPU
. . O

Patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
stable JJ I-POPU
heart NN I-POPU
failure NN I-POPU
were VBD I-POPU
recruited VBN I-POPU
from IN I-POPU
out-patient JJ I-POPU
clinics NNS I-POPU
. . O

The DT O
dependent JJ O
variables NNS O
were VBD O
caregiver JJ B-INTV
burden NN I-INTV
and CC I-INTV
satisfaction NN I-INTV
. . O

Demand NNP B-OC
and CC I-OC
control VB I-OC
were VBD O
measured VBN O
using VBG O
both DT O
patient- JJ B-OC
and CC I-OC
caregiver-derived JJ I-OC
measures NNS I-OC
. . O

RESULTS VB O
The DT O
D-C NNP B-INTV
model NN I-INTV
accounted VBD O
for IN O
15 CD O
and CC O
19 CD O
% NN O
of IN O
the DT O
variance NN O
in IN O
caregiver NN B-OC
burden NN I-OC
, , O
after IN O
controlling VBG O
for IN O
age NN O
, , O
gender NN O
and CC O
relationship NN O
to TO O
the DT O
patient NN O
. . O

Lower JJR O
control NN B-OC
was VBD O
associated VBN O
with IN O
higher JJR B-OC
burden NN I-OC
. . O

The DT O
D-C JJ B-INTV
model NN I-INTV
did VBD O
not RB O
predict VB O
caregiver NN B-OC
satisfaction NN I-OC
. . O

CONCLUSION VB O
The DT O
D-C NNP B-INTV
model NN I-INTV
was VBD O
associated VBN O
with IN O
caregiver NN B-OC
burden NN I-OC
, , O
but CC O
not RB O
satisfaction NN B-OC
in IN O
caregivers NNS O
, , O
with IN O
control NN O
being VBG O
the DT O
dominant JJ O
predictor NN O
. . O

Research NNP O
linking VBG O
the DT O
theory NN O
and CC O
findings NNS O
from IN O
job NN O
strain NN O
and CC O
informal JJ O
caregiving VBG O
studies NNS O
may MD O
elucidate VB O
both DT O
fields NNS O
of IN O
research NN O
. . O

Using VBG O
the DT O
demand-control JJ B-INTV
model NN I-INTV
of IN I-INTV
job NN I-INTV
strain NN I-INTV
to TO O
predict VB O
caregiver NN B-OC
burden NN I-OC
and CC O
caregiver JJ B-OC
satisfaction NN I-OC
in IN O
the DT O
informal JJ B-POPU
caregivers NNS I-POPU
of IN I-POPU
heart NN I-POPU
failure NN I-POPU
patients NNS I-POPU
. . O

-DOCSTART- -X- O O

Clinical JJ O
application NN B-INTV
of IN I-INTV
C-reactive JJ I-INTV
protein NN I-INTV
across IN O
the DT B-POPU
spectrum NN I-POPU
of IN I-POPU
acute JJ I-POPU
coronary JJ I-POPU
syndromes NNS I-POPU
. . O

BACKGROUND NNP O
High-sensitivity NNP B-INTV
C-reactive JJ I-INTV
protein NN I-INTV
( ( I-INTV
hsCRP NN I-INTV
) ) I-INTV
is VBZ O
associated VBN O
with IN O
adverse JJ O
cardiovascular JJ O
outcomes NNS O
in IN O
acute JJ B-POPU
coronary JJ I-POPU
syndromes NNS I-POPU
( ( I-POPU
ACS NNP I-POPU
) ) I-POPU
. . O

The DT O
ability NN O
to TO O
formulate VB O
recommendations NNS O
regarding VBG O
clinical JJ O
use NN O
of IN O
hsCRP NN B-INTV
is VBZ O
limited VBN O
by IN O
a DT O
paucity NN O
of IN O
data NNS O
regarding VBG O
several JJ O
key JJ O
issues NNS O
. . O

The DT O
purpose NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
evaluate VB O
hsCRP NN B-INTV
across IN O
the DT O
spectrum NN O
of IN O
ACS NNP O
. . O

METHODS NNP O
hsCRP NN B-INTV
was VBD O
measured VBN O
on IN O
admission NN O
in IN O
3225 CD B-POPU
patients NNS I-POPU
with IN I-POPU
ACS NNP I-POPU
. . O

hsCRP NN B-OC
concentrations NNS I-OC
were VBD O
compared VBN O
in IN O
patients NNS O
who WP O
suffered VBD O
an DT O
adverse JJ O
cardiac NN O
outcome NN O
within IN O
10 CD O
months NNS O
of IN O
study NN O
entry NN O
and CC O
in IN O
patients NNS O
who WP O
had VBD O
no DT O
adverse JJ O
event NN O
. . O

Because IN O
of IN O
heterogeneity NN O
in IN O
the DT O
relationship NN O
between IN O
hsCRP NN B-INTV
and CC O
clinical JJ O
outcomes NNS O
, , O
evaluation NN O
was VBD O
limited VBN O
to TO O
patients NNS O
from IN O
whom WP O
samples NNS O
were VBD O
collected VBN O
within IN O
48 CD O
h NN O
of IN O
symptom JJ O
onset NN O
. . O

RESULTS JJ O
Patients NNPS O
in IN O
the DT O
highest JJS O
quartile NN O
of IN O
hsCRP NN B-INTV
compared VBN O
to TO O
those DT O
in IN O
the DT O
lowest JJS O
quartile NN O
were VBD O
at IN O
increased VBN O
risk NN B-OC
of IN I-OC
death NN I-OC
at IN O
30 CD O
days NNS O
[ RB O
adjusted VBN O
hazard NN O
ratio NN O
( ( O
adjHR NN O
) ) O
4.6 CD O
, , O
P NNP O
< VBZ O
0.001 CD O
] NN O
and CC O
10 CD O
months NNS O
( ( O
adjHR JJ O
3.9 CD O
, , O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

In IN O
patients NNS O
with IN O
unstable JJ O
angina/non-ST-elevation JJ O
myocardial JJ O
infarction NN O
( ( O
STEMI NNP O
) ) O
, , O
hsCRP JJ B-INTV
> FW O
3 CD O
mg/L NN O
was VBD O
associated VBN O
with IN O
increased JJ B-OC
10-month JJ I-OC
mortality NN I-OC
( ( O
adjHR JJ O
2.3 CD O
, , O
P NNP O
= NNP O
0.002 CD O
) ) O
, , O
whereas RB O
in IN O
STEMI NNP O
a DT O
relationship NN O
with IN O
mortality NN O
was VBD O
seen VBN O
at IN O
hsCRP JJ O
> $ O
10 CD O
mg/L NN O
( ( O
adjHR JJ O
3.0 CD O
, , O
P NNP O
= NNP O
0.008 CD O
) ) O
. . O

Increased VBN O
concentrations NNS O
of IN O
hsCRP NN B-INTV
were VBD O
strongly RB O
associated VBN O
with IN O
the DT O
development NN O
of IN O
heart NN B-OC
failure NN I-OC
at IN O
30 CD O
days NNS O
( ( O
adjHR JJ O
8.2 CD O
, , O
P NNP O
= NNP O
0.001 CD O
) ) O
and CC O
10 CD O
months NNS O
( ( O
adjHR JJ O
2.6 CD O
, , O
P NNP O
= NNP O
0.014 CD O
) ) O
. . O

CONCLUSION NNP O
Increased VBD O
baseline JJ B-OC
concentrations NNS I-OC
of IN I-OC
hsCRP NN B-INTV
are VBP O
strongly RB O
associated VBN O
with IN O
mortality NN B-OC
and CC I-OC
heart NN I-OC
failure NN I-OC
across IN O
the DT O
ACS NNP O
spectrum NN O
. . O

hsCRP JJ B-INTV
measurement NN O
should MD O
be VB O
performed VBN O
early RB O
after IN O
presentation NN O
and CC O
index NN O
diagnosis-specific JJ O
cutpoints NNS O
should MD O
be VB O
used VBN O
. . O

-DOCSTART- -X- O O

Fondaparinux NNP B-INTV
combined VBD I-INTV
with IN I-INTV
intermittent JJ I-INTV
pneumatic JJ I-INTV
compression NN I-INTV
vs. FW O
intermittent JJ B-INTV
pneumatic JJ I-INTV
compression NN I-INTV
alone RB I-INTV
for IN O
prevention NN O
of IN O
venous JJ B-POPU
thromboembolism NN I-POPU
after IN I-POPU
abdominal JJ I-POPU
surgery NN I-POPU
: : I-POPU
a DT O
randomized JJ O
, , O
double-blind JJ O
comparison NN O
. . O

BACKGROUND VB O
The DT O
benefit NN O
of IN O
combined JJ O
mechanical JJ O
and CC O
pharmacologic JJ O
methods NNS O
for IN O
venous JJ B-POPU
thromboembolism NN I-POPU
prevention NN O
after IN B-POPU
abdominal JJ I-POPU
surgery NN I-POPU
has VBZ O
not RB O
been VBN O
clearly RB O
established VBN O
. . O

OBJECTIVES NNP O
To TO O
compare VB O
the DT O
efficacy NN B-OC
and CC O
safety NN B-OC
of IN O
fondaparinux NN B-INTV
in IN I-INTV
conjunction NN I-INTV
with IN I-INTV
intermittent JJ I-INTV
pneumatic JJ I-INTV
compression NN I-INTV
vs. FW O
intermittent JJ B-INTV
pneumatic JJ I-INTV
compression NN I-INTV
alone RB I-INTV
in IN O
this DT O
context NN O
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
This DT O
was VBD O
a DT O
randomized JJ O
, , O
double-blind JJ O
, , O
placebo-controlled JJ B-INTV
superiority NN O
trial NN O
. . O

Patients NNS B-POPU
aged VBN I-POPU
at IN I-POPU
least JJS I-POPU
40 CD I-POPU
years NNS I-POPU
undergoing JJ I-POPU
abdominal JJ I-POPU
surgery NN I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
either DT O
fondaparinux JJ B-INTV
2.5 CD O
mg NN O
or CC O
placebo NN B-INTV
s.c. NN O
for IN O
5-9 JJ O
days NNS O
, , O
starting VBG O
6-8 JJ O
h NN O
postoperatively RB O
. . O

All DT O
patients NNS O
received VBD O
intermittent JJ B-INTV
pneumatic JJ I-INTV
compression NN I-INTV
. . O

The DT O
primary JJ O
efficacy NN O
outcome NN O
was VBD O
venous JJ B-OC
thromboembolism NN I-OC
up RB I-OC
to TO I-OC
day NN I-OC
10 CD I-OC
. . O

The DT O
main JJ O
safety NN O
outcomes NNS O
were VBD O
major JJ B-OC
bleeding NN I-OC
and CC I-OC
all-cause JJ I-OC
mortality NN I-OC
. . O

Follow-up NNP O
lasted VBD O
32 CD O
days NNS O
. . O

RESULTS NNP O
Of IN O
the DT O
1309 CD B-POPU
patients NNS I-POPU
randomized VBN O
, , O
842 CD O
( ( O
64.3 CD O
% NN O
) ) O
were VBD O
evaluable JJ O
for IN O
efficacy NN O
. . O

The DT O
venous JJ B-OC
thromboembolism NN I-OC
rate NN I-OC
was VBD O
1.7 CD O
% NN O
( ( O
7/424 CD O
) ) O
in IN O
the DT O
fondaparinux-treated JJ B-POPU
patients NNS I-POPU
and CC O
5.3 CD O
% NN O
( ( O
22/418 CD O
) ) O
in IN O
the DT O
placebo-treated JJ B-POPU
patients NNS I-POPU
( ( O
odds NNS O
ratio VBP O
reduction NN O
69.8 CD O
% NN O
; : O
95 CD O
% NN O
confidence NN O
interval JJ O
27.9-87.3 JJ O
; : O
P NNP O
= NNP O
0.004 CD O
) ) O
. . O

Fondaparinux NNP B-INTV
significantly RB O
reduced VBD O
the DT O
proximal JJ B-OC
deep JJ I-OC
vein NN I-OC
thrombosis NN I-OC
rate NN I-OC
from IN O
1.7 CD O
% NN O
( ( O
7/417 CD O
) ) O
to TO O
0.2 CD O
% NN O
( ( O
1/424 CD O
; : O
P NNP O
= NNP O
0.037 CD O
) ) O
. . O

Major JJ B-OC
bleeds NNS I-OC
occurred VBD O
in IN O
1.6 CD O
% NN O
( ( O
10/635 CD O
) ) O
and CC O
0.2 CD O
% NN O
( ( O
1/650 CD O
) ) O
of IN O
fondaparinux-treated JJ B-INTV
and CC O
placebo-treated JJ B-INTV
patients NNS O
, , O
respectively RB O
( ( O
P NNP O
= NNP O
0.006 CD O
) ) O
, , O
none NN O
being VBG O
fatal JJ O
or CC O
involving VBG O
a DT O
critical JJ O
organ NN O
. . O

By IN O
day NN O
32 CD O
, , O
eight CD O
patients NNS O
( ( O
1.3 CD O
% NN O
) ) O
receiving NN O
fondaparinux NN B-INTV
and CC O
five CD O
( ( O
0.8 CD O
% NN O
) ) O
receiving NN O
placebo NN B-INTV
had VBD O
died VBN B-OC
. . O

CONCLUSIONS NNP O
In IN O
patients NNS B-POPU
undergoing JJ I-POPU
abdominal JJ I-POPU
surgery NN I-POPU
and CC I-POPU
receiving VBG I-POPU
intermittent JJ I-POPU
pneumatic JJ I-POPU
compression NN I-POPU
, , B-INTV
fondaparinux VBP I-INTV
2.5 CD O
mg NN O
reduced VBD O
the DT O
venous JJ B-OC
thromboembolism NN I-OC
rate NN I-OC
by IN O
69.8 CD O
% NN O
as IN O
compared VBN O
to TO O
pneumatic JJ B-INTV
compression NN I-INTV
alone RB I-INTV
, , O
with IN O
a DT O
low JJ B-OC
bleeding NN I-OC
risk NN I-OC
as IN O
compared VBN O
to TO O
placebo VB B-INTV
. . O

-DOCSTART- -X- O O

Statin NNP B-INTV
treatment NN I-INTV
withdrawal NN I-INTV
in IN O
ischemic JJ B-POPU
stroke NN I-POPU
: : I-POPU
a DT O
controlled VBN O
randomized NN O
study NN O
. . O

BACKGROUND NNP O
Pretreatment NNP O
with IN O
statins NNS O
has VBZ O
been VBN O
shown VBN O
to TO O
reduce VB O
brain NN O
injury NN O
in IN O
cerebral JJ O
ischemia NN O
. . O

In IN O
this DT O
controlled VBN O
randomized NN O
study NN O
, , O
we PRP O
investigated VBD O
the DT O
influence NN O
of IN O
statin NN B-INTV
pretreatment NN I-INTV
and CC I-INTV
its PRP$ I-INTV
withdrawal NN I-INTV
on IN O
the DT O
outcome NN O
of IN O
acute JJ B-POPU
ischemic JJ I-POPU
stroke NN I-POPU
patients NNS I-POPU
. . O

METHODS NNP O
From IN B-POPU
215 CD I-POPU
patients NNS I-POPU
admitted VBD I-POPU
within IN I-POPU
24 CD I-POPU
hours NNS I-POPU
of IN I-POPU
a DT I-POPU
hemispheric JJ I-POPU
ischemic JJ I-POPU
stroke NN I-POPU
, , I-POPU
89 CD I-POPU
patients NNS I-POPU
on IN I-POPU
chronic JJ I-POPU
statin NN I-POPU
treatment NN I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
either RB O
to TO O
statin VB B-INTV
withdrawal NN I-INTV
for IN I-INTV
the DT I-INTV
first JJ I-INTV
3 CD I-INTV
days NNS I-INTV
after IN I-INTV
admission NN I-INTV
( ( I-INTV
n JJ I-INTV
= NNP I-INTV
46 CD I-INTV
) ) I-INTV
or CC I-INTV
to TO I-INTV
immediately RB I-INTV
receive VB I-INTV
atorvastatin NN I-INTV
20 CD I-INTV
mg/day NN I-INTV
( ( I-INTV
n JJ I-INTV
= NNP I-INTV
43 CD I-INTV
) ) I-INTV
. . O

The DT O
primary JJ O
outcome JJ O
event NN O
was VBD O
death NN B-OC
or CC I-OC
dependency NN I-OC
( ( I-OC
modified JJ I-OC
Rankin NNP I-OC
Scale NNP I-OC
[ NNP I-OC
mRS NN I-OC
] NNP I-OC
score NN O
> NNP O
2 CD O
) ) O
at IN O
3 CD O
months NNS O
. . O

Early JJ B-OC
neurologic JJ I-OC
deterioration NN I-OC
( ( I-OC
END NNP I-OC
) ) I-OC
and CC O
infarct JJ B-OC
volume NN I-OC
at IN O
days NNS O
4 CD O
to TO O
7 CD O
were VBD O
secondary JJ O
outcome NN O
variables NNS O
. . O

In IN O
a DT O
secondary JJ O
analysis NN O
, , O
outcome JJ O
variables NNS O
were VBD O
compared VBN O
with IN O
the DT O
nonrandomized JJ O
patients NNS O
without IN O
previous JJ O
statin NN O
therapy NN O
( ( O
n JJ O
= NNP O
126 CD O
) ) O
. . O

RESULTS JJ O
Patients NNS B-POPU
with IN I-POPU
statin NN I-POPU
withdrawal NN I-POPU
showed VBD O
a DT O
higher JJR O
frequency NN O
of IN O
mRS NN B-OC
score NN I-OC
> VBD O
2 CD O
at IN O
the DT O
end NN O
of IN O
follow-up NN O
( ( O
60.0 CD O
% NN O
vs JJ O
39.0 CD O
% NN O
; : O
p CC O
= VB O
0.043 CD O
) ) O
, , O
END NNP O
( ( O
65.2 CD O
% NN O
vs JJ O
20.9 CD O
% NN O
; : O
p CC O
< VB O
0.0001 CD O
) ) O
, , O
and CC O
greater JJR O
infarct NN B-OC
volume NN I-OC
( ( O
74 CD O
[ RB O
45 CD O
, , O
126 CD O
] NN O
vs NN O
26 CD O
[ NN O
12 CD O
, , O
70 CD O
] JJ O
mL NN O
; : O
p CC O
= VB O
0.002 CD O
) ) O
compared VBN O
with IN O
the DT O
non-statin-withdrawal JJ B-INTV
group NN O
. . O

Statin NNP B-INTV
withdrawal NN O
was VBD O
associated VBN O
with IN O
a DT O
4.66 CD O
( ( O
1.46 CD O
to TO O
14.91 CD O
) ) O
-fold VBD O
increase NN O
in IN O
the DT O
risk NN B-OC
of IN I-OC
death NN I-OC
or CC I-OC
dependency NN I-OC
, , O
a DT O
8.67 CD O
( ( O
3.05 CD O
to TO O
24.63 CD O
) ) O
-fold VBD O
increase NN O
in IN O
the DT O
risk NN O
of IN O
END NNP B-OC
, , O
and CC O
an DT O
increase NN O
in IN O
mean JJ B-OC
infarct JJ I-OC
volume NN I-OC
of IN O
37.63 CD O
mL NN O
( ( O
SE NNP O
10.01 CD O
; : O
p NN O
< VBZ O
0.001 CD O
) ) O
after IN O
adjusting VBG O
for IN O
age NN O
and CC O
baseline NN O
stroke NN O
severity NN O
. . O

Compared VBN O
with IN O
patients NNS B-POPU
without IN I-POPU
previous JJ I-POPU
treatment NN I-POPU
with IN I-POPU
statins NNS I-POPU
, , O
statin NN O
withdrawal NN O
was VBD O
associated VBN O
with IN O
a DT O
19.01 CD O
( ( O
1.96 CD O
to TO O
184.09 CD O
) ) O
-fold VBD O
increase NN O
in IN O
the DT O
risk NN O
of IN O
END NNP B-OC
and CC O
an DT O
increase NN O
in IN O
mean JJ B-OC
infarct JJ I-OC
volume NN I-OC
of IN O
43.51 CD O
mL NN O
( ( O
SE NNP O
21.91 CD O
; : O
p NN O
= VBZ O
0.048 CD O
) ) O
. . O

CONCLUSION NNP O
Statin NNP O
withdrawal NN O
is VBZ O
associated VBN O
with IN O
increased JJ O
risk NN O
of IN O
death NN O
or CC O
dependency NN O
at IN O
90 CD O
days NNS O
. . O

Hence NNP O
, , O
this DT O
treatment NN O
should MD O
be VB O
continued VBN O
in IN O
the DT O
acute JJ O
phase NN O
of IN O
ischemic JJ O
stroke NN O
. . O

-DOCSTART- -X- O O

[ JJ B-INTV
Stent NNP I-INTV
and CC I-INTV
surgery NN I-INTV
for IN O
symptomatic JJ B-POPU
carotid NN I-POPU
stenosis NN I-POPU
. . O

SPACE NNP O
study NN O
results NNS O
] NNP O
. . O

The DT O
SPACE NNP O
trial NN O
compared VBN O
risk NN O
and CC O
effectiveness NN O
of IN O
stent-supported JJ B-INTV
angioplasty NN I-INTV
( ( I-INTV
CAS NNP I-INTV
) ) I-INTV
vs NN I-INTV
carotid NN I-INTV
endarterectomy NN I-INTV
( ( I-INTV
CEA NNP I-INTV
) ) I-INTV
using VBG O
a DT O
noninferiority NN O
design NN O
in IN O
patients NNS B-POPU
with IN I-POPU
symptomatic JJ I-POPU
stenoses NNS I-POPU
. . O

Intention-to-treat JJ O
analysis NN O
of IN O
the DT O
entire JJ O
study NN O
population NN O
of IN O
1,214 CD B-POPU
patients NNS I-POPU
showed VBD O
that IN O
primary JJ O
endpoint NN O
events NNS O
( ( O
ipsilateral JJ O
stroke NN O
or CC O
death NN O
between IN O
randomisation NN O
and CC O
day NN O
30 CD O
) ) O
occurred VBD O
in IN O
6.92 CD O
% NN O
of IN O
the DT O
CAS NNP B-INTV
group NN O
and CC O
6.45 CD O
% NN O
of IN O
the DT O
CEA NNP B-INTV
group NN O
. . O

The DT O
95 CD O
% NN O
confidence NN O
interval NN O
( ( O
CI NNP O
) ) O
of IN O
the DT O
absolute NN B-OC
risk NN I-OC
difference NN I-OC
ranged VBD O
from IN O
-1.94 CD O
% NN O
to TO O
+2.87 CD O
% NN O
, , O
therefore RB O
the DT O
noninferiority NN O
was VBD O
not RB O
proven RB O
. . O

The DT O
same JJ O
was VBD O
true JJ O
for IN O
the DT O
analysis NN O
of IN O
protocols NNS O
. . O

No DT O
significant JJ O
differences NNS O
between IN O
the DT O
two CD O
treatment NN O
methods NNS O
were VBD O
found VBN O
in IN O
primary JJ O
or CC O
any DT O
of IN O
the DT O
secondary JJ O
endpoints NNS O
. . O

There EX O
were VBD O
also RB O
no DT O
differences NNS O
in IN O
short-term JJ B-OC
prevention NN I-OC
. . O

The DT O
endpoint JJ O
'ipsilateral JJ B-OC
ischemic JJ I-OC
stroke NN I-OC
or CC I-OC
vascular JJ I-OC
death NN I-OC
between IN I-OC
randomisation NN I-OC
and CC I-OC
6 CD I-OC
months NNS I-OC
' POS I-OC
occurred VBD O
in IN O
7.4 CD O
% NN O
of IN O
the DT O
CAS NNP B-INTV
and CC O
6.5 CD O
% NN O
of IN O
the DT O
CEA NNP B-INTV
patients NNS O
( ( O
odds NNS O
ratio VBP O
1.16 CD O
, , O
95 CD O
% NN O
confidence NN O
interval JJ O
0.74-1.82 NN O
) ) O
. . O

Instent JJ B-OC
restenoses NNS I-OC
were VBD O
significantly RB O
more JJR O
common JJ O
in IN O
the DT O
CAS NNP B-INTV
group NN O
( ( O
4.6 CD O
% NN O
vs JJ O
2.2 CD O
% NN O
, , O
odds NNS O
ratio VBP O
2.14 CD O
, , O
95 CD O
% NN O
CI NNP O
1.10-4.18 CD O
) ) O
. . O

Surgery NN O
remains VBZ O
the DT O
gold JJ O
standard NN O
in IN O
treatment NN O
of IN O
patients NNS B-POPU
with IN I-POPU
symptomatic JJ I-POPU
carotid NN I-POPU
artery NN I-POPU
stenosis NN I-POPU
. . O

Stent-supported JJ B-INTV
angioplasty NN I-INTV
can MD O
be VB O
an DT O
alternative JJ O
only RB O
in IN O
the DT O
hands NNS O
of IN O
an DT O
experienced JJ O
interventionalist NN O
with IN O
proven JJ O
low JJ O
periprocedural JJ B-OC
complication NN I-OC
rate NN I-OC
. . O

-DOCSTART- -X- O O

Timing NN B-OC
of IN I-OC
death NN I-OC
and CC I-OC
myocardial JJ B-POPU
infarction NN I-POPU
in IN I-POPU
patients NNS I-POPU
with IN I-POPU
non-ST JJ I-POPU
elevation NN I-POPU
acute NN I-POPU
coronary JJ I-POPU
syndromes NNS I-POPU
: : I-POPU
insights NNS O
from IN O
randomized VBN O
clinical JJ O
trials NNS O
. . O

BACKGROUND NNP O
Adverse NNP O
events NNS O
occur VBP O
following VBG O
non-ST JJ B-POPU
elevation NN I-POPU
acute NN I-POPU
coronary JJ I-POPU
syndromes NNS I-POPU
( ( I-POPU
NSTE NNP I-POPU
ACS NNP I-POPU
) ) I-POPU
. . O

However RB O
, , O
the DT O
timing NN O
of IN O
these DT O
events NNS O
in IN O
relation NN O
to TO O
index NN O
event NN O
is VBZ O
less RBR O
clear JJ O
. . O

METHODS NNP O
Accordingly RB O
, , O
we PRP B-POPU
evaluated VBD I-POPU
26,466 CD I-POPU
NSTE NNP I-POPU
ACS NNP I-POPU
patients NNS I-POPU
from IN I-POPU
the DT I-POPU
Global NNP I-POPU
Use NNP I-POPU
of IN I-POPU
Strategies NNPS I-POPU
to TO I-POPU
Open VB I-POPU
Occluded NNP I-POPU
Arteries NNPS I-POPU
in IN I-POPU
Acute NNP I-POPU
Coronary NNP I-POPU
Syndromes NNP I-POPU
( ( I-POPU
GUSTO-IIb NNP I-POPU
) ) I-POPU
, , I-POPU
Platelet NNP I-POPU
Glycoprotein NNP I-POPU
IIb/IIIa NNP I-POPU
in IN I-POPU
Unstable JJ I-POPU
Angina NNP I-POPU
: : I-POPU
Receptor NNP B-INTV
Suppression NNP I-INTV
Using NNP I-INTV
Integrilin NNP I-INTV
Therapy NNP I-INTV
( ( O
PURSUIT NNP O
) ) O
, , O
and CC O
Platelet NNP B-INTV
IIb/IIIa NNP I-INTV
Antagonism NNP I-INTV
for IN O
the DT O
Reduction NNP O
of IN O
Acute NNP O
Coronary NNP O
Syndrome NNP O
Events NNP O
in IN O
a DT O
Global NNP O
Organization NNP O
Network NNP O
( ( O
PARAGON NNP O
) ) O
A NNP O
and CC O
B NNP O
trials NNS O
to TO O
ascertain VB O
the DT O
timing NN O
of IN O
adverse JJ O
events NNS O
. . O

Outcomes NNS O
of IN O
interest NN O
were VBD O
death NN B-OC
, , I-OC
myocardial JJ I-OC
infarction NN I-OC
( ( I-OC
MI NNP I-OC
) ) I-OC
, , I-OC
and CC I-OC
death NN I-OC
or CC I-OC
MI NNP I-OC
at IN I-OC
180 CD I-OC
days NNS I-OC
. . O

Logistic JJ B-INTV
regression NN I-INTV
modeling VBG I-INTV
for IN O
death NN O
was VBD O
used VBN O
to TO O
categorize VB O
patients NNS O
into IN O
low- JJ O
, , O
medium- JJ O
, , O
and CC O
high-risk JJ O
groups NNS O
. . O

RESULTS NNP O
At IN O
6 CD O
months NNS O
, , O
6.2 CD O
% NN O
of IN O
patients NNS O
died VBD B-OC
, , O
12.1 CD O
% NN O
had VBD O
MI NNP B-OC
, , O
and CC O
15.7 CD O
% NN O
suffered VBD O
death NN B-OC
or CC I-OC
MI NNP I-OC
. . O

From IN O
15 CD O
% NN O
to TO O
40 CD O
% NN O
of IN O
these DT O
events NNS O
occurred VBD O
beyond IN O
30 CD O
days NNS O
. . O

At IN O
6 CD O
months NNS O
, , O
3 CD O
% NN O
, , O
4 CD O
% NN O
, , O
and CC O
13 CD O
% NN O
of IN O
patients NNS O
died VBN O
in IN O
low- JJ O
, , O
medium- JJ O
, , O
and CC O
high-risk JJ O
groups NNS O
, , O
respectively RB O
. . O

However RB O
, , O
the DT O
proportion NN B-OC
of IN I-OC
patients NNS I-OC
dying VBG I-OC
beyond IN O
30 CD O
days NNS O
was VBD O
similar JJ O
in IN O
the DT O
three CD O
groups NNS O
( ( O
44 CD O
% NN O
, , O
43 CD O
% NN O
, , O
and CC O
41 CD O
% NN O
of IN O
death NN O
, , O
respectively RB O
) ) O
. . O

Similarly RB O
, , O
whereas JJ O
death NN B-OC
or CC I-OC
MI NNP I-OC
increased VBD O
with IN O
higher JJR O
risk NN O
( ( O
11 CD O
% NN O
, , O
14 CD O
% NN O
, , O
and CC O
23 CD O
% NN O
, , O
respectively RB O
) ) O
, , O
the DT O
proportion NN B-OC
of IN I-OC
patients NNS I-OC
with IN O
this DT O
event NN O
beyond IN O
30 CD O
days NNS O
did VBD O
not RB O
differ VB O
in IN O
the DT O
three CD O
strata NNS O
( ( O
22 CD O
% NN O
, , O
20 CD O
% NN O
, , O
and CC O
25 CD O
% NN O
, , O
respectively RB O
) ) O
. . O

CONCLUSIONS NNP O
Our PRP$ O
study NN O
provides VBZ O
important JJ O
insights NNS O
into IN O
the DT O
timing NN O
of IN O
adverse JJ O
events NNS O
and CC O
suggests VBZ O
that IN O
the DT O
substantial JJ O
proportion NN O
of IN O
patients NNS O
suffer VBP O
subsequent JJ O
adverse JJ O
events NNS O
after IN O
their PRP$ O
index NN O
NSTE NNP O
ACS NNP O
. . O

Thus RB O
, , O
these DT O
data NNS O
call NN O
for IN O
continuous JJ O
surveillance NN O
for IN O
these DT O
events NNS O
and CC O
efforts NNS O
beyond IN O
the DT O
acute JJ O
phase NN O
at IN O
increasing VBG O
adherence NN O
to TO O
evidence-based JJ O
therapies NNS O
to TO O
improve VB O
the DT O
outcomes NNS O
of IN O
these DT O
patients NNS O
. . O

-DOCSTART- -X- O O

Transcutaneous JJ B-INTV
electrical JJ I-INTV
nerve NN I-INTV
stimulation NN I-INTV
combined VBN I-INTV
with IN I-INTV
task-related JJ I-INTV
training NN I-INTV
improves NNS O
lower JJR B-OC
limb NN I-OC
functions NNS I-OC
in IN O
subjects NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
stroke NN I-POPU
. . O

BACKGROUND NNP O
AND NNP O
PURPOSE NNP O
Previous NNP O
studies NNS O
have VBP O
shown VBN O
that IN O
repeated VBD O
sensory JJ O
inputs NNS O
could MD O
enhance VB O
brain NN B-OC
plasticity NN I-OC
and CC I-OC
cortical JJ I-OC
motor NN I-OC
output NN I-OC
. . O

The DT O
purpose NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
investigate VB O
whether IN O
combining VBG O
electrically RB O
induced JJ O
sensory NN O
inputs NNS O
through IN O
transcutaneous JJ B-INTV
electrical JJ I-INTV
nerve NN I-INTV
stimulation NN I-INTV
( ( I-INTV
TENS NNP I-INTV
) ) I-INTV
with IN I-INTV
task-related JJ I-INTV
training NN I-INTV
( ( I-INTV
TRT NNP I-INTV
) ) I-INTV
in IN O
a DT O
home-based JJ O
program NN O
would MD O
augment VB O
voluntary JJ B-OC
motor NN I-OC
output NN I-OC
in IN O
chronic JJ B-POPU
stroke NN I-POPU
survivors NNS I-POPU
better RBR O
than IN O
either DT O
treatment NN O
alone RB O
or CC O
no DT O
treatment NN O
. . O

METHODS NNP O
Eighty-eight JJ B-POPU
patients NNS I-POPU
with IN I-POPU
stroke NN I-POPU
were VBD O
assigned VBN O
randomly RB O
to TO O
receive VB O
a DT O
home-based JJ O
program NN O
of IN O
( ( O
1 CD O
) ) O
TENS NN B-INTV
, , I-INTV
( ( I-INTV
2 CD I-INTV
) ) I-INTV
TENS+TRT NN I-INTV
, , I-INTV
( ( I-INTV
3 CD I-INTV
) ) I-INTV
placebo NN I-INTV
TENS+TRT NNP I-INTV
, , I-INTV
or CC I-INTV
( ( I-INTV
4 CD I-INTV
) ) I-INTV
no DT I-INTV
treatment NN I-INTV
( ( I-INTV
control NN I-INTV
) ) I-INTV
5 CD O
days NNS O
a DT O
week NN O
for IN O
4 CD O
weeks NNS O
. . O

Outcome NN O
measurements NNS O
included VBD O
Composite NNP B-OC
Spasticity NNP I-OC
Scale NNP I-OC
, , I-OC
peak NN I-OC
torques NNS I-OC
generated VBD I-OC
during IN I-OC
maximum JJ I-OC
isometric JJ I-OC
voluntary JJ I-OC
contraction NN I-OC
of IN I-OC
ankle JJ I-OC
dorsiflexors NNS I-OC
and CC I-OC
plantarflexors NNS I-OC
, , I-OC
and CC I-OC
gait VBP I-OC
velocity NN I-OC
recorded VBN O
at IN O
baseline NN O
, , O
after IN O
2 CD O
and CC O
4 CD O
weeks NNS O
of IN O
treatment NN O
, , O
and CC O
4 CD O
weeks NNS O
after IN O
treatment NN O
ended VBN O
. . O

RESULTS VB O
When WRB O
compared VBN O
with IN O
TENS NNP B-INTV
, , O
the DT O
combined JJ O
TENS+TRT NNP B-INTV
group NN O
showed VBD O
significantly RB O
greater JJR O
improvement NN O
in IN O
ankle JJ B-OC
dorsiflexion NN I-OC
torque NN I-OC
at IN O
follow-up JJ O
and CC O
in IN O
ankle JJ B-OC
plantarflexion NN I-OC
torque NN I-OC
at IN O
week NN O
2 CD O
and CC O
follow-up JJ O
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

When WRB O
compared VBN O
with IN O
placebo+TRT NN B-INTV
, , O
the DT O
TENS+TRT NNP B-INTV
group NN O
produced VBD O
earlier JJR O
and CC O
greater JJR O
reduction NN O
of IN O
plantarflexor NN B-OC
spasticity NN I-OC
and CC O
improvement NN B-OC
in IN I-OC
ankle JJ I-OC
dorsiflexion NN I-OC
torque NN I-OC
at IN O
week NN O
2 CD O
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

When WRB O
compared VBN O
with IN O
all DT O
3 CD O
groups NNS O
, , O
the DT O
TENS+TRT NNP B-INTV
group NN O
showed VBD O
significantly RB O
greater JJR O
improvement NN O
in IN O
gait NN B-OC
velocity NN I-OC
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

CONCLUSIONS NNP O
In IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
stroke NN I-POPU
, , O
20 CD O
sessions NNS O
of IN O
a DT O
combined JJ B-INTV
TENS+TRT NNP I-INTV
home-based JJ I-INTV
program NN O
decreased VBN B-OC
plantarflexor JJ I-OC
spasticity NN I-OC
, , I-OC
improved VBN I-OC
dorsiflexor NN I-OC
and CC I-OC
plantarflexor NN I-OC
strength NN I-OC
, , I-OC
and CC I-OC
increased VBD I-OC
gait NN I-OC
velocity NN I-OC
significantly RB O
more RBR O
than IN O
TENS NNP B-INTV
alone RB O
, , O
placebo+TRT NN O
, , O
or CC O
no DT O
treatment NN O
. . O

Such JJ O
improvements NNS O
can MD O
even RB O
be VB O
maintained VBN O
4 CD O
weeks NNS O
after IN O
treatment NN O
ended VBD O
. . O

-DOCSTART- -X- O O

Robotic JJ B-INTV
therapy NN I-INTV
: : I-INTV
a DT O
novel JJ O
approach NN O
in IN O
upper-limb JJ B-OC
neurorehabilitation NN I-OC
after IN O
stroke NN B-POPU
. . O

-DOCSTART- -X- O O

Mechanical JJ B-OC
efficiency NN I-OC
and CC I-OC
propulsion NN I-OC
technique NN I-OC
after IN O
7 CD O
weeks NNS O
of IN O
low-intensity JJ O
wheelchair NN O
training NN O
. . O

BACKGROUND NNP O
To TO O
evaluate VB O
the DT O
effect NN O
of IN O
a DT O
7-week JJ O
low-intensity NN O
hand NN O
rim VBZ O
wheelchair JJ O
training VBG O
on IN O
the DT O
submaximal JJ O
metabolic NN O
cost NN O
, , O
mechanical JJ B-OC
efficiency NN I-OC
and CC O
propulsion NN O
technique NN O
in IN O
able-bodied JJ B-POPU
participants NNS I-POPU
. . O

METHODS JJ O
Participants NNS B-POPU
were VBD O
randomly RB O
divided VBN O
over RP O
an DT O
experimental JJ O
group NN O
( ( B-POPU
n=14 CC I-POPU
) ) I-POPU
and CC I-POPU
a DT I-POPU
control NN I-POPU
group NN I-POPU
( ( I-POPU
n=7 RB I-POPU
) ) I-POPU
. . O

The DT O
experimental JJ O
group NN O
received VBD B-INTV
7 CD I-INTV
weeks NNS I-INTV
wheelchair JJ I-INTV
training NN I-INTV
( ( I-INTV
3 CD I-INTV
week NN I-INTV
( ( I-INTV
-1 NN I-INTV
) ) I-INTV
, , I-INTV
70 CD I-INTV
min NN I-INTV
) ) I-INTV
at IN I-INTV
a DT I-INTV
low JJ I-INTV
intensity NN I-INTV
( ( I-INTV
30 CD I-INTV
% NN I-INTV
of IN I-INTV
the DT I-INTV
heart NN I-INTV
rate NN I-INTV
reserve NN I-INTV
) ) I-INTV
, , I-INTV
whereas IN I-INTV
the DT I-INTV
control NN I-INTV
group NN I-INTV
did VBD I-INTV
not RB I-INTV
receive VB I-INTV
training NN I-INTV
. . O

During IN B-INTV
pre- JJ I-INTV
and CC I-INTV
post-tests NNS I-INTV
, , I-INTV
submaximal JJ I-INTV
exercise NN I-INTV
was VBD I-INTV
performed VBN I-INTV
on IN I-INTV
a DT I-INTV
stationary JJ I-INTV
wheelchair NN I-INTV
ergometer NN I-INTV
at IN I-INTV
fixed JJ I-INTV
levels NNS I-INTV
of IN I-INTV
power NN I-INTV
output NN I-INTV
. . O

Mechanical JJ B-INTV
efficiency NN I-INTV
, , I-INTV
oxygen NN I-INTV
uptake NN I-INTV
, , I-INTV
heart NN I-INTV
rate NN I-INTV
, , I-INTV
timing VBG I-INTV
parameters NNS I-INTV
and CC I-INTV
stroke NN I-INTV
angles NNS I-INTV
were VBD I-INTV
measured VBN I-INTV
. . O

Video NNP O
recordings NNS O
were VBD O
made VBN O
to TO O
determine VB O
the DT O
stroke NN B-OC
pattern NN I-OC
. . O

FINDINGS NNP O
Mechanical NNP B-OC
efficiency NN I-OC
increased VBD I-OC
and CC I-OC
metabolic JJ I-OC
cost NN I-OC
decreased VBN I-OC
significantly RB O
in IN O
the DT O
experimental JJ O
group NN O
compared VBN O
to TO O
the DT O
control NN O
group NN O
. . O

Push NNP B-OC
time NN I-OC
increased VBD O
and CC O
cycle NN B-OC
frequency NN I-OC
decreased VBD O
as IN O
a DT O
result NN O
of IN O
training NN O
. . O

The DT O
stroke NN B-OC
angle NN I-OC
increased VBD O
in IN O
the DT O
experimental JJ O
group NN O
during IN O
the DT O
training NN O
period NN O
. . O

The DT O
experimental JJ O
group NN O
preferred VBD O
double-looping NN O
over IN O
propulsion NN O
, , O
while IN O
the DT O
control NN O
group NN O
mainly RB O
used VBD O
single-looping NN B-OC
over IN I-OC
propulsion NN I-OC
patterns NNS O
during IN O
the DT O
post-test JJ O
. . O

INTERPRETATION VB O
A DT O
low-intensity NN O
, , O
7-week JJ O
training NN O
protocol NN O
has VBZ O
a DT O
beneficial JJ O
effect NN O
on IN O
the DT O
mechanical JJ B-OC
efficiency NN I-OC
and CC I-OC
metabolic JJ I-OC
cost NN I-OC
of IN O
wheelchair NN O
propulsion NN O
in IN O
able-bodied JJ B-POPU
participants NNS I-POPU
. . O

The DT O
improved JJ O
mechanical JJ O
efficiency NN O
seems VBZ O
to TO O
be VB O
the DT O
result NN O
of IN O
changes NNS O
in IN O
propulsion NN O
technique NN O
that WDT O
were VBD O
found VBN O
. . O

-DOCSTART- -X- O O

Arterial NNP O
cardiovascular JJ O
risk NN O
factors NNS O
and CC O
venous JJ B-POPU
thrombosis NN I-POPU
: : I-POPU
results NNS O
from IN O
a DT O
population-based JJ O
, , O
prospective JJ O
study NN O
( ( O
the DT O
HUNT NNP O
2 CD O
) ) O
. . O

BACKGROUND NNP O
An DT O
explanation NN O
for IN O
the DT O
increased VBN O
risk NN O
of IN O
myocardial JJ O
infarction NN O
and CC O
stroke NN O
in IN O
patients NNS B-POPU
with IN I-POPU
venous JJ I-POPU
thrombosis NN I-POPU
is VBZ O
lacking VBG O
. . O

The DT O
objective NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
investigate VB O
whether IN O
risk NN O
factors NNS O
for IN O
arterial JJ O
cardiovascular JJ O
disease NN O
also RB O
increase VBZ O
the DT O
risk NN O
of IN O
venous JJ O
thrombosis NN O
. . O

DESIGN NNP O
AND CC O
METHODS NNP O
Cases NNP B-POPU
who WP I-POPU
had VBD I-POPU
a DT I-POPU
first JJ I-POPU
venous JJ I-POPU
thrombosis NN I-POPU
( ( I-POPU
n=515 JJ I-POPU
) ) I-POPU
and CC I-POPU
matched VBN I-POPU
controls NNS I-POPU
( ( I-POPU
n=1,505 NN I-POPU
) ) I-POPU
were VBD I-POPU
identified VBN I-POPU
from IN I-POPU
a DT I-POPU
population-based JJ I-POPU
, , I-POPU
nested JJ I-POPU
, , I-POPU
case-cohort JJ I-POPU
study NN I-POPU
( ( I-POPU
the DT I-POPU
HUNT NNP I-POPU
2 CD I-POPU
study NN I-POPU
) ) I-POPU
comprising VBG I-POPU
71 CD I-POPU
% NN I-POPU
( ( I-POPU
n=66,140 JJ I-POPU
) ) I-POPU
of IN I-POPU
the DT I-POPU
adult NN I-POPU
residents NNS I-POPU
of IN I-POPU
Nord-Trøndelag NNP I-POPU
County NNP I-POPU
in IN I-POPU
Norway NNP I-POPU
. . O

RESULTS VB O
The DT O
age- JJ O
and CC O
sex-adjusted JJ O
odds NNS O
ratio NN O
of IN B-OC
venous JJ I-OC
thrombosis NN I-OC
for IN B-POPU
subjects NNS I-POPU
with IN I-POPU
concentrations NNS I-POPU
of IN I-POPU
C-reactive JJ I-POPU
protein NN I-POPU
in IN I-POPU
the DT I-POPU
highest JJS I-POPU
quintile NN I-POPU
was VBD O
1.6 CD O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
: : O
1.2-2.2 JJ O
) ) O
compared VBN O
to TO O
subjects NNS O
with IN B-OC
C-reactive JJ I-OC
protein NN I-OC
in IN O
the DT O
lowest JJS O
quintile NN O
. . O

This DT O
association NN O
was VBD O
strongest VBN O
in IN B-POPU
subjects NNS I-POPU
who WP I-POPU
experienced VBD I-POPU
venous JJ I-POPU
thrombosis NN I-POPU
within IN I-POPU
a DT I-POPU
year NN I-POPU
after IN I-POPU
blood NN I-POPU
sampling VBG I-POPU
with IN O
a DT O
three-fold JJ O
increased JJ O
risk NN O
of IN O
participants NNS O
in IN O
the DT O
highest JJS O
versus NN O
the DT O
lowest JJS O
quintile NN O
. . O

Having VBG O
first JJ O
degree JJ O
relatives NNS O
who WP O
had VBD O
a DT O
myocardial JJ O
infarction NN O
before IN O
the DT O
age NN O
of IN O
60 CD O
years NNS O
was VBD O
positively RB O
associated VBN O
with IN B-OC
venous JJ I-OC
thrombosis NN I-OC
compared VBN O
to TO O
not RB O
having VBG O
a DT O
positive JJ O
family NN O
history NN O
[ NNP O
odds VBZ O
ratio NN O
1.3 CD O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
: : O
1.1-1.6 JJ O
) ) O
] NN O
. . O

Subjects NNS O
with IN B-OC
blood NN I-OC
pressure NN I-OC
in IN O
the DT O
highest JJS O
quintile NN O
had VBD O
half PDT O
the DT O
risk NN O
of IN O
developing VBG B-OC
venous JJ I-OC
thrombosis NN I-OC
compared VBN O
to TO O
subjects NNS O
whose WP$ O
blood NN O
pressure NN O
was VBD O
in IN O
the DT O
lowest JJS O
quintile NN O
. . O

There EX O
were VBD O
no DT O
associations NNS O
between IN O
the DT B-OC
risk NN I-OC
of IN I-OC
venous JJ I-OC
thrombosis NN I-OC
and CC I-OC
total JJ I-OC
cholesterol NN I-OC
, , I-OC
low JJ I-OC
density NN I-OC
lipoprotein-cholesterol NN I-OC
, , I-OC
high JJ I-OC
density NN I-OC
lipoprotein-cholesterol NN I-OC
, , I-OC
triglycerides NNS I-OC
, , I-OC
glucose NN I-OC
or CC I-OC
smoking NN I-OC
. . O

We PRP O
confirmed VBD O
the DT O
positive JJ O
association NN O
between IN B-OC
obesity NN I-OC
and CC I-OC
venous JJ I-OC
thrombosis NN I-OC
. . O

CONCLUSIONS NNP O
C-reactive JJ O
protein NN O
and CC O
a DT O
family NN O
history NN O
of IN O
myocardial JJ O
infarction NN O
were VBD O
positively RB O
associated VBN O
with IN O
subsequent JJ B-POPU
venous JJ I-POPU
thrombosis NN I-POPU
. . O

Blood NNP B-POPU
pressure NN I-POPU
was VBD O
inversely RB O
correlated VBN O
to TO B-POPU
venous JJ I-POPU
thrombosis NN I-POPU
. . O

These DT O
findings NNS O
should MD O
be VB O
confirmed VBN O
by IN O
further JJ O
investigations NNS O
. . O

-DOCSTART- -X- O O

Long-term JJ O
prospective JJ O
, , O
randomized VBN O
, , O
controlled VBN O
study NN O
using VBG O
repetitive JJ O
education NN O
at IN O
six-month JJ O
intervals NNS O
and CC O
monitoring NN O
for IN O
adherence NN O
in IN O
heart NN B-POPU
failure NN I-POPU
outpatients NNS I-POPU
: : I-POPU
the DT O
REMADHE NNP O
trial NN O
. . O

BACKGROUND VB O
The DT O
effectiveness NN O
of IN O
heart NN O
failure NN O
disease NN O
management NN O
programs NNS O
in IN O
patients NNS B-POPU
under IN I-POPU
cardiologists NNS I-POPU
' POS I-POPU
care NN I-POPU
over IN I-POPU
long-term JJ I-POPU
follow-up NN I-POPU
is VBZ O
not RB O
established VBN O
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
We PRP O
investigated VBD O
the DT O
effects NNS O
of IN O
a DT O
disease JJ B-INTV
management NN I-INTV
program NN I-INTV
with IN I-INTV
repetitive JJ I-INTV
education NN I-INTV
and CC I-INTV
telephone NN I-INTV
monitoring NN I-INTV
on IN O
primary JJ B-OC
( ( I-OC
combined VBN I-OC
death NN I-OC
or CC I-OC
unplanned JJ I-OC
first JJ I-OC
hospitalization NN I-OC
and CC I-OC
quality-of-life JJ I-OC
changes NNS I-OC
) ) I-OC
and CC I-OC
secondary JJ I-OC
end NN I-OC
points NNS I-OC
( ( I-OC
hospitalization NN I-OC
, , I-OC
death NN I-OC
, , I-OC
and CC I-OC
adherence NN I-OC
) ) I-OC
. . O

The DT O
REMADHE NNP O
[ NNP O
Repetitive NNP O
Education NNP B-INTV
and CC I-INTV
Monitoring NNP I-INTV
for IN O
ADherence NNP O
for IN O
Heart NNP O
Failure NNP O
] NNP O
trial NN O
is VBZ O
a DT O
long-term JJ O
randomized NN O
, , O
prospective JJ O
, , O
parallel JJ O
trial NN O
designed VBN O
to TO O
compare VB O
intervention NN O
with IN O
control NN B-INTV
. . O

One CD B-POPU
hundred VBD I-POPU
seventeen JJ I-POPU
patients NNS I-POPU
were VBD I-POPU
randomized VBN I-POPU
to TO I-POPU
usual JJ I-POPU
care NN I-POPU
, , I-POPU
and CC I-POPU
233 CD I-POPU
to TO I-POPU
additional JJ I-POPU
intervention NN I-POPU
. . O

The DT O
mean JJ O
follow-up NN O
was VBD O
2.47+/-1.75 CD O
years NNS O
, , O
with IN O
54 CD O
% NN O
adherence NN O
to TO O
the DT O
program NN O
. . O

In IN O
the DT O
intervention NN O
group NN O
, , O
the DT O
primary JJ O
end NN O
point NN O
composite NN B-OC
of IN I-OC
death NN I-OC
or CC I-OC
unplanned JJ I-OC
hospitalization NN I-OC
was VBD O
reduced VBN O
( ( O
hazard JJ O
ratio NN O
, , O
0.64 CD O
; : O
confidence NN O
interval NN O
, , O
0.43 CD O
to TO O
0.88 CD O
; : O
P=0.008 NNP O
) ) O
, , O
driven VBN O
by IN O
reduction NN O
in IN O
hospitalization NN B-OC
. . O

The DT O
quality-of-life JJ B-OC
questionnaire NN I-OC
score NN I-OC
improved VBD O
only RB O
in IN O
the DT O
intervention NN O
group NN O
( ( O
P NNP O
< NNP O
0.003 CD O
) ) O
. . O

Mortality NNP B-OC
was VBD O
similar JJ O
in IN O
both DT O
groups NNS O
. . O

Number NNP B-OC
of IN I-OC
hospitalizations NNS I-OC
( ( O
1.3+/-1.7 JJ O
versus NN O
0.8+/-1.3 NN O
, , O
P NNP O
< NNP O
0.0001 CD O
) ) O
, , O
total JJ B-OC
hospital NN I-OC
days NNS I-OC
during IN I-OC
the DT I-OC
follow-up JJ I-OC
( ( O
19.9+/-51 JJ O
versus NN O
11.1+/-24 JJ O
days NNS O
, , O
P NNP O
< NNP O
0.0001 CD O
) ) O
, , O
and CC O
the DT O
need NN B-OC
for IN I-OC
emergency NN I-OC
visits NNS I-OC
( ( O
4.5+/-10.6 JJ O
versus NN O
1.6+/-2.4 CD O
, , O
P NNP O
< NNP O
0.0001 CD O
) ) O
were VBD O
lower JJR O
in IN O
the DT O
intervention NN O
group NN O
. . O

Beneficial JJ B-OC
effects NNS I-OC
were VBD O
homogeneous JJ O
for IN O
sex NN O
, , O
race NN O
, , O
diabetes NNS O
and CC O
no DT O
diabetes NN O
, , O
age NN O
, , O
functional JJ O
class NN O
, , O
and CC O
etiology NN O
. . O

CONCLUSIONS NNP O
For IN O
a DT O
longer RBR O
follow-up JJ O
period NN O
than IN O
in IN O
previous JJ O
studies NNS O
, , O
this DT O
heart NN O
failure NN O
disease JJ O
management NN O
program NN O
model NN O
of IN O
patients NNS B-POPU
under IN I-POPU
the DT I-POPU
supervision NN I-POPU
of IN I-POPU
a DT I-POPU
cardiologist NN I-POPU
is VBZ O
associated VBN O
with IN O
a DT O
reduction NN O
in IN O
unplanned JJ B-OC
hospitalization NN I-OC
, , O
a DT O
reduction NN O
of IN O
total JJ B-OC
hospital NN I-OC
days NNS I-OC
, , O
and CC O
a DT O
reduced JJ O
need NN B-OC
for IN I-OC
emergency NN I-OC
care NN I-OC
, , O
as RB O
well RB O
as IN O
improved VBN B-OC
quality NN I-OC
of IN I-OC
life NN I-OC
, , O
despite IN O
modest JJ O
program NN B-OC
adherence NN I-OC
over IN O
time NN O
. . O

-DOCSTART- -X- O O

Long-term JJ O
results NNS O
after IN O
intracoronary JJ B-INTV
injection NN I-INTV
of IN I-INTV
autologous JJ I-INTV
mononuclear JJ I-INTV
bone NN I-INTV
marrow NN I-INTV
cells NNS I-INTV
in IN O
acute JJ B-POPU
myocardial JJ I-POPU
infarction NN I-POPU
: : I-POPU
the DT O
ASTAMI NNP B-POPU
randomised VBD O
, , O
controlled VBD O
study NN O
. . O

OBJECTIVE NNP O
To TO O
investigate VB O
long-term JJ O
safety NN O
and CC O
efficacy NN O
after IN O
intracoronary JJ B-INTV
injection NN I-INTV
of IN I-INTV
autologous JJ I-INTV
mononuclear JJ I-INTV
bone NN I-INTV
marrow NN I-INTV
cells NNS I-INTV
( ( I-INTV
mBMCs NN I-INTV
) ) I-INTV
in IN I-INTV
acute JJ B-POPU
myocardial JJ I-POPU
infarction NN I-POPU
( ( I-POPU
AMI NNP I-POPU
) ) I-POPU
. . O

DESIGN NNP O
Randomised VBD O
, , O
controlled VBD O
trial NN O
. . O

SETTING NN O
Two CD B-POPU
university NN I-POPU
hospitals NNS I-POPU
in IN I-POPU
Oslo NNP I-POPU
, , I-POPU
Norway NNP I-POPU
. . O

PATIENTS NNP O
Patients NNPS B-POPU
from IN I-POPU
the DT I-POPU
Autologous NNP I-POPU
Stem NNP I-POPU
cell NN I-POPU
Transplantation NNP I-POPU
in IN I-POPU
Acute NNP I-POPU
Myocardial NNP I-POPU
Infarction NNP I-POPU
( ( I-POPU
ASTAMI NNP I-POPU
) ) I-POPU
study NN I-POPU
were VBD I-POPU
re-assessed JJ I-POPU
3 CD I-POPU
years NNS I-POPU
after IN I-POPU
inclusion NN I-POPU
. . O

INTERVENTIONS NNP O
100 CD B-POPU
patients NNS I-POPU
with IN I-POPU
anterior JJ I-POPU
wall NN I-POPU
ST-elevation NNP I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
treated VBN I-POPU
with IN I-POPU
acute JJ I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
( ( I-POPU
PCI NNP I-POPU
) ) I-POPU
were VBD O
randomised VBN O
to TO O
receive VB O
intracoronary JJ B-INTV
injection NN I-INTV
of IN I-INTV
mBMCs NN I-INTV
( ( I-INTV
n JJ I-INTV
= NNP I-INTV
50 CD I-INTV
) ) I-INTV
or CC I-INTV
not RB I-INTV
( ( O
n JJ O
= NNP O
50 CD O
) ) O
. . O

MAIN NNP O
OUTCOME NNP O
MEASURES NNP O
Change NNP B-OC
in IN I-OC
left JJ I-OC
ventricular NN I-OC
( ( I-OC
LV NNP I-OC
) ) I-OC
ejection NN I-OC
fraction NN I-OC
( ( O
primary JJ O
) ) O
. . O

Change NN B-OC
in IN I-OC
exercise NN I-OC
capacity NN I-OC
( ( I-OC
peak JJ I-OC
VO NNP I-OC
( ( I-OC
2 CD I-OC
) ) I-OC
) ) I-OC
and CC I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
( ( O
secondary JJ O
) ) O
. . O

Infarct NNP B-OC
size NN I-OC
( ( I-OC
additional JJ I-OC
aim NN I-OC
) ) I-OC
, , I-OC
and CC I-OC
safety NN I-OC
. . O

RESULTS VB O
The DT O
rates NNS B-OC
of IN I-OC
adverse JJ I-OC
clinical JJ I-OC
events NNS I-OC
in IN O
the DT O
groups NNS O
were VBD O
low JJ O
and CC O
equal JJ O
. . O

There EX O
were VBD O
no DT O
significant JJ O
differences NNS O
between IN O
groups NNS O
in IN O
change NN B-OC
of IN I-OC
global JJ I-OC
LV NNP I-OC
systolic JJ I-OC
function NN I-OC
by IN O
echocardiography NN O
or CC O
magnetic JJ O
resonance NN O
imaging NN O
( ( O
MRI NNP O
) ) O
during IN O
the DT O
follow-up JJ O
. . O

On IN O
exercise NN O
testing NN O
, , O
the DT O
mBMC-treated JJ B-INTV
patients NNS O
had VBD O
larger JJR O
improvement NN O
in IN O
exercise NN B-OC
time NN I-OC
from IN O
2-3 JJ O
weeks NNS O
to TO O
3 CD O
years NNS O
( ( O
1.5 CD O
minutes NNS O
vs VBP O
0.6 CD O
minutes NNS O
, , O
p VBP O
= RB O
0.05 CD O
) ) O
, , O
but CC O
the DT O
change NN O
in IN O
peak NN B-OC
oxygen NN I-OC
consumption NN I-OC
did VBD O
not RB O
differ VB O
( ( O
3.0 CD O
ml/kg/min NN O
vs NN O
3.1 CD O
ml/kg/min NN O
, , O
p NN O
= NNP O
0.75 CD O
) ) O
. . O

CONCLUSION VB O
The DT O
results NNS O
indicate VBP O
that IN O
intracoronary JJ O
mBMC NN O
treatment NN O
in IN O
AMI NNP O
is VBZ O
safe JJ O
in IN O
the DT O
long JJ O
term NN O
. . O

A DT O
small JJ O
improvement NN O
in IN O
exercise NN O
time NN O
in IN O
the DT O
mBMC NN B-INTV
group NN O
was VBD O
found VBN O
, , O
but CC O
no DT O
other JJ O
effects NNS O
of IN O
treatment NN O
could MD O
be VB O
identified VBN O
3 CD O
years NNS O
after IN O
cell NN B-INTV
therapy NN I-INTV
. . O

-DOCSTART- -X- O O

Patterns NNS O
of IN O
management NN B-POPU
of IN I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
complicating VBG I-POPU
coronary JJ I-POPU
artery NN I-POPU
bypass NN I-POPU
grafting NN I-POPU
: : I-POPU
Results NNS O
from IN O
the DT O
PRoject NN O
of IN O
Ex-vivo NNP O
Vein NNP O
graft NN O
ENgineering NNP O
via IN O
Transfection NNP O
IV NNP O
( ( O
PREVENT-IV NNP O
) ) O
Trial NNP O
. . O

BACKGROUND NNP O
Current NNP O
practice NN O
related VBD O
to TO O
the DT O
management NN B-POPU
of IN I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
( ( I-POPU
AF NNP I-POPU
) ) I-POPU
complicating VBG I-POPU
coronary JJ I-POPU
artery NN I-POPU
bypass NN I-POPU
grafting NN I-POPU
( ( I-POPU
CABG NNP I-POPU
) ) I-POPU
is VBZ O
uncertain JJ O
. . O

METHODS NNP O
We PRP O
examined VBD O
management NN O
of IN O
post-CABG JJ B-POPU
AF NNP I-POPU
in IN I-POPU
the DT I-POPU
PREVENT-IV NNP I-POPU
trial NN I-POPU
, , O
and CC O
we PRP O
explored VBD O
patterns NNS O
of IN O
use NN O
of IN O
postoperative JJ B-INTV
rhythm NNS I-INTV
versus JJ I-INTV
rate NN I-INTV
control NN I-INTV
and CC I-INTV
anticoagulation NN I-INTV
for IN I-INTV
AF NNP I-INTV
by IN I-INTV
geographic JJ B-POPU
region NN I-POPU
and CC B-INTV
type NN B-POPU
of IN I-POPU
site NN I-POPU
. . O

We PRP O
also RB O
compared VBN O
outcomes NNS O
of IN O
patients NNS B-POPU
who WP I-POPU
developed VBD I-POPU
post-CABG JJ I-POPU
AF NNP I-POPU
( ( I-POPU
663 CD I-POPU
) ) I-POPU
with IN I-POPU
those DT I-POPU
who WP I-POPU
did VBD I-POPU
not RB I-POPU
( ( I-POPU
2,131 CD I-POPU
) ) I-POPU
. . O

RESULTS VB O
The DT O
incidence NN O
of IN O
AF NNP B-OC
was VBD O
24 CD O
% NN O
. . O

Post-CABG JJ B-INTV
AF NNP I-INTV
was VBD O
treated VBN O
with IN O
a DT O
rhythm NN O
control NN O
strategy NN O
in IN O
81 CD O
% NN O
of IN O
patients NNS O
and CC O
with IN O
warfarin NN B-INTV
in IN O
23 CD O
% NN O
of IN O
patients NNS O
. . O

Although IN O
there EX O
were VBD O
significant JJ O
variations NNS O
across IN O
sites NNS O
in IN O
the DT O
management NN O
of IN O
post-CABG JJ B-OC
AF NNP I-OC
, , O
patterns NNS O
of IN O
use NN O
of IN O
postoperative JJ O
rhythm NNS O
versus JJ O
rate NN O
control NN O
and CC O
anticoagulation NN O
did VBD O
not RB O
differ VB O
by IN O
geographic JJ O
region NN O
or CC O
by IN O
whether IN O
or CC O
not RB O
the DT O
enrolling VBG O
site NN O
was VBD O
an DT O
academic JJ O
institution NN O
. . O

Mortality NNP B-OC
was VBD O
higher RBR O
in IN O
patients NNS B-POPU
with IN I-POPU
post-CABG JJ I-POPU
AF NNP O
than IN O
patients NNS B-POPU
without IN I-POPU
AF NNP I-POPU
at IN O
30 CD O
days NNS O
( ( O
1.5 CD O
% NN O
vs JJ O
0.7 CD O
% NN O
, , O
P NNP O
= NNP O
.01 NNP O
) ) O
but CC O
not RB O
at IN O
3 CD O
years NNS O
( ( O
6.9 CD O
% NN O
vs JJ O
4.9 CD O
% NN O
, , O
P NNP O
= NNP O
.41 NNP O
) ) O
. . O

There EX O
was VBD O
a DT O
trend NN O
toward IN O
a DT O
higher JJR O
risk NN B-OC
of IN O
mortality NN B-OC
or CC I-OC
stroke NN I-OC
at IN O
30 CD O
days NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
AF NNP I-POPU
( ( O
2.4 CD O
% NN O
vs JJ O
1.9 CD O
% NN O
, , O
P NNP O
= NNP O
.08 NNP O
) ) O
. . O

CONCLUSION NNP O
Although IN O
a DT O
rhythm NN O
control NN O
strategy NN O
was VBD O
used VBN O
in IN O
most JJS O
of IN O
the DT O
patients NNS O
in IN O
this DT O
trial NN O
and CC O
the DT O
overall JJ O
rate NN O
of IN O
use NN O
of IN O
warfarin NN O
was VBD O
low JJ O
, , O
the DT O
significance NN O
of IN O
these DT O
findings NNS O
is VBZ O
uncertain JJ O
because IN O
of IN O
the DT O
lack NN O
of IN O
data NNS O
from IN O
randomized JJ O
clinical JJ O
trials NNS O
. . O

The DT O
substantial JJ O
variations NNS O
in IN O
the DT O
management NN O
of IN O
post-CABG JJ O
AF NNP O
across IN O
sites NNS O
are VBP O
likely JJ O
because IN O
of IN O
definitive JJ O
data NNS O
on IN O
the DT O
most RBS O
effective JJ O
therapies NNS O
, , O
highlighting VBG O
the DT O
need NN O
for IN O
clinical JJ O
trials NNS O
on IN O
rate NN O
versus IN O
rhythm NN O
control NN O
and CC O
on IN O
anticoagulation NN O
for IN O
AF NNP O
in IN O
this DT O
setting NN O
. . O

-DOCSTART- -X- O O

Intravenous JJ O
platelet NN O
blockade NN O
with IN O
cangrelor NN B-INTV
during IN O
PCI NNP B-POPU
. . O

BACKGROUND NNP O
Intravenous NNP O
cangrelor NN B-INTV
, , O
a DT O
rapid-acting NN O
, , O
reversible JJ O
adenosine NN O
diphosphate NN O
( ( O
ADP NNP O
) ) O
receptor NN O
antagonist NN O
, , O
might MD O
reduce VB O
ischemic JJ O
events NNS O
during IN O
percutaneous JJ B-POPU
coronary JJ I-POPU
intervention NN I-POPU
( ( I-POPU
PCI NNP I-POPU
) ) I-POPU
. . O

METHODS NNP O
In IN O
this DT O
double-blind NN O
, , O
placebo-controlled JJ O
study NN O
, , O
we PRP O
randomly VBP O
assigned JJ O
5362 CD B-POPU
patients NNS I-POPU
who WP I-POPU
had VBD I-POPU
not RB I-POPU
been VBN I-POPU
treated VBN I-POPU
with IN I-POPU
clopidogrel NN I-POPU
to TO I-POPU
receive VB I-POPU
either DT I-POPU
cangrelor NN I-POPU
or CC I-POPU
placebo NN I-POPU
at IN I-POPU
the DT I-POPU
time NN I-POPU
of IN I-POPU
PCI NNP I-POPU
, , I-POPU
followed VBN I-POPU
by IN I-POPU
600 CD I-POPU
mg NNS I-POPU
of IN I-POPU
clopidogrel NN I-POPU
. . O

The DT O
primary JJ O
end NN O
point NN O
was VBD O
a DT O
composite JJ B-OC
of IN I-OC
death NN I-OC
, , I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
or CC I-OC
ischemia-driven JJ I-OC
revascularization NN I-OC
at IN I-OC
48 CD I-OC
hours NNS I-OC
. . O

Enrollment NN O
was VBD O
stopped VBN O
when WRB O
an DT O
interim JJ O
analysis NN O
concluded VBD O
that IN O
the DT O
trial NN O
would MD O
be VB O
unlikely JJ O
to TO O
show VB O
superiority NN O
for IN O
the DT O
primary JJ O
end NN O
point NN O
. . O

RESULTS VB O
The DT O
primary JJ B-POPU
end NN I-POPU
point NN I-POPU
occurred VBD I-POPU
in IN I-POPU
185 CD I-POPU
of IN I-POPU
2654 CD I-POPU
patients NNS I-POPU
receiving VBG I-POPU
cangrelor NN I-POPU
( ( I-POPU
7.0 CD I-POPU
% NN I-POPU
) ) I-POPU
and CC I-POPU
in IN I-POPU
210 CD I-POPU
of IN I-POPU
2641 CD I-POPU
patients NNS I-POPU
receiving VBG I-POPU
placebo NN I-POPU
( ( I-POPU
8.0 CD I-POPU
% NN I-POPU
) ) I-POPU
( ( O
odds NNS O
ratio NN O
in IN O
the DT O
cangrelor NN O
group NN O
, , O
0.87 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
[ NNP O
CI NNP O
] NNP O
, , O
0.71 CD O
to TO O
1.07 CD O
; : O
P=0.17 NNP O
) ) O
( ( O
modified VBN O
intention-to-treat NN O
population NN O
adjusted VBN O
for IN O
missing VBG O
data NNS O
) ) O
. . O

In IN O
the DT O
cangrelor NN B-INTV
group NN O
, , O
as IN O
compared VBN O
with IN O
the DT O
placebo NN O
group NN O
, , O
two CD O
prespecified VBD O
secondary JJ O
end NN O
points NNS O
were VBD O
significantly RB O
reduced VBN O
at IN O
48 CD O
hours NNS O
: : O
the DT O
rate NN B-OC
of IN I-OC
stent JJ I-OC
thrombosis NN I-OC
, , O
from IN O
0.6 CD O
% NN O
to TO O
0.2 CD O
% NN O
( ( O
odds JJ O
ratio NN O
, , O
0.31 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.11 CD O
to TO O
0.85 CD O
; : O
P=0.02 NNP O
) ) O
, , O
and CC O
the DT O
rate NN B-OC
of IN I-OC
death NN I-OC
from IN I-OC
any DT I-OC
cause NN I-OC
, , O
from IN O
0.7 CD O
% NN O
to TO O
0.2 CD O
% NN O
( ( O
odds JJ O
ratio NN O
, , O
0.33 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.13 CD O
to TO O
0.83 CD O
; : O
P=0.02 NNP O
) ) O
. . O

There EX O
was VBD O
no DT O
significant JJ O
difference NN O
in IN O
the DT O
rate NN B-OC
of IN I-OC
blood NN I-OC
transfusion NN I-OC
( ( O
1.0 CD O
% NN O
in IN O
the DT O
cangrelor NN B-INTV
group NN O
and CC O
0.6 CD O
% NN O
in IN O
the DT O
placebo NN B-INTV
group NN O
, , O
P=0.13 NNP O
) ) O
, , O
though IN O
major JJ B-OC
bleeding VBG I-OC
on IN O
one CD O
scale NN O
was VBD O
increased VBN O
in IN O
the DT O
cangrelor NN O
group NN O
, , O
from IN O
3.5 CD O
% NN O
to TO O
5.5 CD O
% NN O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
, , O
because IN O
of IN O
more JJR O
groin JJ B-OC
hematomas NN I-OC
. . O

CONCLUSIONS VB O
The DT O
use NN O
of IN O
periprocedural JJ O
cangrelor NN B-INTV
during IN O
PCI NNP O
was VBD O
not RB O
superior JJ O
to TO O
placebo VB O
in IN O
reducing VBG O
the DT O
primary JJ O
end NN O
point NN O
. . O

The DT O
prespecified JJ O
secondary JJ O
end NN O
points NNS O
of IN O
stent JJ O
thrombosis NN O
and CC O
death NN O
were VBD O
lower JJR O
in IN O
the DT O
cangrelor NN B-INTV
group NN O
, , O
with IN O
no DT O
significant JJ O
increase NN O
in IN O
the DT O
rate NN O
of IN O
transfusion NN O
. . O

Further NNP O
study NN O
of IN O
intravenous JJ O
ADP NNP B-INTV
blockade NN I-INTV
with IN I-INTV
cangrelor NN I-INTV
may MD O
be VB O
warranted VBN O
. . O

( ( O
ClinicalTrials.gov NNP O
number NN O
, , O
NCT00385138 NNP O
. . O

) ) O
-DOCSTART- -X- O O

The DT O
effect NN B-OC
of IN O
posture NN B-INTV
on IN O
Cheyne-Stokes NNP O
respirations NNS O
and CC O
hemodynamics NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

STUDY NNP O
OBJECTIVES NNP O
Cheyne-Stokes NNP O
respirations NNS O
occur VBP O
in IN O
40 CD O
% NN O
of IN O
patients NNS B-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

Orthopnea NNP O
is VBZ O
a DT O
cardinal JJ O
symptom NN O
of IN O
heart NN O
failure NN O
and CC O
may MD O
affect VB O
the DT O
patient NN O
's POS O
sleeping VBG O
angle NN O
. . O

The DT O
objective NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
assess VB B-OC
the DT I-OC
respiratory NN I-OC
and CC I-OC
hemodynamic JJ I-OC
response NN I-OC
to TO O
sleeping VBG B-INTV
angle NN I-INTV
in IN O
a DT O
group NN B-POPU
of IN I-POPU
subjects NNS I-POPU
with IN I-POPU
stable JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

DESIGN NNP O
Twenty-five JJ B-POPU
patients NNS I-POPU
underwent JJ O
overnight JJ O
polysomnography NN O
with IN O
simultaneous JJ O
and CC O
continuous JJ O
impedance NN O
cardiographic JJ O
monitoring NN O
. . O

Sleeping VBG B-OC
polysomnographic JJ I-OC
and CC I-OC
impedance JJ I-OC
cardiographic JJ I-OC
data NNS I-OC
were VBD O
recorded VBN O
. . O

SETTING VBG O
The DT O
study NN O
was VBD O
conducted VBN O
in IN O
a DT O
sleep JJ O
center NN O
. . O

PATIENTS VB O
All DT B-POPU
25 CD I-POPU
patients NNS I-POPU
had VBD I-POPU
clinically RB I-POPU
stable JJ I-POPU
heart NN I-POPU
failure NN I-POPU
and CC I-POPU
left VBD I-POPU
ventricular JJ I-POPU
ejection NN I-POPU
fractions NNS I-POPU
< VBP I-POPU
40 CD I-POPU
% NN I-POPU
. . O

INTERVENTIONS NNP O
The DT O
patients NNS O
slept VBD B-INTV
at IN I-INTV
0 CD I-INTV
degrees NNS I-INTV
, , I-INTV
15 CD I-INTV
degrees NNS I-INTV
, , I-INTV
30 CD I-INTV
degrees NNS I-INTV
, , I-INTV
and CC I-INTV
45 CD I-INTV
degrees NNS I-INTV
in IN I-INTV
random JJ I-INTV
order NN I-INTV
. . O

MEASUREMENTS NNS O
AND CC O
RESULTS NNP O
Seventeen NNP O
patients NNS O
had VBD O
Cheyne-Stokes NNP B-OC
apneas NNS I-OC
( ( O
index NN O
> RB O
5/h CD O
) ) O
and CC O
23 CD O
patients NNS O
had VBD O
hypopneas NNS B-OC
( ( O
index NN O
> RB O
5/h CD O
) ) O
. . O

The DT O
hypopnea NN B-OC
index NN I-OC
showed VBD O
no DT O
response NN O
to TO O
sleeping VBG O
angle NN O
. . O

The DT O
Cheyne-Stokes NNP B-OC
apnea NN I-OC
index NN I-OC
decreased VBD O
with IN O
increasing VBG O
sleeping VBG O
angle NN O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

This DT O
effect NN O
was VBD O
seen VBN O
only RB O
during IN O
supine JJ O
sleep NN O
and CC O
non-rapid JJ O
eye NN O
movement NN O
sleep NN O
and CC O
was VBD O
absent VBN O
in IN O
non-supine JJ O
sleep NN O
, , O
rapid JJ O
eye NN O
movement NN O
sleep NN O
, , O
and CC O
during IN O
periods NNS O
of IN O
wakefulness NN O
. . O

Thoracic NNP B-OC
fluid NN I-OC
content NN I-OC
index NN I-OC
and CC I-OC
left VBD I-OC
ventricular JJ I-OC
hemodynamics NNS I-OC
measured VBN O
by IN O
impedance NN O
cardiography NN O
showed VBD O
no DT O
response NN O
to TO O
sleeping VBG O
angle NN O
. . O

CONCLUSIONS NNP O
Changing VBG O
the DT O
heart NN O
failure NN O
patient NN O
's POS O
sleeping VBG O
angle NN O
from IN O
0 CD O
degrees NNS O
to TO O
45 CD O
degrees NNS O
results NNS O
in IN O
a DT O
significant JJ O
decrease NN O
in IN O
Cheyne-Stokes NNP O
apneas NN O
. . O

This DT O
decrease NN O
occurs VBZ O
on IN O
a DT O
constant JJ O
base NN O
of IN O
hypopneas NNS O
. . O

The DT O
changes NNS O
in IN O
Cheyne-Stokes NNP O
apneas NNS O
are VBP O
not RB O
related VBN O
to TO O
changes NNS O
in IN O
lung NN O
congestion NN O
and CC O
left VBD O
ventricular JJ O
hemodynamics NNS O
. . O

-DOCSTART- -X- O O

Ten-year JJ O
incidence NN O
of IN O
myocardial JJ O
infarction NN O
and CC O
prognosis NN O
after IN O
infarction NN O
. . O

Department NNP O
of IN O
Veterans NNP O
Affairs NNP O
Cooperative NNP O
Study NNP O
of IN O
Coronary NNP O
Artery NNP O
Bypass NNP O
Surgery NNP O
. . O

BACKGROUND NNP O
The DT O
10-year JJ O
incidence NN O
of IN O
myocardial JJ O
infarction NN O
( ( O
fatal JJ O
and CC O
nonfatal JJ O
) ) O
and CC O
the DT O
prognosis NN O
after IN O
infarction NN O
were VBD O
evaluated VBN O
in IN O
686 CD B-POPU
patients NNS I-POPU
with IN I-POPU
stable JJ I-POPU
angina NNS I-POPU
who WP O
were VBD O
randomly RB O
assigned VBN O
to TO O
medical JJ B-INTV
or CC I-INTV
surgical JJ I-INTV
treatment NN I-INTV
in IN O
the DT O
Veterans NNPS O
Administration NNP O
Cooperative NNP O
Study NNP O
of IN O
Coronary NNP O
Artery NNP O
Bypass NNP O
Surgery NNP O
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
Myocardial NNP O
infarction NN O
was VBD O
defined VBN O
by IN O
either DT O
new JJ O
Q NNP O
wave VBP O
findings NNS O
or CC O
clinical JJ O
symptoms NNS O
compatible JJ O
with IN O
myocardial JJ B-POPU
infarction NN I-POPU
accompanied VBN I-POPU
by IN I-POPU
serum NN I-POPU
enzyme NN I-POPU
elevations NNS I-POPU
with IN I-POPU
or CC I-POPU
without IN I-POPU
electrocardiographic JJ I-POPU
findings NNS O
. . O

Treatment JJ O
comparisons NNS O
were VBD O
made VBN O
according VBG O
to TO O
original JJ O
treatment NN O
assignment NN O
; : O
35 CD O
% NN O
of IN O
the DT O
medical JJ O
cohort NN O
had VBD O
bypass NN B-INTV
surgery NN I-INTV
during IN O
the DT O
10-year JJ O
follow-up JJ O
period NN O
. . O

The DT O
overall JJ B-OC
cumulative JJ I-OC
infarction NN I-OC
rate NN I-OC
was VBD O
somewhat RB O
higher JJR O
in IN O
patients NNS O
assigned VBN O
to TO O
surgery VB B-INTV
( ( O
36 CD O
% NN O
) ) O
than IN O
in IN O
medical JJ O
patients NNS O
( ( O
31 CD O
% NN O
) ) O
( ( O
p JJ O
= NNP O
0.13 CD O
) ) O
due JJ O
to TO O
perioperative JJ O
infarctions NNS O
( ( O
13 CD O
% NN O
) ) O
and CC O
an DT O
accelerated JJ B-OC
infarction NN I-OC
rate NN I-OC
after IN O
the DT O
fifth JJ O
year NN O
of IN O
follow-up NN O
( ( O
average JJ O
, , O
2.4 CD O
% NN O
/yr NN O
in IN O
the DT O
surgical JJ O
group NN O
versus VBD O
1.4 CD O
% NN O
/yr NN O
in IN O
the DT O
medical JJ O
group NN O
) ) O
. . O

The DT O
10-year JJ B-OC
cumulative JJ I-OC
incidence NN I-OC
of IN I-OC
death NN I-OC
or CC I-OC
myocardial JJ I-OC
infarction NN I-OC
was VBD O
also RB O
higher JJR O
in IN O
surgical JJ O
( ( O
54 CD O
% NN O
) ) O
than IN O
in IN O
medical JJ O
( ( O
49 CD O
% NN O
) ) O
patients NNS O
( ( O
p JJ O
= NNP O
0.20 CD O
) ) O
. . O

According VBG O
to TO O
the DT O
Cox NNP O
model NN O
, , O
the DT O
estimated VBN B-OC
risk NN I-OC
of IN I-OC
death NN I-OC
after IN I-OC
infarction NN I-OC
was VBD O
59 CD O
% NN O
lower JJR O
in IN O
surgical JJ O
than IN O
in IN O
medical JJ O
patients NNS O
( ( O
p NN O
less JJR O
than IN O
0.0001 CD O
) ) O
. . O

The DT O
reduction NN B-OC
in IN O
postinfarction NN B-OC
mortality NN I-OC
with IN O
surgery NN O
was VBD O
most RBS O
striking JJ O
in IN O
the DT O
first JJ O
month NN O
after IN O
the DT O
event NN O
: : O
99 CD O
% NN O
in IN O
the DT O
first JJ O
month NN O
( ( O
p NN O
less JJR O
than IN O
0.0001 CD O
) ) O
and CC O
49 CD O
% NN O
subsequently RB O
( ( O
p NN O
less JJR O
than IN O
0.0001 CD O
) ) O
. . O

The DT O
estimated VBN O
risk NN B-OC
of IN I-OC
death NN I-OC
in IN I-OC
the DT I-OC
absence NN I-OC
of IN I-OC
infarction NN I-OC
was VBD O
nearly RB O
identical JJ O
regardless NN O
of IN O
treatment NN O
( ( O
p JJ O
= NNP O
0.75 CD O
) ) O
. . O

Exclusion NN O
of IN O
perioperative JJ O
infarctions NNS O
did VBD O
not RB O
alter VB O
the DT O
findings NNS O
. . O

CONCLUSIONS NNP O
Although IN O
surgery NN O
does VBZ O
not RB O
reduce VB O
the DT O
incidence NN O
of IN O
myocardial JJ B-OC
infarction NN I-OC
overall RB O
, , O
it PRP O
does VBZ O
reduce VB O
the DT O
risk NN O
of IN O
mortality NN B-OC
after IN O
infarction NN O
, , O
particularly RB O
in IN O
the DT O
first JJ O
30 CD O
days NNS O
after IN O
the DT O
event NN O
( ( O
fatal JJ O
infarctions NNS O
) ) O
. . O

-DOCSTART- -X- O O

Stress NNP B-INTV
reduction NN I-INTV
prolongs NNS O
life NN O
in IN O
women NNS B-POPU
with IN I-POPU
coronary JJ I-POPU
disease NN I-POPU
: : I-POPU
the DT O
Stockholm NNP O
Women NNP O
's POS O
Intervention NNP O
Trial NNP O
for IN O
Coronary NNP O
Heart NNP O
Disease NNP O
( ( O
SWITCHD NNP O
) ) O
. . O

BACKGROUND NNP O
Psychosocial NNP O
stress NN O
may MD O
increase VB O
risk NN O
and CC O
worsen JJ O
prognosis NN O
of IN O
coronary JJ B-POPU
heart NN I-POPU
disease NN I-POPU
in IN I-POPU
women NNS I-POPU
. . O

Interventions NNS O
that IN O
counteract JJ O
women NNS O
's POS O
psychosocial JJ O
stress NN O
have VBP O
not RB O
previously RB O
been VBN O
presented VBN O
. . O

This DT O
study NN O
implemented VBD O
a DT O
stress JJ B-INTV
reduction NN I-INTV
program NN I-INTV
for IN O
women NNS B-POPU
and CC O
investigated VBD O
its PRP$ O
ability NN O
to TO O
improve VB O
survival NN B-OC
in IN I-OC
women NNS B-POPU
coronary JJ I-POPU
patients NNS I-POPU
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
Two CD B-POPU
hundred VBD I-POPU
thirty-seven JJ I-POPU
consecutive JJ I-POPU
women NNS I-POPU
patients NNS I-POPU
, , I-POPU
aged VBD I-POPU
75 CD I-POPU
years NNS I-POPU
or CC I-POPU
younger JJR I-POPU
, , I-POPU
hospitalized VBN I-POPU
for IN I-POPU
acute JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
, , I-POPU
coronary JJ I-POPU
artery NN I-POPU
bypass NN I-POPU
grafting NN I-POPU
, , I-POPU
or CC I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
were VBD O
randomized VBN O
to TO O
a DT O
group-based JJ B-INTV
psychosocial JJ I-INTV
intervention NN I-INTV
program NN I-INTV
or CC I-INTV
usual JJ I-INTV
care NN I-INTV
. . O

Initiated VBN O
4 CD O
months NNS O
after IN O
hospitalization NN O
, , O
intervention NN O
groups NNS O
of IN O
4 CD O
to TO O
8 CD O
women NNS O
met VBD O
for IN O
a DT O
total NN O
of IN O
20 CD O
sessions NNS O
that WDT O
were VBD O
spread VBN O
over IN O
a DT O
year NN O
. . O

We PRP O
provided VBD O
education NN B-INTV
about IN I-INTV
risk NN I-INTV
factors NNS I-INTV
, , I-INTV
relaxation NN I-INTV
training NN I-INTV
techniques NNS I-INTV
, , I-INTV
methods NNS I-INTV
for IN I-INTV
self-monitoring NN I-INTV
and CC I-INTV
cognitive JJ I-INTV
restructuring NN I-INTV
, , I-INTV
with IN I-INTV
an DT I-INTV
emphasis NN I-INTV
on IN I-INTV
coping VBG I-INTV
with IN I-INTV
stress JJ I-INTV
exposure NN I-INTV
from IN I-INTV
family NN I-INTV
and CC I-INTV
work NN I-INTV
, , I-INTV
and CC I-INTV
self-care NN I-INTV
and CC I-INTV
compliance NN I-INTV
with IN I-INTV
clinical JJ I-INTV
advice NN I-INTV
. . O

From IN O
randomization NN O
until IN O
end NN O
of IN O
follow-up NN O
( ( O
mean JJ O
duration NN O
, , O
7.1 CD O
years NNS O
) ) O
, , O
25 CD O
women NNS O
( ( O
20 CD O
% NN O
) ) O
in IN O
the DT O
usual JJ O
care NN O
and CC O
8 CD O
women NNS O
( ( O
7 CD O
% NN O
) ) O
in IN O
the DT O
stress NN B-OC
reduction NN I-OC
died VBD O
, , O
yielding VBG O
an DT O
almost RB O
3-fold JJ O
protective JJ O
effect NN O
of IN O
the DT O
intervention NN O
( ( O
odds NNS O
ratio NN O
, , O
0.33 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.15 CD O
to TO O
0.74 CD O
; : O
P=0.007 NNP O
) ) O
. . O

Introducing VBG O
baseline JJ O
measures NNS O
of IN O
clinical JJ O
prognostic JJ O
factors NNS O
, , O
including VBG O
use NN B-INTV
of IN I-INTV
aspirin NN I-INTV
, , I-INTV
beta-blockers NNS I-INTV
, , I-INTV
angiotensin-converting JJ I-INTV
enzyme NN I-INTV
inhibitors NNS I-INTV
, , I-INTV
calcium-channel JJ I-INTV
blockers NNS I-INTV
, , I-INTV
and CC I-INTV
statins VBZ I-INTV
into IN I-INTV
multivariate NN I-INTV
models NNS I-INTV
confirmed VBD O
the DT O
unadjusted JJ O
results NNS O
( ( O
P=0.009 NNP O
) ) O
. . O

CONCLUSIONS NNP O
Although IN O
mechanisms NN O
remain VBP O
unclear JJ O
, , O
a DT O
group-based JJ B-INTV
psychosocial JJ I-INTV
intervention NN I-INTV
program NN I-INTV
for IN O
women NNS B-POPU
with IN I-POPU
coronary JJ I-POPU
heart NN I-POPU
disease NN I-POPU
may MD O
prolong VB O
lives NNS O
independent JJ O
of IN O
other JJ O
prognostic JJ O
factors NNS O
. . O

-DOCSTART- -X- O O

PROCLAIM NN O
: : O
pilot NN O
study NN O
to TO O
examine VB O
the DT O
effects NNS O
of IN O
clopidogrel NN B-INTV
on IN O
inflammatory JJ O
markers NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
metabolic JJ I-POPU
syndrome JJ I-POPU
receiving VBG I-POPU
low-dose JJ I-POPU
aspirin NN I-POPU
. . O

Metabolic NNP O
syndrome NN O
is VBZ O
associated VBN O
with IN O
intravascular JJ O
inflammation NN O
, , O
as IN O
determined VBN O
by IN O
increased JJ O
levels NNS O
of IN O
inflammatory NN O
biomarkers NNS O
and CC O
an DT O
increased VBN O
risk NN O
of IN O
ischemic JJ O
atherothrombotic JJ O
events NNS O
. . O

Evidence NN O
suggests VBZ O
that IN O
atherothrombosis NN O
and CC O
intravascular JJ O
inflammation NN O
share NN O
predictive JJ O
biomarkers NNS O
, , O
including VBG O
high-sensitivity JJ O
C-reactive JJ O
protein NN O
, , O
CD40 NNP O
ligand NN O
, , O
P-selectin NNP O
, , O
and CC O
N-terminal JJ O
pro-brain JJ O
natriuretic JJ O
peptide NN O
. . O

Patients NNS B-POPU
who WP I-POPU
had VBD I-POPU
metabolic JJ I-POPU
syndrome NN I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
clopidogrel NN B-INTV
75 CD I-INTV
mg/day JJ I-INTV
plus CC I-INTV
aspirin JJ I-INTV
81 CD I-INTV
mg/day NN I-INTV
( ( I-INTV
n JJ I-INTV
= NNP I-INTV
89 CD I-INTV
) ) I-INTV
or CC I-INTV
placebo JJ I-INTV
plus CC I-INTV
aspirin JJ I-INTV
81 CD I-INTV
mg/day NN I-INTV
( ( I-INTV
n JJ I-INTV
= NNP I-INTV
92 CD I-INTV
) ) I-INTV
for IN I-INTV
9 CD I-INTV
weeks NNS I-INTV
to TO O
assess VB O
the DT O
efficacy NN O
of IN O
each DT O
treatment NN O
in IN O
suppression NN O
of IN O
inflammatory JJ O
markers NNS O
. . O

Change NN O
from IN O
baseline NN O
in IN O
the DT O
levels NNS O
of IN O
high-sensitivity NN B-OC
C-reactive JJ I-OC
protein NN I-OC
, , I-OC
CD40 NNP I-OC
ligand NN I-OC
, , I-OC
P-selectin NNP I-OC
, , I-OC
and CC I-OC
N-terminal JJ I-OC
pro-brain JJ I-OC
natriuretic JJ I-OC
peptide NN I-OC
at IN O
6 CD O
weeks NNS O
was VBD O
assessed VBN O
to TO O
evaluate VB O
each DT O
treatment NN O
. . O

There EX O
was VBD O
a DT O
significant JJ O
difference NN O
at IN O
Week JJ O
6 CD O
in IN O
model-adjusted JJ B-OC
CD40-ligand NNP I-OC
levels NNS I-OC
in IN O
favor NN O
of IN O
clopidogrel NN B-INTV
plus CC I-INTV
aspirin JJ I-INTV
compared VBN O
with IN O
placebo NN B-INTV
plus CC I-INTV
aspirin NN I-INTV
in IN O
both DT O
the DT O
intent-to-treat JJ O
population NN O
( ( O
difference NN O
between IN O
least-squares NNS O
means NNS O
= VBP O
-186.5 NNP O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
-342.3 NN O
to TO O
-30.8 VB O
; : O
P NNP O
= NNP O
0.02 CD O
) ) O
and CC O
the DT O
per-protocol JJ O
population NN O
( ( O
P NNP O
= NNP O
0.05 CD O
) ) O
. . O

No DT O
significant JJ O
differences NNS O
were VBD O
observed VBN O
between IN O
the DT O
treatment NN O
arms NNS O
for IN O
high-sensitivity JJ B-OC
C-reactive JJ I-OC
protein NN I-OC
, , I-OC
P-selectin NNP I-OC
, , I-OC
and CC I-OC
N-terminal JJ I-OC
pro-brain JJ I-OC
natriuretic JJ I-OC
peptide NN I-OC
. . O

There EX O
were VBD O
no DT O
deaths NNS B-OC
or CC I-OC
serious JJ I-OC
adverse JJ I-OC
events NNS I-OC
in IN O
either DT O
treatment NN O
arm NN O
. . O

Data NNS O
from IN O
this DT O
study NN O
suggest VBP O
that IN O
clopidogrel NN B-INTV
can MD O
decrease VB O
the DT O
expression NN B-OC
of IN I-OC
the DT I-OC
CD40-ligand NNP I-OC
biomarker NN I-OC
. . O

-DOCSTART- -X- O O

Epirubicin NNP B-INTV
and CC I-INTV
cyclophosphamide VB I-INTV
versus NN O
epirubicin NN B-INTV
and CC I-INTV
docetaxel NN I-INTV
as IN O
first-line JJ O
therapy NN O
for IN O
women NNS B-POPU
with IN I-POPU
metastatic JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
final JJ O
results NNS O
of IN O
a DT O
randomised JJ O
phase NN O
III NNP O
trial NN O
. . O

BACKGROUND VB O
This DT O
randomised JJ O
phase NN O
III NNP O
trial NN O
was VBD O
carried VBN O
out IN O
to TO O
compare VB O
the DT O
efficacy NN O
and CC O
safety NN O
of IN O
epirubicin NN B-INTV
and CC I-INTV
cyclophosphamide NN I-INTV
( ( I-INTV
EC NNP I-INTV
) ) I-INTV
with IN I-INTV
epirubicin NN I-INTV
and CC I-INTV
docetaxel NN I-INTV
( ( I-INTV
Taxotere NNP I-INTV
) ) I-INTV
( ( I-INTV
ED NNP I-INTV
) ) I-INTV
as IN O
first-line JJ O
chemotherapy NN O
for IN O
metastatic JJ B-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

PATIENTS NNP O
AND CC O
METHODS NNP O
Patients NNP B-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
240 CD I-POPU
) ) I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO O
receive VB O
either DT O
ED NNP B-INTV
( ( I-INTV
epirubicin JJ I-INTV
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
and CC B-INTV
docetaxel $ I-INTV
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
or CC O
EC NNP B-INTV
( ( I-INTV
epirubicin VBP I-INTV
90 CD O
mg/m NN O
( ( O
2 CD O
) ) O
and CC O
cyclophosphamide $ B-INTV
600 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
. . O

The DT O
primary JJ O
end NN O
point NN O
was VBD O
objective JJ B-OC
response NN I-OC
rate NN I-OC
( ( I-OC
ORR NNP I-OC
) ) I-OC
. . O

Secondary JJ O
end NN O
points NNS O
were VBD O
progression-free JJ B-OC
survival NN I-OC
( ( I-OC
PFS NNP I-OC
) ) I-OC
, , I-OC
overall JJ I-OC
survival NN I-OC
( ( I-OC
OS NNP I-OC
) ) I-OC
, , I-OC
and CC I-OC
safety NN I-OC
. . O

RESULTS NNP O
ORR NNP B-OC
for IN O
patients NNS O
randomly RB O
assigned VBN O
to TO O
receive VB O
EC NNP B-INTV
and CC O
ED NNP B-INTV
were VBD O
42 CD O
% NN O
and CC O
47 CD O
% NN O
, , O
respectively RB O
( ( O
P NNP O
= NNP O
0.63 CD O
) ) O
. . O

Median JJ B-OC
PFS NNP I-OC
[ NNP O
10.1 CD O
versus NN O
10.3 CD O
months NNS O
; : O
hazard VBN O
ratio NN O
( ( O
HR NNP O
) ) O
0.98 CD O
; : O
log-rank JJ O
P NNP O
= NNP O
0.38 CD O
] NN O
and CC O
OS NNP B-OC
( ( O
19.9 CD O
versus NN O
30.0 CD O
months NNS O
; : O
HR NNP O
0.663 CD O
; : O
log-rank JJ O
P NNP O
= NNP O
0.21 CD O
) ) O
were VBD O
comparable JJ O
in IN O
both DT O
arms NNS O
. . O

Although IN O
grade JJ B-OC
3/4 CD I-OC
leucopenia NN I-OC
occurred VBD O
more RBR O
frequently RB O
with IN O
ED NNP B-INTV
( ( O
81 CD O
% NN O
versus IN O
73 CD O
% NN O
; : O
P NNP O
= NNP O
0.01 CD O
) ) O
, , O
there EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
the DT O
incidence NN O
of IN O
febrile JJ B-OC
neutropenia NN I-OC
and CC I-OC
grade VBD I-OC
3/4 CD I-OC
infections NNS I-OC
. . O

Grade VB B-OC
3/4 CD I-OC
non-haematologic JJ I-OC
toxicity NN I-OC
was VBD O
infrequent JJ O
in IN O
both DT O
arms NNS O
. . O

Congestive JJ B-OC
heart NN I-OC
failure NN I-OC
was VBD O
observed VBN O
in IN O
one CD O
patient NN O
in IN O
each DT O
arm NN O
. . O

CONCLUSION NN O
In IN O
this DT O
randomised JJ O
trial NN O
, , O
no DT O
differences NNS O
in IN O
the DT O
efficacy NN O
study VBD O
end JJ O
points NNS O
were VBD O
observed VBN O
between IN O
the DT O
two CD O
treatment NN O
arms NNS O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
milrinone NN B-INTV
on IN O
short-term JJ O
outcome NN O
of IN O
patients NNS B-POPU
with IN I-POPU
myocardial JJ I-POPU
dysfunction NN I-POPU
undergoing VBG I-POPU
coronary JJ I-POPU
artery NN I-POPU
bypass NN I-POPU
graft NN I-POPU
: : I-POPU
A DT O
randomized NN O
controlled VBN O
trial NN O
. . O

BACKGROUND NNP O
Myocardial NNP O
dysfunction NN O
needing VBG O
inotropic JJ O
support NN O
is VBZ O
a DT O
typical JJ O
complication NN O
after IN O
on-pump JJ O
cardiac JJ O
surgery NN O
. . O

In IN O
this DT O
study NN O
, , O
we PRP O
evaluate VBP O
the DT O
effect NN O
of IN O
milrinone NN B-INTV
on IN O
patients NNS B-POPU
with IN I-POPU
ventricular JJ I-POPU
dysfunction NN I-POPU
undergoing VBG I-POPU
coronary JJ I-POPU
artery NN I-POPU
bypass NN I-POPU
graft NN I-POPU
( ( I-POPU
CABG NNP I-POPU
) ) I-POPU
. . O

METHODS NNP O
Seventy NNP B-POPU
patients NNS I-POPU
with IN I-POPU
impaired JJ I-POPU
left VBD I-POPU
ventricular JJ I-POPU
function NN I-POPU
[ NN I-POPU
left VBD I-POPU
ventricular JJ I-POPU
ejection NN I-POPU
fraction NN I-POPU
( ( I-POPU
LVEF NNP I-POPU
) ) I-POPU
< VBD I-POPU
35 CD I-POPU
% NN I-POPU
] JJ I-POPU
undergoing JJ I-POPU
on-pump JJ I-POPU
CABG NNP I-POPU
were VBD I-POPU
enrolled VBN I-POPU
. . O

Patients NNS O
were VBD O
randomized VBN O
to TO O
receive VB O
either DT O
an DT O
intraoperative JJ B-INTV
bolus NN I-INTV
of IN I-INTV
milrinone NN I-INTV
( ( I-INTV
50 CD I-INTV
microg/kg NN I-INTV
) ) I-INTV
or CC I-INTV
saline NN I-INTV
as IN I-INTV
placebo NN I-INTV
followed VBN O
by IN O
a DT O
24-hour JJ O
infusion NN O
of IN O
each DT O
agent NN O
( ( O
0.5 CD O
microg/kg/min NN O
) ) O
. . O

Hemodynamic JJ B-OC
parameters NNS I-OC
and CC I-OC
transthoracic JJ I-OC
echocardiographic JJ I-OC
measurement NN I-OC
of IN I-OC
systolic JJ I-OC
and CC I-OC
diastolic JJ I-OC
functions NNS I-OC
were VBD O
the DT O
variables NNS O
evaluated VBN O
. . O

RESULTS NNP O
Serum NNP B-OC
levels NNS I-OC
of IN I-OC
creatine NN I-OC
phosphokinase NN I-OC
( ( I-OC
CPK NNP I-OC
) ) I-OC
, , I-OC
the DT I-OC
MB NNP I-OC
isoenzyme NN I-OC
of IN I-OC
creatine NN I-OC
kinase NN I-OC
( ( I-OC
CK-MB NNP I-OC
) ) I-OC
, , I-OC
occurrence NN I-OC
of IN I-OC
myocardial JJ I-OC
ischemia NN I-OC
or CC I-OC
infarction NN I-OC
, , I-OC
and CC I-OC
mean JJ I-OC
duration NN I-OC
of IN I-OC
using VBG I-OC
inotropic JJ I-OC
agents NNS I-OC
were VBD O
significantly RB O
lower JJR O
in IN O
the DT O
milrinone NN O
group NN O
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
. . O

There EX O
were VBD O
no DT O
significant JJ O
differences NNS O
between IN O
the DT O
two CD O
groups NNS O
regarding VBG O
the DT O
development NN B-OC
of IN I-OC
ventricular JJ I-OC
arrhythmia NN I-OC
, , I-OC
duration NN I-OC
of IN I-OC
cardiopulmonary JJ I-OC
bypass NN I-OC
, , I-OC
intra-aortic JJ I-OC
balloon NN I-OC
pump NN I-OC
and CC I-OC
inotropic JJ I-OC
support NN I-OC
requirement NN I-OC
, , I-OC
duration NN I-OC
of IN I-OC
mechanical JJ I-OC
ventilation NN I-OC
, , I-OC
duration NN I-OC
of IN I-OC
intensive JJ I-OC
care NN I-OC
unit NN I-OC
stay NN I-OC
and CC I-OC
mortality NN I-OC
rate NN I-OC
. . O

Although IN O
mean JJ O
pre-operative JJ O
LVEF NNP O
was VBD O
significantly RB O
lower JJR O
in IN O
the DT O
milrinone NN B-INTV
group NN O
, , O
there EX O
was VBD O
no DT O
significant JJ O
difference NN O
between IN O
post-operative JJ O
LVEFs NNP O
. . O

CONCLUSIONS NNP O
We PRP O
suggest VBP O
that IN O
perioperative JJ O
administration NN O
of IN O
milrinone NN B-INTV
in IN O
patients NNS B-POPU
undergoing VBG I-POPU
on-pump JJ I-POPU
CABG NNP I-POPU
, , O
especially RB O
those DT O
with IN O
low JJ O
LVEF NNP O
, , O
is VBZ O
beneficial JJ O
. . O

-DOCSTART- -X- O O

Catheter NNP B-INTV
ablation NN I-INTV
of IN I-INTV
stable JJ I-INTV
ventricular JJ B-POPU
tachycardia NN I-POPU
before IN I-POPU
defibrillator NN I-POPU
implantation NN I-POPU
in IN I-POPU
patients NNS I-POPU
with IN I-POPU
coronary JJ I-POPU
heart NN I-POPU
disease NN I-POPU
( ( I-POPU
VTACH NNP I-POPU
) ) I-POPU
: : I-POPU
a DT O
multicentre NN O
randomised VBD O
controlled VBN O
trial NN O
. . O

BACKGROUND NNP O
In IN O
patients NNS B-POPU
with IN I-POPU
ventricular JJ I-POPU
tachycardia NN I-POPU
( ( I-POPU
VT NNP I-POPU
) ) I-POPU
and CC I-POPU
a DT I-POPU
history NN I-POPU
of IN I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
, , O
intervention NN O
with IN O
an DT O
implantable JJ B-INTV
cardioverter NN I-INTV
defibrillator NN I-INTV
( ( I-INTV
ICD NNP I-INTV
) ) I-INTV
can MD O
prevent VB O
sudden JJ O
cardiac JJ O
death NN O
and CC O
thereby RB O
reduce VB O
total JJ O
mortality NN O
. . O

However RB O
, , O
ICD NNP O
shocks NNS O
are VBP O
painful JJ O
and CC O
do VBP O
not RB O
provide VB O
complete JJ O
protection NN O
against IN O
sudden JJ O
cardiac JJ O
death NN O
. . O

We PRP O
assessed VBD O
the DT O
potential JJ O
benefit NN O
of IN O
catheter NN B-INTV
ablation NN I-INTV
before IN O
implantation NN O
of IN O
a DT O
cardioverter NN O
defibrillator NN O
. . O

METHODS NNP O
The DT B-POPU
Ventricular NNP I-POPU
Tachycardia NNP I-POPU
Ablation NNP I-POPU
in IN I-POPU
Coronary NNP I-POPU
Heart NNP I-POPU
Disease NNP I-POPU
( ( I-POPU
VTACH NNP I-POPU
) ) I-POPU
study NN I-POPU
was VBD I-POPU
a DT I-POPU
prospective JJ I-POPU
, , I-POPU
open JJ I-POPU
, , I-POPU
randomised VBD I-POPU
controlled VBN I-POPU
trial NN I-POPU
, , I-POPU
undertaken VBN I-POPU
in IN I-POPU
16 CD I-POPU
centres NNS I-POPU
in IN I-POPU
four CD I-POPU
European JJ I-POPU
countries NNS I-POPU
. . O

Patients NNS B-POPU
aged VBN I-POPU
18-80 CD I-POPU
years NNS I-POPU
were VBD I-POPU
eligible JJ I-POPU
for IN I-POPU
enrolment NN I-POPU
if IN I-POPU
they PRP I-POPU
had VBD I-POPU
stable JJ I-POPU
VT NNP I-POPU
, , I-POPU
previous JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
, , I-POPU
and CC I-POPU
reduced VBD I-POPU
left-ventricular JJ I-POPU
ejection NN I-POPU
fraction NN I-POPU
( ( I-POPU
LVEF NNP I-POPU
; : I-POPU
< NNP I-POPU
or=50 IN I-POPU
% NN I-POPU
) ) I-POPU
. . O

110 CD B-POPU
patients NNS I-POPU
were VBD I-POPU
randomly RB I-POPU
allocated VBN I-POPU
in IN I-POPU
a DT I-POPU
1:1 CD I-POPU
ratio NN I-POPU
to TO O
receive VB B-INTV
catheter NN I-INTV
ablation NN I-INTV
and CC I-INTV
an DT I-INTV
ICD NNP I-INTV
( ( I-INTV
ablation NN I-INTV
group NN I-INTV
, , I-INTV
n=54 RB I-INTV
) ) I-INTV
or CC I-INTV
ICD NNP I-INTV
alone RB I-INTV
( ( I-INTV
control NN I-INTV
group NN I-INTV
, , I-INTV
n=56 RB I-INTV
) ) I-INTV
. . O

Randomisation NN O
was VBD O
done VBN O
by IN O
computer-generated JJ O
randomly NNS O
permuted VBN O
blocks NNS O
and CC O
stratified VBN O
by IN O
centre NN O
and CC O
LVEF NNP O
( ( O
< JJ O
or=30 CD O
% NN O
or CC O
> VB O
30 CD O
% NN O
) ) O
. . O

Patients NNS O
were VBD O
followed VBN O
up RP O
for IN O
at IN O
least JJS O
1 CD O
year NN O
. . O

The DT O
primary JJ O
endpoint NN O
was VBD O
the DT O
time NN B-OC
to TO I-OC
first JJ I-OC
recurrence NN I-OC
of IN I-OC
VT NNP I-OC
or CC I-OC
ventricular JJ I-OC
fibrillation NN I-OC
( ( I-OC
VF NNP I-OC
) ) I-OC
. . O

Analysis NN O
was VBD O
by IN O
intention NN O
to TO O
treat VB O
( ( O
ITT NNP O
) ) O
. . O

This DT O
study NN O
is VBZ O
registered VBN O
with IN O
ClinicalTrials.gov NNP O
, , O
number NN O
NCT00919373 NNP O
. . O

FINDINGS NNP O
107 CD B-POPU
patients NNS I-POPU
were VBD I-POPU
included VBN I-POPU
in IN I-POPU
the DT I-POPU
ITT NNP I-POPU
population NN I-POPU
( ( I-POPU
ablation NN I-POPU
group NN I-POPU
, , I-POPU
n=52 RB I-POPU
; : I-POPU
control NN I-POPU
group NN I-POPU
, , I-POPU
n=55 RB I-POPU
) ) I-POPU
. . O

Two CD O
patients NNS O
( ( O
one CD O
in IN O
each DT O
group NN O
) ) O
withdrew VBD O
consent NN O
immediately RB O
after IN O
randomisation NN O
without IN O
any DT O
follow-up JJ O
data NNS O
and CC O
one CD O
patient NN O
( ( O
ablation NN O
group NN O
) ) O
was VBD O
excluded VBN O
because IN O
of IN O
a DT O
protocol NN O
violaton NN O
. . O

Mean JJ O
follow-up NN O
was VBD O
22.5 CD O
months NNS O
( ( O
SD NNP O
9.0 CD O
) ) O
. . O

Time NN B-OC
to TO I-OC
recurrence NN I-OC
of IN I-OC
VT NNP I-OC
or CC I-OC
VF NNP I-OC
was VBD O
longer RBR O
in IN O
the DT O
ablation NN B-INTV
group NN I-INTV
( ( O
median JJ O
18.6 CD O
months NNS O
[ NNP O
lower JJR O
quartile NN O
2.4 CD O
, , O
upper JJ O
quartile NN O
not RB O
determinable JJ O
] NN O
) ) O
than IN O
in IN O
the DT O
control NN B-INTV
group NN I-INTV
( ( O
5.9 CD O
months NNS O
[ JJ O
IQR NNP O
0.8-26.7 NNP O
] NNP O
) ) O
. . O

At IN O
2 CD O
years NNS O
, , O
estimates NNS O
for IN O
survival JJ B-OC
free JJ O
from IN O
VT NNP B-OC
or CC I-OC
VF NNP I-OC
were VBD O
47 CD O
% NN O
in IN O
the DT O
ablation NN B-INTV
group NN I-INTV
and CC O
29 CD O
% NN O
in IN O
the DT O
control NN B-INTV
group NN I-INTV
( ( O
hazard JJ O
ratio NN O
0.61 CD O
; : O
95 CD O
% NN O
CI NNP O
0.37-0.99 CD O
; : O
p=0.045 NN O
) ) O
. . O

Complications NNS O
related VBN O
to TO O
the DT O
ablation NN O
procedure NN O
occurred VBD O
in IN O
two CD O
patients NNS O
; : O
no DT B-OC
deaths NNS I-OC
occurred VBD O
within IN O
30 CD O
days NNS O
after IN O
ablation NN O
. . O

15 CD O
device-related JJ O
complications NNS O
requiring VBG O
surgical JJ O
intervention NN O
occurred VBD O
in IN O
13 CD O
patients NNS O
( ( B-INTV
ablation NN I-INTV
group NN I-INTV
, , O
four CD O
; : O
control NN B-INTV
group NN I-INTV
, , O
nine CD O
) ) O
. . O

Nine JJ B-POPU
patients NNS I-POPU
died VBD I-POPU
during IN I-POPU
the DT I-POPU
study NN I-POPU
( ( I-POPU
ablation NN I-POPU
group NN I-POPU
, , I-POPU
five CD I-POPU
; : I-POPU
control NN I-POPU
group NN I-POPU
, , I-POPU
four CD I-POPU
) ) I-POPU
. . O

INTERPRETATION NNP O
Prophylactic NNP B-INTV
VT NNP I-INTV
ablation NN I-INTV
before IN O
defibrillator NN B-INTV
implantation NN I-INTV
seemed VBD O
to TO O
prolong VB O
time NN O
to TO O
recurrence NN O
of IN O
VT NNP O
in IN O
patients NNS B-POPU
with IN I-POPU
stable JJ I-POPU
VT NNP I-POPU
, , I-POPU
previous JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
, , I-POPU
and CC I-POPU
reduced VBD I-POPU
LVEF NNP I-POPU
. . O

Prophylactic NNP B-INTV
catheter NN I-INTV
ablation NN I-INTV
should MD O
therefore RB O
be VB O
considered VBN O
before IN O
implantation NN O
of IN O
a DT O
cardioverter NN B-INTV
defibrillator NN I-INTV
in IN O
such JJ O
patients NNS O
. . O

FUNDING NNP O
St NNP O
Jude NNP O
Medical NNP O
. . O

-DOCSTART- -X- O O

Biventricular JJ O
pacing VBG O
improves NNS O
cardiac JJ B-OC
function NN I-OC
and CC O
prevents NNS O
further RBR O
left VBD B-OC
atrial JJ I-OC
remodeling NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
symptomatic JJ I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
after IN I-POPU
atrioventricular JJ I-POPU
node JJ I-POPU
ablation NN I-POPU
. . O

BACKGROUND NNP O
Randomized NNP O
trials NNS O
have VBP O
demonstrated VBN O
benefits NNS O
of IN O
biventricular NN B-INTV
( ( I-INTV
BiV NNP I-INTV
) ) I-INTV
pacing NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
heart NN I-POPU
failure NN I-POPU
, , I-POPU
intraventricular JJ I-POPU
conduction NN I-POPU
delay NN I-POPU
, , I-POPU
and CC I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
( ( I-POPU
AF NNP I-POPU
) ) I-POPU
post-atrioventricular NN I-POPU
( ( I-POPU
AV NNP I-POPU
) ) I-POPU
node NN I-POPU
ablation NN I-POPU
. . O

The DT O
AV NNP O
Node NNP O
Ablation NNP O
with IN O
CLS NNP O
and CC O
CRT NNP O
Pacing NNP O
Therapies NNP O
for IN O
Treatment NNP O
of IN O
AF NNP O
trial NN O
( ( O
AVAIL NNP O
CLS/CRT NNP O
) ) O
was VBD O
designed VBN O
to TO O
demonstrate VB O
superiority NN O
of IN O
BiV NNP O
pacing VBG O
in IN O
patients NNS O
with IN O
AF NNP O
after IN O
AV NNP O
node JJ O
ablation NN O
, , O
to TO O
evaluate VB O
its PRP$ O
effects NNS O
on IN O
cardiac JJ O
structure NN O
and CC O
function NN O
, , O
and CC O
to TO O
investigate VB O
additional JJ O
benefits NNS O
of IN O
Closed JJ O
Loop NNP O
Stimulation NNP O
( ( O
CLS NNP O
) ) O
( ( O
BIOTRONIK NNP O
, , O
Berlin NNP O
, , O
Germany NNP O
) ) O
. . O

METHODS JJ O
Patients NNS B-POPU
with IN I-POPU
refractory JJ I-POPU
AF NNP I-POPU
underwent NN I-POPU
AV NNP I-POPU
node CC I-POPU
ablation NN I-POPU
and CC O
were VBD O
randomized VBN O
( ( O
2:2:1 CD O
) ) O
to TO O
BiV NNP B-INTV
pacing VBG I-INTV
with IN I-INTV
CLS NNP I-INTV
, , I-INTV
BiV NNP I-INTV
pacing VBG I-INTV
with IN I-INTV
accelerometer NN I-INTV
, , I-INTV
or CC I-INTV
right JJ I-INTV
ventricular NN I-INTV
( ( I-INTV
RV NNP I-INTV
) ) I-INTV
pacing NN I-INTV
. . O

Echocardiography NN O
was VBD O
performed VBN O
at IN O
baseline NN O
and CC O
6 CD O
months NNS O
, , O
with IN O
paired VBN O
data NNS O
available JJ O
for IN O
108 CD B-POPU
patients NNS I-POPU
. . O

RESULTS VB O
The DT O
RV NNP O
pacing NN O
contributed VBD O
to TO O
significant JJ O
increase NN O
in IN O
left JJ B-OC
atrial JJ I-OC
volume NN I-OC
, , I-OC
left VBD I-OC
ventricular JJ I-OC
( ( I-OC
LV NNP I-OC
) ) I-OC
end-systolic JJ I-OC
volume NN I-OC
, , I-OC
and CC I-OC
LV NNP I-OC
mass NN I-OC
compared VBN O
to TO O
BiV NNP O
pacing NN O
. . O

Ejection NNP B-OC
fraction NN I-OC
decreased VBD O
insignificantly RB O
with IN O
RV NNP O
pacing VBG O
compared VBN O
to TO O
significant JJ O
increase NN O
with IN O
BiV NNP O
pacing VBG O
. . O

Interventricular JJ B-OC
dyssynchrony NN I-OC
significantly RB O
decreased VBN O
with IN O
BiV NNP O
compared VBN O
with IN O
RV NNP O
pacing VBG O
. . O

Closed VBN O
Loop NNP O
Stimulation NNP O
did VBD O
not RB O
result VB O
in IN O
additional JJ O
echocardiographic JJ B-OC
changes NNS I-OC
; : I-OC
heart NN I-OC
rate NN I-OC
distribution NN I-OC
was VBD O
significantly RB O
wider JJR O
with IN O
CLS NNP O
. . O

All DT O
groups NNS O
showed VBD O
significant JJ O
improvement NN O
in IN O
6-minute JJ B-OC
walk NN I-OC
distance NN I-OC
, , I-OC
quality-of-life JJ I-OC
score NN I-OC
, , I-OC
and CC I-OC
New NNP I-OC
York NNP I-OC
Heart NNP I-OC
Association NNP I-OC
class NN I-OC
. . O

CONCLUSION NNP O
In IN O
conclusion NN O
, , O
RV NNP O
pacing VBG O
results NNS O
in IN O
significant JJ O
increase NN O
in IN O
left JJ B-OC
atrial JJ I-OC
volume NN I-OC
, , I-OC
LV NNP I-OC
mass NN I-OC
, , O
and CC O
worsening NN B-OC
of IN I-OC
LV NNP I-OC
contractility NN I-OC
compared VBN O
to TO O
patients NNS O
receiving VBG O
BiV NNP O
pacing VBG O
post-AV JJ O
node JJ O
ablation NN O
for IN O
refractory NN O
AF NNP O
. . O

Closed VBD O
Loop NNP O
Stimulation NNP O
was VBD O
not RB O
associated VBN O
with IN O
additional JJ O
structural JJ B-OC
changes NNS I-OC
but CC O
resulted VBD O
in IN O
significantly RB O
wider JJR B-OC
heart NN I-OC
rate NN I-OC
distribution NN I-OC
. . O

-DOCSTART- -X- O O

A DT O
randomized JJ O
comparison NN O
of IN O
the DT O
Endeavor NNP B-INTV
zotarolimus-eluting JJ I-INTV
stent NN I-INTV
versus IN I-INTV
the DT I-INTV
TAXUS NNP I-INTV
paclitaxel-eluting JJ I-INTV
stent NN I-INTV
in IN O
de FW O
novo FW O
native JJ O
coronary JJ O
lesions NNS O
12-month JJ O
outcomes NNS O
from IN O
the DT O
ENDEAVOR NNP O
IV NNP O
trial NN O
. . O

OBJECTIVES CC O
The DT O
ENDEAVOR NNP O
IV NNP O
( ( O
Randomized NNP O
Comparison NNP O
of IN O
Zotarolimus-Eluting NNP B-INTV
and CC O
Paclitaxel-Eluting NNP B-INTV
Stents NNP I-INTV
in IN O
Patients NNP O
with IN O
Coronary NNP O
Artery NNP O
Disease NNP O
) ) O
trial NN O
evaluated VBD O
the DT O
safety NN B-OC
and CC I-OC
efficacy NN I-OC
of IN O
the DT O
zotarolimus-eluting JJ B-INTV
stent NN I-INTV
( ( I-INTV
ZES NNP I-INTV
) ) I-INTV
compared VBN I-INTV
with IN I-INTV
the DT I-INTV
paclitaxel-eluting JJ I-INTV
stent NN I-INTV
( ( I-INTV
PES NNP I-INTV
) ) I-INTV
. . O

BACKGROUND NNP O
First-generation NNP O
drug-eluting NN O
stents NNS O
have VBP O
reduced VBN O
angiographic JJ O
and CC O
clinical JJ O
restenosis NN O
, , O
but CC O
long-term JJ O
safety NN O
remains VBZ O
controversial JJ O
. . O

A DT O
second-generation JJ B-INTV
drug-eluting JJ I-INTV
stent NN I-INTV
, , O
which WDT O
delivers VBZ O
zotarolimus NN B-INTV
, , O
a DT O
potent JJ O
antiproliferative JJ O
agent NN O
, , O
via IN O
a DT O
biocompatible JJ O
phosphorylcholine NN O
polymer NN O
on IN O
a DT O
cobalt JJ O
alloy NN O
thin-strut JJ O
stent NN O
has VBZ O
shown VBN O
promising JJ O
experimental JJ O
and CC O
early JJ O
clinical JJ O
results NNS O
. . O

METHODS NNP O
This DT O
is VBZ O
a DT O
prospective JJ O
, , O
randomized VBN O
( ( O
1:1 CD O
) ) O
, , O
single-blind JJ O
, , O
controlled JJ O
trial NN O
comparing VBG O
outcomes NNS O
of IN O
patients NNS B-POPU
with IN I-POPU
single JJ I-POPU
de FW I-POPU
novo FW I-POPU
coronary JJ I-POPU
lesions NNS I-POPU
treated VBN I-POPU
with IN I-POPU
ZES NNP I-POPU
or CC I-POPU
PES NNP I-POPU
. . O

The DT O
primary JJ B-OC
end NN I-OC
point NN I-OC
was VBD I-OC
noninferiority NN I-OC
of IN I-OC
9-month JJ I-OC
target NN I-OC
vessel JJ I-OC
failure NN I-OC
defined VBD I-OC
as IN I-OC
cardiac JJ I-OC
death NN I-OC
, , I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
or CC I-OC
target VB I-OC
vessel JJ I-OC
revascularization NN I-OC
. . O

RESULTS NNP O
Among IN O
a DT O
total NN O
of IN O
1,548 CD B-POPU
patients NNS I-POPU
assigned VBN I-POPU
to TO I-POPU
ZES NNP I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
773 CD I-POPU
) ) I-POPU
or CC I-POPU
PES NNP I-POPU
( ( O
n JJ O
= NNP O
775 CD O
) ) O
, , O
at IN O
9 CD O
months NNS O
, , O
ZES NNP O
was VBD O
noninferior JJ O
to TO O
PES VB O
with IN O
rates NNS O
of IN O
target NN B-OC
vessel JJ I-OC
failure NN I-OC
6.6 CD O
% NN O
versus IN O
7.1 CD O
% NN O
, , O
respectively RB O
( ( O
p NN O
( ( O
noninferiority NN O
) ) O
< NN O
or CC O
= VB O
0.001 CD O
) ) O
. . O

There EX O
were VBD O
fewer JJR O
periprocedural JJ B-OC
myocardial JJ I-OC
infarctions NNS I-OC
with IN O
ZES NNP B-INTV
( ( O
0.5 CD O
% NN O
vs. FW O
2.2 CD O
% NN O
; : O
p CC O
= VB O
0.007 CD O
) ) O
, , O
whereas VBP O
at IN O
12 CD O
months NNS O
, , O
there EX O
were VBD O
no DT O
significant JJ O
differences NNS O
between IN O
groups NNS O
in IN O
rates NNS O
of IN O
cardiac JJ B-OC
death NN I-OC
, , I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
target NN I-OC
vessel NN I-OC
revascularization NN I-OC
, , I-OC
or CC I-OC
stent JJ I-OC
thrombosis NN I-OC
. . O

Although IN O
incidence NN O
of IN O
8-month JJ O
binary JJ B-OC
angiographic JJ I-OC
in-segment JJ I-OC
restenosis NN I-OC
was VBD O
higher RBR O
in IN O
patients NNS O
treated VBN O
with IN O
ZES NNP B-INTV
versus NN O
PES NNP O
( ( O
15.3 CD O
% NN O
vs. FW O
10.4 CD O
% NN O
; : O
p CC O
= VB O
0.284 CD O
) ) O
, , O
rates NNS O
of IN O
12-month JJ O
target NN B-OC
lesion NN I-OC
revascularization NN I-OC
were VBD O
similar JJ O
( ( O
4.5 CD O
% NN O
vs. FW O
3.2 CD O
% NN O
; : O
p CC O
= VB O
0.228 CD O
) ) O
, , O
especially RB O
in IN O
patients NNS O
without IN O
planned JJ O
angiographic JJ O
follow-up NN O
( ( O
3.6 CD O
% NN O
vs. FW O
3.2 CD O
% NN O
; : O
p CC O
= VB O
0.756 CD O
) ) O
. . O

CONCLUSIONS NNP O
These DT O
findings NNS O
demonstrate VBP O
that IN O
ZES NNP B-INTV
has VBZ O
similar JJ O
clinical JJ O
safety NN O
and CC O
efficacy NN O
compared VBN O
with IN O
PES NNP B-INTV
in IN O
simple JJ O
and CC O
medium JJ O
complexity NN O
single JJ O
de FW O
novo FW O
coronary JJ O
lesions NNS O
. . O

( ( O
ENDEAVOR NNP O
IV NNP O
Clinical NNP O
Trial NNP O
; : O
NCT00217269 NNP O
) ) O
. . O

-DOCSTART- -X- O O

A DT O
randomized JJ O
, , O
double-blind JJ O
, , O
placebo-controlled JJ B-INTV
, , O
phase NN O
I PRP O
study VBP O
of IN O
MEDI-545 NNP B-INTV
, , O
an DT O
anti-interferon-alfa JJ O
monoclonal NN O
antibody NN O
, , O
in IN O
subjects NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
psoriasis NN I-POPU
. . O

BACKGROUND NNP O
Interferon-alfa NNP O
( ( O
IFN-alpha NNP O
) ) O
has VBZ O
been VBN O
implicated VBN O
in IN O
the DT O
pathogenesis NN O
of IN O
psoriasis NN O
. . O

OBJECTIVE UH O
To TO O
evaluate VB O
the DT O
safety NN O
profile NN O
of IN O
MEDI-545 NNP B-INTV
, , O
a DT O
fully RB O
human JJ O
anti-IFN-alpha JJ O
monoclonal NN O
antibody NN O
and CC O
to TO O
explore VB O
its PRP$ O
effect NN O
on IN O
the DT O
involvement NN O
of IN O
type NN O
I PRP O
IFN-alpha VBP O
activity NN O
in IN O
the DT O
maintenance NN O
of IN O
established VBN O
plaque NN O
psoriasis NN O
. . O

METHODS NNP O
We PRP O
conducted VBD O
an DT O
18-week JJ O
, , O
randomized VBN O
, , O
double-blind JJ O
, , O
placebo-controlled JJ B-INTV
, , O
dose-escalating JJ O
study NN O
in IN O
36 CD B-POPU
subjects NNS I-POPU
with IN I-POPU
chronic JJ I-POPU
plaque NN I-POPU
psoriasis NN I-POPU
. . O

Subjects VBZ O
received VBD O
one CD O
intravenous JJ O
dose NN O
of IN O
MEDI-545 NNP B-INTV
( ( I-INTV
0.3-30.0 JJ I-INTV
mg/kg NN I-INTV
) ) I-INTV
or CC I-INTV
placebo NN I-INTV
. . O

Study NNP O
outcomes NNS O
were VBD O
safety NN B-OC
profile NN I-OC
, , I-OC
pharmacokinetics NNS I-OC
, , I-OC
immunogenicity NN I-OC
, , I-OC
and CC I-OC
clinical JJ I-OC
effects NNS I-OC
. . O

RESULTS NNP O
There EX O
was VBD O
no DT O
difference NN O
in IN O
adverse JJ B-OC
events NNS I-OC
between IN O
MEDI-545 NNP B-INTV
and CC I-INTV
placebo NN I-INTV
. . O

Two CD O
serious JJ O
adverse JJ O
events NNS O
were VBD O
reported VBN O
; : O
one CD O
drug-related JJ B-OC
hypotensive JJ I-OC
infusion NN I-OC
reaction NN I-OC
occurred VBD O
in IN O
one CD O
subject NN O
in IN O
the DT O
30.0 CD O
mg/kg JJ O
MEDI-545 NNP B-INTV
dose NN O
group NN O
, , O
causing VBG O
discontinuation NN O
of IN O
study JJ O
drug NN O
in IN O
that DT O
subject NN O
and CC O
study NN O
dismissal NN O
of IN O
the DT O
other JJ O
subjects NNS O
in IN O
the DT O
same JJ O
cohort NN O
; : O
and CC O
a DT O
myocardial JJ B-OC
infarction NN I-OC
occurred VBD O
in IN O
one CD O
subject NN O
in IN O
the DT O
10 CD O
mg/kg JJ O
MEDI-545 NNP B-INTV
dose NN O
group NN O
, , O
which WDT O
was VBD O
considered VBN O
to TO O
be VB O
unrelated JJ O
to TO O
treatment NN O
. . O

MEDI-545 NNP B-INTV
was VBD O
nonimmunogenic JJ O
, , O
had VBD O
a DT O
half-life NN B-OC
of IN O
21 CD O
days NNS O
, , O
showed VBD O
no DT O
significant JJ O
inhibition NN O
of IN O
the DT O
type NN O
I PRP O
IFN NNP O
gene NN O
signature NN O
, , O
and CC O
had VBD O
no DT O
clinical JJ B-OC
activity NN I-OC
. . O

LIMITATIONS VB O
The DT O
study NN O
addressed VBD O
only RB O
IFN-alpha NNP O
and CC O
chronic JJ O
psoriatic JJ O
lesions NNS O
. . O

CONCLUSION VB O
The DT O
safety NN O
profile NN O
of IN O
MEDI-545 NNP B-INTV
supports NNS O
further RBR O
clinical JJ O
development NN O
. . O

IFN-alpha NN O
does VBZ O
not RB O
appear VB O
to TO O
be VB O
significantly RB O
involved VBN O
in IN O
the DT O
maintenance NN O
of IN O
established VBN O
plaque NN O
psoriasis NN O
. . O

-DOCSTART- -X- O O

Differential JJ O
response NN O
to TO O
resistance VB B-INTV
training NN I-INTV
in IN O
CHF NNP O
according VBG O
to TO O
ACE NNP O
genotype NN O
. . O

BACKGROUND IN O
The DT O
Angiotensin NNP O
Converting NNP O
Enzyme NNP O
( ( O
ACE NNP O
) ) O
gene NN O
may MD O
influence VB O
the DT O
risk NN O
of IN O
heart NN O
disease NN O
and CC O
the DT O
response NN O
to TO O
various JJ O
forms NNS O
of IN O
exercise NN O
training NN O
may MD O
be VB O
at IN O
least JJS O
partly RB O
dependent JJ O
on IN O
the DT O
ACE NNP O
genotype NN O
. . O

We PRP O
aimed VBD O
to TO O
determine VB O
the DT O
effect NN O
of IN O
ACE NNP O
genotype NN O
on IN O
the DT O
response NN O
to TO O
moderate VB O
intensity NN O
circuit NN O
resistance NN B-INTV
training NN I-INTV
in IN O
chronic JJ B-POPU
heart NN I-POPU
failure NN I-POPU
( ( I-POPU
CHF NNP I-POPU
) ) I-POPU
patients NNS I-POPU
. . O

METHODS NNP O
The DT O
relationship NN O
between IN O
ACE NNP O
genotype NN O
and CC O
the DT O
response NN O
to TO O
11weeks CD B-INTV
of IN I-INTV
resistance NN I-INTV
exercise NN I-INTV
training NN I-INTV
was VBD O
determined VBN O
in IN O
37 CD B-POPU
CHF JJ I-POPU
patients NNS I-POPU
( ( I-POPU
New NNP I-POPU
York NNP I-POPU
Heart NNP I-POPU
Association NNP I-POPU
Functional NNP I-POPU
Class=2.3±0.5 NNP I-POPU
; : I-POPU
left VBD I-POPU
ventricular JJ I-POPU
ejection NN I-POPU
fraction NN I-POPU
28±7 CD I-POPU
% NN I-POPU
; : I-POPU
age NN I-POPU
64±12years CD I-POPU
; : I-POPU
32:5 CD I-POPU
male NN I-POPU
: : I-POPU
female NN I-POPU
) ) I-POPU
who WP I-POPU
were VBD I-POPU
randomised VBN I-POPU
to TO O
either DT B-INTV
resistance NN I-INTV
exercise NN I-INTV
( ( O
n=19 JJ O
) ) O
or CC B-INTV
inactive JJ I-INTV
control NN I-INTV
group NN I-INTV
( ( O
n=18 RB O
) ) O
. . O

Outcome NNP O
measures NNS O
included VBD B-OC
V˙O NNP I-OC
( ( I-OC
2peak CD I-OC
) ) I-OC
, , I-OC
peak JJ I-OC
power NN I-OC
output NN I-OC
and CC I-OC
muscle NN I-OC
strength NN I-OC
and CC I-OC
endurance NN I-OC
. . O

ACE NNP O
genotype NN O
was VBD O
determined VBN O
using VBG O
standard JJ O
methods NNS O
. . O

RESULTS NNP O
At IN O
baseline NN O
, , O
patients NNS O
who WP O
were VBD O
homozygous JJ O
for IN O
the DT O
I PRP O
allele VBP O
had VBD O
higher JJR B-OC
V˙O NNP I-OC
( ( I-OC
2peak CD I-OC
) ) I-OC
( ( I-OC
p=0.02 NN I-OC
) ) I-OC
and CC I-OC
peak JJ I-OC
power NN I-OC
( ( O
p=0.003 NN O
) ) O
compared VBN O
to TO O
patients NNS O
who WP O
were VBD O
homozygous JJ O
for IN O
the DT O
D NNP O
allele NN O
. . O

Patients NNS O
with IN O
the DT O
D NNP O
allele NN O
, , O
who WP O
were VBD O
randomised VBN B-INTV
to TO I-INTV
resistance VB I-INTV
training NN I-INTV
, , I-INTV
compared VBN I-INTV
to TO I-INTV
non-exercising JJ I-INTV
controls NNS O
, , O
had VBD O
greater JJR O
peak JJ O
power NN O
increases NNS O
( ( O
ID NNP O
p VBZ O
< JJ O
0.001 CD O
; : O
DD NNP O
p VBP O
< NNP O
0.001 CD O
) ) O
when WRB O
compared VBN O
with IN O
patients NNS O
homozygous JJ O
for IN O
the DT O
I PRP O
allele VBP O
, , O
who WP O
did VBD O
not RB O
improve VB O
. . O

No DT O
significant JJ O
genotype-dependent JJ O
changes NNS O
were VBD O
observed VBN B-OC
in IN I-OC
V˙O NNP I-OC
( ( I-OC
2peak CD I-OC
) ) I-OC
, , I-OC
muscle NN I-OC
strength NN I-OC
, , I-OC
muscle NN I-OC
endurance NN I-OC
or CC I-OC
lactate NN I-OC
threshold NN I-OC
. . O

CONCLUSION NNP O
ACE NNP O
genotype NN O
may MD O
have VB O
a DT O
role NN O
in IN O
exercise NN O
tolerance NN O
in IN O
CHF NNP O
and CC O
could MD O
also RB O
influence VB O
the DT O
effectiveness NN O
of IN O
resistance NN O
training NN O
in IN O
this DT O
condition NN O
. . O

-DOCSTART- -X- O O

Argatroban NNP B-INTV
for IN O
elective JJ O
percutaneous JJ O
coronary JJ O
intervention NN O
: : O
the DT O
ARG-E04 NNP O
multi-center NN O
study NN O
. . O

UNLABELLED IN O
The DT O
synthetic JJ O
arginine-derived JJ O
direct JJ O
thrombin NN O
inhibitor NN O
argatroban NN B-INTV
is VBZ O
an DT O
attractive JJ O
anticoagulant NN O
for IN O
percutaneous JJ B-INTV
coronary JJ I-INTV
intervention NN I-INTV
( ( I-INTV
PCI NNP I-INTV
) ) I-INTV
, , O
because IN O
of IN O
its PRP$ O
rapid JJ O
onset NN O
and CC O
offset NN O
, , O
and CC O
its PRP$ O
hepatic JJ O
elimination NN O
. . O

Argatroban NNP B-INTV
was VBD O
approved VBN O
for IN O
PCI NNP O
in IN O
patients NNS B-POPU
with IN I-POPU
heparin-induced JJ I-POPU
thrombocytopenia NN I-POPU
( ( I-POPU
HIT NNP I-POPU
) ) I-POPU
. . O

However RB O
, , O
there EX O
are VBP O
limited VBN O
data NNS O
about IN O
argatroban NN B-INTV
in IN O
non-HIT JJ O
patients NNS O
. . O

The DT O
objective NN O
of IN O
this DT O
open-label JJ O
, , O
multiple-dose JJ O
, , O
controlled VBD O
study NN O
was VBD O
to TO O
examine VB O
the DT O
safety NN B-OC
and CC I-OC
efficacy NN I-OC
of IN O
argatroban NN B-INTV
in IN O
patients NNS B-POPU
undergoing VBG I-POPU
elective JJ I-POPU
PCI NNP I-POPU
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
Of IN O
140 CD B-POPU
patients NNS I-POPU
randomized VBN O
to TO O
three CD O
argatroban NNS B-INTV
dose JJ O
groups NNS O
( ( B-INTV
ARG250 NNP I-INTV
, , I-INTV
ARG300 NNP I-INTV
, , O
and CC O
ARG350 NNP B-INTV
with IN O
250 CD O
, , O
300 CD O
, , O
or CC O
350 CD O
μg/kg JJ O
bolus NN O
, , O
followed VBN O
by IN O
15 CD O
, , O
20 CD O
, , O
or CC O
25 CD O
μg/kg/min JJ O
infusion NN O
) ) O
and CC O
one CD B-INTV
unfractionated JJ I-INTV
heparin NN I-INTV
( ( I-INTV
UFH NNP I-INTV
) ) I-INTV
group NN O
( ( O
70-100 JJ O
IU/kg NNP O
bolus NN B-POPU
) ) I-POPU
, , I-POPU
138 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
analyzed VBN I-POPU
. . O

Argatroban NNP B-INTV
dose-dependently RB O
prolonged VBD B-OC
activated VBN I-OC
clotting NN I-OC
time NN I-OC
( ( I-OC
ACT NNP I-OC
) ) I-OC
with IN O
more JJR O
patients NNS O
reaching VBG O
the DT O
minimum NN O
target NN B-OC
ACT NNP I-OC
after IN O
the DT O
initial JJ O
bolus NN O
injection NN B-INTV
( ( I-INTV
ARG250 NNP I-INTV
: : I-INTV
86.1 CD I-INTV
% NN I-INTV
, , I-INTV
ARG300 NNP I-INTV
: : I-INTV
89.5 CD O
% NN O
, , O
and CC B-INTV
ARG350 NNP I-INTV
: : I-INTV
96.8 CD O
% NN O
) ) O
compared VBN O
to TO O
45.5 CD O
% NN O
in IN O
UFH NNP O
( ( O
p JJ O
< NNP O
0.001 CD O
) ) O
. . O

The DT B-OC
patient JJ I-OC
proportion NN I-OC
who WP I-OC
did VBD I-OC
not RB I-OC
require VB I-OC
additional JJ I-OC
bolus NN I-OC
injections NNS I-OC
to TO O
start VB O
PCI NNP O
was VBD O
significantly RB O
higher JJR O
in IN B-INTV
argatroban NN I-INTV
than IN O
in IN B-INTV
UFH NNP I-INTV
( ( O
p JJ O
≤ NNP O
0.002 CD O
) ) O
. . O

Consequently RB B-OC
, , I-OC
the DT I-OC
time NN I-OC
to TO I-OC
start VB I-OC
of IN I-OC
PCI NNP O
was VBD O
shortened VBN B-INTV
in IN I-INTV
argatroban JJ I-INTV
groups NNS O
. . O

Composite NNP B-OC
incidences NNS I-OC
of IN I-OC
death NN I-OC
, , I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
and CC I-OC
urgent JJ I-OC
revascularization NN I-OC
until IN O
day NN O
30 CD O
were VBD O
not RB O
significantly RB O
different JJ O
between IN O
the DT O
groups NNS B-INTV
( ( I-INTV
ARG250 NNP I-INTV
: : I-INTV
2.8 CD I-INTV
% NN I-INTV
, , I-INTV
ARG300 NNP I-INTV
: : I-INTV
0.0 CD I-INTV
% NN I-INTV
, , I-INTV
ARG350 NNP I-INTV
: : I-INTV
3.2 CD O
% NN O
vs. FW B-INTV
UFH NNP O
: : O
3.0 CD B-OC
% NN I-OC
) ) I-OC
. . O

Major JJ B-OC
bleeding NN I-OC
was VBD O
observed VBN O
only RB B-INTV
in IN I-INTV
UFH NNP O
( ( O
3.0 CD O
% NN O
) ) O
, , O
while IN B-OC
minor JJ I-OC
bleeding NN I-OC
occurred VBD B-INTV
in IN I-INTV
ARG350 NNP I-INTV
( ( O
3.2 CD O
% NN O
) ) O
and CC B-INTV
UFH NNP O
( ( O
6.1 CD O
% NN O
, , O
n.s. NN O
) ) O
. . O

CONCLUSION NNP B-INTV
Argatroban NNP I-INTV
dose-dependently JJ O
increases NNS B-OC
coagulation NN I-OC
parameters NNS I-OC
and CC O
, , O
compared VBN B-INTV
to TO I-INTV
UFH NNP O
, , O
demonstrates VBZ O
a DT O
superior JJ O
predictable JJ B-OC
anticoagulant JJ I-OC
effect NN B-POPU
in IN I-POPU
patients NNS I-POPU
undergoing VBG I-POPU
elective JJ I-POPU
PCI NNP I-POPU
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
zoledronic JJ B-INTV
acid NN I-INTV
on IN O
disseminated JJ O
tumour NN O
cells NNS O
in IN O
women NNS B-POPU
with IN I-POPU
locally RB I-POPU
advanced JJ I-POPU
breast NN I-POPU
cancer NN I-POPU
: : I-POPU
an DT O
open JJ O
label NN O
, , O
randomised VBN O
, , O
phase VB O
2 CD O
trial NN O
. . O

BACKGROUND NNP O
Treatment NNP O
with IN O
bisphosphonates NNS B-INTV
decreases NNS O
bone VBP O
loss NN O
and CC O
can MD O
increase VB O
disease-free JJ O
survival NN O
in IN O
patients NNS B-POPU
with IN I-POPU
breast JJ I-POPU
cancer NN I-POPU
. . O

The DT O
aim NN O
of IN O
our PRP$ O
study NN O
was VBD O
to TO O
assess VB O
the DT O
effect NN O
of IN O
zoledronic JJ B-INTV
acid NN I-INTV
on IN O
clearance NN O
of IN O
disseminated JJ B-OC
tumour NN I-OC
cells NNS I-OC
( ( I-OC
DTCs NNP I-OC
) ) I-OC
from IN O
the DT O
bone NN O
marrow NN O
in IN O
women NNS B-POPU
undergoing VBG I-POPU
neoadjuvant JJ I-POPU
chemotherapy NN I-POPU
for IN I-POPU
breast NN I-POPU
cancer NN I-POPU
. . O

METHODS NNP O
Patients NNPS O
were VBD O
recruited VBN O
for IN O
this DT O
open-label JJ B-POPU
, , I-POPU
phase VB I-POPU
2 CD I-POPU
randomised JJ I-POPU
trial NN I-POPU
between IN I-POPU
March NNP I-POPU
17 CD I-POPU
, , I-POPU
2003 CD I-POPU
, , I-POPU
and CC I-POPU
May NNP I-POPU
19 CD I-POPU
, , I-POPU
2006 CD I-POPU
, , I-POPU
at IN I-POPU
a DT I-POPU
single JJ I-POPU
centre NN I-POPU
. . O

Eligible JJ B-POPU
patients NNS I-POPU
had VBD I-POPU
clinical JJ I-POPU
stage NN I-POPU
II-III NNP I-POPU
( ( I-POPU
> CD I-POPU
or CC I-POPU
= VB I-POPU
T2 NNP I-POPU
and/or JJ I-POPU
> NN I-POPU
or CC I-POPU
= VB I-POPU
N1 NNP I-POPU
) ) I-POPU
newly RB I-POPU
diagnosed VBN I-POPU
breast NN I-POPU
cancer NN I-POPU
, , I-POPU
Eastern NNP I-POPU
Cooperative NNP I-POPU
Oncology NNP I-POPU
Group NNP I-POPU
performance NN I-POPU
status NN I-POPU
of IN I-POPU
0 CD I-POPU
or CC I-POPU
1 CD I-POPU
, , I-POPU
and CC I-POPU
normal JJ I-POPU
cardiac NN I-POPU
, , I-POPU
renal JJ I-POPU
, , I-POPU
and CC I-POPU
liver JJ I-POPU
function NN I-POPU
. . O

120 CD B-POPU
women NNS I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
, , O
using VBG O
allocation NN O
concealment NN O
, , O
to TO O
receive VB O
4 CD B-INTV
mg NN I-INTV
zoledronic JJ I-INTV
acid NN I-INTV
intravenously RB I-INTV
every DT I-INTV
3 CD O
weeks NNS O
( ( O
n=60 NN O
) ) O
, , O
or CC O
no DT B-INTV
zoledronic JJ I-INTV
acid NN I-INTV
( ( O
n=60 JJ O
) ) O
, , O
for IN O
1 CD O
year NN O
concomitant NN O
with IN O
four CD B-INTV
cycles NNS I-INTV
of IN I-INTV
neoadjuvant JJ I-INTV
epirubicin NN I-INTV
( ( O
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
plus CC B-INTV
docetaxel JJ I-INTV
( ( O
75 CD O
mg/m NN O
( ( O
2 CD O
) ) O
) ) O
and CC B-INTV
two CD I-INTV
cycles NNS I-INTV
of IN I-INTV
adjuvant JJ I-INTV
epirubicin JJ I-INTV
plus CC I-INTV
docetaxel JJ I-INTV
. . O

The DT O
primary JJ O
endpoint NN O
was VBD O
the DT O
number NN O
of IN O
patients NNS O
with IN O
detectable JJ B-OC
DTCs NNP I-OC
at IN O
3 CD O
months NNS O
. . O

Final NNP O
analysis NN O
was VBD O
done VBN O
1 CD O
year NN O
after IN O
the DT O
last JJ O
patient NN O
was VBD O
enrolled VBN O
. . O

Analyses NNS O
were VBD O
done VBN O
for IN O
all DT O
patients NNS O
with IN O
available JJ O
data NNS O
at IN O
3 CD O
months NNS O
. . O

This DT O
study NN O
is VBZ O
registered VBN O
with IN O
ClinicalTrials.gov NNP O
, , O
number NN O
NCT00242203 NNP O
. . O

FINDINGS NNP O
Of IN O
the DT O
120 CD B-POPU
patients NNS I-POPU
initially RB I-POPU
enrolled VBD I-POPU
, , I-POPU
one CD I-POPU
withdrew NN I-POPU
after IN I-POPU
signing VBG I-POPU
consent NN I-POPU
and CC I-POPU
one CD I-POPU
patient NN I-POPU
's POS I-POPU
baseline NN I-POPU
bone NN I-POPU
marrow NN I-POPU
was VBD I-POPU
not RB I-POPU
available JJ I-POPU
. . O

Both DT O
of IN O
these DT O
patients NNS O
were VBD O
in IN O
the DT O
control NN O
group NN O
. . O

At IN O
3 CD O
months NNS O
, , O
109 CD B-POPU
bone-marrow NN I-POPU
samples NNS I-POPU
were VBD I-POPU
available JJ I-POPU
for IN O
analysis NN O
. . O

In IN O
the DT O
zoledronic JJ O
acid NN O
group NN O
, , O
bone NN O
marrow NN O
was VBD O
not RB O
collected VBN O
from IN O
one CD O
patient NN O
because IN O
of IN O
disease NN O
progression NN O
, , O
one CD O
patient NN O
was VBD O
taken VBN O
off RP O
study NN O
because IN O
of IN O
severe JJ O
diarrhoea NN O
, , O
and CC O
two CD O
patients NNS O
had VBD O
not RB O
consented VBN O
at IN O
the DT O
time NN O
of IN O
surgery NN O
. . O

In IN O
the DT O
control NN O
group NN O
, , O
bone NN O
marrow NN O
was VBD O
not RB O
collected VBN O
from IN O
two CD O
patients NNS O
because IN O
of IN O
disease NN O
progression NN O
, , O
one CD O
patient NN O
withdrew VBD O
consent NN O
, , O
and CC O
three CD O
patients NNS O
were VBD O
not RB O
consented VBN O
at IN O
the DT O
time NN O
of IN O
surgery NN O
. . O

At IN O
baseline NN O
, , O
DTCs NNP O
were VBD O
detected VBN O
in IN O
26 CD O
of IN O
60 CD O
patients NNS O
in IN O
the DT O
zoledronic JJ B-INTV
acid NN I-INTV
group NN O
and CC O
28 CD O
of IN O
58 CD O
patients NNS O
in IN O
the DT O
control NN O
group NN O
. . O

At IN O
3 CD O
months NNS O
, , O
17 CD O
of IN O
56 CD O
patients NNS O
receiving VBG O
zoledronic JJ O
acid NN O
versus IN O
25 CD O
of IN O
53 CD O
patients NNS O
who WP O
did VBD O
not RB O
receive VB O
zoledronic JJ O
acid NN O
had VBD O
detectable JJ O
DTCs NNP O
( ( O
p=0.054 NN O
) ) O
. . O

The DT O
most RBS O
common JJ O
grade NN O
3-4 JJ O
toxicities NNS O
were VBD O
infection NN O
( ( O
five CD O
of IN O
60 CD O
patients NNS O
in IN O
the DT O
zoledronic JJ O
acid NN O
group NN O
and CC O
six CD O
of IN O
59 CD O
in IN O
the DT O
control NN O
group NN O
) ) O
and CC O
thrombosis NN O
( ( O
five CD O
of IN O
60 CD O
in IN O
the DT O
zoledronic JJ O
acid NN O
and CC O
two CD O
of IN O
59 CD O
in IN O
the DT O
control NN O
group NN O
) ) O
. . O

There EX O
was VBD O
one CD O
documented JJ O
case NN O
of IN O
osteonecrosis NN B-OC
in IN O
the DT O
zoledronic JJ O
acid NN O
group NN O
. . O

INTERPRETATION NNP O
Zoledronic NNP B-INTV
acid NN I-INTV
administered VBD O
with IN O
chemotherapy NN O
resulted VBN O
in IN O
a DT O
decreased JJ O
proportion NN O
of IN O
patients NNS O
with IN O
DTCs NNP O
detected VBD O
in IN O
the DT O
bone NN O
marrow NN O
at IN O
the DT O
time NN O
of IN O
surgery NN O
. . O

Our PRP$ O
study NN O
supports VBZ O
the DT O
hypothesis NN O
that IN O
the DT O
antimetastatic JJ O
effects NNS O
of IN O
zoledronic JJ B-INTV
acid NN I-INTV
may MD O
be VB O
through IN O
effects NNS O
on IN O
DTCs NNP O
. . O

FUNDING NN O
Novartis NN O
Pharmaceuticals NNP O
and CC O
Pfizer NNP O
Inc NNP O
. . O

-DOCSTART- -X- O O

Weight-adjusted JJ O
dalteparin NN B-INTV
for IN O
prevention NN O
of IN O
vascular JJ B-OC
thromboembolism NN I-OC
in IN O
advanced JJ B-POPU
pancreatic JJ I-POPU
cancer NN I-POPU
patients NNS I-POPU
decreases VBZ O
serum JJ B-OC
tissue NN I-OC
factor NN I-OC
and CC I-OC
serum-mediated JJ I-OC
induction NN I-OC
of IN I-OC
cancer NN I-OC
cell NN I-OC
invasion NN I-OC
. . O

The DT O
aim NN O
of IN O
the DT O
present JJ O
study NN O
was VBD O
to TO O
assess VB O
the DT O
role NN O
of IN O
tissue NN O
factor NN O
and CC O
serum-induced JJ O
cell NN O
invasion NN O
in IN O
patients NNS B-POPU
with IN I-POPU
advanced JJ I-POPU
pancreatic JJ I-POPU
cancer NN I-POPU
( ( I-POPU
APC NNP I-POPU
) ) I-POPU
. . O

A DT O
cohort NN B-POPU
of IN I-POPU
39 CD I-POPU
patients NNS I-POPU
with IN I-POPU
APC NNP I-POPU
, , I-POPU
without IN I-POPU
thrombosis NN I-POPU
, , I-POPU
receiving VBG I-POPU
chemotherapy NN I-POPU
, , O
were VBD O
entered VBN O
in IN O
a DT O
randomized NN O
controlled VBN O
trial NN O
( ( O
ISRCTN NNP O
= NNP O
76464767 CD O
) ) O
of IN O
thromboprevention NN B-INTV
with IN I-INTV
weight-adjusted JJ I-INTV
dalteparin NN I-INTV
( ( O
WAD NNP O
) ) O
. . O

A DT O
total NN O
of IN O
19 CD O
patients NNS O
received VBD O
WAD NNP B-INTV
, , O
the DT O
remaining VBG O
20 CD O
acting VBG O
as IN O
a DT O
control NN B-INTV
group NN I-INTV
. . O

Serum NNP O
from IN O
baseline NN O
and CC O
week NN O
8 CD O
was VBD O
analysed VBN O
for IN O
circulating-tissue JJ O
factor NN O
antigen NN O
using VBG O
ELISA NNP O
. . O

Circulating-tissue NNP B-OC
factor NN I-OC
antigen NN I-OC
rose VBD O
from IN O
324 CD O
pg/ml NN O
, , O
[ NNP O
interquartile NN O
range NN O
( ( O
IQR NNP O
) ) O
282-347 CD O
pg/ml NN O
] NN O
to TO O
356 CD O
pg/ml NN O
, , O
( ( O
IQR NNP O
319-431 NNP O
pg/ml NN O
) ) O
in IN O
controls NNS O
( ( O
C NNP O
) ) O
, , O
and CC O
decreased VBN O
in IN O
the DT O
dalteparin-treated JJ O
group NN O
( ( O
D NNP O
) ) O
from IN O
336 CD O
pg/ml NN O
( ( O
IQR NNP O
281-346 CD O
pg/ml NN O
) ) O
to TO O
303 CD O
pg/ml NN O
( ( O
IQR NNP O
274-339 CD O
pg/ml NN O
) ) O
. . O

The DT O
difference NN O
in IN O
median JJ O
percentage NN O
change NN O
between IN O
D NNP O
and CC O
C NNP O
was VBD O
statistically RB O
significant JJ O
[ JJ O
-4.0 NN O
( ( O
D NNP O
) ) O
vs. FW O
4.7 CD O
( ( O
C NNP O
) ) O
; : O
P NNP O
= VBZ O
0.005 CD O
, , O
n RB O
= VBZ O
39 CD O
] NN O
. . O

Serum-induced JJ B-OC
cellular JJ I-OC
invasion NN I-OC
of IN I-OC
MIA-Paca-2 NNP I-OC
cells NNS I-OC
in IN O
response NN O
to TO O
patient VB O
serum NN O
was VBD O
studied VBN O
using VBG O
a DT O
Boyden NNP O
chamber NN O
assay NN O
in IN O
30 CD O
patients NNS O
( ( O
14 CD O
WAD NNP O
and CC O
16 CD O
C NNP O
) ) O
. . O

The DT O
median JJ B-OC
percentage NN I-OC
change NN I-OC
between IN O
C NNP O
and CC O
D NNP O
was VBD O
significant JJ O
[ JJ O
+54.9 NN O
( ( O
C NNP O
) ) O
vs. FW O
-21.9 FW O
( ( O
D NNP O
) ) O
P NNP O
= $ O
0.025 CD O
, , O
n RB O
= VBZ O
30 CD O
] NN O
. . O

There EX O
was VBD O
a DT O
weak JJ O
correlation NN O
between IN O
BB-tissue NNP O
factor NN O
reduction NN O
and CC O
cellular JJ O
invasion NN O
reduction NN O
( ( O
Spearman NNP O
) ) O
[ VBZ O
0.384 CD O
( ( O
P NNP O
= NNP O
0.037 CD O
, , O
n RB O
= VBZ O
30 CD O
) ) O
] NN O
. . O

APC NNP B-POPU
patients NNS I-POPU
treated VBD I-POPU
with IN O
WAD NNP O
have VBP O
lower JJR B-OC
tissue NN I-OC
factor NN I-OC
antigen NN I-OC
levels NNS I-OC
and CC I-OC
attenuated JJ I-OC
induction NN I-OC
of IN I-OC
cellular JJ I-OC
invasion NN I-OC
in IN I-OC
their PRP$ I-OC
blood NN I-OC
. . O

These DT O
assays NNS O
may MD O
provide VB O
useful JJ O
markers NNS O
to TO O
guide VB O
appropriate JJ O
dalteparin NN O
( ( O
and CC O
other JJ O
low-molecular JJ O
weight NN O
heparin NN O
) ) O
dosing VBG O
schedules NNS O
to TO O
optimize VB O
anticancer JJ B-OC
effects NNS I-OC
of IN O
dalteparin NN O
in IN O
APC NNP O
. . O

-DOCSTART- -X- O O

Echocardiographic JJ O
evaluation NN O
of IN O
children NNS B-POPU
with IN I-POPU
systemic JJ I-POPU
ventricular JJ I-POPU
dysfunction NN I-POPU
treated VBN I-POPU
with IN I-POPU
carvedilol NN I-POPU
. . O

Echocardiography NN B-INTV
is VBZ O
used VBN O
to TO O
measure VB O
the DT O
therapeutic JJ O
effectiveness NN O
of IN O
heart NN O
failure NN O
therapy NN O
in IN O
adults NNS B-POPU
and CC I-POPU
children NNS I-POPU
. . O

The DT O
purposes NNS O
of IN O
this DT O
study NN O
were VBD O
( ( O
1 CD O
) ) O
to TO O
assess VB O
baseline JJ O
echocardiographic JJ O
predictors NNS O
of IN O
clinical JJ O
outcome NN O
, , O
( ( O
2 CD O
) ) O
to TO O
investigate VB O
changes NNS O
in IN O
echocardiographic JJ O
parameters NNS O
, , O
and CC O
( ( O
3 CD O
) ) O
to TO O
compare VB O
these DT O
echocardiographic JJ O
changes NNS O
with IN O
changes NNS O
in IN O
plasma NN O
levels NNS O
of IN O
b-type JJ O
natriuretic JJ B-INTV
peptide NN I-INTV
( ( O
BNP NNP O
) ) O
in IN B-POPU
a DT I-POPU
population NN I-POPU
of IN I-POPU
children NNS I-POPU
with IN I-POPU
systemic JJ I-POPU
ventricular JJ I-POPU
dysfunction NN I-POPU
and CC I-POPU
symptomatic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
treated VBN I-POPU
with IN I-POPU
carvedilol NN I-POPU
or CC I-POPU
placebo NN I-POPU
. . O

All DT O
available JJ O
baseline NN O
and CC O
6-month JJ O
echocardiograms NNS O
from IN O
Pediatric NNP B-POPU
Carvedilol NNP I-POPU
Trial NNP I-POPU
( ( I-POPU
PCT NNP I-POPU
) ) I-POPU
participants NNS I-POPU
( ( I-POPU
carvedilol JJ I-POPU
n RB I-POPU
= JJ I-POPU
161 CD I-POPU
; : I-POPU
placebo NN I-POPU
n IN I-POPU
= $ I-POPU
55 CD I-POPU
) ) I-POPU
were VBD O
reviewed VBN O
. . O

Systolic NNP B-OC
and CC O
diastolic JJ B-OC
sphericity NN I-OC
index NN I-OC
( ( O
SI NNP O
; : O
n CC O
= VB O
110 CD O
) ) O
, , O
TEI NNP O
index NN O
( ( O
n JJ O
= NNP O
145 CD O
) ) O
, , O
and CC O
systemic JJ O
ventricular NN O
dP/dt NN O
( ( O
n JJ O
= NNP O
70 CD O
) ) O
were VBD O
measured VBN O
. . O

The DT O
PCT NNP O
composite JJ O
definition NN O
of IN O
clinical JJ O
outcome NN O
( ( O
i.e. FW O
, , O
worsened VBD O
, , O
improved VBN O
, , O
or CC O
unchanged JJ O
) ) O
was VBD O
used VBN O
. . O

For IN O
all DT O
patients NNS O
, , O
baseline VBP O
TEI NNP O
index NN O
was VBD O
a DT O
predictor NN O
of IN O
worsened JJ B-OC
outcome NN I-OC
. . O

Only RB O
children NNS B-POPU
treated VBD I-POPU
with IN I-POPU
carvedilol NN I-POPU
showed VBD O
a DT O
significant JJ O
decrease NN O
in IN O
systolic JJ B-OC
SI NNP I-OC
( ( O
P NNP O
B NNP O
0.0001 CD O
) ) O
, , O
diastolic JJ B-OC
SI NNP I-OC
( ( O
P NNP O
B NNP O
0.0001 CD O
) ) O
, , O
and CC O
TEI NNP B-OC
index NN I-OC
( ( O
P NNP O
= NNP O
0.02 CD O
) ) O
. . O

An DT O
inverse JJ O
correlation NN O
between IN O
changes NNS B-OC
in IN I-OC
BNP NNP I-OC
and CC O
changes NNS B-OC
in IN I-OC
dP/dt NN I-OC
( ( O
r JJ O
= NNP O
-0.45 NNP O
, , O
P NNP O
= NNP O
0.04 CD O
) ) O
was VBD O
found VBN O
only RB O
in IN O
the DT O
carvedilol NN B-POPU
group NN I-POPU
. . O

In IN O
conclusion NN O
, , O
TEI NNP O
index NN O
predicted VBD O
outcome NN O
in IN O
children NNS B-POPU
with IN O
systemic JJ B-OC
ventricular JJ I-OC
dysfunction NN I-OC
and CC I-OC
heart NN I-OC
failure NN I-OC
. . O

Carvedilol NN B-INTV
may MD O
have VB O
a DT O
beneficial JJ O
effect NN O
on IN O
reversal NN O
of IN O
left JJ O
ventricular JJ O
remodeling NN O
and CC O
global JJ O
ventricular NN O
function NN O
in IN O
pediatric JJ O
heart NN O
failure NN O
. . O

-DOCSTART- -X- O O

Stroke NNP O
team NN O
remote NN O
evaluation NN O
using VBG O
a DT O
digital JJ O
observation NN O
camera NN O
in IN O
Arizona NNP B-POPU
: : I-POPU
the DT O
initial JJ O
mayo NN O
clinic JJ O
experience NN O
trial NN O
. . O

BACKGROUND NNP O
AND CC O
PURPOSE NNP O
Telemedicine NNP O
techniques NNS O
can MD O
be VB O
used VBN O
to TO O
address VB O
the DT O
rural-metropolitan JJ B-POPU
disparity NN O
in IN O
acute JJ O
stroke NN O
care NN O
. . O

The DT O
Stroke NNP O
Team NNP O
Remote NNP O
Evaluation NNP O
Using VBG O
a DT O
Digital NNP O
Observation NNP O
Camera NNP O
( ( O
STRokE NNP O
DOC NNP O
) ) O
trial NN O
reported VBD O
more RBR O
accurate JJ O
decision NN O
making NN O
for IN O
telemedicine JJ B-INTV
consultations NNS O
compared VBN O
with IN O
telephone-only JJ B-INTV
and CC O
that IN O
the DT O
California-based JJ O
research NN O
network NN O
facilitated VBD O
a DT O
high JJ O
rate NN O
of IN O
thrombolysis NN O
use NN O
, , O
improved VBN O
data NNS O
collection NN O
, , O
low JJ O
risk NN O
of IN O
complications NNS O
, , O
low JJ O
technical JJ O
complications NNS O
, , O
and CC O
favorable JJ O
assessment NN O
times NNS O
. . O

The DT O
main JJ O
objective NN O
of IN O
the DT O
STRokE NNP O
DOC NNP O
Arizona NNP O
TIME NNP O
( ( O
The DT O
Initial NNP O
Mayo NNP O
Clinic NNP O
Experience NNP O
) ) O
trial NN O
was VBD O
to TO O
determine VB O
the DT O
feasibility NN O
of IN O
establishing VBG O
, , O
de FW O
novo FW O
, , O
a DT O
single-hub JJ O
, , O
multirural JJ O
spoke VBD O
hospital JJ O
telestroke NN O
research NN O
network NN O
across IN O
a DT O
large JJ O
geographical JJ O
area NN O
in IN O
Arizona NNP O
by IN O
replicating VBG O
the DT O
STRokE NNP O
DOC NNP O
protocol NN O
. . O

METHODS NNP O
Methods NNP O
included VBD O
prospective JJ O
, , O
single-hub JJ O
, , O
2-spoke JJ O
, , O
randomized VBN O
, , O
blinded VBD O
, , O
controlled VBD O
trial NN O
of IN O
a DT O
2-way JJ O
, , O
site-independent JJ O
, , O
audiovisual JJ B-INTV
telemedicine NN I-INTV
system NN I-INTV
designed VBN I-INTV
for IN I-INTV
remote JJ B-POPU
examination NN B-INTV
of IN O
adult NN B-POPU
patients NNS I-POPU
with IN I-POPU
acute JJ I-POPU
stroke NN I-POPU
versus IN I-POPU
telephone NN I-POPU
consultation NN I-POPU
to TO I-POPU
assess VB I-POPU
eligibility NN I-POPU
for IN I-POPU
treatment NN I-POPU
with IN I-POPU
intravenous JJ I-POPU
thrombolysis NN I-POPU
. . O

The DT O
primary JJ O
outcome NN O
measure NN O
was VBD O
whether IN O
the DT O
decision NN B-OC
to TO I-OC
give VB I-OC
thrombolysis NN I-OC
was VBD I-OC
correct JJ I-OC
. . O

Secondary JJ O
outcomes NNS O
were VBD O
rate NN B-OC
of IN I-OC
thrombolytic JJ I-OC
use NN I-OC
, , I-OC
90-day JJ I-OC
functional JJ I-OC
outcomes NNS I-OC
, , I-OC
incidence NN I-OC
of IN I-OC
intracerebral JJ I-OC
hemorrhages NNS I-OC
, , I-OC
and CC I-OC
technical JJ I-OC
observations NNS I-OC
. . O

RESULTS NN O
From IN B-POPU
December NNP I-POPU
2007 CD I-POPU
to TO I-POPU
October NNP I-POPU
2008 CD I-POPU
, , I-POPU
54 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
assessed VBN I-POPU
, , O
27 CD O
of IN O
whom WP O
were VBD O
randomized VBN O
to TO O
each DT O
arm NN O
. . O

Mean JJ O
National NNP O
Institutes NNPS O
of IN O
Health NNP O
Stroke NNP O
Scale NNP O
score NN O
at IN O
presentation NN O
was VBD O
7.3 CD O
( ( O
SD NNP O
6.2 CD O
) ) O
points NNS O
. . O

No DT O
consultations NNS O
were VBD O
aborted VBN O
; : O
however RB O
, , O
technical JJ B-OC
problems NNS I-OC
( ( O
74 CD O
% NN O
) ) O
were VBD O
prevalent JJ O
in IN O
the DT O
telemedicine NN O
arm NN O
. . O

Overall JJ O
, , O
the DT O
correct JJ O
treatment NN B-OC
decision NN I-OC
was VBD O
established VBN O
in IN O
87 CD O
% NN O
of IN O
the DT O
consultations NNS O
. . O

Both DT O
modalities NNS O
, , O
telephone NN O
( ( O
89 CD O
% NN O
correct NN O
) ) O
and CC O
telemedicine NN O
( ( O
85 CD O
% NN O
correct NN O
) ) O
, , O
performed VBN O
well RB O
. . O

Intravenous JJ O
thrombolytic JJ B-INTV
treatment NN I-INTV
was VBD O
used VBN O
in IN O
30 CD O
% NN O
of IN O
the DT O
telemedicine NN O
and CC O
telephone NN O
consultations NNS O
. . O

Good JJ O
functional JJ B-OC
outcomes NNS I-OC
at IN O
90 CD O
days NNS O
were VBD O
not RB O
significantly RB O
different JJ O
. . O

There EX O
were VBD O
no DT O
statistically RB O
significant JJ O
differences NNS O
in IN O
mortality NN B-OC
( ( O
4 CD O
% NN O
in IN O
telemedicine NN O
and CC O
11 CD O
% NN O
in IN O
telephone NN O
) ) O
or CC O
rates NNS B-OC
of IN I-OC
intracerebral JJ I-OC
hemorrhage NN I-OC
( ( O
4 CD O
% NN O
in IN O
telemedicine NN O
and CC O
0 CD O
% NN O
in IN O
telephone NN O
) ) O
. . O

CONCLUSIONS VB O
It PRP O
is VBZ O
feasible JJ O
to TO O
extend VB O
the DT O
original JJ O
STRokE NNP O
DOC NNP O
trial NN O
protocol NN O
to TO O
a DT O
new JJ O
state NN O
and CC O
establish VB O
an DT O
operational JJ O
single-hub NN O
, , O
multispoke VBD O
rural JJ O
hospital NN O
telestroke VBD O
research NN O
network NN O
in IN O
Arizona NNP O
. . O

The DT O
trial NN O
was VBD O
not RB O
designed VBN O
to TO O
have VB O
sufficient JJ O
power NN O
to TO O
detect VB O
a DT O
difference NN O
between IN O
the DT O
2 CD O
consultative JJ O
modes NNS O
: : O
telemedicine NN O
and CC O
telephone-only RB O
. . O

Whether CC O
by IN O
telemedicine NN O
or CC O
telephone NN O
consultative JJ O
modalities NNS O
, , O
there EX O
were VBD O
appropriate JJ O
treatment NN B-OC
decisions NNS I-OC
, , O
high JJ O
rates NNS O
of IN O
thrombolysis NN B-OC
use NN I-OC
, , O
improved VBN O
data NNS B-OC
collection NN I-OC
, , O
low JJ O
rates NNS B-OC
of IN I-OC
intracerebral JJ I-OC
hemorrhage NN I-OC
, , O
and CC O
equally RB O
favorable JJ O
time NN B-OC
requirements NNS I-OC
. . O

The DT O
learning VBG O
curve NN O
was VBD O
steep JJ O
for IN O
the DT O
hub NN O
and CC O
spoke VBD O
personnel NNS O
of IN O
the DT O
new JJ O
telestroke NN O
network NN O
, , O
as IN O
reflected VBN O
by IN O
frequent JJ O
technical JJ O
problems NNS O
. . O

Overall NNP O
, , O
the DT O
results NNS O
support VBD O
the DT O
effectiveness NN O
of IN O
highly RB O
organized VBN O
and CC O
structured VBN O
stroke NN O
telemedicine NN O
networks NNS O
for IN O
extending VBG O
expert JJ O
stroke NN O
care NN O
into IN O
rural JJ B-POPU
remote JJ I-POPU
communities NNS I-POPU
lacking VBG I-POPU
sufficient JJ I-POPU
neurological JJ I-POPU
expertise NN I-POPU
. . O

-DOCSTART- -X- O O

Effects NNS O
of IN O
statins NNS B-INTV
on IN O
progression NN O
of IN O
subclinical JJ B-OC
brain NN I-OC
infarct NN I-OC
. . O

BACKGROUND NNP O
Subclinical NNP B-OC
brain NN I-OC
infarct NN I-OC
( ( I-OC
SBI NNP I-OC
) ) I-OC
is VBZ O
associated VBN O
with IN O
subsequent JJ O
stroke NN O
and CC O
cognitive JJ O
decline NN O
. . O

A DT O
longitudinal JJ O
epidemiological JJ O
study NN O
suggests VBZ O
that IN O
statins NNS B-INTV
may MD O
prevent VB O
development NN O
of IN O
SBI NNP B-OC
. . O

We PRP O
investigated VBD O
the DT O
effects NNS O
of IN O
statins NNS B-INTV
upon IN O
development NN B-OC
of IN I-OC
brain NN I-OC
infarct NN I-OC
by IN O
performing VBG O
a DT O
post-hoc JJ O
analysis NN O
of IN O
the DT O
Regression NNP O
of IN O
Cerebral NNP O
Artery NNP O
Stenosis NNP O
( ( O
ROCAS NNP O
) ) O
study NN O
. . O

METHODS NNP O
The DT O
ROCAS NNP O
study NN O
is VBZ O
a DT O
randomized JJ O
, , O
double-blind JJ O
, , O
placebo-controlled JJ O
study NN O
evaluating VBG O
the DT O
effects NNS O
of IN O
simvastatin NN B-INTV
20 CD O
mg JJ O
daily JJ O
upon IN O
progression NN O
of IN O
asymptomatic JJ O
middle JJ O
cerebral JJ O
artery NN O
stenosis NN O
among IN O
stroke-free JJ B-POPU
individuals NNS I-POPU
over IN I-POPU
2 CD I-POPU
years NNS I-POPU
. . O

A DT O
total NN B-POPU
of IN I-POPU
227 CD I-POPU
subjects NNS I-POPU
were VBD O
randomized VBN O
to TO O
either DT O
placebo NN B-INTV
( ( O
n JJ O
= NNP O
114 CD O
) ) O
or CC O
simvastatin $ B-INTV
20 CD O
mg JJ O
daily JJ O
( ( O
n JJ O
= NNP O
113 CD O
) ) O
. . O

The DT O
number NN B-OC
of IN I-OC
brain NN I-OC
infarcts NNS I-OC
as IN O
detected VBN O
by IN O
MRI NNP O
was VBD O
recorded VBN O
at IN O
baseline NN O
and CC O
at IN O
the DT O
end NN O
of IN O
the DT O
study NN O
. . O

The DT O
primary JJ O
outcome NN O
measure NN O
was VBD O
the DT O
number NN B-OC
of IN I-OC
new JJ I-OC
brain NN I-OC
infarcts NNS I-OC
at IN O
the DT O
end NN O
of IN O
the DT O
study NN O
. . O

RESULTS NNP O
Among IN O
the DT O
227 CD B-POPU
randomized JJ I-POPU
subjects NNS I-POPU
, , I-POPU
33 CD I-POPU
( ( I-POPU
14.5 CD I-POPU
% NN I-POPU
) ) I-POPU
had VBD I-POPU
SBI VBN I-POPU
at IN I-POPU
baseline NN I-POPU
. . O

At IN O
the DT O
end NN O
of IN O
the DT O
study NN O
, , O
significantly RB O
fewer JJR O
subjects NNS O
in IN O
the DT O
active JJ O
group NN O
( ( O
n JJ O
= NNP O
1 CD O
) ) O
had VBD O
new JJ B-OC
brain NN I-OC
infarcts NNS I-OC
compared VBN O
with IN O
the DT O
placebo NN B-INTV
group NN O
( ( O
n JJ O
= VBZ O
8 CD O
; : O
p NN O
= VBZ O
0.018 CD O
) ) O
. . O

The DT O
new JJ O
brain NN B-OC
infarcts NNS I-OC
of IN O
subjects NNS O
in IN O
the DT O
active JJ O
group NN O
were VBD O
subclinical JJ O
. . O

Among IN O
the DT O
placebo NN B-INTV
group NN O
, , O
the DT O
new JJ O
brain NN B-OC
infarcts NNS I-OC
of IN O
3 CD O
subjects NNS O
were VBD O
symptomatic JJ O
while IN O
those DT O
of IN O
the DT O
remaining VBG O
5 CD O
subjects NNS O
were VBD O
subclinical JJ O
. . O

Among IN O
putative JJ O
variables NNS O
, , O
multivariate JJ O
regression NN O
analysis NN O
showed VBD O
that IN O
only RB O
the DT O
baseline NN O
number NN O
of IN O
SBIs NNP B-OC
( ( O
OR NNP O
= VBZ O
6.27 CD O
, , O
95 CD O
% NN O
CI NNP O
2.4-16.5 CD O
) ) O
and CC O
simvastatin JJ B-INTV
treatment NN O
( ( O
OR NNP O
= VBZ O
0.09 CD O
, , O
95 CD O
% NN O
CI NNP O
0.01-0.82 NN O
) ) O
independently RB O
predicted VBD O
the DT O
development NN O
of IN O
new JJ O
brain NN O
infarcts NNS O
. . O

CONCLUSIONS NNP O
Consistent NNP O
with IN O
findings NNS O
of IN O
the DT O
epidemiological JJ O
study NN O
, , O
our PRP$ O
study NN O
suggests VBZ O
that IN O
statins NNS O
may MD O
prevent VB O
the DT O
development NN O
of IN O
a DT O
new JJ O
brain NN B-OC
infarct NN I-OC
. . O

-DOCSTART- -X- O O

Beneficial JJ O
effect NN O
of IN O
etidronate NN B-INTV
therapy NN I-INTV
in IN O
chronically RB B-POPU
hospitalized VBN I-POPU
, , I-POPU
disabled JJ I-POPU
patients NNS I-POPU
with IN I-POPU
stroke NN I-POPU
. . O

Incidence NN O
of IN O
hip NN O
fractures NNS O
is VBZ O
high JJ O
in IN O
chronically RB B-POPU
hospitalized VBN I-POPU
, , I-POPU
disabled VBD I-POPU
, , I-POPU
elderly JJ I-POPU
patients NNS I-POPU
after IN I-POPU
stroke NN I-POPU
. . O

Duration NN B-POPU
of IN I-POPU
hospitalization NN I-POPU
was VBD I-POPU
more JJR I-POPU
than IN I-POPU
1 CD I-POPU
year NN I-POPU
because IN I-POPU
of IN I-POPU
insufficiency NN I-POPU
of IN I-POPU
nursing NN I-POPU
homes NNS I-POPU
. . O

Our PRP$ O
study NN O
showed VBD O
that IN O
immobilization-induced JJ O
hypercalcemia NN O
and CC O
25-hydroxyvitamin JJ O
D NNP O
deficiency NN O
contribute NN O
to TO O
reduced VB O
bone JJ O
mineral JJ O
density NN O
( ( O
BMD NNP O
) ) O
. . O

This DT O
study NN O
was VBD O
designed VBN O
to TO O
address VB O
the DT O
possibility NN O
that WDT O
treatment NN O
with IN O
etidronate NN B-INTV
may MD O
reduce VB O
the DT O
bone NN O
resorption NN O
and CC O
lower JJR O
the DT O
incidence NN O
of IN O
fractures NNS O
in IN O
elderly JJ B-POPU
patients NNS I-POPU
who WP I-POPU
are VBP I-POPU
chronically RB I-POPU
hospitalized VBN I-POPU
and CC I-POPU
disabled VBN I-POPU
as IN I-POPU
a DT I-POPU
result NN I-POPU
of IN I-POPU
hemiparesis NN I-POPU
after IN I-POPU
stroke NN I-POPU
. . O

Patients NNS B-POPU
with IN I-POPU
stroke NN I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
daily VB O
treatment NN O
with IN O
400 CD O
mg NNS O
of IN O
etidronate NN B-INTV
( ( O
n JJ O
= NNP O
40 CD O
) ) O
or CC O
a DT O
placebo NN B-INTV
( ( O
n JJ O
= NNP O
40 CD O
) ) O
, , O
and CC O
followed VBD O
up RB O
for IN O
2 CD O
years NNS O
. . O

At IN O
baseline NN O
, , O
both DT O
groups NNS O
had VBD O
low JJ O
BMD NNP B-OC
with IN O
high JJ B-OC
levels NNS I-OC
of IN I-OC
serum NN I-OC
ionized VBN I-OC
calcium NN I-OC
and CC I-OC
urinary JJ I-OC
deoxypyridinoline NN I-OC
. . O

In IN O
the DT O
etidronate NN B-INTV
group NN O
, , O
serum NN B-OC
calcium NN I-OC
and CC I-OC
urinary JJ I-OC
deoxypyridinoline NN I-OC
levels NNS I-OC
decreased VBN O
significantly RB O
during IN O
the DT O
study NN O
period NN O
, , O
whereas IN O
the DT O
levels NNS O
in IN O
the DT O
placebo NN B-INTV
group NN O
were VBD O
increased VBN O
. . O

BMD NNP B-OC
on IN I-OC
the DT I-OC
hemiplegic JJ I-OC
side NN I-OC
increased VBN O
by IN O
1.4 CD O
% NN O
in IN O
the DT O
etidronate NN O
group NN O
and CC O
decreased VBN O
by IN O
2.2 CD O
% NN O
in IN O
the DT O
placebo NN O
group NN O
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
. . O

Two CD O
patients NNS O
sustained VBD O
hip JJ B-OC
fractures NNS I-OC
in IN O
the DT O
placebo NN B-INTV
group NN O
, , O
and CC O
no DT O
hip NN B-OC
fracture NN I-OC
occurred VBD O
in IN O
the DT O
etidronate NN B-INTV
group NN O
. . O

Treatment NN O
with IN O
etidronate NN B-INTV
increases NNS O
BMD NNP B-OC
in IN O
chronically RB B-POPU
hospitalized VBN I-POPU
patients NNS I-POPU
poststroke VBD I-POPU
, , O
and CC O
may MD O
prevent VB O
hip NN O
fracture NN O
. . O

-DOCSTART- -X- O O

[ JJ O
Assessment NNP O
of IN O
natriuretic JJ B-INTV
peptide NN I-INTV
indices NNS O
and CC O
oxidative JJ B-INTV
stress NN O
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
] NNP I-POPU
. . O

The DT O
authors NNS O
have VBP O
studied VBN O
indices NNS O
of IN O
natriuretic JJ B-INTV
peptide NN I-INTV
and CC O
oxidative JJ B-INTV
stress NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
( ( I-POPU
CHF NNP I-POPU
) ) I-POPU
. . O

52 CD B-POPU
male JJ I-POPU
patients NNS I-POPU
with IN I-POPU
postinfarction NN I-POPU
cardiosclerosis NN I-POPU
( ( I-POPU
PICS NNP I-POPU
) ) I-POPU
who WP I-POPU
have VBP I-POPU
developed VBN I-POPU
CHF NNP I-POPU
have VBP I-POPU
been VBN I-POPU
observed VBN I-POPU
. . O

The DT B-POPU
age NN I-POPU
of IN I-POPU
the DT I-POPU
patients NNS I-POPU
varied VBD I-POPU
from IN I-POPU
38 CD I-POPU
till NN I-POPU
60 CD I-POPU
. . O

It PRP O
was VBD O
established VBN O
that IN O
CHF NNP O
patients NNS O
with IN O
progression NN O
of IN O
the DT O
disease NN O
had VBD O
worsening NN O
of IN O
their PRP$ O
clinical JJ B-OC
condition NN I-OC
together RB O
with IN O
an DT O
increase NN O
of IN O
oxidative JJ B-OC
stress NN I-OC
which WDT O
was VBD O
characterized VBN O
through IN O
decrease NN O
of IN O
NO NNP B-OC
metabolites NNS I-OC
, , I-OC
NADPH NNP I-OC
-- : I-OC
diaphorase NN I-OC
( ( I-OC
eNOS NN I-OC
) ) I-OC
, , O
increase NN O
of IN O
nitrite JJ B-OC
reductase NN I-OC
( ( I-OC
iNOS NN I-OC
) ) I-OC
and CC I-OC
peroxinitrite JJ I-OC
( ( I-OC
ONOO NNP I-OC
) ) I-OC
, , O
correlative JJ O
increase NN O
the DT O
level NN O
of IN O
brain NN B-OC
natriuretic JJ I-OC
peptide NN I-OC
in IN I-OC
blood NN I-OC
plazma NN I-OC
. . O

Reliable JJ O
connection NN O
between IN O
considerable JJ O
increase NN O
of IN O
oxidative JJ B-OC
stress NN I-OC
and CC O
the DT O
level NN B-OC
of IN I-OC
NT-pro NNP I-OC
BNP NNP I-OC
was VBD O
noted VBN O
in IN O
CHF NNP B-POPU
patients NNS I-POPU
, , O
which WDT O
demands VBZ O
necessity NN O
of IN O
correction NN O
of IN O
observed JJ O
disorders NNS O
. . O

-DOCSTART- -X- O O

Letter NN O
by IN O
Begg NNP O
et CC O
al NN O
regarding VBG O
article NN O
, , O
" VBZ O
The DT O
effects NNS O
of IN O
vitamin NN B-INTV
d NN I-INTV
supplementation NN I-INTV
on IN O
physical JJ B-OC
function NN I-OC
and CC I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
in IN O
older JJR B-POPU
heart NN I-POPU
failure NN I-POPU
patients NNS I-POPU
: : I-POPU
a DT O
randomized NN O
controlled VBN O
trial NN O
" NN O
. . O

-DOCSTART- -X- O O

Randomised VBN O
, , O
parallel-group JJ O
, , O
multicentre NN O
, , O
multinational JJ O
phase NN O
2 CD O
study NN O
comparing VBG O
edoxaban NN B-INTV
, , O
an DT O
oral JJ O
factor NN B-INTV
Xa NNP I-INTV
inhibitor NN I-INTV
, , O
with IN O
warfarin NN B-INTV
for IN O
stroke NN B-POPU
prevention NN I-POPU
in IN I-POPU
patients NNS I-POPU
with IN I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
. . O

The DT O
primary JJ O
objective NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
compare VB O
the DT O
safety NN O
of IN O
four CD O
fixed-dose JJ O
regimens NNS O
of IN O
edoxaban NN B-INTV
with IN I-INTV
warfarin NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
non-valvular JJ I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
( ( I-POPU
AF NNP I-POPU
) ) I-POPU
. . O

In IN O
this DT O
12-week JJ O
, , O
parallel-group JJ O
, , O
multicentre NN B-POPU
, , I-POPU
multinational JJ I-POPU
study NN I-POPU
, , I-POPU
1,146 CD I-POPU
patients NNS I-POPU
with IN I-POPU
AF NNP I-POPU
and CC I-POPU
risk NN I-POPU
of IN I-POPU
stroke NN I-POPU
were VBD O
randomised VBN O
to TO O
edoxaban VB B-INTV
30 CD O
mg NN O
qd NN O
, , O
30 CD O
mg NN O
bid NN O
, , O
60 CD O
mg NN O
qd NN O
, , O
or CC O
60 CD O
mg JJ O
bid NN O
or CC B-INTV
warfarin VB I-INTV
dose-adjusted JJ O
to TO O
a DT O
target NN O
international JJ O
normalised JJ O
ratio NN O
of IN O
2.0-3.0 JJ O
. . O

The DT O
study NN O
was VBD O
double-blind JJ O
to TO O
edoxaban VB B-INTV
dose JJ O
, , O
but CC O
open-label JJ O
to TO O
warfarin VB B-INTV
. . O

Primary JJ O
outcomes NNS O
were VBD O
occurrence NN O
of IN O
major JJ B-OC
and/or NNS I-OC
clinically RB I-OC
relevant JJ I-OC
non-major JJ I-OC
bleeding NN I-OC
and CC I-OC
elevated VBD I-OC
hepatic JJ I-OC
enzymes NNS I-OC
and/or VBP I-OC
bilirubin NN I-OC
. . O

Mean NNP B-POPU
age NN I-POPU
was VBD I-POPU
65 CD I-POPU
+/- JJ I-POPU
8.7 CD I-POPU
years NNS I-POPU
and CC I-POPU
64.4 CD I-POPU
% NN I-POPU
were VBD I-POPU
warfarin-naïve JJ I-POPU
. . O

Whereas IN O
major JJ O
plus CC O
clinically JJ O
relevant JJ B-OC
non-major JJ I-OC
bleeding NN I-OC
occurred VBD O
in IN O
3.2 CD O
% NN O
of IN O
patients NNS O
randomised VBN O
to TO B-INTV
warfarin VB I-INTV
, , O
the DT B-OC
incidence NN I-OC
of IN I-OC
bleeding NN I-OC
was VBD O
significantly RB O
higher JJR O
with IN O
the DT B-INTV
edoxaban NN I-INTV
60 CD O
mg NN O
bid NN O
( ( O
10.6 CD O
% NN O
; : O
p=0.002 CC O
) ) O
and CC O
30 CD O
mg NNS O
bid NN O
regimens VBZ O
( ( O
7.8 CD O
% NN O
; : O
p=0.029 NN O
) ) O
, , O
but CC O
not RB O
with IN O
the DT B-INTV
edoxaban NN I-INTV
60 CD O
mg NN O
qd NN O
( ( O
3.8 CD O
% NN O
) ) O
or CC O
30 CD O
mg NNS O
qd JJ O
regimens NNS O
( ( O
3.0 CD O
% NN O
) ) O
. . O

For IN O
the DT O
same JJ O
total JJ O
daily JJ O
dose NN O
of IN O
60 CD O
mg NN O
, , O
both DT B-OC
bleeding VBG I-OC
frequency NN I-OC
and CC I-OC
trough JJ B-INTV
edoxaban NN I-INTV
concentrations NNS B-OC
were VBD O
higher JJR O
in IN O
the DT O
30-mg JJ O
bid NN O
group NN O
than IN O
in IN O
the DT O
60-mg JJ O
qd NN O
group NN O
. . O

There EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN B-OC
hepatic JJ I-OC
enzyme NN I-OC
elevations NNS I-OC
or CC I-OC
bilirubin JJ I-OC
values NNS I-OC
among IN O
the DT O
groups NNS O
. . O

The DT O
safety NN O
profiles NNS O
of IN B-INTV
edoxaban JJ I-INTV
30 CD O
and CC O
60 CD O
mg NN O
qd NN O
in IN O
patients NNS O
with IN O
AF NNP O
were VBD O
similar JJ O
to TO B-INTV
warfarin VB I-INTV
. . O

In IN O
contrast NN O
, , O
the DT B-INTV
edoxaban JJ I-INTV
bid NN O
regimens NNS O
were VBD O
associated VBN O
with IN O
more RBR B-OC
bleeding NN I-OC
than IN B-INTV
warfarin NN I-INTV
. . O

These DT O
results NNS O
suggest VBP O
that IN O
in IN O
this DT O
three-month JJ O
study NN O
, , O
edoxaban VBP B-INTV
30 CD O
or CC O
60 CD O
mg NNS O
qd NNS O
are VBP B-OC
safe JJ I-OC
and CC I-OC
well-tolerated JJ I-OC
. . O

-DOCSTART- -X- O O

Alinidine NNP B-INTV
in IN O
chronic JJ B-POPU
stable JJ I-POPU
angina NN I-POPU
: : I-POPU
the DT O
effect NN O
on IN O
diastolic JJ B-OC
perfusion NN I-OC
time NN I-OC
. . O

The DT O
present JJ O
study NN O
has VBZ O
been VBN O
performed VBN O
to TO O
assess VB O
the DT O
effects NNS O
of IN O
alinidine NN B-INTV
on IN O
diastolic JJ O
duration NN O
during IN O
exercise NN O
in IN O
chronic JJ B-POPU
coronary JJ I-POPU
artery NN I-POPU
disease NN I-POPU
. . O

Twelve VB B-POPU
male NN I-POPU
patients NNS I-POPU
with IN I-POPU
stable JJ I-POPU
effort NN I-POPU
angina NN I-POPU
and CC I-POPU
without IN I-POPU
previous JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
were VBD I-POPU
studied VBN I-POPU
. . O

They PRP O
received VBD O
alinidine NN B-INTV
or CC I-INTV
placebo NN I-INTV
in IN O
a DT O
double-blind JJ O
randomized JJ O
crossover NN O
trial NN O
for IN O
3 CD O
days NNS O
after IN O
a DT O
wash-out JJ O
period NN O
of IN O
4 CD O
days NNS O
. . O

Alinidine NNP B-INTV
was VBD O
administered VBN O
at IN O
a DT O
dosage NN O
of IN O
30 CD O
mg NN O
3 CD O
times NNS O
a DT O
day NN O
. . O

At IN O
the DT O
end NN O
of IN O
each DT O
treatment NN O
the DT O
patients NNS O
underwent JJ O
upright JJ B-INTV
bicycle NN I-INTV
exercise NN I-INTV
. . O

Left NNP B-OC
ventricular JJ I-OC
time NN I-OC
intervals NNS I-OC
were VBD O
obtained VBN B-OC
by IN O
means NNS O
of IN O
carotid NN B-OC
thermistor NN I-OC
plethysmography NN I-OC
. . O

Diastolic NNP B-OC
duration NN I-OC
was VBD O
calculated VBN B-OC
by IN I-OC
subtracting VBG I-OC
the DT I-OC
electromechanical JJ I-OC
systole NN I-OC
from IN I-OC
the DT I-OC
R-R NNP I-OC
interval NN I-OC
and CC I-OC
expressed VBD I-OC
as IN I-OC
a DT I-OC
percentage NN I-OC
of IN I-OC
the DT I-OC
cardiac JJ I-OC
cycle NN I-OC
( ( I-OC
% NN I-OC
D NNP I-OC
) ) I-OC
. . O

Alinidine NN B-INTV
increased VBD O
both DT O
total JJ B-OC
exercise NN I-OC
duration NN I-OC
from IN O
246.7 CD O
+/- JJ O
120.7 CD O
to TO O
346.6 CD O
+/- JJ O
114.1 CD O
s NN O
( ( O
p NN O
less JJR O
than IN O
0.05 CD O
) ) O
and CC O
time NN B-OC
to TO I-OC
0.1-mV JJ I-OC
ST NNP I-OC
segment NN I-OC
depression NN I-OC
from IN O
98.3 CD O
+/- JJ O
53 CD O
to TO O
187.2 CD O
+/- JJ O
105 CD O
s NN O
( ( O
p NN O
less JJR O
than IN O
0.05 CD O
) ) O
. . O

Similarly RB O
the DT O
drug NN O
induced VBD B-OC
a DT I-OC
reduction NN I-OC
of IN I-OC
the DT I-OC
rate-pressure JJ I-OC
product NN I-OC
and CC O
of IN O
the DT O
extent NN B-OC
of IN I-OC
ischemic JJ I-OC
ST NNP I-OC
segment NN I-OC
depression NN I-OC
during IN O
exercise NN O
. . O

% NN B-OC
D NNP I-OC
was VBD O
increased VBN O
by IN O
alinidine JJ O
both DT O
at IN O
rest NN O
and CC O
during IN O
exercise NN O
. . O

A DT O
direct JJ O
linear JJ B-OC
regression NN I-OC
between IN O
R-R NNP O
and CC O
% NN O
D NNP O
was VBD O
found VBN O
after IN O
both DT O
alinidine NN B-INTV
and CC O
placebo NN B-INTV
treatments NNS O
either CC O
at IN O
rest NN O
or CC O
during IN O
exercise NN O
. . O

Nevertheless NNP O
, , O
no DT B-OC
difference NN I-OC
was VBD I-OC
observed VBN I-OC
between IN I-OC
both DT I-OC
slopes NNS I-OC
and CC I-OC
intercepts NNS I-OC
. . O

Therefore RB O
, , O
since IN O
the DT O
relationship NN B-OC
between IN I-OC
R-R NNP I-OC
interval NN I-OC
and CC I-OC
% NN I-OC
D NNP I-OC
was VBD O
unaffected VBN O
by IN O
alinidine NN B-INTV
, , O
it PRP O
was VBD O
possible JJ O
to TO O
hypothesize VB O
that IN O
the DT O
changes NNS O
in IN O
diastolic JJ B-OC
duration NN I-OC
were VBD O
due JJ O
only RB O
to TO O
the DT O
bradycardic JJ O
action NN O
of IN O
the DT O
drug NN O
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
three-year JJ O
clinical JJ B-OC
outcomes NNS I-OC
between IN O
sirolimus-versus JJ B-INTV
paclitaxel-eluting JJ I-INTV
stents NNS I-INTV
in IN B-POPU
diabetic JJ I-POPU
patients NNS I-POPU
: : I-POPU
prospective JJ O
randomized VBN O
multicenter NN O
trial NN O
. . O

BACKGROUND NNP O
Three-year JJ O
follow-up NN O
of IN O
major JJ B-OC
adverse JJ I-OC
cardiovascular JJ I-OC
event NN I-OC
( ( I-OC
MACE NNP I-OC
) ) I-OC
( ( I-OC
death NN I-OC
, , I-OC
nonfatal JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
target NN I-OC
lesion NN I-OC
revascularization NN I-OC
) ) I-OC
and CC O
the DT O
predictors NNS B-OC
of IN I-OC
MACEs NNP I-OC
in IN B-POPU
diabetic JJ I-POPU
patients NNS I-POPU
after IN I-POPU
sirolimus-eluting JJ I-POPU
stent NN I-POPU
( ( I-POPU
SES NNP I-POPU
) ) I-POPU
or CC I-POPU
paclitaxel-eluting JJ I-POPU
stent NN I-POPU
( ( I-POPU
PES NNP I-POPU
) ) I-POPU
implantation NN I-POPU
have VBP O
not RB O
been VBN O
reported VBN O
. . O

METHODS NNP O
Diabetic NNP B-POPU
patients NNS I-POPU
with IN I-POPU
de FW I-POPU
novo FW I-POPU
coronary JJ I-POPU
lesions NNS I-POPU
( ( I-POPU
169 CD I-POPU
patients NNS I-POPU
with IN I-POPU
190 CD I-POPU
lesions NNS I-POPU
) ) I-POPU
were VBD O
randomly RB O
assigned VBN O
prospectively RB O
to TO O
either DT O
SES NNP B-INTV
or CC I-INTV
PES NNP I-INTV
. . O

RESULTS NNP O
Baseline NNP O
characteristics NNS O
were VBD O
similar JJ O
between IN O
the DT O
two CD O
groups NNS O
. . O

The DT O
rates NNS B-OC
of IN I-OC
MACEs NNP I-OC
[ NNP O
5.9 CD O
% NN O
( ( O
n JJ O
= NNP O
5 CD O
) ) O
in IN O
the DT O
SES NNP B-INTV
vs. FW O
9.5 CD O
% NN O
( ( O
n JJ O
= NNP O
8 CD O
) ) O
in IN O
the DT O
PES NNP B-INTV
Group NNP O
, , O
P NNP O
= VBZ O
0.374 CD O
] NN O
and CC O
definite JJ B-OC
stent NN I-OC
thrombosis NN I-OC
[ VBD O
1.2 CD O
% NN O
( ( O
n JJ O
= NNP O
1 CD O
) ) O
in IN O
the DT O
SES NNP B-INTV
vs. FW O
3.6 CD O
% NN O
( ( O
n JJ O
= NNP O
3 CD O
) ) O
in IN O
the DT O
PES NNP B-INTV
Group NNP O
, , O
P NNP O
= VBZ O
0.368 CD O
] NN O
were VBD O
similar JJ O
in IN O
the DT O
two CD O
groups NNS O
during IN O
the DT O
three-year JJ O
follow-up NN O
. . O

Multivariate NNP O
logistic JJ O
analysis NN O
showed VBD O
that IN O
insulin NN O
treatment NN O
was VBD O
the DT O
only JJ O
independent JJ B-OC
predictor NN I-OC
of IN O
MACE NNP B-OC
[ NNP O
odds NNS O
ratio NN O
( ( O
OR NNP O
) ) O
8.60 CD O
, , O
95 CD O
% NN O
confidence NN O
interval NN O
( ( O
CI NNP O
) ) O
3.25-22.76 CD O
, , O
P NNP O
< VBZ O
0.001 CD O
] NN O
and CC O
target NN B-OC
vessel NN I-OC
revascularization NN I-OC
( ( I-OC
TVR NNP I-OC
) ) I-OC
( ( O
OR $ O
9.50 CD O
, , O
95 CD O
% NN O
CI NNP O
3.07-29.44 CD O
, , O
P NNP O
< NNP O
0.001 CD O
) ) O
during IN O
the DT O
three-year JJ O
follow-up NN O
. . O

CONCLUSIONS VB O
The DT O
rates NNS B-OC
of IN I-OC
MACEs NNP I-OC
, , I-OC
TVR NNP I-OC
, , I-OC
and CC I-OC
stent JJ I-OC
thrombosis NN I-OC
during IN O
the DT O
three-year JJ O
follow-up NN O
were VBD O
similar JJ O
in IN O
the DT O
SES NNP B-INTV
and CC I-INTV
PES NNP I-INTV
Groups NNP O
. . O

Insulin NNP O
treatment NN O
was VBD O
a DT O
main JJ O
predictor NN O
of IN O
MACEs NNP B-OC
and CC I-OC
TVR NNP I-OC
during IN O
the DT O
three-year JJ O
follow-up NN O
after IN O
either DT O
SES NNP B-INTV
or CC O
PES NNP B-INTV
implantation NN O
. . O

-DOCSTART- -X- O O

The DT O
effect NN O
of IN O
L-arginine NNP B-INTV
and CC I-INTV
citrulline NN I-INTV
on IN O
endothelial JJ B-OC
function NN I-OC
in IN O
patients NNS B-POPU
in IN I-POPU
heart NN I-POPU
failure NN I-POPU
with IN I-POPU
preserved JJ I-POPU
ejection NN I-POPU
fraction NN I-POPU
. . O

BACKGROUND NNP O
To TO O
evaluate VB O
the DT O
effect NN O
of IN O
the DT O
amino JJ B-INTV
acids NNS I-INTV
L-arginine JJ I-INTV
and CC I-INTV
citrulline NN I-INTV
on IN O
endothelial JJ B-OC
function NN I-OC
in IN O
patients NNS B-POPU
in IN I-POPU
stable JJ I-POPU
diastolic NN I-POPU
and CC I-POPU
right JJ I-POPU
heart NN I-POPU
failure NN I-POPU
using VBG O
photoplethysmography NN O
. . O

METHODS NNP O
Thirty NNP B-POPU
patients NNS I-POPU
from IN I-POPU
the DT I-POPU
Heart NNP I-POPU
Failure NNP I-POPU
Clinic NNP I-POPU
of IN I-POPU
the DT I-POPU
Instituto NNP I-POPU
Nacional NNP I-POPU
de FW I-POPU
Ciencias NNP I-POPU
Médicas NNP I-POPU
y NNP I-POPU
Nutrición NNP I-POPU
" NNP I-POPU
Salvador NNP I-POPU
Zubirán NNP I-POPU
" NNP I-POPU
underwent JJ I-POPU
photoplethysmography NN I-POPU
using VBG I-POPU
the DT I-POPU
hyperemia NN I-POPU
technique NN I-POPU
. . O

Index NNP B-OC
finger VBD I-OC
flow NN I-OC
was VBD O
assessed VBN O
at IN O
baseline NN O
and CC O
after IN O
ischemia NN O
every DT O
30 CD O
s NN O
by IN O
maximum JJ O
amplitude JJ O
time NN O
( ( O
MAT NNP O
) ) O
, , O
total JJ O
time NN O
of IN O
the DT O
curve NN O
( ( O
TT NNP O
) ) O
and CC O
the DT O
index NN O
of IN O
the DT O
two CD O
( ( O
MAT/TT NNP O
< VBZ O
30 CD O
= NNP O
normal JJ O
) ) O
before IN O
and CC O
after IN O
the DT O
administration NN O
of IN B-INTV
L-arginine NNP I-INTV
( ( O
8 CD O
g/day NN O
in IN O
two CD O
doses NNS O
, , O
n JJ O
= NNP O
15 CD O
) ) O
or CC B-INTV
citrulline NN I-INTV
( ( O
3 CD O
g/day NN O
in IN O
one CD O
dose NN O
, , O
n JJ O
= NNP O
15 CD O
) ) O
for IN O
60 CD O
days NNS O
in IN O
addition NN O
to TO B-INTV
optimal VB I-INTV
pharmacological JJ I-INTV
treatment NN I-INTV
. . O

RESULTS CC O
There EX O
were VBD O
no DT O
statistically RB O
significant JJ O
differences NNS O
between IN O
the DT O
two CD O
groups NNS O
at IN O
baseline NN O
. . O

After IN O
the DT O
intervention NN O
, , O
the DT B-OC
MAT/TT NNP I-OC
index NN I-OC
of IN O
all DT O
patients NNS O
normalized VBN O
in IN O
each DT O
evaluation NN O
period NN O
with IN O
statistically RB O
significant JJ O
differences NNS O
. . O

Basal NNP B-INTV
L-arginine NNP I-INTV
group NN O
= VBD O
38.75 CD O
± NN O
11.52 CD O
, , O
final JJ O
23.32 CD O
± JJ O
6.08 CD O
, , O
p NN O
= VBD O
0.007 CD O
and CC O
basal JJ B-INTV
citrulline NN I-INTV
group NN O
= VBD O
41.4 CD O
± NN O
13.47 CD O
, , O
final JJ O
23.65 CD O
± JJ O
6.74 CD O
, , O
p NN O
= VBD O
0.007 CD O
at IN O
60-90 JJ O
s. JJ O
Post-ischemia NN B-INTV
: : I-INTV
basal NN I-INTV
L-arginine JJ I-INTV
36.60 CD O
± JJ O
11.51 CD O
, , O
final JJ O
18.81 CD O
± JJ O
15.13 CD O
, , O
p NN O
= VBD O
0.004 CD O
and CC B-INTV
basal JJ I-INTV
citrulline NN I-INTV
= $ O
49.51 CD O
± NNP O
15.17 CD O
, , O
final JJ O
27.13 CD O
± JJ O
7.87 CD O
, , O
p NN O
= VBD O
0.003 CD O
. . O

CONCLUSIONS VB O
The DT O
administration NN B-INTV
of IN I-INTV
L-arginine NNP I-INTV
and CC I-INTV
citrulline NN O
has VBZ O
a DT O
beneficial JJ B-OC
effect NN I-OC
on IN I-OC
endothelial JJ I-OC
function NN O
as IN O
shown VBN O
by IN O
the DT O
normalized JJ O
MAT/TT NNP O
index NN O
. . O

It PRP O
probably RB B-OC
improves VBZ I-OC
systemic JJ I-OC
and CC I-OC
pulmonary JJ I-OC
hemodynamics NNS I-OC
, , O
which WDT O
could MD O
help VB O
in IN O
the DT O
treatment NN B-POPU
of IN I-POPU
diastolic JJ I-POPU
heart NN I-POPU
failure NN O
. . O

-DOCSTART- -X- O O

Action NNP O
observation NN O
treatment NN O
improves VBZ O
recovery NN O
of IN O
postsurgical JJ B-POPU
orthopedic JJ I-POPU
patients NNS I-POPU
: : I-POPU
evidence NN O
for IN O
a DT O
top-down JJ O
effect NN O
? . O
OBJECTIVE UH O
To TO O
assess VB O
whether IN O
action NN B-INTV
observation NN I-INTV
treatment NN I-INTV
( ( I-INTV
AOT NNP I-INTV
) ) I-INTV
may MD O
also RB O
improve VB O
motor NN O
recovery NN O
in IN O
postsurgical JJ B-POPU
orthopedic JJ I-POPU
patients NNS I-POPU
, , O
in IN O
addition NN O
to TO O
conventional JJ O
physiotherapy NN O
. . O

DESIGN NNP O
Randomized NNP O
controlled VBD O
trial NN O
. . O

SETTING NNP O
Department NNP O
of IN O
rehabilitation NN O
. . O

PARTICIPANTS JJ O
Patients NNPS B-POPU
( ( I-POPU
N=60 NNP I-POPU
) ) I-POPU
admitted VBD I-POPU
to TO I-POPU
our PRP$ I-POPU
department NN I-POPU
postorthopedic NN I-POPU
surgery NN I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
either VB O
a DT O
case NN O
( ( O
n=30 NN O
) ) O
or CC B-INTV
control NN I-INTV
( ( O
n=30 JJ O
) ) O
group NN B-INTV
. . O

Exclusion NN B-POPU
criteria NNS I-POPU
were VBD I-POPU
age NN I-POPU
18 CD I-POPU
years NNS I-POPU
or CC I-POPU
younger JJR I-POPU
and CC I-POPU
90 CD I-POPU
years NNS I-POPU
or CC I-POPU
older JJR I-POPU
, , I-POPU
Mini-Mental JJ I-POPU
State NNP I-POPU
Examination NNP I-POPU
score NN I-POPU
of IN I-POPU
21 CD I-POPU
of IN I-POPU
30 CD I-POPU
or CC I-POPU
lower JJR I-POPU
, , I-POPU
no DT I-POPU
ambulating VBG I-POPU
order NN I-POPU
, , I-POPU
advanced JJ I-POPU
vision NN I-POPU
impairment NN I-POPU
, , I-POPU
malignancy NN I-POPU
, , I-POPU
pneumonia NN I-POPU
, , I-POPU
or CC I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

INTERVENTIONS NNP O
All NNP O
participants NNS O
underwent JJ O
conventional JJ B-POPU
physiotherapy NN I-POPU
. . O

In IN O
addition NN O
, , O
patients NNS O
in IN O
the DT O
case NN O
group NN O
were VBD O
asked VBN O
to TO O
observe VB B-INTV
video JJ I-INTV
clips NNS I-INTV
showing VBG I-INTV
daily JJ I-INTV
actions NNS I-INTV
and CC I-INTV
to TO I-INTV
imitate VB I-INTV
them PRP I-INTV
afterward RB I-INTV
. . O

Patients NNS O
in IN O
the DT O
control NN O
group NN O
were VBD O
asked VBN O
to TO O
observe VB B-INTV
video JJ I-INTV
clips NNS I-INTV
with IN I-INTV
no DT I-INTV
motor NN I-INTV
content NN I-INTV
and CC I-INTV
to TO I-INTV
execute VB I-INTV
the DT I-INTV
same JJ I-INTV
actions NNS I-INTV
as IN I-INTV
patients NNS I-INTV
in IN I-INTV
the DT I-INTV
case NN I-INTV
group NN I-INTV
afterward RB O
. . O

Participants NNS O
were VBD O
scored VBN O
on IN O
functional JJ O
scales NNS O
at IN O
baseline NN O
and CC O
after IN O
treatment NN O
by IN O
a DT O
physician NN O
blinded VBD O
to TO O
group NN O
assignment NN O
. . O

MAIN NNP O
OUTCOMES NNP O
MEASURES NNP O
Changes NNP B-OC
in IN I-OC
FIM NNP I-OC
and CC I-OC
Tinetti NNP I-OC
scale NN I-OC
scores NNS I-OC
, , I-OC
and CC I-OC
dependence NN I-OC
on IN I-OC
walking VBG I-OC
aids NNS I-OC
. . O

RESULTS NNP O
At IN O
baseline NN O
, , O
groups NNS O
did VBD O
not RB O
differ VB O
in IN O
clinical JJ B-OC
and CC I-OC
functional JJ I-OC
scale NN I-OC
scores NNS I-OC
. . O

After IN O
treatment NN O
, , O
patients NNS O
in IN O
the DT O
case NN O
group NN O
scored VBD O
better JJR O
than IN O
patients NNS O
in IN O
the DT O
control NN O
group NN O
( ( B-OC
FIM NNP I-OC
total NN I-OC
score NN I-OC
, , O
P=.02 NNP O
; : O
FIM NNP B-OC
motor NN I-OC
subscore NN I-OC
, , O
P=.001 NNP O
; : O
Tinetti NNP B-OC
scale NN I-OC
score NN I-OC
, , O
P=.04 NNP O
) ) O
; : O
patients NNS O
in IN O
the DT O
case NN O
group NN O
were VBD O
assigned VBN O
more RBR O
frequently RB B-OC
to TO I-OC
1 CD I-OC
crutch NN I-OC
( ( O
P=.01 NNP O
) ) O
. . O

CONCLUSIONS NNP O
In IN O
addition NN O
to TO O
conventional JJ O
physiotherapy NN O
, , O
AOT NNP O
is VBZ O
effective JJ O
in IN O
the DT O
rehabilitation NN O
of IN O
postsurgical JJ B-POPU
orthopedic JJ I-POPU
patients NNS I-POPU
. . O

The DT O
present JJ O
results NNS O
strongly RB O
support VB O
top-down JJ O
effects NNS O
of IN O
this DT O
treatment NN O
in IN O
motor NN O
recovery NN O
, , O
even RB O
in IN O
nonneurologic JJ B-POPU
patients NNS I-POPU
. . O

-DOCSTART- -X- O O

PDE5 NNP B-INTV
inhibition NN I-INTV
with IN O
sildenafil JJ B-INTV
improves NNS O
left VBD O
ventricular JJ O
diastolic JJ O
function NN O
, , O
cardiac JJ O
geometry NN O
, , O
and CC O
clinical JJ O
status NN O
in IN O
patients NNS B-POPU
with IN I-POPU
stable JJ I-POPU
systolic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
: : I-POPU
results NNS O
of IN O
a DT O
1-year JJ O
, , O
prospective JJ O
, , O
randomized VBN O
, , O
placebo-controlled JJ B-INTV
study NN O
. . O

BACKGROUND NNP O
In IN O
heart NN O
failure NN O
( ( O
HF NNP O
) ) O
, , O
a DT O
defective JJ O
nitric JJ O
oxide IN O
signaling VBG O
is VBZ O
involved VBN O
in IN O
left JJ O
ventricular NN O
( ( O
LV NNP O
) ) O
diastolic NN O
abnormalities NNS O
and CC O
remodeling VBG O
. . O

PDE5 NNP O
inhibition NN O
, , O
by IN O
blocking VBG O
degradation NN O
of IN O
nitric JJ O
oxide IN O
second-messenger JJ O
cyclic JJ O
guanosine NN O
monophosphate NN O
, , O
might MD O
be VB O
beneficial JJ O
. . O

In IN O
a DT O
cohort NN O
of IN O
systolic JJ B-POPU
HF NNP I-POPU
patients NNS I-POPU
, , O
we PRP O
tested VBD O
the DT O
effects NNS O
of IN O
PDE5 NNP O
inhibition NN O
( ( B-INTV
sildenafil NN I-INTV
) ) I-INTV
on IN O
LV NNP O
ejection NN O
fraction NN O
, , O
diastolic JJ O
function NN O
, , O
cardiac JJ O
geometry NN O
, , O
and CC O
clinical JJ O
status NN O
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
Forty-five JJ B-POPU
HF NNP I-POPU
patients NNS I-POPU
( ( I-POPU
New NNP I-POPU
York NNP I-POPU
Heart NNP I-POPU
Association NNP I-POPU
class NN I-POPU
II-III NNP I-POPU
) ) I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
placebo VB B-INTV
or CC I-INTV
sildenafil VB I-INTV
( ( O
50 CD O
mg NN O
three CD O
times NNS O
per IN O
day NN O
) ) O
for IN O
1 CD O
year NN O
, , O
with IN O
assessment NN O
( ( O
6 CD O
months NNS O
and CC O
1 CD O
year NN O
) ) O
of IN O
LV NNP B-OC
ejection NN I-OC
fraction NN I-OC
, , I-OC
diastolic JJ I-OC
function NN I-OC
, , I-OC
geometry NN I-OC
, , I-OC
cardiopulmonary JJ I-OC
exercise NN I-OC
performance NN I-OC
, , I-OC
and CC I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
. . O

In IN O
the DT O
sildenafil NN O
group NN O
only RB O
, , O
at IN O
6 CD O
months NNS O
and CC O
1 CD O
year NN O
, , O
LV NNP B-OC
ejection NN I-OC
fraction NN I-OC
, , I-OC
early JJ I-OC
diastolic JJ I-OC
tissue NN I-OC
Doppler NNP I-OC
velocities NNS I-OC
( ( I-OC
E NNP I-OC
' POS I-OC
) ) I-OC
at IN I-OC
the DT I-OC
mitral JJ I-OC
lateral JJ I-OC
( ( O
from IN O
4.62 CD O
to TO O
5.20 CD O
and CC O
5.19 CD O
m/s NN O
) ) O
and CC O
septal JJ B-OC
( ( O
from IN O
4.71 CD O
to TO O
5.23 CD O
and CC O
5.24 CD O
m/s NN O
) ) O
annuli VBZ B-OC
significantly RB I-OC
increased VBN O
, , O
whereas IN O
the DT O
ratio NN O
of IN O
early JJ O
transmitral NN O
( ( O
E NNP O
) ) O
to TO O
E NNP O
' POS O
lateral JJ O
decreased VBN O
( ( O
from IN O
13.1 CD O
to TO O
9.8 CD O
to TO O
9.4 CD O
) ) O
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

Changes NNS O
were VBD O
accompanied VBN O
by IN O
a DT O
reverse NN B-OC
remodeling NN I-OC
of IN I-OC
left JJ I-OC
atrial JJ I-OC
volume NN I-OC
index NN I-OC
( ( O
from IN O
32.0 CD O
to TO O
29.0 CD O
and CC O
29.1 CD O
mL/m NN O
( ( O
2 CD O
) ) O
; : O
P NNP O
< NNP O
0.01 CD O
) ) O
and CC O
LV NNP B-OC
mass NNP I-OC
index NN I-OC
( ( O
from IN O
148.0 CD O
to TO O
130.0 CD O
and CC O
128.0 CD O
g/m NN O
( ( O
2 CD O
) ) O
; : O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

Furthermore UH O
, , O
sildenafil JJ B-INTV
improved VBN O
exercise NN B-OC
performance NN I-OC
( ( I-OC
peak JJ I-OC
Vo NNP I-OC
( ( I-OC
2 CD I-OC
) ) I-OC
) ) I-OC
, , I-OC
ventilation NN I-OC
efficiency NN I-OC
( ( I-OC
ventilation NN I-OC
to TO I-OC
CO NNP I-OC
( ( I-OC
2 CD I-OC
) ) I-OC
production NN I-OC
slope NN I-OC
) ) I-OC
, , I-OC
and CC I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
. . O

Minor JJ O
adverse JJ O
effects NNS O
were VBD O
noted VBN O
: : O
flushing NN B-OC
in IN O
4 CD O
and CC O
headache NN B-OC
in IN O
2 CD O
treated JJ O
patients NNS O
. . O

CONCLUSIONS NNP O
Findings NNP O
confirm NN O
that IN O
in IN O
HF NNP O
, , O
sildenafil NN B-INTV
improves VBZ O
functional JJ B-OC
capacity NN I-OC
and CC I-OC
clinical JJ I-OC
status NN I-OC
and CC O
provide VB O
the DT O
first JJ O
human JJ O
evidence NN O
that IN O
LV NNP B-OC
diastolic JJ I-OC
function NN I-OC
and CC O
cardiac JJ B-OC
geometry NN I-OC
are VBP O
additional JJ O
targets NNS O
of IN O
benefits NNS O
related VBN O
to TO O
chronic JJ O
PDE5 NNP O
inhibition NN O
. . O

-DOCSTART- -X- O O

Dopexamine NNP B-INTV
has VBZ O
no DT O
additional JJ O
benefit NN O
in IN O
high-risk JJ B-POPU
patients NNS I-POPU
receiving VBG I-POPU
goal-directed JJ I-POPU
fluid NN I-POPU
therapy NN I-POPU
undergoing VBG I-POPU
major JJ I-POPU
abdominal JJ I-POPU
surgery NN I-POPU
. . O

BACKGROUND NNP O
Dopexamine NNP B-INTV
has VBZ O
been VBN O
shown VBN O
to TO O
reduce VB O
both DT O
mortality NN B-OC
and CC I-OC
morbidity NN I-OC
in IN O
major JJ O
surgery NN O
when WRB O
it PRP O
is VBZ O
used VBN O
as IN O
part NN O
of IN O
a DT O
protocol NN O
to TO O
increase VB O
oxygen NN O
delivery NN O
in IN O
the DT O
perioperative JJ O
period NN O
. . O

A DT O
European JJ O
multicenter NN O
study NN O
has VBZ O
examined VBN O
the DT O
use NN O
of IN O
dopexamine NN B-INTV
in IN O
patients NNS B-POPU
undergoing VBG I-POPU
major JJ I-POPU
abdominal JJ I-POPU
surgery NN I-POPU
, , O
showing VBG O
a DT O
trend NN O
toward IN O
improved VBN B-OC
survival NN I-OC
and CC I-OC
reduced JJ I-OC
complications NNS I-OC
in IN O
high-risk JJ O
patients NNS O
when WRB O
receiving VBG O
low-dose JJ B-INTV
dopexamine NN I-INTV
( ( O
0.5 CD O
μg NNP O
· NNP O
kg NNP O
( ( O
-1 NNP O
) ) O
· VBP O
min NN O
( ( O
-1 NNP O
) ) O
) ) O
. . O

A DT O
reduced JJ O
oxygen NN O
uptake NN O
at IN O
the DT O
anaerobic JJ O
threshold NN O
( ( O
AT NNP O
) ) O
has VBZ O
been VBN O
shown VBN O
to TO O
confer VB O
a DT O
significant JJ O
risk NN O
of IN O
mortality NN O
in IN B-POPU
patients NNS I-POPU
undergoing VBG I-POPU
major JJ I-POPU
abdominal JJ I-POPU
surgery NN I-POPU
and CC O
allows VBZ O
objective JJ O
identification NN O
of IN O
a DT O
high-risk JJ O
operative JJ O
group NN O
. . O

In IN O
this DT O
study NN O
, , O
we PRP O
assessed VBD O
the DT O
effects NNS O
of IN B-INTV
low-dose JJ I-INTV
dopexamine NN I-INTV
on IN O
morbidity NN O
after IN B-INTV
major JJ I-INTV
abdominal JJ I-INTV
surgery NN I-INTV
in IN B-POPU
patients NNS I-POPU
who WP I-POPU
were VBD I-POPU
at IN I-POPU
increased VBN I-POPU
risk NN I-POPU
by IN I-POPU
virtue NN I-POPU
of IN I-POPU
a DT I-POPU
reduced VBN I-POPU
AT NNP O
. . O

METHODS NNP B-POPU
Patients NNPS I-POPU
undergoing VBG I-POPU
elective JJ I-POPU
major JJ I-POPU
colorectal NN I-POPU
or CC I-POPU
urological JJ I-POPU
surgery NN I-POPU
who WP I-POPU
had VBD I-POPU
an DT I-POPU
AT NNP I-POPU
of IN I-POPU
< NNP I-POPU
11 CD I-POPU
mL NN I-POPU
· NN I-POPU
kg NN I-POPU
( ( I-POPU
-1 NNP I-POPU
) ) I-POPU
· VBP I-POPU
min NN I-POPU
( ( I-POPU
-1 JJ I-POPU
) ) I-POPU
or CC I-POPU
an DT I-POPU
AT NNP I-POPU
of IN I-POPU
11 CD I-POPU
to TO I-POPU
14 CD I-POPU
mL NNS I-POPU
· JJ I-POPU
kg NN I-POPU
( ( I-POPU
-1 NNP I-POPU
) ) I-POPU
· VBP I-POPU
min NN I-POPU
( ( I-POPU
-1 NNP I-POPU
) ) I-POPU
with IN I-POPU
a DT I-POPU
history NN I-POPU
of IN I-POPU
ischemic JJ I-POPU
heart NN I-POPU
disease NN I-POPU
were VBD I-POPU
recruited VBN I-POPU
. . O

Before IN O
surgery NN O
, , O
a DT O
radial JJ O
arterial JJ O
cannula NN O
was VBD O
placed VBN O
and CC O
attached VBN O
to TO O
an DT O
Edwards NNP O
Lifesciences NNP O
FloTrac/Vigileo NNP O
system NN O
for IN O
measuring VBG O
cardiac JJ O
output NN O
. . O

Patients NNS O
were VBD O
given VBN O
a DT O
250-mL JJ O
bolus NN B-INTV
of IN I-INTV
Voluven NNP I-INTV
( ( I-INTV
6 CD I-INTV
% NN I-INTV
hydroxyethyl NN I-INTV
starch NN I-INTV
130/0.4 CD I-INTV
in IN I-INTV
0.9 CD I-INTV
% NN I-INTV
sodium NN I-INTV
chloride NN I-INTV
) ) I-INTV
until IN O
the DT O
stroke NN O
volume NN O
no RB O
longer RBR O
increased VBN O
by IN O
10 CD O
% NN O
, , O
then RB O
received VBD O
either CC B-INTV
dopexamine NN I-INTV
( ( O
0.5 CD O
μg NNP O
· NNP O
kg NNP O
( ( O
-1 NNP O
) ) O
· VBP O
min NN B-INTV
( ( I-INTV
-1 NNP I-INTV
) ) I-INTV
) ) I-INTV
or CC O
saline VB O
0.9 CD O
% NN O
for IN O
24 CD O
hours NNS O
. . O

During IN B-INTV
surgery NN O
, , O
fluid NN O
boluses NNS B-INTV
of IN I-INTV
Voluven NNP O
were VBD O
given VBN O
if IN O
the DT O
stroke NN O
volume NN O
variation NN O
was VBD O
> JJ O
10 CD O
% NN O
. . O

No DT O
crystalloid NN O
was VBD O
given VBN O
during IN O
surgery NN O
. . O

A DT O
standardized JJ O
postoperative JJ O
fluid NN O
regime NN B-INTV
with IN I-INTV
Hartmann NNP I-INTV
solution NN O
was VBD O
prescribed VBN O
at IN O
1.5 CD O
mL NN O
· NN O
kg NN O
( ( O
-1 NNP O
) ) O
· NN O
h NN O
( ( O
-1 NNP O
) ) O
for IN O
24 CD O
hours NNS O
. . O

The DT O
primary JJ O
outcome NN O
measure NN B-OC
was VBD I-OC
postoperative JJ I-OC
morbidity NN O
measured VBN O
by IN O
the DT O
Postoperative NNP O
Morbidity NNP O
Survey NNP B-POPU
. . O

RESULTS NNP B-POPU
One CD I-POPU
hundred VBD I-POPU
twenty-four JJ I-POPU
patients NNS I-POPU
were VBD I-POPU
recruited VBN I-POPU
over IN I-POPU
a DT I-POPU
23-month JJ I-POPU
period NN B-OC
. . O

The DT B-OC
incidence NN I-OC
of IN I-OC
morbidity NN O
as IN O
measured VBN O
by IN O
the DT O
Postoperative NNP O
Morbidity NNP O
Survey NNP O
on IN O
day NN O
5 CD O
was VBD B-INTV
55 CD I-INTV
% NN I-INTV
in IN I-INTV
the DT I-INTV
control NN I-INTV
group NN O
versus VBD B-INTV
47 CD I-INTV
% NN I-INTV
in IN I-INTV
the DT I-INTV
dopexamine NN O
group NN O
( ( O
P NNP O
= NNP O
0.14 CD O
) ) O
. . O

There EX O
was VBD O
no DT O
significant JJ O
reduction NN B-OC
in IN I-OC
morbidity NN O
on IN O
any DT O
measured JJ O
postoperative JJ B-OC
day NN I-OC
. . O

Complication NN B-OC
rates NNS I-OC
, , I-OC
mortality NN I-OC
, , I-OC
and CC I-OC
hospital JJ I-OC
length NN I-OC
of IN O
stay NN O
were VBD O
similar JJ O
between IN O
the DT O
2 CD O
groups NNS O
; : O
however RB O
, , O
administration NN B-INTV
of IN I-INTV
dopexamine NN O
was VBD O
associated VBN O
with IN O
earlier JJR B-OC
return NN I-OC
of IN I-OC
tolerating VBG O
an DT O
enteral JJ O
diet NN O
. . O

CONCLUSION NN O
With IN O
the DT O
effective JJ B-INTV
use NN I-INTV
of IN I-INTV
goal-directed JJ I-INTV
fluid NN B-POPU
therapy NN I-POPU
in IN I-POPU
elective JJ I-POPU
surgical JJ I-POPU
patients NNS O
, , O
the DT O
routine JJ B-INTV
use NN I-INTV
of IN I-INTV
dopexamine NN O
does VBZ O
not RB O
confer VB O
an DT O
additional JJ O
clinical JJ O
benefit NN O
. . O

-DOCSTART- -X- O O

Removal NN O
of IN O
humoral JJ O
mediators NNS O
and CC O
the DT O
effect NN O
on IN O
the DT O
survival NN O
of IN O
septic JJ B-POPU
patients NNS I-POPU
by IN O
hemoperfusion NN B-INTV
with IN O
neutral JJ O
microporous JJ O
resin NN O
column NN O
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
is VBZ O
to TO O
evaluate VB O
the DT O
impact NN O
of IN O
neutral JJ B-INTV
microporous JJ I-INTV
resin NN I-INTV
hemoperfusion NN I-INTV
on IN O
hemodynamic JJ O
improvement NN O
, , O
removal NN O
of IN O
inflammatory JJ O
cytokines NNS O
, , O
and CC O
mortality NN O
in IN O
critical JJ B-POPU
care NN I-POPU
patients NNS I-POPU
with IN I-POPU
severe JJ I-POPU
sepsis NN I-POPU
. . O

Forty-four CD B-POPU
patients NNS I-POPU
with IN I-POPU
severe JJ I-POPU
sepsis NN I-POPU
or CC I-POPU
septic JJ I-POPU
shock NN I-POPU
were VBD O
randomized VBN O
to TO O
HA NNP B-INTV
type NN I-INTV
hemoperfusion NN I-INTV
treatment NN I-INTV
( ( O
N=24 NNP O
) ) O
or CC B-INTV
standard JJ I-INTV
therapy NN I-INTV
( ( O
N=20 NNP O
) ) O
. . O

Those DT O
undergoing JJ O
hemoperfusion NN O
treatment NN O
received VBD O
HA330 NNP B-INTV
hemoperfusion NN I-INTV
. . O

We PRP O
measured VBD O
the DT O
plasma JJ B-OC
concentrations NNS I-OC
of IN I-OC
IL-6 NNP I-OC
and CC O
IL-8 NNP B-OC
at IN O
the DT O
start NN O
of IN O
every DT O
hemoperfusion NN O
treatment NN O
, , O
and CC O
the DT O
following JJ O
parameters NNS O
were VBD O
compared VBN O
between IN O
the DT O
control NN O
group NN O
and CC O
the DT O
hemoperfusion NN B-INTV
group NN O
on IN O
days NNS O
3 CD O
, , O
7 CD O
, , O
and CC O
14 CD O
: : O
hemodynamics NNS B-OC
( ( I-OC
cardiac JJ I-OC
index NN I-OC
, , I-OC
systemic JJ I-OC
vascular NN I-OC
resistance NN I-OC
index NN I-OC
, , I-OC
heart NN I-OC
rate NN I-OC
, , I-OC
and CC I-OC
mean JJ I-OC
arterial JJ I-OC
pressure NN I-OC
) ) I-OC
; : I-OC
change NN I-OC
of IN I-OC
hematology NN I-OC
and CC I-OC
coagulation NN I-OC
function NN I-OC
; : I-OC
organ JJ I-OC
function NN I-OC
; : I-OC
and CC O
the DT O
sequential JJ B-OC
organ JJ I-OC
failure NN I-OC
assessment NN I-OC
( ( I-OC
SOFA NNP I-OC
) ) I-OC
score NN I-OC
. . O

Hospital NNP B-OC
, , I-OC
28-day JJ I-OC
, , I-OC
and CC I-OC
ICU NNP I-OC
mortality NN I-OC
were VBD O
also RB O
observed VBN O
. . O

Patients NNS O
treated VBD O
with IN O
HA NNP B-INTV
hemoperfusion NN I-INTV
showed VBD O
a DT O
significant JJ B-OC
removal NN I-OC
of IN O
plasma JJ B-OC
IL-6 NNP I-OC
and CC I-OC
IL-8 NNP I-OC
over IN O
time NN O
while IN O
in IN O
the DT O
study NN O
. . O

Patients NNS O
in IN O
the DT O
HA NNP O
group NN O
also RB O
demonstrated VBD O
significant JJ B-OC
increases NNS I-OC
in IN O
cardiac JJ B-OC
index NN I-OC
, , I-OC
systemic JJ I-OC
vascular NN I-OC
resistant JJ I-OC
index NN I-OC
, , I-OC
fast RB I-OC
withdrawal NN I-OC
of IN I-OC
vasoactive JJ I-OC
agents NNS I-OC
and CC I-OC
decreases NNS I-OC
in IN I-OC
heart NN I-OC
rate NN I-OC
compared VBN O
with IN O
the DT O
controls NNS O
at IN O
days NNS O
3 CD O
and CC O
7 CD O
. . O

Although IN O
there EX O
was VBD O
no DT O
significant JJ B-OC
difference NN I-OC
between IN O
the DT O
groups NNS O
in IN O
organ JJ B-OC
dysfunction NN I-OC
as IN O
assessed VBN O
by IN O
SOFA NNP B-OC
scores NNS I-OC
from IN O
day NN O
0 CD O
( ( O
baseline NN O
) ) O
to TO O
day NN O
7 CD O
, , O
significant JJ O
improvement NN O
can MD O
be VB O
demonstrated VBN O
in IN O
the DT O
hemoperfusion NN O
group NN O
at IN O
day NN O
14 CD O
. . O

There EX O
was VBD O
no DT O
significant JJ B-OC
difference NN I-OC
between IN O
the DT O
groups NNS O
in IN O
28-day JJ B-OC
mortality NN I-OC
, , I-OC
hospital JJ I-OC
mortality NN I-OC
, , I-OC
or CC I-OC
length NN I-OC
of IN I-OC
hospital NN I-OC
stay NN I-OC
, , I-OC
but CC I-OC
ICU NNP I-OC
mortality NN I-OC
and CC I-OC
the DT I-OC
length NN I-OC
of IN I-OC
ICU NNP I-OC
stay NN I-OC
in IN O
the DT O
HA NNP O
group NN O
were VBD O
markedly RB O
reduced VBN B-OC
. . O

Hemoperfusion NNP O
treatment NN O
using VBG O
the DT O
HA NNP O
type NN O
cartridge NN O
in IN O
sepsis NN O
is VBZ O
safe JJ O
and CC O
it PRP O
may MD O
improve VB O
organ JJ B-OC
dysfunction NN I-OC
, , I-OC
ICU NNP I-OC
mortality NN I-OC
, , I-OC
and CC I-OC
shorten VB I-OC
the DT I-OC
length NN I-OC
of IN I-OC
ICU NNP I-OC
stay NN I-OC
. . O

Clinical JJ O
significant JJ O
removal NN O
of IN O
inflammatory JJ O
cytokines NNS O
such JJ O
as IN O
IL-6 NNP B-OC
and CC I-OC
IL-8 NNP I-OC
from IN O
circulation NN O
by IN O
hemoperfusion NN B-INTV
may MD O
contribute VB O
to TO O
improving VBG O
a DT O
patient NN O
's POS O
outcome NN O
in IN O
an DT O
ICU NNP O
. . O

-DOCSTART- -X- O O

[ JJ O
GISSI-2 NNP O
; : O
the DT O
beginning NN O
of IN O
the DT O
end NN O
or CC O
the DT O
end NN O
of IN O
the DT O
beginning NN O
for IN O
tissue NN B-INTV
plasminogen NN I-INTV
activator NN O
in IN O
acute JJ B-POPU
myocardial JJ I-POPU
infarct NN I-POPU
? . O
] NN O
. . O

-DOCSTART- -X- O O

Mechanisms NNP O
underlying VBG O
the DT O
lack NN O
of IN O
effect NN O
of IN O
implantable JJ B-INTV
cardioverter-defibrillator JJ I-INTV
therapy NN I-INTV
on IN O
mortality NN B-OC
in IN O
high-risk JJ B-POPU
patients NNS I-POPU
with IN I-POPU
recent JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
: : I-POPU
insights NNS O
from IN O
the DT O
Defibrillation NNP O
in IN O
Acute NNP O
Myocardial NNP O
Infarction NNP O
Trial NNP O
( ( O
DINAMIT NNP O
) ) O
. . O

BACKGROUND NNP O
although IN O
implantable JJ B-INTV
cardioverter-defibrillators NNS I-INTV
( ( O
ICDs NNP O
) ) O
lower JJR O
mortality NN O
in IN O
stable JJ B-POPU
patients NNS I-POPU
with IN I-POPU
low JJ I-POPU
ejection NN I-POPU
fraction NN I-POPU
late RB I-POPU
after IN I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
, , O
randomized VBN O
trials NNS O
of IN O
ICD NNP B-INTV
versus FW O
control NN O
subjects NNS O
implanted VBD O
early RB O
after IN O
myocardial JJ O
infarction NN O
do VBP O
not RB O
show VB O
mortality NN O
benefit NN O
. . O

Our PRP$ O
objective NN O
was VBD O
to TO O
investigate VB O
possible JJ O
mechanisms NNS O
underlying VBG O
the DT O
lack NN O
of IN O
mortality NN B-OC
benefit NN O
in IN O
the DT O
Defibrillation NNP O
in IN O
Acute NNP O
Myocardial NNP O
Infarction NNP O
Trial NNP O
( ( O
DINAMIT NNP O
) ) O
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
this DT O
is VBZ O
a DT O
secondary JJ O
analysis NN O
of IN O
the DT O
prospective JJ O
randomized JJ O
clinical JJ O
trial NN O
. . O

Outpatients NNS B-POPU
with IN I-POPU
recent JJ I-POPU
( ( I-POPU
6 CD I-POPU
to TO I-POPU
40 CD I-POPU
days NNS I-POPU
) ) I-POPU
acute VBP I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
, , I-POPU
left VBD I-POPU
ventricular JJ I-POPU
dysfunction NN I-POPU
( ( I-POPU
ejection JJ I-POPU
fraction NN I-POPU
< VBD I-POPU
35 CD I-POPU
% NN I-POPU
) ) I-POPU
, , I-POPU
and CC I-POPU
low JJ I-POPU
heart NN I-POPU
rate NN I-POPU
variability NN I-POPU
were VBD O
randomized VBN O
to TO O
ICD NNP B-INTV
( ( O
n=311 NN O
) ) O
or CC O
to TO O
standard VB B-INTV
medical JJ I-INTV
therapy NN I-INTV
( ( O
n=342 JJ O
) ) O
. . O

In IN O
a DT O
competing-risks JJ O
analysis NN O
, , O
those DT O
factors NNS O
that WDT O
increased VBD O
the DT O
risk NN B-OC
of IN I-OC
arrhythmic JJ I-OC
death NN I-OC
also RB O
increased VBD O
the DT O
risk NN B-OC
of IN I-OC
nonarrhythmic JJ I-OC
deaths NNS I-OC
. . O

After IN O
adjustment NN O
for IN O
these DT O
factors NNS O
, , O
receiving VBG O
an DT O
ICD NNP O
was VBD O
associated VBN O
with IN O
a DT O
decreased JJ O
risk NN B-OC
of IN I-OC
arrhythmic JJ I-OC
death NN I-OC
( ( O
hazard JJ O
ratio NN O
, , O
0.33 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
0.15 CD O
to TO O
0.71 CD O
) ) O
but CC O
an DT O
increase NN O
in IN O
nonarrhythmic JJ B-OC
death NN I-OC
( ( O
hazard JJ O
ratio NN O
, , O
1.70 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
1.00 CD O
to TO O
2.80 CD O
) ) O
. . O

In IN O
an DT O
adjusted JJ O
time-dependent JJ O
analysis NN O
, , O
patients NNS O
receiving VBG O
an DT O
ICD NNP O
and CC O
having VBG O
appropriate JJ O
ICD NNP O
therapy NN O
had VBD O
a DT O
15.1 CD O
% NN O
yearly RB B-OC
hazard NN I-OC
of IN I-OC
mortality NN I-OC
compared VBN O
with IN O
5.2 CD O
% NN O
in IN O
ICD NNP B-POPU
patients NNS I-POPU
with IN O
no DT O
appropriate JJ O
therapy NN O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

The DT O
reduction NN O
in IN O
sudden JJ B-OC
death NN I-OC
in IN O
ICD NNP B-POPU
patients NNS I-POPU
was VBD O
completely RB O
offset VBN O
by IN O
increased JJ O
nonarrhythmic JJ B-OC
deaths NNS I-OC
, , O
which WDT O
were VBD O
greatest JJS O
in IN O
patients NNS B-POPU
receiving VBG O
ICD NNP O
shock NN O
therapy NN O
( ( O
hazard JJ O
ratio NN O
, , O
6.0 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
2.8 CD O
to TO O
12.7 CD O
) ) O
. . O

CONCLUSIONS NNP O
in IN O
patients NNS B-POPU
receiving VBG I-POPU
ICDs NNP I-POPU
early RB I-POPU
after IN I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
, , O
those DT O
factors NNS O
that WDT O
are VBP O
associated VBN O
with IN O
arrhythmia NN O
requiring VBG O
ICD NNP O
therapy NN O
are VBP O
also RB O
associated VBN O
with IN O
a DT O
high JJ O
risk NN O
of IN O
nonsudden JJ B-OC
death NN I-OC
, , O
negating VBG O
the DT O
benefit NN O
of IN O
ICDs NNP O
in IN O
this DT O
setting NN O
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
L-arginine NNP B-INTV
or CC I-INTV
L-citrulline JJ I-INTV
oral JJ I-INTV
supplementation NN I-INTV
on IN O
blood NN B-OC
pressure NN I-OC
and CC I-OC
right JJ I-OC
ventricular NN I-OC
function NN I-OC
in IN O
heart NN B-POPU
failure NN I-POPU
patients NNS I-POPU
with IN I-POPU
preserved JJ I-POPU
ejection NN I-POPU
fraction NN I-POPU
. . O

BACKGROUND IN O
The DT O
effect NN O
of IN O
L-arginine NNP B-INTV
and CC I-INTV
L-citrulline NNP I-INTV
on IN O
blood NN B-OC
pressure NN I-OC
and CC I-OC
right JJ I-OC
ventricular NN I-OC
function NN I-OC
in IN O
heart NN B-POPU
failure NN I-POPU
patients NNS I-POPU
with IN I-POPU
preserved JJ I-POPU
ejection NN I-POPU
fraction NN I-POPU
( ( I-POPU
HFpEF NNP I-POPU
) ) I-POPU
is VBZ O
unknown JJ O
. . O

We PRP O
have VBP O
therefore RB O
evaluated VBN O
, , O
in IN O
a DT O
randomized JJ O
clinical JJ O
trial NN O
, , O
the DT O
effect NN O
of IN O
these DT O
aminoacids NNS O
in IN O
chronic JJ B-POPU
outstanding JJ I-POPU
and CC I-POPU
stable JJ I-POPU
patients NNS I-POPU
with IN I-POPU
HFpEF NNP I-POPU
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
All NNP B-POPU
patients NNS I-POPU
underwent VBD I-POPU
an DT I-POPU
echocardiogram NN I-POPU
and CC I-POPU
radioisotopic NN I-POPU
ventriculography NN I-POPU
rest/exercise NN I-POPU
, , O
and CC O
were VBD O
randomized VBN O
in IN O
a DT O
consecutive JJ O
manner NN O
to TO O
the DT O
L-arginine NNP B-POPU
group NN I-POPU
( ( I-POPU
n JJ I-POPU
= VBZ I-POPU
15 CD I-POPU
; : I-POPU
8 CD I-POPU
g/day NN I-POPU
) ) I-POPU
; : I-POPU
and CC I-POPU
the DT I-POPU
citrulline NN I-POPU
malate NN I-POPU
group NN I-POPU
( ( I-POPU
n JJ I-POPU
= VBZ I-POPU
15 CD I-POPU
; : I-POPU
3 CD O
g/day NN O
) ) O
. . O

The DT O
duration NN O
of IN O
follow-up NN O
was VBD O
two CD O
months NNS O
. . O

The DT O
principal JJ O
echocardiographic JJ O
finding NN O
was VBD O
a DT O
statistically RB O
significant JJ O
decrease NN O
in IN O
pulmonary JJ B-OC
artery NN I-OC
pressure NN I-OC
in IN O
the DT O
L-arginine NNP B-INTV
( ( O
56.3 CD O
± RB O
10 CD O
vs NNS O
44 CD O
± $ O
16.5 CD O
mm NN O
Hg NNP O
, , O
p NN O
< NNP O
0.05 CD O
) ) O
and CC O
the DT B-INTV
citrulline NN I-INTV
( ( O
56.67 CD O
± RB O
7.96 CD O
vs NNS O
47.67 CD O
± $ O
8.59 CD O
mm NN O
Hg NNP O
, , O
p NN O
< NNP O
0.05 CD O
) ) O
groups NNS B-OC
. . O

Duration NN B-OC
on IN I-OC
treadmill NN I-OC
and CC I-OC
right JJ I-OC
ventricular NN I-OC
ejection NN I-OC
fraction NN I-OC
post NN I-OC
exercise NN I-OC
increased VBD O
, , O
while IN B-OC
diastolic JJ I-OC
and CC I-OC
systolic JJ I-OC
artery NN I-OC
pressure NN I-OC
decreased VBN O
significantly RB O
in IN O
both DT O
groups NNS O
. . O

There EX O
were VBD O
no DT O
other JJ O
statistically RB O
significant JJ O
differences NNS O
between IN O
the DT O
groups NNS O
. . O

CONCLUSIONS NNP O
Administration NNP B-INTV
of IN I-INTV
L-arginine NNP I-INTV
and CC I-INTV
citrulline NN B-POPU
to TO I-POPU
patients NNS I-POPU
with IN I-POPU
HFpEF NNP I-POPU
improved VBD B-OC
right JJ I-OC
ventricular NN I-OC
function NN I-OC
by IN O
increasing VBG O
right JJ O
ventricular NN O
ejection NN O
fraction NN O
, , O
and CC O
probably RB O
decreasing VBG B-OC
systolic JJ I-OC
pulmonary JJ I-OC
artery NN I-OC
pressure NN I-OC
. . O

-DOCSTART- -X- O O

Relationship NN O
between IN O
baseline NN O
blood NN O
pressure NN O
parameters NNS O
( ( O
including VBG O
mean JJ O
pressure NN O
, , O
pulse JJ O
pressure NN O
, , O
and CC O
variability NN O
) ) O
and CC O
early JJ O
outcome NN O
after IN O
stroke NN B-POPU
: : I-POPU
data NN O
from IN O
the DT O
Tinzaparin NNP B-POPU
in IN I-POPU
Acute NNP I-POPU
Ischaemic NNP I-POPU
Stroke NNP I-POPU
Trial NNP I-POPU
( ( I-POPU
TAIST NNP I-POPU
) ) I-POPU
. . O

BACKGROUND NNP O
AND NNP O
PURPOSE NNP O
High NNP B-POPU
blood NN I-POPU
pressure NN I-POPU
( ( I-POPU
BP NNP I-POPU
) ) I-POPU
in IN I-POPU
acute JJ I-POPU
stroke NN I-POPU
is VBZ O
associated VBN O
independently RB O
with IN O
a DT O
poor JJ O
outcome NN O
. . O

Recent JJ O
evidence NN O
suggests VBZ O
that IN O
other JJ O
hemodynamic JJ O
parameters NNS O
may MD O
also RB O
be VB O
associated VBN O
with IN O
outcomes NNS O
following VBG O
stroke NN O
. . O

METHODS NNP O
The DT O
relationship NN O
between IN O
baseline NN O
BP NNP O
, , O
heart NN O
rate NN O
, , O
and CC O
other JJ O
hemodynamic JJ O
parameters NNS O
, , O
and CC O
early RB O
outcomes NNS O
were VBD O
assessed VBN O
using VBG B-POPU
data NNS I-POPU
from IN I-POPU
TAIST NNP I-POPU
trial NN I-POPU
. . O

RESULTS NNP O
Death NNP B-OC
or CC I-OC
neurological JJ I-OC
deterioration NN I-OC
at IN I-OC
day NN I-OC
10 CD I-OC
was VBD O
associated VBN O
, , O
both DT O
in IN O
unadjusted JJ O
and CC O
adjusted JJ O
analyses NNS O
, , O
with IN O
systolic JJ B-OC
BP NNP I-OC
( ( O
adjusted VBN O
OR NNP O
, , O
1.02 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.01-1.03 JJ O
) ) O
, , O
mean JJ B-OC
arterial JJ I-OC
pressure NN I-OC
( ( O
OR NNP O
, , O
1.02 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.01-1.04 JJ O
) ) O
, , O
pulse JJ B-OC
pressure NN I-OC
( ( O
OR NNP O
, , O
1.02 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.01-1.03 JJ O
) ) O
, , O
and CC O
BP NNP B-OC
variability NN I-OC
( ( O
OR NNP O
, , O
1.03 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
1.01-1.05 JJ O
) ) O
. . O

Similar JJ O
relationships NNS O
were VBD O
noted VBN O
for IN O
deterioration NN B-OC
alone RB I-OC
, , I-OC
and CC I-OC
recurrent JJ I-OC
stroke NN I-OC
. . O

CONCLUSIONS NNP O
Early JJ O
death NN B-OC
or CC O
neurologic JJ B-OC
deterioration NN I-OC
, , I-OC
deterioration NN I-OC
, , O
and CC O
recurrent JJ B-OC
stroke NN I-OC
are VBP O
associated VBN O
independently RB O
with IN O
high JJ B-POPU
systolic JJ I-POPU
BP NNP I-POPU
, , I-POPU
mean JJ I-POPU
arterial JJ I-POPU
pressure NN I-POPU
, , I-POPU
pulse JJ I-POPU
pressure NN I-POPU
, , I-POPU
and CC I-POPU
BP NNP I-POPU
variability NN I-POPU
. . O

These DT O
measures NNS O
offer VBP O
potential JJ O
therapeutic JJ B-INTV
targets NNS I-INTV
for IN O
improving VBG O
early JJ O
outcome NN O
after IN O
acute JJ B-POPU
ischemic JJ I-POPU
stroke NN I-POPU
. . O

-DOCSTART- -X- O O

Initial JJ O
clinical JJ O
experience NN O
with IN O
implantation NN B-INTV
of IN I-INTV
left JJ I-INTV
ventricular JJ I-INTV
lead NN I-INTV
guided VBN I-INTV
by IN I-INTV
Overlay NNP I-INTV
Ref NNP I-INTV
for IN O
the DT O
treatment NN O
of IN O
congestive JJ O
heart NN O
failure NN O
. . O

BACKGROUND NNP O
Cardiac NNP B-INTV
resynchronization NN I-INTV
therapy NN I-INTV
( ( I-INTV
CRT NNP I-INTV
) ) I-INTV
improves VBZ O
clinical JJ O
outcome NN B-OC
in IN O
selected VBN B-POPU
patients NNS I-POPU
with IN I-POPU
advanced JJ I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

The DT O
Overlay NNP O
Ref NNP O
technique NN O
may MD O
facilitate VB O
the DT O
procedure NN O
for IN O
implanting VBG O
left JJ O
ventricular NN O
( ( O
LV NNP O
) ) O
pacing VBG O
leads NNS O
to TO O
deliver VB O
CRT NNP B-INTV
. . O

AIM NNP O
To TO O
assess VB O
the DT O
feasibility NN O
of IN O
deploying VBG O
a DT O
LV NNP O
pacing VBG O
lead NN O
into IN O
a DT O
coronary JJ O
sinus NN O
side NN O
branch NN O
guided VBN O
by IN O
Overlay NNP B-INTV
Ref NNP I-INTV
. . O

METHODS NNP O
Data NNP O
from IN O
88 CD B-POPU
consecutive JJ I-POPU
patients NNS I-POPU
who WP I-POPU
met VBD I-POPU
the DT I-POPU
CRT NNP I-POPU
implantation NN I-POPU
criteria NNS I-POPU
in IN I-POPU
our PRP$ I-POPU
hospital NN I-POPU
between IN I-POPU
28 CD I-POPU
November NNP I-POPU
2007 CD I-POPU
and CC I-POPU
30 CD I-POPU
December NNP I-POPU
2009 CD I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO I-POPU
two CD I-POPU
groups NNS I-POPU
. . O

Forty-four CD B-POPU
patients NNS I-POPU
underwent JJ I-POPU
CRT NNP I-POPU
device NN I-POPU
implantation NN I-POPU
using VBG I-POPU
Overlay NNP I-POPU
Ref NNP I-POPU
to TO B-INTV
guide VB I-INTV
target NN I-INTV
vein JJ I-INTV
selection NN I-INTV
and CC I-INTV
advance VB I-INTV
a DT I-INTV
specifically RB I-INTV
designed VBN I-INTV
pacing VBG I-INTV
lead NN I-INTV
into IN I-INTV
the DT I-INTV
target NN I-INTV
vein NN I-INTV
( ( I-INTV
Overlay NNP I-INTV
Ref NNP I-INTV
group NN I-INTV
) ) I-INTV
; : I-INTV
44 CD B-POPU
patients NNS I-POPU
were VBD I-POPU
conventionally RB I-POPU
implanted VBN I-POPU
( ( I-POPU
control VB I-POPU
group NN I-POPU
) ) I-POPU
. . O

RESULTS NNP O
LV NNP B-INTV
lead JJ I-INTV
implantation NN I-INTV
was VBD O
successful JJ O
in IN O
all DT O
patients NNS O
. . O

Mean NNP O
CRT NNP B-OC
total JJ I-OC
procedure NN I-OC
times NNS I-OC
( ( I-OC
skin-to-skin JJ I-OC
) ) I-OC
were VBD O
: : O
Overlay NNP B-INTV
Ref NNP I-INTV
group NN O
, , O
80.7 CD O
± NN O
18.0 CD O
min NN O
; : O
control NN O
group NN O
, , O
98.5 CD O
± NN O
32.2 CD O
min NN O
; : O
p CC O
= $ O
0.029 CD O
. . O

Mean JJ B-OC
placement NN I-OC
of IN I-OC
LV NNP I-OC
pacing VBG I-OC
lead NN I-OC
into IN I-OC
target NN I-OC
vein JJ I-OC
times NNS I-OC
were VBD B-INTV
: : I-INTV
Overlay NNP I-INTV
Ref NNP I-INTV
group NN O
, , O
16.2 CD O
± NN O
7.7 CD O
min NN O
; : O
control NN O
group NN O
, , O
36.4 CD O
± NN O
23.4 CD O
min NN O
; : O
p=0.004 NN O
. . O

Mean NNP B-OC
total JJ I-OC
fluoroscopy NN I-OC
times NNS I-OC
were VBD B-INTV
: : I-INTV
Overlay NNP I-INTV
Ref NNP O
group NN O
, , O
13.6 CD O
± NN O
4.3 CD O
min NN O
; : O
control NN O
group NN O
, , O
23.8 CD O
± NN O
15.7 CD O
min NN O
; : O
p=0.007 NN O
. . O

Mean NNP B-OC
LV NNP I-OC
lead NN I-OC
fluoroscopy NN I-OC
times NNS O
were VBD B-INTV
: : I-INTV
Overlay NNP I-INTV
Ref NNP O
group NN O
, , O
5.7 CD O
± NN O
2.9 CD O
min NN O
; : O
control NN O
group NN O
, , O
14.4 CD O
± NN O
4.6 CD O
min NN O
; : O
p=0.003 NN O
. . O

No DT B-OC
major JJ I-OC
complications NNS I-OC
occurred VBD O
. . O

CONCLUSIONS NNP B-INTV
Overlay NNP I-INTV
Ref NNP O
facilitates VBZ O
location NN O
of IN O
and CC O
entry NN O
into IN O
the DT O
coronary JJ O
sinus NN O
, , O
and CC O
shortens VBZ B-OC
the DT I-OC
duration NN I-OC
of IN I-OC
LV NNP I-OC
pacing VBG I-OC
lead JJ I-OC
implantation NN I-OC
into IN O
the DT O
target NN O
vein NN O
. . O

-DOCSTART- -X- O O

Pharmacist NNP B-INTV
directed VBD I-INTV
home NN I-INTV
medication NN I-INTV
reviews NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
: : I-POPU
a DT O
randomised JJ O
clinical JJ O
trial NN O
. . O

BACKGROUND NNP O
Chronic NNP B-POPU
heart NN I-POPU
failure NN I-POPU
( ( I-POPU
CHF NNP I-POPU
) ) I-POPU
accounts NNS O
for IN O
significant JJ O
morbidity NN O
, , O
mortality NN O
and CC O
health NN O
expenditure NN O
. . O

Furthermore NNP O
, , O
patients NNS B-POPU
with IN I-POPU
CHF NNP I-POPU
are VBP O
often RB O
on IN O
numerous JJ O
pharmacological JJ O
agents NNS O
for IN O
their PRP$ O
comorbidities NNS O
. . O

The DT O
objective NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
determine VB O
whether IN O
a DT O
pharmacist NN O
directed VBD O
home NN B-INTV
medication NN I-INTV
review NN O
intervention NN O
had VBD O
positive JJ O
effects NNS O
on IN O
CHF NNP B-POPU
patient NN I-POPU
outcomes NNS O
. . O

METHODS NNP O
A NNP B-POPU
total NN I-POPU
of IN I-POPU
120 CD I-POPU
patients NNS I-POPU
hospitalised VBN I-POPU
for IN I-POPU
CHF NNP I-POPU
were VBD O
randomised VBN O
to TO O
receive VB O
a DT O
pharmacist NN B-INTV
directed VBD I-INTV
post-discharge JJ I-INTV
home NN I-INTV
medication NN I-INTV
review NN I-INTV
( ( O
n JJ O
= NN O
64 CD O
, , O
53.3 CD O
% NN O
) ) O
or CC O
standard JJ B-INTV
care NN I-INTV
( ( O
n JJ O
= NN O
56 CD O
, , O
46.7 CD O
% NN O
) ) O
. . O

Participants NNS O
were VBD O
followed VBN O
for IN O
6 CD O
months NNS O
. . O

Primary JJ O
outcomes NNS O
were VBD O
death NN O
, , O
CHF NNP B-OC
hospitalisation NN I-OC
and CC O
length NN O
of IN O
hospital NN O
stay NN O
. . O

RESULTS CC O
There EX O
were VBD O
no DT O
between IN O
group NN O
differences NNS O
in IN O
mortality NN B-OC
( ( O
hazard JJ O
ratio NN O
= VBD O
1.41 CD O
, , O
0.50 CD O
to TO O
3.97 CD O
; : O
P NNP O
= NNP O
0.514 CD O
) ) O
or CC O
CHF NNP B-OC
hospitalizations NNS I-OC
( ( O
incidence NN O
rate NN O
ratio NN O
[ NNP O
IRR NNP O
] NNP O
= VBD O
1.74 CD O
95 CD O
% NN O
CI NNP O
: : O
0.85-3.60 JJ O
P NNP O
= NNP O
0.131 CD O
) ) O
over IN O
the DT O
6 CD O
month NN O
follow-up JJ O
period NN O
. . O

Days NNS B-OC
of IN I-OC
hospital NN I-OC
stay NN I-OC
for IN I-OC
CHF NNP I-OC
exacerbations NNS I-OC
in IN O
the DT O
6 CD O
month NN O
follow-up NN O
were VBD O
significantly RB O
greater JJR O
in IN O
the DT O
intervention NN O
group NN O
( ( O
IRR NNP O
= NNP O
2.34 CD O
95 CD O
% NN O
CI NNP O
: : O
1.80-3.05 JJ O
P NNP O
= NNP O
0.000 CD O
) ) O
. . O

CONCLUSIONS NNP O
Post-discharge NNP O
pharmacy NN B-INTV
directed VBD I-INTV
home NN I-INTV
medication NN I-INTV
review NN I-INTV
appeared VBD O
to TO O
have VB O
no DT O
effect NN O
on IN O
mortality NN O
and CC O
health NN O
care NN O
utilisation NN O
above IN O
that DT O
achieved VBD O
with IN O
standard JJ O
care NN O
. . O

The DT O
post-acute JJ O
management NN O
of IN O
CHF NNP O
must MD O
be VB O
a DT O
collaborative JJ O
multi-disciplinary JJ O
effort NN O
by IN O
the DT O
health NN O
care NN O
team NN O
as IN O
it PRP O
is VBZ O
the DT O
additive JJ O
effect NN O
of IN O
interventions NNS O
that WDT O
are VBP O
most RBS O
effective JJ O
. . O

-DOCSTART- -X- O O

[ JJ O
Protective NNP O
effect NN O
of IN O
ischemia NN B-INTV
postconditioning VBG I-INTV
on IN O
reperfusion NN O
injury NN O
in IN O
patients NNS B-POPU
with IN I-POPU
ST-segment JJ I-POPU
elevation NN I-POPU
acute IN I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
] NNP I-POPU
. . O

OBJECTIVE NNP O
To TO O
observe VB O
the DT O
effect NN O
of IN O
ischemia NN B-INTV
postconditioning VBG I-INTV
during IN O
the DT O
first JJ O
minutes NNS O
of IN O
reperfusion NN O
for IN O
the DT O
myocardial JJ O
reperfusion NN O
injury NN O
in IN O
ST-segment JJ B-POPU
elevation NN I-POPU
acute IN I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
( ( I-POPU
STEMI NNP I-POPU
) ) I-POPU
patients NNS I-POPU
undergoing VBG I-POPU
emergency NN I-POPU
percutaneous JJ I-POPU
coronary JJ I-POPU
intervention NN I-POPU
( ( I-POPU
PCI NNP I-POPU
) ) I-POPU
. . O

METHODS NNP O
STEMI NNP B-POPU
patients NNS I-POPU
undergoing VBG I-POPU
emergency NN I-POPU
PCI NNP I-POPU
in IN I-POPU
affiliated JJ I-POPU
hospital NN I-POPU
of IN I-POPU
Beihua NNP I-POPU
University NNP I-POPU
between IN I-POPU
October NNP I-POPU
2006 CD I-POPU
and CC I-POPU
January NNP I-POPU
2009 CD I-POPU
were VBD O
randomly RB O
divided VBN O
into IN O
two CD O
groups NNS O
: : O
the DT B-POPU
control NN I-POPU
group NN I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
34 CD I-POPU
) ) I-POPU
without IN B-INTV
any DT I-INTV
intervention NN I-INTV
after IN I-INTV
PTCA NNP I-INTV
, , O
and CC O
the DT O
postconditioning NN B-POPU
group NN I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
30 CD I-POPU
) ) I-POPU
with IN B-INTV
ischemia NN I-INTV
postconditioning VBG I-INTV
within IN O
first JJ O
minutes NNS O
of IN O
reflow NN O
by IN O
3 CD O
episodes NNS O
of IN O
30-second JJ O
inflation NN O
and CC O
30-second JJ O
deflation NN O
with IN O
the DT O
angioplasty JJ B-INTV
balloon NN I-INTV
. . O

Reperfusion NN B-OC
arrhythmias NN I-OC
, , I-OC
CK NNP I-OC
and CC I-OC
CKMB NNP I-OC
, , I-OC
corrected VBD I-OC
TIMI NNP I-OC
frame NN I-OC
count NN I-OC
( ( I-OC
CTFC NNP I-OC
) ) I-OC
, , I-OC
wall JJ I-OC
motion NN I-OC
score NN I-OC
index NN I-OC
( ( I-OC
WMSI NNP I-OC
) ) I-OC
and CC I-OC
left VBD I-OC
ventricular JJ I-OC
ejection NN I-OC
fraction NN I-OC
( ( I-OC
LVEF NNP I-OC
) ) I-OC
by IN O
echocardiography NN O
were VBD O
compared VBN O
between IN O
the DT O
two CD O
groups NNS O
. . O

MI NNP O
areas NNS O
were VBD O
evaluated VBN O
with IN O
the DT O
ECG-54 NNP O
criteria/32 NN O
system NN O
and CC O
myocardial JJ B-OC
blush NN I-OC
grade NN I-OC
( ( I-OC
MBG NNP I-OC
) ) I-OC
was VBD O
measured VBN O
. . O

RESULTS VB O
The DT O
incidence NN B-OC
of IN I-OC
reperfusion NN I-OC
arrhythmias-frequent JJ I-OC
ventricular JJ I-OC
premature NN I-OC
( ( O
26.7 CD O
% NN O
vs. FW O
52.9 CD O
% NN O
) ) O
and CC O
short JJ B-OC
array NN I-OC
ventricular JJ I-OC
tachycardia NN I-OC
beat NN I-OC
( ( O
23.3 CD O
% NN O
vs. FW O
58.8 CD O
% NN O
) ) O
as RB O
well RB O
as IN O
values NNS O
of IN O
peaks NNS B-OC
CK NNP I-OC
[ NNP O
( ( O
1162 CD O
± NNP O
548 CD O
) ) O
U/L NNP O
vs. FW O
( ( O
1732 CD O
± NNP O
480 CD O
) ) O
U/L NNP O
, , O
P NNP O
< VBZ O
0.01 CD O
] NN O
, , O
CKMB NNP O
[ NNP O
( ( O
165 CD O
± RB O
70 CD O
) ) O
U/L NNP O
vs. FW O
( ( O
280 CD O
± RB O
99 CD O
) ) O
U/L NNP O
, , O
P NNP O
< VBZ O
0.01 CD O
] NN O
, , O
CTFC NNP O
( ( O
22.23 CD O
± RB O
3.81 CD O
vs. FW O
26.97 CD O
± $ O
3.42 CD O
) ) O
, , O
WMSI NNP O
( ( O
1.27 CD O
± RB O
0.52 CD O
vs. FW O
1.82 CD O
± $ O
0.83 CD B-OC
) ) I-OC
, , I-OC
and CC I-OC
infarction NN I-OC
areas NNS O
determined VBN B-OC
by IN O
ECG NNP O
methods NNS O
( ( O
10.60 CD O
% NN O
± JJ O
4.97 CD O
% NN O
vs.14.65 NN O
% NN O
± JJ O
6.88 CD O
% NN O
, , O
all DT O
P NNP O
< NNP O
0.05 CD B-OC
) ) I-OC
were VBD I-OC
all DT I-OC
significantly RB I-OC
lower JJR O
in IN O
the DT O
postconditioning VBG O
group NN O
than IN O
in IN O
control NN O
group NN O
while IN O
LVEF NNP O
( ( O
0.55 CD O
± RB O
0.08 CD O
vs. FW O
0.47 CD O
± $ O
0.10 CD O
) ) O
and CC O
MBG NNP O
( ( O
2.27 CD O
± RB O
0.64 CD O
vs. FW O
1.47 CD O
± NN O
0.61 CD O
, , O
all DT O
P NNP B-OC
< NNP I-OC
0.05 CD I-OC
) ) I-OC
were VBD I-OC
significantly RB I-OC
higher JJR O
in IN O
the DT O
postconditioning VBG O
group NN O
than IN O
in IN O
control NN O
group NN B-INTV
. . O

CONCLUSIONS NNP B-INTV
Ischemia NNP I-INTV
postconditioning NN I-INTV
can MD O
significantly RB O
reduce VB O
myocardial JJ O
reperfusion NN B-POPU
injury NN I-POPU
in IN I-POPU
patients NNS I-POPU
with IN O
STEMI NNP O
. . O

-DOCSTART- -X- O O

Modest NNP O
antihypertensive JJ O
effect NN O
of IN O
epanolol NN B-INTV
, , O
a DT O
beta NN O
1-selective JJ O
receptor NN O
blocker NN O
with IN O
beta NN O
1 CD O
agonist NN O
activity NN O
: : O
an DT O
acute NN O
and CC O
long-term JJ O
hemodynamic NN O
study NN O
at IN O
rest NN O
and CC O
during IN O
exercise NN O
and CC O
double JJ O
crossover NN O
comparison NN O
with IN O
atenolol NN O
on IN O
ambulatory JJ O
blood NN O
pressure NN O
. . O

Beta-blockers NNS O
with IN O
less JJR O
cardiodepressive JJ O
effect NN O
than IN O
traditional JJ O
nonselective JJ O
beta NN O
( ( O
1+2 CD O
) ) O
-blocking VBG O
agents NNS O
could MD O
be VB O
useful JJ O
in IN O
the DT O
treatment NN O
of IN O
hypertension NN O
, , O
provided VBD O
the DT O
reduction NN O
in IN O
blood NN O
pressure NN O
was VBD O
satisfactory JJ O
. . O

Epanolol NNP B-INTV
, , O
a DT O
selective JJ O
beta NN O
1-receptor JJ O
blocker NN O
with IN O
intrinsic JJ O
sympathomimetic JJ O
activity NN O
, , O
induced VBD O
a DT O
fall NN O
in IN O
intraarterial JJ B-OC
pressure NN I-OC
of IN O
8 CD O
% NN O
at IN O
rest NN O
sitting VBG O
and CC O
11 CD O
% NN O
during IN O
100 CD O
W NNP O
bicycle NN O
exercise NN O
after IN O
the DT O
first JJ O
dose NN O
of IN O
200 CD O
mg NNS O
in IN O
12 CD B-POPU
patients NNS I-POPU
with IN I-POPU
essential JJ I-POPU
hypertension NN I-POPU
. . O

Heart NNP B-OC
rate NN I-OC
, , I-OC
stroke VBD I-OC
index NN I-OC
, , I-OC
and CC I-OC
cardiac JJ I-OC
index NN I-OC
initially RB O
fell VBD O
by IN O
14 CD O
% NN O
, , O
11 CD O
% NN O
, , O
and CC O
23 CD O
% NN O
, , O
respectively RB O
. . O

The DT O
total JJ B-OC
peripheral JJ I-OC
resistance NN I-OC
index NN I-OC
increased VBD O
by IN O
21 CD O
% NN O
after IN O
2 CD O
hours NNS O
, , O
and CC O
then RB O
reverted VBD O
towards IN O
the DT O
pretreatment NN O
level NN O
. . O

After IN O
10 CD O
months NNS O
of IN O
epanolol JJ B-INTV
treatment NN O
( ( O
mean JJ O
300 CD O
mg/day NN O
) ) O
, , O
the DT O
reduction NN B-OC
in IN O
arterial JJ B-OC
pressure NN I-OC
was VBD O
5 CD O
% NN O
at IN O
rest NN O
and CC O
10 CD O
% NN O
during IN O
exercise NN O
. . O

Cardiac NNP B-OC
index NN I-OC
and CC I-OC
heart NN I-OC
rate NN I-OC
were VBD O
still RB O
reduced VBN O
14-21 CD O
% NN O
, , O
while IN O
total JJ B-OC
peripheral JJ I-OC
resistance NN I-OC
was VBD O
unchanged JJ O
or CC O
slightly RB O
increased VBN O
( ( O
2-10 CD O
% NN O
) ) O
. . O

Twenty-four JJ B-OC
hour NN I-OC
ambulatory NN I-OC
blood NN I-OC
pressure NN I-OC
was VBD O
higher JJR O
on IN O
epanolol NN B-INTV
( ( O
300 CD O
mg/day NN O
) ) O
than IN O
on IN O
atenolol NN B-INTV
( ( O
150 CD O
mg/day NN O
) ) O
treatment NN O
( ( O
137/97 CD O
vs. FW O
128/91 CD O
mmHg NN O
) ) O
. . O

Thus RB O
, , O
the DT O
achieved VBN B-OC
blood NN I-OC
pressure NN I-OC
reduction NN I-OC
induced VBN O
by IN O
epanolol NN B-INTV
was VBD O
moderate JJ O
, , O
while IN O
other JJ O
characteristics NNS O
of IN O
beta-receptor NN O
blockade NN O
, , O
in IN O
particular JJ O
, , O
the DT O
reduction NN B-OC
of IN I-OC
heart NN I-OC
rate NN I-OC
and CC I-OC
cardiac JJ I-OC
output NN I-OC
, , O
were VBD O
maintained VBN O
. . O

This DT O
suggests VBZ O
that IN O
the DT O
compound NN O
may MD O
be VB O
useful JJ O
for IN O
other JJ O
cardiovascular JJ B-POPU
disorders NNS I-POPU
, , O
e.g. NN O
, , O
angina JJ B-POPU
pectoris NN I-POPU
in IN I-POPU
patients NNS I-POPU
without IN I-POPU
hypertension NN I-POPU
or CC I-POPU
cardiac JJ I-POPU
arrhythmia NN I-POPU
. . O

-DOCSTART- -X- O O

Short-term JJ O
effects NNS O
of IN O
denopamine NN B-INTV
on IN O
anaerobic JJ B-OC
threshold NN I-OC
and CC I-OC
related JJ I-OC
parameters NNS I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
: : I-POPU
a DT O
double-blind JJ O
crossover NN O
study NN O
. . O

BACKGROUND IN O
The DT O
short-term JJ O
effects NNS O
of IN O
denopamine NN B-INTV
, , O
an DT O
orally RB O
available JJ O
beta-stimulant JJ O
, , O
on IN O
exercise NN O
capacity NN O
were VBD O
studied VBN O
in IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
Nineteen NNP B-POPU
patients NNS I-POPU
entered VBD I-POPU
the DT I-POPU
study NN I-POPU
. . O

Three CD B-POPU
patients NNS I-POPU
had VBD I-POPU
ischemic JJ I-POPU
heart NN I-POPU
disease NN I-POPU
, , I-POPU
13 CD I-POPU
had VBD I-POPU
dilated VBN I-POPU
cardiomyopathy NN I-POPU
, , I-POPU
and CC I-POPU
three CD I-POPU
had VBD I-POPU
valvular JJ I-POPU
disease NN I-POPU
; : I-POPU
16 CD I-POPU
patients NNS I-POPU
were VBD I-POPU
in IN I-POPU
New NNP I-POPU
York NNP I-POPU
Heart NNP I-POPU
Association NNP I-POPU
class NN I-POPU
II NNP I-POPU
, , I-POPU
and CC I-POPU
three CD I-POPU
patients NNS I-POPU
were VBD I-POPU
in IN I-POPU
New NNP I-POPU
York NNP I-POPU
Heart NNP I-POPU
Association NNP I-POPU
class NN I-POPU
III NNP I-POPU
. . O

Symptom-limited JJ O
exercise NN O
testing NN O
( ( O
ramp VB O
protocol NN O
) ) O
on IN O
a DT O
bicycle NN O
ergometer NN B-INTV
with IN O
gas NN O
exchange NN O
analysis NN O
was VBD O
conducted VBN O
1 CD O
hour NN O
after IN O
oral JJ O
administration NN O
of IN O
either CC O
20 CD B-INTV
mg NN I-INTV
denopamine NN I-INTV
or CC I-INTV
placebo NN I-INTV
. . O

Drug NNP O
administration NN O
sequence NN O
was VBD O
randomly RB O
assigned VBN O
in IN O
a DT O
double-blind JJ O
crossover NN O
method NN O
, , O
with IN O
1 CD O
week NN O
between IN O
drugs NNS O
. . O

Peak NNP B-OC
VO2 NNP I-OC
was VBD O
20.4 CD O
+/- JJ O
3.2 CD O
and CC O
21.2 CD O
+/- JJ O
3.1 CD O
ml/min/kg NN O
, , O
respectively RB O
, , O
for IN O
those DT O
administered VBN O
the DT O
placebo NN B-INTV
and CC O
the DT O
drug NN O
, , O
and CC O
anaerobic JJ B-OC
threshold NN I-OC
was VBD O
13.1 CD O
+/- JJ O
2.1 CD O
and CC O
14.0 CD O
+/- JJ O
2.0 CD O
ml/min/kg NN O
. . O

There EX O
was VBD O
a DT O
significant JJ O
increase NN O
in IN O
peak JJ B-OC
VO2 NNP I-OC
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
and CC O
anaerobic JJ B-OC
threshold NN I-OC
( ( O
p JJ O
< NNP O
0.01 CD O
) ) O
with IN O
denopamine NN B-INTV
, , O
whereas IN O
no DT O
significant JJ O
change NN O
was VBD O
observed VBN O
in IN O
peak JJ B-OC
work NN I-OC
rate NN I-OC
or CC I-OC
exercise NN I-OC
time NN I-OC
. . O

Denopamine NNP B-INTV
increased VBD O
heart NN B-OC
rate NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
but CC O
had VBD O
little JJ O
effect NN O
on IN O
heart NN B-OC
rate NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
sinus JJ I-POPU
rhythm NN I-POPU
. . O

CONCLUSION NNP O
Data NNP O
obtained VBD O
from IN O
gas NN O
exchange NN O
analysis NN O
are VBP O
more RBR O
sensitive JJ O
and CC O
potentially RB O
more RBR O
useful JJ O
in IN O
the DT O
detection NN O
of IN O
short-term JJ O
changes NNS O
in IN O
exercise NN B-OC
capacity NN I-OC
than IN O
data NNS O
obtained VBN O
from IN O
either CC O
exercise JJ O
time NN O
or CC O
peak JJ O
work NN O
rate NN O
, , O
indexes NNS O
that WDT O
are VBP O
commonly RB O
used VBN O
to TO O
assess VB O
drug NN O
therapy NN O
. . O

Patients NNS B-POPU
with IN I-POPU
mild-to-moderate JJ I-POPU
heart NN I-POPU
failure NN I-POPU
with IN I-POPU
sinus NN I-POPU
rhythm NN I-POPU
, , O
but CC O
not RB O
those DT B-POPU
with IN I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
because IN I-POPU
of IN I-POPU
its PRP$ I-POPU
frequent JJ I-POPU
induction NN I-POPU
of IN I-POPU
tachycardia NN I-POPU
, , O
may MD O
be VB O
good JJ O
candidates NNS O
for IN O
denopamine NN B-INTV
therapy NN O
. . O

-DOCSTART- -X- O O

Citalopram NNP B-INTV
for IN O
post-stroke JJ O
pathological JJ O
crying NN O
. . O

Post-stroke NNP O
pathological JJ O
crying NN O
is VBZ O
a DT O
distressing VBG O
condition NN O
in IN O
which WDT O
episodes VBZ O
occur VBP O
in IN O
response NN O
to TO O
minor VB O
stimuli NNS O
without IN O
associated VBN O
mood NN O
changes NNS O
. . O

There EX O
is VBZ O
preliminary JJ O
evidence NN O
of IN O
disturbed JJ O
serotoninergic JJ O
neurotransmission NN O
in IN O
such JJ O
cases NNS O
. . O

We PRP O
investigated VBD O
the DT O
effect NN O
of IN O
the DT O
selective JJ B-OC
serotonin NN I-OC
reuptake NN I-OC
inhibitor NN I-OC
citalopram NN B-INTV
on IN O
uncontrolled JJ B-OC
crying NN I-OC
in IN O
stroke NN B-POPU
patients NNS I-POPU
in IN O
a DT O
double-blind JJ O
placebo-controlled JJ O
crossover NN O
study NN O
. . O

16 CD B-POPU
consecutive JJ I-POPU
patients NNS I-POPU
( ( I-POPU
median JJ I-POPU
age NN I-POPU
58.5 CD I-POPU
years NNS I-POPU
, , I-POPU
range VB I-POPU
40-83 JJ I-POPU
) ) I-POPU
entered VBD O
the DT O
9-week JJ B-INTV
study NN I-INTV
a DT I-INTV
median NN I-INTV
of IN I-INTV
168 CD I-INTV
days NNS I-INTV
( ( I-INTV
range VB I-INTV
6-913 NNP I-INTV
) ) I-INTV
post NN I-INTV
stroke NN I-INTV
and CC I-INTV
were VBD I-INTV
treated VBN I-INTV
with IN I-INTV
citalopram JJ I-INTV
10-20 JJ I-INTV
mg NNS I-INTV
daily RB I-INTV
for IN I-INTV
3 CD I-INTV
weeks NNS I-INTV
. . O

Crying VBG B-POPU
history NN I-POPU
was VBD I-POPU
determined VBN I-POPU
from IN I-POPU
semistructured VBN I-POPU
interviews NNS I-POPU
and CC I-POPU
from IN I-POPU
diaries NNS I-POPU
kept VBN I-POPU
by IN I-POPU
the DT I-POPU
patients NNS I-POPU
. . O

Psychiatric NNP B-OC
assessment NN I-OC
was VBD O
made VBN O
with IN O
the DT O
Hamilton NNP B-OC
depression NN I-OC
scale NN I-OC
( ( O
HDS NNP O
) ) O
, , O
and CC O
unwanted JJ B-OC
effects NNS I-OC
were VBD O
measured VBN O
with IN O
the DT O
UKU NNP B-OC
side-effect JJ I-OC
scale NN I-OC
. . O

In IN O
13 CD B-POPU
patients NNS I-POPU
in IN I-POPU
whom WP I-POPU
frequency NN I-POPU
of IN I-POPU
crying NN I-POPU
could MD O
be VB O
assessed VBN O
, , O
the DT O
number NN B-OC
of IN I-OC
daily JJ I-OC
crying VBG I-OC
episodes NNS I-OC
decreased VBN O
by IN O
at IN O
least JJS O
50 CD O
% NN O
in IN O
all DT O
cases NNS O
during IN O
citalopram JJ O
treatment NN O
vs NN O
2 CD O
patients NNS O
during IN O
placebo JJ O
treatment NN O
( ( O
p JJ O
< NN O
0.005 CD O
, , O
McNemar NNP O
's POS O
test NN O
) ) O
, , O
the DT O
effect NN O
being VBG O
rapid JJ O
( ( O
1-3 JJ O
days NNS O
) ) O
and CC O
pronounced VBN O
in IN O
11 CD O
( ( O
73 CD O
% NN O
) ) O
. . O

There EX O
was VBD O
a DT O
concomitant JJ O
significant JJ O
decrease NN B-OC
in IN I-OC
depression NN I-OC
rating NN I-OC
from IN O
HDS NNP O
8.9 CD O
to TO O
5.3 CD O
( ( O
p NN O
< VBZ O
0.005 CD O
, , O
Wilcoxon NNP O
's POS O
test NN O
) ) O
. . O

Citalopram NNP O
was VBD O
well RB O
tolerated VBN O
, , O
the DT O
few JJ O
side-effects NNS O
being VBG O
mild JJ O
and CC O
transient JJ O
. . O

We PRP O
conclude VBP O
that IN O
serotoninergic JJ O
neurotransmission NN O
plays VBZ O
an DT O
important JJ O
part NN O
in IN O
post-stroke JJ O
pathological JJ O
crying NN O
and CC O
that DT O
citalopram NN B-INTV
is VBZ O
an DT O
effective JJ O
and CC O
well-tolerated JJ O
treatment NN O
. . O

-DOCSTART- -X- O O

Videofluoroscopic NNP B-INTV
evidence NN I-INTV
of IN I-INTV
aspiration NN I-INTV
predicts NNS O
pneumonia NN B-OC
and CC I-OC
death NN I-OC
but CC O
not RB O
dehydration NN O
following VBG O
stroke NN O
. . O

In IN O
order NN O
to TO O
assess VB O
the DT O
risk NN O
of IN O
pneumonia NN O
, , O
dehydration NN O
, , O
and CC O
death NN O
associated VBN O
with IN O
videofluoroscopic JJ B-INTV
evidence NN O
of IN O
aspiration NN B-POPU
following VBG I-POPU
stroke NN I-POPU
, , I-POPU
the DT I-POPU
clinical JJ I-POPU
records NNS I-POPU
of IN I-POPU
26 CD I-POPU
patients NNS I-POPU
with IN I-POPU
aspiration NN I-POPU
and CC I-POPU
33 CD I-POPU
randomly RB I-POPU
selected VBN I-POPU
, , I-POPU
case-matched JJ I-POPU
, , I-POPU
dysphagic JJ I-POPU
controls NNS I-POPU
without IN I-POPU
videofluoroscopic JJ I-POPU
evidence NN I-POPU
of IN I-POPU
aspiration NN I-POPU
were VBD I-POPU
reviewed VBN I-POPU
. . O

The DT B-INTV
videofluoroscopic NN I-INTV
modified VBD I-INTV
barium NN I-INTV
swallow NN I-INTV
technique NN I-INTV
included VBD I-INTV
5 CD I-INTV
ml-thin JJ I-INTV
and CC I-INTV
thick JJ I-INTV
liquid NN I-INTV
barium NN I-INTV
, , I-INTV
5 CD I-INTV
ml NN I-INTV
barium NN I-INTV
pudding NN I-INTV
, , I-INTV
and CC I-INTV
1/4 CD I-INTV
cookie NN I-INTV
coated VBN I-INTV
with IN I-INTV
barium NN I-INTV
, , I-INTV
plus CC I-INTV
additional JJ I-INTV
20 CD I-INTV
and CC I-INTV
30 CD I-INTV
ml NN I-INTV
of IN I-INTV
thin JJ I-INTV
liquid JJ I-INTV
barium NN I-INTV
. . O

Patients NNS B-POPU
were VBD I-POPU
assessed VBN I-POPU
a DT I-POPU
mean NN I-POPU
of IN I-POPU
2 CD I-POPU
+/- JJ I-POPU
1 CD I-POPU
SD NNP I-POPU
months NNS I-POPU
poststroke NN I-POPU
and CC I-POPU
were VBD I-POPU
followed VBN I-POPU
for IN I-POPU
a DT I-POPU
mean NN I-POPU
of IN I-POPU
16 CD I-POPU
+/- JJ I-POPU
8 CD I-POPU
SD NNP I-POPU
months NNS I-POPU
poststroke RB I-POPU
. . O

The DT O
odds NNS B-OC
ratio NN I-OC
for IN O
developing VBG B-OC
pneumonia NN I-OC
was VBD O
7.6 CD O
times NNS O
greater JJR O
for IN O
those DT O
who WP O
aspirated VBD O
any DT O
amount NN O
of IN O
barium NN O
irrespective NN O
of IN O
its PRP$ O
consistency NN O
( ( O
p JJ O
= NNP O
0.05 CD O
) ) O
. . O

The DT O
odds NNS O
ratio NN O
for IN O
developing VBG O
pneumonia NN B-OC
was VBD O
5.6 CD O
times NNS O
greater JJR O
for IN O
those DT O
who WP O
aspirated VBD O
thickened JJ O
liquids NNS O
or CC O
more JJR O
solid JJ O
consistencies NNS O
compared VBN O
with IN O
those DT O
who WP O
did VBD O
not RB O
aspirate VB O
, , O
or CC O
who WP O
aspirated VBD O
thin JJ O
liquids NNS O
only RB O
( ( O
p JJ O
= NNP O
0.06 CD O
) ) O
. . O

Dehydration NN B-OC
was VBD O
unrelated JJ O
to TO O
the DT O
presence NN O
or CC O
absence NN O
of IN O
aspiration NN O
. . O

The DT O
odds NNS O
ratio NN O
for IN O
death NN B-OC
was VBD O
9.2 CD O
times NNS O
greater JJR O
for IN O
those DT O
aspirating VBG O
thickened JJ O
liquids NNS O
or CC O
more JJR O
solid JJ O
consistencies NNS O
compared VBN O
with IN O
those DT O
who WP O
did VBD O
not RB O
aspirate VB O
or CC O
who WP O
aspirated VBD O
thin JJ O
liquids NNS O
only RB O
( ( O
p JJ O
= NNP O
0.01 CD O
) ) O
. . O

Aspiration NNP O
documented VBN O
by IN O
modified JJ B-INTV
videofluoroscopic NN I-INTV
barium NN I-INTV
swallow NN I-INTV
technique NN I-INTV
is VBZ O
associated VBN O
with IN O
a DT O
significant JJ O
increase NN O
in IN O
risk NN B-OC
of IN I-OC
pneumonia NN I-OC
and CC O
death NN O
but CC O
not RB O
dehydration NN O
following VBG O
stroke NN O
. . O

-DOCSTART- -X- O O

Trimetazidine NN B-INTV
: : I-INTV
a DT O
new JJ O
concept NN O
in IN O
the DT O
treatment NN O
of IN O
angina NN O
. . O

Comparison NNP O
with IN O
propranolol NN B-INTV
in IN O
patients NNS O
with IN O
stable JJ B-POPU
angina NN I-POPU
. . O

Trimetazidine JJ O
European JJ O
Multicenter NNP O
Study NNP O
Group NNP O
. . O

1 CD O
. . O

Trimetazidine NN B-INTV
has VBZ O
a DT O
direct JJ O
anti-ischaemic JJ B-OC
effect NN I-OC
on IN O
the DT O
myocardium NN O
without IN O
altering VBG O
the DT O
rate NN B-OC
x JJ I-OC
pressure NN I-OC
product NN I-OC
or CC O
coronary JJ B-OC
blood NN I-OC
flow NN I-OC
. . O

2 CD O
. . O

The DT O
effects NNS O
of IN O
trimetazidine NN B-INTV
( ( O
20 CD O
mg NN O
three CD O
times NNS O
daily RB O
) ) O
were VBD O
compared VBN O
with IN O
those DT O
of IN O
propranolol NN B-INTV
( ( O
40 CD O
mg NN O
three CD O
times NNS O
daily RB O
) ) O
in IN O
a DT O
double-blind JJ O
parallel NN O
group NN O
multicentre VBD O
study NN O
in IN O
149 CD B-POPU
men NNS I-POPU
with IN I-POPU
stable JJ I-POPU
angina NN I-POPU
. . O

3 CD O
. . O

Reproducibility NN O
of IN O
exercise NN O
performance NN O
was VBD O
verified VBN O
during IN O
a DT O
3 CD O
week NN O
run-in JJ O
placebo NN O
washout IN O
period NN O
. . O

All DT O
patients NNS O
had VBD O
> JJ O
1 CD O
mm JJ O
ST-depression NN O
on IN O
exercise NN O
test NN O
. . O

4 CD O
. . O

After IN O
3 CD O
months NNS O
, , O
similar JJ O
anti-anginal JJ B-OC
efficacy NN I-OC
was VBD O
observed VBN O
between IN O
the DT O
trimetazidine NN B-INTV
( ( O
n JJ O
= NNP O
71 CD O
) ) O
and CC O
propranolol NN B-INTV
( ( O
n JJ O
= NNP O
78 CD O
) ) O
groups NNS O
. . O

No DT O
significant JJ O
differences NNS O
were VBD O
observed VBN O
between IN O
trimetazidine NN B-INTV
and CC O
propranolol NN B-INTV
as IN O
regards NNS O
anginal JJ B-OC
attack NN I-OC
rate NN I-OC
per IN I-OC
week NN I-OC
( ( O
mean JJ O
difference NN O
P-TMZ NN O
: : O
2 CD O
; : O
95 CD O
% NN O
CI NNP O
: : O
-4.4 NN O
, , O
0.5 CD O
) ) O
and CC O
exercise NN B-OC
duration NN I-OC
( ( O
mean JJ O
difference NN O
P-TMZ NN O
: : O
0 CD O
s NN O
; : O
95 CD O
% NN O
CI NNP O
: : O
-33 NN O
, , O
34 CD O
) ) O
or CC O
time NN O
to TO O
1 CD O
mm NNS O
ST NNP B-OC
segment NN I-OC
depression NN I-OC
( ( O
mean JJ O
difference NN O
P-TMZ NN O
: : O
13 CD O
s NN O
; : O
95 CD O
% NN O
CI NNP O
: : O
-24 NN O
, , O
51 CD O
) ) O
. . O

Heart NNP B-OC
rate NN I-OC
and CC I-OC
rate NN I-OC
x JJ I-OC
pressure NN I-OC
product NN I-OC
at IN I-OC
rest NN I-OC
and CC O
at IN O
peak JJ O
exercise NN O
remained VBD O
unchanged JJ O
in IN O
the DT O
trimetazidine NN B-INTV
group NN O
but CC O
significantly RB O
decreased VBN O
with IN O
propranolol NN B-INTV
( ( O
P NNP O
< VBZ O
0.001 CD O
in IN O
all DT O
cases NNS O
) ) O
. . O

With IN O
both DT O
drugs NNS O
there EX O
was VBD O
a DT O
trend NN O
to TO O
decreased VBN O
ischaemic JJ B-OC
episodes NNS I-OC
in IN O
the DT O
46 CD O
% NN O
patients NNS O
who WP O
experienced VBD O
ambulatory JJ O
ischaemia NN O
on IN O
Holter NNP O
monitoring NN O
. . O

Six CD O
patients NNS O
stopped VBD O
trimetazidine NN B-INTV
and CC O
12 CD O
propranolol NN B-INTV
. . O

Of IN O
these DT O
, , O
five CD O
in IN O
each DT O
group NN O
were VBD O
withdrawn VBN B-OC
because IN O
of IN O
deterioration NN O
in IN O
cardiovascular JJ O
status NN O
. . O

5 CD O
. . O

The DT O
results NNS O
suggest VBP O
that IN O
trimetazidine NN O
and CC O
propranolol NN O
at IN O
the DT O
doses NNS O
studied VBN O
have VBP O
similar JJ O
efficacy NN O
in IN O
patients NNS O
with IN O
stable JJ O
angina JJ O
pectoris NN O
. . O

( ( O
ABSTRACT NNP O
TRUNCATED NNP O
AT NNP O
250 CD O
WORDS NNP O
) ) O
-DOCSTART- -X- O O

Veterans NNS B-POPU
Affairs VBP I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
antiarrhythmic JJ O
trial NN O
. . O

CHF NNP O
STAT NNP O
Investigators NNP O
. . O

This DT O
is VBZ O
a DT O
prospective JJ O
, , O
double-blind JJ O
, , O
placebo-controlled JJ O
trial NN O
to TO O
determine VB O
the DT O
effect NN O
of IN O
antiarrhythmic JJ O
drug NN O
therapy NN O
on IN O
mortality NN B-OC
in IN O
patients NNS B-POPU
with IN I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
and CC I-POPU
ventricular JJ I-POPU
arrhythmia NN I-POPU
. . O

Patients NNS O
will MD O
be VB O
assigned VBN O
to TO O
receive VB O
either CC O
amiodarone VB B-INTV
or CC I-INTV
placebo VB I-INTV
. . O

Eligible JJ B-POPU
patients NNS I-POPU
include VBP I-POPU
those DT I-POPU
with IN I-POPU
ischemic JJ I-POPU
and CC I-POPU
nonischemic JJ I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
and CC I-POPU
with IN I-POPU
> NNP I-POPU
or CC I-POPU
= $ I-POPU
10 CD I-POPU
ventricular JJ I-POPU
premature NN I-POPU
beats NNS I-POPU
per IN I-POPU
hour NN I-POPU
. . O

All DT B-POPU
patients NNS I-POPU
must MD I-POPU
have VB I-POPU
shortness NN I-POPU
of IN I-POPU
breath NN I-POPU
with IN I-POPU
minimal JJ I-POPU
exertion NN I-POPU
or CC I-POPU
paroxysmal JJ I-POPU
nocturnal JJ I-POPU
dyspnea NN I-POPU
, , I-POPU
a DT I-POPU
left JJ I-POPU
ventricular JJ I-POPU
internal JJ I-POPU
dimension NN I-POPU
( ( I-POPU
LVIDd NNP I-POPU
) ) I-POPU
by IN I-POPU
echocardiogram NN I-POPU
of IN I-POPU
> NN I-POPU
or CC I-POPU
= $ I-POPU
55 CD I-POPU
mm NN I-POPU
or CC I-POPU
a DT I-POPU
cardiothoracic JJ I-POPU
ratio NN I-POPU
of IN I-POPU
> $ I-POPU
0.5 CD I-POPU
and CC I-POPU
an DT I-POPU
ejection NN I-POPU
fraction NN I-POPU
of IN I-POPU
< NN I-POPU
or CC I-POPU
= VB I-POPU
40 CD I-POPU
% NN I-POPU
. . O

All DT O
patients NNS O
will MD O
receive VB O
vasodilator NN O
therapy NN O
, , O
unless IN O
they PRP O
find VBP O
it PRP O
intolerable JJ O
. . O

Patients NNS B-POPU
will MD I-POPU
be VB I-POPU
entered VBN I-POPU
into IN I-POPU
the DT I-POPU
study NN I-POPU
for IN I-POPU
2.5 CD I-POPU
years NNS I-POPU
and CC I-POPU
followed VBD I-POPU
for IN I-POPU
an DT I-POPU
additional JJ I-POPU
2 CD I-POPU
years NNS I-POPU
. . O

Drug NNP O
therapy NN O
will MD O
be VB O
continued VBN O
for IN O
all DT O
patients NNS O
throughout IN O
the DT O
entire JJ O
study NN O
unless IN O
adverse JJ O
reactions NNS O
occur VBP O
that IN O
necessitate JJ O
individualized JJ O
treatment NN O
. . O

The DT O
expectation NN O
is VBZ O
that IN O
674 CD B-POPU
patients NNS I-POPU
will MD I-POPU
be VB I-POPU
entered VBN I-POPU
into IN I-POPU
the DT I-POPU
study NN I-POPU
from IN I-POPU
25 CD I-POPU
participating VBG I-POPU
centers NNS I-POPU
. . O

This DT O
sample JJ O
size NN O
will MD O
allow VB O
for IN O
the DT O
detection NN O
of IN O
a DT O
33 CD O
% NN O
decrease NN O
in IN O
2-year JJ B-OC
mortality NN I-OC
( ( O
20 CD O
% NN O
vs JJ O
30 CD O
% NN O
) ) O
in IN O
the DT O
treated JJ O
patients NNS O
compared VBN O
with IN O
those DT O
in IN O
the DT O
placebo NN O
group NN O
, , O
with IN O
a DT O
power NN O
of IN O
0.90 CD O
and CC O
a DT O
2-sided JJ O
alpha JJ O
level NN O
of IN O
0.05 CD O
. . O

Intermittent JJ O
Holter NNP O
monitoring NN O
, , O
radionuclide JJ O
ventriculograms NN O
, , O
pulmonary JJ O
function NN O
tests NNS O
, , O
echocardiograms NNS O
, , O
and CC O
blood NN O
tests NNS O
, , O
including VBG O
arterial JJ O
blood NN O
gases NNS O
, , O
will MD O
be VB O
required VBN O
for IN O
each DT O
patient NN O
. . O

( ( O
ABSTRACT NNP O
TRUNCATED NNP O
AT NNP O
250 CD O
WORDS NNP O
) ) O
-DOCSTART- -X- O O

Enoxaparin NNP B-INTV
in IN O
the DT O
prevention NN O
of IN O
deep JJ O
venous JJ B-OC
thrombosis NN I-OC
after IN O
major JJ B-POPU
surgery NN I-POPU
: : I-POPU
multicentric NN O
study NN O
. . O

The DT O
Italian JJ B-POPU
Study NNP I-POPU
Group NNP I-POPU
. . O

DVT NNP B-OC
is VBZ O
a DT O
very RB O
frequent JJ O
complication NN O
of IN O
general JJ O
surgery NN O
. . O

Heparin NNP O
and CC O
, , O
more RBR O
recently RB O
, , O
LMWHs NNP B-INTV
can MD O
successfully RB O
prevent VB O
post NN B-OC
surgical JJ I-OC
thromboembolism NN I-OC
. . O

One CD B-POPU
thousand CD I-POPU
one CD I-POPU
hundred CD I-POPU
and CC I-POPU
twenty-two JJ I-POPU
patients NNS I-POPU
( ( I-POPU
533 CD I-POPU
males NNS I-POPU
and CC I-POPU
589 CD I-POPU
females NNS I-POPU
; : I-POPU
mean JJ I-POPU
age NN I-POPU
62.2 CD I-POPU
+/- JJ I-POPU
11.4 CD I-POPU
yrs NN I-POPU
) ) I-POPU
were VBD I-POPU
enrolled VBN I-POPU
in IN I-POPU
a DT I-POPU
multicentre NN I-POPU
controlled VBN I-POPU
study NN I-POPU
, , O
to TO O
evaluate VB O
the DT O
efficacy NN O
and CC O
safety NN O
of IN O
enoxaparin NN B-INTV
in IN O
comparison NN O
to TO O
calcium VB B-INTV
heparin NN I-INTV
in IN O
the DT O
prevention NN O
of IN O
deep JJ B-OC
venous JJ I-OC
thrombosis NN I-OC
( ( I-OC
DVT NNP I-OC
) ) I-OC
following VBG O
general JJ O
surgery NN O
. . O

Patients NNS O
assigned VBD O
to TO O
the DT O
enoxaparin NN B-INTV
and CC O
the DT O
calcium NN B-INTV
heparin NN I-INTV
groups NNS O
received VBD O
1 CD O
daily JJ O
dose NN O
of IN O
20 CD O
mg NN O
( ( O
2000 CD O
I.U NNP O
. . O

) ) O
and CC O
2 CD O
daily JJ O
doses NNS O
of IN O
0.2 CD O
ml NN O
( ( O
5000 CD O
I.U NNP O
. . O

) ) O
, , O
respectively RB O
starting VBG O
2 CD O
hours NNS O
before IN O
the DT O
operation NN O
. . O

Both DT O
drugs NNS O
were VBD O
given VBN O
by IN O
subcutaneous JJ O
route NN O
. . O

A DT O
Doppler NNP O
or CC O
Duplex NNP O
Scan NNP O
diagnosis NN O
of IN O
DVT NNP B-OC
was VBD O
made VBN O
in IN O
3 CD O
( ( O
0.5 CD O
% NN O
) ) O
patients NNS O
in IN O
the DT O
enoxaparin NN B-INTV
group NN O
( ( O
2 CD O
cases NNS O
during IN O
treatment NN O
and CC O
1 CD O
patient NN O
at IN O
the DT O
end NN O
of IN O
treatment NN O
) ) O
and CC O
in IN O
6 CD O
( ( O
1.1 CD O
% NN O
) ) O
patients NNS O
in IN O
the DT O
calcium NN B-INTV
heparin NN I-INTV
group NN O
( ( O
5 CD O
cases NNS O
during IN O
treatment NN O
and CC O
1 CD O
, , O
bilateral NN O
, , O
after IN O
the DT O
end NN O
of IN O
treatment NN O
) ) O
. . O

Pulmonary JJ B-OC
embolism NN I-OC
( ( I-OC
PE NNP I-OC
) ) I-OC
was VBD O
ascertained VBN O
by IN O
angiography NN O
in IN O
1 CD O
patient NN O
( ( O
0.18 CD O
% NN O
) ) O
in IN O
the DT O
enoxaparin NN B-INTV
group NN O
and CC O
in IN O
2 CD O
patients NNS O
( ( O
0.36 CD O
% NN O
) ) O
in IN O
the DT O
calcium NN B-INTV
heparin NN I-INTV
one CD O
. . O

Hemorrhagic NNP B-OC
complications NNS I-OC
occurred VBD O
in IN O
29 CD O
patients NNS O
( ( O
5.2 CD O
% NN O
) ) O
in IN O
the DT O
enoxaparin NN B-INTV
group NN O
and CC O
in IN O
34 CD O
( ( O
6.1 CD O
% NN O
) ) O
in IN O
the DT O
calcium NN B-INTV
heparin NN I-INTV
group NN O
. . O

Haematomas NNP B-OC
located VBN O
in IN O
the DT O
injection NN O
site NN O
were VBD O
reported VBN O
in IN O
16.1 CD O
% NN O
and CC O
25.3 CD O
% NN O
in IN O
the DT O
enoxaparin NN B-INTV
and CC O
calcium NN B-INTV
heparin NN I-INTV
groups NNS O
respectively RB O
( ( O
p JJ O
= NNP O
0.0001 CD O
) ) O
. . O

Local JJ O
pain NN O
in IN O
the DT O
injection NN O
site NN O
at IN O
the DT O
5th JJ O
day NN O
of IN O
treatment NN O
was VBD O
reported VBN O
in IN O
8.4 CD O
% NN O
and CC O
16.6 CD O
% NN O
in IN O
the DT O
enoxaparin NN O
and CC O
calcium NN O
heparin NN O
groups NNS O
respectively RB O
( ( O
p JJ O
= NNP O
0.0001 CD O
) ) O
. . O

( ( O
ABSTRACT NNP O
TRUNCATED NNP O
AT NNP O
250 CD O
WORDS NNP O
) ) O
-DOCSTART- -X- O O

[ JJ O
Hemostatic NNP O
balance NN O
during IN O
treatment NN O
with IN O
the DT O
newest JJS O
contraceptives NNS O
] RB O
. . O

Thirty-four CD B-POPU
healthy JJ I-POPU
young JJ I-POPU
women NNS I-POPU
were VBD O
allocated VBN B-INTV
to TO I-INTV
12 CD I-INTV
consecutive JJ I-INTV
cycles NNS I-INTV
of IN I-INTV
treatment NN I-INTV
with IN I-INTV
monophasic JJ I-INTV
combinations NNS I-INTV
of IN I-INTV
: : I-INTV
20 CD I-INTV
micrograms NNS I-INTV
ethinyl VBP I-INTV
estradiol NN I-INTV
and CC I-INTV
150 CD I-INTV
micrograms NNS I-INTV
desogestrel NN I-INTV
( ( I-INTV
n JJ I-INTV
= NNP I-INTV
15 CD I-INTV
) ) I-INTV
or CC I-INTV
30 CD I-INTV
micrograms NNS I-INTV
ethinyl VBP I-INTV
estradiol NN I-INTV
and CC I-INTV
75 CD I-INTV
micrograms NNS I-INTV
gestodene NN I-INTV
( ( I-INTV
n JJ I-INTV
= NNP I-INTV
19 CD I-INTV
) ) I-INTV
. . O

In IN O
both DT O
groups NNS O
plasma VBP B-OC
levels NNS I-OC
of IN I-OC
fibrinogen NN I-OC
and CC I-OC
factor NN I-OC
VII NNP I-OC
increased VBD O
while IN O
the DT O
capacity NN O
of IN O
coagulation NN O
inhibition NN O
was VBD O
affected VBN O
by IN O
increased JJ B-OC
protein NN I-OC
C NNP I-OC
and CC I-OC
decreased VBN I-OC
protein NN I-OC
S NNP I-OC
levels NNS I-OC
. . O

Increased VBN O
fibrinolytic JJ B-OC
capacity NN I-OC
was VBD O
indicated VBN O
by IN O
elevated JJ O
activity NN O
and CC O
reduced JJ O
antigen NN B-OC
levels NNS I-OC
of IN I-OC
tissue NN I-OC
plasminogen NN I-OC
activator NN I-OC
and CC O
reduced JJ O
activity NN O
and CC O
concentration NN B-OC
of IN I-OC
tissue NN I-OC
plasminogen NN I-OC
activator NN I-OC
inhibitor NN I-OC
. . O

The DT O
ratio NN B-OC
between IN I-OC
thrombin-antithrombin-III-complexes NNS I-OC
and CC I-OC
fibrin JJ I-OC
degradation NN I-OC
products NNS I-OC
were VBD I-OC
unchanged JJ I-OC
signifying VBG O
no DT O
effect NN O
of IN O
hormonal JJ O
intake NN O
on IN O
the DT O
balance NN O
between IN O
thrombin JJ O
formation NN O
and CC O
fibrin JJ O
resolution NN O
. . O

In IN O
conclusion NN O
, , O
the DT O
dynamic JJ O
balance NN O
between IN O
generation NN O
and CC O
resolution NN O
of IN O
fibrin NN O
was VBD O
undisturbed JJ O
during IN O
treatment NN O
with IN O
both DT O
hormonal JJ O
compounds NNS O
and CC O
our PRP$ O
findings NNS O
do VBP O
not RB O
provide VB O
evidence NN O
for IN O
increased VBN O
risk NN O
of IN O
thrombosis NN O
in IN O
normal JJ B-POPU
women NNS I-POPU
. . O

-DOCSTART- -X- O O

Low-dose JJ B-INTV
aspirin NN I-INTV
and CC O
incidence NN O
of IN O
colorectal JJ O
tumors NNS O
in IN O
a DT O
randomized JJ O
trial NN O
. . O

BACKGROUND NNP O
Laboratory NNP O
, , O
clinical JJ O
, , O
and CC O
epidemiologic JJ O
studies NNS O
have VBP O
recently RB O
suggested VBN O
that IN O
regular JJ O
use NN O
of IN O
aspirin NN B-INTV
can MD O
reduce VB O
colorectal JJ O
cancer NN O
incidence NN O
or CC O
mortality NN O
. . O

However RB O
, , O
observational JJ O
epidemiologic NN O
analyses NNS O
have VBP O
had VBN O
limited VBN O
opportunity NN O
to TO O
control VB O
for IN O
confounding VBG O
bias NN O
or CC O
to TO O
specify VB O
aspirin JJ B-INTV
doses NNS O
used VBN O
. . O

PURPOSE VB O
Our PRP$ O
purpose NN O
was VBD O
to TO O
examine VB O
the DT O
relationship NN O
between IN O
regular JJ O
use NN O
of IN O
low-dose JJ B-INTV
aspirin NN I-INTV
and CC O
incidence NN O
of IN O
invasive JJ O
and CC O
noninvasive JJ O
colorectal NN O
tumors NNS O
by IN O
utilizing VBG O
data NNS B-POPU
from IN I-POPU
the DT I-POPU
Physicians NNPS I-POPU
' POS I-POPU
Health NNP I-POPU
Study NNP I-POPU
, , O
a DT O
randomized VBN O
, , O
double-blinded JJ O
, , O
placebo-controlled JJ B-INTV
trial NN O
of IN O
aspirin NN B-INTV
and CC I-INTV
beta NN I-INTV
carotene NN I-INTV
. . O

We PRP O
also RB O
attempted VBD O
to TO O
determine VB O
whether IN O
invasive JJ O
cancers NNS O
among IN O
aspirin JJ B-POPU
users NNS I-POPU
were VBD O
associated VBN O
with IN O
rectal JJ O
bleeding NN O
and CC O
early JJ O
stage NN O
at IN O
diagnosis NN O
. . O

METHODS NNP O
The DT O
Physicians NNPS O
' POS O
Health NNP O
Study NNP O
includes VBZ O
22071 CD B-POPU
U.S. NNP I-POPU
male JJ I-POPU
physicians NNS I-POPU
. . O

The DT O
aspirin JJ B-POPU
arm NN I-POPU
was VBD O
terminated VBN O
in IN O
1988 CD O
after IN O
a DT O
mean JJ O
follow-up NN O
of IN O
5 CD O
years NNS O
. . O

Stage NN O
at IN O
diagnosis NN O
and CC O
signs NNS O
and/or VBP O
symptoms NNS O
during IN O
presentation NN O
were VBD O
abstracted VBN O
from IN O
medical JJ O
records NNS O
. . O

Cox NNP O
proportional JJ O
hazards NNS O
models NNS O
were VBD O
used VBN O
to TO O
estimate VB O
relative JJ B-OC
risk NN I-OC
( ( O
RR NNP O
) ) O
, , O
95 CD O
% NN O
confidence NN B-OC
intervals NNS I-OC
( ( O
CIs NNP O
) ) O
, , O
and CC O
the DT O
association NN O
between IN O
aspirin NN O
and CC O
bleeding NN O
. . O

Differences NNS O
between IN O
aspirin NN B-INTV
and CC I-INTV
placebo NN I-INTV
groups NNS O
in IN O
tumor NN O
risk NN O
over IN O
time NN O
were VBD O
visualized VBN O
with IN O
Kaplan-Meier NNP O
curves NNS O
. . O

We PRP O
assessed VBD O
the DT O
association NN O
between IN O
aspirin NN O
and CC O
stage NN O
at IN O
diagnosis NN O
with IN O
a DT O
Mann-Whitney NNP O
rank NN O
sum NN O
statistic NN O
for IN O
non-parametric JJ O
comparison NN O
of IN O
two CD O
ordinal JJ O
distributions NNS O
. . O

RESULTS VB O
The DT O
RR NNP O
of IN O
developing VBG O
colorectal JJ O
cancer NN O
for IN O
aspirin NNS O
compared VBN O
with IN O
placebo NN O
was VBD O
1.15 CD O
( ( O
95 CD O
% NN O
CI NNP O
= NNP O
0.80-1.65 NN O
) ) O
. . O

For IN O
in IN O
situ NN O
cancers NNS O
and CC O
polyps NNS O
, , O
the DT O
RR NNP O
was VBD O
0.86 CD O
( ( O
95 CD O
% NN O
CI NNP O
= NNP O
0.68-1.10 NN O
) ) O
. . O

There EX O
was VBD O
no DT O
significant JJ O
trend NN O
for IN O
decreasing VBG O
RR NNP B-OC
by IN O
year NN O
of IN O
follow-up NN O
for IN O
invasive JJ O
cancers NNS O
( ( O
P NNP O
= NNP O
.09 NNP O
) ) O
or CC O
noninvasive JJ O
tumors NNS O
( ( O
P NNP O
= NNP O
.96 NNP O
) ) O
. . O

Aspirin NNP O
and CC O
placebo NN O
groups NNS O
did VBD O
not RB O
differ VB O
in IN O
stage NN O
or CC O
prevalence NN O
of IN O
rectal JJ B-OC
bleeding NN I-OC
at IN O
diagnosis NN O
. . O

CONCLUSIONS NNP O
Regular NNP O
aspirin NN B-INTV
use NN O
, , O
at IN O
a DT O
dose JJ O
adequate NN O
for IN O
preventing VBG O
myocardial JJ O
infarction NN O
, , O
was VBD O
not RB O
associated VBN O
with IN O
a DT O
substantial JJ O
reduction NN O
in IN O
the DT O
incidence NN O
of IN O
colorectal JJ B-OC
cancer NN I-OC
during IN O
5 CD O
years NNS O
of IN O
randomized JJ O
treatment NN O
and CC O
follow-up NN O
. . O

A DT O
small JJ O
decrease NN O
in IN O
polyps NNS O
in IN O
the DT O
aspirin NN O
group NN O
could MD O
not RB O
be VB O
reliably RB O
distinguished VBN O
from IN O
a DT O
chance NN O
association NN O
. . O

Our PRP$ O
results NNS O
suggest VBP O
that IN O
among IN O
low-dose JJ O
aspirin NN B-INTV
users NNS O
, , O
( ( O
a DT O
) ) O
colorectal NN O
cancer NN O
mortality NN O
is VBZ O
not RB O
likely JJ O
to TO O
be VB O
reduced VBN O
by IN O
earlier JJR O
detection NN O
and CC O
( ( O
b NN O
) ) O
incidence NN O
is VBZ O
not RB O
likely JJ O
to TO O
be VB O
increased VBN O
due JJ O
to TO O
aspirin-induced JJ O
gastrointestinal JJ O
bleeding NN O
. . O

IMPLICATIONS VBZ O
The DT O
potential NN O
for IN O
a DT O
benefit NN O
from IN O
higher JJR O
doses NNS O
of IN O
aspirin NN O
or CC O
longer JJR O
duration NN O
of IN O
use NN O
should MD O
be VB O
addressed VBN O
by IN O
more JJR O
detailed JJ O
observational JJ O
epidemiologic NN O
studies NNS O
and CC O
prevention NN O
trials NNS O
with IN O
longer JJR O
follow-up NN O
of IN O
randomized JJ O
participants NNS O
. . O

-DOCSTART- -X- O O

Subcutaneous JJ O
low-molecular-weight JJ B-INTV
heparin NN I-INTV
compared VBN O
with IN O
continuous JJ O
intravenous JJ O
unfractionated JJ B-INTV
heparin NN I-INTV
in IN O
the DT O
treatment NN O
of IN O
proximal JJ B-POPU
deep JJ I-POPU
vein NN I-POPU
thrombosis NN I-POPU
. . O

BACKGROUND VB O
A DT O
low-molecular-weight JJ B-INTV
heparin NN I-INTV
, , I-INTV
enoxaparin JJ I-INTV
sodium NN I-INTV
, , O
has VBZ O
been VBN O
shown VBN O
to TO O
be VB O
effective JJ O
and CC O
safe JJ O
in IN O
preventing VBG O
deep JJ B-POPU
vein NN I-POPU
thrombosis NN I-POPU
both DT I-POPU
in IN I-POPU
general JJ I-POPU
surgery NN I-POPU
and CC I-POPU
in IN I-POPU
high-risk JJ I-POPU
orthopedic JJ I-POPU
surgery NN I-POPU
. . O

We PRP O
conducted VBD O
a DT O
controlled VBN O
, , O
randomized VBN O
trial NN O
with IN O
enoxaparin NN O
in IN O
the DT O
treatment NN O
of IN O
established VBN O
deep JJ O
vein NN O
thrombosis NN O
. . O

METHODS NNP O
In IN O
a DT O
multicenter NN O
trial NN O
, , O
we PRP O
compared VBN O
fixed-dose RB O
subcutaneous JJ O
enoxaparin NN B-INTV
, , O
given VBN O
twice RB O
daily RB O
, , O
with IN O
adjusted-dose JJ O
intravenous JJ O
unfractionated JJ B-INTV
heparin NN I-INTV
( ( I-INTV
UFH NNP I-INTV
) ) I-INTV
given VBN O
by IN O
continuous JJ O
intravenous JJ O
infusion NN O
for IN O
the DT O
initial JJ O
10 CD O
days NNS O
of IN O
treatment NN O
of IN O
patients NNS B-POPU
with IN I-POPU
proximal JJ I-POPU
vein NN I-POPU
thrombosis NN I-POPU
. . O

The DT O
primary JJ O
efficacy NN O
outcome NN O
was VBD O
the DT O
change NN B-OC
of IN I-OC
the DT I-OC
size NN I-OC
of IN I-OC
the DT I-OC
thrombus NN I-OC
assessed VBN O
by IN O
repeated JJ O
venograms NNS O
between IN O
day NN O
0 CD O
and CC O
day NN O
10 CD O
. . O

The DT O
primary JJ O
analysis NN O
of IN O
safety NN O
was VBD O
based VBN O
on IN O
the DT O
incidence NN B-OC
of IN I-OC
major JJ I-OC
bleeding VBG I-OC
during IN O
10 CD O
days NNS O
of IN O
treatment NN O
. . O

RESULTS CC O
There EX B-POPU
were VBD I-POPU
67 CD I-POPU
patients NNS I-POPU
in IN I-POPU
each DT I-POPU
group NN I-POPU
. . O

Venographic NNP O
assessment NN O
of IN O
clot NN B-OC
size NN I-OC
evolution NN I-OC
between IN O
day NN O
0 CD O
and CC O
day NN O
10 CD O
showed VBD O
a DT O
statistically RB O
significant JJ O
superiority NN O
( ( O
P NNP O
< NNP O
.002 NNP O
) ) O
of IN O
enoxaparin NN B-INTV
over IN O
the DT O
reference NN O
treatment NN O
with IN O
UFH NNP B-INTV
. . O

Moreover RB O
, , O
the DT O
incidence NN B-OC
of IN I-OC
overall JJ I-OC
recurrent JJ I-OC
thromboembolic JJ I-OC
events NNS I-OC
during IN O
10 CD O
days NNS O
of IN O
treatment NN O
was VBD O
significantly RB O
higher JJR O
( ( O
P NNP O
< NNP O
.002 NNP O
) ) O
in IN O
the DT O
UFH NNP B-INTV
group NN O
( ( O
seven CD O
of IN O
67 CD O
) ) O
than IN O
in IN O
the DT O
enoxaparin NN B-INTV
group NN O
( ( O
one CD O
of IN O
67 CD O
) ) O
. . O

There EX O
were VBD O
no DT O
serious JJ B-OC
bleeding VBG I-OC
complications NNS I-OC
in IN O
either DT O
group NN O
. . O

CONCLUSIONS NNP O
Enoxaparin NNP B-INTV
is VBZ O
at IN O
least JJS O
as IN O
effective JJ O
and CC O
safe JJ O
as IN O
UFH NNP B-INTV
under IN O
the DT O
conditions NNS O
of IN O
this DT O
study NN O
. . O

Moreover RB O
, , O
it PRP O
is VBZ O
more RBR O
comfortable JJ O
for IN O
patients NNS O
and CC O
less JJR O
time-consuming NN O
for IN O
nurses NNS O
and CC O
laboratories NNS O
. . O

Thus RB O
, , O
our PRP$ O
study NN O
confirmed VBD O
, , O
with IN O
the DT O
use NN O
of IN O
enoxaparin NN B-INTV
, , O
other JJ O
observations NNS O
that IN O
low-molecular-weight JJ B-INTV
heparin NN I-INTV
provides VBZ O
a DT O
real JJ O
therapeutic JJ O
advance NN O
in IN O
the DT O
treatment NN O
of IN O
deep JJ B-POPU
vein NN I-POPU
thrombosis NN I-POPU
. . O

-DOCSTART- -X- O O

Clinical JJ O
and CC O
prognostic JJ O
significance NN O
of IN O
serum NN O
magnesium NN O
concentration NN O
in IN O
patients NNS B-POPU
with IN I-POPU
severe JJ I-POPU
chronic JJ I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
: : I-POPU
the DT O
PROMISE NNP O
Study NNP O
. . O

OBJECTIVES NNP O
The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
determine VB O
the DT O
prognostic JJ O
significance NN O
of IN O
alterations NNS O
in IN O
serum JJ O
magnesium NN O
in IN O
patients NNS B-POPU
with IN I-POPU
moderate JJ I-POPU
to TO I-POPU
severe VB I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

BACKGROUND NNP O
Reductions NNPS O
in IN O
serum NN O
magnesium NN O
have VBP O
been VBN O
postulated VBN O
to TO O
play VB O
a DT O
role NN O
in IN O
promoting VBG O
arrhythmias NN O
and CC O
to TO O
have VB O
an DT O
adverse JJ O
impact NN O
on IN O
survival NN O
in IN O
congestive JJ O
heart NN O
failure NN O
, , O
although IN O
support NN O
for IN O
this DT O
postulate NN O
is VBZ O
lacking VBG O
. . O

METHODS NNP O
Serum NNP B-OC
magnesium NN I-OC
levels NNS I-OC
were VBD I-OC
measured VBN I-OC
in IN O
1,068 CD B-POPU
patients NNS I-POPU
enrolled VBN I-POPU
in IN I-POPU
a DT I-POPU
survival NN I-POPU
study NN I-POPU
of IN I-POPU
class NN I-POPU
III NNP I-POPU
or CC I-POPU
IV NNP I-POPU
heart NN I-POPU
failure NN I-POPU
at IN I-POPU
the DT I-POPU
time NN I-POPU
of IN I-POPU
double-blind JJ I-POPU
randomization NN I-POPU
to TO I-POPU
milrinone VB I-POPU
, , I-POPU
a DT I-POPU
phosphodiesterase NN I-POPU
inhibitor NN I-POPU
, , I-POPU
or CC I-POPU
placebo NN I-POPU
. . O

All DT O
patients NNS O
received VBD O
conventional JJ B-INTV
therapy NN I-INTV
with IN I-INTV
digoxin NN I-INTV
, , I-INTV
diuretic JJ I-INTV
drugs NNS I-INTV
and CC I-INTV
a DT I-INTV
converting VBG I-INTV
enzyme NN I-INTV
inhibitor NN I-INTV
throughout IN O
the DT O
trial NN O
. . O

The DT O
median JJ O
follow-up JJ O
period NN O
was VBD O
6.1 CD O
months NNS O
( ( O
range VB O
1 CD O
day NN O
to TO O
20 CD O
months NNS O
) ) O
. . O

RESULTS JJ O
Patients NNS O
with IN O
high JJ O
serum NN O
magnesium NN O
( ( O
defined VBN O
as IN O
> NN O
or CC O
= $ O
1.9 CD O
mEq/liter NN O
, , O
n JJ O
= NNP O
242 CD O
) ) O
were VBD O
less RBR O
likely JJ O
to TO O
survive VB B-OC
than IN O
were VBD O
patients NNS O
with IN O
a DT O
normal JJ O
magnesium NN O
level NN O
( ( O
n JJ O
= NNP O
627 CD O
) ) O
( ( O
p JJ O
< NN O
0.05 CD O
, , O
risk NN O
ratio NN O
= NNP O
1.41 CD O
) ) O
. . O

Patients NNS O
with IN O
a DT O
low JJ O
magnesium NN O
level NN O
( ( O
defined VBN O
as IN O
< NN O
or CC O
= $ O
1.5 CD O
mEq/liter NN O
, , O
n JJ O
= NNP O
199 CD O
) ) O
had VBD O
no DT O
difference NN O
in IN O
survival NN B-OC
compared VBN O
with IN O
the DT O
group NN O
with IN O
a DT O
normal JJ O
magnesium NN O
level NN O
( ( O
p JJ O
= NNP O
NS NNP O
, , O
risk NN O
ratio NN O
= NNP O
0.89 CD O
) ) O
. . O

At IN O
baseline NN O
, , O
the DT O
patients NNS O
in IN O
the DT O
high JJ O
magnesium NN O
group NN O
were VBD O
older JJR O
and CC O
had VBD O
more RBR O
severe JJ O
functional JJ B-OC
and CC I-OC
renal JJ I-OC
impairment NN I-OC
. . O

An DT O
analysis NN O
after IN O
adjustment NN O
for IN O
these DT O
variables NNS O
demonstrated VBD O
no DT O
difference NN O
in IN O
survival NN B-OC
comparing VBG O
the DT O
low JJ O
, , O
normal JJ O
and CC O
high JJ O
magnesium NN O
groups NNS O
. . O

Although IN O
the DT O
three CD O
groups NNS O
had VBD O
no DT O
difference NN O
in IN O
frequency NN O
of IN O
ventricular JJ B-OC
tachycardia NN I-OC
, , I-OC
length NN I-OC
of IN I-OC
longest JJS I-OC
run NN I-OC
or CC I-OC
frequency NN I-OC
of IN I-OC
ventricular JJ I-OC
premature NN I-OC
beats NNS I-OC
on IN O
baseline NN B-OC
Holter NNP I-OC
monitoring NN I-OC
, , O
the DT O
group NN O
with IN O
hypomagnesemia NN O
had VBD O
more RBR O
frequent JJ O
ventricular JJ O
couplets NNS O
. . O

CONCLUSIONS NNP O
Serum NNP O
magnesium NN O
does VBZ O
not RB O
appear VB O
to TO O
be VB O
an DT O
independent JJ O
risk NN O
factor NN O
for IN O
either DT O
sudden JJ B-OC
death NN I-OC
or CC I-OC
death NN I-OC
due JJ O
to TO O
all DT O
causes NNS O
in IN O
patients NNS O
with IN O
moderate JJ O
to TO O
severe VB O
heart NN O
failure NN O
. . O

Hypomagnesemia NNP O
is VBZ O
associated VBN O
with IN O
an DT O
increase NN O
in IN O
the DT O
frequency NN O
of IN O
certain JJ O
forms NNS O
of IN O
ventricular JJ B-OC
ectopic NN I-OC
activity NN I-OC
, , O
but CC O
this DT O
is VBZ O
not RB O
associated VBN O
with IN O
an DT O
increase NN O
in IN O
clinical JJ O
events NNS O
. . O

The DT O
higher JJR O
mortality NN O
rate NN O
among IN O
the DT O
patients NNS O
with IN O
hypermagnesemia NN O
is VBZ O
attributable JJ O
to TO O
older JJR O
age NN O
, , O
more RBR O
advanced JJ O
heart NN O
failure NN O
and CC O
renal JJ O
insufficiency NN O
. . O

-DOCSTART- -X- O O

Sustained VBN O
augmentation NN O
of IN O
parasympathetic JJ O
tone NN O
with IN O
angiotensin-converting JJ B-INTV
enzyme JJ I-INTV
inhibition NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

OBJECTIVES CC O
The DT O
objective NN O
of IN O
this DT O
investigation NN O
was VBD O
to TO O
evaluate VB O
the DT O
changes NNS O
in IN O
parasympathetic JJ O
tone NN O
associated VBN O
with IN O
long-term JJ O
angiotensin-converting JJ B-INTV
enzyme NN I-INTV
inhibitor NN I-INTV
therapy NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

BACKGROUND NNP O
Angiotensin-converting NNP O
enzyme NN O
inhibitors NNS O
provide VBP O
hemodynamic JJ O
and CC O
symptomatic JJ O
benefit NN O
and CC O
are VBP O
associated VBN O
with IN O
improved JJ O
survival NN O
in IN O
patients NNS B-POPU
with IN I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

Angiotensin NNP O
II NNP O
, , O
whose WP$ O
production NN O
is VBZ O
ultimately RB O
inhibited VBN O
by IN O
these DT O
agents NNS O
, , O
exerts NNS O
significant JJ O
regulatory JJ O
influence NN O
on IN O
a DT O
variety NN O
of IN O
target NN O
organs NNS O
including VBG O
the DT O
central JJ O
and CC O
peripheral JJ O
nervous JJ O
systems NNS O
. . O

Accordingly RB O
, , O
it PRP O
would MD O
be VB O
anticipated VBN O
that IN O
angiotensin-converting JJ O
enzyme NN O
inhibitors NNS O
would MD O
significantly RB O
alter VB O
the DT O
autonomic JJ O
imbalance NN O
characteristic NN O
of IN O
patients NNS O
with IN O
congestive JJ O
heart NN O
failure NN O
and CC O
that IN O
this DT O
influence NN O
over IN O
neural JJ O
mechanisms NNS O
of IN O
cardiovascular JJ O
control NN O
may MD O
significantly RB O
contribute VB O
to TO O
the DT O
hemodynamic JJ O
benefit NN O
and CC O
improved VBN O
survival NN O
associated VBN O
with IN O
angiotensin-converting JJ O
enzyme NN O
inhibitor NN O
therapy NN O
. . O

METHODS NNP O
In IN O
the DT O
current JJ O
investigation NN O
, , O
changes NNS O
in IN O
autonomic JJ O
tone NN O
associated VBN O
with IN O
long-term JJ O
administration NN O
of IN O
an DT O
angiotensin-converting JJ O
enzyme NN O
inhibitor NN O
were VBD O
measured VBN O
using VBG O
spectral JJ O
analysis NN O
of IN O
heart NN O
rate NN O
variability NN O
in IN O
13 CD B-POPU
patients NNS I-POPU
with IN I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
who WP O
were VBD O
enrolled VBN O
in IN O
a DT O
double-blind JJ O
randomized JJ O
placebo-controlled JJ B-INTV
trial NN O
of IN O
the DT O
angiotensin-converting JJ B-INTV
enzyme NN I-INTV
inhibitor NN I-INTV
zofenopril NN I-INTV
. . O

Both DT O
placebo NN B-INTV
and CC O
treatment NN O
groups NNS O
were VBD O
balanced VBN O
at IN O
baseline NN O
study NN O
in IN O
terms NNS O
of IN O
functional JJ O
class NN O
, , O
ventricular JJ O
performance NN O
and CC O
autonomic JJ O
tone NN O
. . O

RESULTS NNP O
After IN O
12 CD O
weeks NNS O
of IN O
therapy NN O
with IN O
placebo NN B-INTV
, , O
there EX O
was VBD O
no DT O
change NN O
in IN O
total JJ B-OC
heart NN I-OC
rate NN I-OC
variability NN I-OC
, , I-OC
parasympathetically RB I-OC
governed VBN I-OC
high JJ I-OC
frequency NN I-OC
heart NN I-OC
rate NN I-OC
variability NN I-OC
or CC I-OC
sympathetically RB I-OC
influenced JJ I-OC
low JJ I-OC
frequency NN I-OC
heart NN I-OC
rate NN I-OC
variability NN I-OC
. . O

In IN O
contrast NN O
, , O
therapy NN O
with IN O
zofenopril NN B-INTV
was VBD O
associated VBN O
with IN O
a DT O
50 CD O
% NN O
increase NN B-OC
in IN I-OC
total JJ I-OC
heart NN I-OC
rate NN I-OC
variability NN I-OC
( ( O
p JJ O
= NNP O
0.09 CD O
) ) O
and CC O
a DT O
significant JJ O
( ( O
p JJ O
= NNP O
0.03 CD O
) ) O
twofold NN O
increase NN B-OC
in IN I-OC
high JJ I-OC
frequency NN I-OC
heart NN I-OC
rate NN I-OC
variability NN I-OC
, , O
indicating VBG O
a DT O
significant JJ O
augmentation NN O
of IN O
parasympathetic JJ O
tone NN O
. . O

CONCLUSIONS NNP O
These DT O
results NNS O
demonstrate VBP O
that IN O
long-term JJ B-POPU
treatment NN I-POPU
of IN I-POPU
patients NNS I-POPU
having VBG I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
with IN O
an DT O
angiotensin-converting JJ O
enzyme NN O
inhibitor NN O
is VBZ O
associated VBN O
with IN O
a DT O
restoration NN O
of IN O
autonomic JJ O
balance NN O
, , O
which WDT O
derives VBZ O
in IN O
part NN O
from IN O
a DT O
sustained JJ O
augmentation NN O
of IN O
parasympathetic JJ O
tone NN O
. . O

Such JJ O
augmentation NN O
of IN O
vagal JJ O
tone NN O
is VBZ O
known VBN O
to TO O
be VB O
protective JJ O
against IN O
malignant JJ O
ventricular JJ O
arrhythmias NNS O
in IN O
patients NNS B-POPU
with IN I-POPU
ischemic JJ I-POPU
heart NN I-POPU
disease NN I-POPU
and CC O
therefore NN O
may MD O
have VB O
similar JJ O
benefit NN O
in IN O
the DT O
setting NN O
of IN O
ventricular JJ O
failure NN O
, , O
thus RB O
contributing VBG O
to TO O
the DT O
improved JJ O
survival NN O
associated VBN O
with IN O
angiotensin-converting JJ B-INTV
enzyme NN I-INTV
inhibitor NN I-INTV
therapy NN O
in IN O
patients NNS B-POPU
with IN I-POPU
congestive JJ I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

-DOCSTART- -X- O O

Prevention NN O
of IN O
venous JJ O
thromboembolism NN O
after IN O
knee NN B-POPU
arthroplasty NN I-POPU
. . O

A DT O
randomized JJ O
, , O
double-blind JJ O
trial NN O
comparing VBG O
enoxaparin NN B-INTV
with IN O
warfarin NN B-INTV
. . O

OBJECTIVE UH O
To TO O
compare VB O
the DT O
effectiveness NN B-OC
and CC I-OC
safety NN I-OC
of IN O
fixed-dose JJ B-INTV
enoxaparin NN I-INTV
and CC O
adjusted VBD B-INTV
dose JJ I-INTV
warfarin NN I-INTV
in IN O
preventing VBG O
venous JJ O
thromboembolism NN O
after IN B-POPU
knee NN I-POPU
arthroplasty NN I-POPU
. . O

DESIGN VB O
A DT O
randomized JJ O
, , O
double-blind JJ O
controlled VBN O
trial NN O
. . O

SETTING NN O
8 CD B-POPU
university NN I-POPU
hospitals NNS I-POPU
. . O

PATIENTS VB O
670 CD B-POPU
consecutive JJ I-POPU
patients NNS I-POPU
who WP I-POPU
had VBD I-POPU
knee VBN I-POPU
arthroplasty RB I-POPU
. . O

INTERVENTION NN O
Patients NNPS O
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
enoxaparin NN B-INTV
( ( I-INTV
30 CD I-INTV
mg NN I-INTV
subcutaneously RB I-INTV
every DT I-INTV
12 CD I-INTV
hours NNS I-INTV
) ) I-INTV
or CC I-INTV
adjusted-dose JJ I-INTV
warfarin NN I-INTV
( ( I-INTV
international JJ I-INTV
normalized VBN I-INTV
ratio NN I-INTV
, , I-INTV
2.0 CD I-INTV
to TO I-INTV
3.0 CD I-INTV
) ) I-INTV
. . O

Both DT O
regimens NNS O
were VBD O
started VBN O
after IN O
surgery NN O
. . O

MEASUREMENTS PDT O
The DT O
primary JJ O
end NN O
point NN O
was VBD O
the DT O
incidence NN B-OC
of IN I-OC
deep JJ I-OC
venous JJ I-OC
thrombosis NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
adequate JJ I-POPU
bilateral JJ I-POPU
venograms NNS I-POPU
; : I-POPU
the DT O
secondary JJ O
end NN O
point NN O
was VBD O
hemorrhage NN B-OC
. . O

RESULTS NNP O
Among IN O
the DT O
417 CD B-POPU
patients NNS I-POPU
with IN I-POPU
adequate JJ I-POPU
venograms NNS I-POPU
, , O
109 CD O
of IN O
211 CD O
warfarin NN B-INTV
recipients NNS O
( ( O
51.7 CD O
% NN O
) ) O
had VBD O
deep JJ B-OC
venous JJ I-OC
thrombosis NN I-OC
compared VBN O
with IN O
76 CD O
of IN O
206 CD O
enoxaparin NN B-INTV
recipients NNS O
( ( O
36.9 CD O
% NN O
) ) O
( ( O
P NNP O
= NNP O
0.003 CD O
) ) O
. . O

The DT O
absolute NN B-OC
risk NN I-OC
difference NN I-OC
was VBD O
14.8 CD O
% NN O
in IN O
favor NN O
of IN O
enoxaparin NN B-INTV
( ( O
95 CD O
% NN O
Cl NNP O
, , O
5.3 CD O
% NN O
to TO O
24.1 CD O
% NN O
) ) O
Twenty-two NNP O
warfarin NN B-INTV
recipients NNS O
( ( O
10.4 CD O
% NN O
) ) O
and CC O
24 CD O
enoxaparin NN B-INTV
recipients NNS O
( ( O
11.7 CD O
% NN O
) ) O
had VBD O
proximal JJ O
venous JJ O
thrombosis NN O
( ( O
P NNP O
> NNP O
0.2 CD O
) ) O
. . O

The DT O
absolute NN B-OC
risk NN I-OC
difference NN I-OC
was VBD O
1.2 CD O
% NN O
in IN O
favor NN O
of IN O
warfarin NN B-INTV
( ( O
Cl NNP O
, , O
-7.2 NNP O
% NN O
to TO O
4.8 CD O
% NN O
) ) O
. . O

The DT O
incidence NN O
of IN O
major JJ B-OC
bleeding NN I-OC
was VBD O
1.8 CD O
% NN O
( ( O
6 CD O
of IN O
334 CD O
patients NNS O
) ) O
in IN O
the DT O
warfarin NN O
group NN O
and CC O
2.1 CD O
% NN O
( ( O
7 CD O
of IN O
336 CD O
patients NNS O
) ) O
in IN O
the DT O
enoxaparin NN O
group NN O
( ( O
P NNP O
> NNP O
0.2 CD O
) ) O
. . O

The DT O
absolute NN B-OC
risk NN I-OC
difference NN I-OC
was VBD O
0.3 CD O
% NN O
in IN O
favor NN O
of IN O
warfarin NN O
( ( O
Cl NNP O
, , O
-2.4 NNP O
% NN O
to TO O
1.8 CD O
% NN O
) ) O
. . O

CONCLUSIONS VB O
A DT O
postoperative JJ O
, , O
fixed-dose JJ O
enoxaparin NN B-INTV
regimen NNS O
is VBZ O
more RBR O
effective JJ O
than IN O
adjusted-dose JJ O
warfarin NN B-INTV
in IN O
preventing VBG O
deep JJ O
venous JJ O
thrombosis NN O
after IN B-POPU
knee NN I-POPU
arthroplasty NN I-POPU
. . O

No DT O
differences NNS O
were VBD O
seen VBN O
in IN O
the DT O
incidence NN O
of IN O
proximal JJ O
venous JJ O
thrombosis NN O
or CC O
clinically RB O
overt JJ O
hemorrhage NN O
. . O

-DOCSTART- -X- O O

Comparison NNP O
of IN O
coronary JJ B-INTV
bypass NN I-INTV
surgery NN I-INTV
with IN O
angioplasty NN B-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
multivessel JJ I-POPU
disease NN I-POPU
. . O

The DT O
Bypass NNP O
Angioplasty NNP O
Revascularization NNP O
Investigation NNP O
( ( O
BARI NNP O
) ) O
Investigators NNPS O
. . O

BACKGROUND NNP O
Coronary-artery JJ B-INTV
bypass NN I-INTV
grafting NN I-INTV
( ( I-INTV
CABG NNP I-INTV
) ) I-INTV
and CC O
percutaneous JJ B-INTV
transluminal JJ I-INTV
coronary NN I-INTV
angioplasty NN I-INTV
( ( I-INTV
PTCA NNP I-INTV
) ) I-INTV
are VBP O
alternative JJ O
methods NNS O
of IN O
revascularization NN O
in IN O
patients NNS B-POPU
with IN I-POPU
coronary JJ I-POPU
artery NN I-POPU
disease NN I-POPU
. . O

We PRP O
tested VBD O
the DT O
hypothesis NN O
that IN O
in IN O
selected JJ O
patients NNS B-POPU
with IN I-POPU
multivessel JJ I-POPU
disease NN I-POPU
suitable JJ I-POPU
for IN I-POPU
treatment NN I-POPU
with IN I-POPU
either DT I-POPU
procedure NN I-POPU
, , O
an DT O
initial JJ O
strategy NN O
of IN O
PTCA NNP O
does VBZ O
not RB O
result VB O
in IN O
a DT O
poorer JJR O
five-year JJ O
clinical JJ B-OC
outcome NN I-OC
than IN O
CABG NNP O
. . O

METHODS NNP O
Patients NNPS B-POPU
with IN I-POPU
multivessel JJ I-POPU
disease NN I-POPU
were VBD I-POPU
randomly RB I-POPU
assigned VBN I-POPU
to TO I-POPU
an DT I-POPU
initial JJ I-POPU
treatment NN I-POPU
strategy NN I-POPU
of IN I-POPU
CABG NNP I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
914 CD I-POPU
) ) I-POPU
or CC I-POPU
PTCA NNP I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
915 CD I-POPU
) ) I-POPU
and CC O
were VBD O
followed VBN O
for IN O
an DT O
average NN O
of IN O
5.4 CD O
years NNS O
. . O

Analysis NN O
of IN O
outcome JJ O
events NNS O
was VBD O
performed VBN O
according VBG O
to TO O
the DT O
intention NN O
to TO O
treat VB O
. . O

RESULTS VB O
The DT O
respective JJ O
in-hospital JJ O
event NN O
rates NNS O
for IN O
CABG NNP O
and CC O
PTCA NNP O
were VBD O
1.3 CD O
percent NN O
and CC O
1.1 CD O
percent NN O
for IN O
mortality NN B-OC
, , O
4.6 CD O
percent NN O
and CC O
2.1 CD O
percent NN O
for IN O
Q-wave NNP B-OC
myocardial JJ I-OC
infarction NN I-OC
( ( O
P NNP O
< NNP O
0.01 CD O
) ) O
, , O
and CC O
0.8 CD O
percent NN O
and CC O
0.2 CD O
percent NN O
for IN O
stroke NN B-OC
. . O

The DT O
five-year JJ B-OC
survival NN I-OC
rate NN I-OC
was VBD O
89.3 CD O
percent NN O
for IN O
those DT O
assigned VBN O
to TO O
CABG NNP O
and CC O
86.3 CD O
percent NN O
for IN O
those DT O
assigned VBN O
to TO O
PTCA NNP O
( ( O
P NNP O
= NNP O
0.19 CD O
; : O
95 CD O
percent NN O
confidence NN O
interval NN O
of IN O
the DT O
difference NN O
in IN O
survival NN O
, , O
-0.2 JJ O
percent NN O
to TO O
6.0 CD O
percent NN O
) ) O
. . O

The DT O
respective JJ B-OC
five-year JJ I-OC
survival NN I-OC
rates NNS I-OC
free VBP I-OC
from IN I-OC
Q-wave NNP I-OC
myocardial JJ I-OC
infarction NN I-OC
were VBD O
80.4 CD O
percent NN O
and CC O
78.7 CD O
percent NN O
. . O

By IN O
five CD O
years NNS O
after IN O
study NN O
entry NN O
, , O
8 CD O
percent NN O
of IN O
the DT O
patients NNS O
assigned VBD O
to TO O
CABG NNP O
had VBD O
undergone JJ O
additional JJ O
revascularization NN B-OC
procedures NNS I-OC
, , O
as IN O
compared VBN O
with IN O
54 CD O
percent NN O
of IN O
those DT O
assigned VBN O
to TO O
PTCA NNP O
; : O
69 CD O
percent NN O
of IN O
those DT O
assigned VBN O
to TO O
PTCA NNP O
did VBD O
not RB O
subsequently RB O
undergo JJ O
CABG NNP O
. . O

Among IN B-POPU
diabetic JJ I-POPU
patients NNS I-POPU
who WP I-POPU
were VBD I-POPU
being VBG I-POPU
treated VBN I-POPU
with IN I-POPU
insulin NN I-POPU
or CC I-POPU
oral JJ I-POPU
hypoglycemic JJ I-POPU
agents NNS I-POPU
at IN I-POPU
base NN I-POPU
line NN I-POPU
, , O
a DT O
subgroup NN O
not RB O
specified VBN O
by IN O
the DT O
protocol NN O
, , O
five-year JJ B-OC
survival NN I-OC
was VBD O
80.6 CD O
percent NN O
for IN O
the DT O
CABG NNP O
group NN O
as IN O
compared VBN O
with IN O
65.5 CD O
percent NN O
for IN O
the DT O
PTCA NNP O
group NN O
( ( O
P NNP O
= NNP O
0.003 CD O
) ) O
. . O

CONCLUSIONS NNP O
As IN O
compared VBN O
with IN O
CABG NNP B-INTV
, , O
an DT O
initial JJ O
strategy NN O
of IN O
PTCA NNP B-INTV
did VBD O
not RB O
significantly RB O
compromise VB O
five-year JJ B-OC
survival NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
multivessel JJ I-POPU
disease NN I-POPU
, , O
although IN O
subsequent JJ B-OC
revascularization NN I-OC
was VBD O
required VBN O
more RBR O
often RB O
with IN O
this DT O
strategy NN O
. . O

For IN O
treated JJ B-POPU
diabetics NNS I-POPU
, , O
five-year JJ B-OC
survival NN I-OC
was VBD O
significantly RB O
better JJR O
after IN O
CABG NNP B-INTV
than IN O
after IN O
PTCA NNP B-INTV
. . O

-DOCSTART- -X- O O

Influence NN O
of IN O
acute JJ B-POPU
myocardial JJ I-POPU
infarction NN I-POPU
location NN O
on IN O
in-hospital JJ O
and CC O
late JJ O
outcome NN O
after IN O
primary JJ B-INTV
percutaneous JJ I-INTV
transluminal JJ I-INTV
coronary NN I-INTV
angioplasty NN I-INTV
versus NN I-INTV
tissue NN I-INTV
plasminogen NN I-INTV
activator NN I-INTV
therapy NN I-INTV
. . O

In IN O
the DT O
Primary NNP O
Angioplasty NNP O
in IN O
Myocardial NNP O
Infarction NNP O
trial NN O
, , O
395 CD B-POPU
patients NNS I-POPU
with IN I-POPU
acute JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
( ( I-POPU
AMI NNP I-POPU
) ) I-POPU
were VBD O
prospectively RB O
randomized VBN O
to TO O
tissue VB B-INTV
plasminogen NN I-INTV
activator NN I-INTV
( ( I-INTV
tPA NN I-INTV
) ) I-INTV
or CC I-INTV
primary JJ I-INTV
percutaneous JJ I-INTV
transluminal JJ I-INTV
coronary NN I-INTV
angioplasty NN I-INTV
( ( I-INTV
PTCA NNP I-INTV
) ) I-INTV
. . O

In IN O
138 CD B-POPU
patients NNS I-POPU
with IN I-POPU
anterior JJ I-POPU
wall NN I-POPU
AMI NNP I-POPU
, , O
in-hospital JJ B-OC
mortality NN I-OC
was VBD O
significantly RB O
reduced VBN O
by IN O
treatment NN O
with IN O
PTCA NNP O
compared VBN O
with IN O
tPA NN O
( ( O
1.4 CD O
% NN O
vs JJ O
11.9 CD O
% NN O
, , O
p NN O
= NNP O
0.01 CD O
) ) O
. . O

PTCA NNP O
also RB O
resulted VBD O
in IN O
lower JJR O
rates NNS B-OC
of IN O
death NN B-OC
or CC I-OC
reinfarction NN I-OC
( ( O
1.4 CD O
% NN O
vs JJ O
18.0 CD O
% NN O
, , O
p NN O
= NNP O
0.0009 CD O
) ) O
, , O
recurrent JJ B-OC
myocardial JJ I-OC
ischemia NN I-OC
( ( O
11.3 CD O
% NN O
vs JJ O
28.4 CD O
% NN O
, , O
p NN O
= NNP O
0.01 CD O
) ) O
, , O
and CC O
stroke VBD B-OC
( ( O
0.0 CD O
% NN O
vs JJ O
6.0 CD O
% NN O
, , O
p NN O
= NNP O
0.037 CD O
) ) O
in IN O
anterior JJ O
wall NN O
AMI NNP O
. . O

The DT O
independent JJ O
beneficial JJ O
effect NN O
of IN O
treatment NN O
with IN O
primary JJ O
PTCA NNP O
rather RB O
than IN O
tPA VB O
in IN O
anterior JJ O
wall NN O
AMI NNP O
was VBD O
confirmed VBN O
by IN O
multivariate NN O
analysis NN O
and CC O
interaction NN O
testing NN O
. . O

The DT O
in-hospital JJ B-OC
mortality NN I-OC
of IN O
257 CD B-POPU
patients NNS I-POPU
with IN I-POPU
nonanterior JJ I-POPU
wall NN I-POPU
AMI NNP I-POPU
was VBD O
similar JJ O
after IN O
PTCA NNP O
and CC O
tPA NNP O
( ( O
3.2 CD O
% NN O
vs JJ O
3.8 CD O
% NN O
, , O
p NN O
= NNP O
0.82 CD O
) ) O
. . O

Compared VBN O
with IN O
tPA NN O
, , O
however RB O
, , O
primary JJ O
PTCA NNP O
resulted VBD O
in IN O
a DT O
markedly RB O
lower JJR O
rate NN O
of IN O
recurrent NN B-OC
myocardial JJ I-OC
ischemia NN I-OC
( ( O
9.7 CD O
% NN O
vs JJ O
27.8 CD O
% NN O
, , O
p NN O
= NNP O
0.0002 CD O
) ) O
, , O
fewer JJR O
unscheduled JJ B-OC
catheterization NN I-OC
and CC I-OC
revascularization NN I-OC
procedures NNS I-OC
, , O
and CC O
a DT O
shorter JJR O
hospital NN B-OC
stay NN I-OC
( ( O
7.0 CD O
vs RB O
8.6 CD O
days NNS O
, , O
p VBP O
= RB O
0.01 CD O
) ) O
in IN O
nonanterior JJ O
wall NN O
AMI NNP O
. . O

Thus NNP O
, , O
compared VBN O
with IN O
tPA NN O
, , O
primary JJ O
PTCA NNP O
in IN O
patients NNS B-POPU
with IN I-POPU
anterior JJ I-POPU
wall NN I-POPU
AMI NNP I-POPU
results NNS O
in IN O
significantly RB O
improved VBN B-OC
survival NN I-OC
, , O
with IN O
lower JJR O
rates NNS B-OC
of IN I-OC
stroke NN I-OC
, , I-OC
reinfarction NN I-OC
, , I-OC
and CC I-OC
recurrent JJ I-OC
myocardial JJ I-OC
ischemia NN I-OC
. . O

In IN O
nonanterior JJ O
wall NN O
AMI NNP O
, , O
treatment NN O
with IN O
PTCA NNP O
and CC O
tPA JJ O
results NNS O
in IN O
similar JJ O
early JJ O
mortality NN B-OC
, , O
although IN O
PTCA-treated JJ O
patients NNS O
have VBP O
a DT O
more RBR O
stable JJ O
hospital NN O
course NN O
characterized VBN O
by IN O
reduced JJ O
recurrent NN B-OC
ischemia NN I-OC
, , O
fewer JJR O
subsequent JJ B-OC
invasive NN I-OC
procedures NNS I-OC
, , O
and CC O
earlier RB O
discharge NN B-OC
. . O

-DOCSTART- -X- O O

Prediction NN O
of IN O
the DT O
infarct-related JJ O
artery NN O
in IN O
acute JJ O
myocardial JJ O
infarction NN O
by IN O
a DT O
scoring NN O
system NN O
using VBG O
summary JJ B-INTV
ST-segment JJ I-INTV
and CC I-INTV
T-wave JJ I-INTV
changes NNS I-INTV
. . O

We PRP O
developed VBD O
a DT O
scoring NN O
system NN O
to TO O
predict VB O
the DT O
artery NN O
responsible JJ O
for IN O
an DT O
acute JJ O
myocardial JJ O
infarction NN O
( ( O
AMI NNP O
) ) O
using VBG O
ST-segment JJ B-INTV
and CC I-INTV
T-wave JJ I-INTV
changes NNS I-INTV
on IN I-INTV
the DT I-INTV
initial JJ I-INTV
electrocardiogram NN I-INTV
( ( I-INTV
ECG NNP I-INTV
) ) I-INTV
using VBG O
data NNS O
from IN O
228 CD B-POPU
patients NNS I-POPU
( ( I-POPU
development NN I-POPU
set VBN I-POPU
) ) I-POPU
with IN I-POPU
symptoms NNS I-POPU
compatible JJ I-POPU
with IN I-POPU
AMI NNP I-POPU
and CC I-POPU
tested VBN I-POPU
in IN I-POPU
a DT I-POPU
similar JJ I-POPU
group NN I-POPU
of IN I-POPU
223 CD I-POPU
patients NNS I-POPU
( ( I-POPU
test NN I-POPU
set VBN I-POPU
) ) I-POPU
from IN I-POPU
the DT I-POPU
Thrombolysis NNP I-POPU
and CC I-POPU
Angioplasty NNP I-POPU
in IN I-POPU
Myocardial NNP I-POPU
Infarction NNP I-POPU
( ( I-POPU
TAMI-5 NNP I-POPU
) ) I-POPU
Trial NNP I-POPU
. . O

Using VBG O
stepwise JJ O
logistic JJ O
regression NN O
we PRP O
were VBD O
able JJ O
to TO O
accurately RB O
predict VB O
the DT O
left NN O
anterior JJ O
descending NN O
( ( O
LAD NNP O
) ) O
, , O
right JJ O
, , O
or CC O
left VBD O
circumflex NN O
( ( O
LC NNP O
) ) O
coronary JJ O
artery NN O
as IN O
the DT O
infarct-related JJ O
artery NN O
using VBG O
2 CD O
variables NNS O
: : O
( ( O
1 CD O
) ) O
the DT O
summation NN O
of IN O
the DT O
ST-segment JJ O
elevation NN O
in IN O
leads VBZ O
V1 NNP O
to TO O
V4 NNP O
; : O
and CC O
( ( O
2 CD O
) ) O
the DT O
summation NN O
of IN O
the DT O
T-wave NNP O
negativity NN O
in IN O
leads NNS O
I PRP O
, , O
aVL RB O
, , O
and CC O
V5 NNP O
. . O

In IN O
the DT O
development NN O
set NN O
, , O
these DT O
2 CD O
variables NNS O
demonstrated VBD O
respective JJ O
sensitivity NN B-OC
and CC I-OC
specificity NN I-OC
of IN O
98 CD O
% NN O
and CC O
90 CD O
% NN O
for IN O
LAD NNP O
lesions NNS O
, , O
82 CD O
% NN O
and CC O
85 CD O
% NN O
for IN O
right JJ O
narrowings NNS O
, , O
and CC O
82 CD O
% NN O
and CC O
84 CD O
% NN O
for IN O
LC NNP O
narrowings NNS O
. . O

In IN O
the DT O
test NN O
set NN O
, , O
the DT O
sensitivity NN B-OC
and CC I-OC
specificity NN I-OC
were VBD O
97 CD O
% NN O
and CC O
95 CD O
% NN O
for IN O
LAD NNP O
lesions NNS O
, , O
85 CD O
% NN O
and CC O
86 CD O
% NN O
for IN O
right JJ O
lesions NNS O
, , O
and CC O
73 CD O
% NN O
and CC O
60 CD O
% NN O
for IN O
LC NNP B-OC
coronary JJ I-OC
artery NN I-OC
lesions NNS I-OC
. . O

Information NNP O
easily RB O
obtained VBD O
on IN O
the DT O
ECG NNP O
can MD O
accurately RB O
predict VB O
the DT O
likelihood NN O
of IN O
the DT O
LAD NNP O
, , O
right RB O
, , O
or CC O
LC NNP O
artery RB O
as IN O
the DT O
infarct-related JJ O
artery NN O
. . O

This DT O
may MD O
be VB O
useful JJ O
in IN O
the DT O
decision NN O
to TO O
administer VB O
thrombolytic JJ O
treatment NN O
. . O

-DOCSTART- -X- O O

Deep JJ B-POPU
vein NN I-POPU
thrombosis NN I-POPU
after IN I-POPU
major JJ I-POPU
reconstructive JJ I-POPU
spinal NN I-POPU
surgery NN I-POPU
. . O

STUDY NNP O
DESIGN NNP O
A NNP O
prospective JJ O
study NN O
was VBD O
performed VBN O
. . O

OBJECTIVES IN O
The DT O
goals NNS O
of IN O
the DT O
study NN O
were VBD O
to TO O
determine VB O
the DT O
incidence NN O
of IN O
deep JJ B-POPU
vein NN I-POPU
thrombosis NN I-POPU
after IN I-POPU
major JJ I-POPU
adult NN I-POPU
spinal JJ I-POPU
surgery NN I-POPU
and CC O
the DT O
optimal JJ O
mode NN O
of IN O
prophylaxis NN O
in IN O
this DT O
surgical JJ O
population NN O
. . O

SUMMARY NNP O
OF IN O
BACKGROUND NNP O
DATA NNP O
Few NNP O
studies NNS O
have VBP O
evaluated VBN O
deep JJ B-OC
vein NN I-OC
thrombosis NN I-OC
incidence NN O
and CC O
prophylaxis NN B-OC
after IN O
major JJ B-POPU
adult NN I-POPU
spinal JJ I-POPU
surgery NN I-POPU
. . O

Incidence NN O
rates NNS O
have VBP O
ranged VBN O
from IN O
0.9-14 CD O
% NN O
. . O

METHODS NNP O
Three CD B-POPU
hundred VBD I-POPU
twenty-nine JJ I-POPU
patients NNS I-POPU
were VBD O
evaluated VBN O
. . O

One CD B-POPU
hundred VBD I-POPU
ten JJ I-POPU
patients NNS I-POPU
were VBD O
randomized VBN O
to TO O
3 CD O
different JJ O
deep JJ B-OC
vein NN I-OC
thrombosis NN I-OC
prophylaxis NN I-OC
groups NNS O
. . O

These DT O
patients NNS O
had VBD O
duplex JJ B-INTV
doppler NN I-INTV
scans NNS I-INTV
between IN O
the DT O
fifth NN O
and CC O
seventh JJ O
postoperative JJ O
days NNS O
. . O

The DT O
remaining VBG O
219 CD O
patients NNS O
formed VBD O
a DT O
nonrandomized JJ O
group NN O
and CC O
received VBD O
either CC O
thrombosis JJ B-INTV
embolic JJ I-INTV
deterrent NN I-INTV
stockings NNS I-INTV
alone RB I-INTV
or CC I-INTV
thrombosis VB I-INTV
embolic JJ I-INTV
deterrent NN I-INTV
stockings NNS I-INTV
and CC I-INTV
pneumatic JJ I-INTV
compression NN I-INTV
boots NNS I-INTV
for IN O
deep JJ O
vein NN O
thrombosis NN O
prophylaxis NN O
. . O

The DT O
type NN O
of IN O
deep JJ O
vein NN O
thrombosis NN O
prophylaxis NN O
in IN O
this DT O
group NN O
was VBD O
based VBN O
on IN O
surgeon NN O
preference NN O
. . O

All DT O
329 CD O
patients NNS O
were VBD O
followed VBN O
for IN O
clinical JJ B-OC
signs NNS I-OC
and CC I-OC
symptoms NNS I-OC
of IN I-OC
thromboembolic JJ I-OC
disease NN I-OC
. . O

Patients NNS O
were VBD O
followed VBN O
clinically RB O
for IN O
a DT O
minimum NN O
of IN O
1 CD O
year NN O
. . O

RESULTS NNP O
All DT O
110 CD O
prophylaxis NNS O
study NN O
group NN O
patients NNS O
were VBD O
clinically RB O
asymptomatic JJ B-OC
and CC O
109 CD O
duplex JJ B-OC
scans NNS I-OC
were VBD O
normal JJ O
. . O

One CD O
scan NN O
was VBD O
indeterminate JJ O
and CC O
a DT O
follow-up JJ O
venogram NN B-OC
was VBD O
negative JJ O
. . O

Two CD O
patients NNS O
in IN O
the DT O
coumadin NN O
group NN O
( ( O
5.7 CD O
% NN O
) ) O
experienced VBD O
excessive JJ B-OC
blood NN I-OC
loss NN I-OC
. . O

One CD O
of IN O
the DT O
219 CD O
patients NNS O
from IN O
the DT O
nonrandomized VBN O
group NN O
developed VBD O
a DT O
clinically RB B-OC
detectable JJ I-OC
proximal JJ I-OC
deep JJ I-OC
vein NN I-OC
thrombosis NN I-OC
which WDT O
was VBD O
confirmed VBN O
by IN O
duplex JJ B-OC
ultra-sonography NN I-OC
. . O

The DT O
overall JJ O
clinical JJ B-OC
incidence NN I-OC
of IN O
deep JJ B-OC
vein NN I-OC
thrombosis NN I-OC
was VBD O
0.3 CD O
% NN O
( ( O
1 CD O
in IN O
329 CD O
patients NNS O
) ) O
. . O

CONCLUSIONS VB O
This DT O
low JJ O
0.3 CD O
% NN O
rate NN O
is VBZ O
in IN O
agreement NN O
with IN O
recent JJ O
studies NNS O
that WDT O
focus VBP O
on IN O
thromboembolic JJ B-OC
disease NN I-OC
. . O

Given VBN O
the DT O
low JJ O
incidence NN O
, , O
routine JJ O
screening NN O
for IN O
asymptomatic JJ O
thrombi NN O
appears VBZ O
unwarranted JJ O
. . O

In IN O
addition NN O
, , O
mechanical JJ O
prophylaxis NN O
with IN O
graduated JJ O
compression NN O
stockings NNS O
and CC O
pneumatic JJ O
compression NN O
boots NNS O
is VBZ O
preferable JJ O
to TO O
anticoagulation VB O
therapy NN O
. . O

-DOCSTART- -X- O O

Warfarin NNP B-INTV
for IN O
atrial JJ B-POPU
fibrillation NN I-POPU
. . O

The DT O
patient NN O
's POS O
perspective NN O
. . O

OBJECTIVE UH O
To TO O
determine VB O
the DT O
minimal JJ B-OC
clinically RB I-OC
important JJ I-OC
difference NN I-OC
( ( I-OC
MCID NNP I-OC
) ) I-OC
of IN O
warfarin NN B-INTV
therapy NN I-INTV
for IN O
the DT O
treatment NN O
of IN O
nonvalvular JJ B-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
from IN O
the DT O
perspective NN O
of IN O
patients NNS B-POPU
using VBG I-POPU
2 CD I-POPU
different JJ I-POPU
elicitation NN I-POPU
methods NNS I-POPU
. . O

DESIGN NNP O
All DT O
patients NNS O
completed VBD O
2 CD O
face-to-face JJ O
interviews NNS O
, , O
which WDT O
were VBD O
2 CD O
weeks NNS O
apart RB O
. . O

For IN O
each DT O
interview NN O
, , O
they PRP O
were VBD O
randomized VBN O
to TO O
receive VB O
1 CD O
of IN O
2 CD O
elicitation NN O
methods NNS O
: : O
ping-ponging NN O
or CC O
starting VBG O
at IN O
the DT O
known JJ O
efficacy NN O
. . O

SETTING CC O
The DT O
practices NNS B-POPU
of IN I-POPU
2 CD I-POPU
university-affiliated JJ I-POPU
family NN I-POPU
medicine NN I-POPU
centers NNS I-POPU
( ( I-POPU
8 CD I-POPU
physicians NNS I-POPU
each DT I-POPU
) ) I-POPU
, , I-POPU
14 CD I-POPU
community-based JJ I-POPU
family NN I-POPU
physicians NNS I-POPU
, , I-POPU
and CC I-POPU
2 CD I-POPU
cardiologists NNS I-POPU
. . O

PATIENTS VB O
Sixty-four JJ B-POPU
patients NNS I-POPU
with IN I-POPU
nonvalvular JJ I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
who WP I-POPU
were VBD I-POPU
initiated VBN I-POPU
with IN I-POPU
warfarin JJ I-POPU
therapy NN I-POPU
at IN I-POPU
least JJS I-POPU
3 CD I-POPU
months NNS I-POPU
before IN I-POPU
the DT I-POPU
study NN I-POPU
. . O

INTERVENTION NNP O
During IN O
each DT O
interview NN O
, , O
the DT O
patients NNS O
' POS O
MCIDs NNP O
were VBD O
determined VBN O
by IN O
using VBG O
( ( O
1 CD O
) ) O
a DT B-OC
pictorial JJ I-OC
flip NN I-OC
chart NN I-OC
to TO I-OC
describe VB I-OC
atrial JJ I-OC
fibrillation NN I-OC
; : I-OC
the DT I-OC
consequences NNS I-OC
of IN I-OC
a DT I-OC
minor JJ I-OC
stroke NN I-OC
, , I-OC
a DT I-OC
major JJ I-OC
stroke NN I-OC
, , I-OC
and CC I-OC
a DT I-OC
major JJ I-OC
bleeding NN I-OC
episode NN I-OC
; : I-OC
the DT O
chance NN B-OC
of IN I-OC
stroke NN I-OC
if IN I-OC
not RB I-OC
taking VBG I-OC
warfarin NN I-OC
; : I-OC
the DT O
chance NN B-OC
of IN I-OC
a DT I-OC
major JJ I-OC
bleeding NN I-OC
episode NN I-OC
if IN I-OC
taking VBG I-OC
warfarin NN I-OC
; : I-OC
examples NNS O
of IN O
the DT O
inconvenience NN B-OC
, , I-OC
minor JJ I-OC
side NN I-OC
effects NNS I-OC
, , I-OC
and CC I-OC
costs NNS I-OC
of IN I-OC
warfarin JJ I-OC
therapy NN I-OC
; : I-OC
and CC O
then RB O
( ( O
2 CD O
) ) O
1 CD O
of IN O
the DT O
2 CD O
elicitation NN B-OC
methods NNS I-OC
to TO I-OC
determine VB I-OC
their PRP$ I-OC
MCIDs NNP I-OC
( ( I-OC
the DT I-OC
smallest JJS I-OC
reduction NN I-OC
in IN I-OC
stroke NN I-OC
risk NN I-OC
at IN I-OC
which WDT I-OC
the DT I-OC
patients NNS I-OC
were VBD I-OC
willing JJ I-OC
to TO I-OC
take VB I-OC
warfarin NN I-OC
) ) I-OC
. . O

Patients NNS B-OC
' POS I-OC
knowledge NN I-OC
of IN I-OC
their PRP$ I-OC
stroke NN I-OC
risk NN I-OC
, , I-OC
acceptability NN I-OC
of IN I-OC
the DT I-OC
interview NN I-OC
process NN I-OC
, , I-OC
and CC I-OC
factors NNS I-OC
determining VBG I-OC
their PRP$ I-OC
preferences NNS I-OC
were VBD O
also RB O
assessed VBN O
. . O

MAIN NNP O
RESULTS NNP O
Given NNP O
a DT O
baseline NN O
risk NN O
of IN O
having VBG O
a DT O
stroke NN O
in IN O
the DT O
next JJ O
2 CD O
years NNS O
, , O
if IN O
not RB O
taking VBG O
warfarin NN B-INTV
, , O
of IN O
10 CD O
of IN O
100 CD O
, , O
the DT O
mean JJ B-OC
MCID NNP I-OC
was VBD O
2.01 CD O
of IN O
100 CD O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
1.60-2.42 JJ O
) ) O
. . O

Fifty-two JJ O
percent NN O
of IN O
the DT O
patients NNS O
would MD O
take VB O
warfarin NN B-INTV
for IN O
an DT O
absolute JJ O
decrease NN O
in IN O
stroke NN B-OC
risk NN I-OC
of IN O
1 CD O
% NN O
over IN O
2 CD O
years NNS O
. . O

Before IN O
eliciting VBG O
their PRP$ O
MCIDs NNP O
, , O
patients NNS O
showed VBD O
poor JJ O
knowledge NN B-OC
of IN I-OC
their PRP$ I-OC
stroke NN I-OC
risk NN I-OC
, , O
which WDT O
improved VBD O
afterward RB O
. . O

The DT O
interview NN O
process NN O
was VBD O
well RB O
accepted VBN O
by IN O
the DT O
patients NNS O
. . O

The DT O
MCID NNP B-OC
using VBG O
the DT O
ping-ponging JJ O
elicitation NN O
method NN O
was VBD O
1.015 CD O
of IN O
100 CD O
smaller JJR O
compared VBN O
with IN O
use NN O
of IN O
the DT O
starting NN O
at IN O
the DT O
known JJ O
efficacy NN O
method NN O
( ( O
P NNP O
= NNP O
.01 NNP O
) ) O
. . O

CONCLUSIONS NN O
We PRP O
were VBD O
able JJ O
to TO O
determine VB O
the DT O
MCID NNP B-OC
of IN O
warfarin NN B-INTV
therapy NN I-INTV
for IN O
the DT O
prevention NN O
of IN O
stroke NN O
from IN O
the DT O
perspective NN O
of IN O
patients NNS B-POPU
with IN I-POPU
nonvalvular JJ I-POPU
atrial JJ I-POPU
fibrillation NN I-POPU
. . O

Their PRP$ O
MCIDs NNPS O
were VBD O
much RB O
smaller JJR O
than IN O
those DT O
that WDT O
have VBP O
been VBN O
implied VBN O
by IN O
some DT O
experts NNS O
and CC O
clinicians NNS O
. . O

The DT O
interview NN O
process NN O
, , O
using VBG O
the DT O
flip JJ O
chart NN O
approach NN O
, , O
appeared VBD O
to TO O
improve VB O
the DT O
patients NNS B-OC
' POS I-OC
knowledge NN I-OC
of IN I-OC
their PRP$ I-OC
disease NN I-OC
and CC I-OC
its PRP$ I-OC
consequences NNS I-OC
and CC I-OC
treatment NN I-OC
. . O

The DT O
method NN O
used VBN O
to TO O
elicit VB O
the DT O
patients NNS O
' POS O
MCIDs NNP B-OC
can MD O
have VB O
a DT O
clinically RB O
important JJ O
effect NN O
on IN O
patient NN O
responses NNS O
. . O

The DT O
method NN O
used VBN O
in IN O
our PRP$ O
study NN O
can MD O
be VB O
generalized VBN O
to TO O
other JJ O
conditions NNS O
and CC O
, , O
thus RB O
, , O
could MD O
be VB O
helpful JJ O
in IN O
3 CD O
ways NNS O
: : O
( ( O
1 CD O
) ) O
from IN O
a DT O
clinical JJ O
decision-making NN O
perspective NN O
, , O
it PRP O
could MD O
facilitate VB O
patient-physician JJ O
communication NN O
; : O
( ( O
2 CD O
) ) O
it PRP O
could MD O
clarify VB O
the DT O
patient NN O
perspective NN O
when WRB O
interpreting VBG O
the DT O
results NNS O
of IN O
previously RB O
completed VBN O
trials NNS O
; : O
and CC O
( ( O
3 CD O
) ) O
it PRP O
could MD O
be VB O
used VBN O
to TO O
derive VB O
more RBR O
clinically RB O
relevant JJ O
sample NN O
sizes NNS O
for IN O
randomized JJ O
treatment NN O
trials NNS O
. . O

-DOCSTART- -X- O O

Relation NN O
of IN O
total JJ O
homocysteine NN B-INTV
and CC O
lipid JJ B-INTV
levels NNS I-INTV
in IN O
children NNS B-POPU
to TO O
premature VB O
cardiovascular JJ O
death NN O
in IN O
male JJ B-POPU
relatives NNS I-POPU
. . O

We PRP O
assessed VBD O
the DT O
relative JJ B-OC
importance NN I-OC
of IN O
lipid JJ B-INTV
, , B-OC
apo JJ I-OC
B NNP I-OC
, , I-OC
lipoprotein NN I-OC
( ( I-OC
a DT I-OC
) ) I-OC
[ NN I-OC
Lp NNP I-OC
( ( I-OC
a DT I-OC
) ) I-OC
] NN I-OC
, , I-OC
and CC I-OC
total JJ I-OC
homocysteine NN B-INTV
( ( B-OC
tHcy NN I-OC
) ) I-OC
levels NNS I-OC
in IN O
children NNS B-POPU
in IN O
relation NN O
to TO O
premature VB O
cardiovascular JJ O
disease NN O
in IN O
family NN B-POPU
members NNS I-POPU
. . O

Parents NNS B-POPU
of IN I-POPU
381 CD I-POPU
girls NNS I-POPU
and CC I-POPU
375 CD I-POPU
boys NNS I-POPU
age NN I-POPU
8-12 JJ I-POPU
y NN I-POPU
completed VBN I-POPU
family NN I-POPU
history NN I-POPU
questionnaires NNS I-POPU
. . O

Nonfasting VBG B-OC
serum JJ B-INTV
lipid JJ I-INTV
and CC I-INTV
lipoproteins NNS I-INTV
and CC I-INTV
plasma NN I-INTV
tHcy NN I-INTV
and CC I-INTV
cysteine NN I-INTV
levels NNS B-OC
were VBD O
measured VBN O
in IN O
the DT O
children NNS O
. . O

Serum NNP B-OC
folate NN I-OC
and CC I-OC
vitamin NN I-OC
B12 NNP I-OC
levels NNS I-OC
were VBD O
determined VBN O
in IN O
a DT O
random JJ O
subsample NN O
of IN O
23 CD O
% NN O
of IN O
the DT O
children NNS O
, , O
who WP O
participated VBD O
in IN O
a DT O
food NN O
frequency NN O
interview NN O
. . O

Children NNP O
whose WP$ O
parents NNS O
reported VBD O
hypercholesterolemia NN O
had VBD O
higher JJR O
total JJ B-OC
and CC I-OC
non-HDL JJ I-OC
cholesterol NN I-OC
and CC I-OC
apo NN I-OC
B NNP I-OC
levels NNS I-OC
than IN O
the DT O
rest NN O
, , O
but CC O
these DT O
levels NNS O
were VBD O
not RB O
associated VBN O
with IN O
cardiovascular JJ O
disease NN O
. . O

tHcy NN B-INTV
levels NNS B-OC
were VBD O
similar JJ O
in IN O
girls NNS O
and CC O
boys NNS O
. . O

tHcy NN B-INTV
was VBD O
higher RBR O
in IN O
children NNS B-POPU
whose WP$ O
father NN O
, , O
grandfather NN O
, , O
or CC O
uncle NN O
died VBN O
at IN O
age NN O
< NN O
or CC O
= $ O
55 CD O
y NN O
of IN O
myocardial JJ O
infarction NN O
or CC O
sudden JJ O
cardiac JJ O
arrest NN O
( ( O
n JJ O
= NNP O
42 CD O
) ) O
than IN O
in IN O
control NN O
children NNS O
[ VBP O
5.92 CD O
mumol/L NN O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
[ NNP O
CI NNP O
] NNP O
of IN O
5.47-6.36 NNP O
) ) O
versus NN O
5.25 CD O
mumol/L NN O
( ( O
95 CD O
% NN O
CI NNP O
, , O
5.16-5.34 JJ O
) ) O
] NN O
, , O
also RB O
after IN O
adjustment NN O
for IN O
socioeconomic JJ O
group NN O
. . O

Intake NNP B-OC
and CC I-OC
serum NN I-OC
levels NNS I-OC
of IN I-OC
vitamin NN I-OC
B12 NNP I-OC
and CC I-OC
folate NN I-OC
were VBD O
within IN O
recommended VBN O
or CC O
reference NN O
ranges NNS O
. . O

In IN O
a DT O
stepwise NN O
multiple JJ O
regression NN O
analysis NN O
, , O
serum NN B-OC
folate NN I-OC
( ( I-OC
negative JJ I-OC
correlation NN I-OC
) ) I-OC
, , I-OC
plasma JJ I-OC
creatinine NN I-OC
, , I-OC
and CC I-OC
sugar RB I-OC
intake VB I-OC
as IN O
percent NN O
of IN O
dietary JJ O
energy NN O
( ( O
positive JJ O
correlations NNS O
) ) O
were VBD O
significantly RB O
associated VBN O
with IN O
tHcy NN B-OC
( ( O
multiple JJ O
r NN O
= NN O
0.44 CD O
, , O
adjusted VBN O
r2 NN O
= VBZ O
18 CD O
% NN O
; : O
95 CD O
% NN O
CI NNP O
, , O
5-30 JJ O
% NN O
) ) O
. . O

Our PRP$ O
data NNS O
show VBP O
that IN O
a DT O
modest JJ O
elevation NN O
in IN O
tHcy NN B-OC
in IN O
children NNS O
was VBD O
related VBN O
to TO O
premature VB B-OC
cardiovascular JJ I-OC
death NN I-OC
in IN O
their PRP$ O
male NN O
relatives NNS O
and CC O
may MD O
partly RB O
account VB O
for IN O
the DT O
contribution NN O
of IN O
family NN O
history NN O
to TO O
risk NN O
of IN O
cardiovascular JJ O
disease NN O
. . O

tHcy NN B-INTV
may MD O
be VB O
modifiable JJ O
through IN O
the DT O
diet NN O
, , O
even RB O
in IN O
children NNS O
with IN O
apparently RB O
adequate JJ O
vitamin JJ O
nutriture NN O
. . O

-DOCSTART- -X- O O

The DT O
evolving VBG O
clinical JJ O
status NN O
of IN O
patients NNS B-POPU
after IN I-POPU
a DT I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
: : I-POPU
the DT O
importance NN O
of IN O
post-hospital JJ B-POPU
data NNS I-POPU
for IN O
mortality NN O
prediction NN O
. . O

Studies NNPS O
predicting VBG O
mortality NN O
after IN O
myocardial JJ B-POPU
infarction NN I-POPU
( ( I-POPU
MI NNP I-POPU
) ) I-POPU
usually RB O
rely VBP O
on IN O
in-hospital JJ B-INTV
data NNS I-INTV
, , O
and CC O
combine NN O
patients NNS B-POPU
admitted VBN I-POPU
for IN I-POPU
the DT I-POPU
first JJ I-POPU
MI NNP I-POPU
with IN I-POPU
recurrent JJ I-POPU
MI NNP I-POPU
patients NNS I-POPU
. . O

Since IN O
treatment NN O
decisions NNS O
are VBP O
often RB O
made VBN O
or CC O
modified VBN O
at IN O
the DT O
first JJ O
outpatient NN O
clinic JJ O
visit NN O
, , O
this DT O
study NN O
was VBD O
designed VBN O
to TO O
evaluate VB O
the DT O
importance NN O
of IN O
post-hospital JJ B-INTV
data NNS I-INTV
on IN O
mortality NN O
prediction NN O
after IN O
a DT O
first JJ O
myocardial JJ O
infarction NN O
( ( O
MI NNP O
) ) O
. . O

An DT B-POPU
inception NN I-POPU
cohort NN I-POPU
of IN I-POPU
patients NNS I-POPU
enrolled VBN I-POPU
in IN I-POPU
the DT I-POPU
Beta-Blocker NNP I-POPU
in IN I-POPU
Heart NNP I-POPU
Attack NNP I-POPU
Trial NNP I-POPU
( ( I-POPU
n JJ I-POPU
= NN I-POPU
2830 CD I-POPU
) ) I-POPU
was VBD I-POPU
included VBN I-POPU
. . O

Forty-three JJ B-OC
variables NNS I-OC
( ( O
including VBG O
in-hospital JJ B-POPU
and CC I-POPU
post-hospital JJ I-POPU
data NNS I-POPU
) ) I-POPU
were VBD O
evaluated VBN O
using VBG O
stepwise NN O
logistic JJ O
regression NN O
. . O

Ten CD O
variables NNS O
were VBD O
independently RB O
associated VBN O
with IN O
1-year JJ O
mortality NN O
: : O
five CD O
used VBN O
in-hospital JJ O
data NNS O
( ( B-OC
history NN I-OC
of IN I-OC
hypertension NN I-OC
, , I-OC
hypercholesterolemia NN I-OC
, , I-OC
congestive JJ I-OC
heart NN I-OC
failure NN I-OC
[ NNP I-OC
CHF NNP I-OC
] NNP I-OC
, , I-OC
ventricular JJ I-OC
tachycardia NN I-OC
, , I-OC
and CC I-OC
age NN I-OC
) ) I-OC
; : I-OC
and CC O
five CD O
variables NNS O
depended VBN O
on IN O
post-hospital JJ B-INTV
data NNS I-INTV
collected VBN O
at IN O
the DT O
first JJ O
outpatient JJ O
visit NN O
( ( B-OC
CHF NNP I-OC
after IN I-OC
discharge NN I-OC
, , I-OC
New NNP I-OC
York NNP I-OC
Heart NNP I-OC
Association NNP I-OC
functional JJ I-OC
class NN I-OC
, , I-OC
heart NN I-OC
rate NN I-OC
, , I-OC
pulmonary JJ I-OC
rates NNS I-OC
, , I-OC
and CC I-OC
smoking NN I-OC
) ) I-OC
. . O

Two CD O
predictive JJ O
systems NNS O
were VBD O
developed VBN O
that IN O
partitioned JJ O
patients NNS O
into IN O
one CD O
of IN O
four CD O
classes NNS O
with IN O
distinct JJ O
mortality NN O
risks NNS O
: : O
a DT O
composite JJ O
system NN O
using VBG O
the DT O
10 CD O
in- JJ O
and CC O
post-hospital JJ O
variables NNS O
, , O
and CC O
a DT O
system NN O
using VBG O
only RB O
the DT O
5 CD O
in-hospital JJ O
variables NNS O
. . O

Mortality NNP B-OC
risk NN I-OC
for IN O
the DT O
composite JJ O
system NN O
classes NNS O
ranged VBD O
from IN O
0.6 CD O
to TO O
20.0 CD O
% NN O
( ( O
I PRP O
[ VBP O
n JJ O
= $ O
861 CD O
] NNP O
, , O
0.6 CD O
% NN O
; : O
II NNP O
[ NNP O
n RB O
= VBZ O
1151 CD O
] NN O
, , O
2.3 CD O
% NN O
; : O
III NNP O
[ NNP O
n MD O
=698 VB O
] NNP O
, , O
4.3 CD O
% NN O
; : O
IV NNP O
[ NNP O
n VBD O
= $ O
120 CD O
] NNP O
, , O
20.0 CD O
% NN O
) ) O
. . O

In IN O
contrast NN O
, , O
the DT O
range NN B-OC
of IN I-OC
mortality NN I-OC
risk NN O
using VBG O
the DT O
in-hospital JJ B-INTV
data NNS I-INTV
only RB O
system NN O
was VBD O
less JJR O
( ( O
1 CD O
to TO O
8.3 CD O
% NN O
) ) O
. . O

Most JJS O
importantly RB O
, , O
a DT O
distinct JJ O
gradient NN O
within IN O
each DT O
class NN O
of IN O
the DT O
in-hospital JJ B-INTV
data NNS I-INTV
only RB O
system NN O
was VBD O
created VBN O
by IN O
the DT O
addition NN O
of IN O
the DT O
post-hospital JJ B-INTV
data NN I-INTV
. . O

This DT O
study NN O
demonstrates VBZ O
that IN O
risk NN O
stratification NN O
after IN O
an DT O
acute NN O
first RB O
MI NNP O
is VBZ O
improved VBN O
by IN O
the DT O
addition NN O
of IN O
post-hospital JJ B-INTV
data NNS I-INTV
. . O

-DOCSTART- -X- O O

Ganciclovir NNP B-INTV
use NN O
during IN O
mild JJ B-POPU
renal JJ I-POPU
failure NN I-POPU
in IN I-POPU
heart NN I-POPU
transplantation NN I-POPU
. . O

-DOCSTART- -X- O O

Randomised VBN O
trial NN O
of IN O
effect NN O
of IN O
amiodarone NN B-INTV
on IN O
mortality NN B-OC
in IN O
patients NNS B-POPU
with IN I-POPU
left-ventricular JJ I-POPU
dysfunction NN I-POPU
after IN I-POPU
recent JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
: : I-POPU
EMIAT NNP I-POPU
. . O

European JJ O
Myocardial NNP O
Infarct NNP O
Amiodarone NNP O
Trial NNP O
Investigators NNP O
. . O

BACKGROUND NNP O
Ventricular NNP O
arrhythmias NNS O
are VBP O
a DT O
major JJ O
cause NN O
of IN O
death NN O
after IN O
myocardial JJ O
infarction NN O
, , O
especially RB O
in IN O
patients NNS B-POPU
with IN I-POPU
poor JJ I-POPU
left-ventricular JJ I-POPU
function NN I-POPU
. . O

Previous JJ O
attempts NNS O
to TO O
identify VB O
and CC O
suppress VB O
arrhythmias NN O
with IN O
various JJ O
antiarrhythmic JJ O
drugs NNS O
failed VBD O
to TO O
reduce VB O
or CC O
actually RB O
increase JJ O
mortality NN O
. . O

Amiodarone NNP B-INTV
is VBZ O
a DT O
powerful JJ O
antiarrhythmic JJ O
drug NN O
with IN O
several JJ O
potentially RB O
beneficial JJ O
actions NNS O
, , O
and CC O
has VBZ O
shown VBN O
benefit NN O
in IN O
several JJ O
small-scale JJ O
studies NNS O
. . O

We PRP O
postulated VBD O
that IN O
this DT O
drug NN O
might MD O
reduce VB O
mortality NN O
in IN O
patients NNS B-POPU
at IN I-POPU
high JJ I-POPU
risk NN I-POPU
of IN I-POPU
death NN I-POPU
after IN O
myocardial JJ O
infarction NN O
because IN O
of IN O
impaired JJ O
ventricular JJ O
function NN O
, , O
irrespective NN O
of IN O
whether IN O
they PRP O
had VBD O
ventricular JJ O
arrhythmias NNS O
. . O

METHODS NNP O
The DT O
European NNP O
Myocardial NNP O
Infarct NNP O
Amiodarone NNP O
Trial NNP O
( ( O
EMIAT NNP O
) ) O
was VBD O
a DT O
randomised JJ O
double-blind JJ O
placebo-controlled JJ B-INTV
trial NN O
to TO O
assess VB O
whether IN O
amiodarone NN B-INTV
reduced VBD O
all-cause JJ B-OC
mortality NN I-OC
( ( O
primary JJ O
endpoint NN O
) ) O
and CC O
cardiac JJ B-OC
mortality NN I-OC
and CC I-OC
arrhythmic JJ I-OC
death NN I-OC
( ( O
secondary JJ O
endpoints NNS O
) ) O
in IN O
survivors NNS O
of IN O
myocardial JJ O
infarction NN O
with IN O
a DT O
left-ventricular JJ O
ejection NN O
fraction NN O
( ( O
LVEF NNP O
) ) O
of IN O
40 CD O
% NN O
or CC O
less JJR O
. . O

Intention-to-treat NN O
and CC O
on-treatment JJ O
analyses NNS O
were VBD O
done VBN O
. . O

FINDINGS NNP O
EMIAT NNP B-POPU
enrolled VBD I-POPU
1486 CD I-POPU
patients NNS I-POPU
( ( I-POPU
743 CD I-POPU
in IN I-POPU
the DT I-POPU
amiodarone NN I-POPU
group NN I-POPU
, , I-POPU
743 CD I-POPU
in IN I-POPU
the DT I-POPU
placebo NN I-POPU
group NN I-POPU
) ) I-POPU
. . O

Median JJ O
follow-up NN O
was VBD O
21 CD O
months NNS O
. . O

All-cause NNP B-OC
mortality NN I-OC
( ( B-POPU
103 CD I-POPU
deaths NNS I-POPU
in IN I-POPU
the DT I-POPU
amiodarone NN I-POPU
group NN I-POPU
, , I-POPU
102 CD I-POPU
in IN I-POPU
the DT I-POPU
placebo NN I-POPU
group NN I-POPU
) ) I-POPU
and CC I-POPU
cardiac JJ I-POPU
mortality NN I-POPU
did VBD O
not RB O
differ VB O
between IN O
the DT O
two CD O
groups NNS O
. . O

However RB O
, , O
in IN O
the DT O
amiodarone NN B-INTV
group NN O
, , O
there EX O
was VBD O
a DT O
35 CD O
% NN O
risk NN B-OC
reduction NN I-OC
( ( O
95 CD O
% NN O
CI NNP O
0-58 CD O
, , O
p VBZ O
= NNP O
0.05 CD O
) ) O
in IN O
arrhythmic JJ B-OC
deaths NNS I-OC
. . O

INTERPRETATION NNP O
Our PRP$ O
findings NNS O
do VBP O
not RB O
support VB O
the DT O
systematic JJ O
prophylactic JJ O
use NN O
of IN O
amiodarone NN B-INTV
in IN O
all DT O
patients NNS O
with IN O
depressed JJ O
left-ventricular JJ O
function NN O
after IN O
myocardial JJ O
infarction NN O
. . O

However RB O
, , O
the DT O
lack NN O
of IN O
proarrhythmia NN O
and CC O
the DT O
reduction NN O
in IN O
arrhythmic JJ B-OC
death NN I-OC
support NN O
the DT O
use NN O
of IN O
amiodarone NN B-INTV
in IN O
patients NNS O
for IN O
whom WP O
antiarrhythmic JJ O
therapy NN O
is VBZ O
indicated VBN O
. . O

-DOCSTART- -X- O O

The DT O
benefit NN O
of IN O
low-dose JJ O
dopamine NN B-INTV
during IN O
vigorous JJ O
diuresis NN O
for IN O
congestive JJ B-POPU
heart NN I-POPU
failure NN I-POPU
associated VBN I-POPU
with IN I-POPU
renal JJ I-POPU
insufficiency NN I-POPU
: : I-POPU
does VBZ O
it PRP O
protect VB O
renal JJ O
function NN O
? . O
BACKGROUND NNP O
Low-dose NNP O
dopamine NN B-INTV
, , O
a DT O
renal JJ O
vasodilator NN O
, , O
has VBZ O
been VBN O
used VBN O
empirically RB O
to TO O
improve VB O
renal JJ O
function NN O
or CC O
outcome NN O
in IN O
critically RB B-POPU
ill JJ I-POPU
patients NNS I-POPU
with IN I-POPU
oliguria NNS I-POPU
or CC I-POPU
acute JJ I-POPU
renal JJ I-POPU
failure NN I-POPU
. . O

HYPOTHESIS NNP O
This DT O
study NN O
was VBD O
designed VBN O
to TO O
investigate VB O
the DT O
efficacy NN O
of IN O
low-dose JJ O
dopamine NN B-INTV
( ( O
2 CD O
micrograms/kg/min NN O
) ) O
as IN O
a DT O
renal-protective JJ O
agent NN O
during IN O
vigorous JJ O
diuresis NN O
for IN O
congestive JJ O
heart NN O
failure NN O
( ( O
CHF NNP O
) ) O
associated VBN O
with IN O
mild NN O
or CC O
moderate JJ O
renal JJ O
insufficiency NN O
. . O

METHODS NNP O
Of IN O
20 CD B-POPU
study NN I-POPU
patients NNS I-POPU
( ( I-POPU
mean JJ I-POPU
age NN I-POPU
74.3 CD I-POPU
+/- JJ I-POPU
15 CD I-POPU
years NNS I-POPU
) ) I-POPU
with IN I-POPU
severe JJ I-POPU
CHF NNP I-POPU
, , I-POPU
10 CD I-POPU
( ( I-POPU
Group NNP I-POPU
A NNP I-POPU
) ) I-POPU
were VBD O
randomized VBN O
to TO O
a DT O
treatment NN O
strategy NN O
of IN O
intravenous JJ O
bumetanide NN B-INTV
( ( O
1 CD O
mg NN O
b.i.d NN O
. . O

) ) O
alone RB O
and CC O
another DT O
10 CD O
( ( O
Group NNP O
B NNP O
) ) O
to TO O
low-dose JJ O
dopamine NN B-INTV
and CC O
a DT O
similar JJ O
diuretic JJ O
regimen NNS O
for IN O
a DT O
duration NN O
of IN O
5 CD O
days NNS O
or CC O
less JJR O
if IN O
clinical JJ O
edema NN O
remitted VBN O
. . O

RESULTS NNP O
Group NNP O
B NNP O
patients NNS O
showed VBD O
a DT O
significant JJ O
improvement NN O
in IN O
renal JJ B-OC
function NN I-OC
and CC I-OC
urinary JJ I-OC
output NN I-OC
: : I-OC
serum NN I-OC
blood NN I-OC
urea JJ I-OC
nitrogen RB I-OC
48.9 CD O
+/- JJ O
10.3 CD O
to TO O
32.1 CD O
+/- JJ O
14.4 CD O
mg/dl NN O
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
; : O
serum JJ B-OC
creatinine NN I-OC
1.97 CD O
+/- JJ O
0.24 CD O
to TO O
1.49 CD O
+/- JJ O
0.39 CD O
mg/dl NN O
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
; : O
creatinine JJ B-OC
clearance NN I-OC
35.6 CD O
+/- JJ O
11.6 CD O
to TO O
48.8 CD O
+/- JJ O
12.3 CD O
ml/min NN O
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
; : O
and CC O
indexed JJ B-OC
urinary JJ I-OC
output NN I-OC
0.56 CD O
+/- JJ O
0.16 CD O
to TO O
2.02 CD O
+/- JJ O
0.72 CD O
ml/kg/h NN O
( ( O
p JJ O
< NNP O
0.05 CD O
) ) O
. . O

Group NNP O
A NNP O
patients NNS O
showed VBD O
a DT O
significant JJ O
increase NN O
in IN O
urinary JJ B-OC
output NN I-OC
but CC I-OC
nonsignificant JJ I-OC
renal JJ I-OC
functional JJ I-OC
deterioration NN I-OC
. . O

CONCLUSION VB O
The DT O
renal-protective JJ O
effect NN O
of IN O
low-dose JJ O
dopamine NN B-INTV
in IN O
the DT O
setting NN O
of IN O
CHF NNP O
and CC O
vigorous JJ O
diuresis NN O
is VBZ O
supported VBN O
by IN O
this DT O
study NN O
. . O

-DOCSTART- -X- O O

Safety NN B-OC
of IN O
nifedipine NN B-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
hypertension NN I-POPU
: : I-POPU
a DT O
meta-analysis NN O
. . O

Our PRP$ O
objective NN O
was VBD O
to TO O
compare VB O
cardiovascular JJ B-OC
event NN I-OC
rates NNS I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
mild JJ I-POPU
or CC I-POPU
moderate JJ I-POPU
hypertension NN I-POPU
who WP I-POPU
received VBD I-POPU
nifedipine JJ I-POPU
with IN I-POPU
active JJ I-POPU
drug NN I-POPU
controls NNS I-POPU
. . O

We PRP O
performed VBD O
a DT O
MEDLARS NNP B-POPU
search NN I-POPU
using VBG I-POPU
the DT I-POPU
MeSH NNP I-POPU
heading NN I-POPU
" NNP I-POPU
hypertension NN I-POPU
" NN I-POPU
and CC I-POPU
the DT I-POPU
text NN I-POPU
word NN I-POPU
" NNP I-POPU
nifedipine NN I-POPU
" NN I-POPU
to TO I-POPU
identify VB I-POPU
all DT I-POPU
articles NNS I-POPU
that WDT I-POPU
were VBD I-POPU
published VBN I-POPU
between IN I-POPU
1966 CD I-POPU
and CC I-POPU
August NNP I-POPU
1995 CD I-POPU
in IN I-POPU
English NNP I-POPU
, , I-POPU
French NNP I-POPU
, , I-POPU
German NNP I-POPU
, , I-POPU
Italian NNP I-POPU
, , I-POPU
and CC I-POPU
Spanish JJ I-POPU
languages NNS I-POPU
and CC I-POPU
that DT I-POPU
involved VBD I-POPU
human JJ I-POPU
subjects NNS I-POPU
. . O

The DT O
computerized JJ O
search NN O
was VBD O
supplemented VBN O
by IN O
a DT O
manual JJ O
search NN O
of IN O
article NN O
bibliographies NNS O
. . O

Review NNP B-POPU
of IN I-POPU
1880 CD I-POPU
citations NNS I-POPU
revealed VBD I-POPU
98 CD I-POPU
randomized VBN I-POPU
controlled VBD I-POPU
clinical JJ I-POPU
trials NNS I-POPU
that WDT I-POPU
met VBD I-POPU
protocol NN I-POPU
criteria NNS I-POPU
. . O

Articles NNS B-POPU
were VBD I-POPU
extracted VBN I-POPU
independently RB I-POPU
by IN I-POPU
two CD I-POPU
doctors NNS I-POPU
who WP I-POPU
were VBD I-POPU
blinded VBN I-POPU
for IN I-POPU
author NN I-POPU
, , I-POPU
institution NN I-POPU
, , I-POPU
and CC I-POPU
treatment NN I-POPU
regimen NNS I-POPU
, , I-POPU
using VBG I-POPU
a DT I-POPU
structured VBN I-POPU
, , I-POPU
pretested VBN I-POPU
extraction NN I-POPU
form NN I-POPU
. . O

Differences NNS O
of IN O
opinion NN O
were VBD O
resolved VBN O
by IN O
consensus NN O
. . O

Fourteen JJ O
events NNS O
occurred VBD O
in IN O
5198 CD O
exposures NNS O
( ( O
0.27 CD O
% NN O
) ) O
to TO O
nifedipine VB B-INTV
and CC O
24 CD O
events NNS O
in IN O
5402 CD O
exposures NNS O
( ( O
0.44 CD O
% NN O
) ) O
to TO O
other JJ O
active JJ O
drug NN O
controls NNS O
. . O

Unadjusted VBN B-OC
odds JJ I-OC
ratios NNS I-OC
for IN O
nifedipine JJ O
versus NN O
controls NNS O
were VBD O
0.49 CD O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
[ NNP O
CI NNP O
] NNP O
, , O
0.22-1.09 NNP O
) ) O
for IN O
definitive JJ B-OC
events NNS I-OC
( ( I-OC
death NN I-OC
, , I-OC
nonfatal JJ I-OC
myocardial JJ I-OC
infarction NN I-OC
or CC I-OC
stroke NN I-OC
, , I-OC
revascularization NN I-OC
procedure NN I-OC
) ) I-OC
and CC O
0.61 CD O
( ( O
95 CD O
% NN O
CI NNP O
, , O
0.31-1.17 NNP O
) ) O
for IN O
all DT B-OC
events NNS I-OC
( ( I-OC
definitive JJ I-OC
plus NN I-OC
increased VBD I-OC
angina RB I-OC
) ) I-OC
. . O

The DT O
odds NNS B-OC
ratio NN I-OC
for IN I-OC
nifedipine JJ B-INTV
monotherapy NN B-OC
( ( O
sustained- JJ O
or CC O
extended-release NN O
in IN O
91 CD O
% NN O
of IN O
exposures NNS O
) ) O
was VBD O
nonsignificantly RB O
higher JJR O
for IN O
definitive JJ O
and CC O
all DT O
events NNS O
( ( O
odds NNS O
ratio NN O
, , O
1.40 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.49-4.03 JJ O
and CC O
odds NNS O
ratio NN O
, , O
1.39 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.59-3.32 NNP O
, , O
respectively RB O
) ) O
. . O

The DT O
odds NNS B-OC
ratio NN I-OC
for IN I-OC
nifedipine NN B-INTV
in IN B-OC
combination NN I-OC
with IN I-OC
another DT I-OC
drug NN I-OC
was VBD O
significantly RB O
lower JJR O
for IN O
definitive JJ O
and CC O
all DT O
events NNS O
( ( O
odds NNS O
ratio NN O
, , O
0.09 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.01-0.66 JJ O
and CC O
odds NNS O
ratio NN O
, , O
0.15 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.03-0.65 NNP O
, , O
respectively RB O
) ) O
. . O

Differences NNS B-OC
in IN I-OC
odds NNS I-OC
ratio NN I-OC
for IN I-OC
nifedipine JJ B-INTV
monotherapy NN B-OC
and CC I-OC
combined VBN I-OC
therapy NN I-OC
were VBD O
statistically RB O
significant JJ O
( ( O
P=.02 NNP O
for IN O
definitive JJ O
events NNS O
and CC O
P=.001 NNP O
for IN O
all DT O
events NNS O
) ) O
. . O

Results JJ O
support NN O
the DT O
safety NN B-OC
of IN I-OC
sustained- JJ I-OC
and CC I-OC
extended-release JJ I-OC
nifedipine NN B-INTV
in IN O
the DT O
treatment NN O
of IN O
mild NN O
or CC O
moderate JJ O
hypertension NN O
when WRB O
it PRP O
is VBZ O
used VBN O
in IN O
combination NN O
with IN O
other JJ O
drugs NNS O
. . O

-DOCSTART- -X- O O

[ JJ O
Clinical NNP O
diagnosis NN O
of IN O
deep JJ O
venous JJ O
thrombosis NN O
after IN O
hip NN O
replacement NN O
surgery NN O
] NN O
. . O

Hip NNP O
replacement NN O
surgery NN O
is VBZ O
associated VBN O
with IN O
a DT O
high JJ O
frequency NN O
of IN O
postoperative JJ O
deep JJ O
vein NN O
thrombosis NN O
. . O

This DT O
prospective JJ O
study NN O
was VBD O
performed VBN O
in IN O
order NN O
to TO O
investigate VB O
if IN O
routine JJ B-INTV
bedside NN I-INTV
questioning VBG I-INTV
and CC I-INTV
examination NN I-INTV
by IN I-INTV
the DT I-INTV
visiting NN I-INTV
doctor NN I-INTV
could MD O
reveal VB O
deep JJ O
vein NN O
thrombosis NN O
in IN O
the DT O
legs NN O
of IN O
patients NNS B-POPU
who WP I-POPU
had VBD I-POPU
received VBN I-POPU
a DT I-POPU
hip NN I-POPU
replacement NN I-POPU
. . O

258 CD B-POPU
patients NNS I-POPU
were VBD I-POPU
evaluated VBN I-POPU
. . O

Thromboprophylaxis NNP B-INTV
( ( I-INTV
dextran-70 JJ I-INTV
, , I-INTV
low JJ I-INTV
molecular JJ I-INTV
weight NN I-INTV
heparin NN I-INTV
and CC I-INTV
graded VBD I-INTV
elastic JJ I-INTV
stockings NNS I-INTV
) ) I-INTV
was VBD O
given VBN O
during IN O
the DT O
first JJ O
week NN O
after IN O
operation NN O
. . O

Bilateral NNP B-INTV
venography NN I-INTV
was VBD O
performed VBN O
in IN O
all DT O
patients NNS O
on IN O
day NN O
seven CD O
after IN O
operation NN O
, , O
and CC O
showed VBD O
an DT O
overall JJ O
deep JJ O
vein NN O
thrombosis NN O
incidence NN O
of IN O
16 CD O
% NN O
. . O

The DT O
visiting NN O
doctors NNS O
had VBD O
not RB O
suspected VBN O
deep JJ O
vein NN O
thrombosis NN O
in IN O
any DT O
of IN O
the DT O
patients NNS O
. . O

This DT O
may MD O
have VB O
been VBN O
because RB O
postoperative JJ B-OC
painful NN I-OC
and CC I-OC
swollen JJ I-OC
legs NNS I-OC
effectively RB O
masked VBD O
any DT O
signs NNS O
and CC O
symptoms NNS O
of IN O
deep JJ O
vein NN O
thrombosis NN O
. . O

Our PRP$ O
results NNS O
show VBP O
that IN O
deep JJ B-OC
vein NN I-OC
thrombosis NN I-OC
during IN O
the DT O
first JJ O
week NN O
after IN O
hip NN O
replacement NN O
surgery NN O
can MD O
not RB O
be VB O
discovered VBN O
by IN O
clinical JJ O
diagnostics NNS O
. . O

The DT O
high JJ O
subclinical JJ O
frequency NN O
of IN O
deep JJ O
vein NN O
thrombosis NN O
indicates VBZ O
the DT O
importance NN O
of IN O
improving VBG O
thromboprophylaxis NN O
in IN O
order NN O
to TO O
further RBR O
minimise VB O
the DT O
occurrence NN O
of IN O
deep JJ O
vein NN O
thrombosis NN O
and CC O
the DT O
risk NN O
of IN O
thromboembolic JJ O
complications NNS O
. . O

-DOCSTART- -X- O O

Design NN O
of IN O
a DT O
cost-effectiveness NN O
study NN O
within IN O
a DT O
randomized JJ O
trial NN O
: : O
the DT O
LIPID NNP O
Trial NNP O
for IN O
Secondary NNP O
Prevention NNP O
of IN O
IHD NNP B-POPU
. . O

Long-term JJ O
Intervention NN O
with IN O
Pravastatin NNP B-INTV
in IN O
Ischemic NNP B-POPU
Heart NNP I-POPU
disease NN I-POPU
. . O

The DT O
Long-term JJ O
Intervention NN O
with IN O
Pravastatin NNP B-INTV
in IN O
Ischemic NNP B-POPU
Heart NNP I-POPU
Disease NNP I-POPU
( ( O
LIPID NNP O
) ) O
trial NN O
is VBZ O
a DT O
double-blind JJ O
, , O
randomized VBN O
, , O
placebo-controlled JJ B-INTV
trial NN O
evaluating VBG O
the DT O
long-term JJ O
effect NN O
of IN O
pravastatin NN B-INTV
on IN O
coronary JJ O
mortality NN O
in IN O
patients NNS B-POPU
with IN I-POPU
a DT I-POPU
previous JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
or CC I-POPU
unstable JJ I-POPU
angina-ischemic JJ I-POPU
heart NN I-POPU
disease NN I-POPU
( ( I-POPU
IHD NNP I-POPU
) ) I-POPU
. . O

It PRP O
is VBZ O
planned VBN O
to TO O
run VB O
for IN O
at IN O
least JJS O
five CD O
years NNS O
with IN O
9014 CD B-POPU
patients NNS I-POPU
from IN I-POPU
85 CD I-POPU
centers NNS I-POPU
in IN I-POPU
Australia NNP I-POPU
and CC I-POPU
New NNP I-POPU
Zealand NNP I-POPU
. . O

The DT O
trial NN O
will MD O
monitor VB O
cause-specific JJ O
mortality NN O
and CC O
major JJ O
clinical JJ O
events NNS O
associated VBN O
with IN O
each DT O
treatment NN O
. . O

Running VBG O
in IN O
parallel NN O
with IN O
the DT O
main JJ O
study NN O
is VBZ O
a DT O
prospective JJ O
economic JJ O
analysis NN O
, , O
the DT O
objectives NNS O
of IN O
which WDT O
are VBP O
( ( O
1 CD O
) ) O
to TO O
estimate VB O
the DT O
effectiveness NN O
of IN O
pravastatin NN B-INTV
compared VBN O
with IN O
placebo NN O
in IN O
terms NNS O
of IN O
survival NN B-OC
, , I-OC
quality NN I-OC
of IN I-OC
life NN I-OC
( ( I-OC
QOL NNP I-OC
) ) I-OC
, , I-OC
and CC I-OC
quality-adjusted JJ I-OC
life-years NNS I-OC
( ( I-OC
QALY NNP I-OC
) ) I-OC
; : I-OC
( ( O
2 CD O
) ) O
to TO O
estimate VB O
the DT O
resource NN O
usage NN O
associated VBN O
with IN O
pravastatin NNS B-INTV
compared VBN O
with IN O
placebo-in JJ B-INTV
particular JJ O
, , O
to TO O
study VB O
whether IN O
it PRP O
alters VBZ O
resource JJ O
usage NN O
through IN O
prevention NN O
of IN O
disease NN O
progression NN O
; : O
and CC O
( ( O
3 CD O
) ) O
to TO O
use VB O
this DT O
information NN O
for IN O
a DT O
cost-utility JJ O
analysis NN O
with IN O
cost NN O
per IN O
quality-adjusted JJ O
life-year JJ O
as IN O
the DT O
unit NN O
of IN O
analysis NN O
. . O

A DT O
novel JJ O
aspect NN O
of IN O
the DT O
design NN O
is VBZ O
the DT O
use NN O
of IN O
a DT O
preliminary JJ O
cost-effectiveness NN O
analysis NN O
, , O
based VBN O
on IN O
" JJ O
best-guess JJ O
" NN O
values NNS O
, , O
and CC O
a DT O
sensitivity NN O
analysis NN O
over IN O
plausible JJ O
ranges NNS O
to TO O
guide VB O
the DT O
choice NN O
of IN O
subsample JJ O
size NN O
. . O

Some DT O
data NNS O
, , O
such PDT O
a DT O
mortality NN B-OC
, , I-OC
days NNS I-OC
spent VBD I-OC
in IN I-OC
hospital NN I-OC
, , I-OC
major JJ I-OC
clinical JJ I-OC
events NNS I-OC
, , I-OC
and CC I-OC
drug NN I-OC
use NN I-OC
, , O
are VBP O
being VBG O
collected VBN O
within IN O
the DT O
main JJ O
LIPID NNP O
trial NN O
. . O

However RB O
, , O
additional JJ O
subsamples NNS O
for IN O
the DT O
cost-effectiveness NN B-OC
study NN O
will MD O
include VB O
information NN O
on IN O
quality NN B-OC
of IN I-OC
life NN I-OC
, , I-OC
time NN I-OC
off RP I-OC
work NN I-OC
, , I-OC
and CC I-OC
resources NNS I-OC
used VBN I-OC
, , I-OC
such JJ I-OC
as IN I-OC
time NN I-OC
in IN I-OC
hospital NN I-OC
, , I-OC
procedures NNS I-OC
, , I-OC
and CC I-OC
medications NNS I-OC
taken VBN I-OC
. . O

The DT O
methods NNS O
and CC O
sample NN O
sizes NNS O
for IN O
these DT O
substudies NNS O
have VBP O
been VBN O
a DT O
crucial JJ O
issue NN O
in IN O
validity NN O
and CC O
feasibility NN O
. . O

-DOCSTART- -X- O O

An DT O
open JJ O
, , O
parallel JJ O
group NN O
comparison NN O
of IN O
quinapril NN B-INTV
and CC I-INTV
captopril NN I-INTV
, , O
when WRB O
added VBN O
to TO O
diuretic JJ B-INTV
therapy NN I-INTV
, , O
in IN O
the DT O
treatment NN O
of IN O
elderly JJ B-POPU
patients NNS I-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

This DT O
study NN O
aimed VBD O
to TO O
compare VB O
the DT O
efficacy NN B-OC
, , I-OC
tolerability NN I-OC
and CC I-OC
first-dose JJ I-OC
blood-pressure JJ I-OC
response NN I-OC
of IN O
once-daily JJ O
quinapril NN B-INTV
and CC O
twice-daily JJ O
captopril NN B-INTV
when WRB O
added VBD O
to TO O
diuretic JJ B-INTV
therapy NN I-INTV
in IN O
elderly JJ B-POPU
patients NNS I-POPU
with IN I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

The DT O
study NN O
was VBD O
performed VBN O
at IN B-POPU
a DT I-POPU
single JJ I-POPU
centre NN I-POPU
as IN O
an DT O
open JJ O
randomised VBD O
parallel-group NN O
study NN O
, , O
patients NNS B-POPU
being VBG I-POPU
selected VBN I-POPU
for IN I-POPU
inclusion NN I-POPU
from IN I-POPU
the DT I-POPU
outpatient JJ I-POPU
population NN I-POPU
. . O

Following VBG O
a DT O
starting VBG O
dose NN O
of IN O
either CC O
2.5 CD O
mg JJ O
once-daily RB O
quinapril NN B-INTV
, , O
or CC O
6.25 CD O
mg JJ O
twice-daily JJ O
captopril NN B-INTV
, , O
patients NNS O
were VBD O
reviewed VBN O
at IN O
two-weekly JJ O
intervals NNS O
, , O
and CC O
following VBG O
clinical JJ O
assessment NN O
a DT O
decision NN O
was VBD O
made VBN O
either DT O
to TO O
titrate VB O
up RP O
to TO O
the DT O
next JJ O
medication NN O
stage NN O
or CC O
to TO O
enter VB O
the DT O
patient NN O
into IN O
the DT O
16-week JJ O
maintenance NN O
phase NN O
. . O

Efficacy NN B-OC
was VBD O
assessed VBN B-OC
using VBG O
a DT O
six-minute JJ B-OC
walking NN I-OC
test NN I-OC
, , I-OC
the DT I-OC
New NNP I-OC
York NNP I-OC
Heart NNP I-OC
Association NNP I-OC
( ( I-OC
NYHA NNP I-OC
) ) I-OC
class NN I-OC
, , I-OC
a DT I-OC
functional JJ I-OC
lifescale NN I-OC
( ( I-OC
FLS NNP I-OC
) ) I-OC
questionnaire NN I-OC
and CC I-OC
the DT I-OC
cardiothoracic NN I-OC
ratio NN I-OC
( ( I-OC
CTR NNP I-OC
) ) I-OC
-at NN I-OC
study NN I-OC
entry NN I-OC
and CC I-OC
at IN I-OC
the DT I-OC
end NN I-OC
of IN I-OC
the DT I-OC
maintenance NN I-OC
phase NN I-OC
. . O

Blood NNP B-OC
pressure NN I-OC
was VBD O
measured VBN O
for IN O
5 CD O
h JJ O
post-first-dose JJ O
of IN O
medication NN O
. . O

Sixty-one CD B-POPU
patients NNS I-POPU
were VBD O
randomised VBN O
to TO O
treatment NN O
: : O
30 CD O
to TO O
quinapril VB B-INTV
and CC O
31 CD O
to TO O
captopril VB B-INTV
. . O

Following VBG O
withdrawals NNS O
, , O
data NNS O
from IN O
36 CD O
patients NNS O
( ( O
20 CD O
on IN O
quinapril NN B-INTV
, , O
16 CD O
on IN O
captopril NN B-INTV
) ) I-INTV
were VBD O
available JJ O
for IN O
analysis NN O
. . O

The DT O
distance NN B-OC
walked VBD I-OC
during IN I-OC
the DT I-OC
six-minute JJ I-OC
walking NN I-OC
test NN I-OC
improved VBN I-OC
in IN O
both DT O
groups NNS O
; : O
the DT O
difference NN O
between IN O
the DT O
treatment NN O
groups NNS O
was VBD O
not RB O
statistically RB B-OC
significant JJ I-OC
. . O

There EX O
were VBD O
no DT O
significant JJ B-OC
changes NNS I-OC
in IN O
the DT O
FLS NNP B-OC
or CC I-OC
CTR NNP I-OC
. . O

An DT O
analysis NN O
of IN O
change NN O
in IN O
the DT O
NYHA NNP O
status NN O
from IN O
study NN O
entry NN O
to TO O
study VB O
end NN O
showed VBD O
a DT O
statistically RB B-OC
significant JJ I-OC
difference NN I-OC
between IN O
the DT O
two CD O
groups NNS O
( ( O
p JJ O
= NNP O
0.02 CD O
) ) O
in IN O
favour NN O
of IN O
quinapril NN B-INTV
. . O

Five CD O
patients NNS O
in IN O
each DT O
group NN O
experienced VBD O
hypotension NN B-OC
during IN O
the DT O
5 CD O
h NN O
following VBG O
the DT O
first JJ O
dose NN O
of IN O
medication NN O
. . O

This DT O
study NN O
has VBZ O
shown VBN O
heart NN O
failure NN O
to TO O
be VB O
as RB O
well RB O
controlled VBN O
by IN O
once-daily JJ O
quinapril NN B-INTV
as IN O
by IN O
twice-daily JJ O
captopril NN B-INTV
, , O
with IN O
comparable JJ O
effects NNS O
on IN O
first-dose JJ B-OC
blood-pressure JJ I-OC
response NN I-OC
. . O

-DOCSTART- -X- O O

The DT O
effects NNS O
of IN O
the DT O
angiotensin-converting JJ B-INTV
enzyme NN I-INTV
inhibitor NN I-INTV
imidapril NN I-INTV
on IN O
plasma NN O
plasminogen NN O
activator NN O
inhibitor NN O
activity NN O
in IN O
patients NNS B-POPU
with IN I-POPU
acute JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
. . O

This DT O
study NN O
sought VBD O
to TO O
determine VB O
whether IN O
early JJ O
treatment NN O
with IN O
angiotensin-converting JJ B-INTV
enzyme NN I-INTV
( ( I-INTV
ACE NNP I-INTV
) ) I-INTV
inhibitors NNS I-INTV
in IN O
patients NNS O
with IN O
acute JJ O
myocardial JJ O
infarction NN O
( ( O
AMI NNP O
) ) O
is VBZ O
useful JJ O
for IN O
the DT O
improvement NN O
of IN O
fibrinolytic JJ B-OC
function NN I-OC
, , O
as RB O
well RB O
as IN O
left VBN B-OC
ventricular JJ I-OC
function NN I-OC
. . O

This DT O
study NN O
was VBD O
designed VBN O
to TO O
examine VB O
the DT O
levels NNS O
of IN O
plasma NN B-OC
plasminogen NN I-OC
activator NN I-OC
inhibitor NN I-OC
( ( I-OC
PAI NNP I-OC
) ) I-OC
activity NN I-OC
and CC O
serum JJ B-OC
ACE NNP I-OC
activity NN I-OC
during IN O
the DT O
course NN O
of IN O
2 CD O
weeks NNS O
in IN O
40 CD B-POPU
patients NNS I-POPU
with IN I-POPU
AMI NNP I-POPU
within IN I-POPU
12 CD I-POPU
hours NNS I-POPU
after IN I-POPU
the DT I-POPU
onset NN I-POPU
of IN I-POPU
the DT I-POPU
symptom NN I-POPU
and CC I-POPU
who WP I-POPU
randomly VBP I-POPU
received VBN I-POPU
early JJ I-POPU
treatment NN I-POPU
with IN I-POPU
either CC I-POPU
the DT I-POPU
ACE NNP I-POPU
inhibitor NN I-POPU
imidapril NN I-POPU
or CC I-POPU
a DT I-POPU
placebo NN I-POPU
( ( I-POPU
20 CD I-POPU
patients NNS I-POPU
in IN I-POPU
the DT I-POPU
imidapril NN I-POPU
group NN I-POPU
and CC I-POPU
20 CD I-POPU
in IN I-POPU
the DT I-POPU
placebo NN I-POPU
group NN I-POPU
) ) I-POPU
. . O

The DT O
levels NNS B-OC
of IN I-OC
serum JJ I-OC
ACE NNP I-OC
activity NN I-OC
in IN O
the DT O
imidapril NN B-INTV
group NN O
decreased VBD O
significantly RB O
( ( O
p JJ O
< NNP O
0.01 CD O
) ) O
8 CD O
hours NNS O
after IN O
the DT O
administration NN O
of IN O
imidapril NN B-INTV
, , O
and CC O
the DT O
levels NNS O
24 CD O
hours NNS O
after IN O
administration NN O
were VBD O
significantly RB O
lower JJR O
than IN O
those DT O
in IN O
the DT O
placebo NN B-INTV
group NN O
( ( O
3.6 CD O
+/- JJ O
0.6 CD O
IU/L NNP O
vs VBD O
7.4 CD O
+/- JJ O
0.8 CD O
IU/L NNP O
; : O
p VBZ O
< $ O
0.001 CD O
) ) O
. . O

The DT O
plasma JJ B-OC
PAI NNP I-OC
activity NN I-OC
increased VBD O
gradually RB O
to TO O
peak VB O
levels NNS O
16 CD O
hours NNS O
after IN O
the DT O
administration NN O
of IN O
imidapril NN O
and CC O
placebo NN O
. . O

The DT O
levels NNS O
in IN O
the DT O
placebo NN O
group NN O
decreased VBD O
gradually RB O
but CC O
remained VBD O
high JJ O
during IN O
the DT O
study NN O
period NN O
. . O

On IN O
the DT O
other JJ O
hand NN O
, , O
the DT O
levels NNS B-OC
of IN I-OC
PAI NNP I-OC
activity NN I-OC
in IN O
the DT O
imidapril NN B-INTV
group NN O
decreased VBD O
rapidly RB O
and CC O
those DT O
48 CD O
hours NNS O
after IN O
administration NN O
were VBD O
significantly RB O
lower JJR O
than IN O
those DT O
in IN O
the DT O
placebo NN B-INTV
group NN O
( ( O
7.9 CD O
+/- JJ O
1.9 CD O
IU/ml NNP O
vs VBD O
18.4 CD O
+/- JJ O
3.5 CD O
IU/ml NNP O
; : O
p VBZ O
< $ O
0.01 CD O
) ) O
. . O

The DT O
levels NNS B-OC
of IN I-OC
left JJ I-OC
ventricular JJ I-OC
ejection NN I-OC
fraction NN I-OC
about IN O
2 CD O
weeks NNS O
after IN O
admission NN O
were VBD O
significantly RB O
higher JJR O
in IN O
the DT O
imidapril NN O
group NN O
than IN O
in IN O
the DT O
placebo NN B-INTV
group NN O
( ( O
65.9 CD O
% NN O
+/- JJ O
2.5 CD O
% NN O
vs JJ O
49.1 CD O
% NN O
+/- JJ O
4.4 CD O
% NN O
; : O
p CC O
< VB O
0.01 CD O
) ) O
. . O

This DT O
study NN O
showed VBD O
that IN O
imidapril NN B-INTV
, , O
an DT O
ACE NNP O
inhibitor NN O
, , O
might MD O
be VB O
useful JJ O
for IN O
the DT O
improvement NN O
of IN O
fibrinolytic JJ B-OC
function NN I-OC
and CC O
left VBD B-OC
ventricular JJ I-OC
function NN I-OC
in IN O
the DT O
acute JJ O
phase NN O
of IN O
myocardial JJ O
infarction NN O
. . O

-DOCSTART- -X- O O

Lower JJR B-OC
extremity NN I-OC
deep JJ I-OC
vein NN I-OC
thrombosis NN I-OC
: : I-OC
a DT O
prospective JJ O
, , O
randomized VBN O
, , O
controlled VBN O
trial NN O
in IN O
comatose NN B-POPU
or CC I-POPU
sedated VBN I-POPU
patients NNS I-POPU
undergoing JJ I-POPU
femoral JJ I-POPU
vein NN I-POPU
catheterization NN I-POPU
. . O

OBJECTIVES UH O
To TO O
determine VB O
the DT O
rate NN B-OC
of IN I-OC
lower JJR I-OC
extremity NN I-OC
deep JJ I-OC
vein NN I-OC
thrombosis NN I-OC
after IN O
the DT O
use NN O
of IN O
femoral JJ B-INTV
catheters NNS I-INTV
in IN O
intensive JJ O
care NN O
unit NN O
( ( O
ICU NNP O
) ) O
comatose VBD B-POPU
or CC I-POPU
sedated VBN I-POPU
adults NNS I-POPU
. . O

Results NNS O
were VBD O
then RB O
compared VBN O
with IN O
results NNS O
of IN O
patients NNS B-POPU
undergoing VBG I-POPU
superior JJ I-POPU
vena NNS I-POPU
cava JJ I-POPU
catheterization NN I-POPU
. . O

DESIGN NNP O
Prospective NNP O
, , O
randomized VBD O
, , O
controlled VBD O
, , O
unblinded VBD O
study NN O
. . O

SETTING VB O
A DT O
mixed JJ O
medical/surgical JJ O
ICU NNP O
in IN O
a DT O
university NN O
hospital NN O
. . O

PATIENTS VB O
Sixty-one JJ B-POPU
comatose NN I-POPU
or CC I-POPU
sedated VBN I-POPU
patients NNS I-POPU
admitted VBN I-POPU
to TO I-POPU
the DT I-POPU
ICU NNP I-POPU
who WP I-POPU
underwent JJ I-POPU
central JJ I-POPU
venous JJ I-POPU
catheterization NN I-POPU
. . O

INTERVENTIONS JJ O
Patients NNPS O
were VBD O
monitored VBN O
for IN O
signs NNS O
of IN O
thrombotic JJ B-OC
complications NNS I-OC
. . O

On IN O
catheter NN O
removal NN O
, , O
a DT O
lower-extremity JJ O
bilateral JJ O
phlebographic JJ O
examination NN O
was VBD O
performed VBN O
in IN O
each DT O
patient NN O
. . O

MEASUREMENTS NNP O
AND CC O
MAIN NNP O
RESULTS NNP O
After IN O
randomization NN O
, , O
31 CD B-POPU
patients NNS I-POPU
underwent JJ I-POPU
femoral JJ I-POPU
vein NN I-POPU
catheterization NN I-POPU
and CC I-POPU
30 CD I-POPU
patients NNS I-POPU
underwent JJ I-POPU
superior JJ I-POPU
vena NN I-POPU
cava NN I-POPU
catheterization NN I-POPU
, , I-POPU
either RB I-POPU
by IN I-POPU
axillary JJ I-POPU
( ( I-POPU
21 CD I-POPU
patients NNS I-POPU
) ) I-POPU
or CC I-POPU
internal JJ I-POPU
jugular NN I-POPU
vein NN I-POPU
( ( I-POPU
10 CD I-POPU
patients NNS I-POPU
) ) I-POPU
cannulation NN I-POPU
. . O

Single NNP B-INTV
lumen NNS I-INTV
polyurethane NN I-INTV
catheters NNS I-INTV
were VBD O
inserted VBN O
for IN O
a DT O
mean JJ O
duration NN O
of IN O
7.1 CD O
+/- JJ O
4.6 CD O
( ( O
SD NNP O
) ) O
days NNS O
in IN O
the DT O
femoral JJ B-INTV
vein NN I-INTV
group NN I-INTV
and CC O
9.9 CD O
+/- JJ O
5.5 CD O
days NNS O
in IN O
the DT O
superior JJ B-INTV
vena NN I-INTV
cava NN I-INTV
group NN I-INTV
( ( O
p JJ O
= NNP O
NS NNP O
) ) O
. . O

No DT O
patient NN O
had VBD O
clinical JJ B-OC
signs NNS I-OC
of IN I-OC
leg NN I-OC
venous JJ I-OC
thrombosis NN I-OC
or CC I-OC
pulmonary JJ I-OC
embolism NN I-OC
during IN O
the DT O
study NN O
period NN O
. . O

In IN O
each DT O
patient NN O
, , O
lower JJR B-INTV
extremity NN I-INTV
bilateral JJ I-INTV
phlebography NN I-INTV
was VBD O
performed VBN O
at IN O
the DT O
time NN O
of IN O
catheter NN O
removal NN O
. . O

Leg JJ B-OC
phlebographies NNS I-OC
were VBD O
normal JJ O
in IN O
18 CD O
( ( O
60 CD O
% NN O
) ) O
patients NNS O
in IN O
the DT O
femoral JJ O
vein NN O
group NN O
and CC O
26 CD O
( ( O
84 CD O
% NN O
) ) O
patients NNS O
in IN O
the DT O
superior JJ O
vena NN O
cava NN O
group NN O
. . O

Fibrin NNP B-OC
sleeves VBZ I-OC
which WDT O
developed VBD O
around IN O
the DT O
femoral JJ O
catheters NNS O
were VBD O
seen VBN O
in IN O
seven CD O
( ( O
23.3 CD O
% NN O
) ) O
patients NNS O
in IN O
the DT O
femoral JJ B-INTV
vein NN I-INTV
group NN I-INTV
and CC O
in IN O
no DT O
patients NNS O
in IN O
the DT O
superior JJ B-INTV
vena NN I-INTV
cava NN I-INTV
cannulation NN I-INTV
group NN I-INTV
. . O

Three CD O
patients NNS O
had VBD O
femoral JJ B-OC
vein NN I-OC
thrombosis NN I-OC
, , O
two CD O
( ( O
6.6 CD O
% NN O
) ) O
patients NNS O
in IN O
the DT O
femoral JJ B-INTV
vein NN I-INTV
group NN I-INTV
( ( O
two CD O
nonobstructive JJ O
thromboses NNS O
, , O
adherent NN O
to TO O
the DT O
common JJ O
femoral JJ O
vein NN O
wall NN O
) ) O
and CC O
one CD O
( ( O
3.0 CD O
% NN O
) ) O
patient NN O
in IN O
the DT O
superior JJ B-INTV
vena NN I-INTV
cava NN I-INTV
group NN I-INTV
( ( O
nonobstructive JJ O
thrombosis NN O
which WDT O
developed VBD O
in IN O
the DT O
superficial JJ O
femoral JJ O
vein NN O
) ) O
( ( O
p JJ O
= NNP O
NS NNP O
) ) O
. . O

Lower JJR B-OC
deep JJ I-OC
extremities NNS I-OC
thrombosis NN I-OC
developed VBD O
in IN O
five CD O
( ( O
16.7 CD O
% NN O
) ) O
patients NNS O
in IN O
the DT O
femoral JJ O
vein NN O
group NN O
and CC O
in IN O
five CD O
( ( O
16 CD O
% NN O
) ) O
patients NNS O
in IN O
the DT O
superior JJ O
vena NN O
cava NN O
group NN O
( ( O
p JJ O
= NNP O
NS NNP O
) ) O
. . O

CONCLUSIONS NNP O
Femoral NNP B-INTV
vein POS I-INTV
catheterization NN I-INTV
with IN O
a DT O
polyurethane NN O
catheter NN B-INTV
is VBZ O
associated VBN O
with IN O
a DT O
lower JJR O
rate NN B-OC
of IN I-OC
extremity NN I-OC
deep JJ I-OC
vein NN I-OC
thrombosis NN I-OC
which WDT O
is VBZ O
similar JJ O
to TO O
the DT O
rate NN O
observed VBD O
after IN O
superior JJ O
vena JJ O
cannulation NN O
in IN O
comatose NN B-POPU
or CC I-POPU
sedated VBN I-POPU
patients NNS I-POPU
. . O

Femoral NNP B-OC
vein JJ I-OC
thrombosis NN I-OC
was VBD O
observed VBN O
at IN O
a DT O
rate NN O
of IN O
6.6 CD O
% NN O
after IN O
femoral JJ B-INTV
vein NN I-INTV
cannulation NN I-INTV
and CC O
a DT O
rate NN O
of IN O
3 CD O
% NN O
after IN O
superior JJ B-INTV
vena NN I-INTV
cava NN I-INTV
cannulation NN I-INTV
. . O

Given VBN O
the DT O
acceptable JJ O
rate NN O
of IN O
this DT O
clinically NN O
important JJ O
complication NN O
, , O
femoral JJ B-INTV
vein NN I-INTV
cannulation NN I-INTV
offers VBZ O
an DT O
attractive JJ O
alternative NN O
to TO O
insertion NN O
via IN O
the DT O
vena NN B-INTV
cava NN I-INTV
in IN O
the DT O
critically NN O
ill NN O
. . O

-DOCSTART- -X- O O

[ JJ O
Prevention NNP O
of IN O
vascular JJ B-OC
complications NNS I-OC
following VBG O
cerebral JJ O
ischemia NN O
of IN O
arterial JJ O
origin NN O
; : O
the DT O
ESPRIT NNP O
trial NN O
: : O
mild JJ B-INTV
anticoagulant JJ I-INTV
therapy NN I-INTV
, , O
combination NN O
treatment NN O
with IN O
acetylsalicylic JJ B-INTV
acid NN I-INTV
plus CC I-INTV
dipyridamole NN I-INTV
or CC I-INTV
treatment NN I-INTV
with IN I-INTV
acetylsalicylic JJ I-INTV
acid NN I-INTV
alone RB I-INTV
? . O
] UH O
. . O

The DT O
European JJ O
and CC O
Australian JJ O
Stroke NNP O
Prevention NNP O
in IN O
Reversible NNP O
Ischaemia NNP O
Trial NNP O
( ( O
ESPRIT NNP O
) ) O
is VBZ O
a DT O
randomised JJ O
clinical JJ O
trial NN O
in IN O
which WDT O
patients NNS B-POPU
with IN I-POPU
cerebral JJ I-POPU
ischaemia NN I-POPU
of IN I-POPU
arterial JJ I-POPU
origin NN I-POPU
will MD O
be VB O
randomised VBN O
between IN O
oral JJ B-INTV
anticoagulation NN I-INTV
( ( O
international JJ O
normalized VBN O
ratio NN O
( ( O
INR NNP O
) ) O
: : O
2.0-3.0 JJ O
) ) O
, , O
the DT O
combination NN O
of IN O
acetylsalicylic JJ B-INTV
acid NN I-INTV
( ( O
in IN O
any DT O
dose NN O
between IN O
30 CD O
and CC O
325 CD O
mg NNS O
per IN O
day NN O
) ) O
plus CC O
dipyridamole JJ B-INTV
( ( O
400 CD O
mg NNS O
daily RB O
) ) O
and CC O
acetylsalicylic JJ B-INTV
acid NN I-INTV
only RB O
( ( O
in IN O
any DT O
dose NN O
between IN O
30 CD O
and CC O
325 CD O
mg NNS O
per IN O
day NN O
) ) O
. . O

It PRP O
is VBZ O
planned VBN B-POPU
to TO I-POPU
enroll VB I-POPU
4500 CD I-POPU
patients NNS I-POPU
with IN I-POPU
a DT I-POPU
mean JJ I-POPU
follow-up NN I-POPU
of IN I-POPU
three CD I-POPU
years NNS I-POPU
. . O

Primary JJ O
outcome NN O
is VBZ O
the DT O
composite JJ B-OC
event NN I-OC
of IN I-OC
vascular JJ I-OC
death NN I-OC
, , I-OC
stroke NN I-OC
, , I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
or CC I-OC
major JJ I-OC
bleeding VBG I-OC
complication NN I-OC
; : I-OC
outcome CC O
assessment NN O
will MD O
be VB O
blinded VBN O
. . O

ESPRIT NNP O
is VBZ O
an DT O
international JJ B-POPU
, , I-POPU
multicentre JJ I-POPU
study NN I-POPU
in IN I-POPU
which WDT I-POPU
60-80 JJ I-POPU
hospitals NNS I-POPU
in IN I-POPU
the DT I-POPU
Netherlands NNP I-POPU
and CC I-POPU
other JJ I-POPU
countries NNS I-POPU
in IN I-POPU
Europe NNP I-POPU
and CC I-POPU
Australia NNP I-POPU
will MD I-POPU
participate VB I-POPU
. . O

-DOCSTART- -X- O O

Prevention NN O
of IN O
a DT O
first JJ O
stroke NN O
by IN O
transfusions NNS O
in IN O
children NNS B-POPU
with IN I-POPU
sickle NN I-POPU
cell NN I-POPU
anemia NN I-POPU
and CC I-POPU
abnormal JJ I-POPU
results NNS I-POPU
on IN I-POPU
transcranial JJ I-POPU
Doppler NNP I-POPU
ultrasonography NN I-POPU
. . O

BACKGROUND NNP O
Blood NNP B-INTV
transfusions NNS I-INTV
prevent VBP O
recurrent JJ O
stroke NN O
in IN O
children NNS B-POPU
with IN I-POPU
sickle NN I-POPU
cell NN I-POPU
anemia NN I-POPU
, , O
but CC O
the DT O
value NN O
of IN O
transfusions NNS O
in IN O
preventing VBG O
a DT O
first JJ O
stroke NN O
is VBZ O
unknown JJ O
. . O

We PRP O
used VBD O
transcranial JJ O
Doppler NNP O
ultrasonography NN O
to TO O
identify VB O
children NNS B-POPU
with IN I-POPU
sickle NN I-POPU
cell NN I-POPU
anemia NN I-POPU
who WP I-POPU
were VBD I-POPU
at IN I-POPU
high JJ I-POPU
risk NN I-POPU
for IN I-POPU
stroke NN I-POPU
and CC O
then RB O
randomly RB O
assigned VBN O
them PRP O
to TO O
receive VB O
standard JJ O
care NN O
or CC O
transfusions NNS O
to TO O
prevent VB O
a DT O
first JJ O
stroke NN O
. . O

METHODS NNP O
To TO O
enter VB O
the DT O
study NN O
, , O
children NNS B-POPU
with IN I-POPU
sickle NN I-POPU
cell NN I-POPU
anemia NN I-POPU
and CC I-POPU
no DT I-POPU
history NN I-POPU
of IN I-POPU
stroke NN I-POPU
had VBD I-POPU
to TO I-POPU
have VB I-POPU
undergone JJ I-POPU
two CD I-POPU
transcranial JJ I-POPU
Doppler NNP I-POPU
studies NNS I-POPU
that WDT I-POPU
showed VBD I-POPU
that IN I-POPU
the DT I-POPU
time-averaged JJ I-POPU
mean JJ I-POPU
blood-flow JJ I-POPU
velocity NN I-POPU
in IN I-POPU
the DT I-POPU
internal JJ I-POPU
carotid NN I-POPU
or CC I-POPU
middle JJ I-POPU
cerebral JJ I-POPU
artery NN I-POPU
was VBD I-POPU
200 CD I-POPU
cm JJ I-POPU
per IN I-POPU
second NN I-POPU
or CC I-POPU
higher JJR I-POPU
. . O

The DT O
patients NNS B-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
standard JJ B-INTV
care NN I-INTV
or CC I-INTV
transfusions NNS I-INTV
to TO O
reduce VB O
the DT O
hemoglobin NN O
S NNP O
concentration NN O
to TO O
less JJR O
than IN O
30 CD O
percent NN O
of IN O
the DT O
total JJ O
hemoglobin NN O
concentration NN O
. . O

The DT O
incidence NN O
of IN O
stroke NN O
( ( O
cerebral JJ O
infarction NN O
or CC O
intracranial JJ O
hemorrhage NN O
) ) O
was VBD O
compared VBN O
between IN O
the DT O
two CD O
groups NNS O
. . O

RESULTS VB O
A DT O
total NN O
of IN O
130 CD B-POPU
children NNS I-POPU
( ( I-POPU
mean JJ I-POPU
[ NNP I-POPU
+/-SD NN I-POPU
] NNP I-POPU
age NN I-POPU
, , I-POPU
8.3+/-3.3 CD I-POPU
years NNS I-POPU
) ) I-POPU
were VBD I-POPU
enrolled VBN I-POPU
; : I-POPU
63 CD I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
receive VB O
transfusions NNS O
and CC O
67 CD O
to TO O
receive VB O
standard NN O
care NN O
. . O

At IN O
base NN O
line NN O
, , O
the DT O
transfusion NN O
group NN O
had VBD O
a DT O
slightly RB O
lower JJR O
mean NN B-OC
hemoglobin NN I-OC
concentration NN I-OC
( ( O
7.2 CD O
vs. FW O
7.6 CD O
g NN O
per IN O
deciliter NN O
, , O
P=0.001 NNP O
) ) O
and CC O
hematocrit NN B-OC
( ( O
20.4 CD O
vs. FW O
21.7 CD O
percent NN O
, , O
P=0.002 NNP O
) ) O
. . O

Ten CD O
patients NNS O
dropped VBD O
out IN O
of IN O
the DT O
transfusion NN O
group NN O
, , O
and CC O
two CD O
patients NNS O
crossed VBD O
over IN O
from IN O
the DT O
standard-care JJ O
group NN O
to TO O
the DT O
transfusion NN O
group NN O
. . O

There EX O
were VBD O
10 CD O
cerebral JJ B-OC
infarctions NNS I-OC
and CC O
1 CD O
intracerebral JJ B-OC
hematoma NN I-OC
in IN O
the DT O
standard-care JJ O
group NN O
, , O
as IN O
compared VBN O
with IN O
1 CD O
infarction NN B-OC
in IN O
the DT O
transfusion NN O
group NN O
-- : O
a DT O
92 CD O
percent NN O
difference NN O
in IN O
the DT O
risk NN O
of IN O
stroke NN O
( ( O
P NNP O
< NNP O
0.001 CD O
) ) O
. . O

This DT O
result NN O
led VBD O
to TO O
the DT O
early JJ O
termination NN O
of IN O
the DT O
trial NN O
. . O

CONCLUSIONS NNP O
Transfusion NNP B-INTV
greatly RB O
reduces VBZ O
the DT O
risk NN B-OC
of IN I-OC
a DT I-OC
first JJ I-OC
stroke NN I-OC
in IN O
children NNS B-POPU
with IN I-POPU
sickle NN I-POPU
cell NN I-POPU
anemia NN I-POPU
who WP I-POPU
have VBP I-POPU
abnormal JJ I-POPU
results NNS I-POPU
on IN I-POPU
transcranial JJ I-POPU
Doppler NNP I-POPU
ultrasonography NN I-POPU
. . O

-DOCSTART- -X- O O

Effect NN O
of IN O
pravastatin NN B-INTV
on IN O
cardiovascular JJ B-OC
events NNS I-OC
in IN O
women NNS B-POPU
after IN I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
: : I-POPU
the DT O
cholesterol NN O
and CC O
recurrent JJ O
events NNS O
( ( O
CARE NNP O
) ) O
trial NN O
. . O

OBJECTIVES IN O
We PRP O
sought VBD O
to TO O
determine VB O
the DT O
effect NN O
of IN O
pravastatin NN B-INTV
on IN O
recurrent NN B-OC
cardiovascular JJ I-OC
events NNS I-OC
in IN O
women NNS B-POPU
with IN I-POPU
average JJ I-POPU
cholesterol NN I-POPU
levels NNS I-POPU
after IN I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
( ( I-POPU
MI NNP I-POPU
) ) I-POPU
. . O

BACKGROUND NNP O
Little JJ O
information NN O
is VBZ O
available JJ O
on IN O
the DT O
effectiveness NN O
of IN O
lipid JJ O
lowering VBG O
in IN O
secondary JJ O
prevention NN O
of IN O
coronary JJ B-POPU
heart NN I-POPU
disease NN I-POPU
( ( I-POPU
CHD NNP I-POPU
) ) I-POPU
in IN I-POPU
women NNS I-POPU
; : I-POPU
in IN I-POPU
particular JJ I-POPU
, , I-POPU
those DT I-POPU
with IN I-POPU
CHD NNP I-POPU
and CC I-POPU
average JJ I-POPU
cholesterol NN I-POPU
levels NNS I-POPU
. . O

METHODS NNP O
In IN O
the DT O
Cholesterol NNP O
and CC O
Recurrent NNP O
Events NNP O
( ( O
CARE NNP O
) ) O
trial NN O
, , O
576 CD B-POPU
postmenopausal NN I-POPU
women NNS I-POPU
, , I-POPU
between IN I-POPU
3 CD I-POPU
and CC I-POPU
20 CD I-POPU
months NNS I-POPU
after IN I-POPU
MI NNP I-POPU
, , I-POPU
with IN I-POPU
a DT I-POPU
total JJ I-POPU
cholesterol NN I-POPU
level NN I-POPU
< VBD I-POPU
240 CD I-POPU
mg/dl NN I-POPU
and CC I-POPU
a DT I-POPU
low JJ I-POPU
density NN I-POPU
lipoprotein NN I-POPU
cholesterol NN I-POPU
level NN I-POPU
115 CD I-POPU
to TO I-POPU
174 CD I-POPU
mg/dl NNS I-POPU
, , O
were VBD O
randomized VBN O
to TO O
receive VB O
pravastatin NN B-INTV
40 CD I-INTV
mg/day NN I-INTV
or CC O
matching VBG O
placebo NN B-INTV
for IN O
a DT O
median JJ O
follow-up JJ O
period NN O
of IN O
5 CD O
years NNS O
. . O

The DT O
main JJ O
outcome NN O
measures NNS O
were VBD O
combined VBN B-OC
coronary JJ I-OC
events NNS I-OC
( ( I-OC
coronary JJ I-OC
death NN I-OC
, , I-OC
nonfatal JJ I-OC
MI NNP I-OC
, , I-OC
percutaneous JJ I-OC
transluminal JJ I-OC
coronary NN I-OC
angioplasty NN I-OC
[ NNP I-OC
PTCA NNP I-OC
] NNP I-OC
or CC I-OC
coronary JJ I-OC
artery NN I-OC
bypass NN I-OC
graft NN I-OC
surgery NN I-OC
[ NNP I-OC
CABG NNP I-OC
] NNP I-OC
) ) I-OC
, , I-OC
the DT I-OC
primary JJ I-OC
trial NN I-OC
end NN I-OC
point NN I-OC
( ( I-OC
coronary JJ I-OC
death NN I-OC
or CC I-OC
nonfatal JJ I-OC
MI NNP I-OC
) ) I-OC
and CC I-OC
stroke NN I-OC
. . O

RESULTS NNP O
Women NNP O
treated VBD O
with IN O
pravastatin NN O
had VBD O
a DT O
risk NN B-OC
reduction NN I-OC
of IN O
43 CD O
% NN O
for IN O
the DT O
primary JJ O
end NN O
point NN O
( ( O
p JJ O
= NNP O
0.035 CD O
) ) O
, , O
46 CD O
% NN O
for IN O
combined JJ O
coronary JJ O
events NNS O
( ( O
p JJ O
= NNP O
0.001 CD O
) ) O
, , O
48 CD O
% NN O
for IN O
PTCA NNP O
( ( O
p JJ O
= NNP O
0.025 CD O
) ) O
, , O
40 CD O
% NN O
for IN O
CABG NNP O
( ( O
p JJ O
= NNP O
0.14 CD O
) ) O
and CC O
56 CD O
% NN O
for IN O
stroke NN O
( ( O
p JJ O
= NNP O
0.07 CD O
) ) O
. . O

The DT B-POPU
3,583 CD I-POPU
men NNS I-POPU
in IN I-POPU
the DT I-POPU
CARE NNP I-POPU
trial NN I-POPU
also RB O
showed VBD O
a DT O
reduction NN O
in IN O
risk NN B-OC
, , O
but CC O
the DT O
magnitude NN O
tended VBD O
to TO O
be VB O
less JJR O
. . O

Pravastatin NNP B-INTV
improved VBD O
plasma JJ B-OC
lipids NNS I-OC
similarly RB O
in IN O
men NNS B-POPU
and CC I-POPU
women NNS I-POPU
. . O

There EX O
were VBD O
no DT O
differences NNS O
in IN O
risk NN B-OC
of IN I-OC
coronary JJ I-OC
events NNS I-OC
in IN O
the DT O
placebo NN O
group NN O
between IN O
men NNS O
and CC O
women NNS O
. . O

Minor JJ O
differences NNS O
between IN O
men NNS O
and CC O
women NNS O
were VBD O
present JJ O
in IN O
baseline NN O
characteristics NNS O
and CC O
treatment NN O
for IN O
MI NNP O
, , O
in IN O
general JJ O
, , O
conferring VBG O
a DT O
higher JJR O
risk NN O
status NN O
and CC O
a DT O
lower JJR O
incidence NN O
of IN O
CABG NNP B-OC
in IN O
the DT O
women NNS O
. . O

CONCLUSIONS NNP O
Pravastatin NNP B-INTV
led VBD O
to TO O
significant JJ O
early JJ O
reduction NN O
of IN O
a DT O
wide JJ O
range NN O
of IN O
cardiovascular JJ B-OC
events NNS I-OC
in IN O
post-MI JJ B-POPU
women NNS I-POPU
with IN I-POPU
average JJ I-POPU
cholesterol NN I-POPU
levels NNS I-POPU
. . O

-DOCSTART- -X- O O

Glucosamine NNP B-OC
in IN I-OC
serum NN I-OC
of IN O
patients NNS B-POPU
after IN I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
subjected VBN O
to TO O
rehabilitation VB B-INTV
training NN I-INTV
. . O

This DT O
paper NN O
presents VBZ O
results NNS O
of IN O
3 CD O
weeks NNS O
physical JJ B-INTV
training NN I-INTV
on IN O
glucosamine JJ B-OC
level NN I-OC
in IN I-OC
serum NN I-OC
of IN O
male NN B-POPU
patients NNS I-POPU
after IN I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
( ( I-POPU
MI NNP I-POPU
) ) I-POPU
aged VBD I-POPU
between IN I-POPU
38 CD I-POPU
and CC I-POPU
61 CD I-POPU
. . O

Patients NNS O
were VBD O
randomised VBN O
in IN O
two CD O
groups NNS O
: : O
the DT B-POPU
training NN I-POPU
group NN I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
21 CD I-POPU
) ) I-POPU
, , I-POPU
staying VBG I-POPU
in IN I-POPU
Cardiac NNP I-POPU
Rehabilitation NNP I-POPU
Department NNP I-POPU
and CC I-POPU
the DT I-POPU
control NN I-POPU
group NN I-POPU
( ( I-POPU
n JJ I-POPU
= NNP I-POPU
11 CD I-POPU
) ) I-POPU
, , B-INTV
discharged VBD I-INTV
home NN I-INTV
for IN O
3 CD O
weeks NNS O
. . O

Each DT O
group NN O
received VBD O
identical JJ O
dietary JJ O
instructions NNS O
. . O

The DT B-POPU
training NN I-POPU
group NN I-POPU
performed VBD O
exercises NNS B-INTV
every DT I-INTV
day NN I-INTV
: : I-INTV
on IN I-INTV
bicycle NN I-INTV
ergometer NN I-INTV
during IN I-INTV
30 CD I-INTV
minutes NNS I-INTV
( ( I-INTV
5 CD I-INTV
times NNS I-INTV
a DT I-INTV
week NN I-INTV
) ) I-INTV
, , I-INTV
overall-conditioning JJ I-INTV
exercises NNS I-INTV
for IN I-INTV
30 CD I-INTV
minutes NNS I-INTV
daily RB I-INTV
and CC I-INTV
30 CD I-INTV
to TO I-INTV
60 CD I-INTV
minutes NNS I-INTV
of IN I-INTV
walking VBG I-INTV
each DT I-INTV
day NN I-INTV
. . O

Before IN B-INTV
administering VBG I-INTV
of IN I-INTV
the DT I-INTV
therapy NN I-INTV
and CC I-INTV
3 CD I-INTV
weeks NNS I-INTV
later RB I-INTV
all DT I-INTV
MI NNP B-POPU
patients NNS I-POPU
performed VBD B-INTV
the DT I-INTV
bicycle NN I-INTV
ergometer NN I-INTV
exercise NN I-INTV
test NN I-INTV
until IN I-INTV
the DT I-INTV
ventilatory NN I-INTV
threshold NN I-INTV
was VBD I-INTV
reached VBN I-INTV
. . O

Before IN B-INTV
that DT I-INTV
test NN I-INTV
and CC I-INTV
3 CD I-INTV
minutes NNS I-INTV
after IN I-INTV
its PRP$ I-INTV
termination NN I-INTV
capillary NN I-INTV
and CC I-INTV
venous JJ I-INTV
blood NN I-INTV
samples NNS I-INTV
were VBD I-INTV
drawn VBN I-INTV
. . O

In IN B-INTV
the DT I-INTV
capillary JJ I-INTV
blood NN I-INTV
samples NNS I-INTV
indices NNS I-INTV
of IN I-INTV
acid-base JJ I-INTV
balance NN I-INTV
, , I-INTV
lactate JJ I-INTV
level NN I-INTV
, , I-INTV
and CC I-INTV
glucose JJ I-INTV
level NN I-INTV
were VBD I-INTV
determined VBN I-INTV
. . O

In IN O
venous JJ O
blood NN O
samples NNS O
the DT O
serum NN B-OC
levels NNS I-OC
of IN I-OC
immunoreactive JJ I-OC
insulin NN I-OC
, , I-OC
C-peptide NNP I-OC
and CC I-OC
glucosamine NN I-OC
were VBD O
determined VBN O
as RB O
well RB O
as IN O
binding NN B-OC
of IN I-OC
125I-insulin JJ I-OC
to TO I-OC
erythrocyte VB I-OC
receptors NNS I-OC
. . O

Obtained VBN O
results NNS O
show VBP O
that IN O
administered JJ O
therapy NN O
increased VBD O
physical JJ B-OC
fitness NN I-OC
and CC O
decreased VBN O
of IN O
glucosamine NN B-OC
concentration NN I-OC
, , I-OC
insulinaemia NN I-OC
and CC I-OC
insulin NN I-OC
resistance NN I-OC
. . O

-DOCSTART- -X- O O

Accuracy NN O
and CC O
feasibility NN O
of IN O
contrast NN B-INTV
echocardiography NN I-INTV
for IN O
detection NN O
of IN O
perfusion NN O
defects NNS O
in IN O
routine JJ O
practice NN O
: : O
comparison NN O
with IN O
wall JJ B-INTV
motion NN I-INTV
and CC I-INTV
technetium-99m JJ I-INTV
sestamibi NN I-INTV
single-photon JJ I-INTV
emission NN I-INTV
computed VBD I-INTV
tomography NN I-INTV
. . O

The DT O
Nycomed NNP O
NC100100 NNP O
Investigators NNP O
. . O

OBJECTIVES NNP O
We PRP O
sought VBD O
to TO O
assess VB O
the DT O
feasibility NN O
and CC O
accuracy NN O
of IN O
myocardial JJ B-INTV
contrast NN I-INTV
echocardiography NN I-INTV
( ( I-INTV
MCE NNP I-INTV
) ) I-INTV
using VBG O
standard JJ O
imaging NN O
approaches NNS O
for IN O
the DT O
detection NN O
of IN O
perfusion NN O
defects NNS O
in IN O
patients NNS B-POPU
who WP I-POPU
had VBD I-POPU
a DT I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
( ( I-POPU
MI NNP I-POPU
) ) I-POPU
. . O

BACKGROUND NNP O
Myocardial NNP B-INTV
contrast NN I-INTV
echocardiography NN I-INTV
may MD O
be VB O
more JJR O
versatile JJ O
than IN O
perfusion NN B-INTV
scintigraphy NN I-INTV
for IN O
identifying VBG O
the DT O
presence NN O
and CC O
extent NN O
of IN O
perfusion NN O
defects NNS O
after IN O
MI NNP O
. . O

However RB O
, , O
its PRP$ O
reliability NN O
in IN O
routine JJ O
practice NN O
is VBZ O
unclear JJ O
. . O

METHODS NNP O
Fundamental NNP O
or CC O
harmonic JJ O
MCE NNP O
was VBD O
performed VBN O
with IN O
continuous JJ O
or CC O
triggered JJ O
imaging NN O
in IN O
203 CD B-POPU
patients NNS I-POPU
with IN I-POPU
a DT I-POPU
previous JJ I-POPU
MI NNP I-POPU
using VBG O
bolus JJ O
doses NNS O
of IN O
a DT O
perfluorocarbon-filled JJ B-INTV
contrast NN I-INTV
agent NN I-INTV
( ( I-INTV
NC100100 NNP I-INTV
) ) I-INTV
. . O

All DT O
patients NNS O
underwent JJ O
single-photon JJ B-INTV
emission NN I-INTV
computed VBN I-INTV
tomography NN I-INTV
( ( I-INTV
SPECT NNP I-INTV
) ) I-INTV
after IN I-INTV
the DT I-INTV
injection NN I-INTV
of IN I-INTV
technetium-99m JJ I-INTV
( ( I-INTV
Tc-99m NNP I-INTV
) ) I-INTV
sestamibi NN I-INTV
at IN I-INTV
rest NN I-INTV
. . O

Quantitative NNP B-INTV
and CC I-INTV
semiquantitative JJ I-INTV
SPECT NNP I-INTV
, , O
wall NN O
motion NN O
and CC O
digitized JJ O
echocardiographic JJ O
data NNS O
were VBD O
interpreted VBN O
independently RB O
. . O

The DT O
accuracy NN O
of IN O
MCE NNP B-INTV
was VBD O
assessed VBN O
for IN O
detection NN O
of IN O
segments NNS O
and CC O
patients NNS O
with IN O
moderate JJ O
and CC O
severe JJ O
sestamibi-SPECT JJ O
defects NNS O
, , O
as RB O
well RB O
as IN O
for IN O
detection NN O
of IN O
patients NNS O
with IN O
extensive JJ O
perfusion NN O
defects NNS O
( ( O
> VB O
12 CD O
% NN O
of IN O
left JJ O
ventricle NN O
) ) O
. . O

RESULTS NNP O
In IN O
segments NNS O
with IN O
diagnostic JJ O
MCE NNP O
, , O
the DT O
segmental JJ B-OC
sensitivity NN I-OC
ranged VBD O
from IN O
14 CD O
% NN O
to TO O
65 CD O
% NN O
, , O
and CC O
the DT O
specificity NN B-OC
varied VBD O
from IN O
78 CD O
% NN O
to TO O
95 CD O
% NN O
, , O
depending VBG O
on IN O
the DT O
dose NN O
of IN O
contrast NN O
agent NN O
. . O

Using VBG O
both DT O
segment- JJ O
and CC O
patient-based JJ O
analysis NN O
, , O
the DT O
greatest JJS O
accuracy NN O
and CC O
proportion NN O
of IN O
interpretable JJ O
images NNS O
were VBD O
obtained VBN O
using VBG O
harmonic JJ O
imaging NN O
in IN O
the DT O
triggered JJ O
mode NN O
. . O

For IN O
the DT O
detection NN O
of IN O
extensive JJ O
defects NNS O
, , O
the DT O
sensitivity NN B-OC
varied VBD O
from IN O
13 CD O
% NN O
to TO O
48 CD O
% NN O
, , O
with IN O
specificity NN O
from IN O
63 CD O
% NN O
to TO O
100 CD O
% NN O
. . O

Harmonic NNP O
imaging NN O
remained VBD O
the DT O
most RBS O
accurate JJ O
approach NN O
. . O

Time NNP B-OC
since IN I-OC
MI NNP I-OC
and CC I-OC
SPECT NNP I-OC
defect VBP I-OC
location NN I-OC
and CC I-OC
intensity NN I-OC
were VBD O
all DT O
determinants NNS O
of IN O
the DT O
MCE NNP O
response NN O
. . O

The DT O
extent NN B-OC
of IN I-OC
defects NNS I-OC
on IN I-OC
MCE NNP I-OC
was VBD O
less JJR O
than IN O
the DT O
extent NN O
of IN O
either DT O
abnormal JJ O
wall NN O
motion NN O
or CC O
SPECT NNP O
abnormalities NNS O
. . O

The DT O
combination NN O
of IN O
wall JJ O
motion NN O
and CC O
MCE NNP O
assessment NN O
gave VBD O
the DT O
best JJS O
balance NN O
of IN O
sensitivity NN O
( ( O
46 CD O
% NN O
to TO O
55 CD O
% NN O
) ) O
and CC O
specificity NN O
( ( O
82 CD O
% NN O
to TO O
83 CD O
% NN O
) ) O
. . O

CONCLUSIONS NNP O
Although IN O
MCE NNP O
is VBZ O
specific JJ O
, , O
it PRP O
has VBZ O
limited VBN O
sensitivity NN O
for IN O
detection NN O
of IN O
moderate JJ B-OC
or CC I-OC
severe JJ I-OC
perfusion NN I-OC
defects NNS I-OC
, , O
and CC O
it PRP O
underestimates VBZ O
the DT O
extent NN O
of IN O
SPECT NNP B-OC
defects NNS I-OC
. . O

The DT O
best JJS O
results NNS O
are VBP O
obtained VBN O
by IN O
integration NN O
with IN O
wall DT O
motion NN O
. . O

More RBR O
sophisticated JJ O
methods NNS O
of IN O
acquisition NN O
and CC O
interpretation NN O
are VBP O
needed VBN O
to TO O
enhance VB O
the DT O
feasibility NN O
of IN O
this DT O
technique NN O
in IN O
routine JJ O
practice NN O
. . O

-DOCSTART- -X- O O

Why WRB O
were VBD O
the DT O
results NNS O
of IN O
the DT O
Heart NNP O
Outcomes NNP O
Prevention NNP O
Evaluation NNP O
( ( O
HOPE NNP O
) ) O
trial NN O
so IN O
astounding VBG O
? . O
The DT O
Heart NNP O
Outcomes NNP O
Prevention NNP O
Evaluation NNP O
( ( O
HOPE NNP O
) ) O
study NN O
was VBD O
important JJ O
because IN O
it PRP O
showed VBD O
the DT O
benefits NNS O
of IN O
ramipril NN B-INTV
- : O
an DT O
angiotensin-converting JJ B-INTV
enzyme NN I-INTV
( ( I-INTV
ACE NNP I-INTV
) ) I-INTV
inhibitor NN I-INTV
- : O
in IN O
patients NNS B-POPU
at IN I-POPU
high JJ I-POPU
risk NN I-POPU
for IN I-POPU
cardiovascular JJ I-POPU
events NNS I-POPU
. . O

Treatment NN O
with IN O
ramipril NN B-INTV
significantly RB O
reduced VBD O
the DT O
rates NNS B-OC
of IN I-OC
death NN I-OC
, , I-OC
myocardial JJ I-OC
infarction NN I-OC
, , I-OC
stroke NN I-OC
, , I-OC
coronary JJ I-OC
revascularization NN I-OC
, , I-OC
cardiac JJ I-OC
arrest NN I-OC
and CC I-OC
heart NN I-OC
failure NN I-OC
, , O
as RB O
well RB O
as IN O
the DT O
risk NN B-OC
of IN I-OC
diabetes-related JJ I-OC
complications NNS I-OC
and CC I-OC
of IN I-OC
diabetes NNS I-OC
itself PRP I-OC
. . O

The DT O
effects NNS O
of IN O
therapy NN O
with IN O
vitamin JJ B-INTV
E NN I-INTV
were VBD O
also RB O
evaluated VBN O
, , O
but CC O
no DT O
statistical JJ O
benefits NNS O
were VBD O
shown VBN O
. . O

The DT O
benefits NNS O
of IN O
ACE NNP B-INTV
inhibitor NN I-INTV
therapy NN O
that WDT O
were VBD O
observed VBN O
were VBD O
likely JJ O
due JJ O
to TO O
a DT O
variety NN O
of IN O
mechanisms NNS O
, , O
not RB O
just RB O
a DT O
reduction NN O
in IN O
blood NN O
pressure NN O
. . O

-DOCSTART- -X- O O

[ JJ B-INTV
Neoton NNP I-INTV
and CC O
thrombolytic JJ B-INTV
therapy NN I-INTV
of IN O
myocardial JJ O
infarction NN O
] NNP O
. . O

AIM NNP O
To TO O
evaluate VB O
neoton JJ B-INTV
therapy NN O
effects NNS O
in IN O
acute JJ O
myocardial JJ O
infarction NN O
( ( O
MI NNP O
) ) O
on IN O
systolic JJ B-OC
function NN I-OC
of IN I-OC
the DT I-OC
left JJ I-OC
ventricle NN I-OC
, , I-OC
arrhythmia NN I-OC
and CC I-OC
clinical JJ I-OC
symptoms NNS I-OC
in IN O
patients NNS B-POPU
on IN I-POPU
thrombolytic JJ I-POPU
therapy NN I-POPU
( ( I-POPU
TLT NNP I-POPU
) ) I-POPU
. . O

MATERIAL NNP O
AND NNP O
METHODS NNP O
106 CD B-POPU
males NNS I-POPU
with IN I-POPU
Q-MI NNP I-POPU
entered VBD I-POPU
the DT I-POPU
study NN I-POPU
. . O

47 CD O
received VBD O
treatment NN O
without IN O
TLT NNP B-INTV
and CC O
neoton NN B-INTV
, , O
30 CD O
patients NNS O
received VBD O
TLT NNP B-INTV
with IN O
streptokinase JJ B-INTV
preparations NNS O
, , O
29 CD O
patients NNS O
were VBD O
given VBN O
streptokinase JJ B-INTV
preparations NNS I-INTV
and CC O
neoton NN B-INTV
. . O

Left NNP B-OC
ventricular JJ I-OC
systolic JJ I-OC
function NN I-OC
was VBD I-OC
measured VBN I-OC
by IN I-OC
echocardiography NN I-OC
on IN O
day NN O
1 CD O
, , O
3 CD O
, , O
7 CD O
, , O
14 CD O
, , O
21 CD O
and CC O
28 CD O
; : O
arrhythmia NN B-OC
was VBD I-OC
analysed VBN I-OC
at IN I-OC
Holter NNP I-OC
monitoring VBG I-OC
in IN O
day NN O
1 CD O
and CC O
2 CD O
of IN O
MI NNP O
. . O

RESULTS NNP O
TLT NNP B-INTV
failed VBD O
to TO O
arrest VB O
progression NN O
of IN O
left JJ O
ventricular JJ O
dilation NN O
by IN O
the DT O
end NN O
of IN O
the DT O
hospital NN O
stay NN O
. . O

Patients NNS O
given VBN O
neoton NNS B-INTV
in IN O
acute JJ O
period NN O
of IN O
MI NNP O
had VBD O
no DT O
increase NN O
in IN O
the DT O
end NN O
systolic NN B-OC
and CC I-OC
diastolic JJ I-OC
volumes NNS I-OC
of IN O
the DT O
left JJ O
ventricle NN O
in IN O
the DT O
course NN O
of IN O
the DT O
first JJ O
months NNS O
after IN O
MI NNP O
onset NN O
. . O

Antiarrhythmic NNP O
action NN O
of IN O
neoton NN B-INTV
manifested VBN O
on IN O
MI NNP O
day NN O
2 CD O
. . O

CONCLUSION NNP O
Neoton NNP B-INTV
given VBN O
to TO O
MI NNP B-POPU
patients NNS I-POPU
receiving VBG I-POPU
TLT NNP I-POPU
prevents NNS O
progression NN O
of IN O
left JJ B-OC
ventricular JJ I-OC
systolic JJ I-OC
dysfunction NN I-OC
and CC O
establishment NN O
of IN O
predictors NNS O
of IN O
unfavourable JJ O
outcome NN O
. . O

-DOCSTART- -X- O O

Development NNP B-OC
of IN I-OC
renal JJ I-OC
disease NN I-OC
in IN B-POPU
people NNS I-POPU
at IN I-POPU
high JJ I-POPU
cardiovascular JJ I-POPU
risk NN I-POPU
: : I-POPU
results NNS O
of IN O
the DT O
HOPE NNP O
randomized VBD O
study NN O
. . O

In IN O
people NNS B-POPU
with IN I-POPU
diabetes NNS I-POPU
, , O
renal JJ O
disease NN O
tends VBZ O
to TO O
progress VB B-OC
from IN I-OC
microalbuminuria NN I-OC
to TO O
clinical JJ B-OC
proteinuria NN I-OC
to TO O
renal JJ B-OC
insufficiency NN I-OC
. . O

Little JJ O
evidence NN O
has VBZ O
been VBN O
published VBN O
for IN O
the DT O
nondiabetic JJ O
population NN O
. . O

This DT O
study NN O
retrospectively RB O
analyzed VBD O
changes NNS B-OC
of IN I-OC
proteinuria NN I-OC
over IN O
4.5 CD O
yr NNS O
in IN O
the DT O
HOPE NNP O
( ( O
Heart NNP O
Outcomes NNP O
and CC O
Prevention NNP O
Evaluation NNP O
) ) O
study NN O
, , O
which WDT O
compared VBN O
ramipril NN B-INTV
's POS I-INTV
effects NNS O
to TO O
placebo VB B-INTV
in IN O
9297 CD O
participants NNS O
, , O
including VBG O
3577 CD O
with IN O
diabetes NNS O
and CC O
1956 CD O
with IN O
microalbuminuria NN O
. . O

This DT O
report NN O
is VBZ O
restricted VBN O
to TO O
7674 CD B-POPU
participants NNS I-POPU
with IN I-POPU
albuminuria NNS I-POPU
data NNS I-POPU
at IN I-POPU
baseline NN I-POPU
and CC I-POPU
at IN I-POPU
follow-up JJ I-POPU
. . O

Inclusion NN B-POPU
criteria NNS I-POPU
were VBD I-POPU
known VBN I-POPU
vascular JJ I-POPU
disease NN I-POPU
or CC I-POPU
diabetes VBZ I-POPU
plus CC I-POPU
one CD I-POPU
other JJ I-POPU
cardiovascular JJ I-POPU
risk NN I-POPU
factor NN I-POPU
, , I-POPU
exclusion NN I-POPU
criteria NNS I-POPU
included VBD I-POPU
heart NN I-POPU
failure NN I-POPU
or CC I-POPU
known VBN I-POPU
impaired JJ I-POPU
left VBD I-POPU
ventricular JJ I-POPU
function NN I-POPU
, , I-POPU
dipstick-positive JJ I-POPU
proteinuria NN I-POPU
( ( I-POPU
> JJ I-POPU
1+ CD I-POPU
) ) I-POPU
, , I-POPU
and CC I-POPU
serum JJ I-POPU
creatinine NN I-POPU
> $ I-POPU
2.3 CD I-POPU
mg/dl NN I-POPU
( ( I-POPU
200 CD I-POPU
microM NN I-POPU
) ) I-POPU
. . O

Baseline NNP O
microalbuminuria NN O
predicted VBD O
subsequent JJ O
clinical JJ B-OC
proteinuria NN I-OC
for IN O
the DT O
study NN O
participants NNS O
overall JJ O
( ( O
adjusted VBN O
odds NNS O
ratio VBP O
[ CD O
OR NNP O
] NNP O
, , O
17.5 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
[ NNP O
CI NNP O
] NNP O
, , O
12.6 CD O
to TO O
24.4 CD O
) ) O
, , O
in IN O
participants NNS O
without IN O
diabetes NNS O
( ( O
OR NNP O
, , O
16.7 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
8.6 CD O
to TO O
32.4 CD O
) ) O
, , O
and CC O
in IN O
participants NNS O
with IN O
diabetes NNS O
( ( O
OR NNP O
, , O
18.2 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
12.4 CD O
to TO O
26.7 CD O
) ) O
. . O

Any DT O
progression NN B-OC
of IN I-OC
albuminuria NNS I-OC
( ( O
defined VBN O
as IN O
new JJ B-OC
microalbuminuria NNS I-OC
or CC I-OC
new JJ I-OC
clinical JJ I-OC
proteinuria NN I-OC
) ) I-OC
occurred VBD O
in IN O
1859 CD O
participants NNS O
; : O
1542 CD O
developed VBD O
new JJ B-OC
microalbuminuria NNS I-OC
, , O
and CC O
317 CD O
participants NNS O
developed VBD O
clinical JJ B-OC
proteinuria NN I-OC
. . O

Ramipril NNP B-INTV
reduced VBD O
the DT O
risk NN O
for IN O
any DT O
progression NN B-OC
( ( O
OR NNP O
, , O
0.87 CD O
; : O
95 CD O
% NN O
CI NNP O
, , O
0.78 CD O
to TO O
0.97 CD O
; : O
P NNP O
= NNP O
0.0146 CD O
) ) O
. . O

People NNS B-POPU
without IN I-POPU
and CC I-POPU
with IN I-POPU
diabetes NNS I-POPU
who WP I-POPU
are VBP I-POPU
at IN I-POPU
high JJ I-POPU
risk NN I-POPU
for IN I-POPU
cardiovascular JJ I-POPU
disease NN I-POPU
are VBP O
also RB O
at IN O
risk NN O
for IN O
a DT O
progressive JJ O
rise NN O
in IN O
albuminuria NN B-OC
. . O

Microalbuminuria NNP O
itself PRP O
predicts VBZ O
clinical JJ B-OC
proteinuria NNS I-OC
in IN O
nondiabetic JJ B-POPU
and CC I-POPU
in IN I-POPU
diabetic JJ I-POPU
people NNS I-POPU
. . O

Ramipril JJ B-INTV
prevents NNS O
or CC O
delays VBZ O
the DT O
progression NN B-OC
of IN I-OC
albuminuria NN I-OC
. . O

-DOCSTART- -X- O O

A DT O
randomized JJ O
comparison NN O
of IN O
alternative JJ O
techniques NNS O
to TO O
achieve VB O
coronary JJ O
sinus NN O
cannulation NN O
during IN O
biventricular JJ B-POPU
implantation NN I-POPU
procedures NNS I-POPU
. . O

INTRODUCTION NNP O
Biventricular NNP O
pacing VBG O
system NN O
implantation NN O
is VBZ O
a DT O
time-consuming JJ O
and CC O
challenging JJ O
procedure NN O
. . O

A DT O
critical JJ O
step NN O
in IN O
biventricular JJ O
pacemaker NN O
implantation NN O
is VBZ O
coronary JJ O
sinus NN O
( ( O
CS NNP O
) ) O
cannulation NN O
. . O

CS NNP O
cannulation NN O
can MD O
be VB O
achieved VBN O
either DT O
using VBG O
dedicated JJ O
guiding NN O
catheters NNS B-INTV
( ( I-INTV
guiding VBG I-INTV
catheter NN I-INTV
alone RB I-INTV
positioning VBG O
strategy NN O
, , O
GCA NNP O
) ) O
or CC O
with IN O
the DT O
aid NN O
of IN O
an DT O
electrophysiology NN B-INTV
catheter NN I-INTV
advanced VBD I-INTV
inside IN O
the DT O
guiding NN O
catheter NN O
( ( B-INTV
electrophysiology JJ I-INTV
catheter NN I-INTV
aided VBD I-INTV
positioning VBG O
strategy NN O
, , O
EPA NNP O
) ) O
. . O

AIM NNP O
OF IN O
THE NNP O
STUDY NNP O
To TO O
evaluate VB O
whether IN O
the DT O
EPA NNP B-INTV
technique NN O
is VBZ O
useful JJ O
for IN O
reducing VBG O
CS NNP B-OC
cannulation NN I-OC
time NN I-OC
compared VBN O
to TO O
a DT O
conventional JJ O
GCA NNP B-INTV
technique NN O
. . O

METHODS NNP O
Thirty-four JJ B-POPU
consecutive JJ I-POPU
patients NNS I-POPU
were VBD O
randomly RB O
assigned VBN O
to TO O
the DT O
GCA NNP B-INTV
( ( O
18 CD O
patients NNS O
) ) O
or CC O
EPA NNP B-INTV
( ( O
16 CD O
patients NNS O
) ) O
CS NNP O
cannulation NN O
strategy NN O
. . O

RESULTS JJ O
Time NNP B-OC
to TO I-OC
successful JJ I-OC
catheterization NN I-OC
of IN I-OC
CS NNP I-OC
was VBD O
5.0 CD O
+/- JJ O
2.4 CD O
min NN O
in IN O
the DT O
EPA NNP B-INTV
group NN O
versus VBD O
10.1 CD O
+/- JJ O
5.4 CD O
min NN O
in IN O
the DT O
GCA NNP B-INTV
group NN O
p VBD O
= RB O
0.004 CD O
. . O

Fluoroscopy NN B-OC
time NN I-OC
was VBD O
4.6 CD O
+/- JJ O
2.3 CD O
min NN O
in IN O
the DT O
EPA NNP B-INTV
group NN O
versus VBD O
9.2 CD O
+/- JJ O
4.9 CD O
min NN O
in IN O
the DT O
GCA NNP B-INTV
group NN O
p VBD O
= RB O
0.004 CD O
. . O

Total JJ O
contrast NN B-OC
dye NN I-OC
volume NN I-OC
to TO O
search NN O
and CC O
engage VB O
the DT O
CS NNP O
ostium NN O
was VBD O
0.0 CD O
ml NN O
in IN O
the DT O
EPA NNP B-INTV
group NN O
versus VBD O
14.3 CD O
+/- JJ O
3.4 CD O
ml NN O
in IN O
the DT O
GCA NNP B-INTV
group NN O
p VBD O
< RB O
0.001 CD O
. . O

CONCLUSIONS NNP O
Cannulation NNP O
of IN O
CS NNP O
with IN O
the DT O
adjunct NN O
of IN O
an DT O
electrophysiology NN O
catheter NN O
to TO O
dedicated VBN O
delivery NN O
systems NNS O
significantly RB O
reduces VBZ O
procedural JJ B-OC
time NN I-OC
, , I-OC
fluoroscopy JJ I-OC
time NN I-OC
and CC I-OC
contrast NN I-OC
dye NN I-OC
volume NN I-OC
compared VBN O
to TO O
a DT O
conventional JJ O
strategy NN O
. . O

-DOCSTART- -X- O O

[ JJ O
Postural NNP O
biofeedback NN O
and CC O
locomotion NN O
reeducation NN O
in IN O
stroke NN B-POPU
patients NNS I-POPU
] VBP I-POPU
. . O

AIMS NNP O
To TO O
compare VB O
, , O
in IN O
post-acute JJ B-POPU
hemiparetic JJ I-POPU
patients NNS I-POPU
, , O
gait NN B-OC
improvement NN I-OC
after IN O
conventional JJ B-INTV
physical JJ I-INTV
therapy NN I-INTV
alone RB I-INTV
or CC O
with IN B-INTV
a DT I-INTV
specialised JJ I-INTV
balance NN I-INTV
retraining VBG I-INTV
program NN I-INTV
. . O

PATIENTS VB O
Twenty-six JJ B-POPU
patients NNS I-POPU
within IN I-POPU
3 CD I-POPU
months NNS I-POPU
of IN I-POPU
onset NN I-POPU
of IN I-POPU
stroke NN I-POPU
were VBD O
randomised VBN O
to TO O
receive VB O
physical JJ B-INTV
therapy NN I-INTV
( ( O
control VB O
group NN O
) ) O
or CC O
therapy NN B-INTV
and CC I-INTV
retraining NN I-INTV
( ( O
experimental JJ O
group NN O
) ) O
, , O
most JJS O
of IN O
the DT O
patients NNS O
in IN O
both DT O
groups NNS O
with IN O
left JJ O
hemiplegia NN O
. . O

The DT O
experimental JJ O
group NN O
was VBD O
significantly RB O
older JJR O
than IN O
the DT O
control NN O
group NN O
. . O

METHOD NNP O
Thirteen NNP O
patients NNS O
received VBD O
early JJ O
conventional JJ B-INTV
therapy NN I-INTV
, , O
and CC O
13 CD O
received VBD O
therapy NN B-INTV
combined VBN I-INTV
with IN I-INTV
standing VBG I-INTV
balance NN I-INTV
training NN I-INTV
by IN I-INTV
biofeedback NN I-INTV
( ( I-INTV
BPM NNP I-INTV
Monitor NNP I-INTV
) ) I-INTV
. . O

Clinical JJ B-OC
measures NNS I-OC
were VBD O
collected VBN O
at IN O
entry NN O
( ( O
J0 NNP O
) ) O
, , O
once RB O
when WRB O
subjects NNS O
began VBD O
to TO O
walk VB O
( ( O
JM NNP O
) ) O
and CC O
30 CD O
days NNS O
later RB O
( ( O
JM NNP O
+ NNP O
30 CD O
) ) O
. . O

Gait NNP B-OC
spatiotemporal JJ I-OC
parameters NNS I-OC
were VBD O
collected VBN O
by IN O
use NN O
of IN O
the DT O
Vicon NNP O
system NN O
at IN O
JM NNP O
and CC O
JM NNP O
+ NNP O
30 CD O
. . O

RESULTS VB O
Whatever IN O
the DT O
method NN O
of IN O
rehabilitation NN O
, , O
the DT O
clinical JJ B-OC
scores NNS I-OC
improved VBN O
significantly RB O
between IN O
J0 NNP O
and CC O
JM NNP O
+ NNP O
30 CD O
, , O
except IN O
for IN O
spasticity NN O
. . O

The DT O
time NN B-OC
between IN I-OC
stroke NN I-OC
and CC I-OC
the DT I-OC
beginning NN I-OC
of IN I-OC
walking NN I-OC
was VBD O
not RB O
significantly RB O
different JJ O
between IN O
both DT O
groups NNS O
. . O

Gait NNP B-OC
velocity NN I-OC
increased VBD O
significantly RB O
between IN O
JM NNP O
and CC O
JM NNP O
+ NNP O
30 CD O
in IN O
both DT O
groups NNS O
, , O
with IN O
no DT O
difference NN O
between IN O
groups NNS O
. . O

The DT O
walking NN B-OC
pattern NN I-OC
was VBD O
improved VBN O
for IN O
both DT O
groups NNS O
, , O
with IN O
a DT O
significant JJ O
increase NN O
of IN O
the DT O
duration NN B-OC
of IN I-OC
the DT I-OC
paretic JJ I-OC
limb NN I-OC
single JJ I-OC
stance NN I-OC
. . O

The DT O
experimental JJ O
group NN O
significantly RB O
improved VBD O
the DT O
duration NN B-OC
of IN I-OC
the DT I-OC
reception NN I-OC
double JJ I-OC
stance NN I-OC
on IN I-OC
the DT I-OC
paretic JJ I-OC
limb NN I-OC
between IN O
JM NNP O
and CC O
JM NNP O
+ NNP O
30 CD O
compared VBN O
with IN O
the DT O
control NN O
group NN O
( ( O
P NNP O
= NNP O
0.03 CD O
) ) O
. . O

CONCLUSION NNP O
Both NNP O
groups NNS O
demonstrated VBD O
improvement NN O
in IN O
the DT O
rehabilitation NN O
unit NN O
. . O

The DT O
benefits NNS O
of IN O
visual JJ O
biofeedback NN O
by IN O
forceplate NN O
system NN O
training VBG O
suggest JJ O
particular JJ O
improvement NN O
of IN O
anticipation NN B-OC
equilibrium NN I-OC
with IN O
conventional JJ B-INTV
therapy NN I-INTV
. . O

-DOCSTART- -X- O O

Remote NNP B-INTV
ischaemic JJ I-INTV
conditioning NN I-INTV
before IN O
hospital JJ O
admission NN O
, , O
as IN O
a DT O
complement NN O
to TO O
angioplasty VB O
, , O
and CC O
effect NN O
on IN O
myocardial JJ B-OC
salvage NN I-OC
in IN O
patients NNS B-POPU
with IN I-POPU
acute JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
: : I-POPU
a DT O
randomised JJ O
trial NN O
. . O

BACKGROUND NNP O
Remote NNP B-INTV
ischaemic JJ I-INTV
preconditioning NN I-INTV
attenuates NNS O
cardiac JJ O
injury NN O
at IN O
elective JJ O
surgery NN O
and CC O
angioplasty NN O
. . O

We PRP O
tested VBD O
the DT O
hypothesis NN O
that WDT O
remote VBP B-INTV
ischaemic JJ I-INTV
conditioning NN I-INTV
during IN O
evolving VBG O
ST-elevation NNP B-POPU
myocardial JJ I-POPU
infarction NN I-POPU
, , O
and CC O
done VBN O
before IN O
primary JJ O
percutaneous JJ O
coronary JJ O
intervention NN O
, , O
increases VBZ O
myocardial JJ B-OC
salvage NN I-OC
. . O

METHODS NNP O
333 CD B-POPU
consecutive JJ I-POPU
adult NN I-POPU
patients NNS I-POPU
with IN I-POPU
a DT I-POPU
suspected VBN I-POPU
first JJ I-POPU
acute JJ I-POPU
myocardial JJ I-POPU
infarction NN I-POPU
were VBD O
randomly RB O
assigned VBN O
in IN O
a DT O
1:1 CD O
ratio NN O
by IN O
computerised JJ O
block NN O
randomisation NN O
to TO O
receive VB O
primary JJ O
percutaneous JJ O
coronary JJ O
intervention NN O
with IN O
( ( O
n=166 JJ O
patients NNS O
) ) O
versus NN O
without IN O
( ( O
n=167 NN O
) ) O
remote VBP B-INTV
conditioning VBG I-INTV
( ( O
intermittent JJ O
arm NN O
ischaemia NN O
through IN O
four CD O
cycles NNS O
of IN O
5-min JJ O
inflation NN O
and CC O
5-min JJ O
deflation NN O
of IN O
a DT O
blood-pressure JJ O
cuff NN O
) ) O
. . O

Allocation NN O
was VBD O
concealed VBN O
with IN O
opaque NN O
sealed VBN O
envelopes NNS O
. . O

Patients NNS O
received VBD O
remote JJ B-INTV
conditioning NN I-INTV
during IN O
transport NN O
to TO O
hospital NN O
, , O
and CC O
primary JJ O
percutaneous JJ O
coronary JJ O
intervention NN O
in IN O
hospital NN O
. . O

The DT O
primary JJ O
endpoint NN O
was VBD O
myocardial JJ B-OC
salvage NN I-OC
index NN I-OC
at IN I-OC
30 CD I-OC
days NNS I-OC
after IN I-OC
primary JJ I-OC
percutaneous JJ I-OC
coronary JJ I-OC
intervention NN I-OC
, , I-OC
measured VBN I-OC
by IN I-OC
myocardial JJ I-OC
perfusion NN I-OC
imaging NN I-OC
as IN O
the DT O
proportion NN B-OC
of IN I-OC
the DT I-OC
area NN I-OC
at IN I-OC
risk NN I-OC
salvaged VBN I-OC
by IN I-OC
treatment NN I-OC
; : I-OC
analysis NN O
was VBD O
per IN O
protocol NN O
. . O

This DT O
study NN O
is VBZ O
registered VBN O
with IN O
ClinicalTrials.gov NNP O
, , O
number NN O
NCT00435266 NNP O
. . O

FINDINGS NNP O
82 CD B-POPU
patients NNS I-POPU
were VBD I-POPU
excluded VBN I-POPU
on IN I-POPU
arrival NN I-POPU
at IN I-POPU
hospital NN I-POPU
because IN I-POPU
they PRP I-POPU
did VBD I-POPU
not RB I-POPU
meet VB I-POPU
inclusion NN I-POPU
criteria NNS I-POPU
, , I-POPU
32 CD I-POPU
were VBD I-POPU
lost VBN I-POPU
to TO I-POPU
follow-up NN I-POPU
, , I-POPU
and CC I-POPU
77 CD I-POPU
did VBD I-POPU
not RB I-POPU
complete VB I-POPU
the DT I-POPU
follow-up JJ I-POPU
with IN O
data NNS O
for IN O
salvage NN B-OC
index NN I-OC
. . O

Median JJ B-OC
salvage NN I-OC
index NN I-OC
was VBD O
0.75 CD O
( ( O
IQR NNP O
0.50-0.93 CD O
, , O
n=73 NN O
) ) O
in IN O
the DT O
remote JJ B-INTV
conditioning NN I-INTV
group NN O
versus VBD O
0.55 CD O
( ( O
0.35-0.88 CD O
, , O
n=69 NN O
) ) O
in IN O
the DT O
control NN O
group NN O
, , O
with IN O
median JJ B-OC
difference NN I-OC
of IN O
0.10 CD O
( ( O
95 CD O
% NN O
CI NNP O
0.01-0.22 CD O
; : O
p=0.0333 NN O
) ) O
; : O
mean JJ B-OC
salvage NN I-OC
index NN I-OC
was VBD O
0.69 CD O
( ( O
SD NNP O
0.27 CD O
) ) O
versus NN O
0.57 CD O
( ( O
0.26 CD O
) ) O
, , O
with IN O
mean JJ B-OC
difference NN I-OC
of IN O
0.12 CD O
( ( O
95 CD O
% NN O
CI NNP O
0.01-0.21 CD O
; : O
p=0.0333 NN O
) ) O
. . O

Major JJ B-OC
adverse JJ I-OC
coronary JJ I-OC
events NNS I-OC
were VBD O
death NN B-OC
( ( O
n=3 JJ O
per IN O
group NN O
) ) O
, , O
reinfarction NN B-OC
( ( O
n=1 JJ O
per IN O
group NN O
) ) O
, , O
and CC O
heart NN B-OC
failure NN I-OC
( ( O
n=3 JJ O
per IN O
group NN O
) ) O
. . O

INTERPRETATION NNP O
Remote NNP B-INTV
ischaemic JJ I-INTV
conditioning NN I-INTV
before IN O
hospital JJ O
admission NN O
increases VBZ O
myocardial JJ B-OC
salvage NN I-OC
, , O
and CC O
has VBZ O
a DT O
favourable JJ O
safety NN B-OC
profile NN I-OC
. . O

Our PRP$ O
findings NNS O
merit VBP O
a DT O
larger JJR O
trial NN O
to TO O
establish VB O
the DT O
effect NN O
of IN O
remote JJ B-INTV
conditioning NN I-INTV
on IN O
clinical JJ O
outcomes NNS O
. . O

FUNDING NN O
Fondation NNP O
Leducq NNP O
. . O

-DOCSTART- -X- O O

Visual JJ B-INTV
and CC I-INTV
kinesthetic JJ I-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
integrated VBN I-INTV
with IN I-INTV
auditory JJ I-INTV
step NN I-INTV
rhythm NN I-INTV
for IN O
walking VBG B-OC
performance NN I-OC
of IN O
patients NNS B-POPU
with IN I-POPU
chronic JJ I-POPU
stroke NN I-POPU
. . O

OBJECTIVE UH O
To TO O
compare VB O
the DT O
effect NN O
of IN O
visual JJ B-INTV
and CC I-INTV
kinesthetic JJ I-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
on IN O
walking VBG B-OC
performance NN I-OC
and CC O
to TO O
determine VB O
the DT O
clinical JJ O
feasibility NN O
of IN O
incorporating VBG O
auditory JJ B-INTV
step NN I-INTV
rhythm NN I-INTV
into IN O
the DT O
training NN O
. . O

DESIGN NNP O
Randomized NNP O
crossover NN O
trial NN O
. . O

SETTING NNP O
Laboratory NNP O
of IN O
a DT O
Department NNP O
of IN O
Physical NNP O
Therapy NNP O
. . O

SUBJECTS NNP O
Fifteen NNP B-POPU
subjects VBZ I-POPU
with IN I-POPU
post-stroke JJ I-POPU
hemiparesis NN I-POPU
. . O

INTERVENTION NNP O
Four NNP O
locomotor NN B-INTV
imagery NN I-INTV
trainings NNS I-INTV
on IN O
walking VBG O
performance NN O
: : O
visual JJ B-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
, , I-INTV
kinesthetic JJ I-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
, , I-INTV
visual JJ I-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
with IN I-INTV
auditory JJ I-INTV
step NN I-INTV
rhythm NN I-INTV
and CC O
kinesthetic JJ B-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
with IN I-INTV
auditory JJ I-INTV
step NN I-INTV
rhythm NN I-INTV
. . O

MAIN NNP O
OUTCOME NNP O
MEASURES NNP O
The DT B-OC
timed JJ I-OC
up-and-go JJ I-OC
test NN I-OC
and CC I-OC
electromyographic JJ I-OC
and CC I-OC
kinematic JJ I-OC
analyses NNS I-OC
of IN I-OC
the DT I-OC
affected JJ I-OC
lower JJR I-OC
limb NN I-OC
during IN O
one CD O
gait NN O
cycle NN O
. . O

RESULTS NNP O
After IN O
the DT O
interventions NNS O
, , O
significant JJ O
differences NNS O
were VBD O
found VBN O
in IN O
the DT O
timed JJ B-OC
up-and-go JJ I-OC
test NN I-OC
results NNS O
between IN O
the DT O
visual JJ B-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
( ( O
25.69 CD O
± RB O
16.16 CD O
to TO O
23.97 CD O
± NNS O
14.30 CD O
) ) O
and CC O
the DT B-INTV
kinesthetic JJ I-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
with IN I-INTV
auditory JJ I-INTV
step NN I-INTV
rhythm NN I-INTV
( ( O
22.68 CD O
± RB O
12.35 CD O
to TO O
15.77 CD O
± NNS O
8.58 CD O
) ) O
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
. . O

During IN O
the DT O
swing NN O
and CC O
stance NN O
phases NNS O
, , O
the DT B-INTV
kinesthetic JJ I-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
exhibited VBN O
significantly RB O
increased VBN O
activation NN O
in IN O
a DT O
greater JJR B-OC
number NN I-OC
of IN I-OC
muscles NNS I-OC
and CC O
increased VBD B-OC
angular JJ I-OC
displacement NN I-OC
of IN I-OC
the DT I-OC
knee NN I-OC
and CC I-OC
ankle NN I-OC
joints NNS I-OC
compared VBN O
with IN O
the DT B-INTV
visual JJ I-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
, , O
and CC O
these DT O
effects NNS O
were VBD O
more RBR O
prominent JJ O
when WRB B-INTV
auditory JJ I-INTV
step NN I-INTV
rhythm NN I-INTV
was VBD O
integrated VBN O
into IN O
each DT O
form NN B-INTV
of IN I-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
. . O

The DT O
activation NN O
of IN O
the DT O
hamstring NN O
during IN O
the DT O
swing JJ O
phase NN O
and CC O
the DT O
gastrocnemius NN O
during IN O
the DT O
stance NN O
phase NN O
, , O
as RB O
well RB B-OC
as IN I-OC
kinematic JJ I-OC
data NNS I-OC
of IN I-OC
the DT I-OC
knee NN I-OC
joint NN I-OC
, , O
were VBD O
significantly RB O
different JJ O
for IN O
posttest JJS O
values NNS O
between IN O
the DT B-INTV
visual JJ I-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
and CC O
the DT B-INTV
kinesthetic JJ I-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
with IN I-INTV
auditory JJ I-INTV
step NN I-INTV
rhythm NN I-INTV
( ( O
P NNP O
< NNP O
0.05 CD O
) ) O
. . O

CONCLUSIONS VB O
The DT B-OC
therapeutic JJ I-OC
effect NN I-OC
may MD O
be VB O
further RB O
enhanced VBN O
in IN O
the DT B-INTV
kinesthetic JJ I-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
than IN O
in IN O
the DT B-INTV
visual JJ I-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
. . O

The DT B-INTV
auditory JJ I-INTV
step NN I-INTV
rhythm VBZ I-INTV
together RB O
with IN O
the DT B-INTV
locomotor NN I-INTV
imagery NN I-INTV
training NN I-INTV
produces VBZ O
a DT O
greater JJR O
positive JJ O
effect NN O
in IN O
improving VBG O
the DT B-OC
walking VBG I-OC
performance NN B-POPU
of IN I-POPU
patients NNS I-POPU
with IN I-POPU
post-stroke JJ I-POPU
hemiparesis NN I-POPU
. . O

-DOCSTART- -X- O O

Methodology NNP O
of IN O
serial JJ O
ECG NNP O
classification NN O
using VBG O
an DT O
adaptation NN O
of IN O
the DT O
NOVACODE NNP O
for IN O
Q NNP O
wave VBP O
myocardial JJ O
infarction NN O
in IN O
the DT O
Bypass NNP O
Angioplasty NNP O
Revascularization NNP O
Investigation NNP O
( ( O
BARI NNP O
) ) O
. . O

Serial JJ O
electrocardiographic JJ O
( ( O
ECG NNP O
) ) O
changes NNS O
are VBP O
a DT O
critical JJ O
component NN O
of IN O
the DT O
diagnostic JJ O
algorithm NN O
for IN O
classification NN O
of IN O
myocardial JJ O
ischemic JJ O
events NNS O
in IN O
large-scale JJ O
clinical JJ O
trials NNS O
. . O

This DT O
study NN O
describes VBZ O
a DT O
computerized JJ O
serial JJ O
ECG NNP O
classification NN O
program NN O
developed VBN O
at IN O
the DT O
St. NNP O
Louis NNP O
University NNP O
Core NNP O
ECG NNP O
Laboratory NNP O
for IN O
use NN O
in IN O
the DT O
Bypass NNP O
Angioplasty NNP O
Revascularization NNP O
Investigation NNP O
( ( O
BARI NNP O
) ) O
trial NN O
, , O
in IN O
which WDT O
patients NNS B-POPU
with IN I-POPU
multivessel JJ I-POPU
coronary JJ I-POPU
artery NN I-POPU
disease NN I-POPU
were VBD O
randomized VBN O
to TO O
receive VB O
either DT O
coronary JJ B-INTV
artery NN I-INTV
bypass NN I-INTV
grafting NN I-INTV
or CC O
percutaneous JJ B-INTV
transluminal JJ I-INTV
coronary JJ I-INTV
angioplasty NN I-INTV
. . O

The DT O
St. NNP O
Louis NNP O
University NNP O
program NN O
detects NNS O
and CC O
codes VBZ O
serial JJ B-OC
changes NNS I-OC
in IN I-OC
Q NNP I-OC
, , I-OC
ST NNP I-OC
, , I-OC
and CC I-OC
T NNP I-OC
wave VBP I-OC
items NNS I-OC
according VBG I-OC
to TO I-OC
Minnesota NNP I-OC
code NN I-OC
( ( I-OC
MC NNP I-OC
) ) I-OC
criteria VBP I-OC
using VBG O
a DT O
modified JJ O
NOVACODE NNP O
hierarchical JJ O
classification NN O
system NN O
. . O

Measurements NNS O
using VBG O
a DT O
seven-power NN O
calibrated VBN O
coding NN O
loupe NN O
are VBP O
used VBN O
to TO O
generate VB O
the DT O
MC NNP O
from IN O
a DT O
customized JJ O
software NN O
program NN O
. . O

Significant NNP O
minor VBD O
or CC O
major JJ O
changes NNS B-OC
are VBP O
detected VBN O
by IN O
the DT O
serial JJ O
comparison NN O
program NN O
and CC O
referred VBD O
to TO O
a DT O
physician JJ O
coder NN O
for IN O
verification NN O
. . O

Serial JJ O
comparison NN O
coding NN O
rules NNS O
are VBP O
used VBN O
to TO O
adjust VB O
for IN O
weaknesses NNS O
in IN O
the DT O
standard JJ O
MC NNP O
classification NN O
system NN O
resulting VBG O
from IN O
instability NN O
at IN O
decision NN O
boundaries NNS O
. . O

Of IN O
4,244 CD B-POPU
BARI NNP I-POPU
randomized VBN I-POPU
and CC I-POPU
registry NN I-POPU
study NN I-POPU
participants NNS I-POPU
with IN I-POPU
follow-up JJ I-POPU
ECGs NNP I-POPU
received VBD I-POPU
at IN I-POPU
the DT I-POPU
Core NNP I-POPU
ECG NNP I-POPU
Laboratory NNP I-POPU
as IN I-POPU
of IN I-POPU
March NNP I-POPU
1995 CD I-POPU
, , O
a DT O
grade NN O
2 CD O
MC NNP B-OC
Q NNP I-OC
wave VBP I-OC
progression NN I-OC
was VBD O
noted VBN O
in IN O
568 CD O
participants NNS O
( ( O
13.4 CD O
% NN O
) ) O
using VBG O
MC NNP O
criteria NNS O
alone RB O
, , O
as IN O
compared VBN O
with IN O
367 CD O
( ( O
8.6 CD O
% NN O
) ) O
after IN O
the DT O
St. NNP O
Louis NNP O
University NNP O
coding NN O
rules NNS O
were VBD O
applied VBN O
. . O

The DT O
incidence NN O
of IN O
grade NN O
1 CD O
MC NNP B-OC
Q NNP I-OC
wave VBP I-OC
progressions NNS I-OC
was VBD O
16.4 CD O
% NN O
( ( O
697/4,244 CD O
) ) O
versus NN O
6.1 CD O
% NN O
( ( O
259/4,244 CD O
) ) O
when WRB O
the DT O
St. NNP O
Louis NNP O
University NNP O
program NN O
was VBD O
applied VBN O
. . O

Intraobserver NNP O
variability NN O
for IN O
grade NN O
2 CD O
Q NNP B-OC
wave VBP I-OC
progression NN I-OC
codes NNS I-OC
determined VBD O
from IN O
a DT O
sample NN O
of IN O
812 CD O
serial NN O
. . O

-DOCSTART- -X- O O

Systemic NNP B-OC
hemodynamic NN I-OC
, , I-OC
neurohormonal JJ I-OC
, , I-OC
and CC I-OC
renal JJ I-OC
effects NNS I-OC
of IN O
a DT O
steady-state JJ O
infusion NN O
of IN O
human JJ B-INTV
brain NN I-INTV
natriuretic JJ I-INTV
peptide NN I-INTV
in IN O
patients NNS B-POPU
with IN I-POPU
hemodynamically RB I-POPU
decompensated VBN I-POPU
heart NN I-POPU
failure NN I-POPU
. . O

BACKGROUND NNP O
Human NNP B-INTV
brain NN I-INTV
natriuretic JJ I-INTV
peptide NN I-INTV
( ( I-INTV
hBNP NN I-INTV
) ) I-INTV
is VBZ O
a DT O
promising JJ O
agent NN O
for IN O
the DT O
treatment NN O
of IN O
decompensated JJ O
cardiac JJ O
failure NN O
. . O

However RB O
, , O
the DT O
systemic JJ B-OC
hemodynamic NN I-OC
, , I-OC
neurohormonal JJ I-OC
, , I-OC
and CC I-OC
renal JJ I-OC
effects NNS I-OC
of IN O
hBNP NNS B-INTV
have VBP O
been VBN O
incompletely RB O
studied VBN O
in IN O
human JJ O
heart NN O
failure NN O
. . O

METHODS NNP O
AND CC O
RESULTS NNP O
The DT O
effects NNS O
of IN O
a DT O
continuous JJ O
4-hour JJ O
infusion NN O
of IN O
hBNP NN B-INTV
were VBD O
determined VBN O
in IN O
16 CD B-POPU
decompensated JJ I-POPU
heart NN I-POPU
failure NN I-POPU
patients NNS I-POPU
in IN O
an DT O
invasive JJ O
, , O
randomized VBN O
, , O
double-blind JJ O
, , O
placebo-controlled JJ B-INTV
study NN O
. . O

Patients NNS O
were VBD O
evaluated VBN O
during IN O
three CD O
4-hour JJ O
study NN O
periods NNS O
: : O
baseline NN O
, , O
treatment NN O
( ( B-INTV
placebo JJ I-INTV
[ NNP O
n NN O
= VBD O
4 CD O
] NNP O
versus NN O
hBNP NN B-INTV
0.025 CD O
or CC O
0.05 CD O
microgram/kg/min NNS O
[ JJ O
n JJ O
= NN O
12 CD O
] NN O
) ) O
, , O
and CC O
post-treatment NN O
. . O

Urinary JJ B-OC
volume NN I-OC
losses NNS I-OC
were VBD O
replaced VBN O
hourly RB O
to TO O
separate VB O
the DT O
vasodilatory NN O
and CC O
diuretic JJ O
effects NNS O
of IN O
hBNP NN B-INTV
. . O

Two CD O
patients NNS O
in IN O
the DT O
hBNP NN B-INTV
group NN O
were VBD O
excluded VBN O
from IN O
the DT O
analysis NN O
because IN O
of IN O
adverse JJ B-OC
events NNS I-OC
. . O

hBNP NN B-INTV
significantly RB O
( ( O
P NNP O
< NNP O
.001 NNP O
) ) O
reduced VBD O
right JJ B-OC
atrial JJ I-OC
pressure NN I-OC
and CC I-OC
pulmonary JJ I-OC
capillary JJ I-OC
wedge NN I-OC
pressure NN I-OC
by IN O
approximately RB O
30 CD O
% NN O
and CC O
40 CD O
% NN O
, , O
respectively RB O
. . O

hBNP NN B-INTV
also RB O
significantly RB O
lowered VBN O
systemic JJ B-OC
vascular JJ I-OC
resistance NN I-OC
from IN O
1722 CD O
+/- JJ O
139 CD O
to TO O
1101 CD O
+/- JJ O
83 CD O
dynes.s.cm-5 NN O
( ( O
P NNP O
< NNP O
.05 NNP O
) ) O
. . O

These DT O
unloading JJ O
effects NNS O
of IN O
hBNP NN B-INTV
produced VBD O
a DT O
28 CD O
% NN O
increase NN O
in IN O
cardiac JJ B-OC
index NN I-OC
( ( O
P NNP O
< NNP O
.05 NNP O
) ) O
with IN O
no DT O
change NN O
in IN O
heart NN B-OC
rate NN I-OC
. . O

Compared VBN O
to TO O
placebo VB B-INTV
, , I-INTV
hBNP VB I-INTV
decreased VBN O
plasma JJ B-OC
norepinephrine NN I-OC
and CC I-OC
aldosterone NN I-OC
. . O

Renal JJ B-OC
hemodynamics NNS I-OC
were VBD O
unaffected VBN O
by IN O
hBNP NN B-INTV
; : I-INTV
however RB O
, , O
most JJS O
patients NNS O
were VBD O
resistant JJ O
to TO O
its PRP$ O
natriuretic JJ B-OC
effect NN I-OC
. . O

CONCLUSIONS NNP O
1 CD O
) ) O
The DT O
predominant JJ O
hemodynamic JJ B-OC
effects NNS I-OC
of IN O
hBNP NN B-INTV
were VBD O
a DT O
decrease NN O
in IN O
cardiac JJ B-OC
preload NN I-OC
and CC I-OC
systemic JJ I-OC
vascular JJ I-OC
resistance NN I-OC
. . O

2 CD O
) ) O
hBNP NN B-INTV
also RB O
improved VBD O
cardiac JJ B-OC
output NN I-OC
without IN O
increasing VBG O
heart NN B-OC
rate NN I-OC
. . O

3 CD O
) ) O
Plasma NNP B-OC
norepinephrine NN I-OC
and CC I-OC
aldosterone NN I-OC
levels NNS I-OC
decreased VBN O
during IN O
hBNP JJ B-INTV
infusion NN O
. . O

4 CD O
) ) O
hBNP NN B-INTV
is VBZ O
pharmacologically RB O
active JJ O
and CC O
has VBZ O
potential VBN O
in IN O
the DT O
therapy NN O
for IN O
decompensated JJ B-POPU
heart NN I-POPU
failure NN I-POPU
. . O

